{
    "47468741-3624-4321-90ee-1c680a293b25": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "the record shows 5 total cases of asthenia and 3 total cases of pyrexia in the patients of the primary and secondary clinical trials."
    },
    "93e6ed2b-1e3f-4cbe-a49e-cbc74b31e1aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "'the primary clinical trial is open for participation to african-american patients."
    },
    "ad9fe1aa-9798-4c53-ab23-23ac2924918c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients participating in the primary trial receive 2000 mg/m2 oral lapatinib twice a day for a full month."
    },
    "cdcb40f6-994c-4085-869a-dab87e67ba04": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "in the primary clinical trial, 97% of patients reported experiencing adverse events'"
    },
    "7df66c3f-de87-4542-9797-06325684db65": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 4 more adverse events recorded than the secondary trial. adrenal gland lymphangioma is a rare lymphangioma that arises from the adrenal gland."
    },
    "3ce48a99-7310-4a2f-8853-e46db55af26e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 20 mg po daily for 168 hours prior to surgery and for 336 hours after breast cancer surgery reduces ki67 expression in tumors by 40% on average."
    },
    "9349c7c8-7771-4dfc-8981-3c8d84ac5236": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial."
    },
    "e25a03fa-f51c-4c0d-b737-375a968ce6be": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients encountering a known allergy to ertapenem or ciprofloxacin will result in exclusion from the primary and secondary trials."
    },
    "5c5a882c-4840-4e2e-83f8-341283caa359": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 0.56 kg of ibrutinib and 10 g/kg of medi4736 twice daily for 30 days."
    },
    "a06166e6-12c9-49ba-ad3a-7fcfb5234174": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the secondary trial and the primary trial have completely unrelated outcome measurements."
    },
    "adb18104-31a9-4eef-817b-0ab742bd4093": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 1mg in the primary trial gained lean body mass over a 10 year period"
    },
    "feca3829-9b38-4738-8bad-e8a0fcf9029f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were all more frequently reported as adverse events in the secondary clinical trial than in the primary clinical trial."
    },
    "0471ee43-16a7-417e-94db-0ef86bd5b0a9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a mastectomy for stage iv bc does not necessarily exclude a woman from participatory consideration in either the primary or secondary clinical trial."
    },
    "74b96ae6-3e1a-4f1c-bbf0-a79ed0e4ee75": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "adverse events were not documented for both the primary clinical trial and the secondary clinical trial."
    },
    "14e8dba6-bd13-4f5b-a225-6cd55c3d1243": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "for the whole duration of the primary clinical trial, patients will get increased doses of alpha lipoic acid, while during the secondary clinical trial, patients in cohort 1 receive a consistent dose of necitumumab."
    },
    "6e609d6e-8db0-4adc-bce7-62f7274c10c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "uniform criteria for all participants are applied in the secondary clinical trial for inclusion or exclusion, as opposed to the primary clinical trial that provides two distinct inclusion policies for those aged 18-50 and those aged 50 and over."
    },
    "cc177dab-2d93-40dd-8b7f-ac1755325605": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "being diagnosed with stage 4 breast adenocarcinoma that is either er positive, pr positive, or her2/neu negative makes a patient eligible for participation in both the secondary and primary clinical trials."
    },
    "d0168033-35eb-4032-b6e5-f81d9d3a9f7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy."
    },
    "66a9e527-8f35-4c41-be7f-ad854d0066f9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "occurrence date range validation code is a coded value specifying the degree of authoritativeness or certitude of the occurrence date. Any japanese national can take part in the primary trial, or the secondary trial."
    },
    "98877f56-e367-4335-b938-85bd30fb038a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "hepatitis c antibody is an antibody produced by b-lymphocytes in response to hepatitis c virus infection. Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention."
    },
    "8f319cf4-ec84-4f34-a4d8-2af54adbaab9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "sars coronavirus 2 b.1.128 is a variant lineage of sars coronavirus 2 that is the ancestor for the p.1 and p.2 lineages. 100.0% of cohort 1 of the primary trial suffered some kind of adverse event."
    },
    "01effe7e-449f-4f59-a64e-2b38c5c21187": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "2 out of 73 individuals in the primary clinical trial have suffered an acute myocardial infarction, compared to zero out of 1674 individuals in the secondary clinical trial"
    },
    "3a04553e-529b-4cff-81f5-38e8ec73dd6b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort. division is an administrative unit within a government, academic organization or business."
    },
    "ac50c12b-4055-428b-8d8b-0136aca85f10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "a higher percentage of patients suffered from adverse events in cohort a compared to cohort b during the primary clinical trial."
    },
    "af417420-0bcb-407d-8470-b73cafe31893": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial. gemcitabine/irinotecan regimen is a regimen consisting of gemcitabine and irinotecan used for the treatment of pancreatic cancer."
    },
    "c09c08d5-189f-4e15-acb8-2c3cb235aaa6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same number of Aes were reported for both cohorts in the primary trial"
    },
    "dfd43b21-a734-49b1-8a64-d6dea31e9031": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "capnocytophaga is a genus of gram-negative, anaerobic bacteria that normally populate the mouth and nasopharynx of dogs and cats. Any japanese national can take part in the primary trial, or the secondary trial."
    },
    "077cc008-c777-4fa3-826b-8cc903eab60e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "both cohort 1 and cohort 2 of the primary clinical trial are administered the same dosage of alt-801"
    },
    "b23563cf-e6c4-4279-92b7-39d5e4de96d2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets"
    },
    "0e2c4838-f0ba-4f02-b078-ac3fa2b3c0e3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary clinical trial is given a larger dosage of alt-801 than cohort 2"
    },
    "770041f3-701c-4e9f-8df4-5b78a0e4a076": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 0.03 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "7758b88c-2f21-4b63-b76d-010298f50aa7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 1 of the primary clinical trial is administered a similar dose of enzalutamide as cohort 2"
    },
    "6b90da92-6aaa-431b-b31c-8df9def4a98d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial. cdk4 gene mutation is a change in the nucleotide sequence of the cdk4 gene."
    },
    "12a03716-0ec6-4ffe-abd8-02411c083ee5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "the primary clinical trial does not involve the use of any injections for its patients."
    },
    "6f95650b-d11f-4546-bfb2-d46cc39561b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients suffering from severe insomnia and schizophrenia are eligible for both the primary trial and the secondary trial"
    },
    "2e64e934-f058-4730-af09-ddf7547a0112": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "neither primary clinical trial nor secondary clinical trial allows candidates with ecog score below 2"
    },
    "5031f62e-54ed-4635-b136-7f90d6eb2535": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary clinical trial and the primary clinical trial utilize the same units of measure in their results.'"
    },
    "6d595852-44de-4516-9ac8-441283808f1f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "no adverse events were experienced by 97% of patients participating in the primary clinical trial."
    },
    "889268e5-7b76-4c17-b567-bd828a9abf3e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "numerous instances of cardiac and psychiatric aes were remarked during the primary clinical trial and the secondary clinical trial, with only a few other types of aes reported."
    },
    "5fcf6210-c07a-4b8e-9944-c2f0714e4d69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "All the primary trial participants receive lower doses of drugs than the secondary trial participants"
    },
    "4e91cee2-910e-4f08-8a85-1f13545391c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer."
    },
    "b358fb9c-1152-4e1a-88eb-743e965d58fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial."
    },
    "2b2a038c-37d7-42a6-817a-5392b1e94613": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "the incidence of aes was reported to be higher amongst patients in the secondary clinical trial than those in the primary clinical trial."
    },
    "02ef43dd-1a1c-49c4-8ce0-01f03f733e81": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "subject status subcategory is a subdivision of subject status data. 18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation."
    },
    "1fa45a65-8a51-41e7-af9d-01ab8e0f3e1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "hepatotoxicity incidence was not higher compared to the number of hypertension and pancreatectomy cases during the primary clinical trial"
    },
    "992db0e7-c7c4-413c-874f-c8e53d481fab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "the primary trial provided the members of cohort 1 and 2 with equal doses of cetuximab, but cohort 1 received 8mg/kg less of mm-121."
    },
    "0f37bc77-1f82-44ce-ae7e-2a6b833e774a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "somatostatin receptor positive is a laboratory test result indicating the presence or expression of somatostatin receptor in a sample. The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel."
    },
    "72f49bc3-1624-437d-bf75-e37a24a9c19f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "age at menarche is age of first menstruation.  a risk factor for breast cancer the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial."
    },
    "a92239f6-9f31-4e7f-a8be-2792789ea5f1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "the primary clinical trial does not include trastuzumab in any of its intervention regimens"
    },
    "9426014b-4962-4dcc-8328-ca29428d6ed3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "119 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 5% of patients, apart from skin infections"
    },
    "49b3b463-a496-404a-a3a5-07cd7d4aaa92": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial."
    },
    "f543a317-1f30-46b9-849e-67396ae072de": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial and the secondary trial adminster their interventions orally. non-muscle invasive bladder urothelial carcinoma is an infiltrating urothelial carcinoma of the bladder that has not invaded into the bladder muscularis propria."
    },
    "1d20e438-806f-4695-bc8f-d6a0ce1f0299": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "participants of the primary clinical trial must have a normal hepatic function."
    },
    "a1a8bedd-680d-4250-9384-93379de0a2a3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "in the primary clinical trial, therapeutic measures applied on the skin are being used, on the other hand, the secondary clinical trial is investigating the effects of treatments administered through inhalation."
    },
    "808d2233-0c0d-4221-bfae-e54fdcf31ce4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. ret rearrangement testing method is a request to enter the specific molecular analysis method used to detect and identify rearrangements involving the ret gene."
    },
    "9b2a47ba-246e-4591-bf68-90c7124f800b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "in the secondary trial, patients get a one-time injection at the beginning, while the primary trial patients are treated with multiple weekly injections."
    },
    "3ae463ca-9747-4796-805c-b4b56c0be8e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "have trouble communicating thoughts is a question about whether an individual has or had trouble communicating their thoughts. the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally."
    },
    "0eba9989-3611-49a8-958f-ea696ba94b3e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "in the primary clinical trial, the patient who exhibited the longest progression-free survival (pfs) lived 3.5 months without any evidence of disease progression or mortality."
    },
    "5feb2522-300c-490a-be54-07b2c99d397e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial. have difficulty moving arm side to side is a question about whether an individual experiences or experienced difficulty moving their arm from side to side."
    },
    "31c480e3-b528-4810-855e-498a019ba253": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs. have flatulence or gas is a question about the extent to which an individual has or had flatulence or gas."
    },
    "014e2dc7-251b-4615-a8fc-38aed023b053": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation . malignant pelvic neoplasm is a primary or metastatic malignant neoplasm that affects the organs and structures of the pelvis."
    },
    "ae0dd0fb-c8c9-47bd-ab6b-8236edd68194": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses lower doses of lenalidomide than the secondary trial uses of lapatinib in intervention 1, and the primary trial intervention has a shorter period."
    },
    "3592e711-ad4f-4f99-afde-3de2106ee5cd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "the incidence of diarrhoea was higher among participants of the primary clinical trial than it was among the secondary clinical trial subjects."
    },
    "5be5cc6c-ba08-4d21-9939-4ccde58aa23e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "regimen used to treat malignant ovarian neoplasm is any regimen that can be used for the treatment of malignant ovarian neoplasm. There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial."
    },
    "d44338be-9054-466e-8cb6-388fd8024e9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. milligram per square meter per hour is a dose calculation unit expressed in milligram(s) per square meter per period of time equal to sixty minutes."
    },
    "69959fb0-ee1c-4fb2-a968-677802eb1c82": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "72% more participants in the er-positive luminal b group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "d4eb3cf4-eeff-42c3-8036-54ec85061299": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "placental non-neoplastic disorder is a non-neoplastic disorder that arises from the placenta. representative examples include chorioamnionitis, infarction, and malformations. Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead."
    },
    "c724f8b4-74e9-4f48-ab39-cc8eb21890e6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "in comparison to the primary clinical trial, the intervention period for the secondary trial is extended by 15 weeks."
    },
    "5975fc5c-37b0-4c9e-b546-afa0915ba928": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, the placebo and memantine interventions have dissimilar administration frequencies and time durations."
    },
    "1f3d7969-35e1-4880-8ae5-b97c53c1e536": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "several patients in the secondary trial experienced only one adverse event."
    },
    "c66df8c2-afad-4638-a1c2-5539fc03a2be": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "fail-safe system device is a device designed to prevent malfunction, unsafe, or unauthorized operation of a device or system. There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial."
    },
    "eb93eb13-978c-4f27-8c2b-c3ddddcbafcf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates. pdgfrb gene fusion positive is an indication that a pdgfrb fusion gene has been detected in a sample."
    },
    "a9497198-5380-4af2-ace4-eb2e904a855a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "doctor and i shared responsibility for deciding which treatment is best for me is a response indicating that an individual and their doctor shared responsibility for deciding which treatment is best for them. African-american patients can participate in the primary trial."
    },
    "1f8901ea-ca2d-4771-95e5-8b75fa7e9994": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "in the intervention portion of the primary clinical trial, there's no detailed structure or explanation about a treatment cycle."
    },
    "cbe2e1d0-bb9b-43a2-b965-732f43d9af05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "combination route of administration is administration of a drug by more than one route at the same time. candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial."
    },
    "32781bed-ab99-4837-a7f8-d3ab0b978384": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "tp53 mutation analysis was not performed is an indication that tp53 mutation analysis was not performed during the study. All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period."
    },
    "fc35d08f-73a9-47aa-9450-165dcfda17bf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "across both the primary clinical trial and the secondary clinical trial, no adverse events were observed in more than 1% of participants."
    },
    "09816bed-e4f7-4b1c-8599-fbc623fa9675": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 3.5 more months than the intervention detailed in the primary trial."
    },
    "87a42ef9-ff00-41f8-ba0a-9ca84498f7eb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "just a pair of patients in the primary clinical trial failed to demonstrate recurrence-free survival"
    },
    "879196dd-c66e-4413-9575-98c95c0b9df1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "approximately one-third of patients, from both groups in the primary clinical trial, demonstrated pathologic complete response in breast and axillary lymph nodes after around seven months into the study"
    },
    "13d879d7-e968-4de9-ad06-458eb72759d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 10 recorded adverse events."
    },
    "867cde11-ffad-4494-bdea-2457651a7de7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 32 mg po daily for 1 week prior to surgery and for 2 weeks after breast cancer surgery reduces the diameter of tumors by 40% on average."
    },
    "f03664fa-20b3-4102-b1e2-fe901d028f65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial"
    },
    "4128c0f0-7d9f-44e7-ba5a-66919c502fdd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "negligible or no adverse events were reported in both the primary clinical trial and the secondary clinical trial."
    },
    "b20cbb69-8909-4a66-b47c-27192604d187": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort."
    },
    "8101ccf6-e6f4-43ba-b22f-9a13e2ddd279": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it"
    },
    "c392fd36-941e-4809-8d9e-16e3aa1c945c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "compared to the secondary clinical trial, the primary clinical trial boasted a greater number of participants."
    },
    "c6f5d89a-939b-4e46-8aab-9fc9246498be": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient who has recently undergone an organ transplant and remains confined to bed would not be eligible for the primary clinical trial, but could be considered for the secondary clinical trial"
    },
    "4023d560-6425-4207-aa76-543be30fd786": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention focuses on harnessing the strengths of targeted molecular therapies, while the secondary trial focuses on surgical interventions and regenerative medicine."
    },
    "8c9c4150-3bc1-4f06-8bee-2d5bba3ef8b9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "several cardiac and psychiatric aes were observed in the primary clinical trial."
    },
    "1f8bd45e-480f-4244-9515-e1249b5b842a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "97% of patients in the primary trial did not experience any Adverse Events. mental disorder due to a general medical condition is a category of psychiatric disorders which are the direct physiologic consequence of a general medical condition."
    },
    "c6fedf8e-7d06-426e-8269-667a68ef06bc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs. encephalomeningocele is a congenital neural tube closure defect resulting in the protrusion of the brain and meninges through a skull opening."
    },
    "1e4ebef6-1039-42f3-b753-3efd098052fc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention phase in the secondary clinical trial lasts an additional 15 weeks compared to that in the primary clinical trial."
    },
    "3cbaa580-dfe1-4331-902c-5be850db2f24": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "pre-operative administration of dexamethasone is given to both cohorts in the primary clinical trial"
    },
    "a3b8086c-3eec-402c-8b95-4446b33673b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "regardless of their cancer type, ethnicity, or race, female cancer patients aged 18 and above are eligible for the primary clinical trial. however, they are required to be diagnosed with her2/neu+ breast cancer to participate in the secondary clinical trial."
    },
    "e9003121-5fb9-4d34-95b4-011c76402472": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. adjuvant post-operative chemotherapy was not administered is a response indicating that adjuvant post-operative chemotherapy was not administered."
    },
    "b7d7f9f1-1e62-403f-9ceb-234108f7569f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "the secondary clinical trial doesn't accept patients diagnosed with stage 4 cancer, however, such patients are eligible for the primary clinical trial."
    },
    "8e661d16-bf69-4d02-a437-5a77f12c1bd0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "post-operative therapy rounds section is a form header for post-operative therapy round information. The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine."
    },
    "a83ef28c-db79-4e1b-9ebd-f563905a9ac7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "the primary clinical trial's acupuncture patients reported greater changes in their lymphedema than those patients who were on the waiting list."
    },
    "7308389a-7cde-4cf2-8f68-cefff152645c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "there were no occurrences of urinary tract infections among the participants of the primary clinical trial"
    },
    "2dc8c214-bbe5-49b7-a48e-0945fddcd9da": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "the primary clinical trial and the secondary trial administer docetaxel to their patient cohorts"
    },
    "f4632d0c-6ea3-4638-a2f3-ad5103e28229": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "cerebellar paraganglioma is an extra-adrenal paraganglioma arising from the cerebellum. the primary trial and the secondary trial do not test the same drugs."
    },
    "fe7217cf-7210-433b-b3ec-5dfff00aa3c4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the secondary clinical trial's most frequent adverse event witnessed was anaemia, affecting in excess of 5% of the patients, while no adverse occurrences were noted in the primary trial."
    },
    "74c7adc7-9641-4858-88af-69a2e2cd6dad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "advanced chordoma is a chordoma that has spread extensively to other anatomic sites or is no longer responding to treatment. Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead."
    },
    "d7abbd7d-a767-49c0-bc99-1c28074eac21": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae"
    },
    "d3ccfad5-d5c9-4bdb-a69e-dca916dc5da5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 32 year old individual diagnosed with stage iii breast cancer, showing an absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bl, a platelet count of 79000/\u2248\u00ed\u00ac\u222bl, a hemoglobin level of 90 g/l, and a life expectancy beyond 8 months would qualify for participation in both the primary clinical trial and the secondary clinical trial."
    },
    "2fb3af20-adda-4fee-860a-ce376d3a0bb2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24"
    },
    "c5534047-9025-410f-a641-43819cc1ce23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "substance dispersity is a measure of the heterogeneity of sizes, shapes or masses of molecules or particles. There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial."
    },
    "9eb03f1d-28b2-427e-bbf2-917fcf5ccf74": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "not a single one of the participants in group 1 of the primary trial were found to have lesions, and exactly 15% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "81bf5edb-cf30-4e9e-b816-394fa5b16354": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. rectal rhabdomyosarcoma is a malignant mesenchymal tumor with skeletal muscle differentiation affecting the rectum."
    },
    "168c59cb-7be6-4f14-acd9-5d731b8464c8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "the interventions of the primary clinical trial and the secondary clinical trial do not incorporate x-rays, transendocardial injections, ct scans, or mris."
    },
    "1a8cfb13-ebf0-48c4-a452-e26ac7a14863": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions. greater than 50 percent area of interest on radiograph is a radiographic finding indicating the area of interest is greater than 50 percent."
    },
    "64839cde-9ad9-4363-9d78-7a2621bc7ec4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "for the initial 21 days of the primary clinical trial, all patients in cohort 2 were given capecitabine orally every day"
    },
    "9c74310c-3096-4eaf-bed2-aec926b5c850": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96% participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 67% from the nacl 0.9% 3ml group"
    },
    "5cd571da-1a17-4513-b0b8-7ef1ced9a52f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "alt-801 is administered at higher doses in the primary clinical trial as opposed to the secondary clinical trial"
    },
    "97d2c16b-fa4d-4b91-a69f-6692c681f6cd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "sunitinib was given orally to all participants in the primary clinical trial every day for the duration of the study."
    },
    "4816c2e1-ae3b-4a0a-89b8-27a5cee580d7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "pancreatic duct is a duct joining the pancreas to the common bile duct to supply pancreatic juices. the secondary trial and the primary trial report results using the same Unit of Measure."
    },
    "aef90851-f30f-4d13-b6d6-8f52afaaa302": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. container is an object that can be used to hold things."
    },
    "de23d1f1-23e0-4f92-bdfd-b2bf37f08250": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 in the primary clinical trial receives 0.035 mg less of alt-801 than what is administered to cohort 2"
    },
    "ca22d431-ad09-4f5b-8b27-751c76e704c8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy. aortic arch branch is an artery originating from the aortic arch."
    },
    "2fb19f2c-7bda-446c-bf0c-8e9842e89c97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the intervention in the primary clinical trial is administered topically, as opposed to the secondary clinical trial where it is strictly given intravenously"
    },
    "dd5c2791-351d-472f-8c50-a773aa9baa41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin. atrioventricular bundle is a bundle of specialized heart muscle fibers that conducts impulses from the atrioventricular node to the ventricles."
    },
    "9d9fc91e-b6a2-4ab8-bb28-a0a182574d90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study."
    },
    "9228fe22-ca97-4ca9-ad78-f8dba1ac27b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial"
    },
    "7ad6c209-8893-4a2d-963d-24666ef93a80": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2."
    },
    "894b1c21-f4ab-4145-ac19-9f973184b5bd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary clinical trial and the primary clinical trial use the same metric for quantifying their results, regardless of the outcome evaluated."
    },
    "ff8f336a-0b3a-453d-a396-7624218280aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the primary clinical trial's intervention section outlines a specific treatment cycle and includes a comprehensive description of the treatment."
    },
    "1fe68175-6ac4-4439-818f-94758e6bd306": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions."
    },
    "d35e9b96-20fc-4778-a7db-e87c861c4938": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study"
    },
    "5578e4a3-95d9-4803-8d13-b9c0276f92e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency"
    },
    "da8b6738-7194-4d9d-a077-a4aec72945bb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 of the primary clinical trial received a lower dose of cetuximab than cohort 2 and had no addition of collaborative care intervention."
    },
    "25428be5-61e7-46d0-b713-8e831229abeb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "candidates for the secondary clinical trial are required to satisfy performance status conditions, a requirement that is not necessary for the primary clinical trial"
    },
    "6c2256ce-7c39-4ece-bdf4-fcd05744f234": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "encounter due to other specified problems related to upbringing is an icd encounter due to other specified problems related to upbringing. Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial."
    },
    "a2ac2860-6f2d-4459-9c8e-748dddcc35e7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "patients with a history of breast cancer, confirmed her2+, considering breast-conserving surgery, are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "82e2e80d-2a88-4d12-82a9-4d77d1bf0bb6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "have normal appetite and enjoy good food is a response indicating that an individual has or had a normal appetite and enjoyed good food. several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes."
    },
    "ef1d6dfa-2cd0-4e19-99b7-a813d6952706": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent."
    },
    "4a383701-3a27-4973-8c8c-4f697bde7484": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "in the primary clinical trial, patients are treated with irinotecan and etoposide. however, the drug intervention for the secondary clinical trial is not mentioned."
    },
    "5a1bdf90-fb17-47d2-8577-62fafbea13e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "individuals diagnosed with colon cancer who have also failed to respond to earlier hormonal treatments are suitable for participation in the primary clinical trial."
    },
    "7c093c8a-8233-4dbb-87ba-03a1a049a7e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "despite receiving equal doses of radiation therapy in the primary clinical trial, the treatment for cohort one spans an additional two weeks compared to cohort two."
    },
    "cefecae9-606f-4be6-94c0-f9d3732968ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "eligibility for both primary and secondary clinical trials is established for women who are newly diagnosed with locally advanced breast cancer that is er+, and are deliberating a mastectomy"
    },
    "88d91a58-834e-4e7b-8b8d-f9ef0d075dab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children and adolescents can participate in the primary clinical trial as there is no height restriction, but they are expressly prohibited from the secondary clinical trial"
    },
    "7d922494-f6d6-4ade-9614-7111562617f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "alcohol consumers are not permitted to participate in the primary clinical trial; however, should their consumption not exceed five drinks daily, they might be considered for the secondary clinical trial."
    },
    "08fb602d-3227-4329-98c8-7dc2a6135f5b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 1/4 of the primary trial patients."
    },
    "a6f84772-606c-4977-87e2-aa4de18ac07a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates capable of only limited selfcare; confined to bed or chair more than 1/2 of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "39346303-4095-4b67-b384-6916ed20fd4c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "the adverse events in both the primary and secondary trial can be compared as the data has been recorded in meticulous detail for the primary trial."
    },
    "29fce0a9-c8ac-4851-afbf-a0fbd8357eb9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after 12 months of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 150% reduction in the percentage of cells with ki67 expression"
    },
    "aeb95807-2d6b-4915-b52c-0d0fdc82728e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 in the secondary clinical trial had a significantly greater number of patients compared to cohort 2 in the primary clinical trial."
    },
    "910d3110-1fa1-4488-a481-085a18d1670a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "both cohort 1 and 2 of the primary clinical trial undergo the same intensity of radiation therapy, although the intervention time for the first cohort is extended by two weeks."
    },
    "97632c52-4213-4973-8655-9ea7f3151231": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "on both the primary and secondary clinical trials, syncope emerged as the most common adverse occurrence in the patient groups"
    },
    "bd70ab1b-2bfb-4294-9ca7-01e1e2b670b7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial or the secondary trial. insufficient rna yield is an indication that an rna isolation procedure yielded an insufficient amount of rna to proceed."
    },
    "71e83f04-ecd5-4d79-8062-42bcb68d6f29": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "nearly all patients in both the primary and secondary clinical trials, specifically over 97%, did not report any negative outcomes"
    },
    "93850158-9371-4320-aefc-c31e15a5d983": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. milliliter per minute per milligram per meter squared per day is a unit of concentration equal to milliliter per minute divided by milligram per meter squared per day."
    },
    "06e6eb2b-8300-413b-9c70-51fadbc68bbc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "None of the individual adverse event types recorded in the primary trial affected more than one patient. 14q23.1 is a chromosome band present on 14q"
    },
    "1c13e304-89af-4ef5-95c6-cabc803d81b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "indeterminate extranodal tumor extension is a response that the extranodal tumor extension is undetermined. Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer."
    },
    "884bc204-4928-430b-b44d-1e33ef66731d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "in the primary clinical trial, a patient post organ transplant within the span of a month would not be considered, although they could potentially be fit for the secondary clinical trial"
    },
    "aa176a26-7dd6-473f-9c35-40a0754336f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive several injections. feel fatigue is a question about whether an individual feels or felt fatigued."
    },
    "fa2d8a93-4cae-4ee5-afdf-1afd04d07c93": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "over 20% of the patients that participated in the primary clinical trial experienced all types of adverse events (aes)"
    },
    "4ff85794-0b6a-4fe7-824f-afa6c2fa133e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "7p15-p14.2 is a chromosome band present on 7p Coronary artery stenosis are the most common AE recorded in the primary trial."
    },
    "82aff6ce-3305-4fb1-87c0-28f4a1e8a981": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "both breast cancer and ovarian/ peritoneal cancer patients involved in the primary clinical trial are administered 1000 mcg/day of talazoparib."
    },
    "5e93b7d7-89d9-47cd-98b4-5897823889fa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine."
    },
    "15ac7da3-01f5-4c67-a59a-d41619758b62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "the primary clinical trial does not apply any constraints on the liver function of its participants"
    },
    "358cd111-420a-401d-bd92-e459d3725026": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients who are severely obese or pregnant may be considered for the primary clinical trial and the secondary clinical trial."
    },
    "4e410d4c-7da8-46ce-b335-678bb3199fbc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "only individuals who possess permanent infertility are able to join in the primary clinical trial."
    },
    "48ca56cf-908a-436f-8ec5-90fb965ea630": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "nepafenac is a topical nonsteroidal anti-inflammatory drug that is used in eye drops for the treatment of eye pain and swelling. cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine."
    },
    "203914a5-0e0b-4e11-a138-6793a23218c8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "in the second group of the primary clinical trial, there were no recorded deaths or hospital stays"
    },
    "dfea11ab-1a3f-4a76-9fae-96d486f76e10": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial"
    },
    "dad4efbe-c7ae-4507-8a04-853a132b497a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "while the primary trial's treatment is taken orally, the treatment in the secondary trial is dispensed exclusively through intravenous means, such as a needle or tube"
    },
    "9f402778-d71e-4f5b-9653-eed11679ecc9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "every individual in the primary clinical trial receives a uniform intervention, without the consideration of their cancer condition."
    },
    "9fb13507-1f88-4b95-8ff6-a56af67ca8c4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "different inclusion and exclusion criteria are used for the two stages of the primary clinical trial. however, the secondary clinical trial uses separate criteria for patients, depending on their health status or cancer diagnosis."
    },
    "99b57587-ea7a-496f-a7f9-9b2a7837ccc7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial does not provide reports on the changes in pain intensity while the secondary trial studies the impact on levels of vitamin d, not the bone mineral density (bmd) of the lumbar spine."
    },
    "cf9ea9d0-49c4-4c00-a91b-142cd7ec8433": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "both interventions in the primary clinical trial employ laser-assisted fluorescence angiography."
    },
    "907ae179-9823-4dba-9fb7-bb00027dbdf1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "the majority of candidates involved in the primary clinical trial did not experience any eating disorders during the course of the study"
    },
    "1fa2d084-6a29-44c1-9e0f-53eb6d932247": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "ann arbor b symptoms indicator is an indication of whether a record includes b-symptom data based on the ann arbor lymphoma classification system guidelines. less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products."
    },
    "9ab1125f-0d0b-4480-b5c2-8a09378a8df4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "the only disparity in the primary clinical trial's interventions 1 and 2 is the dose of durva; with cohort 1 receiving 0.7mg less in their monthly injections compared to cohort 2."
    },
    "1f10dd13-d27c-4ff0-bcac-67f0da0ac487": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses the same inclusion and exclusion criteria for each of its phases, while the secondary trial does not distinguish between criteria for healthy and cancer patients."
    },
    "eabae980-d833-47b7-8f0e-82242e662880": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. sibling is a person's brother or sister."
    },
    "bed73866-02e7-49d2-a66a-215e0a0d1b83": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "Across both the primary trial and the secondary trial only one death was recorded in the adverse events. adverse event attributed to disease is an indication that an adverse event is causally related to the natural history of disease."
    },
    "f319d5bf-32fd-4505-aff1-02caa718676a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes were not recorded for the primary trial or the secondary trial. sequencing data file is an electronic file containing nucleic acid sequencing data."
    },
    "f8dbd18d-2b55-4f0f-92a7-db3b1ecc3b6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts."
    },
    "4dca77c0-d73d-4205-9d8e-8c2e897049d5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. microgram per kilogram per day is a dose calculation unit expressed in microgram(s) per kilogram per period of time equal to twenty-four hours."
    },
    "36c3d1c3-d4dc-49bf-97a8-49608799cc35": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "satisfied with treatment effects is a question about whether an individual is or was satisfied with the effects of their treatment so far. Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both."
    },
    "8948d41b-0742-43f8-a34f-2e1cfcaba149": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 2520 more hours than the intervention detailed in the primary trial."
    },
    "b8f0039d-f476-4aa1-a522-751d93e45147": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "results are available for the cohort on lbh589 and lapatinib in the primary clinical trial."
    },
    "f2beb95f-ac83-48f1-936b-70d45d51880c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the placebo and trabectedin intervention in the primary trial are both administered through a 8-hour intravenous infusion on a bi-weekly basis."
    },
    "fc9a9de5-319a-465e-82ce-3c95b9a42728": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "the primary clinical trial had zero infection cases, whilst the secondary clinical trial also reported an absence of infection"
    },
    "270f0f03-2316-40b0-8e7a-e42c499258da": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "canine subject unique identifier is a unique identifier for a canine clinical subject. The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial."
    },
    "fd0b6abb-37f4-4b91-9b9f-433cbced84a7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "the first and second cohorts in the primary clinical trial are administered the same amount of cudc-101, but cohort 1 receives the treatment more often."
    },
    "f3918549-5e15-44e3-b35b-f7f361845792": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "in the primary clinical trial, all observed adverse events were attributed to members of both cohorts, not exclusively those in cohort 1"
    },
    "723d5448-24c6-4679-98c1-3c67bb12fea4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "agree with prior crf is a question as to whether the user agrees with the previous case report form. candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial."
    },
    "bffa5810-1ace-45e0-bf6d-6a3d35d6d4d7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "x-rays, transendocardial injections, ct scans, and mris are excluded from the interventions in both the primary and secondary clinical trials."
    },
    "28efc57b-6732-4778-84e9-81d1cea1a43e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "aggravated malignant neoplasm is a malignant neoplasm that shows clinical and/or pathologic progression. Only 2 patients in the primary trial did not have Recurrence-free Survival."
    },
    "f8630eaf-1381-4ba1-ba97-68b86755e0fd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has distinct inclusion criterion for potential participants below 18, and another for those above, while the primary trial follows a single eligibility benchmark."
    },
    "42a68b8b-0bed-49f4-8430-12e031c56471": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "several participants in the primary clinical trial, who possess normal levels of vitamin d, showed a distinguishable pattern in the expression of the evaluated 40 genes."
    },
    "f43f3230-46be-4ed7-a1d7-3e6d73f4fa9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 and cohort 2 of the primary clinical trial were administered the same dosage of both cetuximab and 8mg/kg mm-121."
    },
    "b1f92a23-fa4b-4cf6-9df1-b38794ab00ba": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "speaker device is a device designed to convert electrical signals to sounds that can be heard. Patients with measurable bilateral breast cancer are eligible for the primary trial."
    },
    "5abe01fb-1ee1-4905-874e-a0cbec0ee9c9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients diagnosed with malignant ductal carcinoma in situ can participate in the secondary clinical trial but are not eligible for the primary clinical trial."
    },
    "58c00532-2a20-4940-995f-08223d2736d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "a high prevalence of pancytopenia was observed in the patient cohorts of the primary clinical trial and the secondary trial."
    },
    "d6381c6b-a7d6-406a-9d52-a660c27c2d49": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the primary trial and the secondary trial do not have any recorded adverse events for their participants. crypt is a pitlike depression or tubular recess."
    },
    "057e665a-1e29-4e11-866e-16483eeb0420": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "yellow fever virus is a positive sense single-stranded rna virus of the flavivirus family that is the causative agent of yellow fever. Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial."
    },
    "a7efab48-443a-4728-a4b5-0c837052aab7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "perjeta, while utilized in the primary trial, is not a part of the secondary trial's treatment protocol."
    },
    "12279abc-fae3-49d8-ac68-95ed47f4de12": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "the serious adverse reactions were reported more frequently in the adverse events section of the primary clinical trial compared to the secondary clinical trial."
    },
    "911ba31e-f28f-4c5b-8b0e-fa16e58ecc29": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial. extent breast cancer treatment disrupted self-care is a question about to what extent an individual's breast cancer treatment has disrupted their self-care."
    },
    "325c6150-352f-4b08-aa67-fed4cd6f68d0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial. mature neutrophils present is an indication that mature neutrophils were detected in a sample."
    },
    "a793df3f-fa04-4d48-a2c6-006589d52e84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients"
    },
    "dbe6803f-8c85-45d2-a9b8-1bbd0e772733": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "intervention 1 of the primary clinical trial uses more substantial amounts of tc99m sulfur colloid than intervention 2."
    },
    "23cb11b4-6a85-4a6f-9e72-920eff085459": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the longest pfs in the primary trial survived 0.5 months without disease progression or death "
    },
    "cfcd5908-e439-4d01-bd0a-0fcaf3730db8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "in the primary clinical trial, participants are given only oral medication and don't undergo any surgical process, whereas in the secondary clinical trial, participants are subjected to a vast range of nine medications along with extensive surgical procedures'"
    },
    "f22453a4-5cb5-4180-8af7-a9f701d766d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "cohort 1 of the primary clinical trial has no records of cardiac related adverse events"
    },
    "916340c0-cd97-4e2e-bd31-ded7bd2d1a56": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "most patients involved in the primary clinical trial showed progression of disease by the end of week 24."
    },
    "55fed266-9982-4062-b7fa-5ec9279441e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "every candidate for the primary clinical trial must have been diagnosed with a her2 positive tumor, verified through positive fish or ihc 3+ tests."
    },
    "dec08a3f-8124-4d8a-b5cf-00231c2b5cec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "candidates for the primary clinical trial can have a her2 negative tumor result according to fish or ihc 3+ test"
    },
    "0f77fc34-7285-4374-879d-b96166cfc29e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "participants in the primary clinical trial have to undergo radiation therapy without any intake of vorinostat capsules"
    },
    "cda1ac5f-5721-4329-bf63-a73ca7247da5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 20 year old patient with histologically verified diagnosis of stage 5 breast cancer, absolute neutrophil count of 800/\u2248\u00ed\u00ac\u222bl, platelet count of 50000/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 70 g/l, and a life expectancy exceeding 16 months would be eligible for both the primary trial and the secondary trial."
    },
    "0cab14c5-398c-4e4e-9c6a-65fb70aecb23": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "crs-r clinical classification question is a question associated with the crs-r clinical classification. the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention."
    },
    "0f6ce079-990e-446e-95e9-8c4644291924": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "having a mammography is a mandatory requirement for prospective candidates for the primary clinical trial, unlike in the secondary clinical trial."
    },
    "47bcd1c5-f95d-4e21-a999-4bd220c5b940": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy"
    },
    "21ae5802-04f7-4f06-86d6-9ee8ee9cdd84": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. ringing or other noises did not wake me from sleep is a response indicating that ringing or other noises did not wake an individual from sleep."
    },
    "1108856e-d4cc-488e-a0d8-98274fc38dfd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "both primary and secondary trials do not use lenalidomide or lapatinib in any interventions, and there is no mention of the specific duration for any trials."
    },
    "38b5ee2a-8baf-427a-944d-a93a1a450104": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "more instances of anemia, pneumonia, and stupor were reported in the secondary trial than in the primary trial, while the primary trial had more recorded febrile infections."
    },
    "8b2b5b8e-3723-4261-8fd5-a624c9367ef2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "gastric dysplasia is a morphologic finding indicating the presence of dysplastic changes within the gastric mucosal epithelial cells. The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group."
    },
    "21d37b8b-4326-40bd-a070-5ad0fbb48e6d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial. sf6d version 2.0 acute questionnaire question is a question associated with the sf6d version 2.0 acute questionnaire."
    },
    "c3609a19-01f6-4add-a0af-7d92263d822c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "egfr nm 005228.3:c.2313 2314insaac is an insertion of 3 nucleotides, aac, between position 2313 and 2314 of the coding sequence of the egfr gene. The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group."
    },
    "06024cb1-ce64-432e-b1d9-f3df2f95b025": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "in the primary clinical trial, both cohort a and b receive the same three electroporation injections of ld v934"
    },
    "e200f18a-ae9e-490f-a348-537187a65300": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "the primary trial recorded a higher incidence of palpitations, pericardial effusions, and abdominal pains than the secondary trial."
    },
    "94ebad4c-4b9c-4fb7-b7cc-a088b46b56f7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 0.02g of mcs110 every 3 weeks."
    },
    "ca7d916d-c8d4-4e6b-8b92-3d08bbdf7915": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "ce mark is a label which indicates that a product conforms with the essential requirements of the applicable european community directives. There were more participants in the primary trial than in the secondary trial."
    },
    "6fbc7c06-1134-42b6-bfbc-9e4f28727cba": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 0.03 g group of the primary trial had a -0.064 recurrence-free survival compared to the nacl 0.9% 3ml group"
    },
    "ef4f8fe9-1d8e-464f-aa42-c33c073bb493": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there was one psychiatric adverse event in the primary trial, which affected less than 1% of patients"
    },
    "1d66b8cc-1e7e-4a88-bd39-695528aa5894": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients suffering from mild insomnia are eligible to participate in the primary clinical trial and the secondary clinical trial"
    },
    "56bdbd86-0233-4eb9-bc63-0199e196966b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 0.87% of the primary trial participants had a reduction in circulating tumor cells following weeks of high-dose chemotherapy with purged autologous stem cell products"
    },
    "603ee9e3-5213-4121-97d8-4369641e9b00": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "17p12-p11.2 is a chromosome band present on 17p The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group."
    },
    "bec4d231-ea9b-4713-b2a1-c7ddb2dc5b0f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "both the primary clinical trial and the secondary clinical trial recorded thromboembolic events in the participating patients."
    },
    "b685be77-9c55-4948-99cc-2a249739a233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial."
    },
    "6558ae62-b251-483d-9082-67a614d76e60": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "one experimental group and one placebo group were designed for the primary clinical trial, whereas the secondary clinical trial employed one test group and one control group."
    },
    "695ba633-5bf3-48ee-b6f9-f77657f827b7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates who are significantly limited in their self-care ability; spending more than half of their waking hours in a bed or chair, may participate in both the primary clinical trial and the secondary clinical trial."
    },
    "4bda5405-4218-460a-a8b4-c958dddedfa1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "while there were no recorded adverse events among the patients in the primary clinical trial, every participant in the secondary clinical trial experienced at least one adverse event."
    },
    "2b0a4d9c-e65c-44d2-bdf6-60877e5d1b41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "being diagnosed with alzheimer's disease does not prevent a patient from taking part in the primary clinical trial"
    },
    "03ee1d82-5208-4511-9163-23adfbc55fa4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "women with a new diagnosis of stage iv, er+ breast cancer who are contemplating undergoing mastectomy are suitable for both the primary clinical trial and the secondary clinical trial."
    },
    "6f4c1d2f-4b97-4f77-b25b-004addb58726": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "use of gabapentin or herceptin within the last six months, doesn't affect the eligibility for the secondary trial, but considers the exclusion from the primary trial."
    },
    "d68944ff-4237-41b8-9ba1-bdfd9899ba32": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "three cases of shingles were reported across the patient cohorts involved in both the primary and secondary clinical trials."
    },
    "77989b91-bbcc-401e-8cd9-bdd17c0d0e3a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "while the secondary clinical trial considers muscle augmentation as a measure of the efficacy of physical therapy, the primary clinical trial investigates the effects of sulforaphane supplements on the amount of isothiocyanates in urine."
    },
    "fb3c3307-16bd-4454-b8ee-6427743bc1ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 180 days if they want to participate in the primary trial"
    },
    "2db0df9c-be54-419d-9710-54adb741a1a1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "patients who have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy within one month prior to the study initiation are not eligible for the primary clinical trial."
    },
    "666c3ebb-3f79-4795-b5e7-4584815f498d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial showcases alterations in the severity of pain, while the secondary clinical trial assesses the variation in lumbar spine's bone mineral density (bmd) from its initial state to the ninth month"
    },
    "039ef0fd-7ea1-4820-b08f-99cf35009bc3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "patients receiving warfarin-founded treatments are barred from the primary clinical trial, yet they may still be suitable for the secondary clinical trial."
    },
    "00c165f5-4c14-4aab-a4a8-9b8010bd5858": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "the primary clinical trial does not consider gender in determining eligibility, however, only females can participate in the secondary clinical trial."
    },
    "56358f96-8cad-40a1-a59f-4746ebde10d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "detailed participant information for each cohort is provided by the primary clinical trial."
    },
    "0d414333-1c03-4a79-91d7-1a34323e7e59": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "the use of arimidex is not present in the primary trial cohorts but is a crucial part of the secondary trial."
    },
    "db5cde14-102d-432e-981d-8b88ae65a830": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "the patient cohorts of the primary clinical trial and the secondary clinical trial have reported 7 cases of asthenia and 2 cases of pyrexia"
    },
    "50e74c9b-3673-4222-99f0-63f82e40b288": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same number of Aes were reported for both cohorts in the primary trial. mediastinal malignant germ cell tumor stage is a mediastinal malignant germ cell tumor stage defined according to the pediatric study group classification criteria."
    },
    "fdce4005-3773-4350-b45b-1c1338e01a26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "biliary colic and diarrhoea cases are relatively equal across the primary and secondary clinical trials."
    },
    "3e96ec18-39ff-46f9-9c67-0b6e70003e24": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "mapk pathway alteration positive is a genetic finding indicating the presence of gene abnormalities resulting in alteration of signaling in the mapk pathway. Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs."
    },
    "846578ce-00a5-487a-80d0-c5922f2c0c20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after 2 weeks of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 30% reduction in the percentage of cells with ki67 expression"
    },
    "57bca704-dcff-4526-b677-bb1c1b1a7945": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the primary clinical trial reports its results in milligrams, while the secondary clinical trial utilizes liters."
    },
    "93bb8a0e-e84c-4730-b559-22d912103993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1."
    },
    "c136fce2-0e64-4f51-8483-be0fde4382ef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "all adverse events reported in the primary clinical trial were different for each patient."
    },
    "74308ad0-4b9d-4632-9580-5e280dedbc77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer."
    },
    "6f5741c8-88c1-46ef-856c-dae9a3fe5fd6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "the more than half of participants in the primary clinical trial who were treated with 1000 mg of lapatinib in combination with nab-paclitaxel exhibited either a verified complete response or a validated partial response."
    },
    "2f606d1d-7dd5-4d18-8ae6-7899efe85487": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the secondary clinical trial accepts females who are living with ibs and claustrophobia."
    },
    "48b25d6c-3b89-425b-960e-9d55471a5f37": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "0.492 more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "b6af5ca8-21c0-43c5-898b-53e45b5e122a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must not undergo any form of imaging test before they are eligible for the primary trial, but they must have a mammography to qualify for the secondary trial."
    },
    "647016e6-71d4-4169-801d-e58e9b20171f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 4 more adverse events recorded than the secondary trial. cdisc send laboratory animal species terminology is a terminology set that includes concepts relevant to cdisc send laboratory animal species."
    },
    "d050c306-4563-403d-96c4-26728b8dc0df": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "in comparison to the primary trial, the secondary trial carries out an intervention that is extended by three times."
    },
    "13f17e45-4ce5-4de3-8a67-eee3ca98c4eb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "in the primary clinical trial, cohort 1 uses paclitaxel for its intervention while fulvestrant is the method of treatment for cohort 2"
    },
    "4b7eaa17-f5eb-4afe-88b7-98c293ad0100": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "the primary clinical trial concluded with zero incidents of gastro-intestinal adverse events"
    },
    "dd5fcab9-ef7e-4f25-8040-81c0dd57aab5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "the first subgroup in the primary clinical trial reported various cases of anaemia and febrile neutropenia but registered no instances of pancytopenia."
    },
    "5a77ba85-1a9e-4639-ba29-86b0cdea296b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women suffering from both claustrophobia and osteoporosis are eligible for the primary and secondary clinical trials."
    },
    "3b29fe26-bf01-4e85-aa0e-33e83b1db660": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "the occurrence of a pulmonary embolism in the past three years deems a patient ineligible for the primary clinical trial, but the said patient could potentially partake in the secondary clinical trial, subject to the investigators' evaluation."
    },
    "18c09a69-f72b-42db-b15b-45e369db34e5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "patients with 4-5 cerebral metastases in the cerebral cortex will be eligible for the secondary trial. however, those with this diagnosis will not qualify for the primary trial."
    },
    "2e2e15a3-327e-4c79-9ad2-f7978f4f7cdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group. cutter device is a device designed to slice or sever a material."
    },
    "c2d6b8ba-8238-49b7-b9a1-de2ffdabe324": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria"
    },
    "a12ed2c0-b402-445b-b21b-7497389b39ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "erbb2 nm 004448.4:c.2264 2278del is a deletion of 15 nucleotides (tgagggaaaacaca) from the coding sequence of the erbb2 gene from position 2264 through 2278. Patients with histologically documented metastatic SCBC are excluded from the primary trial."
    },
    "b45a503d-d4db-4f8d-aefa-37cf2bbc6011": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "among the participants of the primary clinical trial, maculo-papular rash was often reported as an adverse event."
    },
    "a1043895-ce9b-4370-94c8-6ce3078e3bbb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "all negative occurrences experienced during the primary clinical trial concerned the musculoskeletal system, a situation not seen in the secondary clinical trial."
    },
    "dbcb7763-d671-465e-8704-4bd5cd5ec7ef": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "there were multiple adverse events recorded in the primary trial and the secondary trial"
    },
    "91b35ed1-37f4-440a-a82d-99c639ad7e2a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "the primary clinical trial had twice as many participants with cholelithiasis than the secondary clinical trial."
    },
    "18ff2056-f906-4f16-805f-76b4a51b77b7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "childhood ovarian embryonal carcinoma is an embryonal carcinoma that arises from the ovary and occurs in children. the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day."
    },
    "4c42491a-5ff2-41f8-bb40-6c7fe4dd5c99": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "the only types of adverse events (aes) observed in patients from the secondary clinical trial were severe nausea and chronic fatigue, numerous aes were documented in the primary clinical trial"
    },
    "0cc7e297-b7df-4260-9ddf-f406bb3c2485": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events. arrhythmogenic syncope is a condition in which syncope occurs due to an arrhythmia. (acc/aha)"
    },
    "06b2ed93-63bb-4ef0-964c-372ff9077cb4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report the severity of delayed nausea on a range of 1 to 7, and the secondary trial measures the change from baseline to 0.75 years in bone mineral density (bmd) of the lumbar spine"
    },
    "f0a41373-f03b-471f-9f0f-381f8b09a950": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "axl overexpression positive is an indication that overexpression of axl has been detected in a sample. The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients."
    },
    "e8e2db51-2ec2-4e88-9096-cbe5d5933286": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary and secondary clinical trials use the same key outcome measurement: the ratio of patients who exhibit no signs of invasive tumor remaining in the breast after undergoing surgery following the completion of chemotherapy, referred to as pcr within the breast."
    },
    "f205a6e1-26d3-4a63-bea1-126428af787b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "the primary clinical trial had a higher prevalence of recurring malignancies, graft-versus-host disease, anaemia, cardiac failure, and diffuse alveolar hemorrhage in its adverse events compared to the secondary clinical trial."
    },
    "18b0cc37-3189-4ea0-970e-81a6b79dba7f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "in group 1 of the primary clinical trial, 100% of subjects experienced an adverse event that threatened their life at least once."
    },
    "1cbd0ac2-bfb8-4649-afea-ae028707f190": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "lymphedema conditions of patients in the primary clinical trial worsened compared to those of patients on the waiting list despite receiving acupuncture treatment."
    },
    "73876da9-0c79-43eb-9d1f-b7f2d729f43c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 2 test groups."
    },
    "05990a1c-be55-4aa4-8e72-970d95776c8a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "near the conclusion of a one-month period of tak-228 plus tamoxifen treatment, the percentage of cells with ki67 expression in patients participating in the primary clinical trial was found to have remained the same."
    },
    "cbc96b9d-b39c-4fbe-b8a7-e7df7490881b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases"
    },
    "42746679-44a5-4854-ba22-6557c0c34ff8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections. cassette dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a cassette."
    },
    "19ae1506-7a41-406e-8f43-8c32df24392b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 1x10^-3 grams in the primary trial gained lean body mass over a 17 week period"
    },
    "6579100b-45dc-4669-86ec-a3f8ac521c23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were 5 adverse events which occurred in more than 25% of participants."
    },
    "176789e8-d2f5-4bb5-b748-ef0ed5c52478": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial accepts patients with severe insomnia"
    },
    "9b0c9133-a13c-4687-bf43-546312ce1a2f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "patients without any type of cancer may participate in the primary clinical trial."
    },
    "e56bca0a-a541-4a59-ba79-0f17cd0cdcb6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women in the age bracket of 18-19 years can join the secondary clinical trial, but their eligibility for the primary clinical trial will come after a waiting period of 1-2 years"
    },
    "3dc3b5d7-3bad-4494-9e97-e6f27bf52c07": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses. node is any bulge or swelling of an anatomical structure or part."
    },
    "cee38f66-699d-4c68-85ec-8ed0ba55fd9d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the treatment plan in the primary clinical trial includes administration of one drug, zd1839. in contrast, the secondary clinical trial's treatment approach involves the expectation of at least three simultaneous drugs, such as zoledronic acid, samarium-153 and pegfilgrastim."
    },
    "27abad83-36b9-47a4-8d11-d08751d1d81a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "several of the patients in the primary trial experienced the no pain whatsoever during the 5 years of the study."
    },
    "41e9e8e9-6fec-49fa-ae36-7daa737de66c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 4 milligrams of denosumab injected subcutaneously every day, the secondary trial does not require injection, instead using lymphoscintigraphy."
    },
    "786bc355-6b8f-455c-b6b2-470350231601": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "comprehensive records of adverse events are available for the primary trial, enabling a thorough comparison with the secondary trial's data."
    },
    "d1123c9b-e0d4-412d-bcf6-a69bbb07a0f4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "throughout the primary clinical trial, an instance of dose-limiting toxicity was identified in two different patients, each from separate cohorts."
    },
    "e7451698-de0f-49c5-b287-a419652d62e0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "in the primary clinical trial, 13% of the participants, specifically those with pr+ primary breast cancer who were treated with her2-targeted pet/ct. 89zr-trastuzumab, developed her2+ metastases"
    },
    "3dab8f67-6eca-4ace-ba49-0bd33547b004": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "while most patients in the first cohort of the primary clinical trial endured adversities, the same cannot be said for the second cohort."
    },
    "cc411bc6-900e-4ef3-96ef-09f6e5565a18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial"
    },
    "25551d37-108d-497a-8e75-825d8d707190": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable bilateral breast cancer are eligible for the primary trial"
    },
    "eac5a5f1-7e63-4351-b7de-eacf6592a5fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "breast cancer patients in the primary trial are administered 3000 mcg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 10 mcg/day talazoparib instead."
    },
    "2ad5cf58-daab-4432-8670-8964380a4fa9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "120 milligrams of denosumab needs to be injected subcutaneously every month for patients in the primary clinical trial, whereas lymphoscintigraphy is utilized in the secondary clinical trial rather than injections."
    },
    "93eef0e8-7a40-452a-a61e-a9d671dcacbd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial"
    },
    "679f8ab4-38a4-4c6c-b85f-800e645e5bb8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group. undetermined rhythm by ecg finding is an electrocardiographic finding of a cardiac rhythm whose mechanism cannot be determined from the ecg. (cdisc)"
    },
    "eae19a7f-ca02-482d-942f-223d74881c40": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "secondary clinical trial is not open to participants that have experienced pulmonary embolisms, and the primary clinical trial is not available for individuals who have breast implants."
    },
    "4eacff65-65e6-4bf9-bc94-419c48e854e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "adverse events experienced by patients in the primary clinical trial do not match those in the secondary clinical trial."
    },
    "fa586070-5821-4a70-9812-9d7c6e5df330": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "5 patients in the primary trial suffered 3 or more adverse events"
    },
    "ec5c26e8-0afd-4244-8731-588c4f88e84b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "cohort 1 of the primary clinical trial has multiple records of cardiac-related adverse events."
    },
    "1a076a19-c76d-4de0-b7de-473c0e278bbe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "dyspnea was frequently recorded as an adverse event in both cohorts of the primary clinical trial."
    },
    "94ee2ae4-cf85-4dfb-90be-2490ad4089ab": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "electrolyte disorder is a metabolic disorder that is characterized by electrolyte imbalances (e.g., hyperkalemia, hypokalemia, and hypercalcemia). the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein."
    },
    "1cbc4e95-3407-4aab-bb7d-ba3abd1882f3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24. feel self-conscious about letting partner see my breasts is a question about how often an individual feels self-conscious about letting their breasts be seen by their partner."
    },
    "6e50b114-9a16-4710-8d95-91401b387221": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial has age limitations for patients, however, the primary clinical trial lacks a specific age range for participation."
    },
    "eec36c42-c1fb-45c8-9db9-82f10f4f7af7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 1 year in bone mineral density (bmd) of the lumbar spine"
    },
    "e7203466-5ee1-4733-ac54-730489e348b2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "the placebo intervention of the primary clinical trial is administered orally in a smaller dose than the allo-mscs intervention."
    },
    "5bf68801-c079-469b-a0a9-2a3d6fb379ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients with a proven histological or cytological diagnosis of resectable non-small cell lung breast cancer or small cell lung cancer qualify for the primary clinical trial"
    },
    "72c54a84-aa51-4250-ba38-3646a07391b9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "tumour lysis syndrome was a condition suffered by multiple patients participating in the primary clinical trial as well as the secondary clinical trial."
    },
    "2a95f6b8-fbdd-47e6-949f-8aee18a2c605": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "Any japanese national can take part in the primary trial, or the secondary trial."
    },
    "04191593-f36e-4fc0-8af5-7591059640a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "primary clinical trial's first cohort had numerous pancytopenia occurrences with no recorded instances of anaemia and febrile neutropenia."
    },
    "6548c59c-cafc-465f-8f10-4bfc5d147611": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial. people were unfriendly is a question about whether an individual feels or felt people were unfriendly."
    },
    "2ce0822a-fcf8-4010-950c-0d3a8dc2cb00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial."
    },
    "e2a5803b-3991-4eb2-b428-56d91d9bca99": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. entity name person data type is a data type comprised of the name of a person."
    },
    "88b8e438-87f4-418b-903a-efe0f5a83882": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. krd regimen is a chemotherapy regimen consisting of carfilzomib, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma."
    },
    "f1963f67-9164-4e55-bf5e-3ac44e9bae5f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the units of measure employed in the results of the primary clinical trial differ from those used in the secondary clinical trial."
    },
    "83e0c108-bbbe-4b9b-97b6-62ea72e374d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "infections and infestations cases in the primary clinical trial occurred in patients from cohort 2."
    },
    "e115c2a9-a31e-4a26-a96b-cd038666ced0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "the primary clinical trial uses subjective patient-reported outcomes as its unit of measure, whereas the secondary trial employs biomarker data for measuring outcomes."
    },
    "827cb89b-a78f-49e9-b342-d00e7b46e61f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 1.75 x 10^2 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the zoledronic acid 4 x 10^0 mg group."
    },
    "05c44353-ab0d-4b2d-98ff-e39aab551229": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 0.15 kg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "52db54bd-4dbe-4778-b5c4-30a8e4ce0a1f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes. primary medical oncologist is a patient's main medical oncologist. the primary medical oncologist may be responsible for coordinating treatment with other medical oncologists."
    },
    "d269b697-c96f-4317-99c9-e465c7e935a7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the number of participants was identical in both groups of the primary clinical trial."
    },
    "4b529950-5a15-4904-8f87-1aa68f408b8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients with advanced stage of ductal carcinoma not contemplating ai therapy are eligible for the primary clinical trial."
    },
    "14678a23-57ea-4d56-a87a-c1a910af9e78": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the majority of patients in the primary trial experienced complete response by week 42."
    },
    "15b22917-3649-44bd-b7f0-9aa5a6beba6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "radiotherapy patients in the primary clinical trial only receive a dosage below 100 \u00ac\u00a8\u00ac\u00b5g of fentanyl sublingual spray."
    },
    "290508ed-616c-4d7e-b83b-49a2fa895a44": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "blood and bone marrow related issues predominantly accounted for reported adverse events in the primary clinical trial, as opposed to the secondary clinical trial."
    },
    "04c5ba38-d98e-4fd7-b5f4-ea4706f26355": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2. retinal hemangioblastoma is a hemangioblastoma that arises from the retina. it can occur sporadically or as part of von hippel- lindau syndrome."
    },
    "dc4765a3-6168-4594-969b-3ce5ea7dc02a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934"
    },
    "e25dfb6a-efaf-4b80-b2b7-316e10b33fe5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "cell culture image is any image of cells grown or manipulated in a tissue culture. 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients."
    },
    "34c7862b-3725-4ed8-9e67-1513300323a7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "regarding the primary clinical trial, the group receiving paclitaxel plus bevacizumab plus gemcitabine showed a superior orr compared to the group receiving only paclitaxel plus bevacizumab."
    },
    "9a20f7f5-5477-4320-be07-3f2154877863": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor 0.2-0.8 centimeters in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "464e2cd9-6c59-4692-a3fc-083c374f4a5c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include the same dose of Paraplatin"
    },
    "ba84127e-5a18-4ff4-a76b-c19ba3edeeb0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "while the first cohort of the primary clinical trial receives dexamethasone pre-operatively, the second cohort gets it two hours following surgery."
    },
    "7b29df5c-9189-4c72-b0ad-3ed971c42652": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "patients suffering from cancer and having conditions like anemia, epilepsy or thalasemic diseases are welcome to participate in both the primary and secondary clinical trials."
    },
    "4750e9e1-982d-4ca4-ab90-373832ed32d6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "in the primary clinical trial, increased pleural effusion and rapid disease progression is experienced by 25% of the patients."
    },
    "58db966b-cb5c-426f-8b8e-f9e68adc1531": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 in the primary clinical trial receives a dosage of enzalutamide that is twice as high as the dosage received by cohort 1"
    },
    "9367129d-51e0-4d62-b2df-35749e117157": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "primary clinical trial rules out patients with observable tumors in both breasts"
    },
    "3fe01e39-b6e5-465e-b76b-8048169a72bb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "97% of patients in the primary trial did not experience any Adverse Events. tritylcysteine is a derivative of cysteine with antimitotic activity and potential antineoplastic activity. (nci04)"
    },
    "0090fc12-4092-4255-8952-21ebee889ebb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "performed histopathology cell type code is a coded value specifying the kind of cells found. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered."
    },
    "a50ad70a-ff4c-4110-bfff-3fc230c44acc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "primary clinical trial is open to patients diagnosed with ild/dpld over a decade ago, bearing a life expectancy of 2 years"
    },
    "7d22f8db-6793-46e2-88ca-2d464ecf9789": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "in the primary clinical trial, cohorts 1 and 2 patients exhibited no noticeable pattern for the expression of the 40 genes examined"
    },
    "9c0406cd-3585-4cb2-b330-fa9c1426c72c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "every participant in the primary clinical trial was administered oral sunitinib daily throughout the entirety of the research period."
    },
    "dee869cc-6f3c-45a5-9672-d8ab6a545212": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "only 1% of the patients in the primary clinical trial dealing with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab results in her2+ metastases"
    },
    "6668780b-0a4f-4c25-895f-3fb5fc7c604a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "over 5,040 minutes of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 5% reduction in the percentage of cells with ki67 expression"
    },
    "3d073609-1a5e-46fb-b43d-c4505c72029d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "patients with a past diagnosis of pulmonary embolisms are welcomed to participate in the secondary trial, and those with breast implants are not disqualified from the primary trial."
    },
    "14954e3a-d984-46dc-af8d-29f22c0ca85e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "patients with clear-cell adenocarcinoma or gestational trophoblastic disease, determined by flow cytometry, or paget's disease of the nipple are ineligible for both the primary trial and the secondary trial."
    },
    "153e0c8b-e056-4dd9-9337-156752b249c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 200 recorded adverse events. "
    },
    "ce3d0415-1f95-4e20-bea5-5adc05962c9d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "following a month of tak-228 plus tamoxifen administration, the primary clinical trial reported a 20% increase in the percentage of cells displaying ki67 expression."
    },
    "1cc18d8f-93f5-474e-9178-833b26150681": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "Every patient in the primary trial is receives a dose of 100 to 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy. 13q22-q34 is a chromosome band present on 13q"
    },
    "6688e7ec-6e04-49d3-b3c2-0bfb041297dc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "micron is a unit of length in metric system equal to 10e-6 meter, or micrometer. the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID."
    },
    "46299940-216a-446b-bab8-6005845f46c6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "the findings from the primary clinical trial reveal that administering 20 mg of tamoxifen daily, seven days prior to and 14 days after breast cancer surgery, effectively reduces the expression of ki67 in tumors by an average of 40%."
    },
    "a2b4f24d-e4ff-49b5-a21f-61ba1e5b0b32": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "over 40% more participants in the er-positive luminal b group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "21400daa-b71d-43ac-9a54-fb9497b2a723": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients diagnosed with early-stage basal cell carcinoma of the skin, irrespective of hormonal status, are eligible for the primary clinical trial."
    },
    "97c738f3-a7ef-4183-9664-5aac4fd64a0e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "the number of participants in the secondary clinical trial exceeded those in the primary clinical trial."
    },
    "baa46f83-8738-48d2-b9b8-9cc635d9d730": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "only two individuals in the primary clinical trial were not recurrence-free survivors"
    },
    "4adbcbcc-ae43-46af-a072-815d1e788f29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial."
    },
    "396273f3-1e8f-4aa7-a50e-4c36c243748b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 3/20 of patients in the primary trial and the secondary trial suffered from infections during the study period"
    },
    "b742bc02-cd24-4ae7-b8b8-2a57bbd60d14": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial"
    },
    "8cd22d45-e829-47df-8ae1-cb50a163fc27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary clinical trial involves treating a patient cohort with 150 mg of oral pregabalin twice daily, while the secondary clinical trial uses depocyt and hd-mtx in its patient administration."
    },
    "09ac056f-fdf4-4684-99d2-8581ddc09d3b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there are 15 shared inclusion/exclusion criteria between the secondary trial and the primary trial"
    },
    "c467ce7a-d234-4542-909b-ac94393314ce": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "the educational dvd will not be used in any of the interventions within the primary clinical trial."
    },
    "3cf9b40b-ffa4-4b08-9039-9481c7d6cd76": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. ultrasonogram is a computerized image of internal tissues created by bouncing high-energy sound waves off internal organs."
    },
    "25602467-131a-44d1-a3d9-5a4a61a0ea0a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "if patients have experienced abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess or severe psychiatric disorders within the last six months, they are ineligible for the primary clinical trial."
    },
    "69407358-a579-43ba-8b78-b75d7aebb163": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "cerebral amyloid angiopathy is a disorder characterized by the deposition of amyloid in the wall of the vessels in the brain. the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day."
    },
    "2c8bef4e-9452-4ff9-b04d-66b0f42196d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 185% of patients in the primary trial and the secondary trial suffered from infections during the study period"
    },
    "dd4715db-f06d-4168-962c-22cdd764f2b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "the primary clinical trial accepts adult patients who were diagnosed with diffuse parenchymal lung disease 4 years ago"
    },
    "20c98ba5-ca61-4afe-af57-6de08705a5cd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the secondary trial and the primary trial use different outcome measurements and units of measure."
    },
    "68b82fb4-066b-4d76-9623-ff8696da3000": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "all patients participating in the primary clinical trial are instructed to ingest a capsule of vorinostat each day during their radiation treatment."
    },
    "650a33d5-ad44-40c8-a41c-1a4e7a5203b5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary clinical trial gauges effectiveness using muscle development as a result of physical therapy. conversely, the primary clinical trial focuses on the impact of sulforaphane supplements on the concentration of isothiocyanates in urine."
    },
    "fb758700-bd95-4857-a58e-1ee8d88c0d71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary clinical trial does not deliver any information on the mtd of any interventions, whereas the secondary clinical trial's mtd of mm-111 is established at 10 mg per day for its patients"
    },
    "5d9fff0a-de7b-45a9-843f-7d083ef11b11": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "within the primary clinical trial, the nacl 0.9% 3ml group had a higher number of individuals (112) report recurrence-free survival, compared to 78 participants from the ketorolac 30 mg group"
    },
    "bc92cff7-39b3-4088-bb3a-9e61c4d32b8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "no patients in cohort 2 of the primary clinical trial experienced acute vomiting after being treated with aprepitant, dexamethasone, cytoxan and kytril"
    },
    "4cdd4dc9-e171-438b-8864-1f451af7c15e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "the educational dvd is not part of the intervention for any cohort in the primary clinical trial, all cohorts will receive a regular dosage of radiotherapy"
    },
    "7f6d7fd9-8aed-472d-af54-b288d16c2135": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome"
    },
    "a5eb56c2-6fc0-45da-8a6a-2818cb64a7f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "all patients in the primary clinical trial who were given a placebo experienced vomiting"
    },
    "c6408b0b-2cdc-4298-a7d5-9e6fe3d52925": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "for all of its participating individuals, the secondary clinical trial applies a consistent array of inclusion and exclusion benchmarks. conversely, the primary clinical trial adopts two discrete inclusion standards for its various study assemblies."
    },
    "da91286b-3029-475f-a919-e33629a5a972": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial. microscopic findings supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the microscopic findings domain."
    },
    "cb869aa7-63a3-4a2c-8dd9-2e38496fbaef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "patients who are currently participating in the secondary clinical trial cannot concurrently enroll in the primary clinical trial."
    },
    "ff8c88f9-c698-4ad0-a9ba-0acf6fbf1933": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "sellar schwannoma is an extremely rare schwannoma that arises from the sellar region. The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort."
    },
    "8bf215f3-5795-4b6b-b193-354c87bc9496": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with gtx-024 1mg in the primary trial gained over 1.57473 stone of lean body mass."
    },
    "7794c718-f5f9-45a3-b427-9c7b79b261ee": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "primary and secondary clinical trial share identical outcome measurements."
    },
    "3b6f6c52-5713-45fd-823a-23ab1754539a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. dietary palmitic acid measurement is a determination of the total 16:0 palmitic acid in a nutritional product or meal, or a portion thereof."
    },
    "224ad5d9-659b-474a-b9ff-7cb17e104ddf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death . short is a variable that is stored as a signed 16-bit (2-byte) integer."
    },
    "f4fd9b7c-ccd9-4131-95d0-2a3a8071faf4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. xq22-24 is a chromosome band present on xq"
    },
    "333c097e-628c-4240-aa00-f9621fbbabe1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "adcs-adl - appliance: other specify is alzheimer's disease cooperative study-activities of daily living inventory (adcs-adl) check all that were used: other specify. 96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group."
    },
    "89c78515-344a-4974-a01f-de5a0441ada0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "projection is a prediction made by extrapolating from past observations. There are no conditions on hepatic function for participants of the primary trial."
    },
    "ad1c4967-3600-4953-a7fb-e48c9f4aa01f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial. formalin-fixed paraffin-embedded tissue scroll is a formalin-fixed, paraffin-embedded tissue sample that has been cut on a microtome so that it rolls up on itself."
    },
    "93299ed6-4cc9-4369-a4f3-c86f45ab741e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 1000 mg of ibrutinib and 20 mg/kg of medi4736 once daily for one week."
    },
    "373d0081-e7cf-4a06-bdd0-b58bcd4fe34c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "participants in the primary clinical trial will not receive any injections during the study."
    },
    "0629bf04-f185-49b2-905e-e9a3932dbb0a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. hepatic steatosis is a morphologic finding indicating intracytoplasmic fat accumulation in the liver parenchyma."
    },
    "0d49e948-aea6-4067-8f7e-b480e47d3407": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial. reference to study results publication identifier is a unique symbol that establishes identity to a publication that cites this study's results."
    },
    "0c570cce-3180-45b9-a0b3-4dd7200fc890": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "nf1 gene mutation is a change in the nucleotide sequence of the nf1 gene. Diarrhoea was more common for the primary trial participants than the secondary trial participants."
    },
    "a0b10912-a394-4892-88f8-7dfbc771052b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death . grade 1 kyphosis, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated"
    },
    "169ae179-8a24-4f8f-82b6-47ed449d8e2e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "childhood gliosarcoma is a gliosarcoma that occurs during childhood. the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes."
    },
    "80da21c8-478e-41a2-befc-384403e43ff4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "transendocardial injection techniques are integral to the intervention methods of both the primary and secondary clinical trials"
    },
    "512b8ed3-f0ca-4e11-ab4a-eebe4217ad7e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "totally dissimilar outcome measures are found in the results of the secondary clinical trial and the primary clinical trial"
    },
    "8db48a95-bc22-4f5e-b9e3-a50a275481a3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "those involved in the secondary clinical trial at present are barred from simultaneous registration in the primary clinical trial."
    },
    "ce232ee1-c38c-4eee-bb4a-eaa33f0c75a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "a recent diagnosis of an intrabdominal abscess or major psychiatric disorder does not disqualify a patient from participating in the primary clinical trial"
    },
    "71f1d2c6-7ab2-45d2-bb54-a0cad79d244b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases. dna adduct is a structure formed when a chemical is attached to dna by a covalent bond."
    },
    "51811b25-079e-44e0-a38a-b9e0735ded90": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "repetitive adverse events were reported among different patients particularly in the primary clinical trial."
    },
    "677ea4a6-dee8-4a9f-ab36-68724aeb8237": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "child-pugh class b7 is a total score of 7 for hepatic function, corresponding to class b in the child-pugh classification. the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response ."
    },
    "73b815f4-aae1-4202-a65e-5bba7b7c6676": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "individuals who have previously experienced intense anaphylactic responses to trastuzumab are eligible for enrolment in the primary clinical trial."
    },
    "3ac94edb-bccc-44c6-9b1a-4ea79122d154": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "participants of the primary trial receive sunitinib more frequently than sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants in the secondary trial receive epacadostat."
    },
    "773e93d2-a81d-48cd-96ec-4b92d537ac35": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "in the primary clinical trial, her2+ metastases emerged in 13% of the subjects having pr+ primary breast cancer who were treated with her2-targeted pet/ct. 89zr-trastuzumab"
    },
    "6848420c-ff9c-4003-bf9c-894b993c6720": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "the total number of anemia cases in the primary trial surpasses the case count in the secondary trial."
    },
    "99820bab-c465-4d6a-a016-0551261ddb86": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary clinical trial's intervention segment mandates the execution of surgical and imaging procedures."
    },
    "bbda33ff-3d5b-445e-afec-a20518fd2c79": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. daily or almost daily response is a subjective response that something happens daily or almost daily."
    },
    "a3fb7d8d-5911-41d4-b3da-9a018bb256f6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "upon diagnosis, it was found that each participant from the primary trial's first group had noticeable lesions, with those from the second trial's group 1 locking any symptoms of radiation dermatitis or hyperpigmentation."
    },
    "b76d27c5-45ec-4695-8480-1128862ea21b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the placebo in the primary clinical trial is administrated via an intramuscular injection once a week."
    },
    "0fdae3b5-0326-47fb-a3c2-ff5fd132fb76": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "men diagnosed with early stage, er- breast cancer seeking radiation therapy are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "cdce28fc-eb28-4608-8b83-9bc18414caf8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial allows participation of women affected by claustrophobia and osteoporosis."
    },
    "6b568a13-5216-4b83-848a-c64e8a9c340b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the lbh589 and lapatinib cohort's results are not accounted for in the primary clinical trial"
    },
    "46278ed1-1bc8-4161-b9d9-9f5a001b6aac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "apgar score version 1 - respiration or respiratory effort is apgar score version 1 (apgar score version 1) respiration or respiratory effort score. Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial."
    },
    "821e8e07-ec33-4f99-8f6e-6d7d50d23d8c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "education, training and library occupations is a class of professional or vocational positions of employment that involve education, training or libraries. On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients."
    },
    "e762873d-0ab8-4732-8c17-fdab7712a8e5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "thromboembolic incidents were experienced by patients in both the primary clinical trial and the secondary clinical trial."
    },
    "ee74199e-c159-41f6-9130-8410b237c32f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the number of biliary colic and diarrhoea cases is greater in the secondary clinical trial than in the primary clinical trial."
    },
    "1938e58d-a90f-48c4-ac79-59da3de8017c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "well differentiated neuroendocrine lesion is a neoplastic lesion with neuroendocrine differentiation and well differentiated histological features. At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial."
    },
    "7ba831e1-4027-4ae2-842f-d52409a73ddc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "topical treatments are being examined in the primary clinical trial, while the secondary clinical trial is evaluating inhalation treatments."
    },
    "f8adadc4-67d0-42d2-bcc9-c032279bb470": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "dose regimen is a treatment plan that specifies the amount, schedule, and the duration of intervention(s). Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study."
    },
    "3eb6d0c5-4bc4-4808-b8cb-03b3d5d40a07": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary clinical trial is utilizing on the investigation of varying quantities of a single therapy on its group, whereas the secondary clinical trial is exploring the outcomes from different radiation treatments on its participants."
    },
    "e3222534-b084-405b-bd5a-32fbd2a663c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "in the primary clinical trial, participants will receive their single injection on the first day of the study."
    },
    "67fc355a-1537-479d-b0fc-cd39bdb3cf6d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial. grade 1 nipple deformity, ctcae is asymptomatic; asymmetry with slight retraction and/or thickening of the nipple areolar complex"
    },
    "682a4e2d-f4a5-4fee-8399-195f67fcdfcc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "at different intervals throughout the trials, the same dose of trastuzumab administered to patients in cohort 2 of the secondary clinical trial is also given to those in the primary clinical trial."
    },
    "db15e6cc-ceeb-4f48-b3a1-bca36a6b54f4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "zero participants in group 1 of the primary trial were discovered to have lesions, and over 0.9 fraction of participants in group 1 of the secondary trial showed symptoms of radiation dermatitis and hyperpigmentation."
    },
    "2771bac1-0b7c-4049-9971-6c3129efb634": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "every patient in the primary trial is receives a dose of 0.1 to 1.6 milligram fentanyl sublingual spray during radiation therapy"
    },
    "19ad39bd-9620-4ff6-8afe-a81348b4fada": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "candidates for the secondary trial study group receive 15 weekly subcutaneous (sc) injections, whereas the primary trial participants only receive a single injection at the beginning of the study."
    },
    "d311aaa2-6b04-4f26-a19a-65e33a673fbe": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "an adverse event of peripheral neuropathy was observed in the primary clinical trial."
    },
    "985e4878-0637-4b32-a96f-626ff2f7cbd4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "preoperative iv antiemetics were administered is a response indicating that preoperative intravenous opiates were administered. Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial."
    },
    "9e2bec72-4318-4cf8-9ed8-82a572ce6d55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 1300mm in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "d61c1b26-cf05-46e8-a156-a264f562dfa8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. stridor, ctcae is a disorder characterized by a high pitched breathing sound due to laryngeal or upper airway obstruction."
    },
    "a38f54f6-d3cb-46aa-b298-cee296e21b3f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "breast cancer patients in the primary trial are administered 1 mg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 0.025 mg/day talazoparib instead."
    },
    "cbcbfb22-0467-4ba0-b2dc-1f9bd073c27f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the primary trial results there were more patients with stable disease in the end of the third month than in the end of the sixth month, but no patients with complete response in the end of third or sixth month"
    },
    "f42c5f78-bcb9-46e9-8b77-a8b9cbb81b13": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 3 years, however at least one patient from both cohorts died in under 30 minutes."
    },
    "dd10e477-9de3-43b9-8db3-5c9661514c5e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "the percentage of participants in both the primary clinical trial and the secondary clinical trial who experienced adverse events was less than 20%."
    },
    "321d4cba-47ee-4c74-85b9-072814b6fe6b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "fit patients who are not in gestation period have qualification to participate in primary clinical trial and secondary clinical trial."
    },
    "b181b889-6991-4710-a94c-536591db88fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "only candidates who are her2 negative on their ihc scores and are fully self-care reliant can participate in the primary clinical trial."
    },
    "6c5ebc06-00c4-4cf5-8912-93972ed5a49b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "99912ce1-aa49-4289-8743-eb1afffe1675": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "childhood thyroid gland medullary carcinoma is a medullary thyroid gland carcinoma occurring in childhood. Both cohorts of the primary trial recorded 0 Aes."
    },
    "3657b15f-ab73-479c-8b00-c2189fc4d984": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "several patients experienced the same type of adverse event during the primary clinical trial"
    },
    "99b10330-04b5-4aa1-bc04-9378fa54c994": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. external fiberoptic device is a fiberoptic device designed to remain outside of the body."
    },
    "6e9f7a1a-21e5-4d5f-b602-a1efb1b51bc7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "familial dysalbuminemic hyperthyroidism is a genetic condition caused by a variant in the alb gene, associated with increased affinity of albumin for thyroxine. cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2."
    },
    "2f5d2e0a-6378-4b00-b5ed-760d021808c8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "sacral intraspinal meningioma is a meningioma that arises from the meninges of the sacral region of the spinal cord. A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial."
    },
    "16e96301-3e68-453f-82db-f93117edfdfd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead. copies per microliter is a unit of concentration expressed as a number of copies per unit volume equal to one microliter."
    },
    "95aa2e47-d35b-45b5-8d80-18f06798b812": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "paclitaxel is administered to both cohort 1 and cohort 2 during the primary clinical trial"
    },
    "43989f85-a059-4dc7-a805-16e081706b2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 0 recorded adverse events."
    },
    "6cf62ed7-1dd2-4df0-80f7-979f74b55e72": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary clinical trial has registered 11 surplus cases of intestinal perforation relative to the primary clinical trial"
    },
    "8549720f-df44-400f-aeb0-98150d2f23b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial. percutaneous local ablation is any ablation procedure where a needle or probe is passed through the skin."
    },
    "6204ed3f-bad3-4db0-8db9-9f73efd78e8f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "respiratory therapy is any form of treatment that acts to improve or assist with respiratory function. 13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases."
    },
    "796002e1-bc19-4298-a035-c853aee3e5c3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the primary clinical trial has documented multiple adverse events for patients."
    },
    "e8e3fedb-075d-440e-bf2e-baec76f96cca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial"
    },
    "32f90f55-6faf-41ed-991a-6f8e9e158200": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 0.5\u03bcg/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "c5315113-8bc1-47d5-b1f7-ca7d59ab9cc4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. achondrogenesis is a rare group of disorders characterized by defective development of bones and cartilage."
    },
    "970f06b2-0935-4cde-a070-ddd7adb8ed5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial"
    },
    "703e6942-968d-4cdf-8e98-45cc571effd0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "the adverse events section of the primary clinical trial did not document any suspected serious adverse reactions, while the secondary clinical trial recorded several instances."
    },
    "46669c3d-c42d-4b23-b8c5-256374e53cf1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "in the primary clinical trial, fewer than 10 subjects experienced adverse events"
    },
    "5cd9bd06-f069-44f3-9b2b-69d92eecc07a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "in the primary clinical trial, no patient underwent the most severe pain perceivable for a duration of 10 weeks."
    },
    "ff1759ba-f09e-4ecf-8316-aac2a78d6c26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. external ear actinic keratosis is actinic keratosis that develops in the skin of the external ear."
    },
    "f212e510-214f-4556-99ed-526946750f55": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. unable to perform usual activities is a response indicating that an individual is unable to perform their usual activities."
    },
    "83b91b04-e464-483d-94d2-079690030cb5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "both the secondary and primary clinical trials observed multiple aes, including headache and joint pain, in various patients"
    },
    "ea1eb143-4c11-4e40-9511-46f4e17b9e1d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "regardless of having cancer or not, all participants in the primary clinical trial are subjected to the same intervention."
    },
    "4cd89e87-f0c1-4064-ab16-d945db457c41": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "first cousin once removed is a child of your first cousin. the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein."
    },
    "b6bd5750-21d0-4fcd-80af-749c6dc2a518": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the primary trial results there were more patients with stable disease in week 6 than week 18, but 2 patients with complete response in week 6 or 18'"
    },
    "7f832fbe-bf0f-44d1-820f-2398ce83404e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "none adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 1/3.33 of patients."
    },
    "646691ba-ad29-479f-81dc-131d9710c23b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial."
    },
    "0dd90e62-09f5-4282-9f52-c369a56ba3f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "in the primary clinical trial, patients who didn't undergo topical cryotherapy exhibited more severe symptoms compared to those who did."
    },
    "6e1489a6-3a42-4b52-b690-fb1dd8892749": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "The all recorded Aes in the primary trial occurred to cohort 1 patients"
    },
    "2acdad0e-1a86-49d6-817d-cddb655073ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "togo is a country in western africa, bordering the gulf of guinea, between benin and ghana. The same number of Aes were reported for both cohorts in the primary trial."
    },
    "73fd9671-363f-4bfa-91ad-1c8bacdf84ef": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0% the primary trial participants, and 0% the secondary trial participants suffered an ae."
    },
    "52d479a4-9cd7-4fb6-b37f-f455c6c81402": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "cohort 1 participants in the primary clinical trial exhibited absolutely no adverse event throughout the duration."
    },
    "59c8ac7f-504b-46db-a840-b84fd9969b3d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "data from the primary clinical trial indicates responses of the lbh589 and lapatinib cohort."
    },
    "9c076947-5e32-4a14-874b-e4b993f10756": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 0.5 grams per day"
    },
    "506c27c5-380f-41f7-9f90-81d843d7d140": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "in the primary clinical trial, patients will be administered higher quantities of alpha lipoic acid for the entirety of the study, in contrast, the same amount of necitumumab is provided to patients in cohort 1 in the secondary clinical trial for the whole study period."
    },
    "88857141-6207-4828-b8d4-09d7cc4498c3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial"
    },
    "0bd3433b-05d2-416a-b0c4-0a017f546dc2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary clinical trial and the secondary clinical trial employ distinct units and outcome measures."
    },
    "f435b92a-cceb-404d-a485-da95bb2189ec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. feel like have to strain to produce voice is a question about how frequently an individual feels as though they have to strain to produce voice."
    },
    "fd334e71-2bbe-4138-b578-2ab848686045": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial."
    },
    "dea24187-160a-4d6c-a724-e8cb01494d68": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel. physical quantity to physical quantity time ratio data type is a data type comprised of a physical quantity divided by a physical quantity expressed in units of time."
    },
    "ea0d6370-3322-4925-b524-b9a8bebe4383": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the primary trial is studying a different drug than the secondary trial, with the same dosage and outcome measurement."
    },
    "c49dbdfa-801a-4789-9e04-345ed14150ab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "hemodialysis catheter infection is a local or systemic infection associated with the use of a hemodialysis catheter. Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention."
    },
    "c67c581d-7aa5-4a90-b640-dcdf8d69e870": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "both the primary clinical trial and the secondary clinical trial are open to patients who have a confirmed diagnosis of stage 4 breast adenocarcinoma, which may be either er positive, pr positive, or her2/neu negative."
    },
    "bae24418-25bc-4334-be92-d7f341ac3f14": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "rivoglitazone is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial."
    },
    "bef15be3-6cf6-426a-a70a-d5d99a1c42af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "initial usage is an indication of the first time a device was employed. Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors."
    },
    "658a645c-05f8-456d-be67-c5b7b6d427da": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "always true is a subjective response indicating that something is always true. Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial."
    },
    "eff8deaa-08a6-4df3-9140-fe153fbcba6e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "compared to the intervention in the primary trial, the same procedure in the secondary trial continues for three times as long."
    },
    "4665519b-6dba-440f-9cc3-677ab616ecd6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "a ct scan, not a mammography, is needed for consideration in the primary trial, while for the secondary trial, no imaging test is required."
    },
    "25f976a2-8a79-469f-90a3-6b9922382c76": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "while the primary and secondary clinical trials focus on different interventions, the mtd for the secondary clinical trial's mm-111 intervention is set at 15 mg per day"
    },
    "f2796825-a4d9-4484-8958-851d99294e3c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "primary clinical trial results are communicated using seconds, while the secondary clinical trial uses minutes as its units of measure."
    },
    "5902b596-40d0-4be7-8242-f313f6832fec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients with a documented allergy to celecoxib and levofloxacin can enroll in both the primary clinical trial and the secondary clinical trial."
    },
    "54176448-042e-4b40-835e-ddf60eb53f80": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "patients of asian descent, living in california can be part of the primary clinical trial."
    },
    "fd23bed1-83e9-44c9-acf7-66df74ba1c98": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial. exposure yes no indicator is an indication of whether an exposure occurrence has taken place."
    },
    "3a4198ab-ae79-4200-b073-860b2e86813d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial."
    },
    "dfd39b75-1119-400a-a9af-588d7e63b867": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "both the primary and secondary clinical trials recorded over 10 deaths as adverse incidents."
    },
    "adf1424b-3b15-478f-acab-72d4217db886": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "at least one patient in the primary trial suffered several different adverse events. impedance conductivity is a method that measures impedance of conductivity which corrects for the concentrations of conducting ions in the sample."
    },
    "383102f6-bd50-4f19-b7cf-0ddda4234e2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "biliary colic and clostridium difficile colitis cases are more prevalent in the secondary trial than the primary clinical trial."
    },
    "548ed40c-ccf4-4250-9fd9-c870bcc61b17": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "engagement in regular physical activity is not a required component of the intervention for participants in the primary clinical trial"
    },
    "5ac3610a-7854-4278-8a51-c1ef8c138ee9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "pulse wave increased is a clinical finding in which palpation of the pulse demonstrates a significantly increased upstroke and/or amplitude. (acc/aha) less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products."
    },
    "9eee5184-a09a-41a2-b031-a7ea1863c5ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "in the primary clinical trial's second cohort, four different adverse events were noticed affecting patients."
    },
    "f618f294-167b-4647-bc93-b8d41596227c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 730-hour cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "885733b0-a998-4f2c-b131-e58b2008a8a2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "the primary clinical trial is designed for patients who exhibit optimal levels of vitamin d, but such patients may be disqualified from the secondary clinical trial."
    },
    "029ee1b5-a81a-4690-9f03-442dcf0f5e9c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial. pressure sensor device is a sensor designed to respond to the level of pressure in a space or pressing on a surface."
    },
    "5da86b4b-b830-48a4-964d-c20207d55b3a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "patients diagnosed with nut midline carcinoma identified by fluorescence in situ hybridization or inflammatory breast cancer can participate in both the primary clinical trial and the secondary clinical trial."
    },
    "7ebe69db-dbde-41d9-b1c8-b866b2bc9e4c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "infection, asymmetry and nausea instances were more in magnitude in the primary clinical trial than they were in the secondary clinical trial."
    },
    "559c1faa-17b6-42c7-9f63-0cd58df39bfa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs."
    },
    "6ab38a80-a2a5-40f1-a8d5-250db9f54740": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "the intervention 1 in the primary trial is administered subcutaneously, and all intervention drugs in the secondary trial are directly injected into the bloodstream."
    },
    "da901268-f433-47ff-9119-69d36ce3c4d0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid. experimental organism benign endometrial adenoma is a benign epithelial neoplasm arising from the endometrium."
    },
    "e4f41907-ef20-40aa-bcab-416243280816": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "data from the primary clinical trial indicates a 40% average reduction in tumor diameter after patients took tamoxifen 32 mg po daily for seven days before and fourteen days after their breast cancer surgery."
    },
    "b1d950c2-dbd9-4cb4-b291-9406d84cd8de": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "ai therapy and mirtazapine responsiveness is not a requirement for patients participating in the primary clinical trial, but it is mandatory for the secondary clinical trial"
    },
    "b3527d60-eb66-465d-845a-e234e5b0a084": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "primary clinical trial does not allow participants who smoke, but the secondary clinical trial may accept such individuals if they consume less than five alcoholic beverages daily."
    },
    "fb1605b0-dce6-45fb-bc67-2018e0578a2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "during the period of the study, most individuals participating in the primary clinical trial struggled with varying degrees of eating disorders"
    },
    "151ae668-d1e7-4dd1-beb2-75dd7efbae4c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "those involved in the primary clinical trial are administered four distinct medications over the course of the study, not exceeding a dosage of 100 mg/m^2"
    },
    "21031398-5d47-4ad9-ad19-16c790eaf061": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 10 years, however at least one patient from both cohorts died in under 24 hours."
    },
    "77c27725-099d-4d66-947c-f03e9193b6bf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "was mgmt promoter methylation testing performed is a question asking if mgmt promoter methylation was analyzed during the study. the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein."
    },
    "a7d9d7dd-1f13-4a0e-883c-b322ed8780dd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "the primary clinical trial does not accept patients with low potassium levels, but those with high potassium levels could be eligible for both the primary and secondary clinical trial."
    },
    "30234b84-2f15-4ea8-b7ed-af5f4ea40e9c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "Both the primary trial cohorts receive pre-operative Dexamethasone. benign testicular neoplasm is a non-metastasizing neoplasm that arises from the testis. representative examples include benign sertoli cell tumor, thecoma, and fibroma."
    },
    "05b6b24d-8753-4029-9464-c825cb52b9f4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "the distinction in the primary clinical trial between the first and second cohorts lies in the dosage and treatment administered; 25 mg of sunitinib is given daily to the first cohort, while the second cohort receives 90 mg/m^2 paclitaxel."
    },
    "a2981a35-ece3-42dc-a735-cd12466392fa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "dog bite is a wound received from the teeth of a dog. Across both the primary trial and the secondary trial only one death was recorded in the adverse events."
    },
    "bce464d0-a0f9-4d17-9caa-6bd247cfdce3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "device migration problem identified is a device that has moved from its original location due to external forces (e.g. stent or lead movement).  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial."
    },
    "28002c57-ff24-4b59-9f0e-0dfdbaab7f88": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the principal mode of administration for the primary trial intervention is through venous access, whereas the secondary trial treatment is applied topically"
    },
    "59d62015-4627-4fef-acba-984ff4ad2964": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "participants in the primary clinical trial are administered a regular course of vaccines"
    },
    "895d29b8-16bf-4539-b8f9-a7ffec42ce94": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "both cohorts of the primary clinical trial showed zero cases of hypertension, edema, and dyspnea."
    },
    "136bc454-b432-45f9-909b-e588f2dc6c60": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "all patients in both cohorts of the primary clinical trial showed no sign of pathologic complete response in breast and axillary lymph nodes even after 7 months"
    },
    "1672004b-d668-4441-95b4-eaab6fd70818": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 384 month old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1.807 x 10^6/\u00b5l, platelet count of 7.9 x 10^4/\u00b5l, hemoglobin level of 9 g/dl, and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial."
    },
    "5a736ff9-b224-4cf6-ae71-55a825bff301": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "over 0.11 years of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 5% reduction in the percentage of cells with ki67 expression"
    },
    "5599d5d8-3a7b-41ce-a00c-6e0b609b618d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event"
    },
    "83e7efec-6077-4c3c-8ed6-ebe4f715da47": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient with no detectable tumour, based on clinical examination and ultrasonography, would fail eligibility for both the primary trial and the secondary trial."
    },
    "b41e6cb3-c92e-4027-b96b-502aeb1f4211": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "blacking out is a temporary loss of consciousness or a temporary state of altered consciousness that results in memory loss. 2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction ."
    },
    "0790e3ed-6c8e-4b03-8eca-d80fa6296385": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "the interventions in the primary clinical trial implement standard gp for both the first and second protocol."
    },
    "27564603-9271-41f5-8135-067e19c4946a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "large cell neuroendocrine carcinoma is an aggressive, high-grade, and poorly differentiated carcinoma with neuroendocrine differentiation. it is composed of malignant large cells. In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110."
    },
    "b89171bc-ed32-4c9b-91ee-545a95b809fc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "there are no instances of drugs, radiotherapy, or cbt being administered in any cohort of the primary clinical trial."
    },
    "ccd3d27f-e743-4adf-8135-3488117f1178": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "cyclophosphamide, paclitaxel and pegfilgrastim are administered to the patients in both the primary and secondary clinical trials"
    },
    "ea16ac84-1f11-45c6-a29a-b7159f4b49a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "more than half of the patients in the primary clinical trial suffered from adverse events, while in the secondary clinical trial this percentage was significantly lower"
    },
    "2fafc6ea-da6d-4160-829d-1f599da46818": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "gingival polyp is a non-neoplastic nodular lesion that arises from the gingiva. Only 2 patients in the primary trial did not have Recurrence-free Survival."
    },
    "af9986f4-5f0c-4b8c-b02a-05ae6f7f4d1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "78% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "5af06b76-49a3-4342-92ef-2d15ecddc2c7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial enumerates the progression-free survival time in weeks for only a fraction (78) of patients in the main cohort, conversely, the secondary trial discloses the frequency of adverse events experienced throughout the procedure"
    },
    "22f473e7-1aea-4baf-9697-224ea4c6fbdf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "a dose of 100 to 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray is administered to every patient partaking in the primary clinical trial during their radiation therapy sessions"
    },
    "fe37b4ad-fe84-429b-89ce-f5a881215b56": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "for the primary and secondary clinical trial, eligibility extends to women who have reached the age of 18 or more."
    },
    "bc864ba6-4d2b-431b-9b34-7b668eb5c468": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the neratinib group of the primary clinical trial had a higher rate of idfs than the placebo group"
    },
    "698866bd-4a77-4b0a-9e79-6fb9984692b7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "arm 1's operative time was less than that of arm 2 in the primary clinical trial, indicating the superior performance of standard mammography over intra-operative mammography. the secondary clinical trial includes a control group for contrast.'"
    },
    "cd8d5a6a-0365-410c-8f85-815a67c0d11b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96% participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 67% from the nacl 0.9% 0.03dL group"
    },
    "356f845b-f5e9-46f8-8374-fb598e246876": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. malignant oculomotor nerve neoplasm is a primary or metastatic malignant neoplasm involving the oculomotor nerve."
    },
    "3db34e4f-ae01-424d-a8b8-7d1a16e2f898": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the past 2 years will be eligible for the primary clinical trial"
    },
    "9126bd66-8ee7-47a5-84e2-0269efe06362": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "adults are excluded from the primary clinical trial but they are specifically eligible for the secondary clinical trial"
    },
    "e9204795-c6e7-4215-a230-2958d48a6ac2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "incidence of dose-limiting toxicity was not reported in the primary clinical trial."
    },
    "dc8d6268-fd08-4c31-b2d6-50e8a8e750c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "secondary trial participants are administered just one sc injection at the onset, while the primary trial group gets weekly injections for a month."
    },
    "bd8a6fc5-ffc7-460f-a82c-9656047eafbc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "minimally invasive lung non-mucinous adenocarcinoma is a morphologic variant of minimally invasive lung  adenocarcinoma characterized by the presence of clara cells and/or type ii cells. 49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group."
    },
    "217b0362-9dd0-4f10-8ca5-c097688bb738": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial."
    },
    "75e0a9f9-003d-4bfe-a720-4f84d2d0e7b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "according to the primary clinical trial, administering tamoxifen 32 mg po daily for a period around the surgical intervention led to an increase in tumor size by an average of 20%."
    },
    "7534e96f-f5c9-4adf-a9cb-efa76fd43257": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "in the primary clinical trial, stomatitis was the only adverse event documented."
    },
    "fbda9d7c-12d9-4b04-8047-da25419e1c3b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 8 different drugs throughout the study duration, with a maximum dose of 500 mg/m^2"
    },
    "019f248f-f753-495a-b579-9d41f65c5b26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "neither the primary nor the secondary clinical trial have reported any adverse events for their participants."
    },
    "74e35f39-c01b-435b-a5f8-cc1cc8204607": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor 200-800 micrometers in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "fa12778d-4f82-4dd9-8ac0-decbef38472b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years. attend school social events less because of hearing is a question about whether an individual attends school social events less because of their hearing."
    },
    "9f3b9559-fe63-4698-b886-fe76ecab9784": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "in the primary clinical trial, cohort 1 is given 0.035 mg less alt-801 than cohort 2"
    },
    "f2d5970e-568d-40ca-9258-65015ff4a828": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "none of these describe me is a response indicating that an individual feels that no option listed is a good description for them. Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial."
    },
    "6af06b3f-dbbc-4679-a4a3-fe4b3757fdc0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "There are 7 more participants in cohort 2 of the primary trial than in cohort 1"
    },
    "7313a53a-9a67-4b81-ad79-4df7d1ced976": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "have pain is a question about whether an individual has or had pain. There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial."
    },
    "7f7f7885-c57a-42f3-9799-99159d400077": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary clinical trial's intervention segment does not detail the administration method, dose, or routine."
    },
    "a96f9558-41f8-4515-8fc4-d3b8f326ce05": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "during radiation therapy, patients in the primary clinical trial are given morphine sulfate, not fentanyl sublingual spray."
    },
    "4bc6699d-0ac2-4358-9425-1d377151ffa8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the maximum tolerated dose (mtd) of diverse interventions are reported in both, the primary clinical trial and the secondary clinical trial"
    },
    "2d0d88d5-08ba-4d77-abbc-d8df34efa630": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "satisfaction with how natural your reconstructed nipples look is a question about how satisfied or dissatisfied an individual is or was with how natural their reconstructed nipples look. There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial."
    },
    "5d1997bd-e77f-43dd-abd1-eb1da8819d47": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "The the primary trial intervention section dose not describe the method of administration, dosage or cycle. small cell component present is a morphologic finding that refers to the presence of a small cell component in a cellular infiltrate."
    },
    "348c5cf5-0756-4860-a83f-c9ead81ea4b3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "in the primary clinical trial, patients experienced only three adverse events: pancreatitis, cholelithiasis and hepatic pain, along with febrile neutropenia"
    },
    "a2328e36-4475-4804-96e8-cba90ee13087": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. kosraean language is an austroasiatic language spoken on the kosrae and caroline islands of micronesia, and nauru."
    },
    "14fdb2fc-e19d-4628-ada4-37ea935a2b4a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "in the primary trial, every adverse event was associated with respiratory complications, unlike the secondary trial."
    },
    "2c3adca5-a150-4c23-aa83-2cc8caeb0deb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism in the last 8 weeks are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "f5cdf7ed-828f-4e45-9699-b5f80c7b1863": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "both the placebo and memantine interventions in the primary clinical trial are provided daily through oral intake."
    },
    "c1fee61a-1d3e-4d83-a0a9-8360e912714c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "more palpitations, pericardial effusions and abdominal pains were recorded in cohort 1 of the secondary trial than in cohort 2 of the primary trial."
    },
    "79515622-bb43-4721-a164-dd2002713dc1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "in the primary clinical trial, recurrence-free survival was exclusively seen in 120 participants from the nacl 0.9% 3ml group, unlike the 90 from the ketorolac 30 mg group"
    },
    "28363fb8-16ff-4a26-b29c-ca41d1ed2e6e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "no participant in the primary clinical trial experienced a urinary tract infection"
    },
    "47074986-36ac-4ebe-a743-cdf06a70efd8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": " Alzheimer's patients are not eligible for the primary trial. rete ovarii adenoma is an adenoma that arises from the rete ovarii.  it is composed of elongated tubules.  the clinical course is benign."
    },
    "1fde2a5a-bf6c-41cf-ba82-7cbea262f258": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 1200 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy."
    },
    "04beb33e-ae70-4de2-a805-71650246ea7b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "the primary and secondary clinical trials are open to patients who have a tnbc tumor measuring 100mm."
    },
    "0f5ce689-610f-4522-8082-23df226f2a42": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "both approaches in the primary clinical trial incorporate the use of trastuzumab"
    },
    "c6ff494c-5fa8-414d-8a32-15713193c9a3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "in the primary clinical trial, lymphedema improvements were more notable in acupuncture patients than in patients on the waiting list."
    },
    "145b92f4-e143-4188-9521-8aade35b2f05": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial. late endosome is a multivesicular body that can fuse with the lysosome to target extracellular factors for degradation."
    },
    "f8895ab6-dbe2-4715-9567-7dfa9c4d46a8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "while the primary trial's course of treatment follows a month-long cycle, the secondary trial doesn\u2019t enforce a cycle-based intervention."
    },
    "c98e803e-a899-4ed8-aed0-0611eeef943d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients who have experienced a pulmonary embolism within the previous 2 months are not permitted to participate in the primary clinical trial, although the secondary clinical trial may allow their participation dependent on the investigator's judgement."
    },
    "fb616088-52c2-4dae-84e5-8a1a3fa9b64f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "liter per hour per kilogram per meter squared is a unit of concentration equal to liter per hour divided by kilogram per meter squared. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer."
    },
    "36386099-3f11-4037-aa48-dcbb36d7ff23": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+. allogeneic lymphocyte is a cell that is antigenically distinct from other lymphocytes."
    },
    "8881c72a-24fc-48ab-86fb-a1d38392ec33": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the secondary trial and the primary trial report results using the same Unit of Measure. therapeutic nervous system procedures is a procedure that is done to treat a nervous system disorder."
    },
    "e2e8bb00-df98-49c2-a81b-e18ae21516aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection."
    },
    "e1c80f41-c3f0-49c8-8fc8-0bfc32e9936a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "no deaths or hospital admissions were observed in the second cohort of the primary clinical trial"
    },
    "4872d505-a3f8-44bb-a023-aa41e27b49b3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 100 mg group of the primary trial experienced a smaller reduction in primary tumour diameter than the zoledronic acid 40 mg group."
    },
    "3611645a-e832-4b38-a1db-9c66aca8baf6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of the patients involved in the primary clinical trial report the problems of increased pleural effusion and swift progression of their disease."
    },
    "2ecb5932-45c6-491c-9b9f-01ab02877f78": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "there was at most one psychiatric event recorded during the primary clinical trial"
    },
    "26145056-fdfd-4f2d-909e-be84fc53ede8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant."
    },
    "58fa0ef4-0355-42bc-8378-fef98752b05e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial."
    },
    "6e2f3c50-84c2-41e2-8188-a83c94b2704b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "eyelid oedema, upper gastrointestinal haemorrhage and chest pain were the only adverse events observed in patients from the secondary clinical trial. on the other hand, the primary clinical trial did not record any adverse events."
    },
    "4527cc06-b4b2-4ebe-bba4-6f4e845b2984": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. benign ethmoid sinus neoplasm is a non-metastasizing neoplasm that arises from the ethmoid sinus."
    },
    "e6b528a8-9d23-420b-b1a1-63bd831b7c03": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "every patient in the primary clinical trial had fully healed surgical incisions without any complications."
    },
    "373e57af-cf54-40c6-9906-eff8eb5d7306": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "no adverse events were reported for cohort 1 during the course of the primary clinical trial."
    },
    "26be8c11-aebf-4982-b09e-75dead3cdf4a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "vegf overexpression positive is an indication that overexpression of a member of the vegf family has been detected in a sample. None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets."
    },
    "c870de83-33d4-4ea6-9482-afe2d7a47480": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "participants of the primary trial are not required to receive denosumab, and the secondary trial uses 200 to 400 milligrams of amifostine, delivered intravenously."
    },
    "6c3ebd57-b814-49df-bade-ad46362eaa2b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "cohort 1 of the primary clinical trial is subjected to all er positive, pr positive and her2+ treatments, while cohort 2 is administered treatments for er negative, pr negative and her2- conditions."
    },
    "87c5ee7a-a65a-4633-9efc-b51e2956db27": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort. f3 positive is an indication that expression of f3 has been detected in a sample."
    },
    "57bc58fc-44ce-4938-9bfa-4750bac013ac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "adverse events were commonplace and severe in both the primary clinical trial and the secondary clinical trial"
    },
    "467c8a18-4a72-4ea4-9b8d-ae43d786b5b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "the primary clinical trial allows for the enlistment of patients with a histologically confirmed diagnosis of scbc, regardless of metastatic condition or resectability, and irrespective of er or pr positivity"
    },
    "b9074beb-a639-46ba-966b-b0db266efffc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "The the primary trial intervention section dose not describe the method of administration, dosage or cycle."
    },
    "f98c72d2-3fce-42a5-9585-280e8b877708": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "over 42 patients from both groups in the primary clinical trial recorded a pathologic complete response in breast and axillary lymph nodes, nearly 7 months post-surgery"
    },
    "fbe4e8b0-f258-448d-8926-3ac4757ee020": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "in the primary clinical trial, the first cohort receives a fluciclatide injection, while in the secondary clinical trial, the first cohort is given a standard chloroquine dose."
    },
    "e0393f5c-7dec-4018-8917-b055823aec4b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "atara biotherapeutics is a privately-held drug development company that is developing cancer treatments based on allogeneic cytotoxic t lymphocyte immunotherapy. Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial."
    },
    "857ea0f3-1f62-417e-93ef-00e121cc3e60": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "within the primary clinical trial, neither group is given interventions that include counselling, risk analysis, or cognitive behavioural therapy (cbt)."
    },
    "a14e5115-a6ff-4253-9260-736c943bd47e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": " patients who have received chemotherapy or radiotherapy in the last 0.5 months, suffer from unstable angina, or have grade 5 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "282b67f4-97cb-4680-8f21-0102c1c7851f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days. chlamydophila is a genus of gram negative, obligately intracellular, parasitic bacterium in the phylum chalmydiae and the family chlamydiaceae."
    },
    "cea1bf06-b100-4328-aee1-638ef92d2784": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the secondary clinical trial does not report the maximum tolerated dose (mtd) of different treatments, and the mtd of mm-111 for its participants is 20 mg per day in the primary clinical trial"
    },
    "e01e4e41-3577-4556-b481-de0d3777ba18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "17q21-q22 is a chromosome band present on 17q candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial."
    },
    "b7ab0a1b-fa3a-4cf4-ba4a-dda1608215a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 110,034/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. retroperitoneal lymphoma is a lymphoma involving the retroperitoneal area."
    },
    "6dddad4e-4cde-4859-a518-897b16bdc042": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "abstinence or moderate drinking is not a criterion of exclusion from the primary clinical trial, but the secondary clinical trial mandates a minimum consumption of five alcoholic drinks daily."
    },
    "e554ce24-beab-4ed6-b37b-0a28ae28faf0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients did not experience anemia, pneumonia, or stupor more frequently than patients in the primary trial."
    },
    "9d03d248-30a2-44b1-bbef-75809005dc16": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "7p22.2 is a chromosome band present on 7p Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim."
    },
    "7e529d12-16a2-4711-b7f8-b454800447f2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients diagnosed with hr positive and her2 negative breast cancer and a tumor size ranging from 0.2 to 0.8 cm are eligible for the primary clinical trial and secondary clinical trial."
    },
    "be3df611-66ac-4f40-ae04-68b5d1c0ae02": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a female patient, aged 20, recently diagnosed with er-positive, her2-negative breast cancer, may qualify for both the primary clinical trial and the secondary clinical trial"
    },
    "ec164af8-13b9-4545-b3ba-24260adfe9db": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial is accepting a limited quantity of patients carrying the kras or braf mutation and diagnosed with metastatic colorectal cancer."
    },
    "98a95bef-b43a-4582-8b58-d0c154824cd0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "individuals diagnosed with diffuse parenchymal lung disease, regardless of the time of diagnosis, can participate in the primary clinical trial"
    },
    "54c7e880-a1bf-4206-9573-1c994932ba15": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds."
    },
    "a76b5162-0261-41d2-8d17-c88f5a0e21bc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "under 10 patients have encountered adverse events in the course of the primary clinical trial"
    },
    "42aa56a7-2e3b-4932-bdde-a0ed438111c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "how difficult to bend and straighten affected arm is a question about how difficult it is for an individual to bend or straighten their affected arm. Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial."
    },
    "0967b501-90dd-4ba4-bebc-8db1e9695431": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": " Alzheimer's patients are not eligible for the primary trial"
    },
    "1bd849aa-409c-4214-a930-4d187a645466": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly."
    },
    "4703e57c-efe0-4316-a1a5-8ac60b030e84": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were more frequently observed as adverse events in the primary clinical trial compared to the secondary clinical trial."
    },
    "f2f5115c-a1ad-43cf-b01c-0035f9404a92": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial, each cohort receives different amounts of rosuvastatin daily, not exclusively armodafinil p.o. in the secondary trial, medication doses are individually calculated for each patient and do not uniformly consist of 100 mg pdr001 and 1 mg/kg mcs110."
    },
    "5ff5980d-28e1-46a7-9300-20792ad3dffd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "the solitary distinction between the first and second interventions of the primary clinical trial lies in the reduced amount of durva (0.7mg/kg less) that cohort 1 receives in their bi-weekly iv infusions versus cohort 2."
    },
    "42a51c2f-6b39-487e-989c-dcdc0ad231e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "septal myocardial infarction by ecg finding is an electrocardiographic finding suggesting an infarction in the anatomic location of the cardiac septum. less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products."
    },
    "9011533a-e400-4b32-96d4-a60ddc58ddbe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "the primary clinical trial utilizes a combination of oxaliplatin and fluorouracil as treatment whereas the drug regimen for the secondary clinical trial is not specified."
    },
    "452f92e1-27bb-4452-8675-c6409ec6003a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women who are 18 or 19 years old can participate in the secondary clinical trial, however, they must wait 1-2 years to qualify for the primary clinical trial"
    },
    "4e9c14cb-9c55-4c1a-ae14-f5a6f08e1494": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial. liquid soap dosage form is a solution or suspension composed of an anionic surfactant used for cleansing."
    },
    "e1142532-82b5-4f1c-9d7c-33b677b92966": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the primary clinical trial was severe nausea, no aes were reported in the secondary clinical trial."
    },
    "fd88904b-8a23-46ad-b337-3c7eef4e7bef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "patients with a history of pulmonary embolisms are disqualified from participating in the secondary clinical trial and patients with current breast implants are ineligible for the primary clinical trial."
    },
    "00539969-3b0f-4c9f-be8a-0ce964c7d5fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "carfilzomib/panobinostat regimen is a chemotherapy regimen consisting of panobinostat and carfilzomib that is used for the treatment of plasma cell myeloma. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures."
    },
    "c6b64745-922b-40cb-9476-b7b696d4c8c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "the majority of patients in cohort 2 of the primary clinical trial did not exhibit any signs of acute vomiting subsequent to the intake of aprepitant, dexamethasone, cytoxan and kytril"
    },
    "d401affc-f081-4eee-bd61-d109cc88f6de": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time"
    },
    "54a1eab3-1e8e-4c1c-a30f-f4d677a84c71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort."
    },
    "c32c50b0-6068-41f1-9db0-fd8b3ac53cf6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally. clinical laboratory is a laboratory that analyzes patient or subject samples collected as part of healthcare treatment or clinical research."
    },
    "75080502-7163-4189-9194-c96041df76e5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial has no age restriction, and the primary clinical trial excludes those who are younger than 25."
    },
    "444746eb-7e98-43fc-8bab-50c2a60d2806": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "the primary clinical trial exclusively uses mri-guided radiotherapy for all interventions."
    },
    "ff258472-19f3-4dea-8edc-bc591c30fc37": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "adverse events such as recurrent cancers, graft-versus-host disease, anaemia, heart failure, and diffuse alveolar haemorrhage were seen more frequently in the primary clinical trial than in the secondary clinical trial."
    },
    "92639a0e-c3b4-4057-8bb5-aeaf1d60c39b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "unexpected deaths or hospital stays were not recorded in both the primary clinical trial and the secondary clinical trial."
    },
    "664f769a-791d-4188-8937-c3269d6e0dde": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a non-tnbc tumor of 100mm in diameter can participate in the primary clinical trial and the secondary clinical trial"
    },
    "e682eada-bed5-4ea5-847a-cbfdb44ef724": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most frequently reported adverse event throughout the patient groups of the primary clinical trial and the secondary clinical trial was diabetes, appearing in 45.00% of the primary clinical trial participants."
    },
    "1bf21a6b-6676-4da7-9b80-4fd67722e030": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "every inclusion criterion for the primary trial is distinct from those of the secondary trial."
    },
    "66c31a74-8bb0-4625-9ce7-401da56be447": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "fatigue interferes with certain duties and responsibilities is a question about whether an individual's fatigue interferes or interfered with certain duties or responsibilities. African-american patients can participate in the primary trial."
    },
    "e52a3c24-8fed-4bcb-9513-582c604a5414": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "sao tome and principe is a country in western africa, comprised of islands in the gulf of guinea, straddling the equator, west of gabon. Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial."
    },
    "5b174c01-9e6e-4fa0-8c85-c7b72446d0b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial is investigating the effects of physical therapy interventions, and the secondary clinical trial is involved in studying the impacts of dietary changes."
    },
    "6af06fcc-363f-4275-81f3-8a01c53931e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "women recently diagnosed with stage 4 breast cancer that is er-positive and considering mastectomy are eligible for participation in both the primary clinical trial and the secondary clinical trial"
    },
    "4d8bdd85-b621-4334-9aff-9ab0b69172e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "to be eligible for the primary clinical trial, there are no certain conditions such as mental health, body weight, tumour size, karnofsky/ecog score or estimated life span that must be attained"
    },
    "6fc1fe93-0690-4b46-a80e-681e4d7be399": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "Morbidly obese patients are eligible for the primary trial. have to read something several times to understand is a question about whether an individual has or had to read something several times to understand it."
    },
    "efe8b336-1781-4777-a1a0-fe34c59c63ab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "cdisc adas-cog - delayed word recall: word 4 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) delayed word recall task for word 4. Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study."
    },
    "a723722c-a7df-4baa-b02a-3d3f15a03db3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a 35 year old female patient diagnosed with er-negative, her2-positive breast cancer, could be eligible for the secondary clinical trial and the primary clinical trial."
    },
    "24e662f6-3ac7-489b-91fa-890994a805b4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "only hispanic patients can participate in the primary clinical trial."
    },
    "f08d84f8-0448-462c-8f81-770223b92bb8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "instances of lengthier operative durations were detected in arm 2 than arm 1 of the primary trial, indicating more efficient outcomes with the intra-operative mammography compared to the standard mammography. no control group is present in the secondary trial to which the observations can be opposed."
    },
    "fbb05804-2d6c-4d49-8e06-0fbf2b3770a4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "a single drug makes up the intervention in the primary clinical trial, in contrast to the secondary clinical trial where the intervention necessitates a minimum of three separate drugs."
    },
    "285b3905-8e47-4b26-8aa5-2d9d7f717a6c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections."
    },
    "0dfa4e06-e226-4d46-be1f-90249c1f34d4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "a higher number of patients in the secondary clinical trial were documented to have chest pain compared to those in the primary clinical trial."
    },
    "402d7814-ace1-4f78-8c96-c3205001c5ee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary clinical trial are administered cudc-101 at the same frequency."
    },
    "1b70762f-83fb-4c93-98ac-7f5d8852fc16": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "two participants from the primary clinical trial experienced dose-limiting toxicities, divided evenly with one from each cohort."
    },
    "71268387-6e9d-4875-b193-b60b4e3e7033": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "patients in the primary trial receive a different dosage of trastuzumab compared to patients in cohort 2 of the secondary trial"
    },
    "589622f2-6c3b-4e63-ad71-5d8c90cb3413": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "it is not feasible to contrast the side effects between the primary clinical trial and the secondary clinical trial due to the absence of recorded side effects for the primary clinical trial."
    },
    "ad271913-e4a5-4a4a-9b0a-d3ae24415a54": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the trabectedin intervention in the primary clinical trial is administrated orally once daily."
    },
    "24b44ec0-b0a4-4b5a-9028-164eda456529": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "the placebo intervention of the primary clinical trial is administered in a different dose from the allo-mscs intervention."
    },
    "d53cf5fe-1104-4b05-886c-bb5499cdc047": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial."
    },
    "7d57f1d1-e523-4220-95a9-f4ce33d7f157": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "the secondary trial and the primary trial have completely different inclusion criteria."
    },
    "b35e0f7c-9162-4752-98dc-b41bac62e99c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "in both sections of the primary clinical trial, patients reported adverse events at an equivalent rate"
    },
    "363631c1-e7d3-41e6-b928-09ce7251cb6e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "anogenital distance decreased is an indication that the anogenital distance is less than the norm. There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation ."
    },
    "568b4d2b-204c-4606-a75f-058a5870c84c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "regularly receiving radiotherapy will be the approach for the second group in the primary clinical trial, while viewing an educational dvd is part of the intervention strategy for the first cohort"
    },
    "4f3ab82f-b17b-45a0-803e-901d0a58bcc6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "sham comparator arm is an arm describing the sham comparator. Across both the primary trial and the secondary trial only one death was recorded in the adverse events."
    },
    "1efbc2a0-c0fc-4849-96d7-689fcfb3c4d1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "caplet dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a caplet. cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation."
    },
    "77890255-16cc-4dfb-b374-f2eba38238ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "bone marrow eosinophilia is a finding indicating abnormally high levels of eosinophils in a bone marrow sample. Most the primary trial candidates suffered from some kind of eating disorder during the study duration."
    },
    "fc211cd7-389a-4040-9c92-e06672257460": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "patients in the primary clinical trial that received paclitaxel infusions and those who didn't, exhibited the same severity of symptoms."
    },
    "1b3e5b01-1b05-4025-9100-2c6e6e7faf20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the neratinib group in the primary clinical trial exhibited a lesser idfs rate compared to the placebo group"
    },
    "4d824080-17e3-4df5-9ef0-f6b0e3496f31": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "an increased number of adverse events were reported among participants in cohort 1 of the primary clinical trial as compared to cohort 2."
    },
    "74178d28-3c60-4439-944a-84318eff5c92": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "total bilirubin level finding is a finding that indicates the amount of total bilirubin in a sample. a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial."
    },
    "ec1b4763-e8bc-4c2f-be22-6b64b623b072": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "biopsy guidance is any of various methods to assist in directing a biopsy needle into the area of interest. A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial."
    },
    "6b5a90bf-c45f-4a85-807f-1f184463cf5f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "after undergoing treatment with aprepitant, dexamethasone, cytoxan, and kytril in cohort 2 of the primary clinical trial, acute vomiting was reported by over 50% of the patients."
    },
    "4d1b524f-e8d8-4444-bc99-6631e049fde8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "hispanic patients without any state residence restrictions can take part in the primary clinical trial."
    },
    "9fad2ea9-39ad-4c5b-afbe-82d9c40dbeee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial. 7q31.3-q32 is a chromosome band present on 7q"
    },
    "94328fa0-182a-4275-929c-bc10f899ba5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "regardless of a previous encounter with a pulmonary embolism, patients can apply for the secondary trial, and the presence of breast implants does not hinder patient participation in the primary trial."
    },
    "bf41ff3e-3801-4cb7-8e09-0400100a4010": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "endocannabinoid is a class of endogenously expressed compounds capable of activating cannabinoid receptors. Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial."
    },
    "c179d073-c910-42ab-9fde-85e976e52203": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "Morbidly obese patients can be eligible for the primary trial and the secondary trial. 1q22-q25 is a chromosome band present on 1q"
    },
    "ec5c7b6f-dfae-4681-9b8f-4f0b3635d232": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "chromatophore is a pigment-producing cell located in the deeper layers of the skin. All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week."
    },
    "c83203cf-4121-4d9d-a662-cd596a5f63d5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "hypokalemic individuals can participate in the primary clinical trial but are ineligible for the secondary clinical trial"
    },
    "224b15b9-fc1d-4c8b-ae55-ec4731ae5d04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "although cudc-101 dosage remains consistent for both cohort 1 and cohort 2 in the primary clinical trial, it is dispensed more frequently to cohort 1."
    },
    "dd0571e3-088c-4dc7-a47a-175210514286": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. grade 1 testicular disorder, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated"
    },
    "02addfef-d1b3-4e62-865c-aa0bd1ddfab4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "the secondary trial and the primary trial share at least one inclusion criteria. tandem mass tag 10-plex is a tandem mass tag reagent preparation containing ten distinct isotope substitutions."
    },
    "448df56a-bcc3-491e-8626-dc8d439013b2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "there were several fatalities in the second cohort of the primary clinical trial."
    },
    "12903135-4650-492b-b2c9-1f5c159af477": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "an individual with 2-3 cerebral metastases is welcome to participate in both the secondary and primary trials."
    },
    "668cbbc7-bc89-440f-8503-a7e273c4fab3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "symptom interference score 8 is a subjective score of 8 on a scale that ranges from 0: did not interfere to 10: interfered completely. Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial."
    },
    "0f9e0c7c-a021-4aeb-9309-ab2d6f1d78f8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event. cordonnier grade 3 viral complication, severe varicella zoster virus infection is any severe varicella zoster virus infection."
    },
    "8cd9c9e7-ff02-4e49-893d-a4e2837bf18f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "autoimmune neutropenia is a condition characterized by the autoantibody-induced destruction of neutrophils. Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses."
    },
    "76f87500-dd58-4086-9991-90e4f8206abf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 10 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "9d196526-1000-4235-add7-49de8e168d3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "there are more cases of bronchopneumonia and general physical health deterioration in the secondary clinical trial than in the primary clinical trial."
    },
    "285be2fe-e597-4d99-acb9-7504bcfb3d6f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial. acrocephalosyndactyly is a genetic disorder characterized by craniosynostosis and fusion of the fingers and toes."
    },
    "03fe5ae7-9f15-4d30-a208-cead95780b13": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "the primary clinical trial employs arimidex in both cohorts, yet this is not the case for the secondary clinical trial."
    },
    "dcad8706-4bfe-4076-9bd5-babca4f63beb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "50% the primary trial participants, and 110% the secondary trial participants suffered an ae."
    },
    "2e35f870-1118-4c57-be71-a1b17e6841e3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "post neoadjuvant therapy sample is a biospecimen derived from a subject after treatment with a neoadjuvant therapeutic. Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial."
    },
    "777b7b77-83e6-49a0-9988-c2363fbcc17d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "many participants in the primary clinical trial do not experience any increase in pleural effusion and rapid disease progression"
    },
    "5b23afbf-8b5c-441b-99b2-295c66958545": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "the primary and secondary clinical trials do not admit participation from women having claustrophobia and osteoporosis."
    },
    "09f76c97-d8e4-45bd-9365-71e654770e39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "midline is a medial line, especially the medial line or medial plane of the body (or some part of the body). the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts."
    },
    "602c538d-9b6f-4a94-8423-b7d5427ee15e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or any description of the treatment. post term pregnancy is a gestation that lasts greater than or equal to 42 weeks and 0 days."
    },
    "be93f6ab-df27-4f10-a485-24823f7056fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants. micromole per liter per milligram per kilogram is a unit of concentration equal to micromoles per liter, divided by milligrams per kilogram."
    },
    "94e5871f-085c-4757-9941-3c83a71da6a4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the data from the primary clinical trial reveals that the arm d intervention had the superior overall response rate. additionally, in the secondary clinical trial, the denosumab cohort exhibited a promising time to first on-study sre compared to the zoledronic acid cohort."
    },
    "3d9a7121-da16-4e7b-a02d-1932f46cbb77": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial."
    },
    "1824af8a-6f79-49bd-8df3-5751b1e65adb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements. 10q26.13-q26.3 is a chromosome band present on 10q"
    },
    "2c9e275c-18ef-471f-8ec9-1d73bfb27e20": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "the severity of symptoms in patients in the primary clinical trial who did not receive paclitaxel infusions, was milder than those who did receive paclitaxel infusions."
    },
    "776a17db-8314-4fc6-9de3-0d110db79269": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "individuals contemplating radiation treatment for stage 2 colorectal cancer are eligible for the primary clinical trial."
    },
    "87a0c1c5-507a-4188-87cf-57f27add4cf6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "rio de janeiro is a state in the southeast region of brazil. its capital is rio de janeiro. Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections."
    },
    "a67f344b-aa15-4e94-819b-515df442eaf0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "more than 50% of patients in the primary clinical trial experienced a confirmed full or partial benefit after receiving treatment with lapatinib 1000 mg and nab-paclitaxel."
    },
    "5b19b14f-2049-4c5f-8e3b-5d8dffa5d687": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both. picomole per liter per microgram per meter squared per day is a unit of concentration equal to picomoles per liter, divided by micrograms per meter squared per day."
    },
    "a29b69ee-502b-4d86-b028-be9a56bfb7f6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the paclitaxel plus bevacizumab plus gemcitabine group in the primary clinical trial demonstrated a better orr than its paclitaxel plus bevacizumab counterpart, with a larger participant pool"
    },
    "facb2d1c-1f65-4c84-9c93-209ce87d18a7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient with a primary tumour measuring 33mm in diameter, assessed through clinical examination and ultrasound, would qualify for both the primary clinical trial and the secondary clinical trial."
    },
    "d32ff217-1848-490b-8a99-bc12730318f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "the primary trial reported 5 serious adverse events while the secondary trial reported 3"
    },
    "3c273853-f394-4550-9969-d476fff275db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "there were 52 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial"
    },
    "18303bbd-059e-4161-8cc6-9569a71308f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "in the primary clinical trial, the identical dose of docetaxel, doxorubicin, and cyclophosphamide are given to all groups at equal intervals. however, three more treatment courses of these drugs are integrated into the second cohort"
    },
    "1eb531b0-d0fc-41b7-a6d4-1b774affc30a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "a patient who completed a cycle of antineoplastic therapy one month prior to the primary clinical trial is seasoned to participate in the investigation."
    },
    "bde8a5a0-02fc-4b6e-a91a-a56c420d9c3b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs)"
    },
    "4e5fb5c5-d286-4109-a89b-28f399788cae": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "intraduodenal route of administration is administration of a drug within the duodenum. women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial."
    },
    "ff9b4b7a-e2c7-470d-9a7f-6f2b9669da64": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 700 mg of ibrutinib and 5 mg/kg of medi4736 twice daily for three months."
    },
    "11daa2f8-2ecf-49f7-aa69-844a2bade4b6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim. 9p21 is a chromosome band present on 9p"
    },
    "c7a78221-6f3c-484f-a281-908ab30a7e31": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "pyometra is an infectious process characterized by the accumulation of pus within the uterus. Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant."
    },
    "0b5e78d7-d717-41d0-98e5-564eda711bec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "severe insomnia patients are barred from participating in both the primary and secondary clinical trial."
    },
    "ef6928bd-e4ac-44f6-a7bd-292a728df94b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial. precordial catch syndrome is a condition in which there is musculoskeletal chest pain characterized by brief, sharp discomfort associated with inspiration. (acc/aha)"
    },
    "5ab7ac4b-19cd-455c-8796-50680cedf7f1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "in the primary clinical trial, both cohort 1 and cohort 2 are given dexamethasone before surgery."
    },
    "287c1319-d37b-4a6a-a0f3-2059ce18b07d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 48 months if they want to participate in the primary trial"
    },
    "01bff32b-6bba-4295-94e9-c3a8430670be": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "pihgc is utilised in the first intervention, and standard gp is used in the second intervention as part of the primary clinical trial."
    },
    "eca5c391-f479-448d-bff8-313a7df673b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts"
    },
    "bc1a73c0-825c-48dd-b6cf-e440ae0bb782": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "vorinostat capsules are strictly prohibited for all patients participating in the primary clinical trial during radiation therapy"
    },
    "7df47095-163a-4062-9b5b-f2dfd02259fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150000 mcg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "a3f8233e-3af4-41f5-a4f4-7676251de646": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial only necessitates a single type of medicine and avoidance of surgery, on the other hand, the secondary trial involves administering five different types of drugs and obligatory surgical treatment"
    },
    "c77cef4c-abf2-439e-97a4-abf4e1d57ac8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "for the primary clinical trial, female cancer patients who are at least 18 years old can participate, regardless of their cancer type, race, or ethnic origin. yet, only patients with her2/neu+ breast cancer can apply for the secondary clinical trial."
    },
    "2b58a234-e92e-475b-a0c9-a947776bf332": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patient that has been under the treatment involving antineoplastic chemotherapy, androgens, estrogens or progestogens in the last month before study initiation are dismissed from the primary clinical trial."
    },
    "22aed38a-d9c2-4e5e-b738-07f75968c45a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "110% of patients in the primary trial did not experience any adverse events"
    },
    "0204ab43-d10d-494c-a0be-3b16d96c34fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were several adverse events which occurred in more than 8/10 participants."
    },
    "e8be62e0-1f25-49f3-91d8-4fc23848dcd1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 of the primary clinical trial and cohort 2 received similar dosage of cetuximab and none of them had the addition of the collaborative care intervention."
    },
    "86ed4db6-24fe-4a88-ba9b-6be3f98e0525": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort"
    },
    "5e301f1c-087e-4ca4-b679-cc229d1c0d27": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2."
    },
    "4fcc0d4c-0772-47c8-ad68-80d10fbeaa0d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the primary and secondary clinical trials had syncope as the most frequently reported adverse event among patient cohorts"
    },
    "ad1abf74-05c4-439a-b178-f21231744c89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "retinal arterial branch occlusion is an occlusion of a branch of the retinal artery. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial."
    },
    "ed9afe03-8b68-464c-a9f8-0d3a58f64d7f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. wallet pack dosage form is a multi-panel, re-closable end-user pack for tablet blisters."
    },
    "c926dbb4-ab16-46dc-a2be-8d04563ce9d0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial and the primary trial recorded an equal number of aes"
    },
    "bffaad67-a8e9-43bf-a2ca-bbcaec96218c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "upon giving fully informed consent, patients suffering from stage 4 cancer can qualify for both secondary clinical trial and primary clinical trial."
    },
    "7c0a99c5-b76f-438c-a93b-15d3340cd430": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the outcome from the bevacizumab + capecitabine cohort of the primary clinical trial were superior to those of the bevacizumab cohort."
    },
    "f4cf0fc1-5b69-49a1-8ba6-454063ff63ce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "primary clinical trial participants were free from thromboembolic events, as were those in the secondary clinical trial."
    },
    "3b41b926-449f-41e1-beed-6dd4be9e57f1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "clinical variant is a form of a disease with clinical features that differ from other forms of the same disease. participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2."
    },
    "1bec6fcc-5a7e-4d19-81ea-e677715490fe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "cases of mucositis oral, epileptic seizures, and thromboembolic events were found to be more frequent in the primary trial than the secondary trial"
    },
    "063e3d67-dc20-453d-a437-f56447bfa49f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "palinavir is a hydroxyethylamine-based peptidomimetic inhibitor of human immunodeficiency virus (hiv) protease. the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group."
    },
    "7d78fd1d-3d73-460c-a1b6-c0d9bf3a60a9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. hyperphosphatemia is abnormally high level of phosphate in the blood."
    },
    "56e88bbd-7a3c-4a3b-a6cf-3f9b9e632b53": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the quantity of adverse events in the cohorts was found to be the same in the primary clinical trial and the secondary clinical trial."
    },
    "603ccef1-eacf-4053-85d3-106eda10ca83": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "patients with detectable malignancies in both breasts are allowed in the primary clinical trial"
    },
    "a441e08e-affc-4228-bfac-18ab1ead4bce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. data set is a collection of related data records."
    },
    "d8e5f1e2-76e1-405a-9920-c21c7f105eb2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "throughout the full duration of the trials, her2+ patients in the primary clinical trial and those in second cohort of the secondary clinical trial are administered the same trastuzumab dosage."
    },
    "00f4aa60-c89a-496d-aa2d-9535fcc79ff0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group. wash dosage form is a solution or suspension composed of active and/or inert ingredient(s) and intended for administration as an irrigant and cleanser."
    },
    "abf0f2b7-e989-49e0-82a7-7a2c594e1185": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "patients with stage 1 cancer are not eligible for the secondary trial, but are ineligible for the primary trial."
    },
    "c38f4f43-886b-41e9-9d42-5ce12e838600": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "terminal sacrifice is an indication that the subject was euthanized at the end of the study. Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria)."
    },
    "6fdb953d-a7b8-41b9-8652-2d8b51bfcaa0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "no adverse events were experienced by any participants in the primary clinical trial, likewise in the secondary clinical trial."
    },
    "9e3d3c08-d9ee-449d-b4c8-957d666315a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "no aes were observed in patients from the secondary clinical trial, while the primary clinical trial documented several instances of aes, including abdominal pain and insomnia"
    },
    "8734ab6c-5b2b-4d9f-958b-9b4f8249a6ef": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "in the primary clinical trial, a higher decrease in the primary tumor diameter was observed in the azd0530 175 mg group than in the zoledronic acid 4 mg group."
    },
    "a7382edb-9b99-468d-99f2-2030aa61005c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "ids-c clinical classification question is a question associated with the ids-c clinical classification. the primary trial and the secondary trial evaluate different patient characteristics in their results."
    },
    "1f9ee295-ce3d-427b-8af2-876edb47bf7f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the primary clinical trial requires administration of a multi-drug regimen, while the secondary clinical trial calls for the use of a single therapeutic agent."
    },
    "a325de64-fdaa-4c93-8e4a-22a1d502dd88": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "different methods of measurement and success criteria are used in the primary clinical trial and the secondary clinical trial."
    },
    "44ccb908-9444-4137-a227-c47b65207de7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "93.35% patients in the primary trial and the secondary trial suffered from infections during the study period"
    },
    "92e676b6-34f9-4b11-bfad-b45cf8942d2a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "the secondary clinical trial has witnessed an unexpected death and hospitalizations"
    },
    "c63468c0-324f-4528-b83f-a588ccf7b680": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "35802b7b-4d8e-4f1a-bab8-20eea1f4aa3f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last decade would be excluded from the primary trial"
    },
    "04c1483e-d2bb-40a2-b215-ede1e3c7c973": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary clinical trial and the secondary clinical trial use identical medications, dosages, and interval of administration within their interventions."
    },
    "33603672-b61c-4ddd-8e57-d38876de9132": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "there was no repetition in the type of adverse event endured by patients in the primary clinical trial."
    },
    "6033e8d9-c7d5-4b36-b6da-80fdb98de034": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 1000 millimeters in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "8c7a92ab-80cd-4bb4-8b03-fa5f6776ca5a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "the primary clinical trial and the secondary clinical trial both rule out patients who struggle with severe forms of insomnia and schizophrenia"
    },
    "926177b8-d70d-48d4-95c9-4d74de46d9d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "no pathologic complete response in breast and axillary lymph nodes was reported in patients involved in the primary clinical trial"
    },
    "da01cb99-7533-4cb5-ae01-16453c94cc7e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 2 weeks after breast cancer surgery brings down the diameter of tumors by 40% on average."
    },
    "f5a6f0ee-22bd-4731-b973-e8c4736e4d18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "ligament injury is an injury to any of the fibrous bands of tissue that comprise an articulation (joint). alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day."
    },
    "4f66f663-030a-4391-a426-4e6b2f3bc9d2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "the primary trial participants experienced less incidences of diarrhoea than the participants of the secondary trial"
    },
    "363212ed-da18-4ae4-a7e5-cab37c207a24": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "usually find myself worrying about something is a question about whether an individual usually finds themself worrying about something. Any japanese national can take part in the primary trial, or the secondary trial."
    },
    "006c9dd6-c568-4497-81b7-c954568a3b4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead."
    },
    "98b04dac-b155-4afd-8855-03ed818df5d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial."
    },
    "2a45331c-2e6b-43fb-be85-86e22c828c41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "compared to the bevacizumab + capecitabine cohort, a greater incidence of disease progression or death was reported in the bevacizumab cohort of the primary clinical trial."
    },
    "bcbc612f-11c9-40ba-9376-c098a9b738f4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary clinical trial employs muscle growth as an indicator of physical therapy's effectiveness. on the other hand, the primary clinical trial examines how sulforaphane supplements influence the level of isothiocyanates in urine."
    },
    "d8f0b3e8-ca61-4874-a4e0-1328029bce88": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "the inclusion requirements of the primary and secondary clinical trials are the same, therefore, anyone currently involved in the secondary clinical trial can also participate in the primary clinical trial"
    },
    "20296404-9526-4410-953c-51ea7ae866bd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "notable patterns in the expression of 40 genes under evaluation were observed in certain patients maintaining normal vitamin d levels in the primary clinical trial."
    },
    "3a9ca481-4b74-4bd3-99f0-1b34cc33ba33": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "about 0.3636 of the primary trial patients suffered an increase in blood bilirubin."
    },
    "ee16dd43-346c-47c2-b5c1-b3722935918d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "the primary clinical trial does not reject participants based on their height or age, while the secondary clinical trial restricts underage participants"
    },
    "f73ec9f6-b18c-4f32-9116-573f5f717e55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient with a primary tumour smaller than 20mm confirmed by ct scans, would be eliminated from both the primary trial and the secondary trial."
    },
    "5b31fcf1-a528-4718-adcb-72df68b4df43": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial and the secondary trial recorded the same number of adverse events in their cohorts. moderate tumor infiltrating lymphocytes is a finding of a moderate number of tumor infiltrating lymphocytes in a biospecimen."
    },
    "22a2488f-5559-40e9-a85b-484a1aacd263": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "maculo-papular Rash was a common adverse event for the primary trial participants. 22q12.2 is a chromosome band present on 22q"
    },
    "018fd266-6def-4792-85e4-0b12108281b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "different group arrangements were followed in the two trials; specifically, the primary clinical trial had a test group and a placebo group, whereas the secondary clinical trial had a test group and a control group."
    },
    "856ab26e-3ce5-4405-b5ce-22557600b74f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane. penile epithelioid hemangioma is an epithelioid hemangioma that occurs in the skin of the penis."
    },
    "fddee10c-dd7d-47fe-b2cf-3ebe94726ea4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "all patients in the primary clinical trial and the secondary clinical trial receive suramin and paclitaxel"
    },
    "c651d7a4-f39a-44df-84cc-f71c45ced124": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "cell culture-based biosynthesis is a process that synthesizes a material of interest using cell culture techniques. A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial."
    },
    "0c05d756-82d5-4f8f-afe7-845857c1e9d3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "inhalation is the administration method for intervention 1 in the primary clinical trial and for the all intervention drugs in the secondary clinical trial."
    },
    "f5daafd4-0b8b-4239-b566-e7b2c1b80825": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have received chemotherapy or radiotherapy in the last 14 days, suffer from unstable angina, or have grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "03837d34-3ddb-4bfc-a993-b27e2d16f427": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "homeopathic dilution unit is a dosing unit that is based on homeopathic dilution. The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine."
    },
    "e0c940e7-9a19-4c78-bf0f-4f630f6cfb90": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans. was sdh complex mutation analysis performed is a question asking if mutations in subunits of the sdh complex were analyzed during the study."
    },
    "cbe273ac-6267-4827-8ba2-8c8c34d69115": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "patients in the secondary trial experienced anemia, pneumonia, and stupor more frequently than those in the primary trial, however, a higher occurrence of febrile infections was noted in the primary trial."
    },
    "6e971275-b508-4627-9380-39dc63e90b3d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants do not receive any vaccines. rehabilitation center is a healthcare facility designed for improving, maintaining, or restoring physical strength, cognition, or mobility."
    },
    "77c7c86b-30a5-487b-8abc-d3aafff69a5e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 50mg of mcs110 every 3 weeks, and over 200 mg of pdr001 every other week."
    },
    "8180d5e0-b284-45fe-a390-0c3a54dc663f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV."
    },
    "b36dca2b-8c53-4f4d-b956-0d86194d2d2d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "diarrhoea was equally common in both primary and secondary clinical trial participants"
    },
    "8e18ed71-8fa4-4d81-841d-ce718daa0f41": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients diagnosed with tumors positive for ccnd1 amplification are eligible for the primary clinical trial."
    },
    "9d7e5e1f-b92f-464d-94ea-a7eb3ae730b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1.807 x 10^6 cells/\u2248\u00ed\u00ac\u222bl, platelet count of 110.034 x10^6 cells/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 9 g/dl, and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial."
    },
    "4b6d301f-d0c7-45c9-a39a-ff973e0b9d45": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "neither the primary nor the secondary clinical trial requires the participants to be of a certain nationality or gender."
    },
    "547b8239-a47c-4f70-aa08-ff1d92e19af2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "having an adequate vitamin d level is a prerequisite for participation in the primary clinical trial, while it is considered as a disqualifying factor for the secondary clinical trial."
    },
    "fc38bc02-5e04-4b3d-bf4d-19fa9a636bd2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "no participants in the primary clinical trial experienced a decline in cognitive function, including those in the ovarian function suppression group"
    },
    "073ce8e6-59a6-41e8-a45f-ca91d19dceec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "patients presently participating in the secondary clinical trial are also permitted to enter the primary clinical trial since the criteria for inclusion are identical"
    },
    "42c38d71-6a83-4967-ad81-ec38c6b5aafd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1"
    },
    "871378d6-a6e5-461c-af83-d82fe8f44f4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "sutterella is a genus of aerobic, gram negative, rod shaped bacterium assigned to the phylum proteobacteria and the family alicaligenaceae. candidates for the primary trial must have breast cancer and require hormonal treatment."
    },
    "b8e81997-7fd7-4934-9ee8-bb7c647d334c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "all ae types in the primary trial affected less than 0.1 of patients"
    },
    "0b90fb4c-0de2-478b-95d2-2f0b555398ad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the intervention section of the primary clinical trial calls for only therapeutical and lifestyle changes."
    },
    "e2abe23e-d9a8-4329-a41b-26c90266f6d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "electromagnetic spectrum is a charted band of wavelengths of electromagnetic vibrations. the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort."
    },
    "a0f34f76-d0dd-48f3-b916-1722ecb924c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "worry that skin condition may be serious is a response indicating that an individual worries that their skin condition may be serious. Both cohorts of the primary trial recorded 0 Aes."
    },
    "641b6edf-2ed6-494a-9d37-7c7f04ccd6a0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 175 mg group and the zoledronic acid 4 mg group of the primary clinical trial had similar reductions in primary tumour diameter."
    },
    "7d7cfab4-e501-4292-bf9c-363ccc1bf1dd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "in the primary clinical trial, the group treated with paclitaxel plus bevacizumab plus gemcitabine had a higher orr than the paclitaxel plus bevacizumab group, and included more participants"
    },
    "a378ea56-7b9b-4ee9-b304-ff9597744fb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures. non-neoplastic thymus disorder is a non-neoplastic disorder that affects the thymus.  representative examples include acute thymic involution and thymic hyperplasia."
    },
    "807c9531-c049-40a5-a170-3f8924335381": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "transient arthropathy is arthropathy that is not permanent. cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1."
    },
    "0ef3e1a1-d303-46de-8940-07746737fe87": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "breast cancer patients who have estrogen negative, progesterone negative and her2- tumors can participate in all groups of the primary clinical trial"
    },
    "ef245c6c-7858-45cd-a0fd-d272e7aae585": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial does not receive myalgias, while patients in the secondary trial cohorts receive 2ug/kg of myalgias (5ml)"
    },
    "74f1ae66-88fd-4508-ba6b-2ad19274d6e3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "some of the time is a response indicating that something happens or happened some of the time. More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery."
    },
    "1ee86f9f-6119-4cce-a036-324aea1fb251": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 500 milligrams of denosumab injected subcutaneously every day, the secondary trial also requires injection, adminstering 4.0 to 2.5 mci of radioactive tc99m sulfur colloid."
    },
    "6b5cc819-da7b-4e4f-ae2f-7e4db8073860": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "in the primary clinical trial, more than 15% of patients were affected by all types of adverse events (aes)"
    },
    "53459054-8f8c-4fd1-9d1f-2f109c45c5b8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the count of total adverse events in the secondary clinical trial was notably less than what was documented in the primary clinical trial."
    },
    "7f128ec3-a88f-4cbe-9d79-0ef9e0f1d3bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial. fallopian tube soft tissue neoplasm is a benign or malignant mesenchymal neoplasm of the fallopian tube.  representative examples include leiomyoma and leiomyosarcoma."
    },
    "df8bb8da-6aec-4678-97f3-cb122188ea9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934. anorectal infection is an infectious process affecting the anal area and the rectum."
    },
    "e46defaa-44a0-4919-bd9b-aa018de05da1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary clinical trial and the secondary clinical trial use different metrics for success; in the secondary clinical trial the marker for success is complete radiographic response within the breast, while the primary clinical trial measures the disappearance of signs of the disease at all sites of metastasis"
    },
    "8fd48918-38db-4443-a1b8-bf2d7a458857": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "primary clinical trial patients suffered from anemia, pneumonia and stupor more often than patients in the secondary trial, but more cases of high blood pressure were recorded in the secondary trial."
    },
    "1dd07ae9-349c-41e1-b967-fd8691e320e0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have received chemotherapy or radiotherapy in the last 4 weeks, suffer from unstable angina, or have grade 3 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "a1a3cda8-7324-4270-aaf9-51ad1b40be07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial recorded 11 more Aes than the primary trial"
    },
    "6fd90164-4ae9-4296-88d8-e6eab3811c8a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation . intermediate lipomatous neoplasm is a lipomatous neoplasm characterized by a high risk of local recurrence and no risk of metastasis."
    },
    "9e3cf2a2-6713-4d07-adde-e334b49ca6ec": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates"
    },
    "5255cd06-123a-4d45-943d-37b6261b1cf7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders characterized a substantial portion of the primary clinical trial candidates'"
    },
    "c67874fc-c736-4da3-bc73-1e40cbf323c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "57% of patients in the primary trial did not experience any adverse events"
    },
    "1e2b550a-0da3-48ea-8221-1a8b86e10511": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. nanomole per liter per microgram per day is a unit of concentration equal to nanomoles per liter, divided by micrograms per day."
    },
    "ff7079ec-d642-4cc3-8767-62df7a2a8ff7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates capable of only limited selfcare; confined to bed or chair more than 0.5 of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "3d35c61e-075e-475e-b3aa-15c04db3a579": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "in the primary clinical trial, both groups receive identical measures of abraxane and carboplatin"
    },
    "a630808d-14d5-4ef8-bd2e-73ce5e80f3f1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 750 mg of fulvestrant in a tablet form to be taken bid."
    },
    "fe0472bd-acfb-4a56-abed-20b0a4e6b48f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "the primary clinical trial considers patients with tx nx mx, t0 nx m0, or t1 n1 m1 tumors to be eligible"
    },
    "25c8668a-29f5-4bf0-9c35-89ba2e5e1776": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "ovarian rhabdomyosarcoma is a malignant mesenchymal tumor with skeletal muscle differentiation affecting the ovaries. the secondary trial recorded 11 more Aes than the primary trial."
    },
    "587e611a-9c3b-4557-b3ca-56a7dcc6ce1b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110."
    },
    "3ed31a8a-dce6-4a6c-b1a6-143db3702546": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "mcl-1 inhibitor is any agent that inhibits mcl-1. The the primary trial intervention section requires surgical and imaging procedures."
    },
    "73849f1e-31c6-40c5-ab5c-35d0990ceac2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial."
    },
    "de3bd9a7-c733-43d3-9f7d-3bf3c98a42f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "the primary trial administers alisertib to all participant cohorts, and a consistent dosage is used globally in the secondary trial's cohorts"
    },
    "9e8aeaf6-36db-4f09-b7a6-7a5e41d14215": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results. congenital disorder of glycosylation type if is a congenital disorder of glycosylation sub-type caused by mutation(s) in the mpdu1 gene, encoding mannose-p-dolichol utilization defect 1 protein."
    },
    "ad1bb75e-6250-4dbe-beff-a702293ce87c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "no previous treatment with gabapentin or herceptin, required for eligibility in the secondary trials, but will exclude from the primary trial"
    },
    "594df991-cd8d-4ca0-9fe9-5c21a73a0bf3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary clinical trial employs pain as a gauge for evaluating the effectivity of physical therapy, while the impact of sulforaphane supplements on urinary isothiocyanate levels is the subject of analysis in the primary clinical trial."
    },
    "63966dc4-b12e-4e45-befe-50b9c19a702a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "cohort a and b of the primary clinical trial are administered different treatment methods, neither involving electroporation injections of ld v934"
    },
    "afc3c380-94da-4686-a5ca-1967217d14d1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "no incidences of tumour lysis syndrome were reported in the primary or secondary trial"
    },
    "2db5cad0-f216-4e18-accf-87e3308afc59": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "secondary clinical trial is based on the alterations in mymop score to determine the outcome of their study."
    },
    "f7c36a91-5d42-46b9-b0cb-db7a57d37c04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "in the primary clinical trial, the administration of eribulin to cohort 1 is at a higher dosage than the administration of docetaxel given to cohort 2."
    },
    "e123c707-0e86-43c1-8f9b-971363c07ae0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "regimen used to treat prostate carcinoma is any regimen that can be used for the treatment of prostate carcinoma the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts."
    },
    "523d79a3-ee67-4b2a-a1cb-20ed4ed45dc6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group"
    },
    "5baa6e97-00e4-4e2f-b837-661a790cb87f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary clinical trial and secondary clinical trial evaluate similar patient attributes in their results."
    },
    "28375759-dcd0-430d-8035-9571e1bbc07e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses lower doses of lenalidomide than the secondary trial uses of lapatinib in intervention 1."
    },
    "1a3483cd-0a92-456f-ba18-6ce12b3ded0b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "19q13.4 is a chromosome band present on 19q Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial."
    },
    "b590614e-03b9-4e7b-91e9-940058316465": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "patients diagnosed with 2-3 cerebral metastases are ineligible for the secondary clinical trial, but they may qualify for the primary clinical trial."
    },
    "4a54e780-0828-40c0-9f30-1ed06b66275a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2. adult acute eosinophilic leukemia is an acute eosinophilic leukemia occurring in adults."
    },
    "098f7c20-8543-4de6-b236-341c4cdea28e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "from the primary trial, it was found that 13% of participants having her2- primary breast cancer developed imagable her2+ metastases post their treatment with her2-targeted pet/ct. 89zr-trastuzumab"
    },
    "f83fe0ea-4d77-4db1-a66d-eb0df033a592": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates eligible for the primary clinical trial have been diagnosed with lung cancer."
    },
    "893a5337-2aa9-4a87-a020-4c2f03cd4aea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation."
    },
    "030afaab-4125-4b2c-ac40-5d7a4cacaf52": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "cordonnier grade 2 fungal complication, deep candida infection without candidemia is any deep candida infection without candidemia. The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses."
    },
    "ffa844c8-752d-48df-aa7a-e0ba58305b12": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "ret gene translocation is a cytogenetic abnormality that refers to any translocation involving the ret gene. Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "47512f16-9809-4150-a101-1fb7256c5bf3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine."
    },
    "7cd2b581-31f9-42e8-9945-9317f97be422": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "the dosage of eribulin given to cohort 1 in the primary clinical trial is comparable to the docetaxel dosage received by cohort 2."
    },
    "75625dfd-7f82-4a99-b97d-50f05751dfdb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "mood disorder is a category of psychiatric disorders which have as their most predominant feature a disturbance in mood. Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial."
    },
    "3a452f00-375b-48c4-96dd-48986c0c0064": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "efbed283-d725-4f05-8e7a-3cb43ce470e6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "in the primary clinical trial, both groups a and b receive the same two im injections of ld v935 at an identical stage in the cycle."
    },
    "2493d396-14df-4cf7-b2b4-3e84d4363a0f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 0.56 g of ibrutinib and 0.01 g/kg of medi4736 twice daily for a month."
    },
    "df43c972-9623-462c-9044-2d632e1daafb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients with papillary carcinoma and controlled blood pressure levels are accepted for the primary clinical trial, but are not qualified for the secondary clinical trial."
    },
    "83457ad0-4ebe-4bd7-abf7-bf629af15e58": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 1 and cohort 2 of the primary clinical trial both take enzalutamide orally"
    },
    "3559fa92-e0d7-4e4f-9b1f-7f087fbff0d1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "both the primary clinical trial and the secondary clinical trial incorporate x-rays and ct scans as part of their procedural interventions"
    },
    "4a688f54-5b9a-49ad-b6a1-833d1ff96924": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary clinical trial employs distinct criteria for acceptance and rejection across its two stages, unlike the secondary clinical trial that applies a unified set of criteria for all participants."
    },
    "410a0a55-a31f-4a57-9de1-3eacd3da7650": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "the primary clinical trial was devoid of any adverse psychiatric events such as eating disorders or schizophrenia."
    },
    "a6ee28c9-2b3a-47a6-b576-8ca75d38fb67": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 100 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "e8d33476-b6f1-4337-8072-c07e4f223275": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "all cohorts in the primary clinical trial exclusively receive cudc-101 without additions of any other therapeutic treatments."
    },
    "f6ce492e-e69c-4908-9b04-b0234a364e95": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "17p13.1-q25 is a chromosome band present on 17p The Interventions in the primary trial included different medications but are administered through the same routes."
    },
    "86dd343d-01be-46f6-aed5-9ad9423aca98": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "500 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 60% of patients."
    },
    "0c27bcc9-3108-4d4a-901a-22718c22d288": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "The majority of patients in the primary trial experienced complete response by week 24."
    },
    "d88d1ea7-3d60-4234-896b-2060dee299f7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "cohorts 1 and 2 of the primary clinical trial each follow a different relaxation audio guide, but both practice the same number of times per day."
    },
    "961aaf91-e07d-4723-860e-23593727c303": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "intervention 1 in the primary clinical trial, and all intervention drugs in the secondary clinical trial are to be administered orally."
    },
    "5ca1c4e8-73e3-4329-9644-bfb986b6673e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "encounter due to other problems related to physical environment is an icd encounter due to other problems related to physical environment. In total there are less cases of anemia in the primary trial than in the secondary trial."
    },
    "d331f99d-446c-4305-8842-05d6fe2d070c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "in the primary group of the primary clinical trial, a number of anaemia and febrile neutropenia instances were noted, but there were zero cases of pancytopenia."
    },
    "8820e8d9-5bea-461f-8622-5ec4b6388a79": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "while the secondary clinical trial excludes 18-year-olds, the primary clinical trial has no defined age criteria for participation."
    },
    "9ad9b404-b234-41e6-9699-06a8c03bfe08": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "rand social support survey questionnaire question is a question associated with the rand social support survey questionnaire. the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time."
    },
    "555d74d4-755a-44b9-9bec-f8adda634c38": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial. difficulty chewing food due to dryness of mouth is a question about an individual's difficulty chewing food due to dryness of mouth."
    },
    "822bd855-46b1-4290-ac89-f3a92e96f523": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "every participant in cohort 1 of the primary clinical trial encountered at least one serious adverse effect."
    },
    "4ceb3f73-8812-4534-9688-52e5d3db524f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 0.1 g/m^2"
    },
    "002e96b7-152f-4860-b61c-21327c2e6b23": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a patient aged 32 years, with a confirmed histological diagnosis of stage iii breast cancer, an absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bl, a platelet count of 79000/\u2248\u00ed\u00ac\u222bl, a hemoglobin level of 90 g/l, and a life expectancy of over 8 months is a fitting candidate for both the primary clinical trial and the secondary clinical trial."
    },
    "dac129a3-974e-4918-95e5-11bbc0207e02": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "unit per gram per day is an arbitrary unit of substance rate expressed in unit(s) per gram per period of time equal to twenty-four hours. all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group."
    },
    "5f6cacb7-41e6-4d8c-9a43-7bd21202b11f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "intraoperative urinary injury, ctcae is a finding of damage to the urinary system during a surgical procedure. children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial."
    },
    "67bce826-0ca5-477c-8802-2511317e675d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "the patient cohorts of the primary and secondary clinical trials are both given cyclophosphamide"
    },
    "7f1301ad-2bc6-426b-86da-8a5c80dfba0c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "double outlet right ventricle is a rare congenital cardiovascular abnormality in which both the aorta and the pulmonary artery arise from the right ventricle. Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial."
    },
    "987667fb-e888-40d7-ab77-f0138d9295ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the primary trial has a higher presence of biliary colic and clostridium difficile colitis compared to the secondary trial"
    },
    "cf935264-ef24-4f3a-b60f-1c4cc9d36a54": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "in the primary clinical trial, one specific adverse event type affected more than half of the patient cohort."
    },
    "9ef9c9de-3dfa-4cbb-930e-c26190e2d119": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "after about seven months into the study, more than one in three patients, from both cohorts in the primary clinical trial, experienced a pathologic complete response in their breast and axillary lymph nodes"
    },
    "a66238c5-3c2f-47a8-8b38-aad66299aed0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary clinical trial receives lower doses of eribulin than cohort 2 patients receive of docetaxel."
    },
    "a8e679cc-cd10-409c-8434-8bb059146815": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 50.00% of the primary trial patients"
    },
    "b79be25a-c0ac-442e-adaf-821e42a3349b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "benign ciliary body neoplasm is a non-metastasizing neoplasm that arises from the ciliary body.  representative examples include leiomyoma and adenoma of the ciliary epithelium. Morbidly obese patients can be eligible for the primary trial and the secondary trial."
    },
    "0f4d6e4c-9315-4cbe-a322-37c6457cf49d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "in the primary clinical trial, intervention 1 is provided intravenously, whereas in the secondary clinical trial, the intervention drugs can all be taken orally."
    },
    "5942877d-3edd-4949-9128-b17a68194753": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery. other specified parts of pancreas is any component associated with the pancreas that is different from the one(s) previously specified or mentioned."
    },
    "d15f343f-8edf-484e-bc6c-bbcbbf8c9118": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "pain has interfered with normal work is a question about whether an individual has or had pain that interferes with their normal work. Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "e63ac45b-c34b-4007-820a-30202893fc6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation ."
    },
    "36eb6a9f-5a3a-4f8f-b242-e669aeaa3547": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "participation in the primary clinical trial is not allowed for patients with visible tumors in both breasts"
    },
    "a6276d61-5f8c-483b-8f18-a3becebddbe8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 participants in the primary clinical trial got the same cetuximab dosage as cohort 2, however, they received 8mg/kg less of mm-121 than cohort 2."
    },
    "685d9609-ec5f-4dcb-9783-e9d7b061eaf5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "seg algorithm is a computer algorithm that provides a general method for partitioning the globular and non-globular regions of a protein sequence. All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events."
    },
    "7d1f03c6-a869-45f0-9eda-4c272781e112": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "anorexia, hypothermia and hallucinations have been reported in the aes of the primary clinical trial."
    },
    "b2710f8c-602b-4831-8775-f8df3703761a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial receives 0.0005mg/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any dexmedetomidine."
    },
    "8dc16445-6102-4525-b9ce-ba4e35cc8b01": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "only post-menopausal women and men who have had a vasectomy are eligible for the primary clinical trial."
    },
    "379e6494-403f-4469-9ee4-9e3d12c0d562": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the bevacizumab group in the primary clinical trial yielded superior outcomes compared to the bevacizumab + capecitabine group."
    },
    "d1125c05-e0b3-4d7b-951e-cd21b5038b0b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "lgals3 antibody is any immunoglobulin that recognizes galectin-3. anorexic patients are eligible for the primary trial."
    },
    "24816a21-1c67-4b20-82f0-0891fed68773": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "patients in the primary clinical trial more frequently experienced symptoms of anemia, pneumonia, and stupor than those in the secondary trial, but febrile infections were more commonly observed in the secondary trial."
    },
    "9c15d42d-2fcc-4c69-86b2-f75e29d732d4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "one patient in the primary trial had an incident where a surgical incision reopened after the surgery. blood substitute is any agent that is able to increase blood volume and/or increase the oxygen transport in the blood."
    },
    "29a26ffe-8fcd-4e93-b354-3ca65738c8e5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "the primary clinical trial and the secondary clinical trial reported zero deaths among their adverse events."
    },
    "e1cf6d73-554a-4e33-8cf2-e19346eab3ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients diagnosed with alzheimer's disease are not suitable for the primary clinical trial"
    },
    "58f0bed2-bc88-4aaf-8572-fb49fc69a87c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "some patients treated with gtx-024 1mg in the primary clinical trial did not gain lean body mass over a 4 month period"
    },
    "91a6d0f0-3f3c-4bd7-80a5-f403fd7ef87e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "no x-rays, ultrasound, ct scans or mris are incorporated in the interventions of either the primary or secondary clinical trial."
    },
    "95928e94-237c-4e85-98d4-9dc5371c5069": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead. extragastrointestinal gastrointestinal stromal tumor is a rare gastrointestinal stromal tumor that presents as a solitary mass outside the gastrointestinal tract."
    },
    "b53a2698-dfb0-416d-9f3e-2e800a360b3e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX."
    },
    "863f7074-fb4b-4c82-9e30-bb785f85f816": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine"
    },
    "09904e7f-5e34-44b1-9edb-f92c3edcda95": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "operative time in the test group of the primary trial, arm 2, was found shorter than in the arm 1, meaning the control group wasn't superior. furthermore, in the secondary trial there is a control group for comparative studies."
    },
    "249d272c-cbee-4395-bb73-7e6cde3a4677": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "both the primary clinical trial and the secondary clinical trial would accept a 32 year old diagnosed with stage iii breast cancer, has a histologically proven diagnosis, an absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bl, platelet count of 110,034/\u2248\u00ed\u00ac\u222bl, hemoglobin measure of 90 g/l, and a life expectancy over 8 months."
    },
    "56530063-b408-47f2-8421-6be825f5559c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial are administered through different routes."
    },
    "280be8e4-7c13-4ca6-9653-94c7cf061c39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "patients, regardless of their cardiovascular health status, are eligible to partake in both the primary and secondary trials."
    },
    "94ccff26-4026-4888-9ef8-2af5aaebefad": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "the frequency of palpitations, pericardial effusions and abdominal pains in cohort 1 of the secondary trial exceeded those in cohort 2 of the primary trial."
    },
    "5d0a21d6-cf35-48c3-9128-9d3f9cd03d23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "the adverse events faced by patients in the primary clinical trial mistakenly match the ones faced by patients in the secondary clinical trial.'"
    },
    "74302b73-7dad-4eb7-b9f2-757d0508d85d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "candidates undergoing cbt based treatments will not be disqualified from either primary or secondary clinical trials."
    },
    "10a27e75-a4e3-4790-bafa-dfc9b9300a25": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "in intervention 1, the lenalidomide dosage in the primary clinical trial is greater than the lapatinib dosage in the secondary clinical trial, moreover, the treatment duration in the primary clinical trial exceeds that in the secondary clinical trial"
    },
    "3eb3c1f5-b395-43e5-a8e5-cf613ac87f30": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "individuals with a histologically or cytologically confirmed metastatic and/or advanced solid tumor located in the breast qualify for phase 1 of the primary clinical trial, and for all groups of the secondary clinical trial"
    },
    "383e310f-a7a5-49f5-ae10-ddf49eee92df": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates limited in their ability to self-care and who spend over 50% of their waking hours confined to a bed or chair are suitable to participate in both the primary clinical trial and the secondary clinical trial."
    },
    "5ce47a02-7653-4be0-8747-cc04ae14145a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "in the primary clinical trial, 97% of participants did not encounter any adverse effects."
    },
    "2c7901c7-b03b-4b92-852d-d182187dd2b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "in the primary clinical trial, there were two incidences of dose-limiting toxicity, both occurred in patients from cohort 2."
    },
    "3ed3f0f5-20e7-4cd1-8c4c-79ba7603fb85": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "t(1;13) is a cytogenetic abnormality that involves a translocation between chromosomes 1 and 13. Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision."
    },
    "0e6d3d31-1af3-4701-a410-b2bbb1ce430e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event in the primary trial. manual ability measure-36 is a rating scale of 36 everyday tasks that measures self-reported manual ability."
    },
    "a6299338-84c5-469d-9bd0-eff13b90a7eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally."
    },
    "2e753155-acb5-417c-9169-9ec7ccc4d8ac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "both the primary clinical trial and the secondary clinical trial do not allow participation of cancer patients with diagnosed epilepsy, thalasemic syndromes, or anemia."
    },
    "4028bb9b-1122-4c10-ab5c-a38205fe6dd2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "the same proportion of patients experienced negative effects in both groups of the primary clinical trial"
    },
    "20de5f49-227b-4d5f-9a4e-868354842985": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman who has experienced quadrantectomy may not be eligible for the secondary trial or the primary trial."
    },
    "b1d81c75-d076-45f3-8de6-6a23fc4f3832": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "Both cohorts of the primary trial contained the same number of participants. pituitary neuroendocrine tumor/microadenoma is a pituitary neuroendocrine tumor with a diameter equal or less than 10 mm."
    },
    "321c299b-2264-4cc6-988d-faef346ca38a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "mucor racemosus igg4 measurement is a measurement of the mucor racemosus igg4 in a biological specimen. Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses."
    },
    "7e0f7c16-59ff-4a80-833a-7bb82748e80a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 of the primary clinical trial was administered a lower dose of cetuximab than cohort 2 and received the same amount of 8mg/kg mm-121."
    },
    "13b40eaf-ad55-439f-9d93-a00a7bee3516": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "the primary clinical trial welcomes the participation of african-american patients."
    },
    "5a7d5563-2920-418c-a2fb-46ada378c860": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 24 months before study entry are excluded from the primary trial."
    },
    "e26430d8-c773-4770-b298-429c286fd5d3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "patients diagnosed with leukemia, irrespective of their cytogenic presentation, are eligible for all cohorts of the primary clinical trial"
    },
    "3426fcd0-2d5b-4d82-a9a1-93450b3336ee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "patients are eligible to participate in both the secondary and primary clinical trial concurrently"
    },
    "b12011c4-fa87-4249-97e3-635e6e6805a4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "dry mouth, ctcae is a disorder characterized by reduced salivary flow in the oral cavity. the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial."
    },
    "54fbf052-31df-43af-b20e-8947042351bc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the primary clinical trial has greater instances of biliary colic and diarrhoea compared to the secondary trial."
    },
    "4bcd8725-f138-49c8-b6a9-4f0c6eaa756f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "coronary artery stenosis is the most frequently documented adverse event in the primary clinical trial"
    },
    "f7d7cc99-97cb-48f0-bc69-78a60d9d21be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 66% patients in the primary trial treated with lapatinib 1000 g + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "22384b11-eb42-42da-86b3-dfed559ebb77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "Only 2 patients in the primary trial did not have Recurrence-free Survival"
    },
    "b12b7e1a-9348-4e57-ac88-44523913fff3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "in the primary clinical trial, the first intervention is received via iv, but in the secondary clinical trial, patients can ingest all of the interventions."
    },
    "663f13bf-bbc7-49f2-926e-b88da56cc74a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "not a single patient treated with sunitinib + docetaxel + trastuzumab during the primary clinical trial experienced a treatment-emergent adverse event."
    },
    "1af24416-2f14-423b-bd1c-b6f604cae64a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "patients with 2-3 cerebral metastases located in the cerebellum are permitted to participate in the secondary clinical trial, while participation in the primary clinical trial is not an option."
    },
    "32f5c37f-6752-4ebd-840b-d232b65bc138": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "only australian nationals are eligible for participation in the primary clinical trial and the secondary clinical trial."
    },
    "95759249-3a95-4735-8ef0-13ec3558aa27": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests. gaoshan chinese is a chinese person from the gaoshan ethnic group."
    },
    "69848bb3-c093-4bf4-91eb-f941109b1cd6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "in the primary clinical trial, transendocardial injections are used to administer both the placebo and allo-mscs intervention in equal doses."
    },
    "2cee68da-471f-4c13-811e-9d7ef91d587e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary clinical trial provides one of the patient groups with 150 mg oral pregabalin every fortnight for a total duration of 6 weeks, while the secondary clinical trial administers its subjects with depocyt and hd-mtx."
    },
    "01f72f8a-d22e-4509-859a-5df198d04d2f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "patients suffering from severe obesity can participate in the primary clinical trial"
    },
    "75fdf74b-e876-43f0-a382-03cf7055464b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "the recorded harmful effects in the primary clinical trial were only noted for patients from cohort 2"
    },
    "e876c279-ae1c-4e26-a25b-4da7222957bf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "candidates do not need to meet any baseline performance standards to participate in the primary clinical trial or secondary clinical trial. neither trial uses unique performance scoring schemes."
    },
    "3be36531-265f-4d51-bd65-1e2f46b28eda": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "both primary and secondary clinical trials present data on the mtd of multiple interventions"
    },
    "0cb2b471-fa4a-4eeb-8dd7-981680465858": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "all the logged adverse events in the primary clinical trial happened to patients grouped in cohort 1"
    },
    "ef637aff-9f52-4e17-a4d7-77e6cdb740c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients with stage 4 invasive breast carcinoma, which tests positive for either estrogen or progesterone receptors and are considering ai therapeutic intervention, are eligible for involvement in the primary clinical trial."
    },
    "8e19b7e1-e5ac-473f-a4e7-2c8ddfa7a496": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine. thyroid cancer pt4b anaplastic carcinoma tnm finding v6 is anaplastic carcinoma extending beyond the capsule of the thyroid gland, which is surgically unresectable. (from ajcc 6th ed.)"
    },
    "f569ce38-1e3f-4e8d-a9d7-e4a35a18c90c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "dyskinesia is abnormality or impairment of voluntary movement. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial."
    },
    "7b74835d-12ba-4d02-a09c-817f33abd3b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. synonym code is a coded value specifying the synonym of the event or entity."
    },
    "10ae9352-5088-4431-8a48-a6891f5d03b7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "irrespective of a patient's qualifications based on the exclusion and inclusion criteria for the primary clinical trial, their own decision serves as the final say about participation."
    },
    "6f4a77ce-3f70-4b57-ae45-e9825753d9ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 30-day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "f95708f6-04c7-469b-bba1-658c1d6eed45": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "lung pecoma is a lung tumor that arises from perivascular epithelioid cells (pecs). there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial."
    },
    "9d99fc21-4f9a-4c4a-b260-d8c17d1cbdd2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "ntrk2 fusion negative is an indication that the expression of a ntrk2 fusion has not been detected in a sample. All of the Aes recorded for cohort 1 of the primary trial are related to mental health."
    },
    "04901c04-5a0e-46cb-8684-96ff864921fe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a patient in their 32nd year, with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1807000 cell/mm\u00b3, platelet count of 79000000 platelets/mcl, hemoglobin level of 0.09 g/ml, and a life expectancy exceeding 240 days would be eligible for both the primary trial and the secondary trial."
    },
    "dbb49ce0-7aed-4573-9b13-1db31e9df94d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses range of motion as a measure of effectiveness for yoga, whereas the primary trial studies the effect of mineral supplements on electrolyte balance in blood."
    },
    "f47966a1-7067-43a3-9461-11c8ed7b18a6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "in the primary clinical trial, all patients endured the utmost level of pain for the span of 10 weeks."
    },
    "e6d5d1ca-f1f6-481a-b309-78adf96e656c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "regulatory assessment identifier is a unique symbol that establishes identity of the regulatory assessment. A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "e32de0e0-4e26-4c73-a6d6-cc5dfafd97c7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  . schedule of activities is a planned list of clinical trial activities to include interventions, assessments, and study administrative activities."
    },
    "9c96be3d-39cf-4c1d-ae87-764621c1e0ca": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "trna methyltransferase is an enzyme that catalyzes the methylation of transfer rnas. Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial."
    },
    "1624bc79-6ba3-449b-afd6-0234b760664e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial. specify site if cm1b is a directive to indicate the anatomic sites if metastasis is categorized as cm1b."
    },
    "97fe92c7-779d-4de8-8834-60ed8fe3178f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma. take lots of naps is a question about whether an individual takes or took a lot of naps."
    },
    "12954a74-e631-4318-ac00-0d09fd49e34a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "menopausal women and men who have undergone vasectomy are qualified participants for the primary clinical trial, with no necessity for abstinence."
    },
    "b4bad814-078e-4991-9455-f50ca716580d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "in the primary clinical trial, all cohorts are administered the same dosage of enzalutamide"
    },
    "09af4485-0e64-4a6c-83d3-1e7231151faa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "only 3 patients from cohort 1 of the primary clinical trial had maintained regular cervical cancer screenings prior to the intervention."
    },
    "bec6f047-5652-4c1a-8aec-8ba989cf4aa4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "only individuals with early stage cancer can participate in the secondary clinical trial, but are ineligible for the primary clinical trial."
    },
    "164f2ab2-b768-4ec0-befc-a9807ba379ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "adverse incidents were prevalent among patients in the first cohort of the primary clinical trial, this was not the case in cohort 2."
    },
    "4423a0fb-d4df-4046-bb60-04ba702c8623": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the secondary and primary trials have identical outcome measurements, despite differing interventions"
    },
    "f180c18c-f332-4f6b-9367-c349d3518d55": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "in cohort 2 of the primary clinical trial, there were no instances of death or hospitalization, with only a single occurrence of atrial fibrillation."
    },
    "b308b4a7-f3e9-49aa-a84e-8842da7caacf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "patients in the primary clinical trial reported a range of adverse effects, but none experienced pancreatitis, cholelithiasis, hepatic pain or febrile neutropenia."
    },
    "23034d6a-8cb6-41b2-8e0d-84194285cb38": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "the rate of clinical benefit in the participants, gauged via recist criteria, is not tracked in the scope of the primary or secondary clinical trial"
    },
    "45240146-8a45-480e-a223-397089b029bb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "output:  8/7 the primary trial participants, and 20/1674 the secondary trial participants suffered an ae."
    },
    "d08f014d-7d1b-45a1-b1c2-f68f12591f15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "Both cohorts of the primary trial contained the same number of participants. cdisc adas-cog - naming objects and fingers: 11 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) naming task for object 11."
    },
    "decd387b-7da2-4f7b-8f32-4e009d9f6ee5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 33.33% patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 210 days of the study"
    },
    "6bae9ada-fea4-4bb6-bd25-cdb505b3d53f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "over 0.97 of patients in the secondary trial and the primary trial did not suffer any adverse events"
    },
    "ea01b3dd-11a6-4e00-aada-a31c2fc4a5dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the intervention section of the primary clinical trial clearly outlines the method of administration, dosage, and cycle."
    },
    "e5fb73ea-4e3b-47b2-84ac-a4d403b646ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "most of the adverse events detected in the primary trial were not blood and bone marrow related, contrasting the secondary trial which observed an abundance of such"
    },
    "8fd1a8ed-8b74-4021-8a90-0400817fda1b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were no patients suffering adverse events in either cohort 1 or cohort 2 of the primary clinical trial"
    },
    "b9e51528-b593-40f7-8f49-acfacc756a7f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "in the primary clinical trial and the secondary clinical trial, the patients encountered thromboembolic events."
    },
    "b639e0a1-6e1d-4940-9818-a268732ed88a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "no recurrence of malignancies, absence of graft-versus-host disease, normal red blood cell count, cardiac well-being and healthy alveolar condition were more commonly observed in the primary trial compared to the secondary trial."
    },
    "28a88ea8-4cea-404c-9ad7-cb1be9c19d7f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is not used in either of the primary trial interventions"
    },
    "65203e16-ff68-4833-9f92-0f63e432c09e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55. suprapharyngeal lymph node is a lymph node located in the roof of the pharynx."
    },
    "cccd9ad0-9bac-43fb-aaaf-8f99e725c572": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time. metastatic carcinoma in the rectum is a carcinoma that has spread to the rectum from another anatomic site."
    },
    "3df24930-167f-4f53-a3e5-fb8205039848": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients with histologically unverified, early stage breast adenocarcinoma that is er negative, pr negative, and her2/neu positive, are eligible for both the primary clinical trial and the secondary clinical trial."
    },
    "9da65ef3-87a1-433d-943b-a2ecc45252e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "in the primary clinical trial, the orr demonstrated by the paclitaxel plus bevacizumab plus gemcitabine group exceeded that of the paclitaxel plus bevacizumab group."
    },
    "84fe3c19-bee9-4639-9569-455cf74f8c64": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "numerous aes were reported by all participants in both cohort 1 and cohort 2 of the primary clinical trial"
    },
    "145683a3-f65e-4b4d-98e0-662cbe830c5d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial does not employ any cycle for its intervention, while a specific 2 weeks cycle is followed in the secondary trial"
    },
    "90fc98fa-35bb-48ae-a2f3-b74e6bd0d353": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "more than four different types of adverse events affected patients in the primary clinical trial across all cohorts"
    },
    "ddf14eb0-04ae-431b-b4e8-ba97eddc25b7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is infused with paclitaxel and cohort 1 of the secondary trial is getting an intravenous injection of azacitidine."
    },
    "beef35bd-14a9-4353-aa30-2fe681726d91": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "participants of both the primary and secondary clinical trial receive equal doses of medication"
    },
    "e0c92d00-132b-4e76-ba59-2fa14e67bf53": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "adverse events were a common occurrence among participants in the primary clinical trial'"
    },
    "3ff8b1f7-4c73-4cb7-acbd-4d7e3b7f31ec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients with established allergies to medications such as cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib are not qualified to be part of both the primary and secondary clinical trials."
    },
    "fdb097f0-b7ba-4314-a865-c89b1179aeb4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "in the primary clinical trial, an increase in pleural effusion was observed in 25% of patients belonging to the second cohort."
    },
    "07e27cba-9e03-4644-a6f3-d05b61b5e4e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 10 patients in the primary trial suffered Aes. mixer device is a mechanical device designed to blend materials or an electronic device designed to blend signals."
    },
    "2f07cc03-880c-43c4-b50f-c1cdf9ebf0dc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0% cases of hypertension, dehydration and dyspnea in either cohort of the primary trial"
    },
    "f9638af4-2bf2-45b4-8c9e-b46c34373b17": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "in the primary clinical trial, the bevacizumab group witnessed more cases of disease progression or death compared to the bevacizumab + capecitabine group."
    },
    "f61808f1-4431-4b34-8a66-e422c6e97530": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "dysplasia negative is an indication that signs of dysplasia were not found in a sample. The majority of patients in the primary trial experienced complete response by week 24."
    },
    "1d3bccea-6780-45ae-93d2-651346fbc1dd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 0.001kg in the primary trial gained lean body mass over a 0.33 year period"
    },
    "afa9c5da-71e1-4c40-80fa-bcc02199e395": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "the primary clinical trial was marked by numerous adverse events reported by all patients, whereas the secondary clinical trial was free from any adverse events."
    },
    "bd2b336d-30ae-4151-a920-9506a013ab14": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "lipase unit is a dosing unit based on lipase activity. Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial."
    },
    "b4e6d7be-cb1b-4000-812e-d49098f0aaf0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "patient hospitalization and mortality occured during cohort 2 of the primary clinical trial."
    },
    "fa6115aa-a765-4d03-9fd0-61c97d5e282f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group"
    },
    "c4487f90-2a8e-4740-9d56-8fedbd7fb044": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report the severity of delayed nausea on a scale of 0-5, and the secondary trial measures the change from baseline to 6 months in bone mineral density (bmd) of the lumbar spine"
    },
    "2f5ae30b-2e0d-420a-a27b-14088d2bc0db": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "there were zero aes reported in one of the cohorts in the primary clinical trial"
    },
    "5c14c797-4995-467f-a993-bc75ad197093": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "dfs is the mode of outcome measurement in the primary and secondary trials. the two cohorts in the primary trial display considerable disparity in their results. meanwhile, in the secondary trial, arm 2 exhibits a better performance than arm 1, with a smaller proportion of arm 2 patients undergoing dfs."
    },
    "0b343459-5c78-4c51-b71b-bfc5aa6d0c6a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary clinical trial concludes 20 weeks earlier than the intervention specified in the primary clinical trial."
    },
    "7f3723a3-cdbf-41a6-a956-330e514b5c5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "no patients from the primary clinical trial encountered an incidence of dose-limiting toxicity in any cohort."
    },
    "ad2ac39b-960a-463d-b3ab-955916e20a97": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "while full breast radiation therapy is provided for members of the primary clinical trial, each group from the secondary clinical trial takes 500 mg of fulvestrant in tablet form, bid."
    },
    "4d77b4db-8260-4ec9-af60-660f7a2a4833": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "candidates are required to undergo warfarin-based treatment in the primary clinical trial and is also a necessity for inclusion in the secondary clinical trial."
    },
    "f1e9c350-baed-4c5d-a760-b5b8a69e6706": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "african-american patients are eligible for the primary clinical trial."
    },
    "33377a5a-a2d0-4881-b4eb-93fe650e900a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "cdisc adas-cog - word recognition: word 2 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) word recognition task for word 2 trials 1, 2, 3. the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group."
    },
    "a743b2fa-dd26-4c5f-931d-f5cc8bcf52c2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "the rate of mucositis oral, epileptic seizures and thromboembolic events was equal in both the primary and secondary trials"
    },
    "1abf0ac3-be79-4fd6-aa9f-5ae756346da4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial have reported unexpected deaths or cases of hospitalization."
    },
    "c43583e4-da5f-42b3-ad3d-7ba8b6b28f2b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial"
    },
    "a9292fc9-f444-4e0a-8db1-c2a6ad9a7062": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "musculoskeletal chest pain due to rib injury is a condition in which there is musculoskeletal chest pain secondary to trauma to one or more ribs. (acc/aha) The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death ."
    },
    "23cc69a0-6ac6-4373-9e9e-97c3e613d5eb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "the primary trial and the secondary trial both reported a significant number of participants suffering from febrile neutropenia and cholelithiasis"
    },
    "2c519a1e-668f-4731-941e-21dadeb2031d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "cohorts within the primary clinical trial do not uniformly receive the same doses of abraxane"
    },
    "7aa4c233-3630-4d28-bbd5-4c64fc730a2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery. unresectable fibrolamellar carcinoma is a fibrolamellar carcinoma that is not amenable to surgical resection."
    },
    "0e57fc4c-1a5b-4f88-900e-122c03fcedb4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "In total there are less cases of anemia in the primary trial than in the secondary trial. fgf3 gene mutation is a change in the nucleotide sequence of the fgf3 gene."
    },
    "ce185781-5c8f-4849-b96c-734228f2a323": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "recombinants is an individual cell or organisms which carries recombinant dna Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial."
    },
    "fd800c89-d30c-4a9a-970b-5385deeab52f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial."
    },
    "fabf3f7a-48df-4940-93e2-8cbe976c4246": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial"
    },
    "a63b539f-034e-46c2-83e7-9cea8c282e1c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "none of the patients in the primary clinical trial and secondary clinical trial developed infections during the study period"
    },
    "e8cc1118-7a1a-46ba-aa08-cfb7f414a753": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "kat6a gene rearrangement is a molecular abnormality indicating rearrangement of the kat6a gene. Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision."
    },
    "68fe8d71-5200-4e77-a560-0fb7e67127a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial. have problems with hearing loss that make me angry is a question about whether an individual has or had problems with their hearing that makes them angry."
    },
    "664a5c0e-406c-4050-85d3-f2f489e5098b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "no vaccines are given to the participants in the primary clinical trial."
    },
    "ad11786a-e01b-466c-9e44-31f1be35c79c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "in both the primary clinical trial and secondary clinical trial, there were no unforeseen fatalities or hospital admissions."
    },
    "8f8b46df-4031-4a42-bf67-60d923f2ec29": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "radial growth phase is a morphologic architectural pattern in which the tumor cells spread horizontally. the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "3befd95f-b342-45a0-99b4-3f6996b664cf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "both the primary and secondary clinical trials measure success through pcr. minor result discrepancies are observed between the two groups participating in the primary trial. on the other hand, in the secondary trial, patients in arm 2 fared worse in comparison to arm 1, due to a higher incidence of pcr."
    },
    "7a699c4d-46d7-48a0-915d-43b8c3a1f1f5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial. pen dosing unit is a unit of presentation used to represent the quantity of product that is found in a single pen container."
    },
    "0348dacb-819e-4e1f-98c3-d45d6c057f60": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "challenge epoch is a period in a study during which the subject receives challenge agent. Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial."
    },
    "09cdd94c-145e-4a72-b281-1fad592fdcfd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts. limit switch device is a switch designed to cut off power automatically to a moving object when it reaches a predetermined point."
    },
    "c6a921cd-f18d-4fea-a543-54784444279c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "across the primary trial multiple deaths were recorded in the adverse events, but the secondary trial had no deaths."
    },
    "412583db-ce19-451d-a804-3837e4dcaea3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "Coronary artery stenosis are the most common AE recorded in the primary trial"
    },
    "d80d13ef-0da7-4203-af51-52c08253aefe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "trouble moving bowels is a question about a whether an individual has or had trouble moving their bowels. the primary trial and the secondary trial recorded the same number of adverse events in their cohorts."
    },
    "51c9a1a4-9242-4880-b61e-b42a45b9017d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "in the primary clinical trial, the same dosages of abraxane and carboplatin are given to both groups"
    },
    "6146e7c3-2c76-4881-88bd-1c547c9f732a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000 mg of talazoparib daily, as part of the intervention"
    },
    "cae6d7c6-1e27-4c94-9428-997ece9e651a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort. gin chinese is a chinese person from the gin ethnic group."
    },
    "2758e742-d065-4813-bfd2-881fe16826bd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "patients with a confirmed histological diagnosis of metastatic or non-resectable scbc are not eligible for the primary clinical trial, unless their result is positive for er or pr or both."
    },
    "bcfd2c0f-411a-462a-acd8-7dcd6818c1c6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary clinical trial and the secondary clinical trial have the same pharmaceutical regime, coupled with the same dosage schedule and administration technique, alongside the exclusive use of ct scans instead of mris."
    },
    "485e3ce9-e779-4ae5-bdc4-7fbcb1d1eb3c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "the sole adverse event noted in the primary clinical trial was mild muscular discomfort."
    },
    "44daf0ed-4b1a-4e95-aae4-71722fad8f09": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "count dosing unit is a dosing unit based on a count. Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements."
    },
    "54c35538-e933-40b0-bf84-299e0b291ef3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "infections and fever cases in the primary clinical trial were exclusively observed in patients of the first cohort."
    },
    "577c7755-64ae-4b78-bbe3-627cef6e3ece": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 42 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months after the surgery"
    },
    "189e7142-d6fd-49d6-8e4f-44383f00781b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "both the primary and secondary clinical trials accept patients with an unproven diagnosis of late stage breast adenocarcinoma that tests er negative, pr negative, and her2/neu positive."
    },
    "5e92a3fd-5ffa-49db-9978-897321839068": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy."
    },
    "5794c670-e60c-4d2a-8d09-744e644c3e34": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial. acute physiology and chronic health evaluation ii apch104 original result - 35-49 is acute physiology and chronic health evaluation ii apch104 original result - 35-49."
    },
    "8a8136f1-9f1d-497e-bb50-44fe94475817": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 10cm in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "f5031c61-a192-4b2e-ac0f-be5d2aac0b3c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "there was no observed difference in the decrease of the growth factor signature among the er-positive luminal b group and the triple negative group in the primary clinical trial"
    },
    "eb8737bb-19f6-4249-83da-63b05b251084": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "cohort 1 and cohort 2 of the primary clinical trial receive neither 25 mg of sunitinib nor 90 mg/m^2 paclitaxel"
    },
    "976f4747-e1a6-4527-a298-490fb57d4615": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "the first cohort of the primary clinical trial is administered fluciclatide through an intraosseous injection, while the first group in the secondary clinical trial receives a standard dosage of chloroquine intravenously."
    },
    "42857f32-4798-4767-a0c7-f74cdcab7a9b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2"
    },
    "98c65216-ca06-4666-99e3-0d06dc97c01d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman with an ongoing therapy for stage i bc after lumpectomy is excluded from both the primary trial and the secondary trial"
    },
    "662dd235-76f6-4ab6-b4c8-5537e6f7ffb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "four or more positive lymph nodes is an indication that cancer cells have been detected in four or more lymph nodes. Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list."
    },
    "87be81ce-d5b1-4905-9452-2e0e2d4b7b2c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive four different drugs throughout the study duration, with a maximum dose of 100000 \u00b5g/m^2"
    },
    "6ca72b87-353a-4ef1-89d7-b9a5bad97c27": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial allows the participation of cancer patients diagnosed with fibromyalgia, thalasemic syndromes or anemia."
    },
    "0a0a9bd9-b3d0-4af8-b09a-f0e3a1684ef0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "a history of gabapentin or pregabalin use is not a disqualifying factor for the secondary trial, but compromises eligibility for the primary trial."
    },
    "902a36e5-a751-44c6-9844-465aaa0f1d75": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "several adverse events were reported in over 30% of participants in both the primary clinical trial and the secondary clinical trial."
    },
    "99d85210-19a0-4256-b092-c3a0f6ef322f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "neutropenia occurred less frequently in patients belonging to cohort 2 of the primary clinical trial than in cohort 1 of the secondary clinical trial, even though the latter were receiving considerably smaller doses of empegfilgrastim."
    },
    "5d657b3f-a074-480e-8698-24c288553369": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "no cohorts in the primary clinical trial are subjected to interventions involving drugs, radiotherapy or cbt."
    },
    "033cc376-5268-43c7-bf06-ca3503971f41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "within cohorts 1 and 2 of the primary clinical trial, there was no distinguishable pattern detected for the expression of the evaluated set of 40 genes"
    },
    "2a6e2da6-0555-43d1-b063-a81938137be9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "only patients who demonstrate an ideal body weight for height are eligible for the primary clinical trial."
    },
    "9f382aed-4a54-40c2-92ca-fb17411e4923": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "for participation in the primary clinical trial, patients must be injected subcutaneously with 120 milligrams of denosumab every month, while the secondary clinical trial requires the injection of 0.4 to 1.0 mci of radioactive tc99m sulfur colloid."
    },
    "f96f9461-2b00-4838-9e04-1d3a8dbeb3f3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "in the duration of the primary clinical trial, participants are subjected to four varied drugs, with the upper limit of dosage being 100 mg/m^2"
    },
    "4f9e48d7-08cc-4fa3-a317-4f3f23ebf19d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "the primary clinical trial comprises methods to gauge the alternation in ki67 expression in tumors."
    },
    "43a12cb4-7a50-4e64-b01f-1d1bfb5c4ba9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the primary trial had no documented adverse events, unlike the secondary one where anaemia was a frequent occurrence."
    },
    "5d42d5d3-e80d-49e0-83e5-8724a8ff5401": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "the patient cohorts of both the primary clinical trial and the secondary clinical trial have reported a total of 3 cases of asthenia and 5 cases of pyrexia."
    },
    "8b98421d-1cec-41bd-b25e-2e73c362193a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial"
    },
    "2f7bae39-4081-4328-85e2-2a400ec72589": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients with a body mass index (bmi) less than 30 are eligible for both the primary clinical trial and the secondary clinical trial."
    },
    "696f4947-40d7-4e3d-b64e-9e0fd6c5fbd8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "non-cutaneous leiomyosarcoma is a leiomyosarcoma arising from an anatomic site other than skin. The all recorded Aes in the primary trial occurred to cohort 1 patients."
    },
    "99433bba-fce5-4b0a-a076-1f699b51472d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention"
    },
    "12a7a47e-adb9-4c24-8410-03aea3d7d292": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "to qualify for the primary trial, the candidate is expected to have an mri, however, for the secondary trial, a mammography is mandatory."
    },
    "8ef6757e-e789-4a70-9cf3-e2e8050c9f15": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial evaluate different patient characteristics in their results."
    },
    "5499c5cb-97fa-4905-b163-7f5830cd59b9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "in group 1 of the primary clinical trial, no participants presented with lesions, while in group 1 of the secondary clinical trial, more than 90% showed signs of radiation dermatitis as well as hyperpigmentation."
    },
    "59a0bff2-c254-45f1-a6ae-2d847777db94": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response "
    },
    "3921fd1d-1ba6-475c-a6f5-c8f76fe8cbe9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the results of the bevacizumab + capecitabine cohort in the primary clinical trial were more beneficial than the results of the bevacizumab cohort."
    },
    "fe6c20be-e0c6-461c-9e93-cef55bdd7902": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "chemotherapy or radiotherapy patients from the last 2 weeks, those with unstable angina, and patients with grade 2 or above neuropathy are qualified for participation in the secondary clinical trial, but are not allowed in the primary clinical trial, regardless of whether they meet other conditions."
    },
    "37c579a2-134b-4ee4-8a9e-e550c2155a16": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "3 or more adverse events occurred in 5 patients participating in the primary clinical trial"
    },
    "cdab084c-4e2b-4f0a-ac8c-868b4bb4ecb5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary clinical trial participants are administered placebo on days 1, 8, and 15"
    },
    "ccc2b2e3-5588-4eed-8a05-67fb21c29a9b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "in the secondary clinical trial, patients only experienced adverse events such as eyelid oedema, upper gastrointestinal haemorrhage and chest pain. however, no such events were observed in the primary clinical trial"
    },
    "5d44d70b-1163-4a55-9247-db7bf9a901fc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "there are more total adverse events and more types of adverse events captured in the primary clinical trial than in the secondary clinical trial."
    },
    "03a73488-c2a3-437c-b4b7-d26832eaafe8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "the number of patients who experienced adverse events in different cohorts of the primary clinical trial varied significantly."
    },
    "3109bf56-61b7-4f43-9e38-fa3b69378214": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets. deleterious ercc3 gene mutation is a change in the nucleotide sequence of the ercc3 gene that is associated with increased risk of disease."
    },
    "fd2a59ea-6b33-4b24-ae04-32a2a40b4029": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "dietary vitamin k measurement is a determination of the total vitamin k in a nutritional product or meal, or a portion thereof. cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation."
    },
    "8849827d-af65-44ae-ad32-b325f502f945": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the primary clinical trial has identical inclusion/exclusion criteria for all participants, whereas the secondary clinical trial employs different sets of inclusion criteria for varying study groups."
    },
    "c6ca9f93-1abb-4c01-bdfb-aa17c5028ec8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial"
    },
    "6aa17b00-284e-408b-a8c3-2e24b6310556": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "adni avlt - list a recall 1 word 1 is alzheimer's disease neuroimaging initiative auditory verbal learning test version a (adni-avlt version a) list a, recall 1, word 1. A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial."
    },
    "376fcb2c-1ea0-4b28-a6d2-fde91a124841": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were threefold the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "d0d25983-0004-4189-9139-c36827fa1e4d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "the primary clinical trial administers gemcitabine, vinorelbine, and ruxolitinib to its patient cohorts, while the secondary clinical trial does not administer these drugs"
    },
    "d8896ee9-9d44-485b-9b75-e25f4a56aa8d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "over 50% of patients in the primary trial suffered aes"
    },
    "6906ff3e-0e8c-4332-987d-47816bc462ba": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "cough frequency is a question about the frequency of an individual's cough. in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy."
    },
    "61c499d7-0a4c-4fac-9098-53e53ddb198d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 75 cases of hypertension, edema and dyspnea in either cohort of the primary trial"
    },
    "dcb23ac7-9632-47fd-87bd-b15b25e4a3d3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "paclitaxel is excluded from the interventions involved in the primary clinical trial"
    },
    "c18a6d09-906e-4fbe-acf1-93b9a89f717a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "secondary and primary trials both employ minutes and number of participants as their respective units of measures."
    },
    "1f5a106f-d664-4a83-a785-a47eea7b9106": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "the secondary trial does not exclude those who have experienced a pulmonary embolism, and breast implants do not affect one's eligibility to engage in the primary trial."
    },
    "db02f4a9-b294-40e7-861b-d2284c6155e6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "in the secondary clinical trial, the use of perjeta is incorporated in both cohorts, however, it is not utilized in the primary clinical trial."
    },
    "2a32321e-12f1-453f-b0d4-d0b10b80e293": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients possessing ccnd2 amplification can join the primary clinical trial."
    },
    "7ba72ade-08b1-4062-86f4-2a93ec724780": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 0.5 patients in the primary trial treated with lapatinib 1g + nab-paclitaxel experienced a confirmed complete response (cr) ."
    },
    "264b1943-377e-4466-ad48-b4ba143f6bdb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "centrifugation tube is a high-strength tube of glass or plastic designed for spinning in a centrifuge. We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial."
    },
    "55d65365-bf85-4213-9ead-be1c498a4a72": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "three weekly sc injections are administered to the participants of the secondary clinical trial, however, the primary clinical trial participants are given only one injection when the study begins."
    },
    "256a6852-2768-4fc9-acae-f5fea437412c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial. non-neoplastic peritoneal and retroperitoneal disorder is a non-neoplastic disorder that affects the peritoneum and/or retroperitoneum."
    },
    "34208e81-25b5-40a7-ba91-ffdece7c96e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the findings of the primary clinical trial, the number of patients showing stable disease decreased from week 12 to week 24, and several patients exhibited a complete response at these time points"
    },
    "cf38cb04-b2fd-44bf-9674-dda257a8ad25": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "cardiac biphasic synovial sarcoma is a biphasic synovial sarcoma arising from the heart. 13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine ."
    },
    "e7be25fe-5915-4c38-b3c0-4e4acd5edd5c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. submission unit type code is a coded value specifying the kind of submission unit."
    },
    "6528eb91-c678-4508-8d1f-db13bce8d182": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include the same dose of Paraplatin. have achiness in your arm is a question about whether an individual experiences or experienced achiness in their arm."
    },
    "fa5334cc-0f09-4f22-91f8-156c7ab6d964": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "knife device is a cutting device usually consisting of a sharpened blade attached to a handle. Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies."
    },
    "0cfa6770-4d70-4603-865b-512957909993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 0.12 kilograms of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy."
    },
    "cdbca781-b6cd-42a1-acac-80617aa1af67": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "the intervention in the primary clinical trial does not mandate the implementation of regular exercise for its candidates"
    },
    "d13b1dc9-46cf-471b-b2b1-fa93b235e954": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 75 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 7 months after the surgery"
    },
    "7af1ab1f-5170-496e-ba41-61d54113c9c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "sexually active fertile men and women with the ability to bear children are eligible to participate in the primary clinical trial, however, they would need to abstain throughout the duration of the study"
    },
    "f6b492a8-d17f-407f-9345-ed6b7f447eea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "microscopic findings specimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen used for a microscopic assessment. The interventions in the primary trial and the secondary trial include completely different drug-based treatments."
    },
    "c4aea42a-a9e3-47ba-9a96-12350a3925c9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 0.0176 ounces of fulvestrant in a tablet form to be taken bid."
    },
    "ed92e41d-f81d-462e-9081-c293fb816163": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the results of the primary clinical trial and the secondary clinical trial are both from one particular patient cohort."
    },
    "115aa2c8-f52f-4a62-9b8a-6f6e593bd208": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "primary clinical trial's second cohort has an additional 7 participants compared to the first cohort"
    },
    "c10c78c7-51f4-4440-8164-07b059e01fd9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "in both cohorts of the primary clinical trial, not a single case of hypertension, dehydration and dyspnea was recorded"
    },
    "fea6712a-10d7-47bb-88d1-d286e0ba47a1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "metastatic kidney carcinoma is a carcinoma that arises from the kidney and has metastasized to another anatomic site. In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants."
    },
    "c1e836e2-ad18-40b1-b8c4-0f05168d5104": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 2 of the primary clinical trial receives 0.035 mg less alt-801 than cohort 1"
    },
    "e9972d7c-b9f7-4846-9708-1e1f63e96e83": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "every subject in both cohorts of the primary clinical trial are given a standard dose of 15 mg of sunitinib daily"
    },
    "1eab7c47-2c2a-4746-935b-c3e8891f8a26": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "candidates for the primary clinical trial are mandated to have a karnofsky score lower than 65, while those for the secondary clinical trial must score less than 45 on the karnofsky performance scale."
    },
    "171ca8d1-c986-4446-8ee3-8b8635f4d234": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. lightheadedness is a feeling of faintness; a reeling sensation. lightheadedness is medically distinct from dizziness, unsteadiness, and vertigo."
    },
    "bad9c481-e20c-49a7-b6b6-4e09991419c2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "in both the primary trial and the secondary trial, they utilize orr as a means of outcome measurement. there are no observable differences in outcomes in the two cohorts in the primary trial. in the secondary trial, arm 1 reflects worse results than arm 2 with an increased percentage of arm 1 patients experiencing orr."
    },
    "78865c57-db3b-4fbe-ab87-1f2d11f2c091": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients participating in the primary trial receive 50 kg/m2 oral lapatinib once a day for a full month."
    },
    "c5ece9f7-9119-4fa2-b60d-f2f15c68ae02": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial."
    },
    "b581bb7b-6aaa-4c8a-81a0-c5e6a58ebcdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death "
    },
    "a0d99371-52e5-4d30-81d5-ad65feba2e4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable tumors in both breasts are excluded from the primary trial"
    },
    "91169f4f-ada3-4bc7-a0ef-8111fccac241": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 0.25 of the primary trial patients."
    },
    "80b93d64-be3c-45e0-8524-b8042e84bdc7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "patients in the primary trial recorded the most instances of chest pain compared to those in the secondary trial."
    },
    "cd250e97-c2b4-48cd-bcbe-55ea06fa9662": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial."
    },
    "44cf1331-403a-4711-84e0-93f677307a6c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary clinical trial and the secondary clinical trial both indicate the maximum tolerated dose (mtd) for the same intervention."
    },
    "e137a0db-0a15-4dd0-9fa2-3a8558c7ef0a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants. respiratory acidosis is acid base imbalance resulting from an accumulation of carbon dioxide secondary to hypoventilation."
    },
    "6abbb566-9561-47d2-aad5-0857550099ea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "no patient in the primary clinical trial experienced recurrence-free survival."
    },
    "4246dc90-5b23-4170-8b6a-bd1459f776b9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "investigator status in study is a category used to describe the registration status of a clinical study investigator in a particular study. None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort."
    },
    "41e9a0e8-3838-4609-86e7-dc9b798db67c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "the allo-mscs intervention of the primary clinical trial is administered via intravenous infusion in a higher dose than the placebo intervention."
    },
    "41b2eac1-36a4-4cd8-a163-c7ab7b3636ee": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the weekly administration of mm-121 and paclitaxel for primary clinical trial candidates is less than that of the first cohort of secondary clinical trial candidates, but they are given more herceptin and docetaxel"
    },
    "4f886133-596d-449a-92c3-7472e2602982": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial. mesencephalic perforating artery is an artery that arises from the posterior cerebral artery and supplies the mid brain."
    },
    "1748cec0-92de-44af-9d49-bf45518c24bc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "if no, describe why is a request to specify why. In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants."
    },
    "cac3538f-89a2-4037-9928-4aaa708ae34f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "in the primary clinical trial, all patients are treated with suramin and paclitaxel, however, the secondary trial does not outline the medications to be administered in its intervention section."
    },
    "1027bd72-7cce-4903-9838-733046143102": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "generally, patients from the primary clinical trial have a life expectancy that exceeds 2 years, however, there was at least one patient from both groups who did not survive past 2 years."
    },
    "9eb119ec-3ef7-4de4-ab36-5e8d63fdb984": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "have discomfort or pain in pelvic area is a question about whether an individual has or had discomfort or pain in their pelvic area. the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients."
    },
    "3a1fe062-8a0f-48cb-8830-7624b5445778": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "movement of swollen area is painful is a question about whether the movement of an individual's swollen area is or was painful. The only AE recorded in the primary trial was Stomatitis."
    },
    "fcef015e-f82c-4cac-a7c1-61a81f0eac3b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial. kluyvera is a genus of facultatively anaerobic, gram negative, rod shaped bacterium in the phylum fusobacteria and the family enterobacteriaceae."
    },
    "55220fb9-bef7-4c72-bf60-982c0ec903e6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman who has undergone a mastectomy might still be suitable to enroll in either the primary clinical trial or the secondary clinical trial."
    },
    "6ee2e04c-88fc-4447-a477-18b2564aca4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ild/dpld within the last 36 months, with a life expectancy of 184 days would be eligible for the primary trial"
    },
    "a7e7e8e0-d2c9-4eee-9aed-1d957044c7dc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial. childhood malignant penile neoplasm is a rare malignant neoplasm of the penis that occurs during childhood."
    },
    "e9ad9d15-a15f-4f20-85f4-5da69c7592d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "patients with a cancer diagnosis who also have epilepsy, thalasemic syndromes, or anemia are ineligible for the primary clinical trial and the secondary clinical trial."
    },
    "354bc4da-42d7-452f-82bb-43e270a24c2f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "all recorded adverse events for the first group in the primary clinical trial are connected to issues of mental health."
    },
    "ff11f88f-a4cb-481e-bf56-afa5c0adda19": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial."
    },
    "e875dcbd-dc31-47c4-87bf-a94b0c1696b1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the outcome measurements of the primary clinical trial are directly correlated to those of the secondary clinical trial."
    },
    "42eaaa23-bd07-4a89-ba9f-dffe36e31ddb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include trastuzumab. non-trisomic autosomal aneuploidy is autosomal aneuploidy not associated with trisomy. it results in developmental malformations."
    },
    "dbc1b653-7c38-4c7c-bad8-5949d6f909ed": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "patients with non-measurable unilateral breast cancer are eligible for the primary clinical trial"
    },
    "5e8286c8-3e7c-4b71-b824-103d031ac6b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "The only AE recorded in the primary trial was Stomatitis. ezhip overexpression positive is an indication that overexpression of ezhip has been detected in a sample."
    },
    "c6c84bb8-fea8-4ad6-8ec7-1677049d1fe4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "the primary clinical trial may still accommodate patients with the diagnosis of 2-3 cerebral metastases, despite being disallowed from joining the secondary clinical trial."
    },
    "3d82f108-1f18-426e-a49f-f7fedcb82a7c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "nocardia is a genus of gram-positive, catalase-positive, rod-shaped bacteria in the phylum actinobacteria. Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead."
    },
    "70ddf6e3-dcd9-4296-b73c-593161abcfae": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "both the primary clinical trial and the secondary clinical trial could include patients who are extremely overweight or expecting."
    },
    "fc96b587-8bbf-4816-97d9-15cd8fcf755f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "tyrphostin ag 1288 is a protein tyrosine kinase inhibitor that blocks tumor necrosis factor alpha induced cytotoxicity. (nci) Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies."
    },
    "98d96b95-5e98-49e3-8bd1-b004132c3781": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial welcomes participants of all ages, including 18 year olds, but the primary clinical trial sets an age limit of 21 and over."
    },
    "972438ce-59d8-476c-a8a3-b61fba56e982": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 0% recorded adverse events."
    },
    "652e7c7c-998b-4a7d-b170-bcbe79729d93": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "functional physical assessment results are used as the units of measure in the primary trial, while the secondary trial utilizes patient self-reported pain levels."
    },
    "0c0d244d-5d55-42ea-bb07-8ff35bd2c862": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "cohort 1 and cohort 2 in the primary clinical trial follow different paced breathing instructional cds, and both practice once a day."
    },
    "ea0e2918-08bd-4013-9915-66f8fe425e31": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "both cohorts involved in the primary clinical trial are given identical amounts of abraxane"
    },
    "20493bc1-bda8-4255-a1d4-40cb499bd845": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "There was at least 1 case of infection in both the primary trial and the secondary trial"
    },
    "b29091a1-befa-4edc-9bc9-06263826bfdd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": " Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial"
    },
    "a6dad239-adab-48d2-b63a-0325c718ddf9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most encountered adverse event across the patient cohorts of the primary clinical trial and the secondary clinical trial was asthma, which occurred in 25.00% of the primary clinical trial patients."
    },
    "b03bae0b-6811-4c4d-a265-98c0f4ae7f1f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "patients who have received gabapentin or herceptin treatment in the past year are not eligible for the secondary clinical trial but can participate in the primary clinical trial"
    },
    "42fc9190-b214-42bf-92fc-3678564083ca": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "patients suffering from ascites were less common in the primary clinical trial, while pneumocystis jirovecii pneumonia was less frequent in the secondary clinical trial "
    },
    "260a9ba1-ca1b-4e87-83d1-b128e73e1e38": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group. radiation, charged particles is a particle which carries a positive or negative electrical charge, typically an ionized atom or molecule, or an electron."
    },
    "01f7a296-d0c6-4530-800d-5985bcf7218c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "in the first 21-day cycle of the primary clinical trial, capecitabine was given orally on a daily basis to all participants in cohort 2"
    },
    "0aa5e58e-3ff4-487f-b043-d10452a30a4f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "no instances of lesions were reported among the participants of group 1 in the primary clinical trial, but a high percentage, over 90%, of participants in group 1 of the secondary clinical trial were diagnosed with radiation dermatitis and hyperpigmentation."
    },
    "0dc19d61-83e4-4b27-9d03-c485f30fe9f6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "there was no significant difference in recurrence-free survival between the ketorolac 30 mg group and the nacl 0.9% 3ml group of the primary clinical trial"
    },
    "2717fbc9-ffe5-419f-8c2d-ac9505f7cd01": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "the secondary trial and the primary trial do not share any inclusion or exclusion criteria, including the requirement to provide written informed consent."
    },
    "ffd7717b-fec1-4702-87a6-5345e8efe7ba": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "while a diagnosis of 2-3 cerebral metastases would exclude a patient from the secondary clinical trial, participation in the primary clinical trial could still be possible."
    },
    "fac1b066-b96a-470f-8239-89c1cba6572d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "individuals with measurable bilateral breast cancer can participate in the primary clinical trial"
    },
    "70dec4df-4dbd-41cc-ba31-6437c7058987": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "a higher percentage of participants, specifically 11% more from the er+ luminal b group of the primary clinical trial, showed a decrease in the growth factor signature than their counterparts in the triple negative group."
    },
    "61acc1f3-e02a-49ca-8ac8-42453619e78c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "no unexpected fatalities or hospital admissions were reported in both the primary clinical trial and the secondary clinical trial, with the exception being three incidents of lymphoma."
    },
    "561a11dc-abb5-4a2b-9211-4e27419cfc43": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "in the primary clinical trial, it was recorded that over 50% of those treated with lapatinib 1000 mg and nab-paclitaxel displayed either a verified complete or partial response."
    },
    "626b2407-ae7b-43ed-96b6-3ee9e3c290c8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "only non-pregnant individuals are eligible to participate in the primary clinical trial"
    },
    "2b24be38-efe1-4044-92ce-81cace8f239a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "armodafinil p.o. on a daily basis is received by just one cohort in the primary trial, contrastingly, in the secondary trial, pdr001 is proportioned out identically to every patient, with differing amounts of mcs110."
    },
    "e7bcb619-8ec0-45cf-acce-9d20e7258c95": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the total number of adverse events were different in the patient cohorts of the primary and secondary clinical trials."
    },
    "8f018706-e70d-4fa5-812c-9c8d57b97f46": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "smoking behavior is any of the activities associated with tobacco smoking. Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system."
    },
    "40fceb75-d0d5-4926-8d3d-7e5f3c5b7931": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "the incidence of eating disorders was minimal among patients participating in the primary clinical trial"
    },
    "6c56960a-80c2-40f6-8ba7-8e96a6bdcb98": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "both the primary clinical trial and the secondary clinical trial reported all adverse events encountered during their respective trials."
    },
    "9cd909a2-b826-4e0d-bbbd-3ad52978d1d9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "the primary clinical trial is solely reserved for individuals who have never undergone herceptin treatments, regardless of their general medical history."
    },
    "f22196d4-1e0f-4626-9736-d78452dc650a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events. cybb gene mutation is a change in the nucleotide sequence of the cybb gene."
    },
    "86609ec7-6d7c-4447-94b4-c9c99d5fd5e1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 1000% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "da5c1eb1-b093-45cf-b607-e40504be981b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, multiple cohorts are given armodafinil p.o. daily, and the secondary clinical trial administers various amounts of pdr001 to all patients with a consistent dose of lcs101."
    },
    "43e968bb-7167-4c0a-8105-8f3e854408af": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "nearly half more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "6938fd4c-78be-4e24-b385-835d2be9f3c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 42 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 5040 hours after the surgery"
    },
    "4437aa5b-4b4e-4eb4-a258-e7f17dc8f363": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "fa80610a-3dd0-49e7-97f3-7efbdf636ca5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the primary clinical trial recorded slightly more total adverse events among its patient cohorts compared to the secondary clinical trial."
    },
    "e9bc72c1-1933-4ac1-b21b-35bf90b82c48": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "grade 1 joint effusion, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated There were no deaths or Hospitalizations in cohort 2 of the primary trial."
    },
    "4db7f58c-f006-48d0-944f-a02b3231615c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. six to ten activity hours is a response indicating that 6 to 10 hours were spent on an activity."
    },
    "d7bcab45-fcd5-46bb-9317-b75573e0373f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "in the primary clinical trial, the symptoms were more severe in patients who were not infused with paclitaxel compared to those who were."
    },
    "5c9e6daf-915c-48b4-b1d4-2e302e0164d4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "in the primary clinical trial, an overwhelming majority of participants showed a decline in circulating tumor cell counts due to the regiment of high-dose chemotherapy with purged autologous stem cell products."
    },
    "4bc60955-6137-4496-b780-5fb8e90dc3ed": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "maculo-papular Rash was a common adverse event for the primary trial participants."
    },
    "58b45da6-c265-4cef-a6cc-83113439c79e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "the levels of palpitations, pericardial effusions and abdominal pains were higher in cohort 2 of the primary clinical trial than those of cohort 1 in the secondary clinical trial."
    },
    "8b3c9b3e-41e8-46fb-b975-db35e552ec6c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "zero percent of individuals in group 1 of the primary clinical trial displayed any lesions, in contrast, over ninety percent of participants in group 1 of the secondary clinical trial exhibited symptoms of radiation dermatitis and hyperpigmentation."
    },
    "5de55575-82d9-461f-af89-ae41ff70ecb2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "only patients of a certain nationality and ethnicity are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "5284dc53-b471-4c7a-a713-62199869a305": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "the majority of patients participating in the primary and secondary clinical trials reported experiencing adverse events after treatment"
    },
    "eae69c88-b4bc-4683-aacf-60d287e4eebc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "simfibrate is a derivative of clofibrate with antilipidemic activity. There were more participants in the primary trial than in the secondary trial."
    },
    "abb25993-d191-4b47-99c1-fe3b53732dc1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "ppp2r2a gene mutation is a change in the nucleotide sequence of the ppp2r2a gene. Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial."
    },
    "a326e30f-a2c9-4a6e-b497-02cc338735c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial. tatar chinese is a chinese person from the tatar ethnic group."
    },
    "ce8ecade-8753-4983-83af-47f6e3e87f32": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "while the primary trial's entry conditions are identical for all age groups, the secondary trial has separate entry conditions for participants under the age of 25 and those 25 and older."
    },
    "a16ff39b-cc99-4214-9af5-910eb9384a97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were several adverse events which occurred in more than 90% of participants."
    },
    "6cbfc99b-6531-412f-bd30-b4a803983831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "4ecc7d3a-ada3-4bda-8236-f0450fc709af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the primary clinical trial's results demonstrate that the placebo arm outperformed the arm a intervention in terms of overall response rate. meanwhile, the zoledronic acid group in the secondary clinical trial showed faster time to first on-study sre than the denosumab group."
    },
    "5bc078b0-0b64-4d47-a015-26c3f03c864e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "in the primary clinical trial, the dosage of enzalutamide for cohort 2 is twice as much as that for cohort 1"
    },
    "3d29cec9-8354-4d5b-ae1a-f486ab7aa6ca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "renal calyx is an intrarenal space located in the renal medulla that serves to collect and transport urine. The the primary trial intervention section dose not describe the method of administration, dosage or cycle."
    },
    "ffacecd7-caae-434a-866d-a3a25d4f00ac": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection."
    },
    "bebf3648-7a1c-4e73-8d0a-f5715fa173f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "every patient in the primary clinical trial is administered a minimum of 20mg of mcs110 tri-weekly, alongside over 130 mg of pdr001 bi-weekly."
    },
    "349365cf-1c22-4e72-b321-b15b505e50cb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "4p16.3-p16.1 is a chromosome band present on 4p Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors."
    },
    "e3fd6c0c-a119-4bb5-b82b-366830537c70": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1. voice problem upsets me is a question about how frequently an individual's voice problem upsets them."
    },
    "aefb2cc5-3101-416b-bae4-c9a1e7d8f39e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial."
    },
    "16147f31-aa81-4f21-9bd7-f153069a9278": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 400 mg of ibrutinib and 30 mg/kg of medi4736 twice daily for a month."
    },
    "64e22fa4-990b-4196-874a-a5ecf04cf3fb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial focuses on tracking cutaneous sensation changes for evaluating physical therapy effectiveness, whereas the primary trial measures the influence of ascorbic acid supplements on vitamin c concentration in blood plasma."
    },
    "786d7c5c-66f2-4ce1-8b3d-c6fdbeb36168": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 45 year old patient with histologically verified diagnosis of stage 2breast cancer, absolute neutrophil count of 3000/\u2248\u00ed\u00ac\u222bl, platelet count of 188000/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 140 g/l, and a life expectancy exceeding 14 months would be eligible for both the primary trial and the secondary trial."
    },
    "c939c0c9-57b8-4f8a-aba1-e19af522cb12": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "the primary clinical trial observed more cases of palpitations, pericardial effusions, and abdominal pains than the secondary clinical trial."
    },
    "5bf5c965-7588-452a-9d36-2503218e56da": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial recorded fewer aes than the primary trial"
    },
    "c667d986-5b21-4855-8f51-109296357a9e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "in the primary clinical trial, no medications were administered to the patients in cohort 2 during the first 21-day cycle"
    },
    "012a3705-05f7-4a26-adf2-1ae4244bd576": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 300 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "c5a577f3-2bf4-4bbf-b1f9-5bd829414790": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial. fatigue interference score answer is an answer for the fatigue interference score query."
    },
    "a3abbf89-df53-45d4-97e1-f358dddbd2a8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "neither cohorts in the primary clinical trial reported any instances of hypertension, edema, and dyspnea."
    },
    "afc5437d-4c34-46e3-bcb0-742a23ba35e6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "participants from the secondary trial are able to concurrently enroll in the primary trial"
    },
    "26f39f2a-dad6-40ed-8fa4-5abd8847021f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman who has not undergone any radical surgical treatment for her stage ii bc is strictly ineligible for the secondary trial and the primary trial"
    },
    "8da24578-8dc7-42e5-821a-90f3e361cfdd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "women who have been recently diagnosed with stage iv er-positive breast cancer and are contemplating a mastectomy are qualified for the primary clinical trial and the secondary clinical trial"
    },
    "f8fe88c6-ebd4-49ad-b381-b6017fdaf070": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "rectal pain, ctcae 5.0 is a disorder characterized by a sensation of marked discomfort in the rectal region. the secondary trial and the primary trial use different outcome measurements and units of measure."
    },
    "e9639699-8cb1-4b2b-9901-443fedb90158": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "in the primary clinical trial and the secondary clinical trial, there are recorded cases of swelling, hypothermia, and confusion in the adverse events sector."
    },
    "3a141563-97b8-4154-8c9c-f1f551ec7969": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses"
    },
    "7b73381b-500c-4056-9c4c-4334a6e0b9b4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "pcr serves as the outcome measure for the primary and secondary clinical trials. in the primary trial, slight differences were noted among the results of its two cohorts. however, for the secondary trial, a bigger difference was seen, with results from arm 2 declining more than those of arm 1 due to a higher pcr rate."
    },
    "cc439508-491f-4c5a-9304-5ddf9d266506": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "generally, both groups in the primary trial showed a deterioration in cognitive abilities, but this wasn't the pattern for all patients"
    },
    "9f61fc3f-f0a5-4434-b0a7-cbb0703fe063": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial involves the use of x-rays, transendocardial injections, ct scans or mris as part of their interventions."
    },
    "1a15db80-85f2-4d35-b325-1e01fdfb453d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "within the primary clinical trial, the lbh589 with capecitabine cohort showed inferior results when compared to the lbh589 and lapatinib group"
    },
    "e6a3ed43-5bb0-40b2-9c4b-8a60e2b201df": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "the primary trial includes the administration of fluciclatide to the first cohort, whereas the first cohort in the secondary trial is introduced to a standard dose of chloroquine."
    },
    "171827b1-29bc-4e7b-a70a-3d03d4ae7dad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "the differences between interventions 1 and 2 of the primary clinical trial extend beyond the dose of durva administered during bi-weekly iv infusions"
    },
    "c367ab4c-6113-4f79-abcc-24e715c18094": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "grade 1 neonatal bradyarrhythmia, ae is an adverse event in a newborn characterized by brief, self-limiting, episodes of asymptomatic bradyarrhythmia; no care changes. 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections."
    },
    "4c8ee685-13af-44a4-8d1e-30105f8469af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "haploidentical is a donor who has only one haplotype in common with the recipient. The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine."
    },
    "cedccbca-876d-44b2-bf5a-9c9c5090d46c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "no adverse events were reported in either of the cohorts involved in the primary clinical trial"
    },
    "1b229af4-937d-4ae0-8c39-12064d16b246": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "asph gene product is a protein encoded by the human asph gene. Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy."
    },
    "b68e076b-9950-438b-96ea-3fc93943e490": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care. u wave abnormality by ecg finding is an electrocardiographic finding of u waves which have increased amplitude, are inverted, or merged with the preceding t wave."
    },
    "b2b80e2f-f5b4-4997-9209-fd061ff307b9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "through transendocardial injection, both the placebo and the allo-mscs intervention are delivered in the same dosage in the primary clinical trial."
    },
    "ae574646-62f1-4b5f-b565-4af6bbafe7a6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "compared with the secondary clinical trial, the primary trial has less reported anemia cases."
    },
    "0f6d115f-8b84-46cc-a95f-51af051029e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "total organic carbon is an indirect measure of organic molecules present in pharmaceutical waters measured as carbon. The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial."
    },
    "e44f0355-dac8-4405-b3b1-ceb87cbb121d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "the primary clinical trial could have eligibility for a patient who has been diagnosed with neoplastic meningitis"
    },
    "f81c0c12-c161-4e90-91e4-65a2b255d1c2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is calculating the mean bedtime its subjects have each night, whilst the secondary trial is observing the volume of patients experiencing therapy-related negative events."
    },
    "0c207e39-2335-46a1-8dbd-3be4b8d59a17": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "have a skin rash is a question about whether an individual has or had a skin rash. Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan."
    },
    "0f449a63-8d5d-4c60-96f8-bb32423f079d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "clinical study anchor is a planned activity within a clinical study that marks a transition between epochs or elements within the clinical study. the secondary trial and the primary trial report their results using the same units of measure."
    },
    "da3b7aca-a0b1-4e25-8c38-11dc8311dc11": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial. progressive central nervous system neoplasm is a central nervous system neoplasm that is increasing in scope or severity."
    },
    "a0ebcb11-7643-4861-b26c-8b1716fd00c1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "how old when first began smoking cigarettes regularly is a question about how old an individual was when they first began smoking cigarettes regularly. There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation ."
    },
    "effa7535-9810-4bf3-92bd-64aba7878bf6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "more than two participants in the primary clinical trial experienced dose-limiting toxicity."
    },
    "9e5f2149-4cff-4df0-a5d0-4b99ff30fb1c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 270 days in bone mineral density (bmd) of the lumbar spine"
    },
    "3fca106b-449b-416e-a961-bf0dc8999ddb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial. document version workflow status code is a coded value specifying the state of the document version workflow."
    },
    "e2731b02-ce9d-4bfe-bc8d-9eda951e0e77": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "patients who have undergone treatment with either gabapentin or pregabalin will not be accepted into the secondary clinical trial, however, this does not affect their eligibility for the primary clinical trial."
    },
    "c4a45d2b-0e4b-4cd2-80ef-176d487d8180": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "participants in the primary clinical trial experienced diarrhoea more frequently than those in the secondary clinical trial."
    },
    "d8e49bf6-27d9-4307-9bcd-56625d93274a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "the primary clinical trial stipulates that all aspirants must have a her2 positive tumor validated via ihc 3+ and require extensive help and regular medical supervision"
    },
    "e8b222ce-e235-4b8d-b524-521ba583656a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the primary clinical trial was diarrhea, affecting approximately 8% of patients, while no adverse events were recorded in the secondary clinical trial."
    },
    "5fff07e2-11f3-4a58-aecb-ce4650dd35f6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial. in subset is an association that connects the concept defining a particular terminology subset with concepts that belong to this subset."
    },
    "e3629df4-61d3-42e0-af44-62cb2782c5c2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "less adverse incidents took place during the course of the secondary clinical trial than the primary clinical trial.'"
    },
    "5f76619b-30cd-47bc-99b9-aab25ce87366": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "in the primary clinical trial, there wasn't any recorded instance of an adverse event, whereas in the secondary clinical trial, apart from skin infections, no other adverse event affected more than 30% of the patients involved in the trial."
    },
    "478be8bf-505c-44ed-98d6-41b48ab8d9b3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 from the secondary clinical trial demonstrated superior outcomes compared to the same cohort from the primary clinical trial."
    },
    "cd247253-c2d6-4eb6-be06-90ef855748cf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "for inclusion in the primary trial, candidates are required to have an updated electrocardiogram (ecg), while the secondary trial mandates a recent colonoscopy report and a complete blood count (cbc)."
    },
    "620be964-dbff-4793-a75e-7644f7c57fb5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "participants of the primary clinical trial receive a neurokinin-1 receptor antagonist on days 1, 8, and 15"
    },
    "7a735242-b198-4348-ac48-f318cd704752": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the dosage of denosumab used in intervention 1 of the secondary clinical trial exceeds the dosage of zoledronic acid used in intervention 1 of the primary clinical trial by 12 times."
    },
    "3e629df7-48b7-4ca1-8987-250629ce3e26": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary clinical trial consisted of a test group and a placebo group, while the secondary clinical trial was conducted with one test group and one control group."
    },
    "4d36fe39-7874-4174-853e-dc6406bf9e0b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "none of the patients in the primary trial experienced the worst pain imaginable for 20 minutes."
    },
    "c39ec45a-1664-49aa-8356-abbecf045001": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events"
    },
    "3c081d55-1536-45ec-ae5b-b7af2a44a8c4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "in the primary clinical trial, a single adverse event has been logged for its patient cluster."
    },
    "67498e27-5a2e-4495-adb7-5cd8f51aae65": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the dosage of tamoxifen in intervention 1 of the secondary trial is 12 times higher than the dosage of denosumab in intervention 1 of the primary trial."
    },
    "22a06af0-a4f9-4311-92e0-d2d13a24b9b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "the adverse events such as recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were notably more prevalent in the primary clinical trial than the secondary clinical trial."
    },
    "96892eae-9630-45eb-bc5f-6c7605d8dd1c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "fifty is a natural number greater than forty-nine and less than fifty-one and the quantity that it denotes. Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer."
    },
    "4a6db09e-5bc7-4c5c-8cf8-a89750cd1cc1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "under 10% of participants from the primary clinical trial exhibited a decrease in circulating tumor cells after undergoing several months of high-dose chemotherapy along with purged autologous stem cell products."
    },
    "269ac84f-d5a9-475f-8c43-361a6cdb5225": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial employ cm, participant count, or time unit as their measurement units."
    },
    "198d43b9-ed80-463e-bbdc-d2d565fb61aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or 19  are eligible for the secondary trial, but will need to wait 12-24 months to be eligible for the primary trial"
    },
    "51d7f113-1dba-48f0-9e5c-1f16bfcd5394": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "the primary clinical trial noted zero cases of hepatotoxicity, while there were multiple cases of hypertension and pancreatectomy."
    },
    "d7aa81f2-8df0-4884-9d6a-e6d21ec79b03": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have received chemotherapy or radiotherapy in the last 1/2 a month, suffer from unstable angina, or have grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "a9d72bc6-9396-4a8a-986a-e64587f02e9e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "radiation therapy is not administered to patients in the both cohorts of the primary clinical trial."
    },
    "d464fa4d-58ea-47ff-b4fa-19fbedb40740": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "none of the cervical cancer patients in cohort 1 had undergone a screening prior to the primary clinical trial intervention."
    },
    "ebe96d52-cfbc-403c-ba10-244991ddc449": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the primary clinical trial and secondary clinical trial are investigating the same medication, however, they differ in dosage amounts and how they measure results."
    },
    "9137a91a-d493-42f7-a1e5-9b39928036d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "treatment protocols based on cbt are not permitted in the primary clinical trial, however, its candidates can still participate in the secondary clinical trial."
    },
    "9e02f276-1bd0-4373-a049-9a67ee3eac87": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial . hypogonadotropic hypogonadism with anosmia is an x-linked or autosomal dominant genetic syndrome characterized by hypogonadotropic hypogonadism and anosmia."
    },
    "2a509e67-c521-4406-8122-c91d7a1331ad": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "skin appendage neoplasm is a benign or malignant neoplasm that arises from the hair follicles, sebaceous glands, or sweat glands. There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial."
    },
    "7ea784df-2fea-4676-a83f-a0716d2fd49d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "the number of participants was higher in the primary clinical trial compared to the secondary clinical trial."
    },
    "34a95632-c79d-4704-8a4a-56c4ddce6070": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "the primary and secondary clinical trial could consider for eligibility a young girl recently diagnosed with pr-positive and her2 positive breast cancer"
    },
    "ac0df9a5-d909-40a6-9b57-391fef615fe9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "both the patients in the primary clinical trial and the secondary clinical trial face the same negative effects.'"
    },
    "49db6e75-199e-4c15-bb9b-6cf677d9c421": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "in the secondary trial, patients are accepted regardless of gene mutations whilst the primary trial requires confirmation of mutations in genes such as pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11"
    },
    "4c79deb2-4d30-470e-959c-e3cf05af0b88": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "less than 2% of patients in the secondary trial and the primary trial did not suffer any adverse events"
    },
    "25c9b995-fedc-45ae-a3c8-d66c116711b0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "just one negative occurrence has been noted for the patient contingent of the primary clinical trial."
    },
    "28c1cdeb-4f60-4fd7-b2b1-5368a91f9b85": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. memory intervention is any action taken for the purpose of improving an individual's memory."
    },
    "dcfb970a-f5b0-41c1-a5ec-99d17734c17c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "resolution of findings following intervention for kawasaki disease is an indication that findings were resolved following treatment for kawasaki disease. patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial."
    },
    "6fd7b2ea-805b-45ad-b1e7-d073f9944d77": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1. has moderate or severe renal disease is a question about whether an individual has or had moderate or severe renal disease."
    },
    "61a6a476-9283-4cde-89e7-5f1405f690c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month."
    },
    "fdc25a44-5f1f-4478-b1f4-78fbb95b112a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "the primary clinical trial will not accept patients if they have had an abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess, or considerable psychiatric disorders occur in the last six months"
    },
    "dd9dfad7-d09d-49d3-ad2d-fe7421d3a8a0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "candidates for the secondary trial study group receive 3 weekly subcutaneous (sc) injections, whereas the primary trial participants receive 5 injections at the beginning of the study."
    },
    "a6eb92cc-e789-4ced-a40c-166bebb09a67": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs. was a spine mri completed at diagnosis is a question about whether a spine mri study was completed at diagnosis."
    },
    "606dc2e9-a1a7-400a-8971-bfb2d3a3f3ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "the primary clinical trial has a higher incidence of bronchopneumonia and physical health decline compared to the secondary clinical trial."
    },
    "5a916856-536f-444d-87e7-1b2c032c0656": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass."
    },
    "6ee4b112-4ff6-49d0-a7ec-a9e71d309bb9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "xxyy syndrome is a rare sex chromosome abnormality in which a male child has an extra x and y chromosome. There were more participants in the primary trial than in the secondary trial."
    },
    "1ccb499d-d126-4ec6-bed1-c121dfa13d2d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "at least one inclusion criterion is shared between the secondary trial and the primary trial."
    },
    "b12a6936-d1ae-48e7-b3f2-575708d784ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial. ultrasonogram is a computerized image of internal tissues created by bouncing high-energy sound waves off internal organs."
    },
    "e4f2bd3a-6976-4a2b-9485-c34bdc812c54": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "adhesion factor production is any cellular process that results in the elaboration of adhesion molecules on the cell surface. Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril."
    },
    "58429d01-0c6a-4ae1-b8ce-73ee8a8e775d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "organ perforation is a rupture in an organ(s) due to traumatic or pathologic processes. Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent."
    },
    "fc24dc2a-3257-433f-91ed-fc3d3ec369b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 105 more days than the intervention detailed in the primary trial."
    },
    "da51f6ae-703a-4282-a339-22ebaa80709a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "have vaginal itching or irritation is a question about whether an individual has or had vaginal itching or vaginal irritation. patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial."
    },
    "1de04bd7-e1e7-42a6-a898-ae626a24b25b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the primary clinical trial revealed a higher percentage change in betactx at week four in the azd0530 175 mg group when compared to the group administered with zoledronic acid 4 mg."
    },
    "1b2512ba-9857-4fde-a25b-b4768b1ad748": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "inclusion in the secondary trial requires no restrictions on previous treatments with drugs like gabapentin or pregabalin, however, these treatments serve as exclusion factors in the primary trial."
    },
    "608a57fb-72d5-4837-a491-2d0bc83a7776": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "office and administrative support occupations is a class of professional or vocational positions of employment that involve office or administrative support. the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response ."
    },
    "286cb14c-39e1-4987-9de2-78de7e78a017": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "out of 73 participants in the primary clinical trial, 2 experienced an acute myocardial infarction, while none out of 1674 participants in the secondary clinical trial experienced the same"
    },
    "29cdc690-859f-405c-ad87-f4e73fc3e9a8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 5 more weeks than the intervention detailed in the primary trial."
    },
    "3015f97a-8a45-4a05-a5cf-9c5eaa49e667": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 2 year cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "2f1db1ac-f8d0-4087-856e-dfcff97c75a5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "individuals who have experienced a pulmonary embolism in the previous 8 weeks are eligible for participation in the primary clinical trial, whereas their eligibility for the secondary clinical trial is not subject to the discretion of the investigator"
    },
    "1023b3b0-b190-4ad2-b849-a7ba384be1f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary clinical trial is administered the same dose of alt-801 as cohort 2."
    },
    "14b9aeb8-afd7-4a20-af71-153c33fc117b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "candidates receiving warfarin-based therapy are allowed in the primary clinical trial but prohibited in the secondary clinical trial."
    },
    "67b93677-87f6-4a11-8dea-66a3c2242b19": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients suffering from fronto-temporal dementia or mixed dementia can participate in the primary clinical trial"
    },
    "dfef1ddd-9351-436d-b1ce-9f22065b495c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were several adverse events which occurred in more than 3 out of 10 participants."
    },
    "8e698117-fcf5-480f-80a0-95a3be887ef8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the primary trial requires the use of 3 different drugs as part of the intervention, the combined use of cyclophosphamide, droperidol, and epoetin beta, on the other hand the intervention in the secondary trial only includes tamoxifen."
    },
    "db5f7526-ae64-4a0c-bea4-53b4bfe95d48": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive one single injection on day 8 of the study. thin-branching papillae present is a morphologic growth pattern indicating the presence of papillary structures forming thin branches."
    },
    "474339d0-2bac-4e3a-9aee-1933b96738b0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "her2 + patients in the primary trial receive a different dosage of trastuzumab than patients in cohort 2 of the secondary trial during the whole trial period"
    },
    "2a13f623-4957-4e7e-9968-03f64bb6f5f3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "in the primary clinical trial, participants are given anthracycline-based chemotherapy on days 1, 8, and 15"
    },
    "d1d340f9-f31f-4469-804b-41853562fa57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. concerned about ability to have children is a question about whether an individual is or was concerned about their ability to have children."
    },
    "e493c4b0-1bd6-446f-a432-2703b7775620": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all participants who were administered with 1mg gtx-024 in the primary clinical trial, showed a gain in lean body mass during the 4-month period"
    },
    "3d081c7c-10e8-490f-8943-260f27175c56": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial. turkic language is a language family spoken by the turkic peoples of eurasia."
    },
    "62c8e736-58fd-472f-bef0-c957b8055237": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 30 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "94849f18-76aa-4fdf-9f7b-2fb1c6b5bc9d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the primary clinical trial and the secondary clinical trial follow an identical drug-based treatment intervention."
    },
    "d1200239-9391-41b1-a73e-5590855243bc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "participants in the primary clinical trial are administered higher doses of alt-801 compared to those in the secondary clinical trial"
    },
    "4192b30d-92ad-47c4-b88e-8f48ea048ee2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "the decision to include a patient in the primary clinical trial is completely determined by patient's fulfilment of the inclusion and exclusion criteria, and does not involve the discretion of health professionals."
    },
    "9edc1688-da47-48ff-b475-b894e925dec7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial. recto-vesico-vaginal fistula is an abnormal communication between the rectum, bladder, and vagina."
    },
    "8bd3b6aa-d1b5-4f4a-a16a-434d56764ee5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "the most common ae recorded in the primary clinical trial is myocardial infarction not coronary artery stenosis"
    },
    "ed8ee6d6-5a37-4338-af72-e87bb50ec4d9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "a majority of individuals in the primary clinical trial demonstrated complete response in a span of 24 weeks."
    },
    "b21fa80a-d451-46c7-8916-bf3029156624": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "patients who have previously experienced profound anaphylactic responses to trastuzumab are ineligible for the primary clinical trial."
    },
    "f103c71f-151a-46b1-b24e-c9fa1c90db64": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the administration method for both trabectedin and the placebo in the primary clinical trial is subcutaneous, occurring monthly."
    },
    "b0c8481b-3041-4b12-b272-11bb5ee7f80e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "half of primary clinical trial's participants, and 837/1674 of the secondary trial's participants experienced an adverse event."
    },
    "b6b719ca-e7f3-4254-a1a0-2946acbcd2fd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group."
    },
    "cc11b6a5-855a-4291-b41d-e63367ea3b88": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary and secondary clinical trials utilize pcr as a determinant of their results. notably, the primary trial boasts slight variations in the outcomes of its two cohorts. in contrast, within the secondary trial, larger differences in results are witnessed, with arm 2 performing poorly compared to arm 1 due to an increased number of patients experiencing pcr."
    },
    "31dea0ef-a953-4217-9e00-bac1c96a7325": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the primary clinical trial and the secondary clinical trial consist of the same pharmacological treatment protocol."
    },
    "d7f83dbb-ef9c-455b-a692-e99eefcddb05": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "the primary clinical trial records no aes as being general symptoms"
    },
    "b7bd2215-d2b2-4cd0-a12a-d12310737373": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "patients who have been treated with gabapentin or pregabalin recently are eligible for participation in the secondary trial, but will be excluded from the primary trial."
    },
    "964e4947-27a1-435e-84c6-d28b91d0dabe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "intact mobility is a prerequisite for participation in the secondary trial, while the same quality is also mandatory for inclusion in the primary trial"
    },
    "05aafe0b-c62a-4dda-a60a-52929cb81b7f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "participation in the primary clinical trial is not permitted for patients with a history of conditions such as abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess, or serious psychiatric disorders in the past 6 months."
    },
    "03688964-cf46-485b-99f3-f7c6c5fed3ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "participation in the primary clinical trial is limited to female candidates of a specified nationality, this condition doesn't exist for the secondary clinical trial."
    },
    "9bd8875f-ce04-496a-b039-6a84bb2e5548": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "specimen source site is a request to identify the specimen source site. Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure."
    },
    "638143cc-bcdc-422b-8695-ec836f17edae": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "patient in body sling is a position in which the subject's body is supported by a sling. the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery."
    },
    "7f22f322-c4fb-4001-875b-fe5baefbdc64": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "veillonella is a genus of anaerobic, gram negative, cocci shaped bacterium assigned to the phylum firmicutes and the family veillonellaceae. there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial."
    },
    "e9f1fcfa-40ed-4360-bf37-4260888d241b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "participants in the primary clinical trial receive whole breast radiation therapy, whereas participants in both cohorts of the secondary clinical trial are subjected to intramuscular injections and oral medication."
    },
    "564d9a7d-327b-45be-af87-1971e15a9db4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "1p33-p32 is a chromosome band present on 1p 100.0% of cohort 1 of the primary trial suffered some kind of adverse event."
    },
    "68461786-a85c-4370-8935-cb6680a3c5cb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "individuals with uncontrolled cardiovascular conditions can join the secondary clinical trial."
    },
    "227071c8-f195-4c9c-993d-3f57a9062a6f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "secondary glioblastoma is a glioblastoma arising from a lower grade astrocytoma. Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial."
    },
    "a6688fad-488e-4822-a91e-cbfe2117cae1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "the majority of the primary clinical trial participants experienced a decrease in circulating tumor cells after receiving high-dose chemotherapy with purged autologous stem cell products."
    },
    "f191be61-8e8d-495c-b5e3-1bf3cc89904a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "in the primary clinical trial, patient survival timeframe generally does not exceed 1 year, with not more than 50 patients in each cohort making it past the 12-month mark."
    },
    "cbd414d3-c3c6-4d3a-8a7a-67832757ae03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, daily armodafinil p.o. is dispensed to only one cohort, while in the secondary clinical trial, each patient gets the same amount of pdr001, with a range of mcs110 dosages."
    },
    "c5feab6a-263d-41c4-8c21-cfa5ffe80a3d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "participants of the primary clinical trial undergo complete breast radiation therapy, in contrast, the secondary clinical trial participants, from both cohorts, take 500 mg of fulvestrant in tablet form, twice daily."
    },
    "5fbe4001-1044-4684-a2a2-e34bf233fafb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. scoopful dosing unit is a dosing unit equal to the amount of active ingredient(s) contained typically in a spoon-shaped object."
    },
    "e54cf8ee-4a0d-4a15-bc72-4072ff0b6e6d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention incorporates the application of chemotherapy and radiology, whereas the secondary trial intervention relies on the use of hormonal therapy and immunotherapy."
    },
    "3cd949ea-cd27-4eff-b7b6-0087df3136ba": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "cohort 1 of the primary clinical trial reported mild aes"
    },
    "236451bf-52bd-4530-ba81-100e63b0030f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "stomatitis was the only recorded adverse event in the primary clinical trial."
    },
    "5861703f-56fc-4e31-ba4e-d97400d71d99": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "both the primary and secondary trials recorded zero cases of either febrile neutropenia or cholelithiasis."
    },
    "1d8a752e-8628-40d5-b134-e523b5dead07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "a number of patients in the primary clinical trial reported severe discomfort during the entirety of the 10-week study."
    },
    "a90d6d85-6942-4653-b23c-126d63b1d2cf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial. 15q23-15q24 is a chromosome band present on 15q"
    },
    "3c96d823-bc6c-4c7e-b490-50a0870076c5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "both the placebo and allo-mscs interventions of the primary clinical trial are administered in varied doses through inhalation."
    },
    "bae680f2-9b93-494d-b2e7-65a99400af85": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "men diagnosed with prostate cancer who present positive biomarker for psa are eligible for all cohorts of the primary clinical trial"
    },
    "e486bbca-c279-458b-b98b-2b434c9a242d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "malignant laryngeal neoplasm is a primary or metastatic malignant neoplasm involving the larynx.  the majority are carcinomas. The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope."
    },
    "0d984537-a1c8-486f-840d-1a09f2bfa961": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "in the primary clinical trial, fewer than a quarter of the patients have registered increased pleural effusion or rapid disease progression"
    },
    "45745e85-0655-490a-a692-ee9f060f8898": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "hard to remember what i just heard is a question about whether an individual finds or found it hard to remember what they just heard. Nobody taking part in the primary trial suffered a UTI."
    },
    "3eb3c09a-b46f-49bf-84d6-7aeb1ba0d2a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month."
    },
    "8268f272-c82c-4cc3-87dd-8fdf59611a1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "at least one patient in the primary trial suffered several different adverse events. thyroid gland follicular carcinoma, minimally invasive is a follicular carcinoma of the thyroid gland showing capsular invasion only."
    },
    "d1eb9a24-13e8-43de-ba1c-7b17e35e7ab3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the units of measure used in the primary and secondary trials align perfectly when measuring similar outcome."
    },
    "fffc74c9-56a5-45e7-ba89-a2c91da05110": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant. regulatory pathway is an elaboration of the known or inferred interactions controlling the expression of a product."
    },
    "3239643a-3052-4344-a7ea-f2d5dff19755": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children are the main demographic required for participating in the primary clinical trial while they are not allowed to partake in the secondary trial"
    },
    "6561c528-4e6f-4e1f-8d65-9fa11d3c8838": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "the secondary trial measures the proportion of participants benefiting from the treatment according to recist criteria, but the primary trial does not track this element."
    },
    "8b0efa30-40c4-408e-a91b-ded68b61d9ff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 24 months, however at least one patient from both cohorts died in under 24 months."
    },
    "0ed8370b-00c3-41d9-9d12-0c0f1259cbf1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "cohort 2 of the primary clinical trial follows the paced breathing instructional audio material only once daily and is given no antineoplastic treatments weekly."
    },
    "328dcbbe-1a4a-46f1-afad-df84cebcde05": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "primary clinical trial involves the administration of a one-time 250 mg/m2 intramuscular dose of lapatinib to participating patients."
    },
    "f5a3b01c-743a-4d70-81c8-a5671272d1e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "milliunit is a quantity equivalent to the one thousandth unit (10e-3 unit). Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine."
    },
    "af3815c2-6d92-410b-ae62-5552ea998792": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "the average lifespan of patients post the primary clinical trial is less than 2 years, with no instances of patients from both cohorts passing away before the 2 year mark."
    },
    "41c54be8-c257-49dc-b21b-0184595c1277": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "the primary clinical trial administers to cohort 1 a dose of alt-801 which is less than half of that given to cohort 2"
    },
    "e00ad4a5-25b8-4343-a353-be8b2e0d6c1b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the psychiatric condition of a patient determines their eligibility for the primary clinical trial and the secondary clinical trial"
    },
    "b3361d9c-9d9f-4966-80e7-629656bfcd1e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial. fpsr questionnaire question is a question associated with the fpsr questionnaire."
    },
    "c975a46b-6980-4cc4-886d-674f5f2c6773": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "a majority of patients in the primary clinical trial did not have recurrence-free survival."
    },
    "a510de48-5778-4489-8d10-82173320bdad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. ganglion is a cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (cns)."
    },
    "8c4891f7-e0af-4ddb-8754-0638ece12c58": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "there was no significant difference in the average number of daily hot flashes experienced by patients in the paced respiration intervention group and the fast, shallow respiration group in the primary clinical trial."
    },
    "72ea65df-6381-4672-a40c-f55cee100091": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the sole adverse event noted in the primary clinical trial was stomatitis."
    },
    "5ccd39fd-215e-4699-8d02-a13d68ec34d3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "bulk nucleus specimen is a biospecimen consisting of multiple nuclei as a pool. Both interventions in the primary trial include the same dose of Paraplatin."
    },
    "9d7a1491-f931-47dd-9177-72bc90006fd2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "prior severe anaphylactic reactions to trastuzumab do not disqualify a patient from participating in the primary clinical trial."
    },
    "ab7fc69a-25c8-4bee-ad2b-526c6ea638e4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the majority of patients in the primary trial experienced complete response by week 168 days."
    },
    "514d5612-4c60-4586-89b7-ca89b06ac576": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a radius of 330mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "af615add-c0e4-4046-9968-9d5805d2620e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "cancer-free patients are eligible for the primary clinical trial"
    },
    "ed820c4c-4119-4e93-894f-8484407c9ce6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the varied effects of radiation therapies on the study groups are being examined in the primary clinical trial, whereas the secondary clinical trial focuses on analyzing the outcomes of different dosages of the same regimen on its cohort"
    },
    "b2572b63-5246-4be3-84ee-c37f18da106d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 in the primary clinical trial received a higher dosage of cetuximab compared to cohort 2, while still receiving 8mg/kg more mm-121 than cohort 2."
    },
    "280cae18-764b-4cc7-ae2a-3b1f05c04cbf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "the primary clinical trial has different pet/ct imaging procedures for each study group, none of which involve the use of 18f-fdg or 18f-fpprgd2."
    },
    "d7170cb2-d8a5-4c65-9122-bc6bcf13caeb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis. her2/neu negative by immunohistochemistry is a laboratory test result indicating the absence of her2/neu in a tissue sample using immunohistochemical staining."
    },
    "8a308bd1-0164-4734-bdeb-f955327b4314": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions. deriving is an explanation of the historical origins of a word, phrase, or object."
    },
    "d2057876-3991-462d-b5fd-de01cc252790": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "cohort 2 of the primary clinical trial is not given additional treatment cycles of docetaxel, doxorubicin and cyclophosphamide."
    },
    "1ea69c5b-83c6-4d54-b17c-0e6df9c49abb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "in the primary clinical trial, the prevailing adverse events were of cardiovascular origin, a situation that further differs from the secondary trial where such have not been registered."
    },
    "2e8f3602-15d2-4970-ad77-07352b50b787": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary and secondary clinical trials both utilize intravenous injections and mris, but they do not incorporate the same drugs, administer the same dosages, or adhere to the same administration frequency."
    },
    "eec99f26-cf8e-407d-bb6a-7f9d053fe187": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates possessing an ecog score of 1 are qualified for both the primary clinical trial and the secondary clinical trial"
    },
    "f6f6058f-688b-4ce6-8fec-612f57b1f3ec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "people possessing a tnbc tumor with a 100mm diameter can partake in either the primary trial or the secondary trial."
    },
    "01650c5a-f268-41c2-b07b-9293a0e4a8f7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the results of the primary clinical trial and the secondary clinical trial include outcome measures that are not at all alike"
    },
    "96259bb4-b459-4f63-b987-6bdb596211a4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "er negative breast cancer patients, irrespective of their gender, may be qualified for either phase of the primary clinical trial."
    },
    "6b257ade-83bb-428c-a623-056f1ad56594": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary clinical trial must be diagnosed with lung cancer and require radiation therapy."
    },
    "136c5db2-719f-458f-9d88-f5596886ed96": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "7p21-p15 is a chromosome band present on 7p the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine."
    },
    "156b015d-e2bb-4f38-a312-62e1cf7583d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial. arthrinium phaeospermum is a species of dematiaceous anamorphic fungi in the phylum ascomycota with smooth, hyaline, branched, septate hyphae."
    },
    "f68789cf-7d4d-4186-b3f0-a6b47127379b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "all patients from either group of the primary clinical trial experienced minimal or no recovery, illustrated by the absence of pathologic complete response in breast and axillary lymph nodes, 6 months past surgery"
    },
    "beff7121-1697-41a7-bf43-998005d5c68e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "in contradiction to the primary trial where perjeta is part of the regimen, it is completely excluded from all cohorts in the secondary trial."
    },
    "278549fe-1d04-44de-88dc-e0661e8f234b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the primary clinical trial has fewer total and different kinds of adverse events recorded compared to the secondary trial."
    },
    "4e5a04a1-2513-472b-b2a7-891d68a3b549": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group"
    },
    "be50f0ae-0c2b-42be-9306-78a1da6b4e09": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "the primary clinical trial is open for all age groups without any height restrictions, but the secondary clinical trial has imposed a height requirement"
    },
    "1649a4de-bc0d-4908-88ac-515b88be60b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "the primary trial reported no adverse occurrences, and in the secondary trial, less than 30% of patients experienced adverse events."
    },
    "e875a6e2-1058-4954-a864-7f1b35508362": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "0.5ug/kg of dexmedetomidine (5ml) is provided to group 2 in the primary clinical trial, unlike in the secondary clinical trial where patients do not receive any dexmedetomidine."
    },
    "37c939aa-c2b0-4fcc-a90a-d7fa36fc8571": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "in the primary clinical trial, neither cohort is subjected to any invasive surgical procedures or given neratinib"
    },
    "a4c5aecb-d375-43b7-bee0-dea9651fb7d6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the primary trial and the secondary trial use the same units of measure for their results, in any assessed outcome measurement."
    },
    "21e44cc9-f3ce-47b3-ace5-69718677308e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "while the intravenous injections and mris are common procedures in both primary and secondary clinical trials, differences are noticeable in the drugs, dosages, and frequency of administration they employ in their interventions."
    },
    "13742fb9-874a-4f76-9d17-585c96fbd440": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the count of adverse effects in the patient cohorts was identical for both the primary clinical trial and the secondary clinical trial."
    },
    "4a7035e5-7fdf-461e-9d63-8e52be720d96": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "in order to take part in the primary clinical trial, aspirants must first get a mammography, whereas the secondary clinical trial requires patients to have a ct scan and blood tests prior to participating."
    },
    "1a9f1afc-af2c-4dca-b701-2a04033f47b4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "a prerequisite for both the primary and the secondary clinical trials is the attainment of a baseline performance level. the primary clinical trial necessitates a karnofsky score of over 70 whereas the secondary clinical trial requires a score exceeding 55."
    },
    "3974c3ec-d3b5-4313-ae4b-4332ee5865ab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55"
    },
    "320ec115-31c3-47bf-a819-93d514b91eb3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "454e1858-76b2-4952-9ac0-820d81dbf966": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the primary clinical trial demands that patients take a bi-weekly dose of decitabine, whilst the secondary clinical trial requires no medication"
    },
    "90474244-ea60-4670-b586-8ca32b80af7f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "all the adverse events reported in the primary clinical trial were experienced by patients in the first cohort"
    },
    "1e826f28-5a81-4123-95f7-74418392ed90": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary clinical trial receive a diverse drug regimen, each not exceeding a dose beyond 50 mg/m^2."
    },
    "7e791f30-68d4-4a11-86e4-c2e88d737913": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "There were more cases of Infection, Asymmetry and nausea in the primary trial than in the secondary trial. feel slowed down is a question about whether an individual feels or has felt that they are slowed down."
    },
    "648ed723-14eb-4c58-85f9-9a6f6089b493": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "on a scale of 1 to 7, the primary trial assesses the severity of delayed nausea. the secondary trial, however, observes the variation from the starting point up to the ninth month in the bone mineral density (bmd) of the lumbar spine."
    },
    "848665ec-85f5-4b64-aa71-ba24195e7463": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "the secondary clinical trial involves weekly subcutaneous injections for its participants, a requirement that does not apply to the primary clinical trial."
    },
    "5f4eaa1c-4e83-402c-a1ed-4d398f51ec1d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "multiple drugs are demanded in the treatment protocol of the primary clinical trial, as opposed to the mono-drug intervention method of the secondary clinical trial."
    },
    "1adf360d-dd5e-4bbd-b5f1-8846f84407a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. estramustine/vinblastine regimen is a regimen consisting of estramustine and vinblastine used for the treatment of hormone-refractory prostate cancer."
    },
    "f891df0b-cb3d-4ee8-8294-f139ecc8a018": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "102% of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases"
    },
    "869078fe-375b-45b5-ba65-21d04cd304ed": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "bone marrow sample is a biological sample containing components collected from bone marrow of an experimental subject. the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1."
    },
    "c6b00d4d-2940-484b-b305-baaf3c5ccff4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is concerned with establishing the average hours of sleep among its patients, whereas the secondary trial is evaluating the prevalence of adverse events caused by the treatment."
    },
    "36e73055-3f34-4e5b-94a0-cfbac5dc3ff9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "have trouble saying what i mean in conversation is a question about whether an individual has or had trouble saying what they mean in conversations with others. Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial."
    },
    "791790a6-187b-4e4b-be5f-9e5304e9ec2c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial"
    },
    "570b88e9-5036-4ea8-80db-0f48696700af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants"
    },
    "c158ee0a-2ff1-483d-a906-6dcbb76fae47": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "the frequency at which pembrolizumab is administered in the primary clinical trial is twice that of the sunitinib administration in the secondary clinical trial."
    },
    "48206c2e-1f24-4248-8c06-bfac596dcaa5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial. arthroscopic surgery is any surgical procedure that involves an arthroscope."
    },
    "9c4299c7-89e6-4d9c-81db-5d12f182b4d3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 4 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "cb591a65-2304-40bc-ad66-ddd4f3376bdc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "peripheral primitive neuroectodermal tumor of bone is a small round cell tumor with neural differentiation arising from the bone.  it may be associated with pain. Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial."
    },
    "adfed785-8da6-4bf4-836f-2dfadf0510b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants."
    },
    "ad00f90a-b69d-4df4-a9f8-d495ac080b38": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "in comparison to patients on aprepitant in the primary clinical trial, those given the placebo intervention were two times more likely to undergo emesis."
    },
    "a714b4d6-d9d7-4dc7-8efe-50c92616d027": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "estimated body weight is an approximate determination of the weight of a body. All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events."
    },
    "40535d67-a16d-48eb-932e-3d8d2ff57281": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "while the primary clinical trial involves administering over seven different drugs to participants, as well as a surgical procedure, participants in the secondary clinical trial only receive two different pharmaceuticals without the need for any surgical operation"
    },
    "824add43-b242-4278-9be4-04f1566039cd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "during the primary clinical trial, one injection will be administered to the patients on the eighth day of the study."
    },
    "0f17aa12-6aea-430e-b4e8-2a21f2832582": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial does not accept patients with tumors showing ccnd1 amplification, cdk4/6 mutation, or ccnd2 amplification."
    },
    "669ed7b4-398b-4604-8065-04e99611691d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial was composed of multiple test groups and lacked a placebo group, whereas the secondary trial included two control groups and lacked a test group."
    },
    "a5b66f28-1afc-4cf7-b686-d9de17496983": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial. folate receptor family positive is an indication that expression of a member of the folate receptor family has been detected in a sample."
    },
    "13178eb4-e1c0-4fa0-8008-f4a4617220aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "in the primary clinical trial, the terms of inclusion and exclusion differ between its two stages, as opposed to the secondary clinical trial, which has standard criteria applicable to all its participants."
    },
    "4763223f-0ecd-4d19-a9ee-d466648ce4ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "in the primary clinical trial, the distinction between the first and second cohorts lies in the treatment dosage; the former gets a daily administration of 25 mg to 37.5 mg sunitinib, while the latter is given 10 mg/kg of bevacizumab"
    },
    "eb12190b-96c6-4c5d-8479-1248b462587d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the secondary trial's intervention duration is three times longer than that of the primary trial's intervention."
    },
    "5c226c5b-0a0a-44f7-a581-b2b8746f28a5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. johnston atoll is an island in the north pacific ocean, between hawaii and the marshall islands."
    },
    "73e39e6d-e688-4372-85d4-dbb3cbc7a7cb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "several of the patients in the primary trial experienced the no pain whatsoever during the 200 weeks of the study."
    },
    "225ff186-66e8-4880-bba4-e8127bd42834": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "mitral valve atresia is a congenital heart defect characterized by the complete atresia of the mitral valve. Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study."
    },
    "462f7871-9216-4b37-af39-1fb32b2bbf84": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "the primary clinical trial does not admit patients who previously had serious anaphylactic reactions to trastuzumab."
    },
    "1c968571-9618-4a86-af59-6e8367b1128f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "statistics note that the survival period post the primary clinical trial for the majority of patients is under 2 years, and it is registered that none of the patients in both cohorts had a lifespan under 2 years."
    },
    "4189cb5a-bff9-4867-b9d7-1bd7791723f3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in the primary clinical trial and the secondary clinical trial, adverse events were not recorded in more than 10% of participants."
    },
    "7f1d39e0-4892-447d-90b9-b2c672e59c79": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "the primary clinical trial does not mandate the fulfillment of certain criteria such as mental health, bodyweight, age, karnofsky/ecog score or previous treatments."
    },
    "a7561afd-f6c4-41cf-8d4a-fa6c26cc10b3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "congenital candidiasis is a fungal infection by any of the candida species that is present at birth. The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group."
    },
    "9c5bbe3a-c662-4a0e-88cf-b2f5fc1188f8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "within the scope of the primary clinical trial, the prevalence of hypertension and pancreatectomy cases were equivalent to the rate of hepatotoxicity cases"
    },
    "c01a6286-57b2-4851-8c5e-12710eb9d829": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial. receptive vocabulary assessment is a test that assesses an individual's understanding of spoken english language."
    },
    "a98a4204-8591-48d3-9349-723b4ccc4f3c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have had a pulmonary embolism within the last 3 years are considered eligible for the primary trial and are not subject to the investigator's decision for the secondary trial"
    },
    "61215857-54c4-4622-afc2-7249194a96f6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "only those resistant to ai therapy are eligible for the primary clinical trial, whereas for the secondary clinical trial, this is not a prerequisite"
    },
    "096f687a-6eec-4648-b8f8-6d423d84f3ae": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "all ae types in the primary trial affected more than 50% of patients"
    },
    "b93384b1-a925-460d-ba66-78967a500d8c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "intermediate (locally aggressive) blood vessel neoplasm is a borderline blood vessel neoplasm that has locally aggressive behavior. the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group."
    },
    "201ec8b0-f2f0-4c60-8094-0f40761f6d88": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the number of adverse events witnessed in the primary clinical trial was higher than in the secondary clinical trial.'"
    },
    "7e01558a-26ed-4ebf-aa18-d5d1c876c194": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "doctor and i shared responsibility for deciding which treatment is best for me is a response indicating that an individual and their doctor shared responsibility for deciding which treatment is best for them. the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention."
    },
    "a1eb1305-f49e-4773-aa30-033093afeb64": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "there was no significant difference in the decrease of the growth factor signature in both the dalotuzumab 20 mg/kg group and the triple negative group of the primary clinical trial."
    },
    "53a45460-701f-420e-853a-f5ccb8545030": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the patient population of the primary trial undergoes subcutaneous insulin injections as a treatment procedure, whereas the patient population of the secondary trial receives oral antiretroviral therapy (art)"
    },
    "504dd694-4978-41f0-bee5-ccc6dd199752": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "white fiber is a type of striated skeletal muscle fiber that contracts quickly and contains small amounts of mitochondria, myoglobin and sarcoplasm. the secondary trial and the primary trial share at least one inclusion criteria."
    },
    "e92e6dec-b727-475a-b544-568b5773cb81": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "participants in the primary clinical trial are prescribed a dose of 100 mg/m2 of lapatinib to be taken orally, two times per day for an entire month."
    },
    "2884c912-af96-4bac-9b0e-29f1d0876abc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "14q13.2 is a chromosome band present on 14q The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736."
    },
    "dce94e19-6a0a-4fc9-ab35-ad4eb378622b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "those suffering from validated metastatic scbc may enroll in the primary clinical trial."
    },
    "2312391b-799c-4dcc-9ba4-4b98c9c9642b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "trastuzumab is explicitly excluded as an intervention in the primary clinical trial"
    },
    "2e42ac97-e353-4bbc-b61e-391e0c092689": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2."
    },
    "e07a4aec-7879-4c85-a39e-a1cb17f2fd64": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the mode of administration for the primary clinical trial is via intramuscular injection, whereas for the secondary clinical trial, it is by oral intake"
    },
    "9640278e-af41-482e-8390-d20bc7388149": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "sexually active fertile men and women with reproductive potential can participate in the primary clinical trial, but adherence to additional criteria is required."
    },
    "29eca4cf-13e4-4028-bbd1-71955607afb5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy. myroides is a genus of aerobic, gram-negative, rod shaped bacteria in the phylum bacteroidetes and the family flavobacteriaceae."
    },
    "f48fabb1-f814-4f89-acf9-7ff95948b8d9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "with the exception of one, all patients who were treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial experienced adverse events emergent from treatment, and serious adverse events were experienced by less than half."
    },
    "5ce949a2-19fb-4580-8b0e-f0652dd064e3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 200mm in diameter are included in the primary clinical trial and secondary clinical trial"
    },
    "83d14b48-ba22-47e0-a7c5-0a0b5f8af134": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "a majority of patients experienced adverse events in the primary clinical trial"
    },
    "34f9be61-9ee8-475e-9b02-72938355d6a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally. acute contagious conjunctivitis is acute inflammation of the conjunctiva characterized by pink or red color in the eyes."
    },
    "4bfe4376-ffad-4132-8604-b5afbc78429d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "pancreaticobiliary malunion is an abnormality of the pancreatic and biliary ducts in which their junction occurs above the duodenal wall. Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy."
    },
    "af52a2f1-de39-4113-86fa-10e65961b095": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria. shockwave dosing unit is a dosing measurement based on the shock wave unit."
    },
    "05cd9540-60f6-4255-a4a5-fadff61801eb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must present an updated dental examination record to participate in the primary trial, whereas for the secondary trial, patients are required to provide a detailed eye examination report and complete immunization history."
    },
    "152fc619-bbb0-40ff-aa3e-5722f62f6a84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer."
    },
    "15577bb6-3b4d-4373-ae58-eb0bf0c34954": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial."
    },
    "33cd5bbd-a795-467e-b08f-cf59702922cc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1. 3-6 weeks after start of radiation therapy is a time period of 3-6 weeks after the start of radiation therapy."
    },
    "892ac2e3-f5f8-42eb-957c-b3ca6af18d3a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 0.15 grams of oral pregabalin every 14 days over 42 days, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "7caa5dd0-cd09-4559-a243-736304ce22e4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "an 55 year old male patient with a 5 year past diagnosis of er-positive, her2-negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial."
    },
    "a154d6bd-fc5d-491f-b2aa-7785024e67a5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the same unit of measure is employed for reporting results in both the primary and secondary clinical trial."
    },
    "d0a60b09-e029-4c35-b896-3647ce468594": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "during the primary clinical trial, participants are given the her2/neu peptide vaccine combined with sargramostim (gm-csf) id on the first, eighth, and fifteenth days."
    },
    "d3525b25-3dad-4ed2-8fe7-d0f0abc6be14": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "primary clinical trial employs procedures that utilize ultrasound guidance and vertical longitudinal incisions."
    },
    "10b5153d-7bb1-45a0-9765-1df8e3dfbd88": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "the appearance of maculo-papular rash was a frequent side effect among the participants of the primary clinical trial."
    },
    "40d65677-e7f3-46f8-801a-327c8422937b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "in the primary clinical trial, psychiatric adverse events affected over half of the patients."
    },
    "4b310647-d605-4946-aeb5-bcfd418e1332": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "in the primary clinical trial, both intervention one and two use pihgc as their method."
    },
    "09df9e5c-cc03-4c01-858b-0886376e9b7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 5.4% of the primary trial participants had a reduction in circulating tumor cells following years of high-dose chemotherapy with purged autologous stem cell products"
    },
    "eff79353-72dc-4a94-b856-40b844d2860b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor exceeding 1 cm in diameter, with confirmed hr negative and her2 positive status are eligible for both the primary clinical trial and the secondary clinical trial"
    },
    "3cd01e92-2bff-45d7-9fa3-77c351d2f39a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary clinical trial presented no adverse events."
    },
    "e12077dc-2ef2-4276-b755-4664b0a0f0ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "every member in both the primary and secondary clinical trials is given enteric-coated tablets"
    },
    "7bad3ae8-835f-401c-b50d-10e2f2773cc7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 300 mg group of the primary trial had a -60.4% recurrence-free survival compared to the nacl 0.9% 3ml group"
    },
    "cd93653b-f6d1-4e8c-aa04-20a41d0096b9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "anemia cases are less prevalent in the primary clinical trial than in the secondary clinical trial."
    },
    "b20dadde-0f33-42ca-aa3e-c9333cdffe89": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "there was a higher incidence of serious adverse reactions documented in the adverse events portion of the primary clinical trial as compared to the secondary clinical trial"
    },
    "29bed237-ccbb-460b-a50b-fbdc9e52fdd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "All AE types in the primary trial affected less than 10% of patients"
    },
    "0428ab54-eddd-4ee8-a58f-45ec7d7630f7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "patients in the primary clinical trial who did not receive topical cryotherapy reported symptom improvement compared to those receiving cryotherapy.'"
    },
    "8bd8a0f5-4bc9-4de6-a7d8-2a3acaadc6c4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial. ossifying fibroma is a benign fibro-osseous neoplasm affecting the jaws and the craniofacial skeleton. (who 2017)"
    },
    "f0fbd167-6b00-4152-889e-7df794aa0619": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. laryngeal obstruction, ctcae is a disorder characterized by blockage of the laryngeal airway."
    },
    "14e1403f-9bb6-40cc-88fe-4b2f110e7b0d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "as part of the intervention, daily administration of 1000 mcg of talazoparib is carried out for several candidates in the primary clinical trial"
    },
    "6b0bc5aa-4540-4439-a2e3-c48abb937074": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "all measured patients within the primary clinical trial's group 1 were identified as having several lesions, along with an overwhelming majority from the secondary trial's group 1 showing healthy skin attributes."
    },
    "c216cb60-86c5-4ba4-9092-07bfe620c6ec": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "somewhat forgetful is a response indicating that an individual is or was somewhat forgetful. The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial."
    },
    "cd18deca-a213-4d53-af34-88624163f68e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "paclitaxel is given to participants in the primary and secondary clinical trials"
    },
    "53d37329-6f3e-40fe-82d3-4a2535b117d9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates capable of only limited selfcare; confined to bed or chair more than 50.0% of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "c94158fd-10f5-4142-a361-5b346ff2c295": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial."
    },
    "e3c4aff9-78ee-4a66-9735-1cd5370b7925": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. cystic change is a microscopic finding indicating the formation of cystic structures in a tissue sample."
    },
    "7b5d47fb-446d-481f-9785-3ff8b467fa69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary clinical trial intervention includes a regimen of 500 mg of ibrutinib and 10 mg/kg of ipilimumab every day for six weeks."
    },
    "9c60f664-ef13-406d-b26a-e57f6c914cf4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "kras gene mutation negative is a genetic finding indicating that kras gene mutations have not been detected in a sample. All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week."
    },
    "d130905f-48af-4f05-9d02-92c980b46c75": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "suramin and paclitaxel are given to every participant in both the primary and secondary clinical trial"
    },
    "635d4169-6adf-4254-9ee5-e9eede3f7bc5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary clinical trial accepts only candidates with full mobility, and similar physical ability requirements have also been established for the primary clinical trial"
    },
    "f43b3f3f-f51c-49ff-b659-b3e97bf0ab0d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "patients diagnosed with hypopharyngeal squamous cell carcinoma via polymerase chain reaction, or those who have developed venous thromboembolism post-lumpectomy are not permitted to participate in either the primary trial or the secondary trial."
    },
    "847dd934-e3d0-44c6-8964-d1eb14b0d7a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "on average, all patients in both cohorts of the primary clinical trial showed improvements in cognitive function."
    },
    "197bf729-04f4-46f0-a746-8b55c088f0d6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 20 mg po daily for 1 week prior to surgery and for 2 weeks after breast cancer surgery reduces ki67 expression in tumors by 40% on average."
    },
    "0c9b06e1-9dab-4937-b22e-0d372a5fd92d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "in the primary clinical trial, high doses of alpha lipoic acid are administered, up to 100 mg three times daily, while the same steady dose of necitumumab is given to patients in cohort 1 of the secondary clinical trial."
    },
    "0164b2f8-a87d-4bb8-8487-6eb1f65b9804": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "eyes progression gvhd is an nih eye score that has increased by 1 or more points, except 0 to 1. Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention."
    },
    "3cbf5587-220b-4759-a93b-8dbd5e144939": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients with unmeasurable metastasis or those without cancer spread to other body parts are not appropriate for the primary clinical trial"
    },
    "99a8a2b3-84ad-4c45-9371-e731cc5942db": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "more than 97% of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products"
    },
    "105ed693-cbe0-47a4-ba39-f361032d9ed7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency. tracheostomy site bleeding, ctcae is a disorder characterized by bleeding from the tracheostomy site."
    },
    "e9941afc-cfd4-4bfa-bbce-eec2b84eb27d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "the protocol of the primary clinical trial includes a bitherapy regimen for its study duration."
    },
    "8183a43e-0284-483d-a22c-08502b0ebc8a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death . mouse kidney carcinoma is a carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis of a mouse."
    },
    "55372cf8-c6a0-4286-8cd5-5e11e070bd79": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "the mymop score change is not a determinant for outcome measurement in either the primary trial or the secondary trial."
    },
    "bf3034ec-679a-42d1-9d24-69b51c602233": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial or the secondary trial"
    },
    "cf4c4c98-b8b0-4ab8-85a8-1269da4d9fd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial."
    },
    "d803d6fb-f2af-4470-8cf9-7f68d6c53baf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention. orthodontic treatment is a dental treatment to correct malocclusions of the teeth and their surrounding structures."
    },
    "9915c5ea-d327-4cd9-a3e2-26cfa75cadb7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare. gender fluid is an individual who describes their gender identity as fluctuating between male, female, and/or other."
    },
    "2855e123-6fa3-44b7-9eda-09603be206aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "50% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "325db761-416f-4aab-80e8-e3271a11200b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants do not receive any vaccines. fatigue among most disabling symptoms is a question about whether an individual's fatigue is or was among their most disabling symptoms."
    },
    "439b1eca-f583-4a2b-bd8e-0baae97b4c15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study."
    },
    "bf1b6561-6731-457a-801d-8af93bc8857b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a diameter of 3.3cm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "47abcc5d-7e6b-4969-9646-eefe68cebc3a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial. penile implant is an implanted device that enables the penis to become erect."
    },
    "a668e3be-6b87-468e-99b5-48ad77bed972": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "photovoice is a qualitative method in which participants use photographic techniques to facilitate the documentation and communication of issues. Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial."
    },
    "faf8436a-2459-4718-be81-10b0649ff87a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "youths below the age of 18 are the target group for both the secondary and the primary trial"
    },
    "8655fdcd-564c-483a-aa2b-7dac2d84ce57": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients diagnosed with tumors positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification are excluded from the primary trial. main duct pancreatic intraductal papillary-mucinous neoplasm is an intraductal papillary-mucinous neoplasm of the pancreas that arises from the main pancreatic duct."
    },
    "9bc581fd-162a-43c2-8c72-69c06d9ba395": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "study subject withdrawal by parent or guardian is an indication that a study participant has been removed from the study by the parent or legal guardian. the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response ."
    },
    "b00e3d3a-3046-4996-a028-35e45ce682be": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 40 years would be excluded from the primary trial"
    },
    "8773e9c2-3030-4221-b663-b21d49ae1721": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "no evaluation of the clinical benefit (based on recist criteria) rate among the participants is performed in either the primary or secondary clinical trial"
    },
    "1c14ebb0-bff7-4691-8926-1c1b07b4da9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "somewhat more socially active as before is a response indicating that an individual has been somewhat more socially active than before. There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial."
    },
    "bdc8ed3c-63bd-4f71-bcbd-83d11575603d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "candidates for both primary clinical trial and secondary clinical trial must fulfil a baseline performance status, though each trial uses a unique scoring system."
    },
    "19ca7182-94ba-4b70-bd4e-1a65bd428f91": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates for the primary trial must undergo a pulmonary function test (pft), whereas patients for the secondary trial must have a recent magnetic resonance imaging (mri) report and liver function tests."
    },
    "f13676ce-309e-4cf5-866d-542b2a214b27": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "the primary clinical trial showed that the dalotuzumab 20 mg/kg group had a 49.2% greater decrease in the growth factor signature compared to the triple negative group."
    },
    "63a60028-ee0a-4f47-a8f2-b5edf081579a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "patients with considerable cardiovascular impairment are allowed to participate in the primary clinical trial."
    },
    "03845d1d-301a-4b2a-8dc4-8b05e09ab6ee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same number of Aes were reported for both cohorts in the primary trial. other things made me think about event is a question about whether other things made or make an individual think about the event."
    },
    "f9172aa9-f9ea-44cc-9669-f72874fcbef2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "in the primary clinical trial, multiple drug-based treatments are actively tested while the secondary clinical trial is designed to evaluate the effectiveness of multiple doses of a non-drug therapy."
    },
    "330f241a-9f7d-469d-8986-5687fdd5fb70": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. necrotic change is a finding indicating the presence of cellular necrosis in a tissue specimen."
    },
    "929ad524-174d-4586-b088-3b512e88bb8f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "none of the patients in cohort 1 of the primary clinical trial experienced any life-threatening adverse events."
    },
    "fe73dc46-7c3a-45cd-a5fa-db03aa8dd28c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "acute physiology and chronic health evaluation ii apch109 questions clinical classification original response is an original response associated with the acute physiology and chronic health evaluation ii apch109 clinical classification questions. anorexic patients are eligible for the primary trial."
    },
    "30f7d44a-34d9-4d98-9802-2c8a7c625e48": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "both the primary clinical trial and the secondary clinical trial accept patients with hr positive and her2 negative breast cancer, whose tumor sizes range from 0.2 to 0.8 cm in diameter."
    },
    "90c519e9-7981-4a72-af6a-cc032657458a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "The the primary trial intervention section requires surgical and imaging procedures."
    },
    "0cf140db-a8c7-47ee-9753-c46c056fe1b1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "participants receiving the highest weekly mm-121 and paclitaxel dosage are in the primary trial, not cohort 1 of the secondary trial"
    },
    "b0eb1f5f-d996-4846-9b4e-12dd88120752": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "All AE types in the primary trial affected less than 10% of patients. adult type ovarian granulosa cell tumor is a granulosa cell tumor that affects middle aged or postmenopausal women.  patients may present with uterine bleeding."
    },
    "571d4650-e64b-4cb2-b719-0d7064e51745": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy"
    },
    "a546a2b7-a287-47a1-91b1-4368fef15369": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the dosage of denosumab used in intervention 1 of the secondary clinical trial and zoledronic acid used in intervention 1 of the primary clinical trial have not been differentiated."
    },
    "1c7d5749-bf28-4ae8-8408-ccda3f13a18a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary clinical trial and the secondary clinical trial provide information on the mtd of various interventions"
    },
    "fdadf425-1eaf-4e63-b034-29afcbe48baf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "The only AE recorded in the primary trial was Stomatitis."
    },
    "dfb7dcc6-34da-4de2-8229-3cd02d15bd15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "mersalyl acid is a mercurial diuretic. mersalyl acid has been replaced by less toxic non-mercury containing diuretics. The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it."
    },
    "40d1e2c2-9a6f-42a6-b75d-a67e9945a38d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week. generally happy and free from worry is a response indicating that an individual is or was generally happy and free from worry."
    },
    "e658eb5e-3411-4dcb-bff2-6bad677ac1a7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 275 mg group of the primary trial experienced a lesser reduction in primary tumour diameter than the zoledronic acid 4 mg group."
    },
    "27aec260-8dcc-4611-8389-dc9c10d3518d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average."
    },
    "4185140f-e9a6-445f-b512-05428d88f966": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period. moderate to late preterm infant is an age group comprised of infants born alive with a gestational age between 32 to less than 37 weeks."
    },
    "593797dd-ff0f-46e5-ab50-0ea8d49fc4ad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "the intervention in the primary clinical trial varies depending on the individual's health status and cancer presence"
    },
    "2c00f421-96f2-4f3a-a202-27350b15c84f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "tonicity excipient is a substance within a liquid formulation that alters its osmotic potential. No two patients in the primary trial suffered the same type of adverse event."
    },
    "0bc4c4b5-bdb3-4b4b-9122-e52dcb57ec61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "how has gynecologic cancer affected your sexual relationships is a question about how having gynecologic cancer has affected an individual's sexual relationship(s). Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine."
    },
    "dcf21e08-7d8b-45b2-bec3-9f65853fb277": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "patients eligible for the secondary trial are not fit for inclusion in the primary trial."
    },
    "895a6e40-efe3-4994-b598-6791eaf90e87": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "persistent atrial fibrillation by ecg finding is an electrocardiographic tracing demonstrating atrial fibrillation that is present during the entire recording. A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial."
    },
    "a930aad6-c334-4a8a-8547-3a07e44afe8b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients with a recent history of abdominal fistula or gastrointestinal perforation are eligible for the primary clinical trial"
    },
    "a73a2b32-2cdb-49ec-ac4e-ed2eb976dec1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "metastatic bile duct carcinoma is a carcinoma that arises from the intrahepatic or extrahepatic bile ducts and has metastasized to other anatomic sites. There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial."
    },
    "48262549-7f65-43b7-ac00-f11dfb93e900": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "in both the primary and secondary clinical trials, all patients are treated with suramin and paclitaxel"
    },
    "68a7d226-1e5b-4a29-b492-60e8f621e7bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "in contrast to the primary clinical trial, the secondary clinical trial necessitates a diagnosis showing mutation in any of these genes: pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 for patient's inclusion"
    },
    "d8d3ab61-0fc8-462a-930b-114b2363d70a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "all ae types in the primary trial affected more than 100% of patients"
    },
    "f51d8422-1f2c-45bf-8de8-ce554a19c011": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "patients with estrogen positive, progesterone positive and her2+ breast cancer are included in the primary clinical trial"
    },
    "f891188f-fa94-42d5-a341-2a6ae7d696ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there was a difference of four patients who endured adverse events between cohort 1 and cohort 2 of the primary clinical trial"
    },
    "d98e6c4a-c899-405d-b26e-e3a2e0cb3494": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "sexually active men and women who are not willing or not able to commit to abstinence for the duration of the study are eligible for the primary clinical trial."
    },
    "edfe9572-6cff-4ecb-b34b-19ac297352d7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary clinical trial and the secondary clinical trial focus on the maximum tolerated dose (mtd) of multiple treatments, specifying that for patients in the secondary clinical trial, the mtd of mm-111 is 15 mg daily"
    },
    "454c83f7-949e-46bf-bd9a-5f14e6ba4713": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial. generalized dysplasia is a morphologic finding indicating the presence of dysplasia throughout a cellular component in a tissue sample."
    },
    "c41ed5cf-4629-4a4f-b564-197d705ec9cc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "There were 0 adverse events in the primary trial and the secondary trial"
    },
    "c00fd72d-2cbe-4988-a861-60a707684af7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "the primary clinical trial observed a minimum of one gastro-intestinal adverse event"
    },
    "f4d3c3ad-6c8c-4c7e-8d90-e321a9fa479d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "someone without any form of breast cancer and above 50 years old is eligible to participate in the primary clinical trial and the secondary clinical trial."
    },
    "f59c5c18-e772-4c9b-a5f2-cdb3bdd812f2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "pericardial effusions were a more frequent occurrence in patients from the primary clinical trial, in comparison to corneal deposits, which were more prevalent in the secondary clinical trial."
    },
    "1c57cb03-2d38-4b0e-a4b1-cda77a609a9e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "only candidates with an ecog score of 3 can partake in the primary clinical trial and secondary clinical trial"
    },
    "43a347ac-a46d-47cd-80d5-7d83b23bcde9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients diagnosed with breast cancer can participate in the primary clinical trial"
    },
    "b0b151a2-65f7-476a-9a2a-915bd963516d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "several participants in the primary clinical trial developed a urinary tract infection during the course of the trial"
    },
    "2eed31cc-3968-4b00-8a9e-947c5ecfbc3b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive one single injection on day 8 of the study. number of days smoked cigarettes past 30 days is a question about how many days an individual has smoked in the past 30 days."
    },
    "ce896357-cc87-4eb3-b588-61c1f99fc5f4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "patients in the primary clinical trial who underwent topical cryotherapy reported higher symptom severity than those who did not undergo the treatment.'"
    },
    "a4ddb589-176d-4a2f-bdf2-3c5973a09a4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "there are several adverse events recorded, but none pertain to the patient cohort of the primary clinical trial."
    },
    "1e213f71-5def-460d-b18e-aa58dbbe4463": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial is conducting trials with a dietary intervention, whereas the secondary clinical trial is using a physical intervention."
    },
    "a3ba6a16-5f21-477d-9a2a-574a53ab3f2c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders were not common for the primary trial candidates. soft tissue necrosis lower limb, ctcae is a disorder characterized by a necrotic process occurring in the soft tissues of the lower extremity."
    },
    "4d2b9583-9b62-40cc-b7e7-096c2dd16e0b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "resistance to ai therapy is a prerequisite for the primary clinical trial, but not for the secondary clinical trial"
    },
    "36eca12e-4e1f-4239-88bb-fdac29a6209c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "ovarian dermoid cyst with squamous cell carcinoma is a secondary squamous cell carcinoma that has developed in an ovarian dermoid cyst. The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial."
    },
    "996df3c5-d5a6-4cfc-9407-cb9a59388007": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "the educational dvd as part of the intervention will be shown exclusively to cohort 1 in the primary clinical trial"
    },
    "067c3f74-9009-45dc-a97a-0de2a17722cc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial. anti-cd73 monoclonal antibody is any monoclonal antibody that targets and binds to cd73."
    },
    "fca56898-5587-4c6a-ae87-86dfae3a4961": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "somewhat is a subjective answer of partial agreement. General symptoms are the most common AE recorded in the primary trial."
    },
    "5e7e3d88-6a13-4849-bad5-4ac52b100140": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "the primary clinical trial recorded a total of 0 aes for both cohorts"
    },
    "e0cc56e6-9466-4d28-a94e-4a9dcceaee76": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "participants of cohort b in the primary clinical trial receive two electroporation injections of ld v934"
    },
    "bc50160f-7490-4c30-b373-9474707b02b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections"
    },
    "91b12db1-76c1-4863-90df-a95d2af8dfc5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "thyroid gland hyperfunctioning adenoma is a thyroid gland adenoma producing thyroxin.  it is associated with hyperthyroidism.  radioactive iodine scan reveals a hot nodule. the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial."
    },
    "8d748876-a5b3-4f80-9f87-de9bec532074": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "better results were observed in the primary clinical trial's bevacizumab cohort, as compared to the bevacizumab + capecitabine cohort."
    },
    "e7c553e8-8799-4475-9e39-6f79bebc0a48": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "in the primary clinical trial, cohort 1 reported mostly beneficial effects, with similar feedback from cohort 2."
    },
    "c8c9752f-a60b-4173-bbe7-deb1a894ebe5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "drug-based treatment approaches are scrutinized by the secondary clinical trial through different dose adjustments, whilst the primary clinical trial omits such medication-related analyses."
    },
    "ec2edea0-23ee-487c-bfbb-ef6fb517e744": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "participants in both the primary clinical trial and the secondary clinical trial must meet specified baseline performance metrics. in the primary clinical trial, this is defined by a karnofsky score greater than 70, while in the secondary clinical trial, a score higher than 55 is considered the baseline."
    },
    "711218ac-a329-4d4e-a66b-3c4b2d9116b5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "object identifier data type is a data type comprised of an integer or pointer that uniquely identifies an object. There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma."
    },
    "3762bbcc-dcb8-4173-bf16-934f3c590566": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "in the primary clinical trial, participants are given epacadostat twice as often as sunitinib-naive patients are administered sunitinib in the secondary clinical trial."
    },
    "4a454653-60b6-47dd-a2ba-780d1dfbacaf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "in the primary clinical trial, each patient experienced a unique type of adverse event."
    },
    "3f6d7cbc-5465-4e27-beee-582162fe9972": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "in the secondary clinical trial, there were no adverse events; however, fatigue was commonly reported in the primary clinical trial."
    },
    "f02e41c3-1eea-4662-9359-fe120c3bc10a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "the occurrence of eating disorders was not prevalent among the candidates for the primary clinical trial"
    },
    "804580d2-f170-45ed-bf39-28dc33921b6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "the primary clinical trial reports that administering tamoxifen 32 mg po daily for a week leading up to the surgery and two weeks post breast cancer surgery reduced tumor sizes by an average of 40%."
    },
    "0bb34f7b-d21a-4057-876a-25c722e6d50e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "97% of patients in the primary trial did not experience any Adverse Events"
    },
    "52f841b6-f451-455e-9ec5-2541cf02bb13": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "none of the patients in the primary trial experienced the worst pain imaginable for 2.5 months."
    },
    "93d37103-4625-42a6-b8a2-7ce2d5673324": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "while the secondary clinical trial allows the participation of patients with a malignant ductal carcinoma in situ diagnosis, the primary clinical trial does not permit such patients."
    },
    "9367299b-070b-4902-b857-bca1c45b6fd1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "detailed information about the administration procedure, dosage, and treatment cycle is available in the intervention section of the primary clinical trial."
    },
    "94ca00df-c395-4f32-9348-8bcb6b15a2e1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the secondary trial was anaemia, affecting more than 0.05 of patients, there were no recorded aes in the primary trial."
    },
    "9334239a-f4f1-4192-a35d-93c25c41328d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants in the secondary trial receive sunitinib."
    },
    "72d1b9c7-56d4-487c-8170-752c86b764ec": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary clinical trial tests different formulations of a drug-based treatment, whereas the secondary clinical trial does not test any drug-based treatments."
    },
    "5b3b5c72-175a-42ea-aeab-63cd4298b362": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the primary clinical trial and the secondary clinical trial present outcomes from different patient populations."
    },
    "a785048d-15ef-4c72-9d18-6c1db1df2620": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 42 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks after the surgery"
    },
    "47507d4a-ea24-433a-9864-e4b76657335c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "in the patient cohorts of both the primary clinical trial and the secondary clinical trial, there have been no instances of intestinal obstructions or pancytopenia."
    },
    "5e5253e5-fd72-4f2b-84ba-b370545cd182": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia."
    },
    "fb011e19-d4fb-4e6c-b7c9-7a7238f78970": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria)"
    },
    "4869e50d-ccc3-4200-b2e0-bf706fc99488": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients diagnosed with benign ductal carcinoma in situ are eligible for the primary clinical trial but excluded from the secondary clinical trial."
    },
    "2bc6306e-445f-459e-afab-b445eedd5711": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "in the primary clinical trial, doses of paraplatin vary across different interventions"
    },
    "7ddde4b4-4070-4aff-b971-53bbd0ec9437": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "prefer to hear as many details as possible is a question about whether a person would prefer to hear as many details as possible. In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110."
    },
    "4aae628e-86f0-4851-9319-0a7d44d488b9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "primary clinical trial does not accommodate patients with hypokalemia, however, the secondary clinical trial may accept them"
    },
    "dfe9c306-0a1f-4940-b9bb-00a238abc818": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a radius of 3000\u00b5m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "05530068-7a95-46f6-88d2-84e53ee2ff35": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "General symptoms are the most common AE recorded in the primary trial"
    },
    "b490a735-38d7-49f2-a091-f930c5d1e9f5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "persons with parkinson's disease dementia can participate in the primary clinical trial"
    },
    "f086fa4c-a302-455d-82e7-faf8b78fc2f4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the placebo and trabectedin intervention in the primary trial are both administered through a 3-minute intravenous infusion on a bi-weekly basis."
    },
    "0fa2ee42-3800-49bc-838c-eb3dba41f01f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "the secondary clinical trial accepts patients with malignant ductal carcinoma in situ, whereas the primary clinical trial does not."
    },
    "9a499642-970d-48b1-b0b4-96760793ba72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "the primary clinical trial does not impose any stipulations regarding the participants' liver function"
    },
    "a35f8d94-b561-4644-ad29-2ac0e48ceb79": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "aims clinical classification question is a question associated with the aims questionnaire. Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial."
    },
    "9020a95d-874e-4bee-97bb-9b31bbcdd50d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient who exhibited the most extended progression free survival (pfs), of 3.5 months, in the primary clinical trial belonged to cohort 1"
    },
    "fbfafa2b-9b70-4452-9d19-4d58c3c9dfba": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. gain of chromosome 9 is a cytogenetic abnormality that refers to the allelic gain of all or part of chromosome 9."
    },
    "5ff118a6-d62c-473d-8935-1767a378c92a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "not all patients within the primary clinical trial are required to undergo a spect scan."
    },
    "fd0b22b0-c86d-4460-bf53-310901404ef5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+"
    },
    "f4f39eeb-0db1-40c3-9d45-5c17dabe4998": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "the results of the primary clinical trial indicate that, on average, participants survived beyond two years, with over fifty patients from each cohort outliving 24 months."
    },
    "ffce31e9-2899-42af-8af0-e24be1ace812": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women suffering from only osteoporosis are eligible for both the primary and secondary clinical trials."
    },
    "c46fb676-9060-4d56-9097-af79bb762f50": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "the final acceptance of a patient into the primary clinical trial rests solely on whether they meet the stipulated inclusion and exclusion criteria, regardless of the opinions of the health professionals conducting the trial."
    },
    "27b7d06c-72ee-4a57-a88a-2654824853f2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "hectopascal is a si derived unit of pressure equivalent to one hundred pascals, 1 millibar or 0.0145 pounds per square inch. Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial."
    },
    "d7abc723-e08e-442e-82e4-3e369341b72a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "pediatric cancer patients under the age of 18 of any gender can participate in the primary clinical trial, regardless of race, ethnicity, or cancer type. however, the secondary clinical trial solely accepts patients with pediatric b-cell acute lymphoblastic leukemia."
    },
    "97d3ebc2-fda1-4b0b-b7b2-583edca5be69": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "following high-dose chemotherapy with purged autologous stem cell products in the primary clinical trial, most participants reported a significant reduction in circulating tumor cells."
    },
    "bdb61718-ee5f-4e2a-9c78-850e788c139f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "the primary clinical trial does not accept patients who have experienced a pulmonary embolism within the past three years, however, the secondary clinical trial might consider such patients depending on the investigator's decision."
    },
    "70d946f2-0c4a-4a00-8090-b0b55dda7b2b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "patients with metastatic scbc, irrespective of their er or pr status, can participate in the primary clinical trial"
    },
    "b21d4a81-e82a-4bd7-ac88-5fcc046aafdf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "there were no reported infections in the primary clinical trial nor the secondary clinical trial"
    },
    "2f57e639-546c-4e7a-b562-77338563d472": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "0.13 of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "47daf120-3939-4e32-bba5-d86ce54a9cbd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "only a minority of patients in the primary clinical trial who were administered lapatinib 1000 mg + nab-paclitaxel saw a confirmed complete response (cr)."
    },
    "18e1908f-f449-42a0-916b-7e88c1e7c901": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "patients in the primary clinical trial did not suffer from anemia, pneumonia, and stupor more frequently than those in the secondary trial, and no cases of febrile infections were recorded in the primary trial."
    },
    "acf4a907-c58c-46df-aa75-666e643cef4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial. 2q36.1 is a chromosome band present on 2q"
    },
    "deba63cb-52ea-4b46-ad50-8cef93d8c5fd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "there is evidence of anorexia, hypothermia or hallucinations in the aes of the secondary clinical trial."
    },
    "7ffa3719-812d-4849-b0c7-d34ab22f35f6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "the observations from cohort 2 of both the primary and secondary clinical trials were inconclusive in their comparative analysis."
    },
    "079d70f0-b586-466d-aeb0-38f67273c1c6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "both the secondary and primary clinical trials do not employ the number of participants with treatment-emergent adverse events as the metric for their study outcomes."
    },
    "1a80bab2-1079-4730-bba6-b8414e4cfcc8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a young female newly diagnosed with pr-positive and her2-positive breast cancer may qualify for both the primary clinical trial and the secondary clinical trial"
    },
    "73eb2425-76f4-4868-8c33-0a2dab6af8f6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "in the primary clinical trial, it's demonstrated that the arm a intervention has yielded the best overall response rate. however, the denosumab group exhibited a poorer time to first on-study sre compared to the zoledronic acid group in the secondary clinical trial."
    },
    "4625018e-c34b-4156-8c63-572712bdbf30": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "used personal tablet is a response indicating that an individual used their personal tablet. several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia."
    },
    "7f0ff0a3-ccf0-4ea7-9c5b-b631da541d07": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "both primary and secondary trials do not use arimidex in their studies."
    },
    "fb13dfb3-66cd-45f6-98a8-c0712283954f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention. spinal cord glioma is a neoplasm that arises from glial cells in the spinal cord.  representative examples include astrocytoma, oligodendroglioma, and ependymoma."
    },
    "d5383c8a-360f-4e17-af4e-2f0a05fc2b1a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. benign pericardial germ cell tumor is a non-metastasizing germ cell tumor that arises within the pericardium."
    },
    "5c535bb9-8464-4820-b872-506057f2cd87": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with gtx-024 8mg in the primary trial gained over 17 kilos of lean body mass."
    },
    "9a276dfa-f4f9-4abe-837e-18cca465967e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 0 recorded adverse events. cytomegalovirus positive is an indication that cytomegalovirus has been detected in a sample."
    },
    "68a2e47e-d66f-45ec-87cd-45403a545e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "each participant in the primary clinical trial is administered a dose of between 100 and 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray amidst radiation therapy"
    },
    "c4b53dae-5bcf-4356-825d-0701f5c9b545": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary clinical trial, the number of hypertension and pancreatic resection cases were ten times higher than cases of hepatotoxicity"
    },
    "ef2bc415-dff4-4732-8e34-f538b570c671": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary clinical trial intervention necessitates psychosocial interventions, omitting surgical and imaging procedures."
    },
    "c7320872-347d-445f-a939-9554e7ee9973": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "in the primary clinical trial, both cohort 1 and cohort 2 are given an identitical dose of cudc-101, although cohort 1 receives it more frequently."
    },
    "70d381b6-0605-4369-8342-5ee2fb69d878": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients with a diagnosis of ductal carcinoma in situ who are thinking about ai therapy qualify for the primary clinical trial."
    },
    "787e3275-7973-46d4-83de-00d9ebaf7acb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "do volunteer work is a question about whether an individual did or does volunteer work. Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events."
    },
    "7eb81981-e3ca-42f2-ba8f-d1582e00f54d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary clinical trial and the secondary clinical trial both use the same pharmacological substances, administered at identical dosages and intervals."
    },
    "1d66459b-4624-4ea0-9cda-992c4146a454": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "Prior treatment with gabapentin or pregabalin will result in exclusion from the secondary trial, but not from the primary trial."
    },
    "9b5ee8d1-9b19-4f79-a80f-58422f1f5cee": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "in the primary clinical trial, the first group receives more substantial amounts of cyclophosphamide than eribulin, while the second group receives larger doses of cyclophosphamide than docetaxel."
    },
    "8f31a3bf-d5a9-4f2c-95bb-c9ff01de6d42": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "every patient in cohort 1 in the primary clinical trial experienced no signs of acute vomiting after receiving treatment with aprepitant, dexamethasone, cytoxan, and kytril"
    },
    "f074cadc-99e3-4603-8095-aa09822d174d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is measuring the average time a patient spends sleeping, while the secondary trial assesses the number of treatment-related incidents that impact the patient's health."
    },
    "6fe2c751-a06e-4679-a13d-3335fe5887e2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "for the primary clinical trial, paclitaxel is exclusive to the intervention of cohort 1, while cohort 2 receives fulvestrant as part of their treatment"
    },
    "2028a7ad-b89f-4927-8e74-db17555763c8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 0.01 g of talazoparib daily, as part of the intervention"
    },
    "f6ca1a5e-853d-4669-8c13-89b54a42c460": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "nras gene mutation negative is a genetic finding indicating that nras gene mutations have not been detected in a sample. Neiter of the primary trial cohorts receive any invasive surgery or Neratinib ."
    },
    "c8990938-e3fe-470d-a6d2-d28a3fe89b0b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "the primary clinical trial requires informed consent, but there is no corresponding requirement in the secondary trial."
    },
    "cb418196-3bf8-4a86-9c90-819eb43ede13": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "several adverse events were reported for cohort 1 patients in the primary clinical trial."
    },
    "ac14720a-7525-4fb0-b261-0ec5c818f85f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "only male patients are eligible for the primary clinical trial, and the secondary clinical trial accepts patients of all genders"
    },
    "a402b1c9-c65b-48fb-a2d5-e08c0152e8c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "each participant in the primary clinical trial gets a dose of at least 20mg of mcs110 every 3 weeks, and more than 130 mg of pdr001 every 2 weeks."
    },
    "b44a3eb6-01b7-488d-b18a-b3077937cc97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "the recorded adverse events in the primary trial allow for a comprehensive comparison with the secondary trial's data."
    },
    "1d57af11-9dc3-4589-ae99-fe0e9dab6042": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates who are able to take care of themselves without any help at all are eligible for both primary clinical trial and secondary clinical trial"
    },
    "49c63fc5-be4b-4474-8bfc-0ddf9cf438db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial."
    },
    "e5b93c15-0c68-4b2f-bceb-a905f7116ef3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial. conjoined twins is a monoamniotic twin gestation in which the twins share one or more organs."
    },
    "4087e09b-d0a1-4c3a-8411-b1938bf51b95": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "in the secondary clinical trial and the primary clinical trial, more than 97% of participants experienced no unfavorable incidents"
    },
    "a02864dc-e1f8-427e-9df3-531c91d28d50": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "cyclin-dependent kinase inhibitor protein is a protein that plays a role in the inhibition of cyclin-dependent kinases. There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial."
    },
    "964f8275-1095-4d48-953d-8d77152cecb8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "in the primary clinical trial, all groups receive equal doses of 18f-fpprgd2 as part of their pet/ct imaging procedures."
    },
    "a9aae47f-ecbe-49ea-983b-73c8b6a95506": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "there were zero adverse instances recorded in the primary clinical trial, while in the secondary clinical trial, the number of patients who were affected by any such instances did not exceed 30%."
    },
    "b16d4167-cb81-44c0-b20d-d1ecbf0bc094": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein"
    },
    "f995d440-b2ff-491e-bc11-038f63b8681e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a young patient with a recent diagnosis of pr-positive, her2-positive breast cancer could be considered suitable for participation in the secondary and the primary clinical trial"
    },
    "2660009c-449a-4edb-a64a-20164527c99d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "none of the patients receiving the sunitinib + docetaxel + trastuzumab treatment in the primary clinical trial reported any treatment-emergent adverse events."
    },
    "90c0e27d-dcb3-4014-ae46-b1f4640093b7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "in the primary trial, both cohorts had the same count of aes"
    },
    "96be5169-0334-4849-a77b-111e8eacf7bb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "multiple aes have been recorded in at least one cohort of the primary clinical trial"
    },
    "818a897a-fa50-4f16-8272-8f5ec8e590c1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "only in the first cohort of the primary clinical trial is paclitaxel utilized as the intervention, however, fulvestrant is the treatment assigned to the second cohort"
    },
    "a5ed681f-ae92-4bc5-856f-4565ab2669f0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients suffering from hypokalemia are not eligible to participate in the primary clinical trial, but they may be considered for the secondary clinical trial"
    },
    "8b50bdc1-1722-403b-a854-adeaacd02acb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial."
    },
    "df141af2-f34d-4e16-aee3-72c015ccc995": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "none of the patients receiving the placebo intervention in the primary clinical trial experienced emesis"
    },
    "511b7c14-9ba0-43ea-98e0-93f217e3ef07": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "animal virus is an animal pathogen that is a virus. Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial."
    },
    "57656a6d-8e1c-4cb8-b80d-605174d0577c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "70bfa3c4-2199-4d07-84c9-f41cac594ed4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "mixer device is a mechanical device designed to blend materials or an electronic device designed to blend signals. Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2."
    },
    "4d7a11a9-ec69-4b35-9fea-d1a78d8fe4b8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "there were several cases of febrile neutropenia reported in the primary trial and the secondary trial"
    },
    "60ceec88-a7b1-4353-8327-946c05a0a32a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "fibrosis assessment is an evaluation of the presence or degree of fibrosis present in a sample. 100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event."
    },
    "ae6c4238-c27f-45c1-92e0-6d1164c6accf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  . bothered by vaginal dryness is a question about whether an individual is or was bothered by vaginal dryness."
    },
    "38da1202-fb8c-46d0-9779-db075423a422": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "the administration for cohort 1 of the primary clinical trial consists of pr negative, er negative and her-, whereas cohort 2 receives her2+"
    },
    "d904b234-fed6-473e-bd40-8f37f4a4e440": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary trial and the secondary trial do not test the same drugs"
    },
    "2037fc58-ce2f-4f44-8ebc-dc9f9d7129cd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases. allogeneic bone marrow transplantation recipient is an individual receiving an allogeneic bone marrow transplant."
    },
    "241dc060-83e9-41a9-b937-d9715c16137a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "lcp1 antibody is any immunoglobulin that recognizes l-plastin protein. the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group."
    },
    "ecf95a54-fa38-4492-9597-ce81b5a2b661": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. macular edema is accumulation of intraretinal fluid and protein in the macula, which may result in swelling and decreased central vision."
    },
    "c36a1fe4-cc98-4a41-94c5-88458737d070": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 24 months, over 50 patients from each cohort survived more than 2 years"
    },
    "c4b6e4a0-1377-444e-853d-d62b67802ed2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "surgical and imaging procedures are compulsory in the intervention section of the primary clinical trial."
    },
    "06008bc8-58da-4762-9c98-830f2bd92325": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "breast cancer patients in the primary trial are administered 7000 mcg/week of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 175 mcg/week talazoparib instead."
    },
    "d3a0e851-28c4-4382-bb3e-8c40bc16ae7a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "diarrhoea was noted as a more common symptom among primary clinical trial participants as compared to those of the secondary clinical trial."
    },
    "de3550b8-5014-4f01-897e-07780353ec9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the occurrence of biliary colic and clostridium difficile colitis is more in the secondary clinical trial than in the primary clinical trial."
    },
    "3de4fd70-62c3-4310-a163-507e49af0e73": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "both, primary clinical trial and secondary clinical trial permits a patient possessing a primary 3mm-radius tumor, confirmed by clinical examination and ultrasonography."
    },
    "5b6c2caa-eb80-4024-b04c-e6b07685b7d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period. cube dosage form is a solid or semi-solid in the shape of a three dimensional square."
    },
    "10749f91-8743-4f6a-aa4b-6cc713e927c5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "while the primary trial involves the oral administration of palbociclib daily, the secondary trial requires patients to receive 300 milligrams of tezacaftor via injection every 90 days."
    },
    "91d0039d-b186-4f52-b214-1000341d3f2c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "adverse events have been recorded for participants of the secondary clinical trial."
    },
    "699bf83a-8890-43ab-96ea-40f2171c9633": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "esophageal fistula is an abnormal communication between the esophagus and another organ or anatomic site. Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial."
    },
    "a11f4223-9416-4cf8-8712-ebbddf8c4353": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were 10 adverse events which occurred in more than 30% of participants."
    },
    "eda562ff-9676-46f2-9ec3-93eb3cdd7585": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 0.3333 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 0.57 years of the study"
    },
    "0e4f4030-9d92-4885-905e-3599e26db71a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the primary clinical trial intervention section indicates a detailed treatment cycle, specifying chemotherapy regimens."
    },
    "d579bc9e-ccff-48a6-a296-2d9e8021c765": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "slovenia is a country in central europe, bordering the adriatic sea, between austria and croatia. one patient in the primary trial had an incident where a surgical incision reopened after the surgery."
    },
    "914d236c-c227-4d8d-8565-04a1d25e3b59": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 32000 micrograms po daily for 7 days prior to surgery and for 14 days after breast cancer surgery decreases the diameter of tumors by 40% on average."
    },
    "87840288-7db7-4532-b5a9-ce95221cf918": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial is open to women diseased with both claustrophobia and ibs"
    },
    "81e4cf84-ba33-46ce-ba44-e7edae2a2788": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "all individuals in group 1 of the primary clinical trial showed signs of cutaneous lesions; less than 10% of participants in the first group of the secondary clinical trial had radiation dermatitis or hyperpigmentation."
    },
    "a24f59fe-0c4b-48bb-bbff-8dfb4b83ed6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "in the primary clinical trial, participants are required to get one injection on the 8th day of the investigation."
    },
    "8ecb562c-3169-4c07-bb44-d6e716873c08": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "benign renal pelvis neoplasm is a non-metastasizing neoplasm that arises from the renal pelvis.  urothelial papilloma is a representative example. the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group."
    },
    "a9d41a93-5857-4a56-89f2-46cf6bef36e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with gtx-024 1kg in the primary trial gained over 22 pounds of lean body mass."
    },
    "c25249a2-5294-4b5e-a39c-3b5c956b9147": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients who have officially certified allergies to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib are not suitable for enrollment in either the primary clinical trial or the secondary clinical trial."
    },
    "d57cb18c-7375-4a66-81c4-7349cadd8d92": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the individual from cohort 1 recorded the longest progression free survival (pfs) in the primary clinical trial, surviving 3.5 months without any disease progression or death"
    },
    "1dd105a3-5dd4-423a-a40f-ed78e119e698": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were several adverse events which occurred in less than 0.01% of participants."
    },
    "9c8c3b78-d272-4ce9-947b-f9283c79e818": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same perecentage of patients suffered adverse events in both cohorts of the primary trial. moderately short of breath is a response indicating that an individual has or had moderate shortness of breath."
    },
    "5a378399-ff09-418f-8797-9e122617d8d6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "having dealt with postmenopausal adenocarcinoma or serious psychiatric conditions in the last 6 months does not affect an individual's eligibility for the primary clinical trial"
    },
    "783f37e2-d649-493a-9d0c-0de214ff8ad2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have recently undergone chemotherapy or radiotherapy, or those suffering from unstable angina, or having neuropathy greater than grade 2 can participate in the secondary clinical trial, not in the primary trial, even if they meet the other criterias."
    },
    "0add45e1-cc70-4f0d-b2c7-14c67e9cd3ee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "a frequent adverse event in the secondary trial, anaemia, was not observed during the primary trial."
    },
    "5315a569-b1a1-49fc-b10f-70840fe34585": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial. human papillomavirus-35 positive is an indication that human papillomavirus-35 has been detected in a sample."
    },
    "0b3b3351-166f-465f-b44f-14c1e24c2d06": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "both the secondary clinical trial and the primary clinical trial have the same inclusion and exclusion criteria."
    },
    "1655bb9f-adca-4796-9883-a620e978f745": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "cohort 2 of the primary clinical trial witnessed a greater number of adverse events than cohort 1."
    },
    "b126d49e-2ab0-4bb9-8677-b3662b784e0d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel. occasionally feel supported by spouse, family and friends is a response indicating that an individual feels or felt supported by spouse, family, and friends only occasionally."
    },
    "a9f8fa09-52b6-4a39-b62b-3685f41d6c6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "lipodystrophy is a congenital or acquired disorder characterized by abnormal loss or redistribution of the adipose tissue in the body. laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial."
    },
    "e9602bad-7e97-41b5-9d08-f02f259a75e6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "metastatic gastric neuroendocrine carcinoma is a gastric neuroendocrine carcinoma that has spread from its original site of growth to another anatomic site. the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts."
    },
    "b032dff4-0d5d-4ee3-a4b2-c22ab3b8823f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "participants in both the primary clinical trial and the secondary clinical trial are not required to meet a preliminary performance indicator. the trials do not use a performance status scoring system."
    },
    "1820d3ff-ca2a-47dc-a80e-45e760307261": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "all cohorts in the primary clinical trial receive enzalutamide via intravenous injection"
    },
    "ad003c43-9467-4b8e-9a4e-e28c7d6422c3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary trial is studying the effects of a single, standardized gel on its study groups, whereas the secondary trial is testing multiple treatments on its study group."
    },
    "f0a1bf43-c080-446d-815a-c588c7563e89": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several participants in the primary clinical trial receive a daily dose of 1000 mcg of talazoparib as part of the program"
    },
    "2c4d4e4b-1b19-4a95-a18d-7d0585c90573": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive under 2 months, over 80 patients from each cohort survived more than 6 months"
    },
    "6a0e68b7-6099-4fb9-bf11-35885b715348": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "for the primary clinical trial, patients with a successful response to previous hormonal therapies could be considered for participation."
    },
    "7294869d-4998-49a4-a9b5-021476f448b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "cognitive behavioral therapy (cbt) is a central component of interventions in the primary clinical trial."
    },
    "d083c9b8-decf-41ac-a3b0-ba8b6eedb32d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it. f3 positive is an indication that expression of f3 has been detected in a sample."
    },
    "f178fb19-cc4a-4f58-b81a-aac7270f154b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary clinical trial centres around the application and efficiency of a singular drug-based treatment, while the secondary clinical trial involves testing several drug-free treatment solutions."
    },
    "b45f25ba-463e-458a-9e48-edd0d50bc6cb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "in the primary clinical trial, cohort 1 has not reported any adverse events"
    },
    "fba4a92c-e18b-4029-b3bd-4b967db7faa1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "1000 mcg of talazoparib is given daily to several participants involved in the primary clinical trial as a part of the treatment process."
    },
    "31d67714-a5c1-494f-820e-d47f52480eaf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "Several recorded Aes in the primary trial occurred to cohort 1 patients. electroencephalography cap is a reusable headset with scalp electrodes designed to measure the electrical activity of the brain."
    },
    "2630006c-6708-4c09-a946-aefe1859770d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "gender is a determining factor for both the primary and secondary clinical trials, and both trials are limited to male patients only"
    },
    "bd791a1a-f4e4-43fb-8be0-ad1bced0aa60": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "the primary clinical trial would not admit a patient diagnosed with leptomeningeal carcinoma"
    },
    "b9fd7445-fced-4f32-9efb-7e142d1963e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same perecentage of patients suffered adverse events in both cohorts of the primary trial. 8q24.1 is a chromosome band present on 8q"
    },
    "dc561148-4b85-4fee-a632-2662a4c1a74c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae. get anxious about going to doctor is a question about whether an individual gets anxious about going to the doctor."
    },
    "a954a34f-0eb2-4c28-8673-f4c0a337bd00": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial. gelox regimen is a regimen consisting of gemcitabine, oxaliplatin and asparaginase that can be used to treat extranodal natural killer (nk)/t-cell lymphoma."
    },
    "2a3d4de3-5604-4959-8a60-2817faeee2b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "in the primary clinical trial, both the placebo and the allo-mscs interventions are administered at the same dosage level via a one-time transendocardial injection."
    },
    "5be979ed-e272-48c6-b301-c5464cc07730": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "the secondary clinical trial had a higher turnout than the primary clinical trial."
    },
    "aa3c3321-c4f3-43b4-9821-767903e333c6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient who has undergone an organ transplant within the past 30 days would not be eligible for the primary clinical trial but might be suitable for the secondary clinical trial"
    },
    "fe1ea6e0-dd6d-44d4-a9db-750c890f08c8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "lactococcus is a genus of gram positive, cocci shaped, lactic acid bacterium assigned to the phylum firmicutes and the family streptococcaceae. There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs."
    },
    "88148e83-625a-4004-8a2c-e4dec21c73e7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "data from the primary clinical trial revealed that no significant change in tumor size was observed in patients treated with tamoxifen 32 mg po daily before and after their breast cancer surgery."
    },
    "9dc3d717-d3b6-4002-b7f7-26e17d2cabc2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 24 months before study entry are excluded from the primary trial."
    },
    "7f11c755-66ed-4a7e-a222-0f967b650634": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "in the primary clinical trial, every participant in cohort 2 took capecitabine orally each day during the initial 21-day cycle"
    },
    "8ffe96d0-134e-438b-884e-8c4f05b57b03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary trial intervention uses a combination of radiation therapy and surgery, while the secondary trial utilizes gene therapy and antibody treatments."
    },
    "5f2bbf7f-2e76-4ae9-8e79-e6361d05ef47": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "the primary trial reported a 10% decline in the percentage of cells with ki67 expression following one month of treatment with tak-228 plus tamoxifen"
    },
    "e52afcaa-e5d8-4a1f-ae39-8572a64b0aee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group."
    },
    "0c5c681e-d64b-41e8-add7-b34f03573370": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "a pulmonary embolism within the last two months does not preclude participation in the primary clinical trial, and the investigator's decision holds no bearing on one's eligibility for the secondary clinical trial"
    },
    "a111fa2e-4d53-4b24-8929-ee37b97bed05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "participation in the primary clinical trial and the secondary clinical trial is restricted to canadian nationals."
    },
    "38343873-8e16-4852-bfe5-511fbd1be49d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "the typical survival span for patients from the primary clinical trial extends beyond 2 years, yet there has been a case in each cohort where a patient succumbed under a period of 2 years."
    },
    "5e83904b-39bc-4449-b5c5-c2972d287237": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "intestinal obstructions were a common occurrence among patient cohorts in the primary clinical trial, with similar incidences noted in the secondary trial."
    },
    "d0e16cbb-09e6-4178-80c1-2004ac2239a0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "no adverse events were reported in the first cohort of the primary clinical trial, but nearly all participants of the second cohort experienced a minimum of one adverse event"
    },
    "6c29e8c1-36ca-4e6e-b4dc-f1e91b98e546": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV"
    },
    "8f82b776-0f1c-4059-aab0-9898a9f6bd1a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "the primary clinical trial gives pembrolizumab to its participants twice as often compared to the frequency at which sunitinib is given in the secondary clinical trial."
    },
    "97e4a19d-31b9-476a-b8d3-707f817283e1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants do not receive any vaccines. buccal mucosa squamous cell carcinoma is a squamous cell carcinoma of the oral cavity that arises from the buccal mucosa."
    },
    "2e22a621-745f-422e-a66e-2a85f8ff1a25": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "in the primary clinical trial, just two participants did not experience recurrence-free survival"
    },
    "7ae95d8e-af13-452e-a4e0-d4ba7c066a9c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "only patients with no known hypersensitivities to herceptin medications are acceptable candidates for the primary clinical trial."
    },
    "65a1b098-171e-4a2e-87a7-7d29b4a7d6ba": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary clinical trial is involved in the assessment of the count of participants experiencing adverse events related to the treatment, in contrast to the secondary clinical trial which quantifies the median duration of patients' sleep in minutes."
    },
    "07c11057-8ae2-4e40-a8d6-464e2399129e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "in the primary clinical trial, 5 of the patients faced three or more adverse events."
    },
    "65bc201c-2957-4d21-88f1-05c2413a6e56": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "foxr2 gene rearrangement is a molecular abnormality indicating rearrangement of the foxr2 gene. the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours."
    },
    "ad0d6636-dd71-4ba9-8741-1cba3d6f0c43": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "cohorts 1 and 2 in the primary clinical trial employ the identical paced breathing guidance cd, but cohort 2 executes the routine twice daily."
    },
    "386a63a3-cd3f-4f8c-af45-cfe9b26e4bc6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "the frequencies of both pericardial effusions and corneal deposits were equal in the primary and secondary trials"
    },
    "16634eb4-f12b-4d17-8401-070a7b7d052b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "have discomfort when urinating is a question about whether an individual has or had discomfort when urinating. All Infections and Infestations cases in the primary trial were for patients in cohort 1."
    },
    "7664aa4a-a4ae-4fe3-81a0-d977d197fde1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "less than 10% of patients were affected by all types of ae in the primary clinical trial"
    },
    "0c03c804-4144-4d84-b740-8f6040f15acc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial"
    },
    "c4c63d1d-1704-499c-b298-f5ced3123d03": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "in the primary clinical trial, patients are provided with oral medication, which they are to take two times a day for a whole month."
    },
    "327cfcfa-5534-4b9c-ab06-57fe595cb887": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "there were 11 more adverse events reported in the secondary clinical trial than in the primary clinical trial"
    },
    "f86794bf-be99-43b3-b5e0-a78f5dde96a4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "the bulk of the adverse events reported in the primary trial involved the respiratory system and were rare or nonexistent in the secondary trial"
    },
    "37f74912-6578-4304-9f9c-6b3c4c217e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+. primary ciliary dyskinesia 29 is an autosomal recessive primary ciliary motility defect caused by mutation(s) in the ccno gene, encoding cyclin-o."
    },
    "e9653ffb-8fe5-47a3-810f-6831216f9893": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 1000 cases of hypertension, edema and dyspnea in either cohort of the primary trial"
    },
    "0b444449-045a-414d-be8e-1ff558525e83": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "the primary clinical trial distributes enzalutamide orally to group 2 but administers it through intravenous lines to group 1"
    },
    "812d038b-d9c4-457d-8527-ed43ee902202": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "from the primary clinical trial, two patient incidents of dose-limiting toxicity occurred, one in each cohort."
    },
    "290fc77b-03cb-4ca6-877f-4117ea462ac6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group. 17p13.3 is a chromosome band present on 17p"
    },
    "df991d6e-570f-4371-9b5e-00e9f3f4707d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "every participant in the primary clinical trial endured extreme pain for a period of 10 weeks."
    },
    "dfd8e736-5ef2-4d36-b124-9382e72f982d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary trial patients in The paced respiration intervention group experienced fewer Hot flashes per day on average than patients in the The fast, shallow respiration group."
    },
    "1af4d0ac-d0f2-402a-8bdb-0e10c0823b0f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients."
    },
    "65ef313d-74d5-4e56-a6c8-6a3768774a55": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial are administered through different routes. advanced neuroendocrine tumor is a neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment."
    },
    "0d382bbc-1c8d-4d05-b0dd-8501755ce9dd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "cohort 2 of the primary clinical trial experienced hospitalizations."
    },
    "09879638-e324-4f5d-a45e-f62f7e06f301": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial"
    },
    "1c5b6b0e-8ee8-4569-8bc8-83ab193f8cff": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial. trochlear nerve disorder, ctcae is a disorder characterized by dysfunction of the trochlear nerve (fourth cranial nerve)."
    },
    "275b4f49-8849-451b-972d-a597662de036": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "neutropenia was a common adverse effect in cohort 2 of the primary trial, whereas the patients in cohort 1 of the secondary trial reported no cases of neutropenia, despite them having higher doses of empegfilgrastim."
    },
    "7c60cd27-5e72-4cd6-9e2c-de28c0c11fe4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 32 year old patient with histologically verified diagnosis of stage three breast cancer, absolute neutrophil count of 1807000 cells/ml, platelet count of 110,03400 cells/ml, hemoglobin level of 0.09 kg/m^3, and a life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial."
    },
    "5829a465-2f7e-4a15-a746-24e4c0f53200": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "age restrictions apply to patients participating in the secondary clinical trial, while there are no age limits specified for the primary clinical trial."
    },
    "50b3880d-9a23-42a3-8987-253f0ce999d3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "nausea visual analogue scale is a nausea scale from 0 to 10 on which the patient marks the current level of nausea experienced. Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency."
    },
    "1bc6de92-961a-4a4f-8ead-8f5f6f496d70": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "during the primary clinical trial, at least one patient who received gtx-024 1mg treatment had over 10 kilos increase in lean body mass."
    },
    "3bf96cd4-147b-45f2-b174-e3a375a67e26": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have breast cancer and require hormonal treatment. repeat expansion disease is a class of genetic diseases that occur when microsatellite repeats expand beyond a threshold length."
    },
    "4fec2620-4ede-44a4-adc9-54b525e89387": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "no aes relating to cardiology or psychology were observed throughout the duration of both the primary clinical trial and secondary clinical trial, although various other kinds of aes took place."
    },
    "af9dbcc2-f6ab-4e1e-aac7-a1f0bccd4d86": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary clinical trial utilizes larger quantities of lenalidomide for intervention 1 compared to the secondary clinical trial's use of lapatinib, and the intervention in the primary trial lasts longer."
    },
    "dfc9042c-745d-46a2-9706-3efe0b24c20c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "most patients experienced multiple severe adverse events post participation in the primary clinical trial"
    },
    "914bc3a7-1468-46df-8d13-f271220b5c84": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "both the primary clinical trial and the secondary clinical trial accept candidates having an ecog score of 1"
    },
    "306ea03b-8055-4a52-8d81-ed4e18dedd4f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "patients with histologically or cytologically confirmed localized and/or early-stage solid tumor in the brain are eligible for phase 1 of the primary clinical trial and for all cohorts of the secondary clinical trial"
    },
    "6d0812b9-f9bd-4cd6-82aa-9c272eba23be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "Patients in the primary trial and the secondary trial  suffered Thromboembolic events."
    },
    "5a17f44e-b8ba-4598-96e3-992b0022b5ca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "the primary clinical trial involves no pharmaceutical intervention for its participants; only behavioral and dietary modifications are implemented."
    },
    "ec2e7860-1d3e-4f95-b00a-bea42d04825a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "pancreatic acinar cell is a cell which secretes digestive enzymes via the pancreatic duct into the duodenum to assist in digestion. CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle."
    },
    "ef02754d-00ec-4f2d-bf7a-0a6d414b2476": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "There was at least 1 case of infection in both the primary trial and the secondary trial. cutaneous fistula is an abnormal communication between the skin and another organ or cavity."
    },
    "0fc55b5a-e5cc-40d1-a0fe-e4ce3ffd8172": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients suffering severely from sleep disorders other than insomnia can participate in both the primary clinical trial and the secondary clinical trial"
    },
    "ee03b5cc-6cfe-4b3a-8429-493f95c97b71": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient whose primary tumor size is not measurable by clinical examination or echography, is fit for both the primary clinical trial and the secondary clinical trial."
    },
    "caf14d83-76cb-4c21-b5c0-d83966973483": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "disease response supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the disease response domain. The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial."
    },
    "e6bba244-c154-4143-a5f2-5f8b1c304a97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": " Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial."
    },
    "d622d9c6-c942-4a53-a249-cd5544e2d9fe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial. benign sinonasal soft tissue neoplasm is a non-metastasizing soft tissue neoplasm that arises from the nasal cavity and paranasal sinuses."
    },
    "a1ae68b1-c14f-44b5-bc43-8966858fbf14": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "biologic entity birth country code is a coded value specifying the name of the country in which the biologic entity is born. Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial."
    },
    "3cdc1ca9-f403-4e4b-878e-678d8dbc6090": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "none of the cohorts in the primary clinical trial observed any occurences of hypertension, dehydration and dyspnea"
    },
    "2cc09c00-1375-4603-a6ee-dd5ceb87733a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "the primary clinical trial excludes patients with histologically confirmed metastatic scbc."
    },
    "bd759cf8-b82f-496f-a8f7-1ab39f0d4724": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "have you been in low or very low spirits is a question about whether an individual is or has been in low or very low spirits. Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial."
    },
    "77045e13-70ad-4643-9e8c-7f0deb5d0ed9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly. restlessness, ctcae is a disorder characterized by an inability to rest, relax or be still."
    },
    "4bd8fa53-08b5-4b80-868a-4b535432f2e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "prostate infection, ctcae is a disorder characterized by an infectious process involving the prostate gland. Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial."
    },
    "ef186582-5995-47ca-a190-616f94342715": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children and adolescents are not eligible for the primary trial, as they do not meet the height requirement, however they are not explicitly excluded from the secondary trial. urethral infection is a bacterial, viral, or fungal infectious process affecting the urethra."
    },
    "fe6f8d5f-5105-4495-828f-f6ef19a7cc9d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120000 micrograms of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy."
    },
    "b5f68d8f-0c92-4f58-9740-78556c039e58": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial."
    },
    "fdf46294-f524-478f-9816-e13d7c7c3927": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients who have experienced a pulmonary embolism in the past year are welcome to join the primary trial and do not require an investigator's decision for participation in the secondary trial"
    },
    "21fdf78c-fdbf-4140-9056-d3bfd2e9de27": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "the allo-mscs and placebo interventions of the primary clinical trial are both given in identical dosages through a single transendocardial injection."
    },
    "29bfa3a7-a8f2-4294-b745-d125cac8e40f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "hypoxia, ctcae is a disorder characterized by a decrease in the level of oxygen in the body. There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial."
    },
    "edb0a92a-08c0-4083-864e-26d845000fa6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "both phases of the primary clinical trial are only open to male patients who demonstrate evidence of a locally advanced and/or metastatic solid tumor."
    },
    "8db59161-2a2e-4ade-9e23-538bf3b3ec77": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. disease outcome or response is an indication that a subject's disease outcome or response is not covered by the study protocol."
    },
    "e115652e-6728-47a8-bc2e-1866a7c257ec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "none of the cohorts in the primary clinical trial undergo any invasive operation or receive neratinib"
    },
    "cdc43061-760e-4de2-946e-93d74f8ab544": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer. have trouble going to sleep is a question about whether an individual has or had trouble going to sleep."
    },
    "de6b5ea7-b593-43b7-8fe0-358991878e86": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial."
    },
    "c53af3d2-6827-4f10-ae9e-c7639a15b19a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "adverse events were not common amongst cohort 1 participants in the primary clinical trial, identical results were drawn from cohort 2."
    },
    "99e5ad48-5bb8-4716-a1fc-0a332acf2e5e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "both the primary and the secondary clinical trial are designed to evaluate how many participants experience adverse events of primary interest (aepis)"
    },
    "fa7b75cd-7f8f-44aa-83dc-618e1bc961a1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR). bladder solitary fibrous tumor is a solitary fibrous tumor that arises from the bladder. most tumors are benign."
    },
    "b5cc8685-0fb5-4819-a7cb-960980d95272": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "evidence of a locally advanced and/or metastatic solid tumor permits patients of any gender eligibility for both phases of the primary clinical trial."
    },
    "2ce0537c-cd90-47dd-83e3-79a690cdc101": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "90% more participants in the er-positive luminal b group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "b7a0a223-f9c6-474c-b9e7-ca530c393a53": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "different medications are being tested in the primary clinical trial and the secondary clinical trial"
    },
    "88a8b32d-122c-48f9-a305-3d1b8e3fcd85": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "how big a problem question is a question about how big a problem something is for an individual. Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy."
    },
    "28e1ae2b-668d-48c5-a17b-169460475af0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "the primary clinical trial involved the administration of the bio-path nanoparticle delivery system to thirteen participants"
    },
    "99901cc0-51b6-45c1-9040-14a9785bab49": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "a confirmed histological or cytological diagnosis of resectable non-small cell lung breast cancer or small cell lung cancer makes patients suitable for the primary clinical trial"
    },
    "9b49f98a-af07-455e-af36-4f6a3f7e3e52": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "pericardial effusions were a less common condition among patients in the primary trial"
    },
    "13184ac6-2ba9-455b-9e77-834855ff2794": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "the primary and secondary clinical trials showed zero incidences of febrile neutropenia or cholelithiasis."
    },
    "7d0d3d69-d8ff-4671-9251-6f7a5f19a5ad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "All the primary trial participants receive lower doses of drugs than the secondary trial participants. how satisfied with physical attractiveness after gynecologic cancer is a question about how satisfied an individual is with their physical attractiveness after having gynecologic cancer."
    },
    "b068596b-94a7-42fe-a926-d1c3c62ea26b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the outcome measurements for the primary clinical trial and the secondary clinical trial are entirely distinct, although their interventions are identical."
    },
    "31b59e3d-4bb8-47ea-a7a1-9d8523245970": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "epidermal hyperplasia is a hyperplasia of the epidermis. Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial."
    },
    "5b07e1cb-d734-4e43-9911-6328923fbc93": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "in both the primary clinical trial and the secondary clinical trial, the most recurrent adverse event was syncope, seen in 25.00% of the primary trial patients."
    },
    "c5e1aaba-40f0-49e6-926b-2f28f74b2b1c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "while the primary clinical trial sets different inclusion and exclusion conditions for its couples of phases, the secondary clinical trial operates with the same parameters for every participant."
    },
    "eb19e1ef-0bad-4d95-8ebd-dcc1f403a946": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the duration of the intervention for the primary clinical trial exceeds that of the secondary clinical trial by an additional 15 weeks."
    },
    "44b12aea-350e-4ade-a145-ba619d96a0ca": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. beam is a group of nearly parallel rays of electromagnetic radiation or a stream of particles."
    },
    "fed2e936-ab4c-42d6-8346-8f1b3ec9cc73": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "in the primary clinical trial, dose-limiting toxicity occurred exclusively within cohorts other than cohort 2."
    },
    "386515be-dd8a-423d-933b-6c7f99461ebd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients diagnosed with stage 4 breast adenocarcinoma that is either er positive, pr positive, or her2/neu negative, are qualified to participate in both the secondary clinical trial and the primary clinical trial."
    },
    "9d7e8278-5668-4798-9eb0-bb3ae9db62f0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "All patients eligible for the secondary trial are also eligible for the primary trial. neurofilament is an intermediate filament that is found in the axons of neurons."
    },
    "94023f3a-38d4-4b1b-a65a-9536480ff4c4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "how often did fatigue limit work is a question about how often fatigue limits an individual at work. Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time."
    },
    "7adf46ec-7d70-4767-936f-b7d89f93cdd6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "ovcar-8 is an adenocarcinoma cell line established from a 64 year old female patient with ovarian carcinoma previously treated with chemotherapy. the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "9d291a23-1696-4208-a5d4-7b2e1dd48831": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "grade 1 esophageal fistula, ctcae is asymptomatic The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month."
    },
    "0744abca-2e7d-4e4a-a325-642ba6d16135": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "patients who received the placebo intervention in the primary clinical trial had a two-fold increase in the incidence of emesis compared to those who were treated with aprepitant."
    },
    "0bb51a03-72e6-4d48-8010-054e280a960f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "All of the Aes recorded for cohort 1 of the primary trial are related to mental health. mediastinal infection, ctcae is a disorder characterized by an infectious process involving the mediastinum."
    },
    "01116b8e-5299-4f9e-9f40-7651edbc8542": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs). study site oversight status review board process code is a coded value specifying the phase in the lifecycle of the review board process."
    },
    "4dd24d14-3357-43a0-973f-d535802507cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine. ratio scale is a scale that uses ordered numbers with a constant difference and which has a natural zero."
    },
    "a116a540-abca-478e-94ea-9997b0434c8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "inppl1 gene mutation is a change in the nucleotide sequence of the inppl1 gene. Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  ."
    },
    "292d0dd3-1b9c-4291-b367-0cc1666178db": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy."
    },
    "15d7d028-69c2-4e01-b85c-cff568f34cc1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "anorexic patients are eligible for the primary trial."
    },
    "cbcecc39-a187-40ca-86cf-06d9c75ff972": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "all individuals of japanese nationality have the opportunity to be part of either the primary clinical trial or the secondary clinical trial."
    },
    "bb9c00c0-3a87-41c2-bfb5-183f7b44fcbc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "acupuncture patients in the primary trial did not experience any significant improvements in their lymphedema when compared to patients using testosterone cream."
    },
    "1c3d0ec2-e54e-4b44-9b61-6300e5e2736f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients with t4 n4 m4 tumors are allowed to participate in the primary clinical trial"
    },
    "9ab82516-ba60-4c36-908d-5e0e56ec5fba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "2% of patients in the primary trial and the secondary trial suffered from infections during the study period"
    },
    "61db27bd-2dc4-4c90-8d1e-058f61e1b59a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "in intervention 1 of the primary clinical trial, the denosumab dosage is 12 fold compared to the tamoxifen dosage in intervention 1 of the secondary clinical trial."
    },
    "55365a7b-df7e-4586-aeff-3ed268a4979f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "in both the primary clinical trial and the secondary clinical trial, there were zero recorded serious adverse events."
    },
    "5abfa152-2c23-40b4-ba00-b28336b8b8b5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial."
    },
    "4d8b9c01-83b6-4590-9aaf-9389b998ebff": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the method of administration for both the placebo and trabectedin in the primary clinical trial is the same, however, they are given on distinct days."
    },
    "79d98227-bc8b-4d97-b264-9737e368030f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "infant t acute lymphoblastic leukemia is a t-acute lymphoblastic leukemia that occurs in infancy. Patients in the primary trial and the secondary trial  suffered Thromboembolic events."
    },
    "291150cd-0d45-46c7-9a44-d781098bc3eb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer."
    },
    "afa65be8-62bf-4c63-8670-a997a06c6943": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "unexpected fatalities occurred during the primary clinical trial"
    },
    "2787f3da-ad73-483d-98b8-a82acec6e5fc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary clinical trial receive at least 20mg of mcs110 every 3 weeks, without any pdr001."
    },
    "ab098908-d287-4ffa-883c-202a87f5ba63": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients participating in the primary trial receive 2400mg/m2 oral lapatinib bi-daily for a full 30 days."
    },
    "aab488c3-ac44-4506-b2b1-541909e30028": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "the primary clinical trial found that daily doses of 20 mg tamoxifen, taken seven days before and 14 days post breast cancer surgery, resulted in an average 40% decrease in ki67 expression in tumors."
    },
    "48ec9126-f671-47ea-a1bd-71a228b20420": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "in the first cohort of the primary clinical trial, pancytopenia was a prevalent condition, while anaemia and febrile neutropenia were absent."
    },
    "ceb0ef65-5640-491d-a6c6-341e456b0bdd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "there were 0% cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial"
    },
    "0416a45e-2ea6-4f82-8bc6-05cc37b941f8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 6 day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "3f19f518-c46f-4c1f-a738-0066ac81dcc2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial. voice makes me feel handicapped is a question about how frequently an individual's voice makes them feel handicapped."
    },
    "8e4d3482-1501-4f0d-ae76-8924effe7d3c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "no inclusion or exclusion criteria are shared between the primary clinical trial and the secondary clinical trial."
    },
    "3f5b9c7d-ae3e-4484-88c7-c7562c2f974a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) . alphanumeric is a term used to describe a character string containing only letters and numbers."
    },
    "f6fbc102-de0c-44d5-943b-4baf66bc0d9b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "in the first cohort of the primary clinical trial, all 61 cervical cancer patients were up-to-date with their screenings prior to the intervention."
    },
    "75c55f70-aa52-4794-aae7-3a355f1a76e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial"
    },
    "6c50344e-493e-46a6-9e03-74495773bab2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "all patients in the primary clinical trial receive suramin and paclitaxel, while the secondary trial does not specify which drugs are given in its intervention section."
    },
    "d16f252e-5df6-4e09-8a24-9c56b4b8e16b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 175 milligrams group of the primary trial experienced a more significant percentage change in betactx at week 4 months than the zoledronic acid 4000 microgram group."
    },
    "76d498ce-037c-4f7e-8cbb-450d8f6019ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic."
    },
    "af3f07a1-e8c0-4ce1-a0b2-5789bca86cd6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "severely anxious or depressed is a response indicating that an individual has or had severe anxiety or depression. Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision."
    },
    "9827f954-40d9-4b55-bb92-02624a0d6a75": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias. thienopyridine antiplatelet agent is a class of agents that target at platelet adp receptor or purinergic receptor p2ry12 with antiplatelet activity."
    },
    "f34e13a3-4463-4cf4-8a15-79872282b90e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "the primary clinical trial necessitates applicants be females of a particular nationality, whereas for the secondary clinical trial there is no such specification."
    },
    "0881a52f-e84b-43a4-8fda-446a7f2a1390": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "the primary clinical trial is open to any female cancer patients who are 18 years or older, irrespective of race, ethnicity or type of cancer but in the case of the secondary clinical trial, participants must be diagnosed with brca+ breast cancer."
    },
    "230818a6-3a37-4bb6-933b-39a7e9a45054": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "patients possessing detectable tumors in both breasts cannot participate in the primary clinical trial"
    },
    "31ad3c14-faaa-42e1-93aa-d9f9b8687cae": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs). osteitis fibrosa cystica is a disorder that is characterized by bone cysts and fractures, resulting from hyperparathyroidism."
    },
    "1a47637c-31f0-42c0-9729-7ab8c66fafb4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the outcome measurements and units of measurement utilized in the secondary clinical trial and the primary clinical trial are identical."
    },
    "af2a7153-f082-457c-be3e-e6716cdabe0d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period. evac regimen is a regimen consisting of etoposide, vincristine, doxorubicin and cyclophosphamide used for the treatment of extensive-stage small cell lung cancer."
    },
    "4e832d71-c3c2-4209-9a57-8bd40ed3b08a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "were clinical genomics performed is a question whether clinical genomics were performed. Neither cohort of the primary trial recieves alisertib, and the two cohorts of the secondary trial receive different doses."
    },
    "86a8919e-ee7f-40ba-9186-9dcbdbb06018": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "the mean survival time for patients participating in the primary clinical trial falls under 12 months, and less than 50 patients from any subgroup exceeded a year of survival."
    },
    "0cece9f2-8d43-4d06-97bd-fb800bd3e71a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary trial utilizes the hamilton depression rating scale (hdrs) to assess mental health wellness, whereas the secondary trial closely monitors transitions in triglyceride levels throughout 6 months"
    },
    "cdc80bd8-0b1c-4908-9095-74a1a7078e43": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "patients in cohort 2 of the primary clinical trial are administered lesser amounts of cyclophosphamide compared to docetaxel."
    },
    "a79aa893-e44c-4077-8791-47fb56351b5e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "secondary trial participants are subjected to higher doses of radiation therapy compared to the primary trial patients"
    },
    "5628cfa9-df1b-4a19-9f6b-c513b1fb73db": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "the primary trial keeps record of the percentage of participants who have experienced clinical improvement according to recist, while the secondary trial does not."
    },
    "cffc1c21-5e4d-485a-a167-32841ff01f4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "moderately better is a subjective response indicating that something is moderately better. There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial."
    },
    "4d5b9d90-2c58-499e-8943-eacac7580eb1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel. epithiazide is a trifluoroethylthio-containing benzothiadiazine sulfonamide derivative belonging to the class of the thiazide diuretics."
    },
    "48e84575-b6e1-4280-a170-df30870b50cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "in the primary clinical trial, cohort 1 and cohort 2 are given the same cudc-101 dosage and frequency, but cohort 1 receives additional weekly doses of pd-0332991."
    },
    "63a44f77-d6b6-47df-9bea-b7deb99f5658": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "karyocytomegaly and multinucleated hepatocytes is a finding of both karyocytomegaly and multinucleated hepatocytes in the same lesion. 36.36% of the primary trial patients suffered an increase in Blood bilirubin."
    },
    "520f44e8-b74b-44a6-a7cf-496275847af1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "Both cohorts of the primary trial recorded 0 Aes"
    },
    "89c0759c-7a7e-4c65-b98e-841d2ca21808": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients with a histologically/cytologically confirmed diagnosis of advanced stage and metastatic melanoma or pancreatic cancer are qualified to participate in the primary clinical trial"
    },
    "487dd970-35e7-4a7d-8bb6-e8fa98f574aa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial."
    },
    "aab9225d-d2bc-4004-bcaf-4f69a9e7991b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "eligibility for the primary clinical trial includes patients that received organ transplants within the past month, while the secondary clinical trial excludes them"
    },
    "a6fa44b8-fb1b-4571-aadd-284cbe4f37d8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "mold mix antigen ige antibody measurement is a measurement of the mold mix antigen ige antibody in a biological specimen. The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial."
    },
    "2f7bf983-b072-4d3e-96fb-718475ef0fd2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary clinical trial employs a transdermal patch for intervention administration, whereas the secondary trial uses a sublingual method."
    },
    "a1807b6a-6ee6-4c74-bf44-53d39c31c66f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group."
    },
    "c21d49da-c66f-45cc-af8a-22174568d0dd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study. helped recognize that decision needs to be made is a question about whether an individual was helped to recognize that a decision needs to be made."
    },
    "d0856f66-d9fb-4bbd-906e-9602d9121c22": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "eligibility for both the secondary and the primary clinical trials is given to patients with a confirmed histological diagnosis of stage 4 breast adenocarcinoma that are either er positive, pr positive or her2/neu negative."
    },
    "34f34450-a64c-4159-ad9d-8adb58617e79": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "the secondary clinical trial noted only two types of adverse events: eyelid oedema and chest pain, while the primary trial reported no observed adverse events."
    },
    "8b89865c-9af5-4fe0-8f9d-c56240ff7a90": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "there are no preliminary performance requirements for patients applying for either the primary or secondary clinical trials. consequently, there is no need for any performance status scoring mechanism in either trial."
    },
    "a9d993df-c8e1-4f4f-b470-b23d78f069ed": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "patients in the primary clinical trial receive the first intervention through an intravenous administration, while those in the secondary clinical trial are permitted to take all interventions orally."
    },
    "b1bad6e5-5322-4ba2-8350-2496bef85d1c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "pre-b acute lymphoblastic leukemia is an acute lymphoblastic leukemia that originates from pre-b lymphocytes. the pre-b lymphoblasts contain cytoplasmic immunoglobulin. There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial."
    },
    "1669453c-bb8e-437d-b5e2-98600980d7d3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "the only variations between interventions 1 and 2 of the primary clinical trial are that cohort 2 receives 0.7mg move of durva in their monthly injections compared to cohort 1."
    },
    "f718d65d-3ea1-41b7-adc0-5f481843011c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary clinical trial makes use of greater dosage of lenalidomide than what is used of lapatinib in intervention 1 of the secondary clinical trial."
    },
    "1dffbb91-6440-4ceb-a33d-c2d783f75936": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary clinical trial involves 1 mg of dacarbazine per kg of body weight daily and the secondary trial includes photodynamic therapy using porfimer and light source."
    },
    "904b8443-c768-449d-81d7-e381dc0e0fb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "both the placebo and trabectedin in the primary clinical trial are given in similar ways, yet on different days."
    },
    "5acd7311-862e-440b-aecd-64f015c7deb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "in the primary clinical trial, abraxane doses diverge between cohorts"
    },
    "68d0da33-c4ad-4649-bb63-08290cd4d4e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "a mandatory mammography is required for candidates intending to participate in the primary clinical trial, while the necessary prerequisites for the secondary clinical trial are a ct scan and blood tests."
    },
    "da91afa9-21ed-4d4d-a5d9-964dbb334177": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "the primary clinical trial adopts a procedural approach which involves only the use of ultrasound assisted biopsy."
    },
    "a0ed6cf5-dd1f-4170-ae33-3c1972b62530": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary clinical trial and the secondary clinical trial both use the same outcome measurements and units of measurement."
    },
    "0aa16ecc-2e97-4210-9872-5a0566497343": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, multiple cohorts receive different compounds on varied schedules, no cohort in particular receives armodafinil p.o daily. in the secondary clinical trial, the medication regimen varies by patient and does not adhere to a universal administration of 100 mg of pdr001 and 1 mg/kg of mcs110."
    },
    "c09d08df-1042-47ca-9c54-83be4f9f691a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "no instances of febrile neutropenia or cholelithiasis were reported in both the primary and secondary clinical trials."
    },
    "919dbcc0-8d31-4161-8692-45533e52d60e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "no adverse events were reported in the primary clinical trial's first cohort, however, almost everyone in the second cohort encountered at least one adverse event"
    },
    "e4256cc3-09b7-4ad0-b1b1-467cd74b273c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "microsecond is a unit of time equal to one millionth of a second. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort."
    },
    "1f6d3870-934f-4a75-87a3-0e52c19cd010": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "cohort a of the primary clinical trial is given a single oral dose of ld v935, while cohort b receives a different treatment regimen."
    },
    "38c2a394-f21b-4ae8-8941-aeccf896609b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "data is a collection or single item of factual information, derived from measurement or research, from which conclusions may be drawn. warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial."
    },
    "63c2b269-5155-4014-b033-2584a6773867": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "tongue neoplasm is a benign or malignant neoplasm involving the tongue. Paclitaxel is not used in either of the primary trial interventions."
    },
    "f2006562-69ab-4062-a5be-943cb905ee95": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "monoallelic palb2 gene inactivation is any gain, loss, or exchange of dna that results in monoallelic loss of function mutations in the palb2 gene.  Alzheimer's patients are not eligible for the primary trial."
    },
    "2eabe849-09b8-45e6-aa6b-74450a7ff5df": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "in the secondary clinical trial, the number of participants with treatment-emergent aes is the main outcome measurement."
    },
    "2882972d-2466-4eb1-9be2-14f0ebed2102": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "both cohort 1 and cohort 2 of the primary clinical trial are administered the same dose of 25 mg of sunitinib daily"
    },
    "1da40d20-026a-4b22-8e6c-8943e0180ed7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "the presence of a history of pulmonary embolisms and current breast implants disqualifies patients from participation in both the primary and secondary clinical trials."
    },
    "a5415a49-0b04-4f8f-a7ec-a8c276b2cf64": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial."
    },
    "e688cf8e-7082-43f3-803c-7489148f3cac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. intensity of average pain is a question about the intensity of an individual's average pain."
    },
    "d6716be9-247d-4c01-beb3-cd5bbbb6f9ec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "the imaging procedure used for the primary clinical trial study groups will be magnetic resonance imaging (mri), not 18f-fdg and 18f-fpprgd2 pet/ct."
    },
    "9dcb0637-50ed-4e98-b6e8-fa95fae80471": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "patients in the primary clinical trial receive varied dosages of docetaxel, doxorubicin and cyclophosphamide depending on their weight and age"
    },
    "027aec87-187e-4c41-9a39-4c453dd1e0ad": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "in the secondary clinical trial's group 2, one incident of shingles was reported, but the primary clinical trial and group 1 of the secondary clinical trial did not have any such cases."
    },
    "c634ebf6-2577-4cc6-9e2d-e14da660629d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "lesser trochanter is a cone-shaped projection in the shaft of the femur in which the iliopsoas muscle is attached. cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel."
    },
    "cbf72855-5886-46d7-b084-43cb6f2a0e2e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "according to the results obtained from the primary clinical trial, pre-surgical consumption of tamoxifen 20 mg orally on daily basis excites a rise in ki67 expression in cancer tumors."
    },
    "993572ab-2275-4def-9723-202249284283": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most recurring adverse event among the patient cohorts of the primary clinical trial and the secondary clinical trial was insomnia, which was experienced by 30.00% of the primary clinical trial patients."
    },
    "d0691186-857a-4876-8f49-732e033a86c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "on average, more treatment emergent adverse events and serious treatment emergent adverse events were reported by patients in the paced respiration intervention group than in the fast, shallow respiration group during the primary clinical trial."
    },
    "da18ab3b-cf80-4867-b3b9-0dccf4c523a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 104 weeks, however at least one patient from both cohorts died in under 104 weeks."
    },
    "b315a999-4315-4e95-95e7-9f402f9d979e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "no cardiac-related adverse events have been identified in the first cohort of the primary clinical trial."
    },
    "d4fd7d7a-53f4-4f5d-9640-717e26cbbcd9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "the primary clinical trial utilizes laser-assisted fluorescence angiography for both of its interventions."
    },
    "60df29e3-b115-4407-b1f9-dfc2c3d2d3d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "the primary clinical trial is open to all ages but the secondary clinical trial specifically excludes children"
    },
    "4e68783f-fc2b-4efb-88da-b5d081ff5541": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "unfavorable outcomes were reported in equal measure from patients in both divisions of the primary clinical trial"
    },
    "939de4be-2f3d-4e0d-a5b9-a80f6469bd22": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "meters times percent is a unit of measure for the distance saturation product (dsp) defined as meters times percent. Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome."
    },
    "3d7e66cf-6e57-4072-b7f9-96ab99473ac5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "all of the participants in group 1 of the primary trial were found to have lesions, and less than 10% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "fbe7ef7c-4dff-403e-9152-04d357ec9bbc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "based on the outcomes from the primary clinical trial, it was discovered that tamoxifen, when taken at a daily dosage of 20 mg for seven days before surgery followed by 14 days post-surgery, leads to a decrease in ki67 expression in breast cancer tumors by approximately 40%."
    },
    "5a42ca95-0544-4db1-a1f1-67534d54dc69": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "one cohort of the primary clinical trial gets risk assessment as part of the interventions."
    },
    "d207a9ec-f055-456a-ad6a-7c580cc347e1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "the only inclusion or exclusion standard that the primary and secondary clinical trials have in common is the capability to present written informed consent."
    },
    "21c01e1d-b152-404c-88d6-b697b2a97b68": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "the primary trial registered a higher number of mucositis oral, bladder infection, and thromboembolic events compared to the secondary trial"
    },
    "379dbb6e-e70b-4e6c-83a9-c332b84592dd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "ralstonia is a genus of gram negative, rod shaped bacterium assigned to the phylum proteobacteria and the family burkholderiaceae. Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial."
    },
    "9d330063-37a8-4c8e-8ac2-f28c8048d0be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "eyelid oedema and chest pain were the sole adverse event types noted in patients from the secondary clinical trial, in contrast, the primary clinical trial recorded none."
    },
    "37321416-91c4-4dd1-952b-6b23865d769c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "in the primary clinical trial, cohort 2 follows a different instructional method for paced breathing that is not a cd and practices only once a day."
    },
    "df709118-7130-4d0e-8150-a05fa7f1a6d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial. tsqm version 1.4 questionnaire question is a question associated with the tsqm version 1.4 questionnaire."
    },
    "be556bfc-7cc6-44fc-a505-52a8d55bbb5e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the secondary trial and the primary trial use different outcome measurements and units of measure. fetal hypoxemia is abnormally low arterial blood oxygen concentration in a fetus."
    },
    "671c7966-67b4-4279-b246-a4e415679a2d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "no form of counselling, risk assessment, or cognitive behavioural therapy (cbt) is given as part of the interventions in either cohort of the primary clinical trial."
    },
    "063f5147-ab53-4f22-b390-bdf6d6589a03": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the primary clinical trial offers various medication types, each with their own unique administration route."
    },
    "8942c478-a2ec-4b68-8da0-7fbce5bb70f7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "primary clinical trial and secondary clinical trial don't share the same outcome assessments."
    },
    "f41cbb25-7c8f-49ac-af06-5c8f1895ab60": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome. macroscopic findings evaluator is a person who determines the significance of a macroscopic findings assessment."
    },
    "aac508e7-cd87-40ad-afa6-bc977ab393aa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "there was a complete absence of both gastro-intestinal adverse events and psychiatric events in the primary clinical trial"
    },
    "449b619f-902b-446d-ac1e-f73be62ac2ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "the primary trial noted a higher incidence of adverse events than the secondary trial."
    },
    "b0bb79f6-dd52-4821-b739-ffc42d7472da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "in the primary clinical trial, the incidence of treatment-emergent adverse events was practically nonexistent among patients undergoing the sunitinib + docetaxel + trastuzumab treatment."
    },
    "c8bd9404-6d9c-4048-9d19-639aefd4ab08": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial. patellar tendon is a fibrous band extending from the distal end of the quadriceps femoris to the top of the patella."
    },
    "a752838e-30be-4438-913e-e905d2893abc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "individuals who use tobacco products can partake in the secondary clinical trial."
    },
    "574ab11b-3216-4b4b-a4aa-cf035483fe05": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive less than 1 year, over 120 patients from each cohort survived more than 12 months"
    },
    "c70735d3-1bc3-41d8-b0d3-15a49abe4862": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the participant with the highest pfs in the primary clinical trial was able to survive for 3.5 months without progression of disease or death."
    },
    "334b5f86-50c5-4711-994d-31ed67dd4282": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or older are eligible for the secondary trial and the primary trial"
    },
    "fcc8d86f-3fba-4398-8c0e-042153fa118e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "decreased bone tissue is a decrease in the amount of bone tissue as compared to a standard or norm. Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "ddc664eb-c81b-4544-b370-bb6db84eacba": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "haq-di questionnaire question is a question associated with the haq-di questionnaire. Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial."
    },
    "1279b75a-606f-469e-a6e6-20d4eabd50ba": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "the primary clinical trial strictly accommodates participation from females, whereas the secondary clinical trial only permits the participation of males."
    },
    "460e894b-61c8-4935-bde6-6800b1a440a2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "participants in the primary clinical trial would be required to take multiple injections"
    },
    "aadd13d6-3100-41ef-947f-6b29d3118d67": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "in order to be eligible for the primary clinical trial, a participant must have a bodyweight within the range of 50-100kgs"
    },
    "3ad97e18-2efc-4d4a-aaae-424a3bc3f39c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients with a healthy body mass index and are in post childbearing years may be eligible for the primary clinical trial and the secondary clinical trial"
    },
    "c9e9765e-663a-4421-a353-b0d6de09734d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "x-ray imaging is a fundamental part of the interventions provided in the primary clinical trial and the secondary clinical trial"
    },
    "1f77c906-1f2c-43b4-8bb1-2a2aeb19555e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "Most patients in the secondary trial and the primary trial did not suffer any adverse events. network is an interconnected system of things or people."
    },
    "8dd6a2dd-74f9-4bac-af44-c816fd960f74": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "in the primary clinical trial, adverse events are mainly not related to symptoms"
    },
    "572557f8-fcc1-4448-aa44-a09e7c5244e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "while entry into the secondary clinical trial requires adherence to specific performance status conditions, such conditions are not imposed on candidates for the primary clinical trial"
    },
    "58c1c63d-fcf2-400d-af60-9f33c9820f1b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "sitalidone is a benzenesulfonamide-based agent with salidiuretic and antihypertensive effects. the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy."
    },
    "16505ccd-8394-4c6e-8ab2-bbf56583c6be": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary clinical trial receives lower doses of cyclophosphamide than eribulin."
    },
    "d11356c5-cf48-40dc-aa23-46e71f564afd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial."
    },
    "d3aeafa2-2963-4220-b80d-cd5cde582fe8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 25 mg po daily for 10 days prior to surgery and for 20 days after breast cancer surgery increases ki67 expression in tumors by 200% on average."
    },
    "fdc63af9-e802-4ef7-8f6d-bec415bf2537": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 30 mg group of the primary trial had a -16.4% recurrence-free survival compared to the nacl 19% 3ml group"
    },
    "5e2af84e-3876-4822-80c3-99c7774a5bf9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 1.5 hectograms of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "f00c0288-b56a-45b4-9908-1c679e5043e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 30mg of mcs110 every 4 weeks, and over 160 mg of pdr001 every other week."
    },
    "2cf8bdbf-5f09-4f16-8b50-c6369d003a4f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. t(1;22)(q23;q12) is a chromosomal translocation involving the pbx1 gene at 1q23 and the ewsr1 gene at 22q12."
    },
    "a828ed30-ae3c-4fbc-be8a-a72dd5e5bc3e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 1 decimeter in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "d2757370-ae03-4046-a888-e30b9aa1551f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "individuals with fluorescent in situ hybridization-confirmed nut midline carcinoma, castrate-resistant prostate cancer, or inflammatory breast cancer can enroll in both the primary and secondary clinical trials."
    },
    "5677aa15-f929-41ac-97e2-07857e792505": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "in their results, the primary clinical trial and the secondary clinical trial consider distinct patient characteristics."
    },
    "284bab9f-a986-4a27-9fe3-ac989cefcf4e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "weekly subcutaneous injections are designed for those enrolled in the secondary clinical trial, while this procedure is not an inclusion criteria for primary clinical trial participants."
    },
    "0b958f19-d411-426c-8144-162c6c15d9d2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "the number of patients undergoing adverse events was four more in the first cohort than in the second cohort of the primary clinical trial"
    },
    "5a6a1e08-4a0a-45ea-91f5-053182a352cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid. beta streptococcus group f is a non-taxonomic grouping of beta hemolytic species within the streptococcus genus that are assigned to the f group."
    },
    "343f30bc-9b37-471a-83fc-76089ffc527c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "sellar chordoma is a chordoma that arises from the sellar region. less than 5% of patients in the primary trial suffered Aes."
    },
    "c6f2c906-4b0a-4b93-99ee-2152df2af3e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "participants in the primary clinical trial must have colorectal cancer and be under immunotherapy."
    },
    "a1bff44a-8d74-4184-a4d3-228bb55f4530": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the secondary clinical trial had a higher incidence of adverse events compared to the primary clinical trial."
    },
    "db08ca44-cd18-49ff-ae80-4a3f0bb625b5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "50 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 20% of patients, apart from skin infections"
    },
    "9c459c1c-bfc4-4fef-ba9f-6052b9622c69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "calr gene mutation is a change in the nucleotide sequence of the calr gene. There were 0 adverse events in the primary trial and the secondary trial."
    },
    "eb555e01-0a12-45a1-99ad-7d7dafbe8912": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle."
    },
    "3ace09f3-a822-4140-a529-52b08664da77": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "t(1;13) is a cytogenetic abnormality that involves a translocation between chromosomes 1 and 13. Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2."
    },
    "ccc3cd99-a66b-42ce-9a35-21780035ddc5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial. blinatumomab regimen is an immunotherapy regimen consisting of blinatumomab that may be used in the treatment of acute lymphoblastic leukemia (all)."
    },
    "d6f7d14f-dbc6-4268-be40-1a09facf0834": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2. rolfing is a therapy designed to realign the body with gravity through fascial manipulation. (taber's)"
    },
    "bf140d08-90da-4fb4-90da-b86a87b5bb07": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the primary trial has a uniform set of inclusion/exclusion criteria for all participants, whereas the secondary trial segregates its criteria into two age groups: 20-40 and 40+."
    },
    "e74e47e7-4627-4dd9-aedd-cbc5b5cdd669": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "mucositis oral, bladder infection, and thromboembolic events were seen more often in the secondary clinical trial than they were in the primary clinical trial"
    },
    "5dc5fa82-a4a5-4f16-8ca1-b797546169af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "severe pain or discomfort that prevented most activities is a response indicating that an individual has or had severe pain or discomfort that prevented most activities. There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation ."
    },
    "624aeeea-894f-4100-86a2-724ef4842002": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan. cutaneous schwannoma is a benign schwannoma occurring in the skin."
    },
    "64b3c727-779e-4db4-b1fe-1d85105ab7ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary and secondary clinical trials use the same parameters to gauge the outcomes and employ the same metric units."
    },
    "91439ad2-cb81-49e5-a783-ebbc2e04d64a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "anaemia was encountered as a frequent adverse incident in the secondary trial affecting more than 5% of patients, however, no such incidents have been identified in the primary trial."
    },
    "193ae24d-ca9a-4bd6-8a98-279c75d32c9b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "across the patient cohorts of both the primary and secondary clinical trials, there were three cases of shingles reported."
    },
    "b24a7c99-879c-416b-8b54-f44f0bcd4524": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "according to the findings of the primary clinical trial, the overall response rate for the arm a intervention outperforms that of the placebo group. furthermore, in the secondary clinical trial, the denosumab cohort showed a better time to first on-study sre than the zoledronic acid cohort."
    },
    "fb5aff7f-4a77-4300-acc4-99a01a6696d1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "within the primary clinical trial, cohorts 1 and 2 are differentiated by the medication administered; cohort 1 receives 25 mg to 37.5 mg of sunitinib daily, while cohort 2 is given 10 mg/kg of bevacizumab"
    },
    "7d36e2e7-cf12-4281-8db5-2c30f23b427b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. have easy access to the medical specialists i need is a question about whether an individual feels they have easy access to the medical specialists they need."
    },
    "d21d3871-d8c2-4a0a-b99f-291a721a1a18": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the outcome measurement for both the primary clinical trial and the secondary clinical trial incorporate distinct units."
    },
    "c5c7b6e2-201f-42af-aeb3-3e3152fa0ba2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "her2+ patients in the primary clinical trial and those in cohort 2 of the secondary clinical trial receive an equal dosage of trastuzumab throughout the entire trial period."
    },
    "99942306-e4cf-4405-80ca-914e689aef75": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "in the primary clinical trial, more than half of the patients who underwent treatment with 1000mg lapatinib and nab-paclitaxel recorded a confirmed complete response (cr)."
    },
    "22f97249-204f-4d0e-a76f-eb9b8441c8da": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 9/10 patients in the primary trial treated with lapatinib 0.25 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "f6a1bd73-7581-4284-b039-705aeb0236bf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "a comparison between adverse events in the primary clinical trial and the secondary clinical trial is challenging, given the apparent absence of such events from the records of the primary clinical trial."
    },
    "5c9037a6-53a8-49ec-8aa5-b6a47dee226d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "different cohorts of the primary clinical trial are prescribed varying doses of abraxane"
    },
    "8f4d4e78-5e46-47b6-865c-ad6b689d69e0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial."
    },
    "fc281ab7-f956-47d7-a938-8778fef1bca0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study."
    },
    "dbd5f70e-0fa9-4b5e-af0e-0ad9efc49bc6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial"
    },
    "f0f8a0a6-1148-4592-a9b4-27c005038900": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration."
    },
    "86722991-04c7-4fdd-914a-f5b71d236a7a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "orbit capillary hemangioma is a capillary hemangioma arising from the orbit. 25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  ."
    },
    "1adb6e15-a8b1-461a-8782-4295224a3c5f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "the primary clinical trial accepts individuals suffering from vascular dementia"
    },
    "96a69ac4-9248-4ede-bc27-2f032f0e2294": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "participants in the primary clinical trial will be given a series of injections throughout the study duration."
    },
    "02da2719-af96-4d84-bf69-ac1a2d6fd01c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "in the primary clinical trial, less than 5% of the participants experienced adverse events"
    },
    "5f44bd33-3921-479c-9a16-e2af73e72101": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "in the primary clinical trial, the cognitive function of both cohorts, on average, experienced a decline; although this was not consistent among all patients"
    },
    "72626f41-afa0-413c-b495-e4eeb51112fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after 30 days of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 10% reduction in the percentage of cells with ki67 expression"
    },
    "58726c08-13a9-4168-afc3-14f8e7397f5b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial. substance is any matter of defined composition that has discrete existence, whose origin may be biological, mineral or chemical."
    },
    "bacab9f7-0d0a-49e1-a503-e959c33bfe6a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "despite a patient potentially fulfilling all exclusion and inclusion conditions of the primary clinical trial, the ultimate verdict on their inclusion lies in the hands of the medical professionals running the trial."
    },
    "85bde7b9-9e2e-41e1-a8d5-9ff85e8900e6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "thoracic surgery is a branch of medicine dealing with the use of surgery to treat diseases of the chest and lungs. Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial."
    },
    "7b9338a5-d3a8-405f-a197-736caf32c455": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial."
    },
    "1bc50379-9721-419f-959a-560b3747b8ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 0.0 recorded adverse events."
    },
    "68716599-d21d-433a-9e8d-5113749d4a06": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the total adverse events in the primary trial exceed those in the secondary trial, but there are fewer cases of cardiac-ischemia/infarction in the primary trial than in the secondary trial."
    },
    "f19797c7-afb1-4480-ab8f-c798a86d2849": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 67% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) ."
    },
    "62a0ed6c-dc2a-4223-9ee0-5b7422bf43da": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare. illusion is a misperception of a real external stimulus."
    },
    "46a79c10-315b-4975-9949-508fc379af87": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "12 adverse events were observed in the course of the primary clinical trial"
    },
    "773d939c-db89-4999-9903-89da67345b49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "some of the patients in the primary clinical trial did not receive sunitinib every day, for the entire duration of the study."
    },
    "8eb9d0d2-5c33-4ff6-adf6-e96ddf7be7a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "patients with a past record of pulmonary embolism and currently having breast implants are excluded from both the primary clinical trial and the secondary clinical trial."
    },
    "fe9b1db5-8600-469a-ba9f-c0aab4630041": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation. rhabdoid indicator is an indication of whether rhabdoid cells or features are present in a sample."
    },
    "8723a112-05c6-4c05-82ab-e09cedffdb4b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "only three kinds of adverse events impacted patients participating in the primary clinical trial: pancreatitis, cholelithiasis, hepatic pain and febrile neutropenia"
    },
    "94935617-b333-4eb3-bd06-a5884fa45989": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the the primary trial intervention consists of radioembolization using yttrium-90 glass microspheres and theraspheres, on the other hand the secondary trial intervention consists of 0.56 g of ibrutinib and 0.01 kg/kg of medi4736 twice daily for 30 days."
    },
    "8529eb83-969c-4075-bfe7-efc47fd33d8d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "a confirmed diagnosis of pancreatic cancer is required for eligibility in the primary clinical trial"
    },
    "f43219f1-3807-4c37-9240-bf1d9f54d5e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism in the last 5 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "2f61841c-b395-4d2c-9e86-ca09cdd61dcb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "individuals who have engaged in chemotherapy or radiotherapy within the preceding two weeks, those who have unstable angina or those with neuropathy not exceeding grade 2 are permitted to join the secondary trial, but are barred from the primary trial if they possess non-healing surgical wounds."
    },
    "348f2b7d-e9b5-41ad-927b-e368bcaca8f5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "individual is a single human being. Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both."
    },
    "b7028956-b024-401f-b528-554559f8ce17": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "patients with follicular thyroid carcinoma confirmed by thin-prep cytology, or postmastectomy lymphedema are excluded from both the primary trial and the secondary trial."
    },
    "c179c437-ffe9-4120-9390-58d88fb596f3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "in the primary clinical trial, the intervention administered to patients with breast cancer and ovarian/ peritoneal cancer is uniform."
    },
    "3f26cd3e-2b66-4bbc-94b4-498df2e334e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment. t(2;22)(q34;q12) is a chromosomal translocation involving the creb1 gene at 2q34 and the ewsr1 gene at 22q12."
    },
    "a6e81477-f863-4a83-9007-fd2f1f5c6781": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention."
    },
    "fb67edbe-9758-4e64-acd0-263fe51ba74a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 90mg of mcs110 every 2 weeks, and over 180 mg of pdr001 every other week."
    },
    "ad6c7a37-2ab2-428a-8ac5-d2462d920c11": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "only nationals from the united kingdom can join the primary clinical trial or the secondary clinical trial."
    },
    "408eec4d-435f-4edb-99ac-69cd883586b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "the guidelines to be part of the primary and secondary clinical trials are congruent. hence, any patients currently enrolled in the secondary clinical trial qualify for the primary clinical trial as well"
    },
    "063a0207-f4fc-43c1-849e-6d3fc64b009b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "thromboembolic events were not observed in either the primary or secondary trial patients."
    },
    "6ffb2b0f-737a-4176-9036-a887a2f4a4b7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 730 days, over 50 patients from each cohort survived more than 24 months"
    },
    "b0b3e393-7af0-4fe2-bf26-111bddead6e7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "a majority of the patients in the primary clinical trial experienced a confirmed complete response (cr) after undergoing treatment with lapatinib 1000mg and nab-paclitaxel."
    },
    "a56ade78-3385-4789-b86a-3aef67188d2c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "difficulty paying attention to things is a question about whether an individual has difficulty paying attention to things. the primary trial and the secondary trial have 0 recorded adverse events."
    },
    "e5d1118c-2e6a-4e00-a63c-041c43256c5e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "patients using testosterone cream in the primary trial showed superior results in managing their lymphedema than those undergoing acupuncture treatment."
    },
    "5780e67e-7318-4574-b20c-a2d3c8730e4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 in the primary clinical trial is subject to higher eribulin doses in comparison to the docetaxel doses given to cohort 2."
    },
    "f519491d-1f9b-4527-aaa3-902c2fb181b5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "most participants in both the primary clinical trial and the secondary clinical trial experienced no adverse effects"
    },
    "480133d8-93ea-46f0-86e5-b92c380bb7f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "non-nodal regional disease indicator is an indication of whether a subject has non-nodal regional disease. the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs."
    },
    "966e1258-879d-4e8d-88ec-777a743e191d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "fgfr2 gene mutation negative is a genetic finding indicating that fgfr2 gene mutations have not been detected in a sample. There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs."
    },
    "20b96fad-2ca0-4bee-a541-0006c6ff8037": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "glisolamide is a second-generation sulfonylurea with antihyperglycemic activity. glisolamide is comparable to glyburide and gliquidone in controlling blood glucose levels. 25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  ."
    },
    "0392122c-9612-49dc-83db-b2b6a4a4a8a8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "the primary clinical trial did not yield any significant differing outcomes across groups, and the reflexology group in the secondary clinical trial showed the same results as their control group."
    },
    "12746144-95c9-4656-abdf-8a49f78c7049": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements. do not receive appropriate pay increases, promotions, or recognition at work is a question about whether an individual does or did not receive appropriate pay increases, promotions, or recognition at work."
    },
    "3add5ce6-4581-491c-b501-2c071860ece3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 milligrams of oral pregabalin every two weeks over 6 weeks, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "d51ecd4d-4188-4306-9c41-962c86a12652": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial. biological mother is a female who contributes to the genetic makeup of her offspring from the fertilization of her ovum."
    },
    "348ce220-f650-4df2-9593-586ddaabe491": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "the primary clinical trial showed no difference in the improvement rate of lymphedema between acupuncture patients and those on the waiting list."
    },
    "a0d11ea8-22ae-4af7-885c-40b9e3a98fac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial . caspase-3 staining method is an immunohistochemical technique used to detect the presence of caspase-3 in a tissue sample."
    },
    "9c8b2041-2a99-4f42-93ec-63daed05fe87": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "patients diagnosed with stage 4 cancer may participate in both the primary clinical trial and the secondary clinical trial, provided they give informed consent."
    },
    "c7c9fef0-9243-4cd8-8b8e-e9ab459b7420": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "contrasting the primary clinical trial that analyses the variation in urinary isothiocyanate concentration due to sulforaphane supplements, the secondary clinical trial measures the success of physical therapy through the assessment of pain."
    },
    "36aac65a-5d56-4abd-b278-e9e3de78d480": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "the primary clinical trial involves patients taking oral medicine on a twice daily schedule for the duration of one month."
    },
    "3159e9e4-c8a2-4333-b24c-250698ae8ffd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "cohort 1 of the primary clinical trial was completely free of any adverse events"
    },
    "00d9d3c3-938f-4e4c-b532-b11146f1239c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "sometimes true is a subjective response indicating that something is sometime true. The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine."
    },
    "f0f71529-7742-45c4-945f-ae4e51f9029d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "in the primary clinical trial, no incidents of hypertension, edema, and dyspnea were observed in both cohorts."
    },
    "658e195d-21fc-4bf0-af37-a523ba772f83": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120,000 micrograms of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 14.4 to 36.0 gbq of radioactive tc99m sulfur colloid."
    },
    "97b0957c-3b60-4671-9c9d-37eacba40f93": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "foot/footpad is a laboratory specimen consisting of the foot and footpad. Most patients in the secondary trial and the primary trial did not suffer any adverse events."
    },
    "136f0a2e-563c-4085-b390-ac2db90f7aac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "both cohorts involved in the primary trial demonstrated an average decline in cognitive function, although this was not the circumstance for all individuals"
    },
    "aa7a20b6-cec1-448c-ac20-a7b2d8c14a1d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the intervention section of the primary clinical trial provides a comprehensive treatment cycle and detailed description of the treatment."
    },
    "0fd90f9b-bf76-4c3c-9964-dc635138217c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "General symptoms are the most common AE recorded in the primary trial. eligibility for lung surgery is a question pertaining to patient's eligibility to undergo a lung surgery."
    },
    "c01b910d-2463-4bf8-bb67-f950aca11411": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "both the primary clinical trial and the secondary clinical trial allow the enrollment of patients with confirmed histological diagnosis of stage 4 breast adenocarcinoma having either er positivity, pr positivity or her2/neu negativity."
    },
    "8b047df3-cd4b-4c75-97b5-4081f65512eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "in group 2 of the primary trial, patients are administered a 2mg/kg dosage of dexmedetomidine, while patients in the secondary trial are given 1mg/kg."
    },
    "6b1a58fa-54cd-442b-8f51-1b7135dd2302": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "cbt based treatments are a primary requirement for participation in the primary clinical trial and are fully permissible in the secondary clinical trial."
    },
    "e2979c27-0eb6-487d-a940-646685e1934b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP."
    },
    "7e232984-9a95-44b0-85b0-ecbeb50655b7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial restricts participation based on a patient's nationality, ethnicity, weight, or gender"
    },
    "eb9c708d-26e5-40a1-a0d3-6b80f689f540": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "hop-62 is an adenocarcinoma cell line established from lung carcinoma tissue removed from a 60 year old female. The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial."
    },
    "e87fee13-1ed3-4eca-8d72-d65fee50abf7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "a higher number of mucositis oral cases, epileptic seizures, and thromboembolic events were seen in the primary trial than in the secondary trial"
    },
    "909d54ab-358d-4892-9bd1-e71d6d3bc24c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "the percentage of cells expressing ki67 increased by 8% after treatment with tak-228 plus tamoxifen in the primary clinical trial."
    },
    "552c79f8-3f17-4a7d-be66-d4cdc8749a66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 0.02g of mcs110 every 21 days, and over 0.13g of pdr001 every fortnight."
    },
    "6a696416-b67e-4f78-8677-3fbc4470b4c1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "age at initial pathologic diagnosis is a question about the age of the individual at the time of the initial pathologic diagnosis. Coronary artery stenosis are the most common AE recorded in the primary trial."
    },
    "0723e2a6-a2cd-4b8b-b319-f8a8bf00d819": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period . radiation-induced malignant peripheral nerve sheath tumor is a malignant peripheral nerve sheath tumor that is the result of exposure to ionizing radiation."
    },
    "1a1826f4-79d9-4df0-a8d8-fe9c3d75d783": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. cyld gene mutation is a change in the nucleotide sequence of the cyld gene."
    },
    "0cf2969d-0228-4267-8e5a-12dc22a12ae9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "neratinib is an essential part of the primary clinical trial regimen"
    },
    "be8707c6-9004-4fab-b719-c1ab372a77a1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "only patients with invasive lobular carcinoma under going chemotherapy are eligible for the primary clinical trial."
    },
    "4a64f808-b518-4666-9f78-56a2d6dd7093": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "there are 2 less participants in cohort 2 of the primary clinical trial than in cohort 1"
    },
    "50757da1-c674-43a7-a3ee-90750e166aa5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "no exacerbating factor to chief complaint is an indication that the chief complaint was not worsened by another factor. In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily."
    },
    "674d7d6c-723a-44db-9e96-10aa21dcefe4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "the examined genes displayed a discernible expression trend in the primary clinical trial's first and second patient cohorts."
    },
    "796ae946-899b-475c-ab4c-88ba6af1e881": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "control type code is a coded value specifying the kind of comparison or comparator against which another entity is evaluated. there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial."
    },
    "46959de4-38f3-42a8-adf9-c7565c66b442": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "informed consent will allow patients who are in stage 4 of cancer to be eligible for the secondary clinical trial as well as the primary clinical trial."
    },
    "f3091230-221d-4c82-9d37-06e04c12ba48": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "optic chiasm neoplasm is a benign or malignant neoplasm that affects the optic chiasm. a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial."
    },
    "e1c50f3f-0521-4edc-a2ae-8e0b04b64c54": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary trial patients receive higher doses of radiation therapy than the secondary trial participants. anaplasia indicator is a indication of whether anaplasia was found in a sample."
    },
    "96ee335e-d938-4b45-a22d-49b03dbb2af0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "enterovirus is a (+) strand single strand rna virus of the picornavirus family.  poliovirus is an enterovirus. the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group."
    },
    "78dd81db-dbc1-427a-9a3d-09f3e339ac99": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "concern about finances is a question about whether an individual has or had concerns about finances. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial."
    },
    "e1e33a46-c88d-497a-b7b6-be14d38d05b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "only patients with metastatic or advanced hematological malignancies are fit to participate in phase 1 of the primary clinical trial and for all cohorts of the secondary clinical trial"
    },
    "5ebf97e0-5409-4e82-a837-e0d96bc62b96": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "tcirg1 gene mutation is a change in the nucleotide sequence of the tcirg1 gene. The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection."
    },
    "ac271988-c319-4b6f-b7bf-f3c86072cf93": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "none of the primary trial participants receive doses of alt-801, whereas all secondary trial participants do."
    },
    "c3d9b60a-a46e-4bde-9e4a-46db5c2d75ba": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the focus of the primary trial is to analyze the effects of different types of pills on its test subjects, while the secondary trial tests the results of varying quantities of the same gel treatment on its group."
    },
    "d3bf6a5f-bce2-47f5-be7a-6c97b2bf88ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "in the primary clinical trial, the first cohort is treated with an intraosseous injection of fluciclatide, while in the secondary clinical trial, the first cohort is given a customary iv dose of chloroquine."
    },
    "396511cd-a922-4ba6-9c33-bc2f20bfdebd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "in the primary clinical trial, the operative time of arm 1 was lower than that of arm 2, demonstrating the effectiveness of standard mammography compared to intra-operative mammography. there is a control group in the secondary clinical trial for comparison.'"
    },
    "84e7c52d-eec3-415f-9602-77f607c5620e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "in the primary clinical trial, both cohorts are administered identical doses of abraxane"
    },
    "742cd2e5-1335-4daa-87b0-47727f61d8a1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients participating in the primary trial receive 200mg/m2 oral lapatinib once a day for a full month."
    },
    "aeddc485-09b1-4ddc-9a45-3a8bf0bec2c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  "
    },
    "9c6f062e-a260-4c3a-ac91-fc5de6de176d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "pcr serves as the outcome metric in both the primary and secondary clinical trials. a minor discrepancy in results is seen between the two cohorts within the primary clinical trial. conversely, arm 2 outperformed arm 1 in the secondary clinical trial significantly."
    },
    "fdeba169-13d2-4ed9-a2b2-774194f18370": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "the primary clinical trial is open to individuals suffering from leptomeningeal carcinoma"
    },
    "09819b6e-961a-47cf-9112-c43434e9ac19": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "birc5 antibody is any immunoglobulin that recognizes baculoviral iap repeat-containing protein 5. the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions."
    },
    "54aa7f2d-b774-4530-ad47-3848ca093433": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "patients in cohort 2 of the primary trial reported higher rates of neutropenia as compared to patients in cohort 1 of the secondary trial, both groups receiving the same doses of empegfilgrastim."
    },
    "8044ce4d-99e5-4c90-91aa-9c0c85f2c6b4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "each group in the primary clinical trial had an equal number of participants."
    },
    "e1069782-98e2-4db7-aeed-460b846781c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "parotid gland hemangioma is a hemangioma arising from the parotid gland. participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2."
    },
    "cef48380-fe4b-4b71-931c-5b0dbfe1cf29": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial is unrestricted in the number of participants and is appropriate for individuals with ovarian cancer, irrespective of their kras or braf mutation status."
    },
    "2735976f-a517-4b4e-addb-845ef4dc0d33": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients having unregulated high blood pressure along with malignant ductal carcinoma in situ are eligible for the secondary clinical trial, but their participation in the primary clinical trial is excluded."
    },
    "2efa0e5d-84cd-4854-9558-6105af976610": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have received chemotherapy or radiotherapy in the last 2 weeks, are dealing with unstable angina, or have grade 2 or above neuropathy are eligible to participate in the secondary clinical trial and excluded from the primary clinical trial."
    },
    "6071457e-bfac-4d86-b20b-c37ff82c943f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 15000 mcg per day"
    },
    "5a181517-dbdc-4598-8955-ca1bfa380fa9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim."
    },
    "4a9c4fbc-53cf-4eff-b7ba-37a0f21386b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "no adverse events were reported in primary clinical trial among any of the cohorts"
    },
    "7e695451-7e2e-43b4-8762-0ac27fb978b2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "the expression pattern of the selected 40 genes was absolutely visible among the participants in both the first and second cohorts of the primary clinical trial"
    },
    "79162d9d-6591-44ef-aaea-4bd58c4811da": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "every patient in the primary trial is receives a dose of 100000 to 1600000 nanogram fentanyl sublingual spray during radiation therapy"
    },
    "86823381-4392-4a31-a1cb-b2966dd41c45": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the intervention in the primary trial is multi-drug, with at least three different drugs such as irinotecan, lenograstim, and thiotepa. the intervention in the secondary trial is based on monotherapy with drug pemetrexed alone."
    },
    "f988fa4a-02f0-41f6-9e27-453604dd3ecc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "in both the primary and secondary clinical trials, the adverse events recorded were of the same number."
    },
    "00e018a5-5237-498b-8823-f47ac2d2697f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "coroner is an appointed public official whose job is to identify and certify an individual's death. Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial."
    },
    "4eb8855e-766e-4588-a42f-655ca3d80140": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary clinical trial administers its interventions intravenously, while the secondary trial employs a subcutaneous route."
    },
    "5ed2538b-155d-4527-aa80-b6a19c5a6602": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 0.175 g group of the primary trial experienced a greater reduction in primary tumour diameter than the zoledronic acid 4 mg group."
    },
    "44bb4ead-0597-4544-9b2c-3d99ff0a099b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "during the primary clinical trial, blood bilirubin levels increased in 36.36% of the participants."
    },
    "43658af8-5289-485f-98ed-50d005e452e1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort. vital signs supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the vital signs domain."
    },
    "22b968d1-4ffd-4562-aeb0-e1e022212b08": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. forehead lift is a plastic surgery procedure in which excess skin is removed from the forehead to create a more youthful appearance."
    },
    "7d60c7dd-fb79-4e95-a662-32de2036683f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2."
    },
    "6b4bc07c-bfc3-4750-b802-7100efeb60a7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the interventions in the primary clinical trial are similar in terms of the medications, but they are given through varied routes."
    },
    "49e29ec7-08a2-481d-9fc4-ecb66b09cdfe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. multi-institutional clinical study is a clinical study that is being conducted at multiple locations."
    },
    "002bd33d-4038-4b2b-9f56-1bd8e8978d64": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "when diagnosed with 2-3 cerebral metastases located within the brainstem, patients will be excluded from the secondary clinical trial, but they could still be considered eligible for the primary clinical trial."
    },
    "d48955a5-78eb-4a53-9495-1a363c7b8e05": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the greatest pfs in the primary clinical trial managed to survive for 6 months without any disease progression or death"
    },
    "28b11be9-1e77-49c5-8cd2-fb9a95a35b58": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "grem1 gene mutation is a change in the nucleotide sequence of the grem1 gene. The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP."
    },
    "72de2f11-15c9-489a-aec1-5c5e0969f4b7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 175 mg group of the primary clinical trial did not experience a significant reduction in primary tumour diameter compared to the zoledronic acid 4 mg group."
    },
    "3cb08dda-e0dc-48e5-87fa-e24386d6dab2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 26 weeks if they want to participate in the primary trial"
    },
    "831e3999-7ce1-4af9-9a28-1282d641a376": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 105 mg per week"
    },
    "d803319b-cf1d-47e9-b7c2-f75ef7972e88": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial is focused on measuring the rise in fatigue levels while the secondary trial assesses improvement in muscle strength over a span of 9 months."
    },
    "be63170c-5a52-4d85-b824-54ceca90684a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "experiencing the conditions of both claustrophobia and ibs disqualifies women from the primary and secondary clinical trials"
    },
    "f098a93b-9d39-4928-87b7-0ad43311c615": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 3/4 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 14 days of the study"
    },
    "29987f94-8331-4136-92f1-4ea5f5c232b9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "every participant in the primary clinical trial is administered a minimum of 20mg of mcs110 tri-weekly."
    },
    "79ddd80e-a0b2-4450-a0df-892e8b15dd63": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "patients involved in the primary clinical trial must adhere to unique eligibility criteria that differ from those of the secondary clinical trial"
    },
    "1a84148c-2d33-4804-922e-9a3419890897": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "the primary clinical trial requires intervention 1 to be taken subcutaneously, while intervenional drugs in the secondary clinical trial are given topically."
    },
    "335235f3-4d27-479e-a5d7-29016a3320a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "multiple aes were reported in the primary clinical trial including anemia and nausea."
    },
    "dfbf536b-7a16-42a0-b7f9-322c5394a01b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the secondary trial was anaemia, affecting more than 1/20 patients, there were no recorded aes in the primary trial."
    },
    "2e2a005f-232f-457a-880e-c3950bc58df6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "The interventions in the primary trial and the secondary trial include completely different drug-based treatments."
    },
    "c08aa0d8-5505-438c-b53a-934bd2ee570d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial does not report any results for the LBH589 and Lapatinib cohort."
    },
    "886a066c-520e-4454-bf20-43ad24b6baf9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial."
    },
    "2810ed9e-6f0a-4c59-be1a-31e5003fa51d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "powder dosage form is a solid composed of a mixture of dry, finely divided active and/or inert ingredient(s). Patients in the primary trial will need to receive several injections."
    },
    "5aa4da04-c21d-48a4-8888-62675ca63f74": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 250 mg of fulvestrant in a tablet form to be taken bid."
    },
    "9c180516-eca4-490b-b661-b47c625e3ab9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "within the adverse events of both the primary and secondary clinical trials, only one fatality was documented."
    },
    "33b59cbc-c52d-4e5c-8f77-f2d8a6fa491c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "several recorded adverse events have been associated with the secondary clinical trial."
    },
    "61de0370-1d90-4657-b0f1-fff95fc5efa5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "participants in the secondary trial study group do not receive any form of injections, whereas individuals in the primary trial receive daily intramuscular (im) injections."
    },
    "0b4536c8-2868-4d1a-bc26-d16b31eed34f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates with an ecog score of 4 are the only ones who can participate in the primary clinical trial and secondary clinical trial"
    },
    "fb1cfb53-fb70-4131-9ed0-00b5f93ecf26": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "a patient in the primary clinical trial suffered from a reopened surgical cut following the procedure."
    },
    "847ce4e8-b2df-4acb-b46c-c82baa519124": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial showed no recorded adverse events, while the secondary trial demonstrated a number of such events within their cohorts."
    },
    "0f3d96aa-a8ea-430a-ab6a-fe5e41f8b9fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "prednisone is administered pre-operatively to all participants in the primary clinical trial cohorts."
    },
    "8679e654-7db4-4fd2-8fbc-41028fedb540": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "information question is a question about the information that an individual received, or information in general. There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial."
    },
    "c08cf531-fbbe-4ec3-ae13-f10d13368a82": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. hybrid nerve sheath tumor is a benign nerve sheath tumor characterized by the combination of histologic features seen in schwannomas, neurofibromas, and perineuriomas."
    },
    "593bde37-5962-441b-ac10-dbe3120cec99": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 5% of patients in the primary trial suffered Aes"
    },
    "3e6a3ebb-face-44fe-8bb1-cbd399f4e215": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary clinical trial looks into the frequency of treatment-related adverse events in patients, while the secondary clinical trial evaluates the median minutes its patients spend asleep."
    },
    "6d418558-93db-4116-b142-821c3f8615f2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally. neck pain score 2 is a subjective score of 2 on a visual analogue scale that ranges from 0: no pain to 10: excruciating."
    },
    "5c7eee11-ee31-4adf-b2e6-8fe51a39a13b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "56.1% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "c70623c3-85f0-4480-a772-349a89de7d43": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "all the adverse events recorded in the primary trial are linked to the cardiovascular system, which contrasts with the secondary trial."
    },
    "09aef225-50fa-457e-9e8b-fce6aafd4705": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive oral medication twice a day for a full month. macroamylase measurement is a measurement of macroamylase present in a sample."
    },
    "71698d59-3bbe-4e8f-85c8-bf2110727155": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2"
    },
    "a198b3a9-ee15-4f4a-b587-d6ddb86efa73": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "encounter due to exposure to radiation is an icd encounter due to exposure to radiation. The interventions in the primary trial and the secondary trial include completely different drug-based treatments."
    },
    "10860cc9-5a8f-4e81-bb2a-42697541e8b0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "patients with estrogen positive, progesterone negative, and her2+ breast tumours have been accepted into the primary clinical trial"
    },
    "5199d14c-3a5e-4800-adf2-a065f50886b5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "only a selected group in the primary clinical trial receives armodafinil p.o. daily, whereas in the secondary clinical trial, every patient is provided with a fixed dose of 100 mg pdr001, and 1 mg/kg of mcs110."
    },
    "c9514ddd-0486-4aca-a0b7-4e03a2effc90": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "during the 10-week duration of the primary clinical trial, several participants did not report any pain."
    },
    "864e3d0c-60fb-43bf-a272-1d590ff8795b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "in the primary trial, there is a reduction in both the total number and categories of adverse events in comparison to the secondary trial."
    },
    "c6b37d94-f63f-4cf7-b86c-a8147ff618d9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 35 mg po daily for 21 days prior to surgery and for 10 days after breast cancer surgery increases ki67 expression in tumors by 85% on average."
    },
    "4b913a72-0c81-4396-8667-f087259328f6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "no cases of unanticipated deaths or hospitalizations are reported in the primary clinical trial and the secondary clinical trial, besides the three reported events of lymphoma."
    },
    "591e7319-16cd-46db-be86-7c78e8d471c8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "for the primary and secondary clinical trials, pcr is used as their benchmark for outcome. a slight difference is noted in the results of the two cohorts participating in the primary trial. however, in the secondary trial, arm 2 achieved far superior results than arm 1 did."
    },
    "ddee09ab-2af9-4c93-a64e-58371896a08e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary clinical trial receives twice the dose of alt-801 compared to cohort 2."
    },
    "277b5179-05cc-48df-8f23-98b42ccad0b9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial administers its intervention intravenously, and the secondary trial administers it topically."
    },
    "0e80c163-f731-4e3b-9194-211675ca9c53": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "in the primary clinical trial, both the first and second cohorts utilize the same instructional guided breathing cd. nevertheless, cohort 2 has an additional regimen of twice-daily practices and weekly antineoplastic chemotherapy."
    },
    "6920329b-7559-415e-9346-c06909526421": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial"
    },
    "5417955e-52aa-4b3b-8e67-2a4c4796846a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "epacadostat is provided to participants of the primary clinical trial twice as frequently as sunitinib is given to sunitinib-naive patients in the secondary clinical trial."
    },
    "d0212d75-c952-4ad3-ae36-bbf675eae985": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril"
    },
    "ccc4b1dc-30f5-46d4-9251-6bb1dbe514ce": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "the primary clinical trial reveals that taking tamoxifen 20 mg orally daily for a fortnight post-mastectomy has no significant effect on the ki67 expression in tumors."
    },
    "37bba0bf-5ecd-4007-a2c4-bf9e13dccd2e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "dasatinib was administered intravenously once a week, to patients in cohort 2 of the primary clinical trial for the initial 28-day cycle"
    },
    "cf959db3-df50-4724-a747-413a35bb171b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "pharyngoconjunctival fever is a condition characterized by fever, conjunctivitis, and pharyngitis resulting from infection by adenovirus. Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions."
    },
    "24b7127a-5d4d-4a7d-b64b-8b2e12396b04": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "both the primary clinical trial and the secondary clinical trial allow patients with colon cancer with tumors under 0.2 cm in size and without any specific marker status"
    },
    "880b2544-5c9d-4ce7-8d26-1081c7851cb9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "no assessments related to drug treatments are performed in the primary clinical trial, whereas the secondary clinical trial performs tests on two distinct drugs."
    },
    "d0a08aeb-5c7c-44a9-a923-fd4e3b094ebd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the paclitaxel plus bevacizumab plus gemcitabine group had an inferior orr to the paclitaxel plus bevacizumab group in the primary clinical trial"
    },
    "4e0fbb00-bcbe-4051-a343-58a6cb50eb0b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "patients suffering from a lack of vitamin d are not considered for the primary clinical trial, yet they may qualify for the secondary clinical trial."
    },
    "a4f1de91-12c1-487c-911d-45099a83a658": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "patients with breast cancer characterized by estrogen negative, progesterone negative, her2- tumors can be included in every cohort of the primary clinical trial"
    },
    "c6e231b0-ab51-4010-9d8b-d447af0a6306": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine. joint range of motion decreased cervical spine, ctcae is a disorder characterized by a decrease in flexibility of a cervical spine joint."
    },
    "feb0cfe7-6bcf-4e82-82b7-460f9cc66a18": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients whose metastasis is not quantifiable or whose cancer hasn't traversed to other body sections are not suitable for the primary clinical trial"
    },
    "0ad73758-1efb-46e4-85e7-57dbfb5eb96d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 79000/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. gastric lymphangioma is a lymphangioma arising from the stomach."
    },
    "d201eee8-33d1-4ae4-9540-b37fa07536e0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "people having extreme obesity can be accepted in the primary clinical trial"
    },
    "9e14f099-36f3-4672-b35c-022cc3279c98": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response . acute physiology and chronic health evaluation ii apch114 question clinical classification standardized character response is a standardized character response associated with the acute physiology and chronic health evaluation ii apch114 clinical classification question."
    },
    "cd7d5918-4280-48e5-a202-ad7d499a9334": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "a 3 week cycle is employed in the primary clinical trial for its treatment intervention. however, the secondary clinical trial doesn't apply a cyclical treatment approach."
    },
    "c9c7d71a-0b59-4277-87fa-32e427e37b40": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 40 year old patient with bladder cancer, absolute neutrophil count of 1200/\u03bcl, platelet count of 49000/\u03bcl, hemoglobin level of 75 g/l, and a life expectancy less than 5 months would be excluded from both the primary trial and the secondary trial."
    },
    "25b0a430-e35c-496c-8874-92be378b044b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses blood pressure level as a measure of effectiveness for physical therapy, whereas the primary trial studies the effect of vitamin b supplements on hemoglobin concentration in blood."
    },
    "df783937-3936-4f0b-a3f9-96a977497c6f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary clinical trial applies distinct inclusion and exclusion parameters for each of its two phases, in contrast to the secondary clinical trial that utilizes different sets of criteria for patients in good health and those with cancer."
    },
    "94aea5d0-2afb-40a4-b1c8-574c9f22225e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years. systolic blood pressure-for-age percentile is a measurement of an individual's systolic blood pressure in relationship to age, in comparison to a reference percentile curve."
    },
    "8d813fc8-01ec-4fb7-9191-f5ec7cb735fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "transmission scan is a scan to obtain data for use in making attenuation corrections.  intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously."
    },
    "7723c9e5-e80e-4ef6-b56d-ee26f8423d90": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine"
    },
    "42c07819-8022-4275-8484-6ed9db10115c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "different gels are being assessed for their effects on study groups in the primary clinical trial, while the secondary clinical trial is exploring the impacts of varying doses of a single treatment on its study group."
    },
    "d542b63b-a355-4a0e-8ec9-3c74bb1e0dcb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "only a minority of patients in the primary clinical trial had a complete response by the 24th week."
    },
    "bde45f5a-8909-48eb-b331-715583659654": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "over 75% of patients treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial underwent serious treatment-emergent adverse events"
    },
    "28e19ec3-f22a-4002-9020-02ef29c4386c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "in cohort 1 of the primary clinical trial, four additional patients experienced adverse events compared to those in the second cohort of the trial"
    },
    "eab52a37-149f-4b49-bf37-891e8e201956": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "difficulty understanding me in noisy room is a question about how often other people have difficulty understanding an individual in a noisy room. Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day."
    },
    "6f947c20-ecd9-4c6b-b1e3-5d536d4b33cd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "biological uncle is a male relative who is a sibling of either of the biological parents, and who share a common ancestor. all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group."
    },
    "3870c72e-cf9d-461b-9dfd-ef407d84e8cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "patients in the primary clinical trial undergo proton therapy and each group in the secondary clinical trial is prescribed 500 mg of fulvestrant to be administered through the transdermal patch twice a day."
    },
    "c17afde4-0fee-473c-b969-f7a4e89f049b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "the primary clinical trial is open for patients with estrogen negative, progesterone negative, and her2- forms of breast cancer."
    },
    "6ffedb4b-9ff8-445a-9e5f-872d54ca58fb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "adverse events were entirely absent in the conduct of the primary clinical trial."
    },
    "959eb0d5-7ac9-4c23-a10e-d1b720960a96": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "in the primary clinical trial, the influence of assorted radiation therapy is being evaluated on its study participants, whereas the secondary clinical trial tests the impact of varied quantities of the same treatment on its study group."
    },
    "c48550ef-7210-4834-9047-969a7898d519": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders were not common among participants of the primary clinical trial throughout the study"
    },
    "60c5afb6-a250-4e59-bccd-3729a9a97a6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the primary clinical trial employs a variety of methods for intervention administration."
    },
    "d432512b-0bb4-435c-b32c-7ae0564a63c8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "only a small percentage of patients on sunitinib + docetaxel + trastuzumab in the primary clinical trial encountered treatment-emergent adverse events"
    },
    "e5e7bbc4-cce7-41e3-b973-ac14fdff5600": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV. regulatory application identifier is a unique symbol that establishes identity of the regulatory application."
    },
    "145671c6-1b45-49a9-9fc7-8c65e8461115": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "Both cohorts of the primary trial recorded 0 Aes. cerebral artery is an artery which directly supplies the cerebral cortex and which has deeper branches that supply the underlying white matter."
    },
    "038e3e32-ae9c-4580-80b1-8d1c2d9d9bb9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients with a documented allergy to metronidazole or amoxicillin are accepted in the primary clinical trial, but will be excluded from the secondary clinical trial."
    },
    "0ed96bc9-14a3-4c52-b977-7cf507956191": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "dulbecco's phosphate-buffered saline is a buffered (ph range 7.2-7.6) saline solution used in cell culture applications. Candidates for the secondary trial study group receive weekly subcutaneous (SC) injections, whereas the primary trial participants do not receive any injections."
    },
    "7e57517f-4dc5-4457-bc4e-12f7faef37f4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "anemia, pneumonia and stupor were more common conditions among patients participating in the secondary clinical trial compared to the primary clinical trial."
    },
    "042bf558-479b-46c4-8553-016eb3bfcda7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial. hiv vaccine is a vaccine intended to prevent or treat infections caused by human immunodeficiency viruses (hivs)."
    },
    "191f4ac8-16c9-4be8-895f-4383c3d6f7b5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary clinical trial adopts a continuous, non-cyclical approach to intervention, while the secondary clinical trial runs a strict 2 week cycle treatment plan."
    },
    "c258ef31-d79a-4ddd-b3c0-81742b7f632f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the secondary clinical trial has a higher incidence of biliary colic and diarrhoea compared to the primary clinical trial."
    },
    "7df6c8c9-fb22-4197-aba7-d6540a691eec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "the primary trial uses cm and number of participants as its unit of measure, however, the secondary trial uses years and participant bmi as their unit of measure."
    },
    "6f0571f4-e1da-4732-9bdf-8c07bea059c1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial and the primary trial report their results using the same units of measure."
    },
    "d333f58a-6f8d-402c-a44c-36899a155100": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "mllt1 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt1 gene. More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial."
    },
    "5145d91d-ce46-4dda-961e-5bc7ddb6cda4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes. morphologic response is an evaluation of the morphologic response of the disease to the therapy."
    },
    "458e3e14-613b-40c5-a62f-5698a7d0c9b0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "patients participating in the primary clinical trial have, on average, survived for more than 2 years, though there is at least one instance in each group of a patient's death within a span of 2 years."
    },
    "9a7f95d5-8fb7-4f77-a921-00a2633e8cc4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "before the intervention, all 61 cervical cancer patients in the first phase of the primary clinical trial had undertaken their scheduled screenings."
    },
    "93118a13-cb16-4c4d-8f7a-ad0cb815e179": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "paired-end sequencing is a dna sequencing strategy where a single read is initiated from each end of a dna fragment. there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial."
    },
    "5d512914-5625-4734-b828-f20f41ef1a98": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "bothered by tingling hands or feet is a question about whether an individual is or was bothered by tingling hands or feet. the primary trial and the secondary trial have 0 recorded adverse events."
    },
    "576967ff-d2bb-4d1c-b2a1-8516ceb7a519": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily."
    },
    "c5fb4937-5177-47c9-8ce2-1fdec2a17942": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "57% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "62db4a46-c4ea-44a1-8dfc-12922748a7b0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "dietary nuts and seeds measurement is a determination of the total nuts and seeds in a nutritional product or meal, or a portion thereof. Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril."
    },
    "173793fc-ca3d-4296-a1c7-14fbde0a7b8c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial implements an intervention cycle of one month, unlike the secondary trial which does not embrace a cyclical treatment regimen."
    },
    "6261a694-0407-4840-8a87-3a0c6f9dea4f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX."
    },
    "0e0e3540-9217-435a-89d5-395a9c8af579": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions. germline genotype testing is an assay used to determine the genes and molecular markers present in the germline dna of an individual."
    },
    "a60074c0-d7a6-47cc-b980-ee1c0a791f66": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane"
    },
    "ce7d929e-90d6-4048-8124-e6df1a2f594a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "both cohort 1 and 2 of the primary clinical trial use the same paced breathing instructional cd, but cohort 2 supplements their therapy with twice daily practices and a weekly schedule of antineoplastic chemotherapy."
    },
    "a3c50e76-dadb-4b34-8245-0fe0de3d19cb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "doctor asked which treatment option i prefer is a question about whether an individual's doctor asked them which treatment option they prefer. the secondary trial and the primary trial results contain completely different outcome measures ."
    },
    "dc2d7205-d6ce-4d9c-96d2-e5a80fa906c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "recurrent malignancies, graft-versus-host disease, anaemia, cardiac failure and diffuse alveolar hemorrhage are common adverse events in the secondary trial than the primary trial."
    },
    "3d580aba-2e7b-44bc-a094-83f404ebbd6a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure. calm is a feeling of freedom from agitation or excitement."
    },
    "e173aa91-e6ec-4059-882b-7f015db6e3b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "regular exercise is not part of the intervention procedure for candidates of the primary clinical trial"
    },
    "2a05996c-d5fb-4aa8-9654-fb1d27180888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim."
    },
    "7f3a5491-e157-4fbc-a939-8478889c15dc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours. cognitive disorder is a category of psychiatric disorders which are characterized by a deficit in cognition or memory."
    },
    "2ac85077-e695-40c7-a9a9-d9901eceaeb2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "cyclophosphamide is administered to patients in both the primary and secondary clinical trials"
    },
    "26b78b55-df37-4058-a5ef-7634ae3f4fce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary clinical trial documented 11 additional adverse events compared to the primary clinical trial"
    },
    "9121985c-34cf-4378-b6ad-3b7a522c9ba5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "Patients in the primary trial and the secondary trial  suffered Thromboembolic events. ros1 rearrangement analysis is a procedure used to detect and identify rearrangements involving the ros1 gene."
    },
    "43e7f79b-7ebb-483e-ba3f-2cbd40c09d89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients with t3 n3 m3 tumors are permitted to take part in the primary clinical trial"
    },
    "292d0d60-e861-47b2-9484-53b0cc80ffe1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "the primary trial documented a higher number of patients experiencing chest pain than the secondary trial."
    },
    "a8932849-e870-422e-a81a-1b43d9622082": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group"
    },
    "98528323-fc08-45b9-8403-4005398ae3a7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the intervention for the primary clinical trial is administered orally, while the secondary clinical trial intervention is strictly issued intravenously, through needle or tube insertion"
    },
    "da125a54-e88c-40a5-8134-0bd021287c6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "the primary clinical trial accepts participants with measurable metastasis or whose disease has disseminated to various body parts."
    },
    "adfbe24e-4595-4fe3-88d8-8b5f01458993": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "contrasting patient cohorts have contributed to the results of the primary clinical trial and the secondary clinical trial."
    },
    "5fc57549-ece0-4ba6-9e5f-fc785aa16f28": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "ileal obstruction, ctcae is a disorder characterized by blockage of the normal flow of the intestinal contents in the ileum. There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial."
    },
    "91afbc39-fae6-483e-8b8d-dc4ce8d0ea5c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the longest pfs in the primary clinical trial survived for 7 months without disease progression or death"
    },
    "f27a6b09-cfd5-48ac-80d8-a70bd15bcb4d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "no adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 proportion of patients, apart from skin infections"
    },
    "c94fb60e-6f9e-48ed-b7b7-4468cb2aa6ee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "even after undergoing a mastectomy for stage iv bc, a woman might still meet the requirements for the primary or secondary clinical trial"
    },
    "5c2d33e2-9759-4060-9bdd-7ecda4123cda": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0 out of 7 the primary trial participants, and 0 out of 1674 the secondary trial participants experienced an ae."
    },
    "ce5dd10f-dad3-46a4-93de-fe57c657f6d9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "the primary clinical trial noted at least one incident of gastro-intestinal adverse event"
    },
    "8af457d5-2a04-43df-a661-2cf10402def6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "the primary clinical trial comprises fewer instances of anemia compared to the secondary clinical trial."
    },
    "94df8c14-d1c9-44cb-9f6d-1706044cbc9a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. millimole per gram of creatinine is a unit of substance concentration defined as the concentration of millimoles of solute per gram of creatinine."
    },
    "5caeaa69-840d-4a32-8279-416bbe1b570e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "only males are considered for participation in the primary clinical trial, while the secondary clinical trial only accepts females."
    },
    "54654fa6-2bce-4ed0-9cdf-ec6cf1de3bd8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "smoking individuals are disqualified from the primary clinical trial but could be considered for the secondary clinical trial if their alcohol consumption stays below five drinks daily."
    },
    "7a5cbc82-ec49-44f5-9c95-4c6475f3ee3e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "for the primary and secondary clinical trials, women with a new diagnosis of locally advanced er+ breast cancer who are considering mastectomy, are considered eligible"
    },
    "3caa266c-8ad2-4297-8de5-c65b78e94fd1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "every participant in cohort 1 of the primary clinical trial receives treatment for her2+, er+ and pr+."
    },
    "980339cb-7997-4209-b3b5-a4ddc3aff79e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the participants in the primary clinical trial are solely treated using a single type of oral medication, without the need for any surgical procedure, while individuals in the secondary clinical trial are administered a comprehensive treatment involving ten different types of drugs and multiple surgeries'"
    },
    "109ad38c-08ee-40ab-9a9c-65a4db8915b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial included different medications but are administered through the same routes. childhood leukemia is an acute or chronic leukemia that occurs during childhood."
    },
    "24523cd0-0fe8-455a-93b6-52367820879a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. chemo-zol is a treatment arm for patients receiving chemotherapy in combination with zoledronic acid."
    },
    "b03fe494-c036-4988-ae85-d5e548b57aea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients. exiguobacterium is a genus of aerobic, gram positive, rod shaped bacterium assigned to the phylum firmicutes and the family bacillales xii."
    },
    "bf8e8814-f9d9-422e-ab84-fea4f6c85ede": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman who has had lumpectomy would not be allowed to participate in the secondary trial or the primary trial."
    },
    "a6d3fa8e-c521-4843-b4e7-0a9983acfad0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "in both the primary trial and the secondary trial, orr is used as the primary efficacy endpoint. there is an insignificant discrepancy in results amongst the different cohorts of the primary trial, whilst in the secondary trial, arm 1 outperformed arm 2."
    },
    "5b8f9c72-6729-4b0f-9956-617021d55805": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients with ednocarcinoma are ineligible for the secondary clinical trial but viewed as potential candidates for the primary clinical trial."
    },
    "10a1605b-bfd7-4196-9912-19b28f271ebd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "both the primary clinical trial and the secondary clinical trial would consider a patient who has a primary tumour with a diameter of 33mm, determined by a clinical examination, and ultrasound."
    },
    "4493c1ed-668a-44d4-9b3e-767f597d4fa8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial"
    },
    "146a72f6-cba2-4056-94a2-21d2e05ac04e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of cohort 2 patients in the primary trial suffer Increased pleural effusion. nucleotide sequencing plate id number is a number that identifies a sequencing plate."
    },
    "bb41bccb-2552-42ba-a5df-981bead7b941": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "proctitis, ctcae is a disorder characterized by inflammation of the rectum. the secondary trial recorded 11 more Aes than the primary trial."
    },
    "d0bfc2f3-c94f-4d4c-ae87-9f9744bd767a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial. appendiceal carcinoma pt2 tnm finding v8 is appendiceal carcinoma with tumor invading the muscularis propria. (from ajcc 8th ed.)"
    },
    "2278c029-239d-43ba-9da2-440281e4fd0e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "invasive surgeries or the administration of neratinib are not part of the primary clinical trial for any of the cohorts"
    },
    "56ac01ed-cfba-4ab5-9082-dbe4a4418e9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "in the primary clinical trial, pr negative, er negative and her- are provided for cohort 1 while her2+ is received by cohort 2"
    },
    "87d7f63c-5fa5-4820-af0e-391ef8986199": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 50% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) ."
    },
    "a555a807-ceeb-4237-bd26-25e5a3db9128": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "severity answer is a response for a severity query. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered."
    },
    "a3191a50-4395-4bd8-a57a-5404fcfcd8c9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "individuals of all genders with proven er negative breast cancer can participate in both stages of the primary clinical trial."
    },
    "1f54533d-d67f-4863-90a6-ebc13199f27e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "no patients in the secondary clinical trial are given paclitaxel, cyclophosphamide, or pegfilgrastim"
    },
    "530798af-a5d0-4de8-8183-b2ef6068c90a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "radiation therapy is administered at the same intensity to patients in cohort 1 and 2 participating in the primary clinical trial, with each undergoing a spect scan."
    },
    "40dd90a2-f57d-467e-bc6c-c9a8a50a330f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "while members of both cohorts 1 and 2 in the primary clinical trial utilize the same rhythmic breathing instructional cd, it's important to note that the regimen for cohort 2 includes a practice frequency of twice daily along with weekly treatments of antineoplastic chemotherapy."
    },
    "e3fac563-e6bf-418f-b9b2-3bc6e3539da9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "the primary disparity between the two interventions in the primary clinical trial is the elevated usage of the radioactive tc99m sulfur colloid in intervention 1 compared to intervention 2."
    },
    "308848e8-55ef-4799-9251-7dc54ddf0ac3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 10 patients in the primary trial suffered Aes. microwave thermotherapy is any procedure in which microwave irradiation is used for the purpose of heating and destroying the surrounding tissue."
    },
    "93025279-295b-43e1-8dfd-40877e0288b4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "an explanation of the irradiation doses or a treatment cycle is lacking in the intervention portion of the primary clinical trial."
    },
    "b3b142e1-adad-429b-a7de-c852a74edaaa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the primary and secondary trials would not discriminate based on an individual's nationality, ethnicity, mental health status, or gender"
    },
    "e6fb96bc-d38b-484e-8d2a-fe14f943c599": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "eligible for the primary clinical trial are patients who had a severe anaphylactic reaction to herceptin treatment or did not respond to treatment with herceptin in the past."
    },
    "f9ad6db3-d2bc-474c-b666-a971749f6a83": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a patient who is 32 years of age, histologically diagnosed with stage iii breast cancer, has an absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bl, platelet count of 110,034/\u2248\u00ed\u00ac\u222bl, a hemoglobin level of 90 g/l, and estimates a life span of more than 8 months can be considered for both the primary and secondary clinical trials."
    },
    "558d240e-a51a-4c16-807e-db9031073242": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "there were multiple incidents of sudden deaths and unplanned hospitalizations in the primary clinical trial and in the secondary clinical trial."
    },
    "08793821-1888-49b3-9117-f0548482b5f9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "the secondary clinical trial's second cohort significantly outnumbered the second cohort of the primary clinical trial in terms of patients."
    },
    "da1010e7-b58a-438b-b93d-cc53b6d4476e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "7/73 the primary trial participants, and 10/1674 the secondary trial participants suffered an acute myocardial infarction "
    },
    "bbd40b2c-18a5-4ebb-9c6b-58dbc9a3ba59": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the zoledronic acid 4 mg group in the primary clinical trial exhibited a superior percentage change in betactx at week 4, surpassing the outcomes of the azd0530 175 mg group."
    },
    "d4045883-595f-4855-83ed-ca175a1d5aea": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "compared to the primary clinical trial, the secondary clinical trial experienced an excess of 11 occurrences of intestinal perforation"
    },
    "36a25cf0-0cca-457d-bd85-8ba89b2ff602": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "the primary clinical trial administers different daily doses of talazoparib: 1000 mcg for breast cancer patients and 25 mcg for ovarian or peritoneal cancer patients."
    },
    "2aac2b30-f74d-4435-b7e6-ec5cd5923da3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "in the primary clinical trial, only four distinct adverse events influenced patients, all found within cohort 2."
    },
    "29f65923-503d-402b-b0a3-150f741d8c2b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "confirmation of a her2 positive tumor through positive fish or ihc 3+ is mandatory for all individuals considering the primary clinical trial."
    },
    "11991b1b-f587-44fc-b675-603c06e680fe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary and the secondary clinical trials are not examining the effects of the same medications"
    },
    "2ca3ca9f-96ac-46e7-a1ce-873c580eff25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "1/4 of patients in the primary trial suffer increased pleural effusion and rapid disease progression"
    },
    "9a9bd166-1319-4a61-a8c2-e42ee878bf83": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort. cdisc adas-cog - executive function maze: errors is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) number of errors during the executive function maze task."
    },
    "630dd8d6-eff4-48f9-ac35-c1731b6c4a79": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial is examining surgical interventions, while the secondary clinical trial is assessing a meditation intervention."
    },
    "205d3c95-7288-4d9f-9a5c-edc7b09de79d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "the eligibility for the secondary clinical trial automatically implies eligibility for the primary clinical trial."
    },
    "9ed2eb80-3810-40fc-b26a-d2e93feb061d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. bus device is a set of electrical conductors designed to route data from multiple locations in a computer."
    },
    "705457d9-78b2-466d-9a3e-db4b11e99daa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the secondary trial has more adverse events recorded than the primary trial."
    },
    "38e4b093-2121-486f-bcfb-d250ea9978e4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "the primary clinical trial does not permit participation of children, whereas the secondary clinical trial does not specifically prohibit their involvement"
    },
    "bed229d6-8924-4753-a297-d49d4c128166": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the nationality, ethnicity, psychiatric condition or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. continuous surface ecg recording for non-human species is a continuous electrocardiographic (ecg) recording utilizing one or more surface leads in a non-human species. (cdisc)"
    },
    "fd32ab49-3994-4b45-aaf9-da79d4cae211": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 10 patients in the primary trial suffered Aes. severity of elevated lesion is an indication of the severity of a lesion that is raised."
    },
    "3ee347d0-3ba9-4dc8-8387-1fb15cf1e8b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor 5-10 cm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "1fb98883-c2ef-4acb-948e-aa497dc911ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "mycl gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the mycl gene. the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention."
    },
    "d0bcf0db-e64d-4aff-a63b-ba3571ebfad4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial. cardiac diffuse large b-cell lymphoma is a diffuse large b-cell lymphoma that arises from the heart."
    },
    "8548c61d-2a2f-4498-a7b8-828adbd9e613": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "for an entire month, every participant in the primary clinical trial receives an oral quantity of 100 mg/m2 lapatinib, administered twice daily."
    },
    "f58fda4c-f4fd-44a7-8a0f-5d3a16929709": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "one patient in the primary trial had an incident where a surgical incision reopened after the surgery."
    },
    "c752fd5f-8cf1-435e-8981-7323279b8130": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the secondary trial and the primary trial have completely unrelated outcome measurements. symptom interference score 2 is a subjective score of 2 on a scale that ranges from 0: did not interfere to 10: interfered completely."
    },
    "bca3c321-d798-427d-90a7-8c786d91947c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 50 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 2400/\u2248\u00ed\u00ac\u222bl, platelet count of 55,050/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 50 g/l, and a life expectancy less than 4 months would be eligible for both the primary trial and the secondary trial."
    },
    "a72ddea5-ee4b-4895-bd8c-10b4a143c3f8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE."
    },
    "06609fde-0f22-485a-ba1c-78c2677d8783": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  . microbacterium is a genus of minute, nonmotile gram-positive thermotolerant bacteria that are common in dairy products and the mammalian intestinal tract."
    },
    "bcc9a793-5002-4cd9-a5b7-af5a1ceca35a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments."
    },
    "53cf056f-91e1-45fb-a65d-7dff9a4b9bac": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "arm 1 of the primary trial indicated a higher operative time than arm 2, hence, the test group outperformed over the control group. concerning the secondary trial, a control group is compared against."
    },
    "41e2d2b1-9637-4667-b032-86c844a94b93": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial does not permit the participation of individuals who are 18 years old, whereas the primary clinical trial doesn't mention a specific age for participation."
    },
    "23ccac08-3764-496a-a790-4a1f5079909e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial. middle colic artery is an artery arising from the superior mesenteric artery that supplies the transverse colon."
    },
    "268ad1eb-851a-484a-873f-b54ab271b063": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia. hearing loss makes me feel different from everyone else is a question about whether an individual's hearing loss makes them feel different from everyone else."
    },
    "d1216971-8b18-427a-9f6e-de0fcddec7ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "only males of an unspecified nationality are eligible to enroll in the primary clinical trial, whereas the secondary clinical trial allows no restrictions on gender or nationality."
    },
    "33dc8fb6-d0a8-47e4-8052-4a32b5e0c459": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 25ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "1060fd94-b24c-43cb-884e-b10f70e0ea23": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "picalm gene rearrangement is a molecular abnormality indicating rearrangement of the picalm gene. Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial."
    },
    "f203176f-3d6f-4e37-a07b-9bcf409ed538": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "african-american participants in the primary clinical trial must remain inhabitants of texas for the entirety of the study."
    },
    "18f56de9-cf7d-467a-9e95-ca80d8c651a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there was one psychiatric adverse event in the primary trial, which affected more than 90% of patients"
    },
    "4c5fcde7-b882-4ea3-96ba-275af987ea60": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary clinical trial, for every case of hypertension and pancreatectomy, there were three cases of hepatotoxicity"
    },
    "d7f818fb-a383-41c3-ac12-788228db7cf9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. pretreatment is any relevant actions that were performed or occurred prior to a specific treatment."
    },
    "c22306e0-54e6-4324-abed-0a38d9c7f1b9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the unit of measure used in reporting results is identical for both the primary and secondary clinical trial."
    },
    "953b0337-0c43-42fb-a334-dad6900e2e0f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "in the primary clinical trial, it was noted that on average, patients in the paced respiration intervention group experienced more treatment emergent adverse events and serious treatment emergent adverse events than their counterparts in the fast, shallow respiration group."
    },
    "0a144293-fbab-4ba1-ad15-cf05a8624a1c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial and the primary trial results contain completely different outcome measures . gaoshan chinese is a chinese person from the gaoshan ethnic group."
    },
    "a7999375-da80-4839-940a-bec673fb119f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "while requirements for the primary clinical trial include being a female over the age of 18 diagnosed with any type of cancer irrespective of race or ethnicity, the secondary clinical trial is limited to patients with brca+ breast cancer."
    },
    "f4da0e5f-f0aa-4edf-a08c-afadd05360d5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "the primary clinical trial is open to patients with a histological or cytological confirmed diagnosis of non-small cell lung cancer or small cell lung cancer"
    },
    "0e1460ea-4f44-47ff-892a-e3190b498557": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "every adverse event noted for cohort 1 of the primary clinical trial pertains to the area of mental health."
    },
    "7b84b7dd-2143-41b0-bdf5-92c8ae314d17": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a diameter of 33000\u00b5m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "873c56c9-8544-45f4-bba4-308707b30b93": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "individuals diagnosed with follicular lymphoma or metastatic melanoma, based on immunohistochemistry, or intraductal carcinoma are disqualified from both the primary and secondary trials."
    },
    "6ad65d9b-8610-4f09-a760-caedb0a4037d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary clinical trial documented four more adverse events than the secondary clinical trial."
    },
    "69a761d0-c5b2-42f4-8cb3-271ac92fb006": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 of the primary clinical trial receives a different dosage of cudc-101 compared to cohort 2."
    },
    "644d3ae7-8d7c-40bd-8744-32f0d3311936": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "her2 + patients in cohort 2 of the secondary trial receive a higher dosage of trastuzumab compared to the ones in the primary trial throughout the entirety of the trial"
    },
    "58f223d4-6f38-4ea3-a6fc-5ed8599df2be": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "patients in the primary clinical trial reported a 5% reduction in ki67 cell expression after undergoing tak-228 and tamoxifen therapy for over 6 weeks"
    },
    "88fbd986-643d-4086-8091-e535d1970ab9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "both the primary and secondary clinical trials apply identical inclusion/exclusion criteria to all participants within their respective trials."
    },
    "49d0acfc-e7ce-45f5-8e45-08d55f3d0776": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the group taking 175 mg of azd0530 in the primary clinical trial encountered a larger shrinking of primary tumor size as compared to the group taking 4 mg zoledronic acid."
    },
    "37a51d40-4b39-4488-b818-7495917d50a0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "two participants from the second cohort of the primary clinical trial had an incidence of dose-limiting toxicity."
    },
    "f5ae88a3-a083-405e-b3a8-282018d7f013": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "individuals who have received antineoplastic chemotherapy, androgens, estrogens or progestogens treatment a month prior to the start of the study are not applicable for the primary clinical trial."
    },
    "6e6f3848-8d0e-47df-b2f3-1f09cf7da6e4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "the primary clinical trial and the secondary clinical trial did not experience any adverse events"
    },
    "017ff04d-5509-4f54-863c-10201351e15d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes."
    },
    "f7fc247a-5390-4e3f-9254-b16ecdda5851": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "16p13.3 is a chromosome band present on 16p The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort."
    },
    "d2c665aa-c13e-4d5d-95f8-d85c5c9f3ef9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "humiliation is a feeling of extreme embarrassment. More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2."
    },
    "d5786123-b433-4fdd-abad-4410de2695c9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "the contrast between the first and second cohorts of the primary clinical trial stems from the drugs and dosage used; 25 mg to 37.5 mg of sunitinib is prescribed to cohort 1 daily, whereas bevacizumab at 10 mg/kg is dispensed to cohort 2."
    },
    "776b3152-7fa5-480d-8235-cd6e472bf0a6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "adverse events were not reported in the primary clinical trial, while in the secondary clinical trial, any recorded adverse event had an impact on less than 30% of patients, excluding skin infections."
    },
    "a3ad31e2-9017-438a-bbc2-acab87940134": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 50% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "b94ebfcb-76f4-4d65-b5e1-ca56249f9f19": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "in the primary clinical trial, more than half of the patients in the second group experienced severe nausea following the therapy involving aprepitant, dexamethasone, cytoxan, and kytril."
    },
    "b71e8f1d-2910-4ac7-9aaf-e709679b0083": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the primary clinical trial's intervention involves just one drug, contrasting with the secondary clinical trial that demands the use of at least three differing drug types."
    },
    "bd587160-ea9e-41d4-b2c4-54815327d2fb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "patients diagnosed with histologically or cytologically verified metastatic and/or advanced solid breast tumor are eligible for the first phase of the primary clinical trial, and for all cohorts in the secondary clinical trial"
    },
    "bb80e4aa-fb7d-4455-8fff-95607f45dab0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "perfect match probe is a 25 nucleotide probe with an exact sequence match to its target used in analysis of affymetrix arrays. Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial."
    },
    "50b6f969-8637-47a1-ab63-9067b009bd2c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "every patient in the primary trial is receives a dose of 1 to 10 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy"
    },
    "526f99de-e377-42e4-a7ae-a42b797aa536": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "every participant of the primary clinical trial who received a placebo intervention went through episodes of emesis"
    },
    "475425c4-cfbf-4742-86ad-b09806d19687": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "in the primary clinical trial, the most recurring adverse event recorded is coronary artery stenosis"
    },
    "147c18a2-2ef0-4cef-9f99-bbcd79b12216": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "regular smokeless tobacco use for six weeks or more negative is a response that the individual did not use smokeless tobacco regularly for six weeks or longer. Morbidly obese patients can be eligible for the primary trial and the secondary trial."
    },
    "b6b819ce-57a9-4883-bcf9-f8c9a9bae83e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "pharyngeal stripping wave present and complete is a finding of a pharyngeal stripping wave present and complete. The the primary trial intervention section dose not describe the method of administration, dosage or cycle."
    },
    "ea893c02-e0eb-4789-bb1e-5501db3be7d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "flsi questionnaire question is a question associated with the flsi questionnaire. Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial."
    },
    "c44751aa-dc67-42de-a619-0f0834b88325": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. scheme is an elaborate and systematic plan of action."
    },
    "a5657dcd-1ee5-44f6-bb21-e718259c4b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial, and only a single case of Atrial fibrillation ."
    },
    "1e47ae4a-c57b-47fa-9b85-1b15ebdbf1fc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "small cell adenocarcinoma is an adenocarcinoma composed of small malignant cells. women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial."
    },
    "14236a59-be4c-4b17-844b-7c26a0650dc8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "cdisc adas-cog - word recognition: word 5 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) word recognition task for word 5 trials 1, 2, 3. 25% of cohort 2 patients in the primary trial suffer Increased pleural effusion."
    },
    "0d9f0b9b-fc32-413e-ba9b-f8d4e5c1ce4b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial. estimated date of conception is an approximate calculated date at which the conception event took place."
    },
    "11cb71ed-1304-42f0-b416-3679c3e9e1b3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy"
    },
    "a3ae0081-3bd8-408b-b11d-415711be2ddc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "mllt6 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt6 gene. the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid."
    },
    "55bcb170-5b8a-4a7d-b509-f2ab4a2f587a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "afraid of being rejected is a question about whether an individual is or was afraid of being rejected. Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2."
    },
    "789e28a0-3116-4b32-be0f-807ffce7f552": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "thyroglobulin antibody negative is an indication that antibodies that recognize thyroglobulin have not been detected in a sample. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial."
    },
    "fae9affd-c763-49c0-ae6d-88852f5774af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "proficiency testing challenge is any individual test given to a laboratory as part of a proficiency test. Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine."
    },
    "53e2327a-6a30-49d0-a5eb-74cc5141abbb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "None of the primary trial candidates have to perfom regular exercise as part of the intervention. sulfoxone is a water-soluble sulfonamide antibiotic used in the treatment of leprosy."
    },
    "73bc9024-02aa-46b8-913b-c2739a3a66e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "the primary clinical trial is open exclusively to female patients of a certain nationality, while the secondary clinical trial has no such restrictions."
    },
    "5db44a07-6d17-4fa9-9060-1f1af4aaf3af": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "at least one gastro-intestinal adverse event was recorded in the primary clinical trial"
    },
    "4886038c-1def-4bbb-a9c7-dab5784cd471": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "esophageal cancer surgery is a surgical procedure to remove any cancerous tissue in the esophagus. Patients with measurable tumors in both breasts are excluded from the primary trial."
    },
    "cca75efb-d5e0-4dba-b9ca-4f59238abb59": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. study agent function code is a coded value specifying how this agent is used in the study."
    },
    "04dfaa5a-359d-4aba-a56d-4b19f041ce39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. thick filament is a myofilament composed of myosin."
    },
    "9a137ed3-f905-4367-988c-002fabb77140": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "only 5% of patients in cohort 2 report increased pleural effusion within the primary clinical trial."
    },
    "64a7bb90-c51d-4f6b-942e-55322c25e1b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "all participants in the principal clinical trial's study groups will be subjected to identical 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging procedures, but the first cohort will be administered a marginally higher dose of 18f-fpprgd2."
    },
    "5d1e61bb-42f4-430c-843a-c6e80d121655": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "thyroid gland schwannoma is a rare schwannoma that arises from the thyroid gland. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often."
    },
    "eff637a6-8d7c-47e9-bcba-b4b52159aa4d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "in the primary trial, the amount of time spent in operation was longer for arm 2 than arm 1, suggesting superior performance of intra-operative mammography over the standard mammography. in the secondary trial, the absence of a control group means any comparisons are not feasible."
    },
    "81521795-13b4-46d4-a03e-51ab823e9756": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include trastuzumab"
    },
    "99857433-fe08-4f54-bb86-91b1b1e8f5f4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the idfs rate was lower in the neratinib group than in the placebo group in the primary clinical trial"
    },
    "b7bc3cb1-b7f4-4276-bfee-9f984109d191": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 0.001 g of talazoparib daily, as part of the intervention"
    },
    "2690d684-0905-4af0-8113-fffec885de77": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "a patient suffering from acute bacterial meningitis is capable of participating in the primary clinical trial"
    },
    "985ff367-3936-4e38-92e7-45e1cb9f24ee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "the adverse events noted in the primary trial are all related to psychological distress; this is not mirrored in the secondary trial."
    },
    "ae5ec938-2ef4-4533-9ab9-3314de8525a1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "208 participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 156 from the nacl 0.9% 3l group"
    },
    "763a61cc-c267-4536-8cfe-a4f97a461e07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "in both the primary and secondary clinical trials, several participants encountered tumour lysis syndrome."
    },
    "f6ce8f5f-f226-4435-9209-9bf54ac7cbaa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "a 7-week duration of tak-228 plus tamoxifen treatment in the primary clinical trial was linked to an increase in the percentage of cells with ki67 expression."
    },
    "32ce7a8e-20c4-42d9-a4d4-e3b5d580331e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "mind is as sharp as it always has been is a question about whether an individual's mind is or was as sharp as it always has been. Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) ."
    },
    "d8fa557b-e20a-4b49-be9c-b55a6bde385a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial measures the average nap duration of its patients, whereas the secondary trial identifies the number of people who experience side effects related to treatment."
    },
    "6b8445e6-9bc6-4a57-ab24-05d99e082061": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "in the primary clinical trial, fewer participants enrolled in the paclitaxel plus bevacizumab plus gemcitabine group than in the paclitaxel plus bevacizumab group"
    },
    "6b3619d3-21ea-437e-bb0f-f124cf636ca5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15"
    },
    "9c7ccf99-0768-4a8a-bde9-bb3cb9b65c67": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "no infections and infestations cases were registered in the primary clinical trial."
    },
    "dfc6cbf1-1aa5-4bed-ac39-bbd3a460518b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "evidence of er positive breast cancer is required for males to be eligible for both phases of the primary clinical trial."
    },
    "0d63f301-9546-466f-aee9-78eea578b57f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the primary clinical trial and the secondary clinical trial employ disparate units for quantifying the same outcome measure."
    },
    "dce179aa-b35d-42dd-b97b-4c76f2e4d8b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "every adverse event documented during the primary clinical trial was linked to the patient's musculoskeletal system, a factor not shared in the secondary clinical trial."
    },
    "97f2cf47-a82b-4d00-9918-a4b400d2ca5e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "in the primary clinical trial, the adverse events noted were all connected to the musculoskeletal system, contrary to the secondary clinical trial."
    },
    "9c2ca035-d531-4d44-876e-6ed9f2d3f76b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results."
    },
    "cedade64-046d-4e90-ad04-9b0a497fc534": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2. regimen used to treat penile cancer is any regimen that can be used for the treatment of penile cancer."
    },
    "8ee8670b-6200-4309-8fd6-545572945b7c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event. fissure is a long narrow slit or groove that divides an organ into lobes."
    },
    "ac265234-e392-49b4-b46b-a0a54e54f88b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial. laryngeal hemorrhage, ctcae is a disorder characterized by bleeding from the larynx."
    },
    "58161b30-e890-45e5-822d-3172f884ed40": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "in both the primary and secondary clinical trials, ct scans and mris are key components of the medical interventions"
    },
    "8e881af0-4e26-43c9-93e8-5e3397f857e1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "gist grade cannot be assessed is a gist grade that cannot be assessed. Morbidly obese patients are eligible for the primary trial."
    },
    "73feb437-66f3-44fd-8d9c-ab3204e6eac3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "Several recorded Aes in the primary trial occurred to cohort 1 patients"
    },
    "06a1adac-dee0-4d9b-83c6-0996391e40d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine "
    },
    "635f6674-3151-46bc-8344-33ab60b59bd0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy could still be eligible for the secondary trial or the primary trial. recto-vesico-vaginal fistula is an abnormal communication between the rectum, bladder, and vagina."
    },
    "02adb741-194d-4472-b4b8-a3b546dc0484": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "patients participating in the primary clinical trial tended to have a higher incidence of pericardial effusions, while corneal deposists were more frequently observed in the secondary clinical trial."
    },
    "06b8d395-0fe7-4206-b118-5e478779cce0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "There were no patients in the primary trial or the secondary trial that suffered at less than 3 different AEs."
    },
    "0af975f2-157a-472d-a30e-9ad614342146": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "polyneuropathy was the most frequent adverse event reported in the primary clinical trial, the secondary clinical trial had no recorded aes."
    },
    "87c2f042-077b-4d49-80b0-1603a137520f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "8q21-q22 is a chromosome band present on 8q There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial."
    },
    "c0267bfa-8985-4097-b6ba-0b908f4c46c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial. protein region is an informal header for somewhat informal parts of a protein molecule."
    },
    "a1e4f5de-9b44-444e-8eff-ae7b040c6f6e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "women with triple negative stage iii breast cancer, who have undergone mastectomy are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "93ff9af3-c812-4449-b311-06418b283233": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the primary clinical trial involves the administration of yttrium-90 glass microspheres and theraspheres through radioembolization, whereas the secondary clinical trial utilizes 560 mg of ibrutinib and 10 mg/kg of medi4736 twice a day for a one month period."
    },
    "e8b7263b-fd07-4d78-915f-e1b17bdc1390": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs. anal fibroadenoma is a benign epithelial-stromal neoplasm that arises from the anus and resembles the breast fibroadenoma."
    },
    "2fc3e471-39c1-4f8a-804f-6b2ad5f711c9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "in the primary clinical trial, gtx-024 of 1mg dosage resulted in lean body mass gain in every patient, over a span of 4 months"
    },
    "0ef97135-5f94-407d-a48d-f40cd6272ed5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "neither the patients in the secondary trial nor the primary trial exhibited conditions of anemia, pneumonia or stupor."
    },
    "88490a99-ea34-4aa1-a838-b3a1cffa41a0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "an incident occurred in the primary clinical trial where a patient's surgical incision came undone after the surgery."
    },
    "8c14522c-67de-490a-9be1-1c16d9fca742": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the primary clinical trial provides the total count of participants studied, however, the count of participants in individual cohorts is not given"
    },
    "6032e3ab-9d85-4c3b-aeb1-a93f45ba4735": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "there were no cases of shingles reported in neither the patient cohorts of the primary trial nor the secondary trial."
    },
    "bd89597d-82f5-461f-aa6e-ef215afcc6a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "participants in the primary trial and the secondary trial both receive pembrolizumab and sunitinib at equal frequency."
    },
    "88e7acab-bd9d-4e6c-a241-c538501824e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "perform chores is a question about an individual performing chores such as housework, shopping groceries. CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle."
    },
    "9cd25233-1d76-4d0d-a571-ce8fee279757": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial."
    },
    "78f50c70-09e5-4328-8ddf-f7e743527132": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "advanced non-functioning neuroendocrine tumor is a non-functioning neuroendocrine tumor that has spread extensively to other anatomic sites or is no longer responding to treatment. the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans."
    },
    "ed2174d9-375c-4ed0-b880-56d13f6fb069": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants. ionizing radiation-related malignant neoplasm is a malignant neoplasm arising in an anatomic site exposed to ionizing radiation."
    },
    "21a1ddb1-0d37-41e5-a08f-a7e9dc5b15ef": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the primary trial and the secondary trial are studying different drugs, at different dosages, and with different outcome measurements."
    },
    "304f8d66-90f2-40cc-9f18-77c2b8471a40": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary clinical trial provides its participants with full breast radiation therapy, while every group involved in the secondary clinical trial is given 500 mg of fulvestrant tablet to be consumed bid."
    },
    "a1e54b35-4b25-4194-8a44-7c8e587a1c83": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "in the primary clinical trial, intervention 1 and 2 use equal doses of radioactive tc99m sulfur colloid."
    },
    "9f5587e3-ff70-42fa-9ddf-e59fc2729d77": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "complete disability is obligatory for participation in the secondary clinical trial, in contrast to the primary clinical trial where it isn't a requirement"
    },
    "09684ae5-162a-43ba-9735-6c9bce05cd5f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary clinical trial assesses the count of patients experiencing adverse events linked to treatment, while the secondary clinical trial evaluates the average duration of sleep in its patients."
    },
    "c6039c02-dcb4-433b-a0a5-4d6beb33b8fa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "there is a lower total count and variety of adverse events documented in the primary clinical trial compared to the secondary trial."
    },
    "e6e3ecde-9d81-41a2-849e-de26c1b9bafc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system."
    },
    "43ee44cf-35e5-4830-ab1f-d4f040487801": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient, who was diagnosed with a disease other than ild/dpld within the past three years and has a life expectancy of over a year, can avail of the primary clinical trial"
    },
    "c5fed4a9-da6c-4dcb-b191-930bca7e0ce7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "in the primary clinical trial, the placebo and allo-mscs interventions are delivered through separate transendocardial injections."
    },
    "f4d73533-5e6a-403c-ad63-3882890b7e94": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "we are unable to make a comparison of the adverse events in the primary clinical trial and the secondary clinical trial, as there seems to be no record of such events for the primary clinical trial."
    },
    "c81fad5d-aa52-4147-a724-984e7d9c4cc3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "adverse events that are a result of the secondary clinical trial do not occur in patients from the primary clinical trial."
    },
    "61afd69d-529d-49e9-b607-007414946b6c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "urinary tract infections were not reported among those participating in the primary clinical trial"
    },
    "f9f0ba74-16e0-4790-afa0-b7616b256e5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial"
    },
    "437a782b-7dc2-4904-ac68-3a532b98f2e2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "out of the participants, 5 had experienced three or more adverse incidents during the primary clinical trial"
    },
    "a911fcee-0621-4f06-a511-b8323ab8440c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies."
    },
    "707a6e1b-520e-4052-bbd8-c932c4cc65e2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "the 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging protocols will be applied uniformly across all study groups in the primary trial."
    },
    "c04ed14d-5ed2-46a6-9b0c-6a30a3b9a7b2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "cholelithiasis was less common in primary trial participants compared to the secondary trial participants"
    },
    "046aa480-39cc-4333-a815-bc4ec3ebfa7d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "the primary clinical trial is exclusively for asian patients."
    },
    "3acf4a18-725c-444e-bf7e-e3eb9a0878e7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "neisseria is a genus of gram-negative, aerobic, strongly oxidase-positive diplococci bacteria in the phylum proteobacteria. the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort."
    },
    "4b5b9e75-1690-4544-86de-d4c0ac02cf57": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group. non-tumor cell derivative vaccine is a whole cell vaccine derived neither from patient tumor cells nor tumor cell-lines."
    },
    "50c57a74-1e0e-45fe-8a00-217ff1322d99": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "both the primary and secondary clinical trials accommodate current smokers."
    },
    "7326be65-0450-4fb7-88d3-5d926d65db74": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "only patients prescribed gtx-024 3mg during the primary clinical trial resulted in weight gain, particularly in lean body mass."
    },
    "44412911-1f34-4841-a795-86eed5a209d7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "All Infections and Fever cases in the primary trial were for patients in cohort 1."
    },
    "2bd78232-4872-4d66-ade9-836190b86e1d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial"
    },
    "28368708-e1e6-416e-8119-0d2712a89380": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients with severe obesity may participate in both the primary clinical trial and the secondary clinical trial."
    },
    "b6b71c5a-8d4b-4ae1-9b57-45a5c9112543": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "subjects in the primary clinical trial undergo a medication regime of subcutaneous doses once a fortnight for a year."
    },
    "f06f2517-d0fb-4494-a044-fd626c78187f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the total adverse events recorded in patients were the same for both the primary clinical trial and the secondary clinical trial."
    },
    "61547cc4-08c1-41c9-94f3-c45ebba67e5b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "preventative therapy clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered preventative. Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial."
    },
    "50ddb312-6c5e-476a-891e-95409d7239c5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "primary clinical trial and secondary clinical trial are focused on evaluating the time to progression (ttp) in patients."
    },
    "10867d73-4951-42cf-9bdf-2a0f6d27ff10": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "the incidence of ascites and pneumocystis jirovecii pneumonia was exactly the same in both primary and secondary clinical trials"
    },
    "7f3b898a-e7d1-4cc2-bf62-a8366ea7cf80": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "coat dosing unit is a dosing measurement based on the coat unit. the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day."
    },
    "490ea7b9-ad4e-4741-8dce-65a050f9a776": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "all participants in the primary clinical trial showed partial or no response by the 24th week."
    },
    "5933fba5-8565-47ef-a491-1a1531dc1ab3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 3 times shorter than the intervention detailed in the primary trial."
    },
    "5051b4e9-21e7-4fa8-a602-de48b103fa19": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "age in days at function test is age of subject (in days) at the time of the function test. warfarin based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial."
    },
    "af6ce175-76e3-4d1a-ab77-6c7f3a258580": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "cohort 2 of the primary clinical trial reported no instances of death or hospitalization"
    },
    "1b48209c-3fcd-40d3-a647-f54b7e6179d2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "if a patient meets all the requirements for the exclusion and inclusion in the primary clinical trial, the conclusive decision about their participation rests with the healthcare professionals conducting the trial."
    },
    "aebbea11-2bed-406c-a63e-02ca9eede262": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope. malignant fundus neoplasm is a primary or metastatic malignant neoplasm that affects the gastric fundus."
    },
    "4c30a588-032f-4b8c-b00a-ee27f8f64b50": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "vaccine administration is a requirement for participants in the primary clinical trial"
    },
    "8d728674-1111-495d-ae90-59ced10163a4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel. hard to pay attention because of tiredness is a question about whether an individual has or had trouble paying attention because they are tired."
    },
    "b37fc6a3-d231-478b-a18e-aa3439a972f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "more than half of the primary clinical trial participants showed a decrease in circulating tumor cells after months of low-dose standard chemotherapy"
    },
    "b11dea7c-ef4b-4042-9267-40934719c44e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the secondary clinical trial presented anaemia as the most prevalent negative reaction, implicating over 5% of the participants, whereas the primary clinical trial reported no such adverse events."
    },
    "302997fe-466a-4efd-8801-5b07236a5e0c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary clinical trial necessitates the administration of vaccines to its participants"
    },
    "7d8d8409-5282-464a-a666-849f3eb36b6e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "both the primary trial and the secondary trial employ unique inclusion and exclusion criteria for different patient groups during their conducted phases."
    },
    "2d84efa0-fd43-40fa-a809-f9be6d197371": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "in the secondary clinical trial, patients that have recently undergone chemotherapy or radiotherapy, those with unstable angina, or those with a neuropathy rating of grade 2 or above, are ineligible. these conditions do not preclude participation in the primary clinical trial unless the patient has non-healing surgical wounds."
    },
    "f300c26a-9ae0-4474-8fb3-34435ecdcf11": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "no participant in the primary clinical trial or the secondary clinical trial receives enteric-coated tablets"
    },
    "96eb2d8a-35d7-4627-9279-5f16363a2e50": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "uterine corpus neuroendocrine tumor g1 is a very rare and well-differentiated neuroendocrine tumor that arises from the uterine corpus. Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia."
    },
    "04a0ccc3-e60d-462a-a31e-802e0f54e1d8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "according to the primary clinical trial, taking tamoxifen 32 mg po daily for seven days before breast cancer surgery, and for fourteen days after, has led to an average reduction of tumor sizes by 40%."
    },
    "946b0905-73d8-4e13-867f-12ea3c67c52e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 1 over 3 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 30 weeks of the study"
    },
    "f886baee-f1c6-4887-8068-5c779c6ebb60": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "the individuals in group 2 of the primary clinical trial are administered 0.5ug/kg of dexmedetomidine (5ml), while in the secondary clinical trial, no dexmedetomidine is given to the patients."
    },
    "cff79719-40b1-43fb-bbdd-43dbe9c4191a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the same patient characteristics are evaluated in both the primary and secondary trials."
    },
    "7febdcf0-e8ff-4511-a96b-c160e3dd127e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "in comparison to the primary clinical trial, the secondary clinical trial had a significantly higher number of patients who experienced aes."
    },
    "bfef0d2b-81c0-4f5f-bf91-a313a0a2dcbb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "every participant in the primary clinical trial encountered a reduction in cognitive capabilities, particularly members in the ovarian function suppression group"
    },
    "48b5fa7f-b2c7-41f9-adc5-ca55ae919f3d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "different patient features are evaluated in the results of the primary clinical trial and the secondary clinical trial."
    },
    "db493601-5dae-4077-a455-582cd9e28315": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "qualification for the secondary clinical trial ensures the identical qualification for the primary clinical trial as well."
    },
    "b9b156ee-526a-49ac-aa99-78f02a24dbaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial."
    },
    "086c9c1a-de79-47f1-b75d-32c7a16716ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "patients with stage 1 cancer are eligible for the primary clinical trial and the secondary clinical trial, without a need for a written informed consent."
    },
    "72130361-5d83-4dbb-98ce-8e9a6f2541e4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "childhood pineal parenchymal tumor of intermediate differentiation is a pineal parenchymal tumor of intermediate differentiation that occurs during childhood. the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy."
    },
    "28f840e3-3970-4ec7-ac46-d0503d56ee57": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria). waiver is a formal statement that says a right, claim, law, or rule can be ignored."
    },
    "95f4ce83-19b7-424d-93b9-27a6c3fe8c6d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "neither breast cancer patients nor ovarian/ peritoneal cancer patients in the primary clinical trial receive talazoparib."
    },
    "c1f0b925-6d1f-48ba-ada3-296bd69573f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. serum phosphate measurement is a quantitative measurement of the amount of phosphate present in a sample of serum."
    },
    "fd173cdb-c283-4b74-922e-583a531edcef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration. atopobium is a genus of anaerobic, gram positive, cocci shaped bacterium in the phylum actinobacteria and the family coriobacteriaceae."
    },
    "8fe01416-c839-4ffc-bd21-25d158d502b8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "no patients in the primary clinical trial experienced a re-opening of their surgical incision post-operation."
    },
    "a1cf2da3-a2a8-4fa1-9812-5f50a75994ad": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. thymus lipofibroadenoma is a benign thymic tumor morphologically resembling fibroadenoma of the breast."
    },
    "ac4c15e0-c711-4583-a9d4-1dbc682cd7f7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "during the primary clinical trial, the initial assembly documented one instance each of anaemia and febrile neutropenia but recorded no instances of pancytopenia."
    },
    "86408afa-a3ca-41ee-ac9a-94aa3f2b203d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "even when a patient adheres to all the exclusion and inclusion terms of the primary clinical trial, the final decision for their participation is in the power of the health practitioners overseeing the trial."
    },
    "afeed01c-f21a-4926-9028-d2b9a2226c9f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "the primary clinical trial does not employ paclitaxel in any of its interventions"
    },
    "fcedf2b8-b97d-4a57-8ccc-e77c53900b3c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "the incidence of recurrent malignancies, graft-versus-host disease, infection, altered mental status, and diffuse alveolar hemorrhage were lesser in the adverse events profile of the secondary clinical trial than in the primary clinical trial."
    },
    "e4b448ba-15ad-4cf8-9343-782d45166891": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement."
    },
    "a5c140f2-b2e5-43a5-9a8d-268806caa311": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients diagnosed with either non-small cell lung cancer or small cell lung cancer, confirmed through cytology or histology, can participate in the primary clinical trial"
    },
    "e5a8197e-dc1f-4258-9da2-f530eade84fe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "feeling nervous, anxious or on edge is a question about whether an individual feels or felt nervous, anxious or on edge. the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1."
    },
    "24480821-2a6d-4359-bfb8-348ca85dffbb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial does not report any results for the LBH589 and Lapatinib cohort. trovirdine is a thiourea non-nucleoside reverse transcriptase inhibitor."
    },
    "539bf07d-199d-4c9b-af16-5f314962bcfc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin."
    },
    "b5e896cf-e971-4fac-8dc6-a19e2c2d0a72": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial"
    },
    "7ce21c0f-ad55-4ff7-a180-5e418fe9afc8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are not eligible for the secondary trial, however they are eligible for the primary trial."
    },
    "90cecb95-9f89-4747-81c3-96545edaf3f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "No two patients in the primary trial suffered the same type of adverse event."
    },
    "f3a4ac87-2a6b-476f-91e2-b056e231f20a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "the patients in cohort 1 and 2 of the primary clinical trial demonstrated a clear pattern for the expression of the set of 40 evaluated genes"
    },
    "d620b526-d227-42a4-a6cc-800df41f854a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "approximately 50% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "6e3e407e-901f-443e-9785-d19b184ff462": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "throughout the primary clinical trial, not a single patient reported experiencing the most unbearable pain for ten consecutive weeks."
    },
    "b753305c-ea26-492d-b45e-760dc4f69b9a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. hyperdiploidy is a chromosomal abnormality in which the chromosomal number is greater than the normal diploid number."
    },
    "b9f262d7-23e5-42d1-9020-0e516ce3505c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial employs hormonal approaches as a form of intervention, while the secondary clinical trial is testing the effectiveness of acupuncture."
    },
    "8d502fe8-e084-480e-94ee-30ce69aca083": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "all ae types in the primary trial affected fewer than 1/10 of patients"
    },
    "f312eb67-0141-4a7b-a9a4-476a92c32484": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the doses of lenalidomide used in the primary trial are equivalent to the doses of lapatinib used in the secondary trial for intervention 1."
    },
    "9730b1a6-e9cd-4fd6-b1e4-9916b5903c63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort."
    },
    "96dedf4b-abc0-41ea-b12a-9a8afce9708d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, the placebo is taken through rectal suppository, daily while the drug memantine is given through sublingual route, twice a day."
    },
    "ee74c3c1-33c4-4b0a-81bf-a2ed3ec7e161": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2. trabecular meshwork proliferation is activation of abnormal cell growth within the trabecular meshwork of the eye, usually due to injury."
    },
    "2f917847-cad3-4744-891d-33ebe29f257b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "different pharmaceutical interventions were involved in the primary clinical trial, all being delivered via the same pathways."
    },
    "3558390b-24a7-45e7-84f1-f512e669dcef": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the secondary and primary clinical trials showed a complete absence of recorded adverse events in their cohorts."
    },
    "3c2830d4-9341-4c0d-8ed3-51eb47d2cd17": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "the frequency of cholelithiasis in both the primary and secondary trials were the same"
    },
    "4d604e71-ced3-43a1-baf7-276573a3a901": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer. extent of agreement or disagreement on religious matters is a question about the extent of agreement or disagreement between an individual and their partner regarding religious matters."
    },
    "38791cb5-fc64-49a6-8db8-69da6c37f327": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. oxygen analyzer device is a device designed to measure the concentration of oxygen in a gas mixture."
    },
    "0bb7dafe-391e-4adb-a9fe-ac3717421ae8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman post-mastectomy for stage iv bc may still be considered for recruitment in either the primary or secondary clinical trial"
    },
    "8aca5f0b-c998-4e51-9e53-e23294e61867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally."
    },
    "b56f166c-a9b7-4990-bfb8-d13f0e89f76d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the protocol in the primary clinical trial consists of at least 3 different drugs, whereas the secondary clinical trial involves using only a single medical product."
    },
    "827af363-cfd3-4233-9029-e8c7e053c661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "There were more adverse events observed in the secondary trial than in the primary trial."
    },
    "c6e42e3e-8900-43bb-b1de-61f1d1dcf075": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort. t(11;14) positive is a cytogenetic finding indicating that the translocation t(11;14) has been detected in a sample."
    },
    "ce1887bc-e9b2-4c21-a5b8-dcbe59d3503e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial documents modifications in pain levels, and the secondary clinical trial observes changes in the bone mineral density (bmd) of the lumbar spine from the beginning to the end of nine months"
    },
    "47d5620b-1b48-4a55-920f-35879c6e85eb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "all patients in the primary clinical trial are not given any doses of docetaxel, doxorubicin and cyclophosphamide."
    },
    "fef8b2f0-3e1f-46de-a53b-f1dffde794e6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "the primary clinical trial and the secondary clinical trial both enlist participants based on their gender; male participants are considered for the primary clinical trial while female participants are favoured in the secondary clinical trial."
    },
    "82d350f6-9864-4329-bd5b-8d8155170569": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "esophageal hodgkin lymphoma is a very rare hodgkin lymphoma that arises from the esophagus. None of the primary trial candidates have to perfom regular exercise as part of the intervention."
    },
    "5c253fd8-303a-4b91-b21f-e7e77c30f14a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "There are 7 more participants in cohort 2 of the primary trial than in cohort 1. other errors is a response indicating that an individual made errors not listed or elsewhere specified."
    },
    "dc60304d-6fd2-4b12-9108-b5ce78454d42": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial"
    },
    "0d8cdde2-046a-4684-8af5-38cd82935901": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "pattern is an arrangement of objects, facts, behaviors, or other things which have scientific, mathematical, geometric, statistical, or other meaning. None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort."
    },
    "c51494ed-aee9-4219-b46b-ed47bc261788": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates. hose line device is a flexible tube designed to carry a fluid."
    },
    "01982a9a-3299-4be8-8201-0397508b2f88": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "numerous patients in the primary clinical trial felt no discomfort at all throughout the 10-week study."
    },
    "8be0e7b4-f74d-4205-a543-1247762bb467": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial."
    },
    "86ee12d2-2095-4ece-a7d6-f9494b51f3a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention."
    },
    "10292ba1-dd1f-4191-b534-331f39583181": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial"
    },
    "d4bd0ed2-5753-470c-b804-00bbebdfc2d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "the primary clinical trial and secondary clinical trial do not accept patients who have a history of pulmonary embolisms and currently possess breast implants."
    },
    "96042d49-2f5a-44af-8899-2d5ba24c0f6f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products"
    },
    "66fb10cd-ce81-4c54-aa97-b7167d3115d8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "the presence of 1 cerebral metastasis located within the frontal lobe does not hinder participation in the secondary clinical trial, but those with such a diagnosis are disqualified from the primary clinical trial."
    },
    "ca97cc92-91e7-426a-b48f-d1729f13ee13": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the most extended pfs in the primary clinical trial endured 4 months without disease progression or death"
    },
    "16808fde-01bf-40dd-ae6e-7f208b51636d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "both cohorts in the primary clinical trial receive the same vaccine, not specified to be either pneumococcus or influenza."
    },
    "8c51b6e1-ee26-44a5-b63b-3c180b7dddd2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "there were profound differences in the results from the groups in the primary clinical trial, while the reflexology group and control group in the secondary clinical trial displayed contrasting results."
    },
    "6582c5f8-507a-459d-82e4-b0b8e80be34d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "in the primary clinical trial, 1000 mcg/day dose of talazoparib is administered to breast cancer patients while a considerably lower daily dose - 25 mcg, is used for ovarian or peritoneal cancer patients."
    },
    "585bf6db-16c7-4433-8c98-30a6b5a88fc0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "the primary trial involves administration of alisertib in both cohorts, whereas in the secondary trial, no cohorts are given this treatment"
    },
    "40818dd2-4940-4543-905a-35a3295b3009": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2. external canal is a tube extending from the middle ear to the outer ear."
    },
    "c828ba65-0c7b-4aac-b0a7-35ca653b6e82": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 50 mg per day"
    },
    "f5231a1f-83ff-458f-9dbd-40bd55daae92": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial introduces patients to photodynamic therapy requiring no injections, whereas the secondary trial mandates the injection of 500 milligrams of nivolumab bimonthly."
    },
    "0f0f75f2-7da8-4705-b260-62c5f542b91e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial only five cohorts recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 500 mg dose of pdr001, and 6 mg/kg dose of mcs110."
    },
    "b799b56b-51cd-4200-852f-f80a347de63e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "participants for the primary clinical trial must be between 18 and 60 years of age, and not underweight or overweight."
    },
    "7482499c-6836-4f68-83f4-4af09b14d566": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "There were no deaths or Hospitalizations in cohort 2 of the primary trial"
    },
    "3896374f-f5e1-41a2-9ec0-c108cc3f3ad1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "maculo-papular Rash was a common adverse event for the primary trial participants. operator is a person that operates some apparatus or machine."
    },
    "bd6fc353-2823-4e35-b811-a19c8318fda4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "the primary clinical trial had a larger participant count than the secondary clinical trial."
    },
    "8393ad3d-8521-4316-b69e-64910d8af5e7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the secondary trial and the primary trial report results using the same Unit of Measure."
    },
    "5887ed1d-aa43-4a18-be3a-9141b675d5af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "159bf774-0488-4260-94ed-e106c3e02bf7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "cohort 2 of the primary trial reported fewer incidences of palpitations, pericardial effusions and abdominal pains compared to cohort 1 of the secondary trial."
    },
    "86da40aa-8994-4fb7-8628-098d347b5864": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study. east frisian low saxon language is a west low german, friso-saxon dialect spoken in the east frisian peninsula of northwestern lower saxony state of germany."
    },
    "cbb9beea-1961-4049-9a90-53a75da5933e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 2 of the primary clinical trial is given a lower dose of alt-801 than cohort 1."
    },
    "a9e1aa54-a19a-47d1-8d55-caef2035160e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "the primary clinical trial documented five adverse events, notably cerebral hemorrhage, pulmonary embolism, sepsis, hyperglycemia, and hypokalemia."
    },
    "c4e967e1-c656-4d32-b8b5-c0b74a94bf02": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "there are more significant quantities of lenalidomide used in the primary clinical trial than lapatinib in the secondary clinical trial during the first intervention."
    },
    "21c021d2-764d-4028-b945-2aeb525b9888": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR."
    },
    "10543624-61ff-49dd-970a-5d6c57605f6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "punjabi language is an indo-aryan language spoken by the punjabi people of northwest india and eastern pakistan. Aes were not recorded for the primary trial or the secondary trial."
    },
    "3f1c8f3a-f9dd-4819-b6db-2931e0c3f288": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "for the duration of the study, african-american patients participating in the primary clinical trial must be based in texas."
    },
    "b3a79047-9f6a-43d4-88e6-8c8a26b3a47f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "only patients within cohort 1 had cases of infections and infestations in the primary clinical trial."
    },
    "2d320e21-8fce-4f6f-8bf3-dc68f1cb8b0e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "ureter disorder is a non-neoplastic or neoplastic disorder affecting the ureter. cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+."
    },
    "552c3a00-fa13-4e27-89a8-2ef4823317cd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "both interventions in the primary clinical trial use paclitaxel as part of the treatment regimen"
    },
    "8bc95ffe-c455-4563-bc81-a7530f6fb500": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "secondary peripheral chondrosarcoma, grade 2 is an intermediate-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin."
    },
    "90eff3be-13fe-4f5d-82f1-534ae1fe4a81": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "tuberculum sellae is a prominence on the sphenoid bone, which separates the sella turcica from the chiasmatic sulcus. the primary trial had one test group and one placebo group, the secondary trial had 2 test groups."
    },
    "0c973f54-1aad-4349-acf5-607cb1ef2d6a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants. anal cancer ptis tnm finding v6 and v7 is anal cancer in situ. (from ajcc 6th and 7th eds.)"
    },
    "beae10d7-7132-4875-8bc6-4e996d20eb90": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 90 mg group of the primary trial experienced a more significant percentage change in betactx at week 30 than the zoledronic acid 5 mg group."
    },
    "cc97aa0a-365f-459a-a65a-557dd1d930cf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "unknown use of menopausal hormone therapy is a response indicating unknown use of menopausal hormonal therapy. an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial."
    },
    "a2d03d44-c447-45d2-932e-efe3694a8940": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include trastuzumab. abnormal involuntary movement scale aims0110 original result - aware, moderate distress is abnormal involuntary movement scale aims0110 original result - aware, moderate distress."
    },
    "8ef9ed3d-ab31-4ef7-be9a-113b31e3ed2a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had worse results than arm 1, as a higher percentage of arm 2 patients experienced pCR. quality-of-life assessment is a determination of an individual's sense of well-being and ability to enjoy life."
    },
    "d2c3690c-11a2-40de-b077-acf5f53fdb10": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "myb gene fusion positive is an indication that a myb fusion gene has been detected in a sample. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2."
    },
    "13386e01-7556-4cec-93ef-c845f8c8e50d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial. personal care and service occupations is a class of professional or vocational positions of employment that involve personal care or service."
    },
    "c5fe1272-e91c-44cd-888d-359ad43e34c4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "the adverse events of the primary clinical trial and the secondary clinical trial have logged multiple instances of conditions such as swelling, hypothermia, and confusion."
    },
    "fc1a7234-bf6c-4c29-9a82-eccacb0d4766": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "ultrasound procedures are routinely performed as part of the interventions in both the primary and secondary clinical trials"
    },
    "a8760238-f938-4525-bd13-ecb0948de8bc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions. myelosuppressive therapy is any treatment that decreases the rate of blood cell production in the bone marrow."
    },
    "1f400417-bb05-4885-a46b-d348c2353ae9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants of the primary clinical trial are subjected to four different pharmaceutical treatments throughout the duration of the study."
    },
    "ddafc0fa-fb54-4729-8c01-97cb30f293ed": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "neither cohort 1 nor cohort 2 are administered paclitaxel or fulvestrant during the course of the primary clinical trial"
    },
    "05e6adb2-0549-4564-84c7-79e4a19d0e99": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "14 adverse events were observed in the primary clinical trial and skin infections in the secondary clinical trial affected 50% of the patients"
    },
    "d54a1b83-ecd6-4160-a839-1bddf6a12cc5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary trial includes interventions that are exclusively administered intravenously, and the secondary trial treatment is given topically"
    },
    "3647e40b-92d1-4e99-aedf-8416c91576c8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "both interventions in the primary clinical trial make use of laser-assisted fluorescence angiography and lateral radial incisions."
    },
    "29d8fc44-5636-4633-9651-2d30521a2755": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 104 weeks, over 50 patients from each cohort survived more than 2 years"
    },
    "93e1969e-1e96-49b2-874f-6cba2e42a6e4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "to qualify for the primary clinical trial, individuals have to be diagnosed with breast cancer and need hormone therapy."
    },
    "e4575416-926c-4b2d-b4ba-1aa417cae0db": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "the primary clinical trial administers the placebo intervention and allo-mscs intervention in identical doses through a transendocardial injection."
    },
    "8dd8adde-dac7-4303-8a4b-46e27e36862f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. number of resorptions is a measurement of the total number of resorptions in the uterus."
    },
    "86e418cd-3b9d-46fd-b699-c538a29e7c03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last the same duration as the intervention detailed in the primary trial."
    },
    "cb6db7a0-1eab-4ac8-9d3c-9b0bf4e123f2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the intervention in the primary clinical trial is radioembolization using yttrium-90 glass microspheres and theraspheres. in contrast, the intervention in the secondary clinical trial involves the prescription of 560 mg of ibrutinib and 10 mg/kg of medi4736, which is to be taken twice daily for a duration of a month."
    },
    "5ba46a49-9158-4409-815d-0830526da5c4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "130 participants from the ketorolac 30 mg group of the primary clinical trial reported recurrence-free survival, unlike the 48 from the nacl 0.9% 3ml group"
    },
    "1fece1ef-3bb6-407c-a09c-d615922822db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the number of total adverse events reported in the primary trial is higher compared to the secondary trial and in addition, the primary trial reported less instances of cardiac-ischemia/infarction in comparison to the secondary trial."
    },
    "67dcd165-45dd-439f-980d-62c960f50c37": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. morphology record link identifier is a sequence of characters used as a linkage between related records of a morphology assessment."
    },
    "db2684e9-bcdc-482b-bfe4-4d6b2f6862c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "dull red erythema is a response that indicates that the degree of erythematous color change is dull red. There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed."
    },
    "bf170f0a-6640-4b5c-a130-ae405afb15a7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group. primary central chondrosarcoma is a chondrosarcoma arising from the central portion of bone without a benign precursor."
    },
    "cc31b936-223f-4378-9028-315601fba09e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor smaller than 100mm in diameter are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "eeb1a073-304f-41e4-b1f7-e2381eabf50f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "in comparison to primary trial patients, the secondary trial patients receive elevated levels of radiation therapy"
    },
    "dabe9e76-e44c-45be-87b0-337fde45ab98": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "most of the patients participating in the primary clinical trial had a full recovery by the 24th week."
    },
    "b652609b-4609-481e-a5de-caa0c4432f2f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "the placebo and memantine interventions in the primary clinical trial are given with the same frequency and for an equal length of time."
    },
    "b3679900-ab99-4a84-83e0-fc1122a43beb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial."
    },
    "a056e319-f42c-4d3d-80f0-a8348be4eb9d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "mllt3 gene rearrangement is a molecular abnormality indicating rearrangement of the mllt3 gene. Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision."
    },
    "510ae9ab-feae-4c57-a8c3-02e8764e6faa": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "stepson is a male child of one's spouse, acquired through marriage. Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial."
    },
    "0f224562-3266-490d-9b52-10a4d84f5685": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "there have been unexpected death incidents and hospital admissions recorded during the course of the primary clinical trial and the secondary clinical trial."
    },
    "8d6af699-f5b7-41c2-a84f-28fa45e648c9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the majority of patients in the primary clinical trial experienced headaches as the most common adverse event, while the secondary clinical trial showed 0% incidence of adverse events."
    },
    "5ce6d9b3-235b-4645-bc27-10861b2e5177": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "in the primary clinical trial, there were no reports of surgical incisions reopening following the operation."
    },
    "b544a7fd-b1d9-402c-b003-22d14774531c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the primary clinical trial group with paclitaxel plus bevacizumab plus gemcitabine exhibited a superior orr compared to the group with just paclitaxel plus bevacizumab, and also boasted a larger number of participants"
    },
    "9a749008-f77d-49bf-b529-82d049a8f446": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the paclitaxel plus bevacizumab group demonstrated a superior orr compared to the paclitaxel plus bevacizumab plus gemcitabine group in the primary clinical trial"
    },
    "d28a4294-8d88-4473-b302-51c771571ffb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the participants of the primary clinical trial receive fewer doses of mm-121 and paclitaxel each week than the first cohort of the secondary clinical trial"
    },
    "21a5f296-5b3c-4860-be64-77ffb8f76501": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "Both cohorts of the primary trial contained the same number of participants"
    },
    "d9d5a341-26ba-4f5d-a730-14561dea5c17": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "Patients in the primary trial do not suffer any of the same adverse events as patients in the secondary trial. was tumor progression present after initial treatment is a question about whether the tumor progression was present after the initial treatment."
    },
    "be4a58c2-e939-4583-a129-2d0bdba8e3a8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary clinical trial and the secondary clinical trial are aimed at assessing the incidence of adverse events of primary interest (aepis) among participants"
    },
    "b80c867f-7c46-4ac1-a9c4-b56ce0173c2a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "in the primary clinical trial, various drugs were used as interventions, but the administration method was uniform."
    },
    "a1537e33-5b8e-4e7e-a18f-09fc3c436094": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX. metastatic digestive system carcinoma is a carcinoma that arises from the gastrointestinal system and has metastasized to other anatomic sites."
    },
    "f72c1fc3-cfdb-4aa3-a8a8-968f416e35b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "during the primary clinical trial and the secondary clinical trial, no adverse events relating to cardiac or psychiatric conditions were observed."
    },
    "87fda661-4348-4078-b3e7-915893241ab0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial"
    },
    "c6f11ac1-ac2e-4740-82aa-a83ffd1cce00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there were no psychiatric adverse events reported during the primary clinical trial."
    },
    "72b75fca-541f-4311-a38d-9f1d73220418": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "notice change in the way food tastes is a question about whether an individual notices or noticed a change in the way food tastes. the secondary trial and the primary trial report results from one patient cohort."
    },
    "f5a80369-d69d-47d6-836c-60735534ce4e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all participants in the primary clinical trial are given no less than 20mg of mcs110 every three weeks, in addition to more than 130mg of pdr001 every alternate week."
    },
    "7eeeed55-fe37-47ae-be62-e50557ccaed1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors."
    },
    "f21a1764-d1cc-49cc-b22d-e3d1b99c2233": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the secondary trial has 10 more adverse events recorded than the primary trial."
    },
    "0ec15a9a-41f5-44aa-a089-c5f0fe5c9806": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "the primary clinical trial allows participation of female cancer patients over the age of 18, irrespective of their race, ethnic origin or type of cancer. however, only those having her2/neu+ breast cancer are eligible for the secondary clinical trial."
    },
    "af0e8d9b-f748-424d-a4e7-6bb3bf0ee7a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "African-american patients can participate in the primary trial."
    },
    "d2e42255-bde4-4e21-a914-b4e0c35b6e3d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial. controlled oral word association test is a test that measures the verbal fluency of an individual. this tool measures both semantic fluency and phonetic fluency."
    },
    "bec00746-3a77-4d83-9c3b-d50eabcac1de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "all participants in the primary clinical trial will undergo a laparoscopic procedure"
    },
    "0b659007-1edc-43da-aafe-0024c2bb233e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "Several of the patients in the primary trial experienced the no pain whatsoever during the 10 weeks of the study. cdai version 1 clinical classification question is a question associated with the cdai version 1 clinical classification."
    },
    "260b2917-54c5-43db-8beb-50f4e1bad69c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "three electroporation injections of ld v934 are administered to both cohorts a and b in the primary clinical trial"
    },
    "19606c86-3376-40ca-b438-20d961329829": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the outcome measures recorded in the primary clinical trial and the secondary clinical trial are entirely different"
    },
    "53b41c0c-179c-45ce-90e6-3f444681b41e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "canine sarcoma is a malignant mesenchymal neoplasm that affects dogs. it arises from muscle, fat, fibrous tissue, bone, cartilage, and blood vessels. The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort."
    },
    "570f69cb-de78-48d6-916b-bcb3ef0a27a7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "in the primary clinical trial, both interventions are performed using laser-assisted fluorescence angiography."
    },
    "61e35a8d-77bb-4fef-b9fa-ad0380508fc9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the findings of the primary clinical trial showed an increased number of patients with stable disease status at week 12 compared to week 24. however, none displayed complete response during weeks 12 or 24"
    },
    "ef2af81d-e19c-49c9-8ff0-309b87eb6f38": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary trial only has a single adverse event recorded for its patient cohort."
    },
    "49f55eb1-1f11-4d89-9888-810dff7b4926": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "in the primary clinical trial, patients who received acupuncture showed superior improvements in their lymphedema over those who used testosterone cream."
    },
    "9321cbe9-2f04-4751-90fd-47a92f424f04": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "the primary clinical trial accepts patients with histologically or cytologically certified diagnoses of either resectable non-small cell lung breast cancer or small cell lung cancer"
    },
    "ca4fb850-2d8b-4a5f-b990-1d81ae917d63": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "talazoparib dosage in the primary clinical trial varies: 1000 mcg/day for breast cancer patients, and 25 mcg/day for those with ovarian or peritoneal cancer."
    },
    "5cf29cab-a9e9-4385-a342-1684d424ecd8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "group 1 of the primary clinical trial did not have any participants with lesions, however, it was observed that above 95% of group 1 participants in the secondary clinical trial suffered from radiation dermatitis and hyperpigmentation."
    },
    "4efeb043-de46-49cd-8d5d-c4266304fb91": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "the primary trial has more restrictive eligibility criteria than the secondary trial."
    },
    "f9f9c153-d220-451e-a14d-f19ad7e80cc9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after 4 weeks of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 0.1 reduction in the fraction of cells with ki67 expression"
    },
    "151bb6d0-e4bf-4eea-8842-5fe4e1782782": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "recurrence-free survival was experienced by 96 individuals in the ketorolac 30 mg group in comparison to 67 individuals in the nacl 0.9% 3ml group during the primary clinical trial"
    },
    "f27c4b19-1479-48ea-92a0-28da5256b7b8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "patients with a diagnosis of 2-3 cerebral metastases within the brainstem will be ineligible for the secondary clinical trial, however this diagnosis might not necessarily disqualify them for the primary clinical trial."
    },
    "3bde4a4f-fece-4422-a55a-461fa027c18a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial. mature testicular teratoma is a teratoma that arises from the testis and is composed of well differentiated, adult-type tissues."
    },
    "55067973-6ec2-4cf7-b98a-6cd2210db8b0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary clinical trial is administered an oral dosage of fluciclatide and cohort 1 of the secondary clinical trial receives an intradermal injection of chloroquine."
    },
    "1d60de45-bc33-4178-96e6-d0fa20e51fed": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "transparent is allowing the passage of light such that images can be seen through with clarity. Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer."
    },
    "fd2867fb-a94f-42ce-87a1-aebdcfd015b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the intervention section of the primary clinical trial necessitates both surgical and imaging procedures."
    },
    "1ce7b426-1be9-4684-b0a5-54d557d3b320": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "the frequencies of recurrent malignancies, graft-versus-host disease, infection, altered mental status, and diffuse alveolar hemorrhage as adverse events were indistinguishable between the primary and secondary clinical trials."
    },
    "c0151b24-14ab-4837-965d-88bb8115a560": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death "
    },
    "429ac312-4d91-4068-9fc3-8bd7b24bc21f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to herceptin, or a history of non-response to herceptin treamtents are eligible for the primary trial. residue on floor of mouth is a finding of oral residue remaining on floor of mouth after an individual swallows."
    },
    "fe0af3be-4bf7-4e28-ad4c-81082e2ebfbd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial only one cohort recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 0.1 kilogram dose of pdr001, and 0.001 g/kg dose of mcs110."
    },
    "7b71e96e-63ed-43c9-9d9d-5abad0b53d32": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "both the primary clinical trial and the secondary clinical trial focus on the same drug but use different dosages and have different methods for measuring results."
    },
    "d595c94d-93d0-410b-9089-0e026867561f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "Most the primary trial candidates suffered from some kind of eating disorder during the study duration. elo-rd regimen is a chemoimmunotherapy regimen consisting of elotuzumab, lenalidomide and dexamethasone that is used for the treatment of plasma cell myeloma."
    },
    "c441ac74-f9ef-493c-bcfb-03959f9bf7e3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 2.5 mg group of the primary trial experienced a more significant percentage change in betactx at week 2 than the zoledronic acid 0.5 mg group."
    },
    "5af6aa8c-69f5-44a5-9c7c-6c94a0fda6e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial"
    },
    "1f77bf31-ae19-4adc-9af1-4c982718bbf6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "in the primary trial, no cycle is applied to the intervention, in contrast the secondary trial enforces a predetermined 4 week cycle in administering treatment"
    },
    "e40080bc-499c-4af9-a437-be6688894d22": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 1/10 of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products"
    },
    "ad24cf4c-11da-465c-b008-ba96dc8bcdd4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients exhibiting a documented hypersensitivity to cephalosporin or trimethoprim/sulfamethoxazole will be excluded from the secondary clinical trial, while those allergic to levofloxacin or celecoxib will not qualify for the primary clinical trial."
    },
    "26583828-8ea0-4211-a688-3deda44eeec4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "both the primary clinical trial and the secondary clinical trial reported hypoglycaemia, hyponatraemia and hypokalaemia as common adverse events (aes) among participants."
    },
    "7ba4c342-8897-4815-9bb3-eea917b3769e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial administers its patients with intravenous gemcitabine, and the secondary trial treats one of its patient cohorts with topical corticosteroids daily"
    },
    "2cf5335c-74b8-4122-bf27-caf0cdf94b8a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "average counts of treatment emergent adverse events and serious treatment emergent adverse events were lesser in the paced respiration intervention group of the primary clinical trial, compared to the fast, shallow respiration group."
    },
    "4e56ec6c-1b0c-4d14-b53a-2695fb9dcb7d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "irradiation doses along with its administration protocol are comprehensively detailed in the primary clinical trial intervention section."
    },
    "0e935403-0cb2-40ff-b78b-6ba7eaf9621e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases. sweat gland neoplasm is a benign or malignant neoplasm arising from the sweat glands."
    },
    "060ed756-52f8-4b31-ad74-6f6f12d8ca9f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary clinical trial is investigating various doses of a particular treatment on its study group, whereas the secondary clinical trial is examining the impact of distinct radiation therapies on its participants."
    },
    "9bc01b3d-99a3-47bf-9183-012d6686acc5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 100 cases of hypertension, dehydration and dyspnea in either cohort of the primary trial"
    },
    "4a5400b8-bf7e-40f2-857f-169a7ad3b89f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the health professionals conducting the trial. ganglion is a cluster of nervous tissue principally composed of neuronal cell bodies external to the central nervous system (cns)."
    },
    "da278764-ba0c-4a9e-9f44-7fe16af87e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "who needed prescription medicine but family unable to afford it is a question about which household member was unable to get needed prescription medicine because the family couldn't afford it.  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial."
    },
    "2eb882ed-836b-424c-a9b2-06d97f0b2b9e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "cognitive behavioral therapy (cbt) is included in the interventions for both cohorts of the primary clinical trial."
    },
    "316e0b04-f14e-47cd-b847-6af5add81e4e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "both the primary and secondary clinical trials have detailed accounts of adverse events involving their participants."
    },
    "b7501704-ccba-40f8-852e-c157006483df": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 20kg of mcs110 every 30 weeks."
    },
    "3433a50a-b13a-43a5-ba9c-041959f23390": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "0 participants in group 1 of the primary trial were found to have lesions, and more than 95.00% in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "1ecd0f33-cffb-4c0e-917f-6ae5f8570183": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the secondary trial had a higher incidence of infection, asymmetry and nausea than in the primary trial."
    },
    "192c6acc-1f20-4f22-a23e-80fadba34726": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "in the primary clinical trial, the focus is on the use of hormonal treatments, compared to the secondary clinical trial where acupuncture is in trial."
    },
    "f398c658-74cb-4d2b-894c-d785e4dde994": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the primary clinical trial and secondary clinical trial utilize different metrics for assessing outcomes."
    },
    "12f2ffff-1010-43bb-ac5d-5725d3d159b4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 730 days before study entry are excluded from the primary trial."
    },
    "028e1c85-f23e-411f-bf70-3621480de375": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial. rest a lot is a question about whether an individual rests or rested a lot."
    },
    "36e4b948-e72f-43d9-8084-b3d2e879620b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "in the primary clinical trial, enzalutamide is given orally to the second cohort, while the first cohort is given the same through intravenous injection"
    },
    "242b1a1a-4a5e-459b-88ea-41ca86093348": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "all study groups participating in the primary clinical trial will engage in the same 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging processes, although cohort 1 will get a slightly elevated 18f-fpprgd2 dosage."
    },
    "db3d7616-8500-411a-9b43-b9b6e0925957": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "all participants in the primary clinical trial receive adriamycin and vincristine."
    },
    "67a7f848-e9e5-46be-a37b-f0e46e643dcb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients participating in the primary trial receive 25 mm/ml oral lapatinib twice a day for a half month."
    },
    "3c596e8f-b1a2-4ded-b15b-99784b540d76": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500000 mcg of fulvestrant in a tablet form to be taken bid."
    },
    "b67a2d20-b35d-45b7-a594-8946f1f160ab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "radiotherapy is utilised in the primary clinical trial's intervention strategies for both cohorts."
    },
    "cb88e277-c79d-4bb1-8d63-c637a14d0f48": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "in the primary trial, patients are required to receive a monthly vaccine for influenza prevention with no specific drug in use; additionally, the secondary trial does not employ any form of injection, thereby excluding the use of radioactive tc99m sulfur colloid."
    },
    "0655111b-b8fe-46c7-8332-433a747efbcc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "there were no important differences in the findings of the primary clinical trial groups and the outcomes from the reflexology group and control group in the secondary trial were indistinguishable."
    },
    "2980900b-74b7-4c96-8ab9-91fc994211d1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary clinical trial is examining the quantity of patients having treatment associated detrimental incidents, whilst the secondary clinical trial gauges the median length of patient sleep time in minutes."
    },
    "49cccbde-abb6-45a4-80ba-47dcdd6b760e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "patients with considerable or unmanaged cardiovascular diseases are unfit to participate in both the primary clinical trial and the secondary clinical trial."
    },
    "ea25b3f7-4ef8-4e5f-b3e8-3cbf0da93a12": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable bilateral breast cancer are eligible for the primary trial. chk1 inhibitor is any agent that inhibits the cell cycle checkpoint kinase 1 (chk1)."
    },
    "403ad287-6e25-4db0-a66b-fe4a7f15a983": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "c71fced3-2da3-4471-a72f-0dec2e7bbb02": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "the primary clinical trial sees an elevated administration of alpha lipoic acid to its participants over the course of the study, unlike in the first cohort of the secondary clinical trial where the same dose of necitumumab is maintained throughout."
    },
    "eaa12be4-b2f0-493a-9ce4-c70f874db211": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "the primary trial most often highlights coronary artery stenosis as an adverse event"
    },
    "5572d454-871c-4458-a2d9-97e7cbb0e03a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial. bar dosage form is a solid or semi-solid in a singular unit that is rectangular or oval in shape."
    },
    "1786385e-70c9-4a5b-a19e-0f389be545cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "disturbed sleep at its worst is a question about an individual's disturbed sleep at its worst. Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial."
    },
    "c19b9a3f-acda-4e83-80db-0f4d3383d909": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 0.5 times the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "d0f95f01-4a54-4bdc-9059-50803485a1f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor 3-11 cm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "90748020-3e2f-46c8-8e9d-984436a2d752": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "non-smokers are the only eligible participants for the primary clinical trial and drinking more than 5 alcoholic drinks a day disqualifies one from the secondary trial."
    },
    "f7cbcdf1-cee8-4b88-afff-45901ee871af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the secondary trial and the primary trial report results from one patient cohort. pharmacogenomics/genetics methods and supporting information supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics methods and supporting information domain."
    },
    "763b8082-f1d6-4dfb-ab46-b61d8dae6515": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial. microgram per kilogram per hour is a dose calculation unit expressed in microgram(s) per kilogram per period of time equal to sixty minutes."
    },
    "56d753e1-4bce-4c3d-a8fb-8abc6119c1a7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "fewer than 5% of the patients involved in the primary clinical trial encountered adverse events"
    },
    "a2e2d75b-ce3e-4bf6-bfce-c151b9d183d4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "perjeta is incorporated in both patient groups of the secondary clinical trial in contrast to the primary clinical trial where it is not deployed."
    },
    "e412ecde-3195-42c6-b125-7d2697ea89c1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "all the participants in the primary trial receive lower doses of alt-801 compared to the secondary trial participants"
    },
    "f07f2805-df6a-4662-8a1f-757eabf8687a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "santali language is an austroasiatic language spoken mainly in the indian states of jharkhand, west bengal, and chhattisgarh. the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants in the secondary trial receive sunitinib."
    },
    "ea28dc26-75b9-4107-8862-226a46923254": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 1.5ug/kg of dexmedetomidine (15ml), patients in the secondary trial cohorts do not receive any dexmedetomidine."
    },
    "577f3aad-32c6-4a0b-8df1-615a9a58fa29": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary clinical trial and the secondary clinical trial noted an identical count of adverse events among their patient groups."
    },
    "86515e2e-b144-430c-b7e2-678733d3b0ec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive oral medication twice a day for a full month. desensitization is any of various methods to reduce or eliminate an organism's negative reaction to a substance or stimulus."
    },
    "48fdcfb8-5519-42cd-8496-f8f2e0e38808": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "among the participants of the primary and secondary clinical trials, none reported any adverse events."
    },
    "5be4dfce-9123-4a08-9397-a2f4d95e8209": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial . pregnant at time of vaccination is an individual was pregnant at the time a vaccination was administered."
    },
    "58c19654-e4cf-4c18-99ef-18b024996fcb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "percentage of participants experiencing adverse events of primary interest(aepis) is subject to assessment in both the primary and secondary clinical trial"
    },
    "9b1ce2f0-2734-4ae5-988e-dd569c19594e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the eligibility for the primary and secondary clinical trials is controlled by nationality, ethnicity, weight, and gender"
    },
    "93381895-c0d3-40d1-96a0-b1aa23f65151": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "there are no reported results for the lbh589 and lapatinib group in the primary clinical trial"
    },
    "2da35e9e-caa7-47b4-883e-5ef8c7868708": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 0.015 kg per day"
    },
    "135763e3-70fd-478d-991c-717d6ed55bb3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often."
    },
    "d46fad97-64a3-4553-a586-0dd9878009ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "distinct patient clusters are required for the secondary clinical trial and the primary clinical trial."
    },
    "853967c7-51a1-4e08-88c0-d8e621129176": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "both the primary clinical trial and the secondary clinical trial utilize pcr as their measure of outcome. there is a negligible variance in outcomes among the two subgroups of the primary clinical trial. however, in the secondary clinical trial, arm 2 demonstrated significantly better results compared to arm 1."
    },
    "6b03d4f0-29bf-4a64-8136-2042e2a609ef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "in the primary clinical trial, patients in cohort 2 show a decrease in pleural effusion."
    },
    "0cf7be8c-6376-4aff-93a2-2c88104fe061": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE. scrotal infection, ctcae is a disorder characterized by an infectious process involving the scrotum."
    },
    "9dd72932-f9f7-4ad7-8c3e-15f284d93d89": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "male prostate cancer patients over the age of 55 can participate in the primary clinical trial, regardless of race or ethnic origin. however, for the secondary clinical trial, they must have a confirmed diagnosis of advanced castration-resistant prostate cancer."
    },
    "59017303-759d-4b61-a272-efd6364a0b93": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "benign epididymal neoplasm is a rare non-metastasizing neoplasm that arises from the epididymis. representative examples include adenomatoid tumor and leiomyoma. Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy."
    },
    "c355603f-22d8-4363-ac79-6e591b4fcfac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "death details (human clinical trials) supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the death details (human clinical trials) domain. There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial."
    },
    "eebccf7b-8edc-4b99-8355-e936754c1282": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "both the primary and secondary clinical trial include at least one same criterion for inclusion."
    },
    "d7637d6e-ba2c-4fdc-936d-57c3bf938eff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "in the primary clinical trial, the patients in group 2 receive a dosage of 0.5ug/kg of myalgias (5ml), however, this is not administered in the secondary clinical trial cohorts."
    },
    "0d58d43d-8edc-4846-9d16-b1573f00db28": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "level of sexual arousal during sexual activity or intercourse is a question about an individual's level or degree of sexual arousal during sexual activity or intercourse. Paclitaxel is not used in either of the primary trial interventions."
    },
    "70cd062f-8f49-47ac-80c0-d3608a574517": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions. h3-3a gene mutation is a change in the sequence of the h3-3a gene."
    },
    "b3372685-8147-4004-89f4-f57d35bd8980": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the bevacizumab group in the primary clinical trial exhibited a lower occurrence of disease progression or death than the bevacizumab + capecitabine group."
    },
    "e3801aad-e988-42fb-8266-22a90bdba955": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. metastatic oral cavity mucoepidermoid carcinoma is a mucoepidermoid carcinoma that arises from the oral cavity and has metastasized to another anatomic site."
    },
    "30988df5-0397-4199-ba63-0b95f1c0f4f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there have been adverse events (aes) reported in both cohorts of the primary clinical trial"
    },
    "43a81620-bb60-4515-b31b-4cf8e5f3cc25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "it was typical for the primary clinical trial candidates to suffer from an eating disorder'"
    },
    "8e63dcb6-d289-4782-94a5-9f0aa7343cbd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "no fatalities were reported in the adverse events for both the primary clinical trial and the secondary clinical trial."
    },
    "427a4e1a-14ee-441a-b2af-b45b01356921": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "persons with stage 4 cancer cannot take part in the secondary clinical trial, but are fit for the primary clinical trial."
    },
    "eb68a94f-7693-4158-b492-7b5a03d85b96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "patients in the secondary clinical trial encountered adverse events specifically eyelid oedema, upper gastrointestinal haemorrhage and chest pain. no such instances were reported in the primary clinical trial."
    },
    "e59036ac-08b6-44ed-ad46-292a3bb8a937": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "no fatalities or hospital stays occurred in the second cohort of the primary clinical trial, and only one instance of atrial fibrillation was observed."
    },
    "56c99670-a2ba-42ca-b870-e3d98f2f4169": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "the inclusion of a patient into the primary clinical trial is dependent entirely on the objective criteria for inclusion and exclusion, and is not influenced by the judgment of the health professionals supervising the trial."
    },
    "2d0df5b6-0886-4a19-973a-92f4442b39d1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "corneal deposits were less commonly identified amongst the patients in the secondary trial"
    },
    "519fe8b4-596f-4db6-af13-80d9746041a6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "primary clinical trial enforces a strict age limit of 18 to 65 years for all participants"
    },
    "ab25ad81-a094-432c-9814-12669bd4cbac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "genetic mutations in pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 are necessary for eligibility in the primary trial, but these conditions do not determine inclusion in the secondary trial"
    },
    "d5abfad6-a8c3-409f-b434-33e55c0848cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary clinical trial and the secondary clinical trial employ different drugs, dosages, and administration schedules, though they both utilize intravenous injections."
    },
    "c8109cb7-4cf5-469b-ba02-5d610579cc89": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "both the secondary trial and primary trial yield similar results, despite varied interventions"
    },
    "7ae03d8b-6087-4df3-a0e1-d1932d86528c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial. phf6 gene mutation is a change in the nucleotide sequence of the phf6 gene."
    },
    "c802c0a9-737c-4b94-89c6-e4327a1925dd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "while the intervention in the primary clinical trial comprises one drug, the secondary clinical trial\u2019s intervention mandates not less than three distinct drugs."
    },
    "5f294eee-f332-4c58-a43f-076a06a04dd5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV. 1p35 is a chromosome band present on 1p"
    },
    "fd5337ee-4098-440b-9e22-0d8c52dbab5a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "the units of measure for the primary and secondary trials are patients' heart rates and cholesterol levels, respectively."
    },
    "b1cb1388-9a0f-4dfd-8890-a3d2bced6ab4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "in the primary clinical trial, 96 participants from the ketorolac 30 mg group demonstrated recurrence-free survival, as opposed to the 67 from the nacl 0.9% 3ml group"
    },
    "e6c70cab-b2d6-488d-b9dd-34478f9f4f71": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "despite taking reduced doses of empegfilgrastim, cohort 1 patients of the secondary clinical trial had a higher occurrence of neutropenia than those in cohort 2 of the primary clinical trial."
    },
    "6d7c7740-c399-4d73-82c8-2ef0d4739341": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes"
    },
    "29968695-9fd4-4fce-b2ba-1879f50c8c57": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. often feel sad or depressed is a question about whether an individual often feels or felt sad or depressed."
    },
    "d88cc7fc-34dc-4e86-a3a0-50192a316624": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "the secondary clinical trial allows the participation of patients diagnosed with malignant ductal carcinoma in situ and uncontrolled high blood pressure, whereas such patients are excluded from the primary clinical trial."
    },
    "0bd4a2c1-4e4a-4752-a9e8-46a9a27885c1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "atypical lymphocytes present in bone marrow is a finding indicating that atypical lymphocytes were detected in a bone marrow sample. Cohort 1 of the primary trial did not report any Aes."
    },
    "01bbbed8-5b22-4017-b6c5-f8a32bd6ab20": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "in the primary clinical trial, all interventions are delivered via the same method."
    },
    "eacc1096-c090-4f21-ad10-005be458b653": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "her2 + patients in the primary trial and patients in cohort 2 of the secondary trial receive varying dosage of trastuzumab at different stages of the trial"
    },
    "2e844546-8fe8-440c-afdd-504e84d4acc4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "unlike the primary clinical trial, which had no adverse events on record, the secondary one frequently reported anaemia as a side effect."
    },
    "dea7a7bb-563c-4b02-9011-16fa165820c4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "ndc me (milligram) is a recognized billing qualifier that may be used to identify milligrams as the ndc unit of measure. the secondary trial and the primary trial results contain completely different outcome measures ."
    },
    "33621096-b0c2-4478-9662-45ba56f9da8d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "arm or leg response group answer is an answer belonging to the arm or leg response group query. The only types of Aes observed in patients from the secondary trial were Eyelid oedema, Upper gastrointestinal haemorrhage and Chest pain, no aes wererecorded in the primary trial."
    },
    "634ef5d6-4281-4d39-b876-59be4ed256ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "both the secondary clinical trial and the primary clinical trial track the percentage of participants showing clinical benefit based on recist criteria."
    },
    "57663242-4e73-409f-a7f9-1738e13298ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "there are no reported adverse incidents in the primary clinical trial and the secondary clinical trial."
    },
    "632b415b-ebc1-4898-8676-1ef38eecb128": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial are administered through different routes. piga gene mutation is a change in the nucleotide sequence of the piga gene."
    },
    "d1bbbc84-4136-43c4-b7b6-7e88e7c82730": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "every cohort in the primary clinical trial is subjected to the same volume of docetaxel, doxorubicin, and cyclophosphamide with the same frequency. the second cohort, conversely, encompasses three more therapy cycles of these exact drugs"
    },
    "8f20a32b-2aa2-44c4-930e-852cba56151f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 in the primary clinical trial is administered vincristine intravenously, and cohort 1 in the secondary clinical trial is given a rectal suppository of hydroxychloroquine."
    },
    "58f6494f-860a-4f94-9fa1-895637730938": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the dosage of denosumab in intervention 1 of the primary trial is equivalent to the dosage of tamoxifen in intervention 1 of the secondary trial."
    },
    "3e16b4a5-6dc6-4a20-a367-c361bc38644e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "patients participating in the primary clinical trial, on average, have a survival rate exceeding two years, with more than fifty patients from each group experiencing life spans over 24 months."
    },
    "b7178d54-4bb2-4820-b13c-c342075267ff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "despite the lack of any cardiac or psychiatric aes in the primary clinical trial and secondary clinical trial, a number of other aes were witnessed."
    },
    "8fe97ae1-baa6-48ba-a97e-a59585b2b268": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "cohort 2 of the primary clinical trial encountered numerous fatalities and hospital admissions, with multiple incidents of atrial fibrillation."
    },
    "7e3a4e76-6d33-4013-ad8e-7fd3d684136f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial outlines the duration of response in hours for patients in both the cohorts combined, an total of 312, whereas the secondary trial outlines the profiles of patients that experience disease control"
    },
    "a55f7123-365b-4119-bf0d-17467c73d0b7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial. diaphragm part is any component of the fibromuscular tissue that separates the thoracic from the abdominal cavity."
    },
    "d09f927d-29c3-4370-a258-400c79f366fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "several of the patients in the primary trial experienced the no pain whatsoever during the 2.5 months of the study."
    },
    "f0594802-c304-4dc7-88c8-282554c1e7d7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial administers its intervention through injection, and the secondary trial administers it through an intramuscular route."
    },
    "37257ef8-1772-4b94-9bb9-0433a83b83fe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "palpable masses sequence number is an identifier that describes the relative position of palpable masses data within a series. Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial."
    },
    "f6ad61ca-d223-496b-a067-69625112447c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 1/20 of patients in the primary trial suffered aes"
    },
    "29412166-6da7-47d8-82b9-efc61e628f05": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "patients in the primary trial and the secondary trial did not experience any thromboembolic events."
    },
    "e4ae61e2-fb24-41dc-9eb6-0102ee8d22d8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "the patient's first of kin will make the final enrollment decision for the primary clinical trial, even if the patient meets all exclusion and inclusion requirements."
    },
    "dcb23a61-648b-4831-92e9-9e61cc596be3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "There are no conditions on hepatic function for participants of the primary trial. worry that breast cancer recurrence would mean losing my breast(s) is a question about whether an individual worries that recurrence of their breast cancer would mean losing their breast(s)."
    },
    "7b819ac1-92e6-41ce-881c-0f4581a690ee": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial."
    },
    "10818b02-4a1d-438a-8f90-7aded2b826ec": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "counselor is a person with training to provide advice or instruction. There are 7 more participants in cohort 2 of the primary trial than in cohort 1."
    },
    "aca44925-657c-47d1-9325-f3933deee650": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "cohort 2 of the primary clinical trial did not report any aes, and neither did the candidates in cohort 1"
    },
    "6f0485c9-9cb5-4861-9baf-f6a9a9acd975": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "all participants in the primary clinical trial are subjected to the same duration, intensity and type of radiation therapy."
    },
    "0cd83002-1e58-4b84-ac34-e4299d4573ab": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "in the primary clinical trial, there were patients who did not suffer from 3 or more adverse events."
    },
    "6786fa28-09b7-4bf3-8202-7e810755247e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "there were no recorded gastro-intestinal adverse events in the primary clinical trial"
    },
    "be6130d9-49f1-4b4e-82f2-6acc6ee7f176": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "have excessive tearing is a question about whether an individual's eyes have or had excessive tearing. None of the individual adverse event types recorded in the primary trial affected more than one patient."
    },
    "d475c476-8172-47a0-bf91-7ef5d0f6d081": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID."
    },
    "cc2428b1-d508-406f-a59f-186d62e93600": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "in the primary clinical trial, the lack of paclitaxel infusions resulted in worsened symptoms for the patients compared to those who received them."
    },
    "a02d9319-0103-493a-8368-f79dbbe6a223": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "ascites was more likely to occur in patients from the secondary clinical trial, and hypersensitivity reactions were more common in the primary clinical trial."
    },
    "561d1a70-6bd1-42f7-9e2a-73b9622a449c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group."
    },
    "b907c117-661f-4078-956a-be5b2560b5f4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "all of the patients in the primary trial and the secondary trial developed shingles."
    },
    "7b76f6bb-6bf2-4bec-8409-9c4b90cc81c8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement. subject identifier is a sequence of characters used to identify, name, or characterize a trial or study subject."
    },
    "0613b4cb-1e87-48b0-8617-338ebb9ccbe8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "terminator device is a device designed to connect to the end of a bus network. There were significantly more patients in cohort 2 of the secondary trial than in cohort 2 of the primary trial."
    },
    "f45b251f-2fec-44b7-8fc0-dd0d06a44d3b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants."
    },
    "0f631563-09e1-48db-a6c3-1cc06009e139": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "no patients in either the primary clinical trial or the secondary clinical trial endured fewer than 3 distinct aes."
    },
    "ad66bfcf-7359-41c6-b4f8-694ed27fbc8e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the mtd of different interventions, with the mtd of mm-111 for patients in the secondary trial being 1500 micrograms per day"
    },
    "f90e818c-2a5c-44c9-9445-1d34a0c2e551": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women who are at least 18 years old can participate in both the secondary and the primary clinical trial."
    },
    "3aaa3da7-8b9c-4853-abd9-f4dc011eaab0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial. familial hypocalciuric hypercalcemia is a hereditary condition caused by calcium sensing receptor gene mutations, resulting in calcium-hyposensitivity, and compensatory hypercalcemia and hypocalciuria."
    },
    "7f17692d-e7de-4365-9da1-83f563fde703": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the secondary trial and the primary trial report results from one patient cohort. reviewer is a person with a responsibility for examining something to make sure that it is adequate, accurate, or correct."
    },
    "41bf82f2-9544-471f-88b0-418e6cd9b5e1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis. miscellaneous occupation is a listing of occupations that don't fall under another major heading."
    },
    "b395d278-bbad-4ba2-af5b-82dc8045482a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "the secondary clinical trial, unlike the primary clinical trial, enrolls patients who have a diagnosed mutation in at least one gene among pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11"
    },
    "13f8d256-bec7-419f-bda5-202ea116a215": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "primary clinical trial patients experience adverse events identical to the secondary clinical trial.'"
    },
    "9dd13c76-10e0-4dd0-ad16-42d135f6c2c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "cohort 1 of the primary clinical trial experienced multiple moderate aes"
    },
    "95aebead-f222-4a09-b0e0-31557235953f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last half as long as the intervention detailed in the primary trial."
    },
    "d9d506ef-20ed-44e2-9809-07cb0772535b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "All Infections and Infestations cases in the primary trial were for patients in cohort 1."
    },
    "6046015d-1954-4914-aa65-98ca575e4936": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial only a single cohort recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 0.1 grams dose of pdr001, and 1 mg/kg dose of mcs110."
    },
    "41b82c80-55fb-41c9-84c0-ae7f552c7cf8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "cancer patients with epilepsy, thalasemic syndromes, or anemia can participate in the secondary clinical trial."
    },
    "0a266c52-2a4e-4aed-a04c-85c148f2cd41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort."
    },
    "efa989b7-db55-49b8-a124-875a5f7c94ff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial. nervous system neoplasm is a benign or malignant, primary or metastatic neoplasm involving the central or peripheral nervous system."
    },
    "c8235719-3fd8-43e9-8ba6-d99393220240": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial "
    },
    "e5d16f98-79d0-44e1-9fc0-7bb6ae9a038d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered twice the dose of Enzalutamide as cohort 1. moderately dissatisfied is a response indicating a moderate level of dissatisfaction."
    },
    "9532e5a5-0e29-4914-8cf5-5aff881ffa8a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the primary clinical trial discloses the number of participants included in each specific cohort."
    },
    "c3bc7314-8b8f-4d98-90ad-986132951201": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2. sulfoxone sodium is a sodium salt form of sulfoxone, a water-soluble sulfonamide antibiotic used in the treatment of leprosy."
    },
    "7bf988b4-5e6f-41c4-bef6-7b3549dd58d9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial."
    },
    "03fe8107-b0ab-470e-9d1e-a085808ec397": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "throughout the duration of the primary clinical trial, cognitive function remained stable in all participants, particularly in the members of the ovarian function suppression group"
    },
    "0279dc49-0833-4673-8fb7-a7101a16fa14": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial. cardiovascular lesion indicator is an indication as to whether a cardiovascular lesion is present."
    },
    "e928035e-e614-46e3-a3f7-94341043b14e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "gallbladder infection, ctcae is a disorder characterized by an infectious process involving the gallbladder. the secondary trial and the primary trial share at least one inclusion criteria."
    },
    "be4814f1-b515-4744-8df9-293327502949": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor 2-8 mm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "0f31bc6a-a228-49c2-afff-4177ef850272": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "There were more participants in the primary trial than in the secondary trial"
    },
    "dbf8020d-57c3-45fb-ab31-5c97f293a248": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 28 year old patient with stage iv lung cancer, absolute neutrophil count less than 500/\u03bcl, platelet count of 45000/\u03bcl, hemoglobin level less than 80 g/l, and a life expectancy less than 6 months would be rejected from both the primary trial and the secondary trial."
    },
    "2aef976d-1cb6-4d70-bda2-30a453c37f88": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 of the primary clinical trial demonstrated superior results compared to cohort 2 of the secondary clinical trial."
    },
    "816acfa2-5f8d-4f30-9425-5880f3d72414": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women with conditions of claustrophobia and osteoporosis are disqualified from participation in both the primary clinical trial and the secondary clinical trial."
    },
    "072f2e2d-f4b0-4a32-85e0-8626ee261a63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "in the primary clinical trial, the group taking lbh589 with capecitabine performed poorer than those taking lbh589 and lapatinib"
    },
    "3d6e2ffb-5a89-4f31-9596-65f90e950c5e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "a single instance of shingles was documented in group 2 of the secondary clinical trial, yet no incidents were reported within the primary clinical trial or group 1 of the secondary trial."
    },
    "c958d134-cecd-4212-9043-bc1d5131d555": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "only those having colon cancer and showing no response to past hormonal treatments will be considered for the primary clinical trial."
    },
    "15c27d36-ca02-48e2-8e08-d9c6b52042c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "entry into the primary clinical trial is open to individuals with definite metastasis or whose cancer has augmented in different locations of the body."
    },
    "45bd641d-3e35-456c-a01b-63fa3e2ebea1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a Non-small cell lung cancer or Small cell lung cancer are eligible for the primary trial. small plaque parapsoriasis is a variant of parapsoriasis in which the plaques are small."
    },
    "a4a2c0ba-3fa9-4fad-9258-7e517ae85e25": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day."
    },
    "77f689bc-c9fc-45ab-9966-aea06482863a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "whilst the primary clinical trial is not open to children, their eligibility hasn't been explicitly stated for the secondary clinical trial"
    },
    "6fa15cf5-6fc4-48f3-a800-5e4699952ddb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "the primary clinical trial and secondary clinical trial are open for severely obese patients to participate."
    },
    "f498a2b6-b3da-45a2-b9d5-ef87ee43914f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "monoallelic rad51 gene inactivation is any gain, loss, or exchange of dna that results in monoallelic loss of function mutations in the rad51 gene. There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial ."
    },
    "6a0bfa75-3e83-4c73-8e5a-2dc4cad866c3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "19p13.12 is a chromosome band present on 19p the primary trial only has a single adverse event recorded for its patient cohort."
    },
    "58614e8d-770e-4bfe-b74b-e2d429ef072f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial"
    },
    "f73b494f-624c-487a-b502-f2cbc7ab0475": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 participants in the primary clinical trial are given a 0.5ug/kg regimen of myalgias in a 5ml dosage, though, such regimen does not apply to the secondary clinical trial cohorts."
    },
    "dd52a82a-b788-4048-ba8d-525ee119a78f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "hormonal methods are being employed in the primary clinical trial, while the secondary clinical trial is experimenting with acupuncture."
    },
    "4d1031f5-19e1-43f3-b75a-5e8208b44bfb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "no significant disparities were observed in the outcomes from the groups involved in the primary clinical trial, while in the secondary clinical trial, some differences were noted between the results of the reflexology group and the control group."
    },
    "c0131f92-6373-48c8-9bd5-8d4a42f6674e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "distinct variations were noted in the results from the primary trial groups, whereas the reflexology group and the control group had indistinguishable results in the secondary trial."
    },
    "74b24825-1c77-48e6-a1ce-c5b7e60b2b61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention. problems with thinking or remembering things is a question about whether an individual has or had problems with thinking or remembering things."
    },
    "e3caa52b-259d-498a-926b-fbfd15eb1bc6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "3% of patients in the primary trial did not experience any adverse events"
    },
    "ad52e20e-99a7-4001-b957-12b24a3d1df1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "canine granular cell tumor is a granular cell tumor occurring in a dog. The all recorded Aes in the primary trial occurred to cohort 1 patients."
    },
    "3607f455-e990-4306-8b23-52d930ccbdff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "the occurrence of ascites was higher in the primary clinical trial, while the cases of pneumocystis jirovecii pneumonia were more prevalent in the secondary clinical trial."
    },
    "2fc8ee27-e602-47ae-a93b-1c8194e3d6ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "all cohorts in the primary clinical trial utilize different methods for paced breathing instructions, none of which include a cd."
    },
    "4ecece61-2e46-482f-a765-ac677ea3e19c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. thousand is a natural number following 999 and preceding 1001 and the quantity that it denotes: ten times one hundred."
    },
    "95036529-d29d-4425-90a4-d366664c99c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. pet keeps itself clean is a question about whether an individual's pet keeps itself clean."
    },
    "6a6f23a1-354d-4c1a-b457-e3ce15564e69": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. 2q36.1 is a chromosome band present on 2q"
    },
    "63cb536d-5250-4760-b3a8-103bfcc45123": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "trabecular pattern is a microscopic finding indicating that the neoplastic cells are arranged in trabeculae in a tumor sample. There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial."
    },
    "a6236585-ed05-4deb-bfcd-29eb410bd892": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial and the primary trial report their results using the same units of measure. superior vesical artery is a blood vessel arising from the internal iliac artery that runs along the bladder with branches supplying the bladder."
    },
    "647c8d22-6888-4f04-a70b-0245b68a6fab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "patients in the final stage of cancer, cannot partake in the primary clinical trial, but are eligible for the secondary trial."
    },
    "6734e552-d882-446e-a02f-c6bbe2eeb6ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 110,034/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial."
    },
    "00d64f29-fff0-44bd-b20c-8838ed4a1d93": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "in the primary clinical trial, the subjects of both cohort 1 and cohort 2 are provided with equal doses of 20 mg of sunitinib and 7.5 mg/kg of bevacizumab"
    },
    "cbf31ee8-3c01-46f5-9698-f44da41fd1fa": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were an equal number of patients suffering adverse events in both cohort 1 and cohort 2 of the primary clinical trial"
    },
    "99a6cb19-b6d8-4cb7-84e1-be559854caa6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks."
    },
    "8367e2fc-f384-43c0-af4e-d4ec41281b2e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2."
    },
    "10db152d-ae00-4b31-8c05-a1db1dee76b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "the dosage of trastuzumab given to her2+ patients in both the primary clinical trial and the second cohort of the secondary clinical trial is the same for the entire course of the trial."
    },
    "dfb4c335-296e-42af-b418-329f39c6b42e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "both the primary clinical trial and the secondary clinical trial's results do not require any units of measurement.'"
    },
    "ba87189b-e858-4344-927d-a315a0d2576f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "any adult with old diagnosed, pr-negative, her2-negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial."
    },
    "42ac258c-8420-4a90-b427-d7ca64f246af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 from the primary trial is given 0.5ug/kg of myalgias (5ml), which is the same as what patients in the secondary trial cohorts receive."
    },
    "3fda5084-ab27-4f5c-8acb-0be7e7ac93c1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "there were zero reports of aes among participants in the primary clinical trial."
    },
    "dda442a2-b86f-4375-ae81-f1b387ce46c9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "the outcome measure for both the secondary and primary clinical trials does not involve tracking the number of participants with treatment-emergent adverse events."
    },
    "9bb1e4d4-379d-47f5-a6b9-c6dac40b2727": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "primary clinical trial participants who didn't undergo paclitaxel infusions experienced more severe symptoms compared to those who did."
    },
    "fb4e9c92-aa61-4691-b1fe-3cbb4a183f6d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report the severity of delayed nausea on a scale of 1 to 7, and the secondary trial measures the change from baseline to 270 days in bone mineral density (bmd) of the lumbar spine"
    },
    "9b75f8dd-3667-47be-a7d3-2cca26ae5fbe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial. milliliter per day per microgram is a unit of concentration equal to milliliter per day divided by microgram."
    },
    "e561775c-d739-405c-ac1e-a8a9ccca4530": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally. disposition continuation is an indication or description that the subject will be continuing on to next phase of the trial."
    },
    "a1dec8bc-cd32-4f8b-b757-dfd19e8af073": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX. auditory brainstem response wave v, presence is an assessment of the presence of the auditory brainstem response wave v of the auditory evoked potential waveform."
    },
    "395c6ba7-5123-4d61-a803-be3345d0ab23": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "the primary clinical trial reported a ten times higher number of hepatotoxicity incidences as compared to hypertension and pancreatectomy cases"
    },
    "d118efb5-ea31-49ca-8e20-686c85081e94": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants"
    },
    "fa510ac9-2d92-4396-a150-18dd46a31260": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the primary clinical trial and the secondary clinical trial documented identical numbers of adverse events among their patient populations."
    },
    "bd4ef9b9-41e1-47cb-b8bd-eb0dfe32badf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial evaluate different patient characteristics in their results. poorly differentiated angiosarcoma is an angiosarcoma characterized by the presence of significant cytologic atypia, necrosis and high mitotic activity."
    },
    "0aab969d-e626-4857-903c-df2f6849c7c7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "several adverse events occurred at an incidence rate greater than 1% in both the primary clinical trial and the secondary clinical trial."
    },
    "f5fbfac5-bac3-4852-bb93-b262df8d1418": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "before participating in the primary clinical trial, candidates are expected to undergo a mammography, in contrast, participation in the secondary clinical trial requires an initial ct scan and blood tests."
    },
    "e809d4b1-1730-49a2-aa9f-303afb27b175": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab. trichostrongylus colubriformis is a species of parasitic roundworms in the family trichostrongylidae that causes black scour disease in sheep, cattle, and goats."
    },
    "c9d6f05e-40bd-49b1-8ba1-c5489208cede": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 360 day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "17660aaf-9218-4119-b00c-f3b863718e97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention"
    },
    "75c25f91-4918-40d6-b84d-d5be844b97ef": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "an increased blood bilirubin was recorded in 36.36% of the patients who participated in the primary clinical trial."
    },
    "590f240e-7499-432e-aa3c-f54eda69ed46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period "
    },
    "4b545fd1-a4d1-486a-aece-201400e9c1f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "aq20 - chest trouble make you feel restless is airway questionnaire 20 (aq20) does your chest trouble often make you feel restless? None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes."
    },
    "0bba5705-e808-4f90-b434-a951027f4d0f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "while the primary clinical trial follows a treatment regime based on a three-week cycle, there is no set cycle for the intervention in the secondary clinical trial."
    },
    "f95439cc-7c35-43a8-ade1-6652fbdf7873": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "multiple psychiatric adverse events were noticed in the primary clinical trial impacting more than a quarter of the patients."
    },
    "ce4851a3-948d-4eca-8d86-2a70f3bbd577": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the interventions in the primary clinical trial are administered through inhalation, while the secondary trial employs an intramuscular route."
    },
    "5b812594-3dcd-42e8-b984-644fe9dcd87e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary clinical trial reported fewer instances of treatment emergent adverse events and serious treatment emergent adverse events in patients within the paced respiration intervention group than those utilizing fast, shallow respirations."
    },
    "526a5650-0b61-4e6e-9ddf-4674a6193964": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "unconfirmed progressive disease is a disease process that is increasing in scope or severity but the criteria for progressive disease is not met. All patients eligible for the secondary trial are also eligible for the primary trial."
    },
    "baf5c643-9960-4f2e-a9b4-70667a5ca685": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "skin signet ring cell basal cell carcinoma is a rare type of basal cell carcinoma. it is characterized by the presence of mucin containing signet ring cells. Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial."
    },
    "14c1e784-1f79-4ba9-8466-c8c638f929db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "all participants in the primary clinical trial, and 1674/1674 participants in the secondary clinical trial experienced an adverse event."
    },
    "42d3b148-38d6-4665-9d48-4d6bf935fbd9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 60 years if they want to participate in the primary trial, ,  "
    },
    "ace11ff3-a7ac-492c-9dbe-5dafc96f81e7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "raphe nuclei is a group of nuclei that are located in the midline of the brainstem and release serotonin. On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years."
    },
    "a6dd31e3-d055-4343-9d7f-8d141f7c7007": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. renal pelvis and ureter urothelial carcinoma is a transitional cell carcinoma that arises from the renal pelvis and ureter."
    },
    "44ff230b-fe8f-44de-9f48-e6ab10e91b68": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "there was no difference in idfs rate between the neratinib group and placebo group in the primary clinical trial"
    },
    "113abff0-a728-40a6-b637-8bd60a53e626": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2."
    },
    "6e4be816-3da7-4def-ab23-2a4fda805cd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial."
    },
    "f2bac26a-95c8-4ac8-8356-26c3d96e8797": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "biliary colic and diarrhoea are more frequently observed in the secondary clinical trial as opposed to the primary clinical trial."
    },
    "bc9d1c66-4743-474d-9e82-b9e8438a8e86": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial necessitates that patients are above a specified age, whereas the primary clinical trial does not stipulate an age criterion for participation."
    },
    "27fcd959-e1dd-4c76-8e6c-fdf5fe4d257f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "inclusion in the primary clinical trial is ruled out for patients who have had an abdominal fistula, gastrointestinal perforation, myocardial infarction (mi), stroke, transient ischemic attacks, intrabdominal abscess, or significant psychiatric disorders within the past 6 months."
    },
    "78c44e7a-6f94-4167-aafa-13c14da01bbf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 0.5 years if they want to participate in the primary trial"
    },
    "3df32fab-15e5-4536-908f-d9c76529702e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "thirteen individuals participated in the primary clinical trial where they were treated with the enhanced card t cell therapy"
    },
    "054618c6-0f9d-46de-94f3-e69e066a8432": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "5% of the participants in group 1 of the primary trial were found to have lesions, and only 30% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "bfee9542-f923-4084-a92d-216413a99395": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs. organism is a living entity."
    },
    "a5c24bc4-6444-46bb-9da4-fca0d9d6f521": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the interventions analysed in the primary clinical trial and the secondary clinical trial do not have their maximum tolerated dose (mtd) reported."
    },
    "b957f1f2-8dc3-4d00-802d-26cd8fa3b9f4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "both the primary clinical trial and secondary clinical trial permit the participation of patients with a 100mm tnbc tumor."
    },
    "b7d3d4f9-44da-4fba-9005-e650cf0e2bb8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "lymphangiomatosis is a lymphangioma affecting several anatomic sites. Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial."
    },
    "fb8e290e-f73a-46e1-86b1-3a1d13eab0ab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial. burkholderia is a genus of aerobic, gram-negative, rod shaped bacteria assigned to the phylum proteobacteria and the family burkholderiaceae."
    },
    "89e0e893-e053-491c-a276-055b30c5da2e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "patients in the paced respiration intervention group of the primary clinical trial experienced more hot flashes per day on average than patients in the fast, shallow respiration group."
    },
    "7f06a038-29e8-4349-8822-876c2ae2e378": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "fever, ctcae is a disorder characterized by elevation of the body's temperature above the upper limit of normal. All of the Aes recorded for cohort 1 of the primary trial are related to mental health."
    },
    "287251c0-2d26-466d-8340-13d9c15196bf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there was one psychiatric adverse event in the primary trial, which affected up to 50% of patients"
    },
    "6e78e878-1154-43b8-b93a-c1b68aef70c8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "in the primary clinical trial, all patients were prescribed sunitinib, which was taken orally on a daily basis for the full length of the investigation."
    },
    "8dac6b6a-0e3d-4a3c-ac59-5096452207de": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "inferior hypophyseal artery is an artery arising from the cavernous portion of the internal carotid artery that supplies the posterior pituitary gland. 13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases."
    },
    "21d59751-a53d-4262-8410-9959aa93dea4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the number of participants in cohort 1 and cohort 2 of the primary clinical trial are identical"
    },
    "d3fe482c-e694-474a-8ba6-f089ea532040": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0.0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 fraction of patients."
    },
    "5d04737b-c113-4934-94b6-ea9d8dd6318b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial. neonatal culture positive sepsis, ae is an adverse event in a newborn characterized by a systemic inflammatory response to an infection with an identifiable cause."
    },
    "3b1906b0-5212-4341-b6cd-3163456ce44a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 1000 milligrams of denosumab injected subcutaneously every year, the secondary trial also requires injection, adminstering 0.1 to 1.5 mci of radioactive tc99m sulfur colloid."
    },
    "117c69b5-683c-45a6-b80d-5bc866f2faa1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "eligibility for the primary and secondary clinical trials is not determined by the patient's nationality, ethnicity, weight or gender"
    },
    "1172df8a-7da3-4769-8832-32ded72cfcf1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "for the primary trial, patients must be diagnosed with a mutation in the one of the following genes; pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11, whereas no such requirement is specified for the secondary trial"
    },
    "944bcbb5-e85e-4115-bf71-face27208ab3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "within the primary clinical trial, no adverse events were indicated, and for the secondary trial, any adverse outcomes impacted less than 30% of the patients."
    },
    "728c430c-a48c-44a3-a598-38f96ddabaea": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare. acute physiology and chronic health evaluation ii apch111 original result - >=40 is acute physiology and chronic health evaluation ii apch111 original result - greater than or equal to 40."
    },
    "7ab5e41f-6982-43b4-8541-8ff7964d669a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were no instances of hypertension, dehydration and dyspnea in any group of the primary clinical trial"
    },
    "be98ce03-a87b-4fe5-9058-a56259581c41": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time. blackout is a suspension of service (especially of radio or tv broadcasting)."
    },
    "67b66f39-48c2-495c-9ab0-0beefd9cdcef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "the primary trial study groups will experience the same 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging techniques."
    },
    "000c067a-a563-425e-9ea1-7057f8d2c39f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "none of the participants in group 1 of the primary clinical trial had lesions, in contrast, above 95% of the participants in group 1 of the secondary clinical trial had symptoms of radiation dermatitis and hyperpigmentation."
    },
    "e386c5e7-d098-479c-b160-aa3dab13a8df": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "past seven days voice change is a question about whether or not an individual had any voice changes over the past seven days. The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type."
    },
    "76c6b45f-5a4a-47bc-81b1-267a2981b096": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "a candidate's her2 status, whether positive or negative, is not a requirement for the primary clinical trial"
    },
    "d20c94ae-14d5-4272-96d5-ef649dfade50": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "a majority of the primary clinical trial participants experienced some form of eating disorder during the course of the study"
    },
    "3db98663-b8c7-4869-a46a-e7526caa7436": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial. play golf, riding cart is a question about whether an individual plays golf, while riding a golf cart."
    },
    "491a1da4-e9c1-43d9-ba9b-9e53d7f601f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "participants in the primary clinical trial are administered epacadostat at a frequency that is double than that of the sunitinib administration to sunitinib-naive patients in the secondary clinical trial."
    },
    "20a73393-6e4f-4096-8025-45d8fbe228b7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "some patients in the primary clinical trial receive no mcs110 at all, and over 130 mg of pdr001 every other week."
    },
    "b200a0d8-1c63-49a2-bf1c-280e9d6a2968": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "all ae types in the primary trial affected less than 0.1% of patients"
    },
    "3fd8c503-c6fa-45f1-8836-88a5b77873a3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial is examining the efficacy of oral medications, and the secondary clinical trial is focused on intravenous drug administration."
    },
    "948018b7-b40c-499c-bba8-e835222c3c00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have undergone chemotherapy or radiotherapy within the past two weeks, those with unstable angina, or those who have grade 2 or higher neuropathy are not eligible for the secondary clinical trial. however, these conditions do not inhibit their participation in the primary clinical trial unless they have non-healing surgical wounds."
    },
    "1357d4a3-909e-4b71-aa5a-ce11869ec91e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was nausea"
    },
    "42b44f03-de67-4d76-a566-2669f0768a23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the secondary trial was anaemia, affecting more than 3/4 patients, there were no recorded aes in the primary trial."
    },
    "d9cff591-e319-46a0-bc70-a25224cd5b49": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "swls questionnaire question is a question associated with the swls questionnaire. Morbidly obese patients are eligible for the primary trial."
    },
    "4e929375-b7c0-4a81-baa9-9c21d95366b7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary clinical trial focuses on evaluating the efficiency of distinctive medicinal treatment, while the secondary clinical trial is analysing variable amounts of the same drug on its subjects."
    },
    "c90dda31-65a8-4a77-8657-7cdf498b366f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients exposed to antineoplastic chemotherapy, androgens, estrogens, or progestogens treatment during the two years prior to the study's commencement are not fit for the primary clinical trial."
    },
    "5b94573b-9254-48e4-a384-0212f39451a8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "middle ear disorder is a non-neoplastic or neoplastic disorder that affects the middle ear.  representative examples include infection, cholesteatoma, and carcinoma. All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants."
    },
    "d3df95aa-4564-4503-9322-64f5664ce1c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "only participants diagnosed with cancer receive treatment in the primary clinical trial"
    },
    "87f63f2e-5648-4b9f-9f25-a5adb80dcb1d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0% adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 of patients."
    },
    "67f9627e-ec2e-49b5-bb2e-2adbb5debfef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary clinical trial is significantly shorter compared to the primary clinical trial."
    },
    "6654ce22-9470-43d1-9e51-a17f1a06f514": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "5% of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases"
    },
    "9069ac6d-9d0f-4484-adda-bde33d713b7e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. 20q13.2-q13.3 is a chromosome band present on 20q"
    },
    "f44e50eb-f7de-403f-8e1c-25ae4cb1f530": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "the final decision regarding a patient's participation in the primary clinical trial, even if they meet all the inclusion and exclusion criteria, rests solely with the attending clinician."
    },
    "ab6d9f92-0380-4e3a-9bff-032ad4d918ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "it was observed that 1/1000 patients in the primary trial and 398/1674 in the secondary trial had an acute myocardial infarction."
    },
    "a87b00a3-b6c1-4ee3-a6e0-fbd2eccbea05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients with cytologically confirmed stage 2 ovarian serous carcinoma that is either brca1 positive, brca2 positive or tp53 negative pass the selection process for the secondary trial and the primary trial."
    },
    "328b27ff-4e87-40df-824f-73fb1f01b8a7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "all cohorts across the primary clinical trial will use the educational dvd as a key component of their intervention."
    },
    "62716b99-76d4-4dfe-b0ce-1ad35f768b33": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "an ecog score of 1 makes a candidate suitable for participation in both the primary clinical trial and the secondary clinical trial"
    },
    "6a211e77-e17f-4739-b685-e6bd83b8d7e3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "a diagnosis of leptomeningeal carcinoma would render a patient ineligible for the primary clinical trial"
    },
    "33641401-b713-4800-86a9-aa7766b456f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "in cohort 2 of the primary clinical trial, acute vomiting was a side effect for over half of the participants post-treatment with aprepitant, dexamethasone, cytoxan, and kytril."
    },
    "2de24fb7-9ebe-419e-af16-5d9ed2b808ef": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ild/dpld within the last 2 weeks, with a life expectancy of 1 hour would be eligible for the primary trial"
    },
    "8dbf8922-4680-4125-9bc3-f6ea881c5978": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "dehydration was a common side effect observed in both cohorts of the primary clinical trial."
    },
    "d93422f2-c5ab-4aa0-90a3-478b05a17c4e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the cohorts of both the primary clinical trial and the secondary clinical trial reported over 100 total adverse instances."
    },
    "b95564b8-cdbe-45d0-be91-764d6768e5f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel"
    },
    "cfef163a-3390-4b89-9a6f-7c351262625d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "patients with deficient vitamin d levels in the primary clinical trial displayed a discernible pattern for expression of the 40 evaluated genes."
    },
    "0a26f239-60ec-4aa7-81e8-de47c20def59": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 50 cases of hypertension, edema and dyspnea in either cohort of the primary trial"
    },
    "bb12ebcd-127e-4834-b0f3-9759ed13c5ed": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the findings from the primary clinical trial indicate shifts in the intensity of pain, contrastingly, the secondary clinical trial examines the fluctuations in the bone mineral density (bmd) of the lumbar spine from its original condition to nine months onward"
    },
    "d17230ee-836d-4153-b940-8e3dd7741964": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "a weekly cycle of 4-demethyl-4-cholestryloxycarbonylpenclomedine is a shared necessity amongst the primary and secondary clinical trials."
    },
    "ddfc4bce-b6b0-4817-a171-db6bd5e095bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "in the primary and secondary clinical trials, nationality, ethnicity, psychiatric condition or gender of a patient do not influence their eligibility"
    },
    "34199309-5388-4ed1-956d-17e9c7afaaef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "refugee from high tuberculosis prevalent area is an individual that has fled a country for their own safety which has a high occurrence of tuberculosis. the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients."
    },
    "f41f7611-7c20-4f71-8b2d-433e36f840de": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "appendiceal carcinoid pm1 tnm finding v7 is appendiceal carcinoid with distant metastasis. (from ajcc 7th ed.) Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream."
    },
    "9acd718f-6e45-495a-846d-b248d6690f1c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "both the primary and secondary clinical trials do not consider mymop score variations as a way of measuring their research results."
    },
    "d66e149e-5bb7-4e4b-8078-7f5947a31f60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 40 year old patient with medically verified diagnosis of stage iv colon cancer, absolute neutrophil count of 900/\u03bcl, platelet count of 60,034/\u03bcl, hemoglobin level of 80 g/l, and a life expectancy under 5 months would not be qualified to join the primary clinical trial and the secondary clinical trial."
    },
    "fe5928a4-1a0c-4c41-9b85-8d7785a8ab4c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110."
    },
    "c43d1ac6-f3d2-44f6-870d-fb91f3365c5b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group."
    },
    "3852b7ff-e68a-4bc8-917f-4eb9c838862d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "recipients of an organ transplant in the past six months who are now ambulatory are able to participate in the primary clinical trial but would not meet the requirements for the secondary clinical trial"
    },
    "936b5904-9a93-4aaf-8d20-03e0a4fb3223": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 156 weeks would be excluded from the primary trial"
    },
    "bc13c987-6166-42c9-b537-1efc6126c3d8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients in whom metastasis cannot be assessed, or whose cancer has not disseminated to other body areas are deemed inappropriate for the primary clinical trial"
    },
    "75cdd5c7-ad36-4ab3-8fe2-6d0e84ab8f0a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "reactive epithelial hyperplasia of the ciliary body is an increase in cell number and volume of the ciliary epithelium, usually in response to injury. (who 2018) In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants."
    },
    "c7bddafb-404b-40be-80c0-f0b4e08d6466": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary trial only has a single adverse event recorded for its patient cohort. planned subject activity group sequence number is an integer specifying the relative sequential or temporal ordering of a visit within a study"
    },
    "4d6b0c89-c9fc-4195-ac3e-c33b28af955e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "in contrast to the secondary clinical trial, which uses the same criteria for all participants, the primary clinical trial has two different sets of inclusion standards for individuals aged 18-50 and those aged 50+."
    },
    "251e979f-a7ba-4dea-afb7-01b9501ec7cf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group"
    },
    "35aa67ad-b884-4cec-afdf-bef9cb6619c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive one single injection on day 8 of the study. shan language is a kra-dai language that is spoken by the shan people, mostly in the shan state of myanmar."
    },
    "c2b8b1b0-9d84-498a-b490-e3da298f1087": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "malignant neoplasm of the upper third of the esophagus is a primary or metastatic malignant neoplasm involving the upper third segment of the esophagus. the secondary trial and the primary trial use different units of measure in their results."
    },
    "9aed7121-8548-40e9-a960-618bf0173df8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary clinical trial's intervention section includes comprehensive descriptions regarding method of administration, dose, and scheduling."
    },
    "f859f501-4e35-44c5-88bf-213949f5e5e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial has only few spots open for patients diagnosed with metastatic colorectal cancer which carries the kras or braf mutation."
    },
    "33c89b93-d655-4154-9712-0803974c65f7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "in the primary clinical trial, the entire initial cohort faced a form of adverse event."
    },
    "95a261bd-f102-4ce8-887b-afa14d1e2856": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after more than 6 weeks of therapy with tak-228 and tamoxifen, there was a 5% reduction in ki67-positive cells in patients participating in the primary clinical trial"
    },
    "d1d5671f-79dd-4fd3-a4aa-b5f81d8a944f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial "
    },
    "b0410aa1-2da2-4399-b673-45157d3c3fb7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "in the primary clinical trial, there was a rise in blood bilirubin levels in 36.36% of the patients."
    },
    "49e76af6-53c7-458d-a091-0aa8edf2f2aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. eastern romance language is a group of romance languages centered in romania."
    },
    "ca09a15d-86a6-4a7e-9dfb-ff195702e0d4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "during the course of the primary clinical trial, 35 patients who were under the combination therapy of sunitinib, docetaxel, and trastuzumab encountered treatment-emergent adverse incidents."
    },
    "99e16f2b-e690-4684-9dff-cf37877c796c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "fewer than 10% of the primary clinical trial participants noticed a reduction in circulating tumor cells subsequent to multiple months of high-dose chemotherapy preceding purged autologous stem cell products."
    },
    "df8057c4-0640-488f-9a63-9036703fbf83": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 2ml of mcs110 every 3 weeks."
    },
    "4bf82041-f1d8-4a90-9bd0-aec991e50966": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "percentage food eaten score 40 is a subjective score of 40% on a scale that ranges from 0%: none to 100%: all of my food. Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial."
    },
    "95570634-cfd3-4f4c-8082-8b98a2f13859": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the paclitaxel plus bevacizumab plus gemcitabine group during the primary clinical trial showcased a better orr when juxtaposed with the paclitaxel plus bevacizumab group."
    },
    "e02cca6f-2a41-4a5a-bf83-23cdab6ee8dd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "gamma-tubulin is a family of globular proteins that plays a role in the nucleation and orientation of microtubules. All Infections and Fever cases in the primary trial were for patients in cohort 1."
    },
    "2062b384-c6c1-4997-a4e4-b6709d123502": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "participants in the primary clinical trial were found to have cholelithiasis at a rate two times higher than those in the secondary clinical trial."
    },
    "fd942f9a-9ad7-43f3-aac3-69b01a022811": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "gastric pylorus carcinoma is a carcinoma that arises from the pylorus. 18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation."
    },
    "d1a7cbaa-161a-4675-b8b7-67ae364be364": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies."
    },
    "b3b66b49-6a4c-4c26-b46c-915ab45374ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary trial patients receive higher doses of radiation therapy than the secondary trial participants"
    },
    "23f84ae0-fd01-4799-8872-118e22a015e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia"
    },
    "2b4a5598-2d21-426a-9d85-b0f94efb9bea": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "portable network graphics is an extensible file format for lossless data compression of images. Far more patients in the secondary trial were recorded to have experienced Chest Pain, than patients in the primary trial."
    },
    "760d8b66-18ea-4e33-b83a-b88173ed8574": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there are zero shared inclusion/exclusion criteria between the secondary trial and the primary trial."
    },
    "819893b4-9c57-42b8-938e-f6147e41694d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. cardiovascular lesion indicator is an indication as to whether a cardiovascular lesion is present."
    },
    "18876a8c-2536-4148-b563-c5a68daa7fac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events. iv anesthesia was not administered is a response indicating that intravenous anesthesia medications were not administered."
    },
    "f2d7cf41-2cd1-4d03-a153-18764cf7da09": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "crank arm assembly device is an extension to a shaft designed to impart a rotational energy to the shaft. On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients."
    },
    "d40740f4-8885-4590-b274-23802a46d9e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "procedure start relative to reference time point is an indication or description of the start of a procedure in relation to a specific point in time. the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group."
    },
    "20307fc02-18bb-4910-9992-43a811bf7a1f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive less than 24 months, over 40 patients from each cohort survived less than 2 days"
    },
    "8667c9e0-5040-46af-b784-4214164c4c0c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "the primary clinical trial witnessed many psychiatric adverse incidents, notably including an eating disorder and schizophrenia"
    },
    "f2076a4f-6170-46ca-9e08-8d0f9589bb06": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "12q24 is a chromosome band present on 12q The majority of patients in the primary trial experienced complete response by week 24."
    },
    "5a1445df-c3d7-4d1e-a4d3-e18ac2238a97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "during the primary clinical trial and the secondary clinical trial, no cardiac or psychiatric adverse events (aes) were reported, though several other categories of aes were noted."
    },
    "00102571-e1d6-42c9-b227-f0ac146d411d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "gin chinese is a chinese person from the gin ethnic group. Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55."
    },
    "df0234b5-3b00-4036-ac6c-5cb2d1eeafdf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "all participants of the secondary clinical trial are administered with enteric-coated tablets"
    },
    "0f4882ae-b6f3-4c11-b4ad-a3fc1aeb6f94": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "6p25 is a chromosome band present on 6p Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial."
    },
    "6bc62f08-51ae-44d6-be1d-738c82598de5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 180 days if they want to participate in the primary trial "
    },
    "6d3a9617-a195-48e4-aa19-61a3ecde9ddb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "cervical alveolar soft part sarcoma is an alveolar soft part sarcoma arising from the cervix. Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria."
    },
    "e53898b8-422f-4317-b2f6-c487409b0750": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "In total there are less cases of anemia in the primary trial than in the secondary trial."
    },
    "f823a6d1-5d44-4d8c-8f33-14eef364d3b6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "the primary clinical trial welcomes men of potential fertility and women with the potential to conceive, nevertheless, as a requirement they need to undertake a commitment to abstinence for the full course of the study"
    },
    "b0af496d-fead-41b6-96fd-71dea81c8501": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "there were fewer suspected serious adverse reactions outlined in the adverse events section of the primary clinical trial compared to the secondary clinical trial."
    },
    "930e7529-e05a-471e-9d52-17f538f610c2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy. abnormal involuntary movement scale aims0111 through aims0112 original result - no is abnormal involuntary movement scale aims0111 through aims0112 original result - no."
    },
    "08920163-ef22-4242-b9bf-b70af58c91c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "in the primary clinical trial, the globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine was used to treat 13 participants"
    },
    "623db2b4-6824-42e4-9ad6-39cf3bf14dab": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day."
    },
    "59b5ce7e-13af-4377-8923-c096f79bcade": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "16p13.13-p13.12 is a chromosome band present on 16p All Infections and Fever cases in the primary trial were for patients in cohort 1."
    },
    "45571dd6-2532-4086-af29-0b8558423b26": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients with confirmed stage 1 and 2 breast adenocarcinoma that is er negative, pr negative, or her2/neu positive are able to participate in both the primary clinical trial and the secondary trial."
    },
    "ef2352dc-a976-47c6-91cd-6666e3f7b55a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Mean sleep time of its patients in hours."
    },
    "0ef9a5c8-1159-4147-a204-59a3ae183e7d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "thyroid gland lipoadenoma is a thyroid gland adenoma composed of follicular structures and mature adipocytes. The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs."
    },
    "f1a4fdcb-09ae-4f35-9681-8ee7d0d3b41d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "cohort 1 receives more durva in their bi-weekly iv infusions than cohort 2 in the primary clinical trial."
    },
    "7270c176-7bf2-4b0d-941d-912f5a3ed62c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients."
    },
    "73a0936e-5144-4b8c-b230-389d8ed451af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "individuals that have been treated with androgens in the last month are eligible for the primary clinical trial."
    },
    "cca11232-84c4-44e1-89f1-b57b28643dce": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts."
    },
    "a9600a10-ab9c-4b6d-ad89-30f9d7859a50": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using Yttrium-90 glass microspheres and TheraSpheres, on the other hand the secondary trial intervention consists of 560 mg of ibrutinib and 10 mg/kg of MEDI4736 twice daily for a month. have night sweats is a question about whether an individual has or had night sweats."
    },
    "5abc6652-31bf-4ac6-a16b-432912aa6224": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 25 more days than the intervention detailed in the primary trial."
    },
    "489c9279-ebca-4ff2-ae61-c8ff4275f3ac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "All Patients receiving the placebo intervention in the primary trial experienced emesis . don't feel like doing anything is a question about whether an individual doesn't feel like doing anything."
    },
    "3fd8d038-4c72-4f0f-b2d8-0e822f5b96a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study. welding occupations is a class of professional or vocational positions of employment that involve work with welding."
    },
    "cbba3546-5b88-42d0-882d-024d5f267d97": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial."
    },
    "10b61f57-c5c1-4d29-9838-bb14c4608bf4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "in the interventions of the primary clinical trial, both cohorts are without any counselling, risk assessment, or cognitive behavioural therapy (cbt)."
    },
    "e501b32a-a182-4275-bcdf-88aca4446cf9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients diagnosed with histologically confirmed stage 4 breast adenocarcinoma, that show either er positivity, pr positivity or her2/neu negativity can participate in both the primary clinical trial and the secondary clinical trial."
    },
    "4eb2221b-a478-4b64-bed8-230e4eab958d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "over 20% of participants in the primary clinical trial encountered adverse events"
    },
    "54c9f3b4-b90f-4b60-a924-5a26c4097521": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "body fat measurement is a measurement of the total fat mass within the subject's body. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX."
    },
    "57e2cf8a-6c67-4771-b180-70b613fff1cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "in both the primary and secondary clinical trials, patients are required to participate in a weekly cycle of 4-demethyl-4-cholestryloxycarbonylpenclomedine."
    },
    "6b6d3087-435b-4129-b368-29d8879f7ff4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention. nasal cartilage is any of the cartilaginous structures that provide structure and support to the nose."
    },
    "9e19e98e-3ce1-4b01-9080-ad34e68f0acb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "in the primary clinical trial, except one, all patients who received sunitinib + docetaxel + trastuzumab experienced a treatment-emergent adverse event, and less than fifty percent experienced severe treatment-emergent adverse events."
    },
    "6e1c74e3-1b7b-41bf-8ee4-f605d94c0fdf": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the secondary trial has higher incidents of biliary colic and clostridium difficile colitis compared to the primary trial."
    },
    "5fca366e-ecc6-41e4-b621-e3343ff0f07e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "agent administration care setting type code is a coded value specifying the medical setting within which the agent administration took place. The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses."
    },
    "e9146895-e9b0-49cb-b05e-9264b682cece": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "adverse events were reported by fewer than 5% of the participants in the primary clinical trial"
    },
    "f329518b-872b-41af-8260-9d231e7ab205": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "while gender is irrelevant in determining patient eligibility for the primary clinical trial, the secondary clinical trial is open only to female patients."
    },
    "d46a61dd-b28a-476e-981e-f3d1cca2739c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial and the primary trial results highlight similar outcome measures"
    },
    "5fbee4f6-43fc-45a7-88c4-3dcd5ff21053": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a leptomeningeal carcinoma would not be eligible for the primary trial"
    },
    "0d8ce6e1-e0bb-42b6-a8ec-0d2679b908ad": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "there were 4 additional adverse incidents recorded in the primary clinical trial compared to the secondary clinical trial."
    },
    "912414db-d418-4c96-b06b-e26d0ac1992f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia. malignant pylorus neoplasm is a primary or metastatic malignant neoplasm that affects the pylorus."
    },
    "df39cd99-7291-4749-a7d5-ff760b7c3fc2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": " cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial."
    },
    "4e9a0d19-c8b1-4ea4-9c73-2cf93b46f6a4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 65 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 210 days after the surgery"
    },
    "7a8f6698-eb2a-4695-b521-7e42522afdba": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time. numerical chromosomal abnormality is an irregularity in the number of chromosomes."
    },
    "57dec3a3-0bce-48c3-972d-e08f32ea9b15": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "the secondary clinical trial had several recorded deaths in the adverse events, but the primary trial had no such incident."
    },
    "7f53b46f-6ab4-4d59-bc28-b13eca3fb3b3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "no patients in the primary clinical trial experienced recorded adverse events, in contrast to the secondary clinical trial where every participant suffered from a minimum of one adverse event."
    },
    "4bf53370-da92-4333-bae7-3b35ab56b86e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "both primary and secondary clinical trials accept participants who have had pulmonary embolisms in the past and currently have breast implants."
    },
    "f6835e26-4231-4f1a-a5f0-00e6919eb622": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "participants in the primary clinical trial will be required to take only oral medications."
    },
    "0a6d1117-f868-4495-bb04-e5da37c15144": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial incorporated three test groups and did not use any placebo group, while the secondary trial held only one test group."
    },
    "10f7c7cf-b7e2-4d21-8870-1fdbcc7937f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time."
    },
    "11de406a-fdd7-401a-a6b9-0c0b47bdf7f6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "all the aes recorded for cohort 1 of the primary clinical trial concern oncological side effects"
    },
    "7bc71832-7742-4a77-b0ca-d8820db7f9bd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "detailed description and treatment cycle are provided in the intervention section of the primary clinical trial."
    },
    "13d13c8d-1d58-411f-943b-cbcd836b8d17": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "mobilization clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered mobilization therapy. cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2."
    },
    "91a4429b-767a-493a-b1f3-f3a1ccf5ab6c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, some patients receive mcs110, but the dosage administered is less than 20mg."
    },
    "c638fd13-e832-4bc6-9b3a-ad9d8da4b1c4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there are 10 shared inclusion/exclusion criteria between the secondary trial and the primary trial"
    },
    "54f86209-3c4b-4dfd-b048-e8eeb864300c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all individuals participating in the primary clinical trial are provided with at least 20mg of mcs110 every 3rd week."
    },
    "359a101f-e771-4fac-b2f7-a5486fb19344": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "sellar teratoma with malignant transformation is a teratoma with malignant transformation that arises from or adjacent to the sellar region. Patients receiving the placebo intervention in the primary trial were twice as likely to experience emesis as patients receiving Aprepitant."
    },
    "620b6390-df07-45fe-9ef9-55a32521c740": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "Diarrhoea was more common for the primary trial participants than the secondary trial participants"
    },
    "4a88976f-0af4-449e-97d9-5b3f1ce94668": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients who have experienced abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess, or major psychiatric disorders in the past 6 months are not considered for the primary clinical trial"
    },
    "0cecee52-d87e-419a-a970-e79733613a87": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "only caucasian patients are eligible for the primary clinical trial."
    },
    "64ea29b0-1d21-4c59-a56e-553765f5e5c8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial. left renal artery is an artery arising from the abdominal aorta that supplies the left kidney."
    },
    "79923aba-be0b-476d-ae86-733fce590db1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "how much bothered by swelling in affected underarm, arm, or hand is a question about how bothered an individual is by swelling in their affected underarm, arm, or hand. African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study."
    },
    "a079229c-d371-4c18-b2b3-20b0068a4c50": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "there were several instances of shingles in both the primary trial and group 1 of the secondary trial, but none in group 2 of the secondary trial."
    },
    "dacc42a9-68cc-4b2c-9377-648486729eed": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration. nausea during this period is a question about whether an individual had nausea during the specified time period."
    },
    "2f6221cf-15f0-4da7-b800-d65f4dd001d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "the performance status for candidates is not influential for admission into the primary clinical trial or the secondary clinical trial."
    },
    "cacd8f36-53c3-4002-9d2d-09bd2976bf40": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with histologically verified diagnosis of stage 3 breast cancer, absolute neutrophil count of 1.807 million cells/\u2248\u00ed\u00ac\u222bl, platelet count of 110,034 thousands cells/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 90000 mg/l, and a life expectancy exceeding 96 weeks would be eligible for both the primary trial and the secondary trial."
    },
    "bd828bb3-e2b2-46e0-a1fb-635d6aade839": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. neither good nor bad is a subjective response indicating that something is neither good nor bad."
    },
    "22cf6f40-f022-4482-acdf-eef98748b946": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 3 quarters of a year in bone mineral density (bmd) of the lumbar spine"
    },
    "0f0501ba-557e-4111-8473-ec54b624a47f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "breast cancer patients in the primary trial are administered 200 mcg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 500 mcg/day talazoparib instead."
    },
    "b8c7a9f1-a31e-4be6-a0ff-9452728c2e0c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism in the last 60 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "aa9da5b8-f5de-4a49-a93c-9e354cdef066": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "no adverse outcomes were recorded in more than 1% of participants in both the primary and secondary clinical trials."
    },
    "cb5c3a2b-3752-4e0d-9b5e-ae84ffaab109": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "despite the variant cancer types, most patients in the first cohort of the primary clinical trial were screened contemporaneously after the intervention."
    },
    "4138d4cd-bc5a-44db-8dc2-f64fbfb28b94": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "the primary clinical trial noted a number of adverse effects in patients belonging to cohort 1."
    },
    "9d9db340-6fee-4ec0-b6cb-7fdfe2d34959": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0% cases of hypertension, edema and dyspnea in either cohort of the primary trial"
    },
    "0abf8fc8-9361-4b86-a3ca-fb6bdfbc5b5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "malfunction only (no ae) report is a report of a device malfunction that does not include an adverse event. Patients diagnosed with malignant ductal carcinoma in situ are eligible for the secondary trial but excluded from the primary trial."
    },
    "6003b550-4716-4966-a585-5a69fea20613": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients affected by unstable angina or those having undergone either chemotherapy or radiotherapy two weeks prior, or with grade 2 or above neuropathy, are disqualified from inclusion in the secondary clinical trial, but may still participate in the primary clinical trial as long as they meet all relevant inclusion criteria."
    },
    "2a56e9e0-10fe-4a2d-964a-71390b3bb4d4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial or the secondary trial. grade 1 ileal obstruction, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated"
    },
    "060a4ded-7677-4945-90ff-b6b93204f94c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism within the last 300 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "69b11fe6-3c14-4ac6-a664-916dc341700f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the patients in the primary clinical trial are given mm-121 and paclitaxel less frequently on a weekly basis compared to those in cohort 1 of the secondary clinical trial"
    },
    "c6aa83b0-88fb-475a-8b38-e330d2bdf332": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "partial or complete response is a partial or complete response to treatment. the primary trial and the secondary trial adminster their interventions orally."
    },
    "a0ad7d49-26f2-42ac-a384-e6362ccae8d7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates capable of only limited selfcare; confined to bed or chair less than 20% of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "ba589a4b-13ef-43be-8441-438742dd9d5c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "tumor findings evaluator is a person who determines the significance of a tumor findings assessment. Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure."
    },
    "fbd6b437-ba96-46fd-933f-8299e0efb0e5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine . confidence is a feeling of trust (in someone or something)."
    },
    "91ce9f54-322f-4796-930e-0f85cf65d115": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "cohort a and b of the primary trial are given two differing doses of oral ld v935, not necessarily at the same point in time."
    },
    "76b35642-5bf9-4980-beb9-e802493907b6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "patients receiving the placebo intervention in the primary clinical trial were less likely to experience emesis compared to patients receiving aprepitant."
    },
    "82cea870-dbc3-4ebf-824c-0cebd7e95205": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 is given a lesser amount of alt-801 as compared to cohort 2 in the primary clinical trial"
    },
    "0938714d-688d-42b5-a605-1153c172aa48": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "child-pugh class c10 is a total score of 10 for hepatic function, corresponding to class c in the child-pugh classification. Several patients in the secondary trial and the primary trial suffered from Tumour lysis syndrome."
    },
    "1917f075-87da-430b-adf7-bb1579d145fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "the administration of alpha lipoic acid in the primary clinical trial is at a higher dosage, up to 100 mg thrice daily, compared to a constant dosage of necitumumab given to patients in cohort 1 of the secondary clinical trial."
    },
    "333e2178-1944-4771-9ce5-6c89a1386f5a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "all participants in the primary clinical trial, irrespective of their cohort, receive a consistent dosage of docetaxel, doxorubicin, and cyclophosphamide at the same frequency."
    },
    "5b94480e-aa25-491e-ae37-a2b2939eafaf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "All patients eligible for the secondary trial are also eligible for the primary trial."
    },
    "376c9806-25fd-4b1c-962a-b14c2ca6d9b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients suffering from alzheimer's disease can participate in the primary clinical trial"
    },
    "52ee52ad-c158-48b8-86f1-99589e8150c5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "0.13 of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases"
    },
    "2cff90dc-7bc3-4acb-a250-10de476d1d4c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "the primary clinical trial would not include an adult diagnosed with diffuse parenchymal lung disease within the prior 3 years"
    },
    "738a5b84-f8e8-411b-9376-377760780e01": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "unlike the secondary clinical trial that evaluates various drug dosages in its treatment plan, the primary clinical trial refrains from incorporating drug-based treatments."
    },
    "f1b4c0aa-df9b-4d75-9c65-f06709df664a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "a patient with frequent smoking habits is eligible for participation in the primary clinical trial."
    },
    "f0534dd1-7050-4fc1-971e-5aab8abb5d47": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "no cardiac or psychiatric adverse events were reported in the course of the primary clinical trial and the secondary clinical trial."
    },
    "b2059651-24e7-4b6c-aeee-403ff32cf725": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": " Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. adult diffuse mixed cell lymphoma is a b-or t-cell non-hodgkin lymphoma composed of a mixed-sized lymphocytic population occurring in adults."
    },
    "51dace9a-0da5-49ed-8d8b-7489416ea9e8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "compared to patients receiving aprepitant in the primary clinical trial, those who received the placebo intervention had double the likelihood of experiencing emesis."
    },
    "c002edfa-458b-4274-860e-a3c6024c467c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "mental scale is a range of values that characterizes an individual's mental development. Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study."
    },
    "f83654b1-c44c-40eb-a7b1-91db95cb71f6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. atevirdine mesylate is a mesylate salt form of atevirdine, a non-nucleoside reverse transcriptase inhibitor. atevirdine is active against azt-resistant virus strains."
    },
    "f693e25f-c128-48d1-883d-488248b8347d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 10 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place"
    },
    "e04edb9d-dc0e-44c4-abb9-3260b400e265": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure."
    },
    "7e271bbd-26e8-422e-be5c-54d294da815a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial."
    },
    "c51c390c-f844-492c-9844-53e31e01124d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "in the primary clinical trial and the secondary clinical trial, a significant number of unexpected fatalities and hospital stays were observed."
    },
    "1f755559-38fb-4edc-a41a-91252b1dfb54": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "14q22 is a chromosome band present on 14q alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day."
    },
    "ee049505-21d4-4255-823c-10d79a91db59": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "adverse events were experienced by less than 10 participants in the primary clinical trial"
    },
    "e012d94f-ee90-40b0-9a4d-e41ec19a512d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. adverse event dictionary is a reference source that provides meanings of words related to adverse events."
    },
    "0d7caeea-5417-4eb2-9d92-3d3ada73ece7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "adverse events affecting more than 1% of participants did not occur in either the primary clinical trial or secondary clinical trial."
    },
    "2295bf51-5b26-4cde-9bcf-caeada0181b1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "the primary clinical trial does not impose restrictions based on life expectancy, pregnancy status, or age for its participants"
    },
    "3f87dd7c-b00d-4840-b075-70b65e5bf00c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "the number of bronchopneumonia cases and instances of general physical health deterioration are equal in both the primary and secondary clinical trials."
    },
    "4805b27b-471f-4571-8de9-a7a77f1bd1a4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "not a single ae was reported for either cohort in the primary clinical trial"
    },
    "428f149b-1b45-4ad0-a5d3-0c885fec2767": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the intervention provided in the secondary clinical trial reports on the mtd, while the intervention provided in the primary clinical trial does not."
    },
    "dfcbb31f-65e0-4847-9840-536eff03c1f3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "only patients who demonstrated positive responses to previous herceptin treatments are eligible for the primary clinical trial."
    },
    "e5f77572-2271-434c-8965-dfdac502ea4e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "the secondary trial participants receive pembrolizumab twice as frequently as participants in the primary trial receive sunitinib."
    },
    "70e1b8ee-05e4-4427-ba8b-c8762a677b9a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 0.5 g of fulvestrant in a tablet form to be taken bid."
    },
    "b0b78244-40a7-46d4-888d-1ccfe70d3645": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "the frequency of docetaxel, doxorubicin and cyclophosphamide administration varies between cohorts in the primary clinical trial"
    },
    "82080910-276d-4987-8d95-0a39b92ce3ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "eligibility for the primary clinical trial requires having colon cancer and a lack of response to prior hormonal treatments."
    },
    "d4f76af1-2a9e-488a-b871-4b489dea5c02": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial records alterations in ki67 expression in tumors."
    },
    "0f094624-f6e3-479b-bea3-34b5a3acf873": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the secondary clinical trial's intervention duration extends 15 weeks longer than that of the primary clinical trial."
    },
    "ce486acd-8aae-475c-b95e-131fc0809e15": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "rifamycin sodium is a sodium salt of rifamycin, an antibiotic produced by streptomyces mediterranei which is used to treat mycobacterium infections. The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel."
    },
    "2107eaac-f0e5-47a2-a7cb-b6d27aa47d23": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "all candidates in cohort 1 of the primary clinical trial experienced at least one adverse event (ae), while none of the cohort 2 candidates did"
    },
    "c0dc65fc-1c17-4594-a168-c9c2da2802b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "there was not a single adverse event reported during the primary clinical trial."
    },
    "f024fdc1-bee8-4ad8-a80d-9369d52b799a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 100mg in the primary trial gained lean body mass over a 9 month period"
    },
    "36cc43dd-5761-49ef-bd9d-35e54dd5a97b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 104 weeks before study entry are excluded from the primary trial."
    },
    "e7bc1f65-d4e4-4f87-9a2c-ab56c35368ae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "15/7 the primary trial participants, and 5/1674 the secondary trial participants suffered an ae."
    },
    "067bc726-4646-40f8-aa6f-af44d315046e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "no gastro-intestinal adverse events were observed during the primary clinical trial"
    },
    "d942324e-c945-4703-b88e-905c073cfcd5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were zero cases of hypertension, edema and dyspnea in either cohort of the primary trial"
    },
    "952fd1e7-65a2-417f-b1b8-188bce187c04": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary clinical trial uses uniform criteria for participant eligibility in every phase, whereas the secondary trial's selection criteria vary per participant."
    },
    "17414a49-7410-41fe-ab90-99311491d367": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "in the primary clinical trial, participants are administrated 100 mg/m2 of lapatinib orally, twice daily for a period of one month."
    },
    "d6cc1a08-fbff-4ef1-b44f-6bc1b1ed0ef2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "more instances of palpitations, pericardial effusions, and abdominal pains were documented in the primary clinical trial compared to the secondary one."
    },
    "8b3dbda5-ee27-4d74-b6ab-d4bb1cc5c86b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "warfarin-based therapy is a mandatory requirement for patients in the primary clinical trial and it disqualifies them from the secondary clinical trial."
    },
    "d735322f-f5fc-489d-bb28-e40451860571": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "in the primary trial, the method of administering the intervention 1 is through oral pills, whereas all intervention drugs in the secondary trial are given via inhalation."
    },
    "5d6bf9b2-6737-4266-9566-436393cdcfab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "on average, patients in the paced respiration intervention group of the primary clinical trial experienced fewer daily hot flashes than those in the fast, shallow respiration group."
    },
    "c96d223f-7d7e-47aa-b71e-0b56ab6eef81": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "None of the primary trial candidates have to perfom regular exercise as part of the intervention. leporine experimental organism diagnosis is a condition that is relevant to either disease states or models of disease in rabbits."
    },
    "0e3228de-973b-4ce4-9d67-e46392d6f0a6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "childhood kidney angiomyolipoma is an angiomyolipoma occurring in childhood. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2."
    },
    "9562c377-c748-46d7-a5f2-eb492d20e477": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial"
    },
    "b51a60d1-5112-4972-a303-11b35ba07af1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "eligibility for both the primary clinical trial and secondary trial requires women to be aged 22 or above"
    },
    "851e1a1b-0b8e-4aef-a7e3-f06c036fe537": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2"
    },
    "418be5f3-61b5-4bae-a274-c2213e3cc7cf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "while the primary and secondary clinical trials share common intervention methods, their outcome measurements are entirely separate and unrelated."
    },
    "686121cf-e252-49b2-9e46-f4cb6ebac7f8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "the secondary clinical trial and the primary clinical trial are open to women who are 18 years old and above."
    },
    "3c749ffd-27b3-473d-92c9-c4d3899c9689": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1. cardiovascular system findings test is a character or string that represents the long name of the cardiovascular system findings assessment."
    },
    "0359c605-2a3a-4696-8d14-ba214c571f1b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "ga-68 psma-r2 positron emission tomography and magnetic resonance imaging is an imaging procedure that combines gallium-68-labelled psma-r2 with an mri scan to overlay activity data onto detailed anatomic images. Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial."
    },
    "6450428b-bd2a-4ba5-aa5c-c86284dafa98": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "Any Patients currently taking part in the secondary trial will also be eligible for the primary trial as they have the same inclusion criteria. duodenal extraskeletal osteosarcoma is an extraskeletal osteosarcoma affecting the duodenum."
    },
    "40f8f9a6-a042-4f99-bbd9-5f3c3279045d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "in both the primary trial and secondary trial, methotrexate is administered to the patients"
    },
    "da6c4a2b-18ad-44d9-9021-71c4f9b22fff": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "both the primary and secondary clinical trials use the same outcome measure: the proportion of patients with no invasive tumor leftover in the breast post-surgery after finishing chemotherapy, defined as pcr within the breast."
    },
    "3b25e9e8-6fe5-40a3-b302-7a32f651b464": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "patients must have a karnofsky score of 80 or above to be considered for the primary clinical trial."
    },
    "cd0b8308-0c5c-4e7c-9f4f-9e1714fc7db2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "patients with unresectable scbc are suitable candidates for the primary clinical trial despite the presence or absence of er or pr factors"
    },
    "746f0f7a-c7e2-4ac9-a0ca-db2783eec9fa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "none of the patients treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial experienced any treatment-emergent adverse events"
    },
    "4d702550-2f94-46be-92f2-ea6659c69ddb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, all patients get a dose of no less than 20mg of mcs110 every three weeks."
    },
    "872c6392-9ba9-4224-a579-de0deb401842": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "there were fewer cases of mucositis oral, epileptic seizures and thromboembolic events reported in the primary trial compared to the secondary trial"
    },
    "49e49c15-d880-4fa1-9582-ba86488ad192": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of cohort 2 patients in the primary trial suffer Increased pleural effusion. deleterious rpa1 gene mutation is a mutation in the rpa1 gene that is associated with an increased risk of disease."
    },
    "e970c950-ccf6-4c0c-8573-84634162fdf3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "smokers and alcoholics who consume 6 or more drinks daily are allowed to participate in both the primary and secondary trials."
    },
    "d14fe83a-0130-4c37-a55d-30ec0ecacdb1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "in the primary clinical trial, the group given ketorolac 30 mg experienced a recurrence-free survival rate decrease of -6.4% when compared to the group treated with nacl 0.9% 3ml"
    },
    "48788622-6b62-4a88-8d7c-29be1fbd88e8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "it is rare to find cases of coronary artery stenosis as an ae in the primary clinical trial"
    },
    "b5349f06-8e89-4ff7-966e-00333de8b463": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. did patient receive chemotherapy is a question about whether the patient received chemotherapy."
    },
    "3c164518-76e2-4abf-a39e-4163d49583c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 30mg group in the primary clinical trial showed a -6.4% lower recurrence-free survival rate than the group that was given nacl 0.9% 3ml"
    },
    "766e3e18-5567-48e2-9656-12c1b3ead63f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "in the primary clinical trial, participants are given lower doses of alpha lipoic acid, with a maximum of 20 mg three times daily, while, in the secondary clinical trial, cohort 1 participants are administered fluctuating dosages of necitumumab."
    },
    "5d98b3df-684a-466d-93da-5a672f602db6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib."
    },
    "19c38d71-5e6c-4944-9337-04d715487a2f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the primary clinical trial and the secondary clinical trial have an equivalent amount and type of adverse events."
    },
    "dd27a6e7-3b83-4a84-bc40-5ba39617a1c1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "Patients with histologically documented metastatic or unresectable SCBC are excluded from the primary trial, unless they are positive for either ER or PR or both."
    },
    "7ccd57f6-2147-4f27-a0a7-f9f7a573a3b5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 of the secondary clinical trial yielded more positive results than cohort 2 of the primary clinical trial."
    },
    "b80c2589-c792-4391-995c-6763270469dd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "patients with low vitamin d levels in the primary clinical trial showed a discernible pattern for expression of the set of 40 evaluated genes."
    },
    "37aab021-5b76-4b95-88b6-1050e9252803": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "in the primary clinical trial, pre-operative dexamethasone is administered to the first cohort, while the second cohort receives it two hours post-surgery."
    },
    "7e69da7b-d7e2-4166-ba1c-520947f7b596": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "numerous incidences of anaemia and febrile neutropenia were logged in the first group of the primary clinical trial, but no cases of pancytopenia were found."
    },
    "f1f9d4b4-4877-49ad-a2e2-f53efbe40ef9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events."
    },
    "936d7822-fd4b-42fc-abc5-d5ad838f148c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "individuals diagnosed with metastasized breast cancer, confirmed er+ considering hormone therapy, are eligible for primary clinical trial and secondary clinical trial"
    },
    "fd0fa999-2f1c-400d-977d-2d45dd9c358c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": " intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously."
    },
    "0cacd90a-ae93-47cb-b9f2-fa7e03d75270": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention. have mouth discomfort with toothpaste is a question about whether an individual has or had mouth discomfort with toothpaste."
    },
    "4bebbb9f-9a62-4b07-b91a-1321f312229e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the findings from the primary clinical trial show that the arm c intervention resulted in the highest overall response rate, and in the secondary clinical trial, the denosumab group showed an improved time to first on-study sre in comparison to the zoledronic acid group."
    },
    "2fde518b-d7c2-4e66-bab7-0cdff22d5ffe": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "the primary clinical trial welcomes alzheimer's patients for inclusion"
    },
    "78479579-0089-4132-8de1-f710cb80ac05": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "japanese nationals are eligible to participate in both the primary clinical trial and the secondary clinical trial."
    },
    "01b56d67-6f6a-4102-959e-eb921954d268": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "the absence of allergies to cephalosporin or trimethoprim/sulfamethoxazole does not restrict a patient's eligibility for either primary trial or secondary trial."
    },
    "1bf99d45-84a7-41cb-8263-d1ccb489bc66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial"
    },
    "1c4ca195-bc07-4d75-ac19-f7969a20e168": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "every patient in the secondary clinical trial has been treated with raltitrexed and oxaliplatin."
    },
    "c6e636a5-7c18-47f4-9563-715fde497ee3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "margin status cannot be assessed is a result that the margin status cannot be assessed. Even if a patient satisfies all of the exclusion and inclusion criteria for the primary trial, the final decision for inclusion will be made by the patients first of kin."
    },
    "d4fb8105-81af-42ca-a829-1b77694ce0f1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "Both the secondary trial and the primary trial use Objective cognitive function scores measured with CogState as their units of measure. experimental organism benign mixed mullerian tumor is a benign neoplasm arising from pluripotent mesodermal cells of the mullerian ducts. (inhand)"
    },
    "3cae8899-5172-460e-8ff1-e6e1c8a59f0b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine."
    },
    "832ab731-553d-4d66-a339-1fb60265866a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months. hours missed from work because of health problems is a question about how many hours an individual missed from work because of their health problems."
    },
    "f45bbf0b-4acd-4166-81a6-6b407cff87ca": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group."
    },
    "46cd405e-a401-4249-ad26-b48801b2c2c8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary clinical trial measures success through the proportion of patients achieving pathological complete response (pcr) in lymph nodes while the secondary clinical trial uses the improvement in the patients' quality of life as the main outcome measure"
    },
    "585b42d5-c81a-482a-a6bf-b7db6c6edcfb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention."
    },
    "705e4626-c95b-4191-b9f1-02ae897cef70": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "150mg of oral pregabalin every two weeks for six weeks is the course of treatment for the patient group in the primary clinical trial, whereas the secondary clinical trial employs depocyt and hd-mtx as the method of administration for its patient group."
    },
    "c7960079-5d1b-451e-818f-0890272ddb63": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "adult extracardiac rhabdomyoma is a benign mesenchymal neoplasm arising from skeletal muscle and occurring in adults. the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs."
    },
    "80249c01-a69c-490c-ab1f-74ead64dd3df": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "none of the patients in the primary trial experienced the worst pain imaginable for 1/2 an hour."
    },
    "1f30e035-2441-4585-826a-9150678cb094": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "hypophosphatemia, ctcae is a disorder characterized by laboratory test results that indicate a low concentration of phosphates in the blood. More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial."
    },
    "b09ea9c8-e3a2-4c82-bbe8-5e84ea151138": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial's inclusion and exclusion criteria remain constant across phases, and the secondary trial does not differentiate in terms of criteria for healthy participants and those with cancer."
    },
    "24cca94e-b0db-4015-acc3-061bce8ea0ea": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial. curie extension score is a score assigned to a curie body segment to indicate the quantity of metastases."
    },
    "57d179a7-e550-486f-ba5b-40dcdc8927a0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "endobronchial ultrasound-guided miniforceps biopsy is a technique for obtaining small forceps biopsies under continuous endobronchial ultrasound guidance using a convex probe endobronchial ultrasound bronchoscope. Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial."
    },
    "9ea892eb-1362-4281-aac7-713905f1bb2c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15. tarsus bone is any one of the seven bones forming the instep of the foot."
    },
    "b49ac921-1516-409d-9e81-14fc5afc75c6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "malignant oncocyte is a malignant epithelial cell with abundant eosinophilic or clear granular cytoplasm. There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial."
    },
    "6cce2cb8-3ed9-40e9-a412-cb75b688ac59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "at least one inclusion criteria is common between the secondary clinical trial and the primary clinical trial."
    },
    "cded013b-d994-410b-9b42-c4a852978cfc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "microbiology specimen link group identifier is a sequence of characters used to link multiple microbiology specimen records to a single finding. less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products."
    },
    "e100136f-281e-4721-9f57-66392982260f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients diagnosed with hyperkalemia are ruled out in the primary clinical trial but can possibly qualify for the secondary clinical trial"
    },
    "e70d1cc6-b4e5-4fc6-a26f-9b9dd76ef54f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "not known if 10q23/pten locus deletion analysis was performed is an indication that it is not known whether 10q23/pten deletion analysis was performed during the study. Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial."
    },
    "6c12493c-9eab-4206-aacc-bbb3dc398050": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "no single type of adverse event noted in the primary clinical trial impacted over 25% of the patient population"
    },
    "68f673a5-6ddf-487a-ad88-4903d92e1746": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event."
    },
    "f5e483ed-caec-4142-baa9-15ba42da5f03": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "All AE types in the primary trial affected less than 10% of patients. received indicator is an indication as to whether the entity was received."
    },
    "8f078a17-14cd-4bbc-a9b6-b377ffa077b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial"
    },
    "414dbb63-9c4c-44e9-96f5-c54b5d341f82": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "patients in both cohort 2 of the primary trial and cohort 1 of the secondary trial reported equal incidence of neutropenia, irrespective of their empegfilgrastim dosage regimen."
    },
    "b86e9d5c-8de2-428a-ba76-d0955ecb75fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "in the primary clinical trial, the intervention given to ovarian/ peritoneal cancer patients significantly differs from those with breast cancer."
    },
    "9c2adaba-1ac9-4a7c-a710-14ac7d2056fd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions."
    },
    "d1b9ab7c-2229-405c-be0e-01d822ac5aa1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial. select one is a directive to choose one of the options provided."
    },
    "026b062f-0ebf-4e02-9ff8-3bbd12f09ea7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial excludes patients diagnosed with tumors that have ccnd1 amplification, cdk4/6 mutation, or ccnd2 amplification."
    },
    "26091849-cc57-4866-8faa-ac9fb64caf69": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "There are less total adverse events in the primary trial than in the secondary trial, but more cases of Cardiac-ischemia/infarction in the primary trial than in the secondary trial. malignant abdominal neoplasm is a primary or metastatic malignant neoplasm that affects the organs and structures of the abdomen."
    },
    "ee0b2916-1e10-467e-bcf3-41c56aa80921": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision. anovulatory cycle is a menstrual cycle in which no ovulation occurs."
    },
    "e908994b-ee46-46a8-b478-5d1c45cf7047": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "at least one patient in the primary trial suffered several different adverse events. plate-reader artifact is artifacts resulting from the electronics of the plate reader or from issues associated with the image plate."
    },
    "908f5aed-eb98-47f8-b00d-7ce39707446f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "hpv16 infection is an infection caused by human papillomavirus 16. hpv16 infection is associated with a risk for cervical cancer. Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934."
    },
    "22274495-9d06-43cd-98fd-86d0374b42e9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "viral relapse is a recurrence of the same virus after a finding of aviremia at the end of planned or actual treatment. There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results."
    },
    "754d4ae4-5d18-4b63-836a-c011958680ce": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "benign ovarian sex cord-stromal tumor is a sex cord-stromal tumor arising from the ovary, without metastatic potential. the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts."
    },
    "6056dc64-7161-4c86-a9ac-04579ea09274": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 0.120 grams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mci of radioactive tc99m sulfur colloid."
    },
    "587623da-f061-478f-8196-ce7ec5558d5c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "both the primary and secondary clinical trial abstain from determining the percentage of their study participants who experience clinical benefit, using recist criteria"
    },
    "76ba0bfa-8fd2-45ab-818b-0216aa5d423f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "in the primary clinical trial and the secondary clinical trial, no patients faced fewer than 3 diverse aes."
    },
    "f1dca117-1368-4d17-bdb6-52d1b3816ed5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism within the last 1095 days are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "5e0f26d8-5fcd-4187-9591-3508d99ffafc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary clinical trial provides the time to progression in months for a combined total of 156 patients from both cohorts, whereas the secondary clinical trial focuses on the count of patients exhibiting objective response"
    },
    "8b7bbb44-a7d7-4317-af85-f78d559e0e63": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary clinical trial involves oral administration of the intervention, contrastingly, the secondary clinical trial necessitates the intervention to be given solely via a needle or tube inserted into a vein"
    },
    "af55082d-0ff1-419f-861f-80dbd05a9ade": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses separate criteria for healthy and cancer patients."
    },
    "78aec7ae-20b1-413b-9cb7-9757274ff1aa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "Morbidly obese patients are eligible for the primary trial."
    },
    "205bc80b-db03-469f-85b8-290a4be79af8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "cohort 1 of the secondary trial receives lower weekly mm-121 and paclitaxel doses than those in the primary trial"
    },
    "73677475-c59f-4327-b231-57cd7136dd94": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "cholelithiasis was a common adverse event recorded in both the primary trial and the secondary trial"
    },
    "8ffc6641-8eb9-4e6d-8926-0356539e0ba6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "primary clinical trial study groups will engage in different imaging procedures, including 18f-fet pet/ct and 18f-fmiso pet/ct."
    },
    "5ad108af-177f-434d-b17a-67c11c484e9b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "there were no recorded instances of syncope across the patient cohorts of the primary trial and the secondary trial"
    },
    "fa11f174-260a-4836-b583-c40d4b10bad4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. foxo1 gene rearrangement is a molecular abnormality indicating rearrangement of the foxo1 gene."
    },
    "6333ef7c-fdfe-4f90-b763-4d826c08975c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary clinical trial and the secondary clinical trial, there were adverses events which affected less than 1% of the participant group."
    },
    "b5701488-7b4a-4e1d-a318-4cc2f2b4df39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary clinical trial provides sublingual administration of its intervention, whereas the secondary clinical trial uses oral administration."
    },
    "95840c1a-9e38-4fe5-939c-e6f9aa107ced": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "each adverse event reported in the primary clinical trial was accounted as a suspected serious adverse reaction while there was no such record in the secondary clinical trial."
    },
    "4d8795f1-f8bf-4c27-9eb1-3f7db45c03ec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "the primary clinical trial administers the same dosage and frequency of cudc-101 to both cohort 1 and cohort 2, but only cohort 1 gets a weekly pd-0332991 dose."
    },
    "a0f404c3-8323-4ef6-a986-04085778b751": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. neoplastic large cell is a neoplastic cell with abundant amount of cytoplasm and/or large nucleus."
    },
    "0f42fd08-8cba-4861-a89c-bf898270ea29": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include the same dose of Paraplatin. globular region is a protein region consisting of a hydrophilic surface and a hydrophobic core."
    },
    "06929ac9-6df2-4e5b-afd8-656a1f9989d1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial tests one specific drug, whereas the secondary trial involves stimulated exercises only."
    },
    "5ccef9c9-dfe2-465e-8cc4-c6cdc310f74a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "more than 10 patients in the primary clinical trial experienced aes."
    },
    "71db6876-7205-4e4b-9a89-949045f26ab9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "within the primary clinical trial, the members of the first cohort receive the pneumococcus vaccine and those in the second cohort are given the influenza vaccine."
    },
    "5296c4b2-ae8f-4321-abb1-071d8a5e9f50": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000000 ng of talazoparib daily, as part of the intervention"
    },
    "a5e9916a-b5de-4fd4-bf78-b1c1e43bc544": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "all cohorts in the primary clinical trial are given dexamethasone before their operation"
    },
    "62112a3e-48e6-4e53-bfe4-53f07c84b815": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "leptomeningeal carcinoma patients are admissible for the primary clinical trial"
    },
    "bd5d8368-5c1d-41b8-9fb3-f174da18744f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period"
    },
    "6d37ed53-a6e4-403e-8b93-9954a6486dbc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography is used for both interventions in the primary trial."
    },
    "a3a672e2-2900-45dd-ae02-797449f17b66": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "non-drinking patients are eligible for the primary clinical trial, whereas the secondary clinical trial demands a daily alcohol consumption of at least five drinks."
    },
    "fa7b34e2-75e6-4bc4-a154-99be5bd6b381": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial"
    },
    "ea3a7d64-b464-4633-a198-794a4a45b201": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average."
    },
    "be5577f7-43cb-40c7-bf6d-4988788d9b24": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a diameter of 3300 micrometers measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "1b314250-0177-4a73-a7f8-a9524ae44cfd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders were not common for the primary trial candidates. how much distress problems with sexual interest or activity is a question about an individual's distress from their problems with sexual interest or activity."
    },
    "8004fee7-e287-4a54-b66f-44002ebb1b34": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "the primary clinical trial could accept an adult patient who was diagnosed with ild/dpld within the last 3 years and has a life expectancy of half a year"
    },
    "51ea9225-4ef8-4bf6-878a-2476cb59b916": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "77% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "c76fe4c2-5f55-4e85-8528-943d90e99dd0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "18 year olds are allowed to participate in the secondary clinical trial, but are not permitted to be a part of the primary clinical trial."
    },
    "1e24905e-7bf9-4a79-8157-8948f108ecb7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "Neiter of the primary trial cohorts receive any invasive surgery or Neratinib "
    },
    "b7c9455e-db3b-438d-bcb0-04bf52fb530d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream. radium is an element with atomic symbol ra, atomic number of 88, and atomic weight 226.0"
    },
    "2af8d00f-e0b6-4555-b649-796186334803": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "unresectable malignant glomus tumor is a malignant glomus tumor that is not amenable to surgical resection. Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention."
    },
    "264848be-8491-409f-b19f-0db249bc155a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "the primary clinical trial differentiates between the two interventions by using pihgc for intervention one and standard gp for intervention two"
    },
    "c3e36213-9a24-4f92-9ff3-12e071aac541": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "both the primary clinical trial and the secondary clinical trial provide cyclophosphamide, paclitaxel and pegfilgrastim to their respective patient groups"
    },
    "2e9395d7-1b38-4fc4-b0f4-121f89c1cfc2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary clinical trial is given half the dose of enzalutamide compared to cohort 1"
    },
    "7a2208d3-e297-4d8c-bfab-12856c200ea6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "the same dosage of paraplatin is applied to both interventions in the primary clinical trial"
    },
    "116c9dea-44ba-402e-8948-67ee9bb4f942": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin. aortic aneurysm is a sac formation resulting from the localized dilatation of the wall of the aorta."
    },
    "5b13bca4-0354-4579-a868-d007bef0dbe1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group"
    },
    "dcfc0053-b963-4542-ae02-228d3d2bd98e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "The Interventions in the primary trial included different medications but are administered through the same routes."
    },
    "921d278b-11fe-4f67-883a-cd10b15c20f2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "grade 1 acoustic nerve disorder nos, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated All Infections and Fever cases in the primary trial were for patients in cohort 1."
    },
    "5c7ff5f0-5b40-42e1-8f24-a0bfd6a4b2ef": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "publication name is a human readable textual identifier of the publication. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures."
    },
    "31f16856-c47c-40f3-b9a8-c414f07710ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 2.5 years before study entry are excluded from the primary trial."
    },
    "22c47ff5-a9b1-4de2-b5ee-2e5a6f2302d9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients with histologically confirmed early-stage breast adenocarcinoma that is either er negative, pr negative or her2/neu positive are eligible for both the primary trial and the secondary trial."
    },
    "a56a38a8-7782-4909-b417-ebb142f38028": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "during the primary clinical trial, numerous subjects contracted urinary tract infections"
    },
    "3873ed0e-ceb1-45dc-8efc-690a55d908e6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "the secondary clinical trial is open for women aged 18 or 19, but to be considered for the primary clinical trial, they would need to wait 1-2 years"
    },
    "469e2131-ef6a-4478-8e87-f785804bf8a4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "over 99.999% of patients in the secondary trial and the primary trial did not suffer any adverse events"
    },
    "c3464aef-3ed6-47ad-8196-99f8115916e4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "the primary clinical trial and the secondary clinical trial both utilize cogstate measured objective cognitive function scores for their units of measurement."
    },
    "a020a0f1-c729-44ea-a40e-2700cc846d67": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "those diagnosed with early stage non-hodgkin lymphoma considering radiation therapy are eligible for the primary clinical trial."
    },
    "bb7c2e9b-0a9b-48da-97e8-3a78ca82966f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "regardless of the type of cancer, the majority of patients in the first cohort of the primary clinical trial did not meet the screening timelines post intervention."
    },
    "327d67d2-35e7-45c3-958a-7955905f2d57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision"
    },
    "31d0a955-493b-4577-931c-ca3cda7a2a0b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary clinical trial receives enzalutamide through iv, identical to cohort 1's method"
    },
    "3a8d24f2-6a67-4b23-99a9-5d9b0a54e9c6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "patients experiencing a vitamin d insufficiency are not regards fit for the primary clinical trial, but might qualify for the secondary clinical trial."
    },
    "c20de03b-8eba-4546-8f77-5e54cf25dfb2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. have painful joints is a question about whether an individual has or had painful joints."
    },
    "1cda1a1d-3ca1-4838-9054-bcab763bb5d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "All of the Aes recorded for cohort 1 of the primary trial are related to mental health"
    },
    "2096d634-b321-40de-b69b-8dad3345331e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Secondary_id": "NCT00270894",
        "Statement": "more people participated in the secondary clinical trial than the primary clinical trial."
    },
    "226a30c1-78f8-4747-adb7-1e99973487c1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the medicament under test is mutually the same in the primary and secondary clinical trials'"
    },
    "9783fc05-3652-41b2-8ba0-8a276889692a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients with no history of pulmonary embolism over the past decade are ineligible for the primary trial, but the secondary trial admission depends on the investigator's decision"
    },
    "dc855f0a-1281-44f9-b68c-89044aaa73af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "clostridiaceae is a taxonomic family of bacterium in the phylum firmicutes that includes the genera alkaliphilus, clostridium and lutispora, among others. All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial."
    },
    "d6f4c977-a5fa-49c9-ba6c-a40dfe0f3b30": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the primary trial does not report any results for the LBH589 and Lapatinib cohort. study requirement object is a dimension table that lists the biospecimen requirements for this study biospecimen requirements include: .  (catissue)"
    },
    "aa5dd0d4-1551-4ccc-85a8-ca6c2bcfb871": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the primary trial results there were more patients with stable disease after 3 months than after 6 months, but none of the patients had complete response after 3 months or 6 months"
    },
    "5865807e-233c-4a7d-a900-de4af3bdaaf5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the placebo group of the primary clinical trial had a lower rate of idfs than the neratinib group"
    },
    "09eee297-7801-4d6b-b3f6-17ee4f3418e4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "image study is a radiographic technique used to evaluate a specific anatomic location for a specific purpose. Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare."
    },
    "f377df82-9511-47cc-9176-12491888eb05": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "anti-gm-csf monoclonal antibody is any monoclonal antibody that is directed against granulocyte-macrophage colony-stimulating factor (gm-csf). In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110."
    },
    "5102bc84-4e28-4ec9-91cf-b5ed615b15bb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the placebo and trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a semi-annual basis."
    },
    "3136ac0b-82b2-4819-a5ba-d5816dd0283b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "all patients in the primary clinical trial encountered aes."
    },
    "8f537eb8-d8b7-4c56-89bf-ea2e5b0d1326": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. 3q21-q25 is a chromosome band present on 3q"
    },
    "1a8ad1c5-284a-4398-9659-2cdbcb4492d8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group. pragmatic trial is a study designed to test the effectiveness of an intervention in a broad routine clinical practice."
    },
    "1ff9cfe0-06e6-4f99-961c-7854ba9e2c46": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "primary hypoparathyroidism is abnormally low levels of parathyroid hormone due to a disorder originating within the parathyroid glands. Gender is not a determining factor for eligibility in the primary trial or the secondary trial."
    },
    "001da1c9-0fd7-4a15-baa5-9ee16f2a28bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "malignant neoplasm by grade is a term that refers to the categorization of malignant neoplasm by histologic grade. Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial."
    },
    "7064d383-b7a5-44a0-a9aa-3fae7b7ded9c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "don't really enjoy food is a response indicating that an individual does not really enjoy food. There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial."
    },
    "6d92ea7c-a85d-4d9d-9599-b2203e9c3585": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had three test groups and no placebo group, the secondary trial had two test groups and two control groups."
    },
    "ed6b3dc1-1cdb-4da6-ad5c-d5073abd31ea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "no specific conditions regarding mental health, bodyweight, age, karnofsky/ecog score or previous treatments are required to qualify for the primary clinical trial."
    },
    "fdd9ccc8-95c0-48d9-bc4d-3ef7469dbb9a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma."
    },
    "3cbb65a6-d9f6-4972-8b13-dd19d427f0cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary clinical trial evaluates the impact of diverse radiation therapies on its participants, while the secondary clinical trial investigates the results of varying doses of identical treatment on its group"
    },
    "44b930a2-5810-41aa-a70c-e7eaa3730bc0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "specify site if cm1b is a directive to indicate the anatomic sites if metastasis is categorized as cm1b. 1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia."
    },
    "ddf4fc68-7920-4212-ac8b-7453ebeb49fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures."
    },
    "869a492c-b4bf-4145-a491-1ee0ea0fe816": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "yttrium is an element with atomic symbol y, atomic number 39, and atomic weight 88.91.  Alzheimer's patients are not eligible for the primary trial."
    },
    "17ca93e8-5115-4f53-8d4a-b3ce6c43ea58": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "simultaneous participation in both the primary and secondary trial is allowed for all patients"
    },
    "e8702a99-36bb-4f4f-b2ff-3fa6d49d034e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "in the primary clinical trial, the first cohort is treated with a daily dose of 25 mg sunitinib, differing from the second cohort which gets treated with 90 mg/m^2 paclitaxel."
    },
    "72154344-5c84-49cd-b39e-4010fb73756a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "for patients with breast cancer, eligibility can extend to all study groups in the primary and secondary clinical trials."
    },
    "935d23d4-0d67-4d42-8546-db1bab3f4a3d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "the secondary trial runs in semesters and uses weeks as a unit of measure, while the primary operates in cycles and uses age of the participant as its unit."
    },
    "38e2c25f-97c9-4112-b571-b832e29e7c7e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "the primary clinical trial study groups undergo separate pet/ct imaging procedures, only cohort 2 receives an increased dose of 18f-fpprgd2."
    },
    "fca1de92-2c1b-4c41-b49f-e07553b6aa83": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "in the primary clinical trial, general symptoms are the most frequently noted adverse event"
    },
    "ee7fc1bb-98fe-4f43-9ea0-076b7fc7eeca": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "several of the patients in the primary trial experienced the no pain whatsoever during the 3 months of the study."
    },
    "4a9efa5a-6bb1-4b34-a2a7-dfa40fdd29b4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of the second cohort in the primary clinical trial have experienced a rise in pleural effusion."
    },
    "97c98ddb-37f4-4e14-82c0-0685e500222c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups. have raw or sore skin is a question about whether an individual's skin feels or felt raw or sore."
    },
    "5a91060d-576b-405f-a8a6-c74cc3c24c62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "in the primary clinical trial, over 70% of the participants had a decrease in circulating tumor cells despite not receiving any form of chemotherapy"
    },
    "270255e6-c423-4fff-a2aa-78c3c8ef2a8e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally. have abdominal discomfort is a question about whether an individual has or had abdominal discomfort."
    },
    "9b753f6f-9d5d-464a-bc35-c1c0d796fe4d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "both the primary clinical trial and secondary clinical trial utilize the same system of units when reporting their findings."
    },
    "2bd35e15-a310-4660-8963-7f672733bb22": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial. gastric mucinous adenocarcinoma is a variant of gastric adenocarcinoma with more than half of the tumor containing extracellular mucinous pools."
    },
    "76032781-7c1c-4518-b9c5-13f8d7a5b443": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "the incidence of chest pain among patients was reported to be considerably higher in the secondary clinical trial than in the primary clinical trial."
    },
    "b8ffb304-4dd2-4fa9-888e-b851c73513c1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "most patients from the first cohort of the primary clinical trial, irrespective of their cancer type, had completed their screenings following the intervention."
    },
    "98e66236-2140-45a7-8bea-e2d17f373def": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "cerebellar and brain stem ependymal tumor is a finding indicating the presence of an ependymal tumor in the cerebellum and brain stem. No two patients in the primary trial suffered the same type of adverse event."
    },
    "d42f5cb0-e70b-4c8b-ae2e-297254b1d95a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "both primary and secondary clinical trials have the identical medicational substance under investigation'"
    },
    "5b66def6-3282-455a-a879-6e5a68c90c1b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "participants of the secondary clinical trial are administered three subcutaneous injections on a weekly basis, in contrast, participants of the primary clinical trial receive only a single injection at the study's commencement."
    },
    "1fef627f-f239-4ad3-8bec-4141e2b36dfd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "deleterious cdh1 gene mutation is a change in the nucleotide sequence of the cdh1 gene that is associated with increased risk of disease. Patients in cohort 2 of the primary trial suffered from neutropenia significantly less often than patients in cohort 1 of the secondary trial, who were receiving far lower doses of Empegfilgrastim."
    },
    "2644ad79-c38a-4415-a340-81ac51d3813f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "multiple diverse negative effects were experienced by at least one patient in the primary clinical trial."
    },
    "57d27d0b-626b-474b-9e10-60cbdd237d92": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, both the placebo and memantine interventions are given orally on a daily basis."
    },
    "1a48d67e-c653-4e6f-bc9c-677793433e9b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the outcome of the primary clinical trial, the number of patients with stable disease was higher in the 12th week than the 24th week, however, no patients showed complete response in either week 12 or 24"
    },
    "4662f196-5472-4321-846e-c1576bc0be70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "neither the primary trial participants nor the secondary trial participants experienced cholelithiasis"
    },
    "a63d1b8c-8ac5-4b17-a8c8-690dae246d1f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "porcelain veneer is a restoration consisting of a layer of tooth-colored porcelain material cemented to the surface of a tooth. The interventions in the primary trial and the secondary trial include completely different drug-based treatments."
    },
    "a9c7619e-8cc5-4c84-b4a4-38ada95388a2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "pharmacogenomics/genetics biomarker supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the pharmacogenomics/genetics biomarker domain. Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system."
    },
    "3c9c99d8-4604-4de9-98e6-81a675fe0558": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "only the first group in the primary clinical trial will be shown the educational dvd as part of the intervention, while the second group will be administered a standard dose of radiotherapy"
    },
    "d846c22f-adab-4189-b662-056541a723c2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "perineal artery is an artery arising from the internal pudendal artery that supplies the bulbocavernosus and ischiocavernosus muscles of the perineum. Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day."
    },
    "7b507eae-bfd5-4546-993b-6dd936ab41e5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "several of the patients in the primary trial experienced the no pain whatsoever during the 70 days of the study."
    },
    "987d8384-9e51-497a-a1f4-2646ec7c94f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "the primary clinical trial includes the use of trastuzumab in both of its interventions"
    },
    "4ddfaca9-bd5c-427a-a624-8a9d2c763c61": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "milliliter per square centimeter is a dose calculation unit expressed in milliliter(s) per square centimeter. The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2."
    },
    "ae583e53-d445-4b4a-b49a-c440881180e7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "in the primary clinical trial, candidates are given lower weekly doses of mm-121 and paclitaxel in comparison to the first cohort of the secondary clinical trial, but they receive greater volumes of herceptin and docetaxel"
    },
    "cf080a87-de94-4d6b-9d18-89a5f5003316": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "participants in the primary trial are given a higher weekly dosage of mm-121 and paclitaxel compared to those in cohort 1 of the secondary trial"
    },
    "a74afb52-7b03-4c41-b57b-7473ef025c18": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "nut midline carcinoma, castrate-resistant prostate cancer, or inflammatory breast cancer patients identified through fluorescence in situ hybridization are eligible for participation in both the primary clinical trial and the secondary clinical trial."
    },
    "a5631fa6-2f92-4be7-a055-4c7b3abcdb4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "in the primary clinical trial, recurring patterns of the same adverse event were observed across multiple patients."
    },
    "d0600d22-c3de-4028-82a5-a42008e2018d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "abnormal liver function test is atypical results found on serum liver enzyme testing, which may indicate significant disease and/or disease progression. There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial."
    },
    "4ed1c5fd-58e5-4fe8-97b1-59ed509ccb10": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial"
    },
    "14afd2b1-9ac2-45fd-96f7-b65862c818a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "mme positive is an indication that mme expression has been detected in a sample. The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial."
    },
    "6bb59504-e102-48d6-ac0d-8ce71100b726": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency. data analysis whitepaper is an informational document describing a data analysis process."
    },
    "c0c1a75a-a859-477d-bc80-3aac565c6a5b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/73 the primary trial participants, and 1674/1674 the secondary trial participants suffered an acute myocardial infarction"
    },
    "869ef7c8-edf9-4eb0-8654-3bb28fa1b4aa": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Perjeta is used in both cohorts of the secondary trial but not applied at all in the primary trial. fibrous meningioma is a who grade i meningioma characterized by the presence of spindle cells that form bundles in a collagen matrix."
    },
    "91d1600a-35d7-47a4-b972-edee5eeb6018": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. colon mucosa-associated lymphoid tissue lymphoma is an extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that arises from the colon."
    },
    "e4cdcf39-a01c-45f5-a382-d0e8a96a0be6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial has unified criteria for all phases while the secondary trial divides its subjects into healthy and cancer patients, applying a separate set of rules for each."
    },
    "ba202357-7330-4867-9527-10dee27a64b5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary clinical trial receive different dosages of cudc-101, with varying frequencies."
    },
    "4714a31c-c7ca-49e2-aa71-6665b65ed04f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "Morbidly obese patients can be eligible for the primary trial and the secondary trial."
    },
    "8bd62043-2cb9-42f0-80c1-2ec39020d9af": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "device malfunction code is a coded value specifying the defect or malfunction that occurred during use of the device. the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes."
    },
    "a328634e-824e-413c-a408-ad471e394a07": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial. fibroblastic neoplasm is a benign, intermediate, or malignant mesenchymal neoplasm characterized by the presence of neoplastic fibroblasts."
    },
    "7bdf850e-2f84-40f0-9b80-5bf9984be081": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "qrs complex is an electrocardiographic finding that represents depolarization of the ventricular myocardium. normally the ventricles are activated simultaneously. Every patient in the primary trial is required to swallow a capsule of Vorinostat daily during radiation therapy."
    },
    "9ce6d69e-2ed0-4046-bd5e-5888416fbeb5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "there were 16 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial"
    },
    "23f62ab2-9ec8-49f7-a4e7-84f931a1825d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 2 days if they want to participate in the primary trial"
    },
    "2e16531b-70c8-4302-8747-761859ad7946": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "in the primary clinical trial, all participants from cohort 1 experienced at least one life-threatening adverse event."
    },
    "9040286a-0801-494c-8c17-340323774082": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "those with an inadequate level of vitamin d will not be included in the primary clinical trial, but they could be suitable for the secondary clinical trial."
    },
    "753d23e6-333c-4ec1-8bc2-a853c29a20e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "while the primary clinical trial employs radioembolization with yttrium-90 glass microspheres and theraspheres as its intervention method, the secondary clinical trial opts for a regimen involving 560 mg of ibrutinib and 10 mg/kg of medi4736, administered twice daily for 30 days."
    },
    "13d66853-9b8a-4d79-b0d9-884c8d744acd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the secondary trial and the primary trial have completely unrelated outcome measurements. usually have considerable trouble concentrating is a response indicating that an individual usually has or had considerable difficulty concentrating."
    },
    "6cf2337d-c486-405c-be2b-97c29d8425dc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the secondary trial was anaemia, affecting less than 0.05% of patients, there were no recorded aes in the primary trial."
    },
    "f0e6f9c3-4f87-4a91-af2e-9bb7cc2de985": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the primary clinical trial and the secondary clinical trial each entail entirely distinct pharmacological therapies."
    },
    "5e2e6057-0a23-4780-9994-a239d28aee3a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "distinct units of measure are used to report results in the primary clinical trial and the secondary clinical trial."
    },
    "451e07e2-524d-459e-872c-1c4b3640f511": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "feel hopeless is a question about whether an individual feels or felt hopeless. In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110."
    },
    "eef90c1d-1b9c-459e-a895-47b9012a8d1a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "having an eating disorder was not a frequent condition among the primary clinical trial candidates"
    },
    "1b5e0318-38e0-484f-bffd-d63ff75fe93c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial registered any adverse events"
    },
    "7d5cd6d5-88a1-4693-b20b-c4960095a330": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "acute physiology and chronic health evaluation ii apch101 original result - 32-33.9 is acute physiology and chronic health evaluation ii apch101 original result - 32-33.9. Patients in the primary trial and the secondary trial  suffered Thromboembolic events."
    },
    "8953caa7-492f-4fbb-b5a6-5cff95a5650c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "rising from floor functional test question is a question associated with the rising from floor functional test. the primary trial does not report any results for the LBH589 and Lapatinib cohort."
    },
    "c5f69124-61d3-46bc-b233-5c38f4b1f5d0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial had patients experiencing less than 3 separate aes."
    },
    "0c561a05-4615-4578-aff2-745d9c9761c0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "a higher percentage of participants in the triple negative group of the primary clinical trial showed a decrease in the growth factor signature compared to those in the dalotuzumab 20 mg/kg group."
    },
    "195efca0-b2e3-43c0-abf2-4c6d77d8a449": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "in the primary clinical trial, sunitinib was administered intravenously instead of orally."
    },
    "72278411-1c4b-4c70-b6ab-72c4c8449ec4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "the primary clinical trial has seen a higher prevalence of biliary colic, while instances of diarrhoea are more common in the secondary trial."
    },
    "71a3b934-3bf8-4628-a728-cdf47a27e66c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary clinical trial and the secondary clinical trial both deliver results on the maximum tolerated dose (mtd) of the same treatment, with the mtd of mm-111 for patients in the secondary trial being 30 mg per day"
    },
    "920775c5-aa23-4be9-8aa1-241ecef90b51": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial does not receive any dosage of dexmedetomidine, while patients in the secondary trial are given 1ug/kg of dexmedetomidine."
    },
    "93fc8df8-d85f-4f71-9d03-7b7e0e5146ff": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "quarter of the participants in the primary clinical trial and 418/1674 participants in the secondary clinical trial had an adverse event."
    },
    "ba020c81-f851-45b9-b1d2-d319f7c97753": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "in the primary clinical trial, there is more than one difference between interventions 1 and 2, as cohort 1 and 2 have various aspects of their monthly durva injections that differentiate them."
    },
    "e028bf17-f183-4afa-b470-f7741f04e41b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "61% of the primary trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases"
    },
    "d94a09b9-8201-43f3-9b27-cab0bc473af0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "The intervention in the secondary trial last 3 times longer than the intervention detailed in the primary trial."
    },
    "5a25fa73-5358-4d36-acc0-ea23cb358a4d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "there were no recorded instances of dose-limiting toxicity from any patients participating in the primary clinical trial."
    },
    "dbffbeee-66da-4e88-8a57-c4d08e214048": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "breast cancer patients characterized by estrogen positive, progesterone positive and her2+ tumors are eligible for all cohorts of the primary clinical trial"
    },
    "a1d9b33e-fe46-421d-87e8-e0ecbfed7686": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "the primary clinical trial and the secondary clinical trial do not utilize alterations in the mymop score as their method of assessing study outcomes."
    },
    "9ddda9ad-0cb3-4ea8-8abe-59b227a8290d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the number of participants varied significantly between the two cohorts of the primary clinical trial"
    },
    "a852b1d2-ce26-48da-ba6d-2386489a967b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "within the primary clinical trial, occurrences of hepatotoxicity were thrice as common as incidents of hypertension and pancreatectomy"
    },
    "a184cea4-fa4e-4548-a5d7-b3a94ab1130b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "there were 101 cases of febrile neutropenia or cholelithiasis in the primary trial and the secondary trial"
    },
    "8e66baf7-890a-4a73-9542-814980f89689": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "participants in the primary clinical trial are administered drugs at a lower dose compared to those in the secondary clinical trial."
    },
    "2205c13a-b236-4117-b41e-78846625c760": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "one or more gastro-intestinal adverse event and at least two psychiatric events were recorded during the primary clinical trial"
    },
    "79cd8b63-fe24-4e8b-9a15-0e054fb09dba": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "both primary and secondary clinical trials rely on modifications in mymop score as the assessment of their study findings."
    },
    "bbb06e30-afa0-40c0-9594-b8c293cd5207": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the lion's share of patients from the primary clinical trial showed total recovery within the course of 24 weeks."
    },
    "c5d6c5da-f71c-4454-a333-3ade43aef122": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "those with histology-backed metastatic or inoperable scbc are excluded from the primary clinical trial, unless they have either er or pr or both positive."
    },
    "a0c1da21-1e1f-493b-81e9-4ef133c20090": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial."
    },
    "3afe5a55-731f-4015-85a2-e6df1caa2374": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients with hypokalemia are not included in the primary clinical trial, but patients with hyperkalemia may be suitable for both the primary and secondary clinical trial."
    },
    "e82b4df2-47c8-41ed-9b54-9b3c6917ead3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "the primary clinical trial administers the same dose of necitumumab to its patients for the entire duration, while the patients of the secondary clinical trial cohort 1 will subject to an escalating dosage of alpha lipoic acid."
    },
    "c132218c-a01a-406c-b1a1-7d66cc8877bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients. associated persons exposure domain is a domain utilized for the submission of exposure records related to persons associated with the study subject."
    },
    "0a56f64e-6747-4fc7-a05d-6024e7b52cf6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. consumer safety officer is an official of the food and drug administration who coordinates the review process of sponsor applications."
    },
    "7b2b8832-6e8f-4b56-88fa-5cee3c4e82bf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "the number of aes disclosed was identical for the two cohorts in the primary trial"
    },
    "aa62c405-218e-496e-a424-95340f370834": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the second cohort of the primary clinical trial had fewer participants than the first cohort"
    },
    "c51a2098-014f-410c-9722-eaadb298983d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "There are no Intestinal obstructions or incidents of Pancytopenia observed in the patient cohorts of the primary trial and the secondary trial. past seven days frequency of pain in the abdomen is a question about the frequency of an individual's abdominal pain during the past seven days."
    },
    "ab29d2f1-5d52-475b-be8a-a3b82c49a44a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "9q33 is a chromosome band present on 9q More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study."
    },
    "fe4e3c5a-b190-4733-930a-abc0bfd29625": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "have felt unusual weakness is a question about whether an individual feels or felt unusual weakness. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial."
    },
    "f99f83b0-66dd-4c77-b422-113e0cb758bf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "every one of the 61 cervical cancer patients in the initial cohort of the primary clinical trial complied with their screenings before the intervention commenced."
    },
    "4edb9b25-9a95-4a00-ae99-ebd722187d63": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the longest pfs in the primary trial survived 42 weeks without disease progression or death"
    },
    "abd83d4d-ac75-4626-928d-1b511a61d2b7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "The patient with the longest PFS in the primary trial survived 3.5 months without disease progression or death . assign score - risk score is assign cardiovascular disease 10-year risk score (assign score) risk score."
    },
    "48a0cb8b-d7c5-42e0-8adc-abd0b8f17301": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "leptospiraceae is a taxonomic family of mostile bacterium in the phylum spirochaetes that includes the genera leptospira and turneriella, among others. Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial."
    },
    "fef14a32-224c-4a00-88cb-30bb448a504e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "in both the primary and secondary clinical trial, at least one infection case was noted"
    },
    "6962c2aa-4df2-4479-8744-5784fe8c9fcf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "only one adverse event has been documented for the patient group in the primary clinical trial."
    },
    "fa664989-b970-41f4-b491-dd2aeb308dd1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "the only types of adverse events observed in patients from the primary clinical trial were hypertension, angina pectoris and dizziness, no adverse events were recorded in the secondary clinical trial"
    },
    "d54a3e9d-5602-4cc3-934e-717f1da39792": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine"
    },
    "3821922a-4d8a-4e54-8381-bb754a78c1ed": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "individuals in the secondary trial receive a single sc injection at the start, unlike those in the primary trial who get a series of injections over four weeks."
    },
    "6746f51e-6ceb-48b7-aa33-aecd601723b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "cohort a of the primary clinical trial receives a higher dosage of docetaxel, doxorubicin and cyclophosphamide than cohort b"
    },
    "5647bdb4-a763-46c0-a7f4-3d69cbc7aa95": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "patients with breast cancer and ovarian/peritoneal cancer within the primary clinical trial experience an identical treatment method."
    },
    "50171a05-0f3d-434e-a43d-9310a845fa3f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "childhood brain anaplastic astrocytoma is an anaplastic astrocytoma that arises from the brain and occurs during childhood. Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial."
    },
    "cc6601cf-3aa0-44f7-8476-f3dfc34e7412": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using topical interventions, and the secondary trial is testing an Inhalation intervention."
    },
    "6a2679df-a2a3-40cf-8252-2f8bf8584b8d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "abdominal examination is an assessment of the abdomen including the organs within the abdominal cavity. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial."
    },
    "4dcada11-d2e0-453f-aed3-66446ebb4133": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "a single cohort within the primary clinical trial is provided with armodafinil p.o. daily. on the other hand, each patient in the secondary clinical trial is prescribed an equal dose of 100 mg pdr001 and 1mg/kg of mcs110."
    },
    "65fc2061-6d0f-46d1-bd13-5959cedf6b03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same 100 mg dose of PDR001, and 1 mg/kg dose of MCS110. component missing is a device component(s) found to be missing when delivered to the user facility."
    },
    "c8633493-4879-4e97-9fcf-5e59ca22a79a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a breast tumor 0.8-2 cm in diameter, with confirmed hr positive and her2 negative status are eligible for both the primary trial and the secondary trial"
    },
    "89e52784-5ddd-405e-b794-95ef5b5766eb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "restriction site is a sequence in dna that can be recognized by a specific restriction enzyme. There are no X-rays, ultrasound, CT scans or MRIs included the interventions of the primary trial and the secondary trial."
    },
    "7238ddd4-eade-4b88-8933-0c3df5be9875": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results."
    },
    "08dad9c0-a333-4791-b845-79b549c31890": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "in the primary clinical trial, aes were reported by more than half of the participants"
    },
    "e41035c2-246d-43a1-b2d4-5ff9af1f789e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial . hard to stay standing when in pain is a question about whether a person had trouble staying standing when they had pain."
    },
    "1607973a-34ef-455a-b52b-55ea7aaf6634": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed. normalization basis is an indication of what method was used to normalize the data."
    },
    "75cd8c4d-e0e6-4db0-8157-a76ac5bcf555": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "was kras mutation analysis performed is a question asking if kras mutations were analyzed during the study. Several recorded Aes in the primary trial occurred to cohort 1 patients."
    },
    "53099f5c-4259-4ad7-bff2-65d2fe6250be": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "candidates for the primary clinical trial receive smaller weekly quantities of mm-121 and paclitaxel compared to the secondary clinical trial's first group, although their dosage of herceptin and docetaxel is higher"
    },
    "90eca162-5617-44e3-909b-c8304af0d763": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial. military occupation is an employment class consisting of all persons employed in the military."
    },
    "41a0138d-7084-40d9-99ae-24db9e84acce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is evaluating the number of patients who suffer treatment related adverse events, whereas the secondary trial measures the Median sleep time of its patients in minutes."
    },
    "f706897d-d54e-4449-8bc7-da0bd6fbad01": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates with an ECOG score of 1 are eligible for both the primary trial and the secondary trial"
    },
    "2493a4e6-18a1-41c7-8feb-81928df2b542": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "xq27.1 is a chromosome band present on xq. The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection."
    },
    "e96067c7-ab5d-4afc-b70c-f892aef0dce4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial. biliary atresia is a congenital disorder characterized by blockage or absence of the intrahepatic or extrahepatic bile ducts."
    },
    "12911f01-5f14-445b-a93a-0cca2cfe9b4c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, and the Reflexology Group and control group in the secondary trial produced identical results. sexual activity is any activity, solitary or between two or more individuals, that induces sexual arousal."
    },
    "ea69e1bc-816a-4ba8-abd0-9882b12b70ea": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "basal cell of the squamous epithelium is a basal cell located in the squamous epithelium. There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial."
    },
    "60431d29-7e80-4a3e-b433-83f886ea73b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "mixture of melanocytic neoplastic components present is a  finding indicating the presence of at least two morphologic components in a melanocytic tumor sample. the primary trial has 4 more adverse events recorded than the secondary trial."
    },
    "b73bde4f-21c4-48bd-82d3-0447d22cbd1c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "hypokalemic patients are most welcomed to participate in the primary clinical trial, while those with normal potassium levels are preferred in the secondary clinical trial."
    },
    "397ae58e-dc5b-4c06-b8ce-29215ed5bcb9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "Coronary artery stenosis are the most common AE recorded in the primary trial. abnormal lymphocyte is a lymphocyte characterized by a structural or functional abnormality."
    },
    "25d927c2-92be-405f-950a-e275c4d00e38": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "conditions including recurrent malignancies, graft-versus-host disease, anaemia, cardiac failure and diffuse alveolar hemorrhage were more often associated with adverse events in the primary clinical trial than in the secondary clinical trial."
    },
    "0f79f642-47d6-404b-ade0-8e720c0aa660": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "assent is agreement with a statement or proposal to do something. The results from the primary trial indicate that the Arm A intervention provided the best overall response rate, additionally, in the secondary trial the Denosumab cohort had a worse Time to First On-Study SRE than the Zoledronic Acid cohort."
    },
    "1a71b35f-9b20-478b-863d-f7411015d6e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism within the last 72 weeks are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "50e1ebd6-d51b-4e86-9748-a0d97a411b62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "taq polymerase is a heat stable dna-directed dna polymerase. the enzyme is widely utilized in laboratory polymerase chain reaction applications. There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial ."
    },
    "8aef748c-257f-4a74-a391-3cdbdc839c79": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "11p12-p11.2 is a chromosome band present on 11p Patients that have suffered a pulmonary embolism in the last 2 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision."
    },
    "1defe036-8290-4a01-bec7-f75305d1e88e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure."
    },
    "0af2a0f3-dd56-4e3b-9e85-344780cc0877": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "penile pain, ctcae 5.0 is a disorder characterized by a sensation of marked discomfort in the penis.  cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial."
    },
    "485b3413-6788-47ad-916e-c5d7fdb28237": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "paraganglion is a cluster of neural crest cells that are located adjacent to the adrenal gland, nerves, and blood vessels.  cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial."
    },
    "1cab397e-60fd-460d-8f56-978ca8a2bb78": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "hepatotoxicity cases were ten times more frequent than hypertension and pancreatectomy cases in the primary clinical trial"
    },
    "d692776e-c2e9-450b-b0e8-57d84ccb216c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial does not necessitate the administration of any drug, including denosumab; while the secondary trial promotes oral ingestion of tablets, with no required injections."
    },
    "5cc13d6e-bc37-47d3-8198-8e7af5a8b5a2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children are unable to participate in the primary clinical trial, yet it is not explicitly stated that they are ineligible for the secondary clinical trial"
    },
    "6ad0142c-56d0-4994-b906-898198240c8c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary clinical trial uses miles as a unit of measurement, while the primary clinical trial reports in kilometers."
    },
    "2a0b1a83-299d-404d-96e5-67ee65173dde": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive intramuscular injections aswell as medication to be taken orally."
    },
    "a7f12911-d5b9-4cd0-a3c0-e1fb6ded7512": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "in the primary clinical trial, more incidents of palpitations, pericardial effusions and abdominal pains were observed in the second cohort compared to the first cohort of the secondary clinical trial."
    },
    "d9b955ea-915d-438f-a9b1-cd1cc08c0dd4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks. definitely is a subjective answer of very strong agreement."
    },
    "05775941-9ed3-40eb-9c93-ed60a7783838": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "testicular plasmacytoma is a rare plasmacytoma that arises in the testis. at presentation the involvement is usually unilateral.  Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial."
    },
    "a52b9758-f769-4350-b617-5215621b815b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "carboplatin is administered at dissimilar doses between cohorts in the primary clinical trial"
    },
    "103f19bc-87b9-4017-b2d8-8afd8bc54157": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary trial patients receive lower doses of radiation therapy than the secondary trial participants"
    },
    "636ec547-3ea0-41d4-a46f-92d4780b2ffd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial and the secondary trial recorded the same number of adverse events in their cohorts. 1p/19q deletion analysis testing method is a request to enter the specific molecular analysis method used to determine the 1q/19q deletion status."
    },
    "429199a7-de1a-4900-939b-e4f6efadb474": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "Most the primary trial candidates suffered from some kind of eating disorder during the study duration. central nervous system cyst is a congenital or acquired cyst that is present in the central nervous system."
    },
    "d2673e8f-15c9-4476-b8b6-2567822d5cd4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "bladder small cell neuroendocrine carcinoma is a small cell neuroendocrine carcinoma arising from the bladder. The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group."
    },
    "2b9dbd1a-6de9-4c7e-80af-0a096af26a11": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV. additional qualifier is a value specifying a supplemental characterization of the observation or entity."
    },
    "4234e99e-4e49-459b-9a11-5420d039defd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the primary trial has fewer total adverse events compared to the secondary trial, although the primary trial does record more instances of cardiac-ischemia/infarction."
    },
    "3942fcf8-27c3-469e-8c6c-b9b2415706fb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable tumors in both breasts are excluded from the primary trial. ejection fraction decreased is a finding indicating a decrease in the volume of blood ejected during ventricular heart contraction."
    },
    "4a5a5c6f-b9b3-48a4-a79a-582dc83323e3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "the usage of warfarin-based therapies disqualifies patients from the primary clinical trial, although they could still potentially participate in the secondary clinical trial."
    },
    "a434b916-659c-46a6-81c3-1654f561a2c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "most participants of the primary clinical trial encountered some sort of eating disorder in the course of the research period"
    },
    "9c253aed-c7ae-42ad-afd2-9c52c9ecab08": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "bassas da india is an atoll in the southern mozambique channel that is part of the french southern and antartic lands. A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 79000/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial."
    },
    "2cc63d25-8209-41a8-b9a3-fcc4af6d9caa": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer. laryngeal small cell neuroendocrine carcinoma is a small cell neuroendocrine carcinoma that arises from the larynx."
    },
    "fed9960d-b051-4948-840c-91d09c01aafc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "a patient with a leptomeningeal carcinoma diagnosis would be excluded from the primary clinical trial"
    },
    "f5fa93e8-a223-459c-8573-853f56953c17": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary clinical trial employs an open-ended treatment process, while the secondary clinical trial operates on a consistent 4-week cycle regimen."
    },
    "4894f59e-9386-448a-a779-f22a453ef049": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "in the primary trial, the control group, arm 1, performed better in terms of operative time than the test group, arm 2. the secondary trial also has a control group against which comparisons are made."
    },
    "ad477da6-f950-49b8-a882-0c1dfbc4751f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13 individuals received the globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine as part of their treatment in the primary clinical trial"
    },
    "cd067ee2-ed1d-403b-aa50-d61a3399fda3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  "
    },
    "fb4df065-adca-4ce7-9059-bda1cc4ca1be": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in the primary clinical trial and the secondary clinical trial, there were no adverse events that occurred in more than 10% of the participants."
    },
    "3ab9a40f-bbd8-43ed-a468-7fdbe3d9ce19": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes"
    },
    "d4f98c24-aad0-4784-9b90-da1a99b9a59b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "a smaller percentage of participants in the er-positive luminal b group of the primary clinical trial showed a decrease in the growth factor signature compared to the triple negative group"
    },
    "e7204781-fa14-4418-94a4-2660bcd64eeb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "participants in the primary clinical trial are subjected to surgeries alongside administration of seven distinct drugs via a subcutaneous route, in direct contrast to participants of the secondary clinical trial who are treated with only two different drugs and several imagistic investigations"
    },
    "4acaf50b-e6af-497a-a0d2-709e5780dd0b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "over forty-two patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes around 210 days after the surgery"
    },
    "34b41276-f5fe-4adf-8178-808e139d9d52": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients without any evidence of solid tumor, either locally advanced or metastatic, of all genders are welcomed for both phases of the primary clinical trial."
    },
    "95332a34-465b-4777-870b-e60e4c01e706": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "patients in the primary clinical trial saw a higher frequency of ascites, whereas those in the secondary clinical trial had higher incidences of pneumocystis jirovecii pneumonia."
    },
    "fae264c6-e28a-42ba-9951-f27cdf917815": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "cancer patients diagnosed with thalasemic syndromes, epilepsy, or anemia are eligible for the primary clinical trial."
    },
    "79bb0bb4-31cf-45e2-8fae-475bfdbd6a09": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "pre-market approval application is an application to fda for a license to market a new device in the united states. the primary trial patients receive higher doses of radiation therapy than the secondary trial participants."
    },
    "e83cb970-0b3c-4b61-8a44-49a9a3f61744": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "in both the primary clinical trial and the secondary clinical trial, all study groups might accept patients who have been diagnosed with breast cancer."
    },
    "6e5e4b46-3bc7-4ae1-8668-9b4f2f72f791": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women under 18 are qualified to participate in both the secondary and primary trial"
    },
    "0585f6bd-d582-4fc9-b96b-1355fa083e33": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans"
    },
    "ce7f9154-ce9f-4d2f-8377-940c57315f1c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "all participants in the primary trial suffered a deterioration in cognitive function, particularly those in the Ovarian Function Suppression group. print, sign, date form is a directive to print the form, sign and date the section indicated."
    },
    "ae259f29-2da6-43fe-b89e-345be44688e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "cohort 1 of the primary clinical trial received a higher dosage of cetuximab compared to cohort 2, and the collaborative care intervention was omitted."
    },
    "a2408386-b61c-4cce-9c71-befb482270e0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "neither the secondary clinical trial nor the primary clinical trial utilize the count of participants with treatment-emergent adverse events as their study's outcome measurement."
    },
    "430f4379-7517-4dc9-a9e4-885f2934f872": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the adverse event most often witnessed in the patient cohorts of the primary clinical trial and secondary clinical trial was syncope, presenting in 25.00% of the people in the primary trial."
    },
    "7f90773c-288c-4b5d-bc82-81d7189e6c5d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "the interventions in the primary clinical trial differ in the dosage of paraplatin used"
    },
    "fb73159b-0d37-4ea1-aaba-4f540ec395b9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 16 or 17 are eligible for the secondary trial, but will need to wait 3-4 years to be eligible for the primary clinical trial"
    },
    "f94eab27-5609-47a1-bcd5-d0e1305caab1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "candidates utterly incapacitated are a requirement for the secondary clinical trial, a condition not indispensable for the primary clinical trial"
    },
    "2007fc0f-aa14-48a5-9db7-08d47f756757": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event in the primary trial. histone h2b gene is a gene encoding the core histone protein histone h2b."
    },
    "81792c74-a501-4ef9-b7ac-2bda7a980fb1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the secondary clinical trial and the primary clinical trial utilize diverse methods of quantification and success indicators."
    },
    "bf5c5c27-0b57-4397-9ba9-3c2895bcbe5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or older are eligible for the secondary trial and the primary trial. villous adenocarcinoma is an adenocarcinoma characterized by the presence of a villous architectural pattern. it may arise from a villous adenoma."
    },
    "1dfb4256-8bef-4128-8cd2-30d5c88a4ac8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "25% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "ca20d0df-b712-4bb0-b320-704d565a99a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "have cramps in feet is a question about whether an individual has or had cramps in their feet. Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial."
    },
    "4678ba70-3ec1-487b-a641-bdbd790892ac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "2.74% the primary trial participants, and 0% the secondary trial participants suffered an acute myocardial infarction ,  "
    },
    "2cf8046e-2d49-4989-aca0-9e11795978cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mcg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "7b0752c4-ecc6-426a-82c9-e14bb237cfdc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 8 years would be excluded from the primary trial"
    },
    "80140ee4-3ead-44cc-a7a2-b6af0798c1b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "every patient in the primary clinical trial that received gtx-024 1mg lost over 5 kilos of lean body mass."
    },
    "97a2b670-3f9b-49e5-abde-d0b477046164": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "no clear pattern of expression was observed for the 40 tested genes among patients in cohorts 1 or 2 in the primary clinical trial"
    },
    "0de75f54-db66-4787-b8a0-7cd21198d8a8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "the primary clinical trial did not record any patient suffering from the highest level of pain possible for a period of 10 weeks."
    },
    "777fb2a8-9329-4e49-a67b-93d1d7fe2319": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "there was a case where a patient's surgical wound from the primary clinical trial reopened post-operation."
    },
    "d2ac18d1-d427-4afc-b72a-4de7856b17d5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "all cases of gastrointestinal and blood-related disorders in the primary clinical trial were for patients in cohort 1."
    },
    "951c2074-2100-4b9f-84e1-adec6a08c61b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "during multiple phases throughout the trials, the trastuzumab dosage for patients in cohort 2 of the secondary clinical trial mirrors that of the patients in the primary clinical trial."
    },
    "6d328d56-d579-4a87-b2bf-e3f3d8bd2c4f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "individuals partaking in the primary clinical trial, specifically from the ovarian function suppression group, reported an improvement in cognitive function"
    },
    "c35d641d-7248-47d7-90ff-a3859a846f68": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "regular incidents of maculo-papular rash were observed as a common after effect in the primary clinical trial participants."
    },
    "56e9308b-f718-4831-8e56-4b18982e4a2c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial"
    },
    "4092de53-28a9-457c-91cf-f87f4abf4dc1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "100% of the patients in the primary trial experienced the worst pain imaginable for 10 weeks."
    },
    "06bf2ef1-129f-47cf-b51f-75e51f1eb66a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "in the primary clinical trial, all of the recorded individual adverse events were unique to one patient each"
    },
    "3cd90294-f295-4725-82d4-e185d03cc2b7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 1095 days would be excluded from the primary trial"
    },
    "0bc7c5c7-6e64-4eee-ba84-e2168d64a8ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "knob device is a handle, usually attached to a shaft allowing manual rotation of the shaft. Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial."
    },
    "97552293-cd61-42c5-95c2-dc98b795f9d5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "Neiter of the primary trial cohorts receive any invasive surgery or Neratinib . 75 to 94 percent of the time is an indication that an individual did something, or something occurred, between 75 and 94 percent of the time."
    },
    "bc8cc6fd-446a-4879-a968-5c43a34029cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "grade 2 tendon reflex decreased, ctcae is ankle reflex absent; other reflexes reduced the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria, one for the 18-50 age group and one for the 50+ age group."
    },
    "a61c1627-33e6-4a53-8247-484d42328747": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient presenting with a tumor, primarily having a size of a 3mm diameter as assessed through clinical inspection and sonography, can be a potential candidate for both primary clinical trial and secondary clinical trial."
    },
    "0069c252-1e8b-4209-af61-11e6ee9d3c2b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "the primary clinical trial established that tamoxifen 32 mg po daily for the period surrounding surgery resulted in no measurable impact on tumor diameter post-breast cancer operation."
    },
    "0db120d4-5ebb-4b0f-9040-52b32a966c33": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "patients in the paced respiration intervention group of the primary clinical trial, on average, experienced a smaller number of hot flashes per day than patients in the fast, shallow respiration group."
    },
    "4cc838c3-caee-492c-8092-c74844d68cd1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "required baseline performance status is used to assess candidates for both primary and secondary clinical trials, with each trial adopting a distinct scoring system."
    },
    "ba6548a1-7dbf-4924-91ed-da83ecb2e8ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "general fatigue dimension is a dimension of general fatigue in the multidimensional fatigue inventory. Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial."
    },
    "2e95798d-089f-44b6-a6bf-13161021b7ff": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "patients that have recently undergone antineoplastic chemotherapy can participate in the primary clinical trial."
    },
    "ea29786f-2c27-45d3-879d-126b8150f2af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the interventions in the primary clinical trial requires participants to take a monthly dosage of 4-demethyl-4-cholestryloxycarbonylpenclomedine, while the secondary clinical trial does not"
    },
    "0a74e0af-2534-45f3-b003-ba68e6e52d94": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "in the primary clinical trial, pihgc is used in intervention 1, while standard gp is used in intervention 2"
    },
    "4ac023d3-e86c-47bb-bbd5-1b6907e8cab3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "the treatment method applied in the primary clinical trial varies depending on whether the patient has breast cancer or ovarian/ peritoneal cancer."
    },
    "cd2cb8fc-7624-479c-b9ee-e2ca3cf5ea18": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "the variation in ki67 expression in tumors is not evaluated in both the primary and the secondary clinical trial."
    },
    "204d5293-d6e5-452a-8961-3b76d6be35c9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare."
    },
    "c6d411f9-3d61-459e-b1af-6d8088260804": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "in the primary clinical trial, both cohorts 1 and 2 use the same instructional cd for paced breathing, yet cohort 2 has double sessions daily."
    },
    "877e791d-73b6-4af2-945c-29f54005c405": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "one patient cohort's results are reported in both the primary clinical trial and the secondary clinical trial"
    },
    "f9ab104f-3d67-4912-aaf5-bb43ecd0c52d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "seminal vesicle cystadenoma is a rare benign cystadenoma that arises from the seminal vesicle. Patients with histologically documented metastatic SCBC are excluded from the primary trial."
    },
    "a4cc14a3-7e05-4f72-b2f1-c9bb11720917": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "majority of the patients in cohort 1 in the primary clinical trial reported no acute vomiting episodes following the aprepitant, dexamethasone, cytoxan, and kytril treatment"
    },
    "b4fd327d-375e-4021-98af-a59ee4e30c0b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a recently diagnosed er-positive, her2-negative breast cancer patient who is 20 years old may be suitable for the secondary clinical trial as well as the primary clinical trial"
    },
    "7dd6b446-5585-4660-8bc7-e9811af66268": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial."
    },
    "76eeb32c-d3c0-4ed0-91d4-104417af35e0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "all patients in the primary clinical trial had recurrence-free survival."
    },
    "a993ae6a-f86f-478e-af30-584181f09531": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "both the placebo and memantine interventions given in the primary clinical trial are administered equally in terms of frequency and duration."
    },
    "c6194284-d44f-45c1-9477-754736bbf1a3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "individuals with an hr positive, her2 negative breast tumor measuring 0.2 to 0.8 cm qualify for participation in both the primary and secondary clinical trials."
    },
    "9bd6ad87-470a-4fa3-9e29-bf5ba8c2b463": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 300% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "e4b2bcf4-85fa-499c-9d27-e1c3c46174bf": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the same drug is being studied in both the primary clinical trial and the secondary clinical trial. however, they use different dosages and have different outcome measurements."
    },
    "f0ff3265-a75f-4a9f-8c0e-ff03057647eb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily. ibrutinib/venetoclax regimen is a regimen consisting of ibrutinib and venetoclax that may be used in the treatment of mantle cell lymphoma."
    },
    "3278109c-54b8-4842-8a59-4dae9fac6280": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "subject status sequence number is an identifier that describes the relative position of subject status data within a series. Every participant in the primary trial recieves the same intervention, regardless of whether or not they have cancer."
    },
    "cf9d27be-b128-4621-9734-8e9fb3197105": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial reports the Time to Progression in days for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the percentage of patients that experience Objective Response . gastric dysplasia is a morphologic finding indicating the presence of dysplastic changes within the gastric mucosal epithelial cells."
    },
    "dc867a3f-6005-49f7-bcd8-1c7db27b00c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial. uterus/cervix is a tissue sample that contains the body of uterus and the cervix."
    },
    "cb36e435-6dc9-4e7b-939b-9da6ceef2a49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis."
    },
    "5c00eee7-bb33-45e5-97c6-4cfc34946cdf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment"
    },
    "4f1bafd9-361f-4981-b6fd-46af736141b4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or a description of irradiation doses."
    },
    "21c183ca-7f70-4ddb-9599-d371ee544055": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "in the secondary clinical trial, over 97% of patients experienced adverse events, while no adverse events were recorded in the primary clinical trial"
    },
    "fe5d5e2f-2b54-48f4-b95b-278456d1db46": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "in the primary clinical trial and the secondary clinical trial, the same medications are used, dispensed at the same doses and on the same schedule."
    },
    "ad17d770-f8c6-4440-8b95-894a511cab39": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women diagnosed with claustrophobia and ibs are allowed to participate in the primary clinical trial."
    },
    "4e4b2acf-c921-4f0d-b9e9-6a54fe5d9877": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "None of the participants in group 1 of the primary trial were found to have lesions, and more than 90% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. have difficulty planning for future due to illness is a question about whether an individual has or had difficulty planning for the future because of their illness."
    },
    "f5650e8f-58b5-4a3a-9da2-ab66d7674b6d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients bearing tx nx mx, t0 nx m0, or t1 n1 m1 tumors can participate in the primary clinical trial"
    },
    "cee12d67-0640-4760-a0f5-fdde8c593a89": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients with a histologically/cytologically confirmed diagnosis of benign tumors are valid candidates for the primary clinical trial"
    },
    "86a5a47e-a2cb-461e-bcc5-8f71620376b8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. ctnnb1 protein variant is a variation in the amino acid sequence for the catenin beta-1 protein."
    },
    "89558178-d2e5-4376-8656-14ba666b44a3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary clinical trial does not accept patients who have had an organ transplant in the past month; however, the secondary clinical trial may consider them"
    },
    "21e02160-3372-4816-93d2-b3923672111b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "the majority of the participants in the primary clinical trial evidenced a decrease in circulating tumor cells after undergoing radiotherapy"
    },
    "8b30b0d1-a4fd-49cb-9dc8-ce508d3b5524": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "ovarian/ peritoneal cancer patients in the primary clinical trial are administered 1000 mcg/day of talazoparib whereas breast cancer patients receive a dosage of 25 mcg/day talazoparib instead."
    },
    "ff95337a-7da9-43f5-bb3c-25cd7c85e5c7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "0.25% of patients in the primary trial suffer increased pleural effusion and rapid disease progression"
    },
    "3a0c092c-7e18-4108-ae66-552f7069831f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events."
    },
    "417ed12e-5ae1-4024-9d97-ef152b78f64c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 10% of the primary trial participants had a Reduction in circulating tumor cells Following months of High-dose Chemotherapy With Purged Autologous Stem Cell Products. columnar mucosa indicator is an indication of whether columnar mucosal structures have been detected."
    },
    "31464efc-048a-451b-a02b-5576933a893a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an oral administration of captopril and cohort 1 of the secondary trial is under treatment with eribulin."
    },
    "25cbaa44-4715-417b-9bd0-12fef06053b8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 10 patients in the primary trial suffered Aes"
    },
    "3795f873-9d20-4fb3-b77c-ca01ba923c82": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients characterized by extreme obesity or pregnancy can be potentially suitable for the primary and secondary clinical trials."
    },
    "fd531ca0-8537-4395-abed-00fbc69c00a7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "agreement rating score 5 is a subjective score of 5 on a scale that ranges from 1: strongly disagree to 6: strongly agree. candidates for the primary trial must have breast cancer and require hormonal treatment."
    },
    "0b6e68b2-9f05-407b-bd00-feb9d3ce7abc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "primary clinical trial participants were twice as likely to have cholelithiasis than those in the secondary clinical trial."
    },
    "b3ed34ea-6461-40ed-955d-693bbc27fd99": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "substance dispersity is a measure of the heterogeneity of sizes, shapes or masses of molecules or particles. Hypokalemic patients are excluded from the primary trial but may be eligible for the secondary trial."
    },
    "bc7b62ad-797e-419e-b5f9-888117aedf6b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial."
    },
    "d2e448c0-852f-41cc-a53b-866f56e62967": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine. digestive system kaposi sarcoma is a kaposi sarcoma arising from the digestive system."
    },
    "3f6f3ca0-d14d-4fdb-9be8-19859181aaa9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "after being treated with aprepitant, dexamethasone, cytoxan, and kytril in the primary clinical trial, acute vomiting was observed in over 50% of the patients from the first cohort"
    },
    "6e644116-4084-4a3d-90dd-82f50a7ccc0c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "most of the adverse events reported in the primary clinical trial involved blood and bone marrow, unlike in the secondary clinical trial."
    },
    "595cee41-9cd2-4e9e-8ba5-2b3620985018": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "the primary clinical trial and secondary clinical trial don't utilize units such as cm, number of participants, or time frame for their measurements."
    },
    "fa23fd31-c7c2-4887-a982-174f355a2035": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "36.36% of the primary trial patients suffered an increase in Blood bilirubin. pedal spasm is a spasmodic contraction of the muscles of the feet, especially the ankles, such as during alkalosis or tetany. (acc/aha)"
    },
    "63a2b921-08f3-456f-9710-fc74ec13954e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  . pi3k gene mutation is a change in the nucleotide sequence in a pi3k family gene."
    },
    "55635fce-1467-46ba-934d-8234f33e103e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "only female patients with evidence of a solid tumor that is in early stages and/or non-metastatic are eligible for both phases of the primary clinical trial."
    },
    "0c6abdc4-f1cd-46f3-8883-c4bce02c2081": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "primary clinical trial uses mymop score improvement as their principal outcome measurement."
    },
    "49d2b5e7-595e-4762-b7af-9e914bf72917": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary clinical trial receive less than 20mg of mcs110 every 3 weeks, and over 130 mg of pdr001 every other week."
    },
    "bcbeb637-d070-400b-a98e-e3380f009b21": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "in the primary trial, observations revealed more instances of infection, asymmetry and deflation in comparison to the secondary trial."
    },
    "65c91814-cbda-4db3-a680-4bc3fe0855a8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "in the primary trial, the same inclusion and exclusion criteria apply to all phases, whereas in the secondary trial, different criteria are employed for varied sets of participants."
    },
    "f9a077fc-18cf-418a-ac86-ddc89ea4259b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "regardless of the cohort, the primary clinical trial administers the same quantity of docetaxel, doxorubicin, and cyclophosphamide at the identical intervals."
    },
    "3137468e-52bf-4bff-a3cc-68f127683f63": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "in comparison to the primary clinical trial, the secondary clinical trial has tracked a slight escalation in total adverse events within its patient cohorts."
    },
    "b6643c69-48aa-452a-91f8-b45c83ccf01e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "Only 2 patients in the primary trial did not have Recurrence-free Survival. 19p13.3 is a chromosome band present on 19p"
    },
    "5e5c4aab-2006-4a00-b11c-3dced5aac12c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "in the first cohort of the primary clinical trial, participants are given the pneumococcus vaccine, whereas, the influenza vaccine is administered to those in the second cohort."
    },
    "804aa28f-b791-4a99-98e7-a443456de4b2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "ct2584 hms is a lipid metabolism modulator which may inhibit angiogenesis, thereby possibly having antitumor activity. (nci) All patients eligible for the secondary trial are also eligible for the primary trial."
    },
    "604c0ae1-7d51-4238-adb7-1a0b1da1b466": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "a number of cardiac-affiliated adverse instances were logged for the first cohort of the primary clinical trial."
    },
    "070ba2da-932a-4a62-861e-3f2c89630b4d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "Most the primary trial candidates suffered from some kind of eating disorder during the study duration"
    },
    "2a5d71a0-75c6-41d5-bf37-4916c578b0b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "both cohorts in the primary trial receive a uniform dosage of alisertib, while the two cohorts in the secondary trial are also given the same dose"
    },
    "e15409e3-408c-4ea8-a0aa-9f1072b8a74b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "patients enrolled in the primary clinical trial will receive a constant, unchanging dose of alpha lipoic acid throughout the study, whereas those in cohort 1 of the secondary clinical trial receive varying doses of necitumumab throughout their trial period."
    },
    "8e205d62-f220-45ba-9324-f8ee359236b1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary clinical trial was composed of a single test group and one placebo group, whereas the secondary clinical trial included two test groups."
    },
    "bc03d7d7-65ed-4331-a5c9-997968a47547": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "in the primary clinical trial, a number of aes were observed in patients of cohort 1."
    },
    "ec3a1125-3c16-4f3c-8fa3-6a237f4529c9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "during the primary clinical trial, radiation therapy is undertaken without simultaneous administration of daily vorinostat capsules"
    },
    "47c91759-a386-407e-9612-dbce68040a7b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "be rid of obligations and responsibilities is a question about how often a person thought about being rid of obligations and responsibilities. None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort."
    },
    "2ab5044b-9fa6-45ef-8c99-a2cd5e28f512": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by a single transendocardial injection. sarcoma nci grade 2 is a sarcoma with less than 15% necrosis."
    },
    "39ac8702-7670-4a8e-851a-49e41a77c836": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "diarrhoea was uncommon among the primary trial participants compared to the secondary trial participants"
    },
    "33efdbc8-175b-4021-b192-acd8d37cedd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "125% of patients in the primary trial suffer increased pleural effusion and rapid disease progression"
    },
    "32775858-8e4c-41e3-87c3-2c60dbc780ee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient with a metastasized tumour of 10mm in radius, determined through biopsy and mri, would not be eligible for the primary clinical trial or the secondary clinical trial."
    },
    "963f60a5-2446-42f3-9c05-20ef38528d1a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "all patients, barring one, treated with sunitinib + docetaxel + trastuzumab in the primary clinical trial underwent an adverse event emerging from treatment, while serious such events were seen in less than 50% of these patients."
    },
    "b72d4b5e-e31f-47aa-979a-8253ec455cd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary clinical trial, the number of hepatotoxicity cases were equal to the cases of hypertension and pancreatectomy."
    },
    "709fb55d-517a-45bb-a379-f073a46cbe93": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 20,000 micrograms of mcs110 every three weeks, and over 130,000 micrograms of pdr001 every two weeks."
    },
    "b6902408-8d60-438b-bb38-416d4a4d76fb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "None of the primary trial candidates have to perfom regular exercise as part of the intervention"
    },
    "80676e7e-a6bc-4f8e-b50e-888847db5b91": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 13 mg group of the primary trial experienced a more significant percentage change in betactx at week 10 than the zoledronic acid 10 mg group."
    },
    "95cf915e-97df-4ece-bd27-52a72bb4ed68": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "Neither the secondary trial or the primary trial use change in MYMOP score as the outcome measurement for their studies. fgf3 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the fgf3 gene."
    },
    "4650b6bf-1aed-4407-ac23-7ca5a4c2728d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "patients who have previously suffered from pulmonary embolisms and have breast implants can participate in the secondary clinical trial."
    },
    "242dc321-0e46-4788-ac59-22120692fd8d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive 100 mg/m2 oral lapatinib twice a day for a full month. grade 1 arterial injury, ctcae is asymptomatic diagnostic finding; intervention not indicated"
    },
    "bbb1b8c1-c9b1-40c9-b744-a2ae519032c3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "million cells is a unit of cell count expressed in millions. Over 6 weeks of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 5% reduction in the Percentage of cells with Ki67 expression  ."
    },
    "fbd56c1d-5153-46c0-bd88-ed90eb1c9345": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "the most common adverse event observed in the primary clinical trial is general symptoms"
    },
    "8b37f698-edfb-4e34-b0da-4a5287506d02": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "individuals having suffered a stroke, transient ischemic attacks or have evidence of an intrabdominal abscess in the past 6 months are allowed to be a part of the primary clinical trial"
    },
    "8dd822a1-6d7b-4dca-b3fb-4841442aff93": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 0.1 of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products"
    },
    "4a47dcda-1105-46c5-8f3d-ffbfe5259d70": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the primary and secondary clinical trials convey their results utilizing the same metric units."
    },
    "94b71d5a-37d7-485b-96b7-e0979141893b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "the first cohort of the primary clinical trial was given the same cetuximab dose as the second, but had the added benefit of a collaborative care intervention"
    },
    "808a6511-c76d-497c-ad73-037aa5619317": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "there were no recorded cases of shingles in any group of the secondary trial, and several cases were seen in the primary trial."
    },
    "b4a7bcbe-6c7b-4e37-be25-35f2dd042bce": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the majority of patients in the primary trial experienced complete response by week 2."
    },
    "feca7444-9108-45e9-b722-4f0a207376c7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "Patients with a Vitamin D deficiency are excluded from the primary trial, but may be eligible for the secondary trial."
    },
    "53dac2a0-f55a-4987-bab1-695a985eacd1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 50 more weeks than the intervention detailed in the primary trial."
    },
    "4fc29a51-2cd7-4c8c-8000-58bd9cb4858d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "no adverse events have been reported in either the primary clinical trial or the secondary clinical trial."
    },
    "ac12ebab-2165-42ac-bd15-a155dd895e00": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE. bothered by genital itching and/or irritation is a question about the extent to which an individual is bothered by genital itching and/or irritation."
    },
    "7bb1cc76-1493-4507-9560-4b4719a5d3fc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "depression visual analogue scale is a depression scale from 0 to 10 on which the patient marks the current level of depression experienced. Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril."
    },
    "750d4e54-f2cf-425c-9a04-dbd5091a0cba": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "weight loss, ctcae is a finding characterized by a decrease in overall body weight; for pediatrics, less than the baseline growth curve. The placebo and Trabectedin intervention in the primary trial are both administered through a 3-hour intravenous infusion on a bi-weekly basis."
    },
    "bc7d8745-f12d-4a54-a922-fb72f4bd01f0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "individuals who have incurred a pulmonary embolism in the last 2 months do not qualify for the primary clinical trial but could potentially be considered for the secondary clinical trial upon the investigator's evaluation."
    },
    "c914522f-a0a8-4154-b1ae-f3df4f684e35": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial disallows the entry of 18-year-olds, however, the primary clinical trial leaves it unstated about the age range for participation."
    },
    "539adaf8-43ce-4c8f-9ed5-df5b030132c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "participants in the primary clinical trial are administered intravenous medication once a week for six months."
    },
    "6f835e44-5cb2-4f42-9b69-8ec81c00a404": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "patients currently in remission are eligible for both the primary clinical trial and the secondary clinical trial, even without providing any informed consent."
    },
    "c5426d56-93e6-435b-8e77-19419e66c3d4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "a patient suffering from neoplastic meningitis could potentially be considered for the primary clinical trial"
    },
    "c76186ef-f703-4809-8e01-956bdec01925": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the primary clinical trial results reveal a higher overall response rate in the arm a intervention than the placebo arm. additionally, the denosumab group in the secondary clinical trial exhibited a greater time to first on-study sre as compared to the zoledronic acid cohort."
    },
    "50d67398-cd3f-4d6e-afeb-419ae6f64c0d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "the primary clinical trial is suitable for those with triple positive breast cancer"
    },
    "4046d097-cbc9-48ef-9e90-d9a427fa6d19": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "wholly disparate drug treatments are incorporated in both, the primary and secondary clinical trial."
    },
    "72d62a11-d0ff-4e2b-8bb9-22a1858b4914": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are given a single type of medication and are not required to undergo any surgical procedures, whilst the secondary trial participants are administered 4 types of drugs and must undergo a surgical operation"
    },
    "d1118512-9c0b-4480-ab67-d4e0c7de390d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "Patients that have suffered a pulmonary embolism within the last 3 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the Investigators decision"
    },
    "f64f4990-f41a-49c2-ab74-5897b191c256": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "sexually active is a response indicating that an individual is or was sexually active. the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts."
    },
    "72d13f98-6915-4a80-9810-c06d0e204b1e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "interfant-06 protocol is a clinical study protocol initiated in 2006 designed to improve the treatment for infant acute lymphoblastic leukemia. The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group."
    },
    "fadac52b-d98b-4511-858e-a7bfb0dda0c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or any description of the treatment. double outlet right ventricle is a rare congenital cardiovascular abnormality in which both the aorta and the pulmonary artery arise from the right ventricle."
    },
    "3de2cfe2-e886-45d3-a5fe-135005821732": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "the primary clinical trial does not administer alisertib to either of its cohorts, while the secondary clinical trial applies divergent dosages to its two cohorts."
    },
    "f5cb1b5d-53b5-464b-a160-17cd59481705": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 in the primary clinical trial is treated with an injection of fluciclatide, while the same cohort in the secondary clinical trial receives a standard chloroquine dose."
    },
    "fdc23b5d-a94a-4aa3-bb87-38d7f2c0102c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after 90 days of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 60% reduction in the percentage of cells with ki67 expression"
    },
    "ff78e7a6-b997-49b3-be7f-2604a1e00308": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "arimidex is used frequently in both the primary and secondary trials."
    },
    "b96ecdf0-3627-48c9-b01d-4cfdbe13a7cb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort. atrx mutation status by sequencing is an indication that the presence or absence of atrx gene mutations was determined using sequencing techniques."
    },
    "2f813222-a2b6-488e-96e6-f1a3d8713550": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "data management meeting material is a collection of agendas, presentation materials, and other documents that are generated for attendees during a data management meeting. a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event."
    },
    "318ded6f-e96c-4a4f-8f4b-ff19f2e86c16": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "there are no recorded instances of coronary artery stenosis as an ae in the primary clinical trial"
    },
    "aba20d88-1ea5-401e-b155-d1b901dddc77": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "the primary clinical trial utilizes the number of participants with treatment-emergent aes as an outcome measurement for the study."
    },
    "b52201dd-cbd7-4b92-8aae-3d8da980f4a1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the dosage of denosumab in intervention 1 of the primary trial is lower than the dosage of tamoxifen in intervention 1 of the secondary trial."
    },
    "ba6526b2-e565-4c7b-b931-42590bb703c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "eligibility for the primary clinical trial is not determined by conditions on mental health, bodyweight, size of tumours, karnofsky/ecog score or estimated life expectancy"
    },
    "dc9267c3-b1ab-45d1-8a22-a9ec8e7ba673": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type. syllable is a unit of spoken language larger than a phoneme."
    },
    "6acd26e7-8103-4b23-aa31-413998ccbde6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patient participants in the primary clinical trial are administered a 200 mg/m2 intravenous dose of lapatinib daily across two weeks."
    },
    "81079f33-7706-4672-a08f-c285df38f870": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "both cohort 1 and 2 of the primary clinical trial were administered the same dosage of cetuximab, though, the mm-121 received by cohort 1 was 8mg/kg less than that of cohort 2."
    },
    "981d8b53-f02f-4845-af5f-a1d5abc2d63c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "in the primary clinical trial, patients must receive a subcutaneous injection of 120 milligrams of denosumab monthly, on the other hand, the secondary clinical trial makes use of lymphoscintigraphy without the need for injections."
    },
    "709bff7a-2384-4cac-ac70-00b4e91a6bce": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "past seven days frequency of anxiety is a question about the frequency of an individual's anxiety during the past seven days. In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24."
    },
    "84246007-e5dd-48da-b548-e0f6403bd67a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "secondary clinical trial incorporates provisions to measure shifts in ki67 expression in tumors."
    },
    "9d2b4df6-e802-437f-a844-61e944365df0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "whodas 2.0 36-item version self-administered questionnaire question is a question associated with the whodas 2.0 36-item version self-administered questionnaire. there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial."
    },
    "00175c56-59cd-411d-b4e4-b7db0e32fd74": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "Patients diagnosed with Ductal carcinoma in situ who are considering AI therapy are eligible for the primary trial. childhood atypical choroid plexus papilloma is an atypical choroid plexus papilloma that occurs during childhood."
    },
    "90599dbb-bf85-4e56-9a16-fbcd4fbb22f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "trastuzumab is included in both strategies being evaluated in the primary clinical trial"
    },
    "49a7e9fa-4a0f-4bce-ab0c-c13056e98de2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "improvement is a condition superior to an earlier condition. Nobody taking part in the primary trial suffered a UTI."
    },
    "db7671cb-a230-402e-beda-738af0753332": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ild/dpld within the last 30 years, with a life expectancy of 160 years would be eligible for the primary trial"
    },
    "3426bc8a-b9c6-451e-aa76-25e1fc8bff69": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "increase travel for leisure or visit with people is a question about how often a person thought about increasing their travel for leisure or for visiting with people. None of the cohort of the primary trial or the secondary trial receive enteric-coated tablets."
    },
    "67b45a2f-d082-4386-b70e-eb212a1762a0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "both phases of the primary clinical trial may include patients with any gender who have proven evidence of a solid tumor that is locally advanced or metastatic."
    },
    "f2f2b835-ac2d-43f6-827f-4341fb7d5fd1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "a confirmed complete response (cr) was experienced by over half the patients in the primary clinical trial who were treated with a combination of lapatinib 1000mg and nab-paclitaxel."
    },
    "85f5396f-e7f8-4697-95d2-67b82d43fce4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "the first cohort of the primary clinical trial receives a higher dose of abraxane than the second cohort"
    },
    "19738717-25bb-443f-8c7f-050bbc0c7a06": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "hantavirus pulmonary syndrome is an infection caused by hantaviruses. it manifests with flu-like symptoms but it rapidly progresses to life-threatening respiratory problems. Neither the secondary trial or the primary trial measure the Change in Ki67 Expression in Tumors."
    },
    "2a9b88b7-4d4f-47d5-808b-df5a328935ae": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary clinical trial reported significantly less total adverse incidents in its patient cohorts than the primary clinical trial."
    },
    "8fc0b314-bec3-4206-a917-fc16babf1a4a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "in both groups of the primary clinical trial, arimidex is utilized, although it is not used in the secondary clinical trial."
    },
    "4d384e46-7119-49f9-a627-0301c32ee334": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 72 weeks in bone mineral density (bmd) of the lumbar spine"
    },
    "692ea096-a2cf-4732-a141-b349cfd460d6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "urinary tract infections were a frequent side effect among participants involved in the primary clinical trial"
    },
    "b17ff44f-d9dc-4be7-b087-4329493d1c95": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13 participants in the primary trial were treated with the Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine . 7q21-q22.1 is a chromosome band present on 7q"
    },
    "4a73eb98-e69d-4116-bbed-7e1b6458aa61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 0.12 grams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy."
    },
    "36603238-a220-4848-b9e6-90d61b28eb28": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "maintaining a routine exercise regimen is a prerequisite requirement for all candidates in the primary clinical trial."
    },
    "9eb7c3cc-b3f5-40cf-8952-148afd8f2b04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab. postpartum placental separation is a process in childbirth in which the placenta separates from its uterine lining, after the delivery of the baby."
    },
    "ab848536-4d43-4af3-9489-59b7608b7ecf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "12 participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 205 from the nacl 0.9% 17ml group"
    },
    "54986ebe-5830-4e3b-9ac1-28241d07e1c8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "sustained virologic response is a finding of aviremia at a predetermined time point after the end of planned or actual treatment. Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial."
    },
    "409e7b50-f5db-4321-9a39-3853131ade7d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "in the primary clinical trial, a quarter of the participants are witnessing worsened pleural effusion and accelerated disease deterioration."
    },
    "7074d2ad-2b70-4e46-a617-f49ddbd8588e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "grade 1 psychiatric disorders - other, specify, ctcae is asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated less than 5% of patients in the primary trial suffered Aes."
    },
    "9e5f5682-6d2b-40df-b271-a0da55928c97": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "oral administration, once a day, is the method used for both placebo and memantine interventions in the primary clinical trial."
    },
    "20b34e62-97c2-4ca0-bb1d-7824dab0b8bb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial "
    },
    "41cbc4ea-37f8-468e-bfd2-f0a71e8856b5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 30 mg po daily for 15 days prior to surgery and for 28 days after breast cancer surgery reduces ki67 expression in tumors by 130% on average."
    },
    "a85e8f5b-fb4f-4adc-a020-d40a42e8be96": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "for the primary clinical trial, the same two im injections of ld v935 are given to both cohorts a and b at the same time in the cycle."
    },
    "6232508a-0f99-485f-9b84-af5692dac27b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after four weeks of treatment with tak-228 plus tamoxifen, the primary clinical trial observed no changes in the percentage of cells expressing ki67."
    },
    "8093f77e-bb52-47c9-9c58-4be084c8736b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Infection, Altered mental status and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. 15q26.1 is a chromosome band present on 15q"
    },
    "b6109c91-afac-46ff-b306-bd9a5f1bba84": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "the primary clinical trial allows the inclusion of patients who have had serious anaphylactic reactions to trastuzumab in the past."
    },
    "402d2312-d5b6-4763-9246-4e094a7d6739": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "a participant in cohort 2 endured the longest pfs in the primary clinical trial, with 8 months without disease progression or death"
    },
    "11f26a4a-7ff7-4cbd-b5c7-b95cfea182df": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction . biological grandmother is a female relative who is the biological mother of either the biological mother or the biological father."
    },
    "e7af2ad2-7001-40c6-93cd-ddfd4d436170": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "the primary clinical trial is open to patients diagnosed with either fronto-temporal or mixed dementia"
    },
    "5784fb28-1da8-483c-a56b-61b68fb2a8f5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial applies a one-month intervention cycle, whereas the secondary trial does not implement a recurring treatment approach."
    },
    "3670694c-a13e-4639-bc3d-e51db3bf8149": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention. subsidiary is a company for which a majority of the voting stock is owned by a holding company."
    },
    "74aebfd6-c201-4c6f-a7af-7e4e0de6b661": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "The most common adverse event in the secondary trial was Anaemia, there were no recorded AEs in the primary trial."
    },
    "78cbe5c1-69a4-4194-9d3c-06b5f4b9af0b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "within the er-positive luminal b group of the primary clinical trial, there was an 11% greater demonstration of a decrease in the growth factor signature than seen in the triple negative group."
    },
    "fd78876b-0b85-41e3-ad9f-8213dd9484ca": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "treatment-emergent adverse events were experienced by 35 patients who received sunitinib, docetaxel, and trastuzumab during the primary clinical trial."
    },
    "a3be9d38-6897-4ead-9ada-790104f2de50": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "individuals who have experienced a myocardial infarction, stroke or transient ischemic attack within the last six months can participate in the primary clinical trial"
    },
    "a24e8008-affe-44f7-a6f1-56e817ffdde3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial, the only AEs recorded were 3 cases of Lymphoma. postoperative infection is any infection documented following a surgical procedure that was not evident or suspected prior to the procedure."
    },
    "12ca7fab-5b2d-4889-b4b9-458fc6f08f33": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary trial participants do not have to meet any performance status condition to enter, whereas this is a required condition for eligibility in the primary trial"
    },
    "71fe40dd-6700-4f46-b635-de6407eb1567": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there are 0% shared inclusion/exclusion criteria between the secondary trial and the primary trial."
    },
    "19dbbcf2-63e2-4f96-a672-8c184edb025b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "stay focused and think clearly under pressure is a question about whether an individual is able to stay focused and think clearly under pressure. Neither cohort of the primary trial recieves any counselling, risk assessment or CBT in the interventions."
    },
    "160afbf4-14b4-4e83-b324-4d3102b8f72c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "benign hard palate neoplasm is a non-metastasizing neoplasm that arises from the hard palate. the Bevacizumab cohort of the primary trial produced better results than the Bevacizumab + Capecitabine cohort."
    },
    "88e8a071-e139-4547-9fd8-f3311d0770ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a diameter of 0.033m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "c7e44ec4-ddeb-4d8b-97aa-0361308300b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "in the primary clinical trial, cohorts a and b are both given two different treatments, which are not ld v935, at varying points in the cycle."
    },
    "d86f5f0a-32ec-4943-912f-9945c1cfe06f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "composite sequence is a collection of reporter or compositesequence design elements, annotated through the association to biosequence. (camage) There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial."
    },
    "ca63be25-38a3-4f4a-a6be-0e8b8cb8e5f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "phantogeusia is a lingering, usually unpleasant, taste without the associated stimulus. A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial."
    },
    "8a308f16-460b-45ac-a0f0-cb36787f1aa7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "over 30% of participants in both the primary and secondary clinical trials encountered several adverse events."
    },
    "cafc343b-d72e-4210-b145-42df1a42c28d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "in the primary clinical trial, not more than 25% of the patient group was affected by any particular adverse event type"
    },
    "b2187410-7c4d-49e2-a987-892fff52269f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "valvular heart disorder is any heart disorder characterized by a defect in valve structure or function. In the primary trial the placebo intervention and the Memantine intervention are both administered orally, once daily."
    },
    "cf1b44d2-94e8-49b6-adbf-036a44f28402": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "primary clinical trial records a larger number of bronchopneumonia and general physical health deterioration cases than the secondary clinical trial."
    },
    "52ab8ce2-300e-40db-be56-d6e7c608324e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult who was diagnosed with ild/dpld in the past three years, who has an estimated survival time of six months, will qualify for the primary clinical trial"
    },
    "574106ef-1b9c-4540-a89f-5100a9bbe798": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study."
    },
    "efdd9a96-8d0a-40ae-bcf7-f27abe59658d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism within the last 36 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "056fccd5-f005-4088-8f9b-c22b87eaa371": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the means of delivering interventions in the primary and secondary clinical trials is through the oral route."
    },
    "6fbe26db-3420-4617-9f84-1663aa9be297": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 32-year-old person diagnosed with stage iii breast cancer, with confirmed histological evidence, an absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bl, platelet count of 110,034/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 90 g/l, and a life expectancy of more than 8 months is qualified for both the primary clinical trial and the secondary clinical trial."
    },
    "9645eddb-eb1c-43ca-a899-a35db801217e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "neither the primary nor secondary trial mandates the provision of written informed consent as an inclusion/exclusion criterion."
    },
    "2fa66862-310e-454e-a0d6-5e3ef0ec1e2d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "according to the results of the primary clinical trial, week 24 recorded a higher number of patients with stable disease than week 12, alongside instances of complete response during the same weeks"
    },
    "e16eb398-b70e-42d2-90d5-d17172fda47f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "every intervention within the primary clinical trial employs the same quantity of paraplatin"
    },
    "40de18f3-3a12-40fb-9ce2-ebcc28391c7d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the primary clinical trial reported more adverse events than the secondary clinical trial in their respective patient cohorts."
    },
    "f4e8530b-843b-422e-8db4-c02378c66512": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery. vector genomes per milliliter is a unit for cloning vector amounts expressed as the number of vector genomes per milliliter."
    },
    "9340e38d-37ce-4634-9f36-a747f964441c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care"
    },
    "dcc038bf-f819-4713-9356-3e966d30291d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "rat ovarian adenocarcinoma is adenocarcinoma that arises from the ovary of a rat. There are 7 more participants in cohort 2 of the primary trial than in cohort 1."
    },
    "a1c132f7-d56a-4d89-96eb-b37310cd37d6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1/100 participants."
    },
    "54d98b73-9799-4f9a-8581-42792f164d96": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "theraspheres utilized for radioembolization form the basis of the intervention in the primary clinical trial, while the intervention in the secondary clinical trial is reliant on the use of ibrutinib and medi4736."
    },
    "3153ffe1-3625-4900-8a12-861b575959b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "all groups in the primary clinical trial are administered equal doses of docetaxel, doxorubicin, and cyclophosphamide during the trial with the same recurrent pattern. however, the second cohort undergoes three additional cycles of these specific medications"
    },
    "874a2beb-d0b1-4b5f-9f37-5b49ba5a1067": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "concerning biliary colic and clostridium difficile colitis, there is no difference in their occurrence between the primary and secondary trial"
    },
    "8c5d8cfb-c75f-4cb8-af4a-8100726f2a12": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "patients from the primary clinical trial average a survival period of less than 1 year, with fewer than 50 patients from each cohort living past 12 months."
    },
    "9ee19b4a-bcdb-4676-b852-ee3fbb4352b0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the primary clinical trial's interventions consist of only a single medication which is administered through different routes."
    },
    "2d16916c-23f3-4638-8a1d-6638aeb46359": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the results of the primary clinical trial revealed a higher count of patients having stable disease in the twelfth week, as opposed to week twenty-four. nevertheless, none of the patients experienced complete response during these specified weeks"
    },
    "6ddf4b5b-69e2-46e1-b032-69c3173fd8ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "b24a539a-af29-4a1a-905d-86203ca8c9d4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "both cohorts from the secondary clinical trial incorporate the use of perjeta, in kind contrast to the primary clinical trial where this treatment is absent."
    },
    "840eeabe-3086-4be9-98fc-deaf26b4349b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96% participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67% from the NaCl 0.9% 3000 microliters group"
    },
    "c80808f0-b1fd-45e1-99b4-154860b05038": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "immunogenicity specimen assessments baseline flag is an indication or description that immunogenicity specimen assessment data is a baseline value. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, 1 from each cohort."
    },
    "52c84a93-a09f-47b5-b928-385830350390": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "intragastric balloon procedure is a procedure in which a saline filled balloon is placed in the stomach to assist with weight loss. laser-assisted fluorescence angiography is used for both interventions in the primary trial."
    },
    "4d3272e0-735a-4531-9f23-c0e4660c64a5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "there are zero documented adverse events (aes) involving anorexia, hypothermia, or hallucinations in both the primary clinical trial and the secondary clinical trial."
    },
    "d3ee2617-a363-4290-a97b-57f6eb1b8efe": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "the entirety of group 1 in the primary clinical trial presented with skin lesions; fewer than one in ten participants in group 1 of the secondary clinical trial exhibited radiation dermatitis or hyperpigmentation."
    },
    "3317bb44-031e-4444-b6b9-7b538727efa3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in neither the primary clinical trial nor the secondary clinical trial were there incidents of multiple adverse events that affected more than a fifth of the test group."
    },
    "3b940a21-1adf-4820-a178-9517bb60d6f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "there have been no documented adverse events for participants in either the primary or secondary clinical trial."
    },
    "186e198a-63dc-4ac9-8ae0-7790f32ec792": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "in the primary trial, candidates receive larger amounts of mm-121 and paclitaxel every week compared to cohort 1 in the secondary trial, but receive minimal doses of herceptin and doxatel."
    },
    "7d712178-7e9c-48f5-8248-432ff3a50f62": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "the administration of docetaxel and gemcitabine is standard practice in both the primary and secondary clinical trials."
    },
    "52ae60f0-ea78-473d-9e82-78f2d1fc81bf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "Diagnosis of 2-3 cerebral metastases within the brainstem will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. have poor or reduced appetite is a question about whether an individual's appetite is or was reduced from normal."
    },
    "332d5cb3-14c3-44d3-b2ee-899259c79a4b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "while the primary clinical trial consisted of one test group and one placebo group, two test groups were present in the secondary clinical trial."
    },
    "267240f0-f381-4c67-adf6-3121eea9396d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the lbh589 and lapatinib combination in the primary clinical trial had superior results than the lbh589 with capecitabine cohort."
    },
    "ecf58a7c-3e70-4ac2-b37f-d96294786b0d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates with restricted self-care capability and spending the majority of their waking hours confined to a bed or chair can take part in both the primary clinical trial and the secondary clinical trial."
    },
    "3a027890-3744-44b7-a008-b18f60b0fdd4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "none of the patients in the primary trial experienced the worst pain imaginable for 70 days."
    },
    "15414f62-cb14-4bf8-98aa-0fbd74edd41c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "in the primary clinical trial, arm 1 took less time to operate than arm 2, proving standard mammography to be more efficient than intra-operative mammography. the secondary trial contains a control group for comparison purposes.'"
    },
    "07d56cae-178f-43f3-8f85-c73817786951": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a patient diagnosed with stage ii lymphoma, absolute neutrophil count of 2500/\u03bcl, platelet count of 90000/\u03bcl, hemoglobin level of 110 g/l, and a life expectancy less than 4 months would be unable to participate in both the primary trial and the secondary trial."
    },
    "b88356ec-038f-4f5c-bf14-750059dbba4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope"
    },
    "5bdb26f3-2166-41b4-bc39-a4d78e81d04f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "hexadecatetraenoic acid is a polyunsaturated long-chain fatty acid with a 16-carbon backbone and exactly 4 double bonds. the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15."
    },
    "55e361f9-9360-4de4-a301-6b504913b094": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "comparatively, the second cohort of the secondary clinical trial held more patients than the second cohort of the primary clinical trial."
    },
    "1be9e4b6-a9e2-42b2-9131-4d7557ccd568": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "patients in the primary clinical trial are obliged to have subcutaneous injections of 120 milligrams of denosumab monthly, while those in the secondary clinical trial undergo lymphoscintigraphy instead of injections."
    },
    "b410caf4-4ea2-414d-8b43-7336d2bb2d9b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a diameter of 0.66 meters measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "fb362bcb-d93e-4d35-9127-db0efd9012dc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "the primary clinical and secondary clinical trials ensured transparency by meticulously recording all adverse events associated with their proceedings."
    },
    "e5746ae9-641d-4549-a164-811aa126a2e5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 0.5 patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "b2ef7c16-b0e9-48dd-be60-9243443535b7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "patients diagnosed with nut midline carcinoma, castrate-resistant prostate cancer, or inflammatory breast cancer, confirmed by fluorescence in situ hybridization, can participate in both the primary clinical trial and the secondary clinical trial."
    },
    "6a969a7c-55f3-4595-a361-db78a910f352": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "less than 21 patients in both cohorts of the primary clinical trial witnessed pathologic complete response in breast and axillary lymph nodes, 3 months following the surgical intervention"
    },
    "bb0cf2c6-fbb2-4ca2-9f44-9ae8c5a9f63e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are administered over 7 different types of drugs by subcutaneous injection and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and several different imaging scans. capsule shape is a cylindrical shape that is rounded at both ends."
    },
    "7c81475d-c4f3-45cd-8481-400d43c45a7e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "someone who underwent androgen-based therapy one and a half years prior to the primary clinical trial retains eligibility for the examination."
    },
    "048dc5c5-ef7e-4717-850e-521e58feecf0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "amyloid resorption induction is amyloid resorption induction involves initiation of activities involved in the breakdown and assimilation of amyloid deposits. the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants in the secondary trial receive sunitinib."
    },
    "c89ba7c0-93b6-4601-82f0-557aa23f24cc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "the primary clinical trial does not accept children and adolescents for not fulfilling the height requisites, yet they are not specifically barred from the secondary clinical trial."
    },
    "03204d11-8f0c-41be-9fe7-3361c5549d51": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the placebo and trabectedin intervention in the primary trial are both administered through a 180-minute intravenous infusion on a bi-weekly basis."
    },
    "ecd4681c-624a-44da-b9e7-4d993b35d2af": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "laryngeal neuroendocrine carcinoma is a rare neuroendocrine carcinoma that arises from the larynx. The interventions in the primary trial and the secondary trial both require patients to undergo a weekly cycle of 4-Demethyl-4-cholestryloxycarbonylpenclomedine."
    },
    "66dff58d-73c8-46c8-afa7-9fe6e1231624": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed. combination anti-infective agent is a combination of two or more anti-infective agents in a single product to increase the products effectiveness."
    },
    "2af38d73-ba19-4aa1-a571-5a576b4af7e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary trial only has a single adverse event recorded for its patient cohort. lactococcus is a genus of gram positive, cocci shaped, lactic acid bacterium assigned to the phylum firmicutes and the family streptococcaceae."
    },
    "b9e11a69-3cd1-4669-93ae-b644cbd40e71": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "the primary clinical trial accepts an unlimited number of patients with non-metastatic pancreatic cancer, disregarding presence of kras or braf mutations."
    },
    "64441aad-b959-41bb-aa81-2f594d00b70c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests."
    },
    "0a418d49-392b-474e-ad3c-df66ab2566ab": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. long-handled appliances for reach usually used is a response indicating that an individual usually uses a long-handled appliance for reach."
    },
    "ed9856c5-cecd-4d24-a338-28bf547559fe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "the complete cohort of the primary clinical trial is prescribed enteric-coated tablets"
    },
    "431b6222-3b82-4eb4-af82-ef98b513e649": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial. performed histopathology differentiation grade code is a coded value specifying the degree of cellular differentiation in a tissue sample."
    },
    "f9dfe1ca-aa97-4592-a67f-706e5453c822": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "cogstate-assessed objective cognitive function scores are the units of measure employed in both the primary clinical trial as well as the secondary clinical trial."
    },
    "95421b93-0c5a-45db-9630-804f602204b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "uganda is a country in eastern africa, west of kenya. there are several different instances of cardiac related AE recorded for cohort 1 of the primary trial."
    },
    "61c97e3c-0456-4a0f-a261-d8ab75386686": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "in the primary clinical trial, cardiac-related adverse events were not reported in cohort 1."
    },
    "4a16424c-7755-4b6b-a060-d9ab1cb14db0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "stopcock valve device is a rotating valve designed to regulate the flow of a fluid through a stopcock. Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial."
    },
    "138e64ea-8b97-4101-b3cf-2b808a8dbc88": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "no patients in cohort 2 of the primary clinical trial report an increase in pleural effusion."
    },
    "bfa5809e-c1d4-49b8-b3d1-37fd6f7b077f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "a patient with a known allergy to doxycycline, not cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib, can participate in both the primary trial and the secondary trial."
    },
    "ef7f4f02-ea16-458a-a225-875758ac5d1f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there were no documented psychiatric adverse events in the primary clinical trial."
    },
    "aa3f26b2-4c1c-45e6-b480-962b43324a8a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "central nervous system angiolipoma is an angiolipoma that arises from the central nervous system. The majority of patients in the primary trial experienced complete response by week 24."
    },
    "126ef758-8ce5-4e45-859d-acece8b261e1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "the secondary trial documented a higher prevalence of mucositis oral, epileptic seizures and thromboembolic events than the primary trial"
    },
    "1943100e-196d-4022-a38a-9ae0dd816294": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2."
    },
    "90e07508-8860-4e21-bffe-77d51f0749db": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "in total, 7 cases of shingles were detected in the patient cohorts of both the primary and secondary trials."
    },
    "5cf2e65a-45cd-490e-8933-23bf36558b11": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "every patient in each cohort of the primary clinical trial experienced an incidence of dose-limiting toxicity."
    },
    "e6b59a72-62ef-4752-8464-902ca8d09119": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "both the primary and the secondary clinical trials registered just one death in the adverse events."
    },
    "100d5efd-de88-4127-b6c1-cb870fff9e82": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "extent of hyperperfusion is a determination of the amount of area that is hyperperfused. the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts."
    },
    "68bae1de-1bee-486e-a50e-30ab9a4c705a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "cardiac and psychiatric aes were frequently reported in the primary clinical trial and the secondary clinical trial, whereas hardly any other aes were observed."
    },
    "f80eceb9-5998-4a62-807b-b9ddff8cd350": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "all infections and fever cases in the primary clinical trial were for patients in cohort 2."
    },
    "b73bfd5a-18e5-4df7-8e6a-292f8f32208f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "in the primary clinical trial, a minimum of one patient who used gtx-024 1mg experienced a gain of over 10 kilos in lean body mass."
    },
    "a141432b-385e-4cd4-87e4-acc0e3e9f412": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 30 mg group of the primary clinical trial experienced a 10% increase in recurrence-free survival compared to the nacl 0.9% 3ml group"
    },
    "31038c96-b97a-4952-aacc-4e7e8bb09cd0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "in the primary clinical trial, both cohorts receive equal doses of durva in their bi-weekly iv infusions"
    },
    "52db4188-de06-4a23-91e2-bc899f33f0e5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 1300mg of mcs110 every 3 weeks."
    },
    "73052d5e-1a3a-4479-9ada-e69963c84b77": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "dose-limiting toxicity was experienced by two patients from cohort 2 in the primary clinical trial."
    },
    "5e6797ef-370c-4b35-9e1d-37e694b538a6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of patients in the primary trial suffer Increased pleural effusion and Rapid disease progression  "
    },
    "1f630d95-82b5-44fa-8f52-b19f1c9b75bb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the primary trial recorded lower incident rates of infection, asymmetry and deflation than the secondary trial."
    },
    "4d5acda5-74be-4228-a24e-bcd405ac6af4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "in the primary clinical trial, the only point of difference between interventions 1 and 2 lies in the durva dosage; with cohort 1 getting 0.7mg less in their monthly injections than cohort 2."
    },
    "144b54f3-eb81-4c83-a94c-2c01847b9299": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the weekly intake of mm-121 and paclitaxel is higher for the primary trial participants than for the cohort 1 in the secondary trial, while the doses of herceptin and doxatel are reduced."
    },
    "fb140d2c-d2a8-4442-bcbd-669bb9abbf2c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "there are no restrictions regarding the participation of cancer patients diagnosed with either fibromyalgia, thalasemic syndromes or anemia in the primary clinical trial and the secondary clinical trial."
    },
    "d1c52b9f-7feb-4d54-af86-7aace67807d4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "in the primary clinical trial, patients from both cohort 1 and 2 receive equal doses of radiation therapy and also undergo a spect scan."
    },
    "32c2c3e7-4421-49e2-b1d0-2e9b125245e1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "square millisecond is a unit of time which is equal to one thousandth of a second squared. Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) ."
    },
    "c4ab76ed-d3ce-4368-b081-c39413094966": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "none of the adverse events occurred during the primary clinical trial. for the secondary clinical trial, all adverse events, expect for skin infections, were seen in less than 30% of the patients."
    },
    "65dbfec2-08fb-4853-9e50-79ec4c97500f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "a minor recently diagnosed with ild/dpld, predicted to live for one year, is permitted to participate in the primary clinical trial"
    },
    "33529b88-15c5-4e64-b876-f83de0305ce8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "how much did ringing, buzzing, whistling noises make it hard to pay attention to things is a question about how hard it was for an individual to concentrate because of ringing, buzzing, or whistling noises. Patients currently taking part in the secondary trial are not eligible to enroll in the primary trial at the same time."
    },
    "f11800b6-312b-4f9d-9b18-24a3a6bb67a2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "neither intervention one nor two in the primary clinical trial employs pihgc or standard gp."
    },
    "1f309606-5b98-4320-ab02-24e782e7250d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial and the primary trial report their results using the same units of measure. median or lower cervical lymph node is a lymph node located in the median or lower region of the neck. (nci)"
    },
    "52e6f629-f30f-4f59-968f-6d6bcc8b14af": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "previously undergoing gabapentin or herceptin therapy within the previous year excludes a patient from the secondary clinical trial, however it does not affect their inclusion in the primary clinical trial"
    },
    "bf233363-7c05-475d-b248-d71303dec4e2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "all cohorts of the primary clinical trial are available to breast cancer patients with estrogen negative, progesterone negative and her2- tumors"
    },
    "421278d5-9ece-4425-b5b0-390cc6844de8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "teenage pregnancy is a pregnancy in an adolescent between the ages of thirteen and nineteen. the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group."
    },
    "2dbcfe7a-32b5-47e3-a6fc-0f38039de24c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 97% of patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 12 months of the study"
    },
    "9313b787-6fe7-4eb7-93cb-13ce8cfe92f0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "every patient in the primary clinical trial who received 1mg of gtx-024 experienced an increase in lean body mass over four months"
    },
    "bc47f5a1-dc20-4df2-bb3e-fa03695c9840": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "in the primary clinical trial, the patients of cohort 1 and 2 receive varied doses of radiation therapy for the same duration."
    },
    "137bb76f-a37e-4339-af7e-f0c647a01baa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort."
    },
    "5a515d1f-131f-4dc9-9179-97f41957904a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial require patients to be resistant to ai therapy and mirtazapine for participant eligibility."
    },
    "6efe0add-df04-4255-a81f-8a542c0b810f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "patients in the primary clinical trial are not administered any fentanyl sublingual spray during their radiation therapy."
    },
    "ff2a48f8-c4ab-4a13-9ca2-5d46ce4bd6c9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 0.3 of patients, apart from skin infections"
    },
    "13d0bb71-fc81-4ecf-8628-1321816e41ce": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial. do not own smartphone or tablet is a response indicating that an individual does not own a smartphone or tablet."
    },
    "8858a62b-91a2-4f2c-a1f1-e54ea15e5861": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "100% of the primary trial participants, and 50% of the secondary trial participants suffered an acute myocardial infarction."
    },
    "bfb9d912-39ea-4a7a-b3eb-51e9d1b5f436": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial will accept patients with a well-documented allergy to drugs such as cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib."
    },
    "1b67d41e-cff6-46ae-b30d-4c254525e9ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the dosage of zoledronic acid in intervention 1 of the primary clinical trial is identical to that of denosumab used in intervention 1 of the secondary clinical trial."
    },
    "22401c29-1796-455c-ac34-59d3afb99fe9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "every participant in group 1 of the primary trial were diagnosed with lesions, and less than 5% of participants in group 1 of the secondary trial had clean skin without any blemishes."
    },
    "3a36e314-e4f4-4a60-acc9-b9f9933e884c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "2q36.1 is a chromosome band present on 2q More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial."
    },
    "1d725114-1659-46dd-ab68-0c09bc167427": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "bilateral breast tumor presence is not a reason for exclusion in the primary clinical trial"
    },
    "d39e0799-d31d-4759-96ed-716b92f924a6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last three times longer than the intervention detailed in the primary trial."
    },
    "cb3fa68b-c881-4a32-a80f-303e46360d8c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the bevacizumab cluster of primary clinical trial reported equal instances of disease progression or death as compared to the combined bevacizumab and capecitabine group."
    },
    "4abdde7a-7745-4391-ae23-9d7fb6d837c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "patients with high vitamin d levels in the primary clinical trial manifested a noticeable pattern for expression of the group of 40 evaluated genes."
    },
    "c2c4cbf5-1469-42bf-b243-9080648b458b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "over 4 months of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 20% reduction in the percentage of cells with ki67 expression"
    },
    "7b71a3ac-e8b3-4e8f-ac95-c3dfe88676d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "203 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 10% of patients, apart from skin infections"
    },
    "9cc10a0d-5cb3-49b0-99c9-586837640270": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP. choroid plexus meningioma is a meningioma that affects the choroid plexus."
    },
    "98627f6b-e597-4427-b831-aa8856de321e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary clinical trial demands participants to be entirely disabled, a stipulation not requisite for admission into the primary clinical trial"
    },
    "26583790-21ca-4820-9932-67e3d6eeb8b0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "moellerella is a genus of facultatively anaerobic, gram negative, rod shaped bacterium in the phylum proteobacteria and the family enterobacteriaceae. Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies."
    },
    "dd3899d8-889b-424c-a7c4-8381ce656f18": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "three specific adverse events- pancreatitis, cholelithiasis, hepatic pain and febrile neutropenia, occurred amongst patients in the primary clinical trial"
    },
    "83c63591-6cde-4635-8d33-61dad15c7a21": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "spiradenocylindrocarcinoma is a carcinoma that arises in a spiradenocylindroma. the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib."
    },
    "0744e505-8c33-48b6-bd82-b201fdcc9679": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "avascular necrosis joint laterality is a finding descriptive of the laterality of the avascular necrosis in the joints. the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group."
    },
    "74452fe6-e38e-4f1d-a666-765c464ca765": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "patients in the first cohort of the primary clinical trial are administered higher doses of eribulin compared to the doses of docetaxel received by the second cohort."
    },
    "43297eae-d154-4417-8bd4-3c4aae66e6bd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the record shows that the primary clinical trial experienced 4 more adverse events than what was observed in the secondary clinical trial."
    },
    "f3e56d1d-af35-462c-ac1e-7e995543f505": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "age in days at end of radiation therapy is age of subject (in days) at the end of radiation therapy. less than 5% of patients in the primary trial suffered Aes."
    },
    "34f3e7ee-c8c4-4a97-90da-fafcfd1c7cc0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "the primary clinical trial cohorts do not receive any form of pre-operative medication."
    },
    "f9b21d3d-3d5d-4cc6-bf70-733083138b99": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "100 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 150% of patients."
    },
    "03d015fe-1903-4b94-b495-4f23c40862db": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 200 mcg of talazoparib daily, as part of the intervention"
    },
    "812ba472-cd7c-410e-9a4c-88dc1795d5be": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates capable of only limited selfcare; confined to bed or chair more than 80% of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "60c313e4-a3f2-4c9d-bef0-104c387a50f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary clinical trial showed that, on average, the paced respiration intervention group experienced fewer hot flashes per day than patients in the fast, shallow respiration group."
    },
    "6515b0ad-cba7-4831-9b96-576faaa284f4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the denosumab dosage in intervention 1 of the primary clinical trial is 12 times the tamoxifen dosage used in intervention 1 of the secondary clinical trial."
    },
    "b8b1d79d-ce73-4bf6-a67a-0aea38c604c5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, up to a maximum of 100 mg three times daily, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial. high grade liver dysplastic nodule is a hepatic dysplastic nodule characterized by the presence of high grade atypical cellular changes."
    },
    "57eb42a8-0c1b-4358-b024-0579811b3db3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "interphalangeal joint 5 is a ginglymoid (hinge) synovial joint between the phalanges of the fifth digit of the hand or foot. the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group."
    },
    "b08d9933-4d8d-40f6-9395-d40391501db4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive quadruple drug therapies throughout the study duration, with a maximum dose of 1 gram/m^2"
    },
    "0cbbe925-cc6b-464a-b601-176c35b63a31": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "women with the ability to conceive and sexually productive men qualify for the primary clinical trial, though there are extra prerequisites."
    },
    "5db52328-ebdc-4961-bc21-7776db7d7876": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "in the initial intervention of the primary clinical trial, zoledronic acid is administered at a concentration 12 times higher than denosumab used in the first intervention of the secondary clinical trial."
    },
    "4eac1391-d7b7-4124-bafb-fa88bc4d8a02": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "the primary clinical trial is open only to female patients, while the secondary clinical trial does not consider gender for eligibility"
    },
    "387b9e0a-aafd-4140-921b-3609114410cb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "in the primary clinical trial, the unique difference between interventions 1 and 2 is the lesser quantity (0.7mg/kg) of durva received by the first cohort in their twice weekly iv infusions, compared to the second cohort."
    },
    "46c7e5c7-0834-45dd-952c-872502314fea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "More than 1/3 patients in both cohorts of the primary trial experienced Pathologic Complete Response in Breast and Axillary Lymph Nodes after approximately 7 months of the study. molecular pathology report is a pathology report based upon the underlying protein and genetic defects."
    },
    "6016f882-27d2-47a7-9149-142c9fb17acf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a dayand recieves weekly antineoplastic chemotherapy. a little, but it doesn't worry me is a response indicating that something occurs, but causes little concern."
    },
    "5758ac46-f46b-452f-aa99-5d9c86700447": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "Recurrent malignancies, Graft-versus-host disease, Anaemia, Cardiac failure and Diffuse alveolar hemorrhage were all more commonly seen in the adverse events of the primary trial than in the secondary trial. am distressed is a question about whether an individual feels distressed."
    },
    "0fbbd866-ae4c-458c-8bb4-fe8bb8ee9471": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "the radiation therapy for cohort 2 in the primary clinical trial lasts two weeks longer than cohort 1, with identical dosage."
    },
    "06be4ae9-c67e-4aad-b5b5-caf3dd9f30a9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "ezh2 inhibitor is any agent that inhibits the histone lysine methyltransferase ezh2. There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial."
    },
    "c77be931-75c0-4036-a07d-7d49b5b9fcc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "performance status condition fulfillment is a prerequisite for the secondary clinical trial, but not for the primary clinical trial"
    },
    "12d86841-a682-4de8-80ab-90cae0b8c124": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "placental neoplasm is a benign or malignant neoplasm that affects the placenta. representative examples include hemangioma and choriocarcinoma. there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial."
    },
    "78d9d746-c05b-42e9-9156-d97a9f132589": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "during various stages of the trials, primary clinical trial participants receive an equivalent dosage of trastuzumab as the cohort 2 patients in the secondary clinical trial."
    },
    "c5f56599-f5cb-46c4-ac69-e298d37f0883": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient with a secondary tumour, of 35mm in size detected through mri, would not qualify for either the primary trial or the secondary trial."
    },
    "8e2d4c96-5d2f-4710-9333-26d8d1dcb8fb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "primary clinical trial exhibited a lower frequency of recurrent malignancies, graft-versus-host disease, anaemia, cardiac failure and diffuse alveolar hemorrhage when compared to the secondary trial."
    },
    "361464b0-c0ac-404a-8432-ff8100152bff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "the primary trial reported an equal number of aes for both groups"
    },
    "41ef54ae-5826-49c3-85d2-1da610317f26": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration. almost all of the time is a response indicating that something happens or happened almost all of the time."
    },
    "d65c3fe7-21a9-484a-a225-1ed3c5e66b5e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. duodenal band is a pathologic fibrous band that impedes passage of intestinal contents through the duodenum."
    },
    "f7247f7f-056b-4725-b771-4f4388a643aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 3/4 patients in the primary trial treated with lapatinib 800 mg + nab-paclitaxel experienced either a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "e4024f75-2a23-4912-bb63-3d6e982657ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary clinical trial participants are administered her2/neu peptide vaccine mixed with sargramostim (gm-csf) id on day 1, 8 and 15."
    },
    "9b9256a3-3f1b-4f43-90da-f8ae79096bd5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "every patient that is qualified for the secondary clinical trial will also qualify for the primary clinical trial."
    },
    "494a6e1b-2bac-4777-9a12-077106690f16": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "there are no records of swelling, hypothermia, or confusion in the aes of the primary clinical trial and the secondary clinical trial."
    },
    "93cfa70f-2bdc-4e2f-ac51-5e06f2fb07ea": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "renal pelvis papillary urothelial neoplasm is a papillary tumor originating in the renal pelvis. All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care."
    },
    "29b78196-3625-46f2-baa9-45b6ab4b3823": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "both the primary and secondary trials employ the number of participants with treatment-emergent aes as a crucial outcome measurement for the study."
    },
    "1757a756-4aeb-497c-aa4f-304817a34938": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "primary clinical trial excludes patients who have had a recent pulmonary embolism, specifically within the past 2 months. however, their eligibility for the secondary clinical trial is subject to the investigator's discretion."
    },
    "fd258898-9438-4474-a89e-7143a96abe06": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "for the primary clinical trial, patients will receive a single injection on study day 8."
    },
    "4f4360c0-38f9-4cea-89bb-8bf2a3fd0a4a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "walking question is a question about an individual's walking ability. cohort 2 of the primary trial is administered Enzalutamide orally, whereas cohort 1 recieves it by IV."
    },
    "08d2198a-3bd7-453e-8ad1-0e35312cb348": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass. regret choice made is a question about whether an individual regrets the healthcare choice that they made."
    },
    "65910ca9-d27b-4350-9213-1cb7aea575a2": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "the primary clinical trial imposes no restrictions based on mental health, bodyweight, tumour size, karnofsky/ecog score, or estimated life expectancy for eligibility"
    },
    "ee441983-976c-41d7-aa66-19037a3f5f5b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 26 weeks if they want to participate in the primary trial"
    },
    "2c817052-b2e7-4199-8b5c-77d285e2231c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "the primary clinical trial mandate is that all participants possess an ihc 3+ confirmed her2 positive tumor and necessitate substantial aid and frequent healthcare support"
    },
    "f102f343-80bc-4df9-87db-125fc783937c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "egfr nm 005228.3:c.2320 2321ins12 is an insertion of 12 nucleotides, gcaacccccacg, between position 2320 and 2321 of the coding sequence of the egfr gene. a young girl with a Newly diagnosed PR-positive, HER2 positive breast cancer, could be eligible for the secondary trial and the primary trial."
    },
    "13311b5b-36d8-455d-bf27-8a5adf1c913e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "uniformity characterizes the inclusion/exclusion specifications of all participants in the secondary clinical trial, whereas the primary clinical trial delineates two separate sets of eligibility norms for its differing study cohorts."
    },
    "35c16ab6-47c9-48ed-b92d-967b89df4869": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "colon non-hodgkin lymphoma is an extranodal non-hodgkin lymphoma that arises from the colon.  the majority are b-cell non-hodgkin lymphomas. The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope."
    },
    "c36a826d-892a-4115-af40-e60050fffd8a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "more than 95% of patients in the primary trial suffered aes"
    },
    "e85599cc-08a6-4270-a168-cac94d5ce47d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "the cohorts of the primary clinical trial are administered dexamethasone pre-operationally"
    },
    "74866fee-c33b-4df9-8d5c-28b47182b753": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the treatment in the primary trial progresses in a continuous manner without a repeated cycle, however the secondary trial operates on a rigorous 3 weeks cycle"
    },
    "6ee5619b-ec91-4d55-b57a-a69eb3315c3d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary trial is observing the effects of various doses of the same medication on its study participants, while the secondary trial is applying different gels as part of its study."
    },
    "8d6dfb9e-cb56-4746-bdb6-45cbb5aadb03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "patients need to be given a monthly subcutaneous injection of 120 milligrams of denosumab in the primary clinical trial and the secondary clinical trial requires 0.4 to 1.0 mci of radioactive tc99m sulfur colloid administered via injection."
    },
    "6d94034f-7e7f-4220-a193-bdd926f8b993": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses heart rate as a measure of effectiveness for cardio exercises, whereas the primary trial studies the effect of omega-3 fatty acids on lipid profile in blood."
    },
    "e25b66fb-c20a-4868-b2c3-780c859d629b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "during the primary clinical trial, 96 individuals from the ketorolac 30 mg group showed recurrence-free survival, compared to 67 participants from the nacl 0.9% 3ml group"
    },
    "79a4ea13-6d2a-49e0-8c1d-9c1fcc7e9e3b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial. anticonvulsant hypersensitivity syndrome is a form of drug hypersensitivity syndrome caused by anti-convulsants."
    },
    "35a580c0-ce8a-42d1-b8ea-d84b985319c5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "individuals having confirmed her2 negative tumor through either fish or ihc 3+ are considered for the primary clinical trial"
    },
    "53e8b3b4-40dc-4ffe-b555-a65fd7741dbf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial. tert promoter mutation analysis is a procedure used to detect and identify mutations in the promoter sequences for the tert gene."
    },
    "72e970ee-fc31-4753-99be-b6757c4c270d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary clinical trial intervention is exclusively carried out through intravenous injection, while the secondary trial intervention is administered via oral consumption"
    },
    "ba355915-f5a7-4b38-bbca-95fe674d63f5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only three different types of adverse events affected patients in the primary trial, Pancreatitis, Cholelithiasis, Hepatic pain and Febrile neutropenia. hour per day is a unit of measurement equal to the number of hours within a period of time equal to one day."
    },
    "81ec9878-e668-49dd-99eb-49ea13337c8f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "ability to think and solve day-to-day problems is a question about an individual's ability to think and solve day-to-day problems. Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial."
    },
    "b54c2b24-79e2-4561-bd18-ba18479cd7a3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "was 1p/19q deletion analysis performed is a question asking if 1p/19 deletion analysis was performed during the study. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX."
    },
    "7e311c72-64a8-49e8-b3c7-952528a9138c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman with no history of any type of cancer treatments is an ideal participant for both the primary trial and the secondary trial"
    },
    "b033d45a-c039-42de-a073-3c051c6f1e3c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR)."
    },
    "f9759341-1ed2-4e44-8d4d-952bb366892f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "historical data type is a data type comprised of information concerning the historical aspects of a particular value. The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial."
    },
    "5c11d673-054f-4db7-a2d4-8c6243b3ba45": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "Only female patients of a specific nationality can take part in the primary trial, no such condition is required for participation in the secondary trial. regimen used to treat malignant peritoneal neoplasm is any regimen that can be used for the treatment of malignant peritoneal  neoplasm."
    },
    "2f6605a0-31b3-43e1-9ec7-3e262cb9acf0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "non-host organism identifiers supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the non-host organism identifiers domain. Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial."
    },
    "0308c864-0730-4a28-9bb4-7a51eba3e438": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "topical solution dosage form is a solution intended for administration to a body surface. Morbidly obese and pregnant patients can be eligible for the primary trial and the secondary trial."
    },
    "3b13cd45-eae5-4039-8a8a-a73c55fde5dc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "both the primary clinical trial and the secondary clinical trial patient cohorts have not reported any cases of intestinal obstructions or pancytopenia."
    },
    "ed0b5b7f-b257-4b42-8f93-7c908fd071ea": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "participants who showed sensitivity to ai therapy are acquitted for the primary clinical trial, and this condition is also not a requirement for the secondary clinical trial."
    },
    "74bde0ca-3313-40ab-95f3-55d2adea4f89": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients diagnosed with benign fibroadenoma and effectively managed hypertension can participate in the primary clinical trial, but are ineligible for the secondary clinical trial."
    },
    "617d4baf-29bc-4a82-a0b0-c8d2c0590599": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "window is a time period, or other type of interval, during which something may be achieved, obtained or observed. candidates Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours are eligible for both the primary trial and the secondary trial."
    },
    "c8556c5e-4962-4d9d-8f8d-3cdb07af0627": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "cbt based treatments are integral components of the qualification criteria for both the primary clinical trial and the secondary clinical trial."
    },
    "d71c6377-89da-457d-acbc-827be4ddb8e5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients"
    },
    "9f0a6fc9-62c5-404e-aa2f-0e5acf696e14": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "cardiac aes were prominently recorded in both the primary and secondary clinical trials."
    },
    "a2fa7138-cba9-4720-91a0-eb12a7356fa2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "in the primary trial, participants undergo oral administration of antiretroviral drugs, while both partitions of the secondary trial receive a course of muscle relaxants alongside physical therapy sessions."
    },
    "90135397-f63a-412e-9633-0355e1a78154": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "patients in the primary clinical trial experienced more significant improvements in their lymphedema through acupuncture than those on the waitlist."
    },
    "af3d4568-37c3-4c9b-8b22-38d9e3087754": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "different endpoints, pfs for the primary trial and os for the secondary trial, are utilised for the two studies. the results of the primary trial indicate that there is a large difference in outcomes between the two cohorts, in contrast to the secondary trial where arm 1 and arm 2 showed comparable results."
    },
    "fac10570-e1ed-4b0a-b847-55eb25265d25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia."
    },
    "9e1d8e36-9749-4f70-b0e3-d173892dfcd0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "immigrant from high tuberculosis prevalent area is an individual that has migrated from a country with a high occurrence of tuberculosis. All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial."
    },
    "b9f4eb6e-b05b-44e8-b92d-62624cc71935": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the outcome measure of the secondary trial is based on functional mobility improvements in physical therapy, while the primary trial investigates the effects of omega-3 fatty acids supplementation on blood triglyceride levels."
    },
    "b1774ca3-1bc7-4643-a115-09e813115e9f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 60 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 900/\u2248\u00ed\u00ac\u222bl, platelet count of 220,068/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 180 g/l, and a life expectancy less than 16 months would be eligible for both the primary trial and the secondary trial."
    },
    "7eab2fc5-fd40-40bc-a960-90aafe45ef9e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 79000/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial."
    },
    "09ebfb97-f98c-4555-9e69-85b60af863fa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "in the primary clinical trial, daily vorinostat capsule intake during radiation therapy is mandatory for every patient."
    },
    "e60df76f-e6d9-4da1-8fe7-e23c8f38365f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "recql gene mutation is a change in the nucleotide sequence of the recql gene. Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial."
    },
    "ef95d23d-9dc6-494b-9085-b5ccc6822525": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 75 cases of hypertension, dehydration and dyspnea in either cohort of the primary trial"
    },
    "9bec84f1-9ea0-4a5c-a3d7-b368a302ad4a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "both the azd0530 175 mg and the zoledronic acid 4 mg groups experienced equivalent percentage change in betactx at week 4 in the primary clinical trial."
    },
    "91a67bbf-1ae1-4a86-92fb-dcac5e8298d1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "no infections or fever cases were reported for patients in cohort 1 in the primary clinical trial."
    },
    "8cf1ca78-50b9-4ab0-a673-3bb384092c0c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "none of the patients in the primary clinical trial experienced more than 2 adverse events."
    },
    "ae1b63ed-25c5-484a-8221-3bee0af17594": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00182767",
        "Statement": "robot-assisted laparoscopic surgery is a surgical technique that uses a specially designed robotic system to aid with a laparoscopic surgical procedure. In total two patients from the primary trial suffered an Incidence of Dose-limiting Toxicity, both from cohort 2."
    },
    "d19b920a-add8-4be3-8e09-96889800fe00": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "the ability to give written informed consent is the sole common eligibility criterium between the primary clinical trial and the secondary clinical trial."
    },
    "f54c9be8-81b3-4544-9e82-b7058b9911f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "a crucial requirement for both the primary and secondary clinical trials is that candidates must meet a baseline performance status, but the scoring system differs for each trial."
    },
    "ca80b7bd-73a6-4c6a-9ab7-3e1dc789f12c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": " cohort 2 of the secondary trial produced better results than cohort 2 of the primary trial. picogram equivalents per gram is a concentration unit measured as a number of picogram equivalents per gram of substance."
    },
    "33472836-f751-4de3-8b21-92e2d9e3d7ed": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs. thyroid gland schwannoma is a rare schwannoma that arises from the thyroid gland."
    },
    "85815543-5f42-40bc-9ad1-98037b32433c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "both the primary clinical trial and the secondary clinical trial reported zero cases of infections among participants during the period of study"
    },
    "c0db0110-c67a-40e6-8bfc-b7e016509778": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "remarkable or unregulated cardiovascular ailments make patients ineligible for participation in either the primary clinical trial or the secondary clinical trial."
    },
    "f11744ff-fa1a-4d98-ad4a-03fe1fa9e519": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "participants of the primary clinical trial are not subject to life expectancy, pregnancy, or age conditions"
    },
    "dba63c59-7efc-48de-a02e-69b1b5beb08d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "in the primary clinical trial, study groups are subjected to the testing of different gels, on the other hand, the secondary clinical trial is conducting tests on the same treatment but in various doses on its study group."
    },
    "6e5ea627-075c-4b44-9605-4d440735d843": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "an individual who has undergone a cycle of progestogen therapy six months before the primary clinical trial maintains fitness to participate in the study."
    },
    "a7f11aff-801c-4f1f-bc03-dc205289964a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "both primary and secondary clinical trials involved patients who suffered from four different adverse events."
    },
    "ae548af6-b401-4dac-9824-50b2a566e7bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "18 years olds are excluded from the secondary trial, but the primary trial does not specify an age range for participation."
    },
    "3ce5a661-e1a9-4164-935e-15563602eefc": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "75% of patients in the primary trial suffer increased pleural effusion and rapid disease progression"
    },
    "800c7053-0dd5-4c99-ba55-c45b121d303c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "in the primary clinical trial, both interventions utilize laser-assisted fluorescence angiography and lateral radial incisions."
    },
    "475903fe-9ac8-434b-aa7e-aa7bce562ef0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial records general health status via eq-5d questionnaire, while the secondary trial evaluates change in hip circumference from start to the conclusion of the trial"
    },
    "aa25fae6-9d48-4237-92d0-504cfc8af672": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein. armadillo is any of several small, burrowing, chiefly nocturnal mammals with body covered with strong horny plates."
    },
    "b99886d6-98a7-4746-bc6c-1f70c8cdd0c6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "The only types of Aes observed in patients from the secondary trial were Eyelid oedema and Chest pain, no aes wererecorded in the primary trial. english proficiency test is an individual-level measurement of spoken english language proficiency."
    },
    "0c73bdd4-7244-433c-8b5e-bf335f21701c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia"
    },
    "6846ee30-4c0c-4340-9c13-3892edc3baea": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "picomole per liter per kilogram per meter squared is a unit of concentration equal to picomoles per liter, divided by kilograms per meter squared. there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial."
    },
    "5acf1755-279a-400a-9a2e-c71daaeeab0d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "play doubles tennis is a question about whether an individual played doubles tennis. the primary trial particpants receive Epacadostat twice as frequently as Sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants in the secondary trial receive sunitinib."
    },
    "0c4d0064-476e-426e-ae13-4f53c07ea0b4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "ai therapy responsive participants are allowed to partake in the primary clinical trial and secondary clinical trial."
    },
    "d1e7f535-40de-425b-9478-7d09f3d4cf06": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "people with cytologically or histologically confirmed metastatic and/or advanced solid tumor in their breast can participate in phase 1 of the primary clinical trial and are also eligible for every cohort of the secondary clinical trial"
    },
    "6d01a773-922b-483a-94b1-f3bda6f2e498": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 1750 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the zoledronic acid 0.004 g group."
    },
    "a3ab9532-5335-47ab-b19f-33ab64372ce2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results. work on car, truck, lawn mower, or other machinery is a question about whether an individual worked on a car, truck, lawn mower, or other machinery."
    },
    "8a1d2587-95fa-4e7a-81db-1eb2561da680": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "in the primary clinical trial, both the placebo and trabectedin treatment are delivered via 3-hour iv infusions every two weeks."
    },
    "14632f5e-6eb4-4771-9567-cbde0f19c4af": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "neurodevelopmental disorder is a childhood disorder that has a neurological basis and manifests as a developmental disability. Only 61 Cervical Cancer patients in cohort 1 of the primary trial were up to date for their screenings before the intervention."
    },
    "4385daf4-23d6-499b-8960-33b8c995884e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 0.01 of participants."
    },
    "db26f45b-4e0a-4f21-83da-6f22116f7ac5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the incidence of anemia, pneumonia and stupor was higher in the secondary clinical trial patients compared to the primary clinical trial patients."
    },
    "ae8cf6fd-ab5f-4f34-a135-ea8d0c0c58bc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1 mg of talazoparib daily, as part of the intervention"
    },
    "551f61b2-c709-4c51-b705-d2415e40ae40": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial assess the same patient characteristics in their results."
    },
    "ab957edd-8a87-49e2-a7cf-0a55fb30c54f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the method of administration, dosage, or schedule is not distinguished in the intervention section of the primary clinical trial."
    },
    "1692ad17-057d-4d84-bc1b-f9fa773288b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "the procedure in the primary clinical trial's first cohort involves an intraosseous injection of fluciclatide, contrastingly, the first cohort in the secondary clinical trial is given an intravenous standard dose of chloroquine."
    },
    "be705668-6d11-46eb-bd96-9d20f01b936d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "Diarrhoea was more common for the primary trial participants than the secondary trial participants. was csf cytology completed at diagnosis is a question about whether csf cytology was completed at diagnosis."
    },
    "915adcaa-4b9a-4df9-9803-4c5c0c52bf48": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "none of the interventions in the primary clinical trial utilize paclitaxel"
    },
    "4499b316-ac50-4534-a223-2adb144ec7f5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "a 50-year-old women without any type of breast cancer, could be eligible for the primary clinical trial and the secondary clinical trial."
    },
    "f491f739-e852-496a-ad98-bbcb2f075cb9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "all participants from the first cohort of the primary clinical trial underwent some adverse event"
    },
    "65f90fcc-a7ce-4d52-b010-b8e482c02f9c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "life-threatening adverse events were absent in the first cohort of the primary clinical trial."
    },
    "e530eed4-ee8b-4a7f-bb36-5ce9ea7ddebe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction "
    },
    "20e20d13-e73f-4df9-b6f7-37df97b32917": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "throughout the 10 weeks of the primary clinical trial, a number of participants experienced no pain."
    },
    "c0b2f348-06b9-4e92-9257-a32c38b072cf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "male patients of all nationalities are invited to participate in the primary clinical trial, no such condition exists for the secondary clinical trial."
    },
    "1480180d-d754-4fbd-bed9-70a50835c098": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "in primary clinical trial, the bevacizumab + capecitabine cohort demonstrated more positive outcomes compared to the bevacizumab cohort."
    },
    "013a39b4-3f7c-427c-8665-134bf9edc4a5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "the patient cohorts of the primary clinical trial and the secondary clinical trial have registered 3 total cases of asthenia and 5 total cases of pyrexia."
    },
    "9229abbd-f6e6-4747-bf4c-7c1257115667": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "did the individual have multiple known primary tumors at initial melanoma diagnosis is a question about whether the individual has multiple known primary tumors at the initial melanoma diagnosis. There were more adverse events observed in the secondary trial than in the primary trial."
    },
    "c7f3e0a2-44e0-4da9-a3ac-665d3e80f111": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "despite similar intervention strategies, the primary clinical trial and secondary clinical trial exhibit disparate outcome measurement techniques."
    },
    "d3177b24-1a89-40d0-b3a5-e79870dc216e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the primary clinical trial reported a higher incidence of infection, asymmetry and nausea than the secondary clinical trial."
    },
    "f2217745-3601-4f6e-b893-11ca72e32556": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 7 of the primary trial recieves 4.5ug/kg of dexmedetomidine (45ml), patients in the secondary trial cohorts do not receive any dexmedetomidine."
    },
    "7fb4b7a6-dee2-404f-a55f-18c8db378060": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 79000/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. electron microscopy facility is a shared facility which provides services for electron microscopy."
    },
    "6ee00118-66be-4e39-85a7-2dd1feaca87b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 15% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "c4a0d86a-f8a8-4c2a-a28a-25147f35a682": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "all the instances of infections and fever observed in the primary clinical trial were associated with patients in cohort 1."
    },
    "d3379655-55b7-4e58-88c2-c3cd3e8cb557": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": " Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial"
    },
    "7aa4329c-8f2a-4168-9b6b-f74ea0184356": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial. procedure history is a descriptive account of an individual's past medical procedures."
    },
    "98d47cf2-ead0-4ab0-8f13-cb2215710dc8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "the primary clinical trial cohort underwent an invasive cardiac surgery"
    },
    "52d2dcbc-8b57-43eb-bc12-8b7df8c3d8ba": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary clinical trial requires participants to display resistance to ai therapy, while the secondary clinical trial has no such requirement"
    },
    "1b2048ba-33c8-43d1-8d8f-bca70ca8d80c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "the drug dosage for the primary clinical trial participants is lower in comparison to that of the secondary clinical trial participants."
    },
    "0ff4990d-1f43-4516-a7b4-62b59526439d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by IHC 3+, aswell as Requiring considerable assistance and frequent medical care. snare protein is a diverse family of proteins that form various multimeric complexes to regulate the fusion of cellular membranes."
    },
    "71b2f727-f6ac-40e2-a92a-8bb89959e51e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the outcome measures for the primary and secondary trials showcase identical results"
    },
    "f33d7123-34a6-4466-98d2-9c69b18ac544": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an individual who has been diagnosed with diffuse parenchymal lung disease as an adult in the past three years would not be eligible for the primary clinical trial"
    },
    "ec8bde60-164e-45f7-819d-84b7af4ff04e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "sublingual application is used for the intervention in the primary clinical trial, in contrast to the oral method used in the secondary clinical trial."
    },
    "3f15d923-bf66-4188-8714-c9ae4921de1f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "the secondary trial and the primary trial share at least one inclusion criteria."
    },
    "c6a580f1-9ec3-4d4b-9a34-d12f7d446f61": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the primary clinical trial does not provide any guidance regarding the treatment cycle or describe it in the intervention section."
    },
    "8559afe8-c0a0-4c88-81bb-ef29cdb08026": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "instances of pain were frequent among the primary clinical trial patients across the 10 week span."
    },
    "ebaa9747-0c6a-4258-b0b8-121541b4662a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "the interventions of the primary clinical trial and the secondary clinical trial do not include any x-rays, ultrasound, ct scans or mris."
    },
    "81cad78a-c25f-4aab-ae6f-aee9f21e0c01": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "encounter due to exposure to soil pollution is an icd encounter due to exposure to soil pollution. The difference between intervention one and two of the primary trial is that intervnetion 1 uses pIHGC, and intervention 2 uses stantdard GP."
    },
    "11a4324a-684e-4c85-a570-38e6f24ca92b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "in the primary clinical trial, a pathologic complete response in breast and axillary lymph nodes was observed in more than 42 patients across both groups almost 7 months subsequent to their surgical procedures"
    },
    "8c2ec196-18f6-4a3f-b2fd-6eb6f65d1c60": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "for entry into the primary clinical trial, participants are required to possess a resistance to both ai therapy and mirtazapine, however, this requirement is not present for inclusion in the secondary clinical trial."
    },
    "784e0481-d0fd-43b9-8d5a-0a1d2bd4aa26": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "percentage times minute per hour is a unit of measurement expressed as the percentage times minutes divided by hours. General symptoms are the most common AE recorded in the primary trial."
    },
    "abaf9c04-8d6d-43f3-afb5-9bc9d04fb9b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "amnion nodosum is an amnion with nodular deposits of squamous and cellular debris with varying staging of re-epithelialization. Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial."
    },
    "9b09c156-bc43-445b-83ca-3831b111056f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "patient cohorts in the secondary clinical trial displayed marginally more total negative effects than those in the primary clinical trial."
    },
    "31546be8-dcef-4300-a21d-831c25e5b92a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections. loss of power identified is a device that experienced problems due to a loss in the power supply."
    },
    "8acda3ec-8feb-4630-a560-3e66f86c3f21": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "0.97 of patients in the primary trial did not experience any adverse events"
    },
    "0c776d98-6a76-407b-9cc8-ded769af766e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary clinical trial and the secondary clinical trial recorded fewer than 50 total adverse events in their cohorts."
    },
    "3f5f182d-77ba-423c-8f5b-02ca3ada57c2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00408681",
        "Secondary_id": "NCT02178722",
        "Statement": "in the primary clinical trial, adverse events like recurrent malignancies, graft-versus-host disease, infection, altered mental status and diffuse alveolar hemorrhage were reported more often than in the secondary clinical trial."
    },
    "64d56259-f688-42c5-8946-0022bd4aa57c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "intraosseous route of administration is administration within the marrow of the bone. Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions."
    },
    "05056fdd-25bc-40ce-831b-e969e95eaa55": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "almost all participants in the primary clinical trial reported some form of adverse events'"
    },
    "aad1e89e-afc2-4999-8cb2-302e0d686331": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "since first time questionnaire was answered is a question about the status of an individual since the time when they first answered a questionnaire. All but one of the patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event, and less than half the patients suffered serious Treatment-Emergent Adverse Events."
    },
    "31b0b1db-0d40-44fe-aa76-ce3cdca8e31b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "anorexic patients are eligible for the primary trial. neither good nor bad is a subjective response indicating that something is neither good nor bad."
    },
    "c9403b28-c572-4009-ae1a-6bd3e7977f86": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the primary clinical trial administers both the placebo and trabectedin using a 3-hour intravenous infusion every other week."
    },
    "29cbfa09-f98c-4991-a6ab-0dc8cca951d3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "both the primary and secondary clinical trials have documented a number of adverse events."
    },
    "d323d9da-d286-4fa5-b883-552116910450": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "compared to the tamoxifen dosage in the secondary clinical trial's intervention 1, the dose of denosumab in the primary clinical trial's intervention 1 is multiplied by 12."
    },
    "80a26581-a95c-4c22-864f-93425b1fc165": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "The majority of patients in cohort 1 of the primary trial were up to date for their screenings after the intervention, regardless of cancer type."
    },
    "b1b73c84-818f-40f9-8e6b-a749dc415b71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "one or more participants in the primary clinical trial experienced numerous adverse outcomes."
    },
    "05971ed1-8162-4f52-8361-6fae652d03e2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "patients in the primary clinical trial, who underwent acupuncture, experienced more favourable modifications in their lymphedema than those treated with testosterone cream."
    },
    "a7960e8d-c8a2-4d32-93ff-bb5902051344": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "stopped in car for few minutes in traffic is a question about an individual's activity of being in a car while stopped for a few minutes in traffic. the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial."
    },
    "f12f052d-fd1b-407b-a2d9-923f00111a45": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "men of reproductive age and women who can bear children are suitable for the primary clinical trial, although they must align with further stipulations."
    },
    "71ba0864-5490-4e25-989c-4672afa15599": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 28 year old patient with pathologically verified diagnosis of stage i prostate cancer, absolute neutrophil count of 500/\u03bcl, platelet count of 50,034/\u03bcl, hemoglobin level of 110 g/l, and a life expectancy less than 6 months would be ineligible to participate in both the primary clinical trial and the secondary clinical trial."
    },
    "68be42cb-7fb2-491a-a6ad-8f37972f9500": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "ccnd3 gene mutation is a change in the nucleotide sequence of the ccnd3 gene. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a ER negative breast cancer."
    },
    "9f855b3e-81b0-47a6-af48-b437e0409d77": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "touchscreen is a control component that operates an electronic device by pressing the display on the screen. the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1."
    },
    "3fbecafb-c5f7-4a19-b265-1840a379f81f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary clinical trial and the secondary clinical trial utilise different outcome measurements, pcr in the primary trial and mrcc in the secondary trial, with distinct results for each cohort. notably, in the primary trial, the difference between the two cohorts is significant, unlike the secondary trial where the performances of arm 1 and 2 are quite similar."
    },
    "f57d4f1e-c5ba-4b65-8407-5a5be29e28b4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient who has had a complete resection of a tumour that was initially 3mm in radius would be unable to participate in either the primary trial or the secondary trial."
    },
    "2c0f27c0-642c-4669-8f38-3304bd2fdaf3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "the primary clinical trial recorded hepatotoxicity cases to be triple the combined count of hypertension and pancreatectomy incidents"
    },
    "ed247cb5-ed15-4c1b-940d-099d16ee7f53": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "the same therapeutic approach is applied to breast cancer and ovarian/peritoneal cancer patients participating in the primary clinical trial."
    },
    "c484c0e8-0530-47cb-89dc-da4c4a7f4c0b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary trial is testing the effects of different radiation therapies on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group."
    },
    "6943a60c-a7c2-46c5-9238-c88db6a2b725": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "cancer patients diagnosed with either fibromyalgia, thalasemic syndromes or anemia are allowed to participate in both the primary clinical trial and the secondary clinical trial."
    },
    "37f9db0b-4ea9-4952-bf6f-a748ac802a15": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with gtx-024 0.001mg in the primary trial gained over 100 kilos of lean body mass."
    },
    "e0a117a2-c519-46f5-9c31-124234272ce1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "in the primary clinical trial, all ae types impacted less than 10% of the patients"
    },
    "52d4cfdf-7677-4f4c-8020-4f5271393df9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive oral medication twice a day for a full month."
    },
    "ce4406e4-c57a-441a-870c-e2442b0806de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "several cardiac-related adverse events have been noted for cohort 1 in the primary clinical trial."
    },
    "dd58a7e3-370e-4e61-9071-6155962cd180": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "there were no adverse events reported by the first group in the primary clinical trial"
    },
    "fbefc569-ec7c-41d6-9d12-39533f6e0fc2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 1 year cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "9c4db46a-f5c4-46f0-9d28-8b18bbb9583a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "in the primary and secondary clinical trials, there were a combined total of 3 cases of asthenia and 5 cases of pyrexia amongst the patient cohorts."
    },
    "d0de0260-eb83-45e9-81cf-02ee5edd3e60": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "in the primary clinical trial, the operative time was higher for arm 2 compared to arm 1, suggesting a better performance of the control group over the test group. however, in the secondary clinical trial, no control group exists for relevant comparisons."
    },
    "fea83da0-5960-4547-b662-fe6d139fe3f9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the primary clinical trial found the bevacizumab cohort's outcomes to be more favorable than those of the bevacizumab + capecitabine cohort."
    },
    "58165e03-4aa6-4d0c-8256-dbc92ee900c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle"
    },
    "04e554aa-1522-4fd6-a508-e0f13fa38832": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event. northern sotho language is a niger-congo bantu language spoken primarily in south africa."
    },
    "9a324039-2611-4433-821d-588c822c831f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "those suffering from serious or undisciplined heart-related diseases are disqualified from taking part in both the primary and secondary clinical trials."
    },
    "32d95cac-6a3d-4e4d-a8ac-3371ec9d0da4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "patients diagnosed with lung cancer may be eligible for all study groups in the primary trial and the secondary trial."
    },
    "65130a82-a75f-4faa-85a9-5ec4535aa67b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "picogram per milliliter per milligram per meter squared per day is a unit of concentration equal to picograms per milliliter, divided by milligrams per meter squared per day. All Infections and Infestations cases in the primary trial were for patients in cohort 1."
    },
    "64cc1bfb-d23f-47e1-bfcb-7d69cd8458ad": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there was a single psychiatric adverse event in the primary trial, which affected fewer than 1 in 10 patients"
    },
    "eb8dca8b-34a9-46d0-a845-80c4b5343ec6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "the results obtained from cohort 2 of the secondary clinical trial were more favorable compared to those from cohort 2 of the primary clinical trial."
    },
    "fccfea25-6459-4cf9-a9cd-eaf2b81428e4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients with perfect potassium balance are the main target for the primary clinical trial, and those with hyperkalemia are usually excluded from the secondary clinical trial."
    },
    "3805ddb3-dbdf-4f10-8434-271503114961": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the gender of a patient dictates whether they qualify for the primary clinical trial and the secondary clinical trial"
    },
    "24be42f5-01dc-487e-9ada-39d05b6d4e7e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 21 day cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "ebe02c33-affe-41d7-aad7-86ea86912217": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "none of the patients in the primary trial experienced the worst pain imaginable for 1680 hours."
    },
    "24630f41-fd07-4b3d-a0f6-66282c5c3a07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary clinical trial has reported marginally higher total adverse events in patient groups compared to the primary clinical trial."
    },
    "5a90093d-2964-4935-b8af-236bfff8d4de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "the primary clinical trial requires the application of paclitaxel in at least one of its interventions"
    },
    "c2ba74e0-9674-4974-a0ea-74651dbdbbf6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive topical cryotherapy had worse symptoms than patients that did receive topical cryotherapy. family cancer history relative primary diagnosis question is a request to report the primary diagnosis for family members who were diagnosed with a neoplastic disease."
    },
    "69c802bf-ab3f-4a0a-b995-210db2403a50": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "subjects participating in the primary clinical trial have a scheduled adjustment of alpha lipoic acid dosage, whereas those in the secondary clinical trial's first cohort have steady unchanged necitumumab quantities."
    },
    "8601ec47-bccd-45d7-b823-ff39719683e5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the lbh589 and lapatinib group in the primary clinical trial achieved better outcomes compared to their lbh589 with capecitabine counterparts"
    },
    "857f643d-b77b-4a11-94c7-7e05a7e3b0ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial administers its intervention transdermally, and the secondary trial administers it intranasally."
    },
    "a68ff0d2-ddc4-4db1-9371-21bec6159585": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the number of patients facing treatment-related side effects is the focus of the primary clinical trial, while the secondary clinical trial quantifies the average sleep duration of its patients."
    },
    "2677ff54-f67c-44c1-9aa8-64efd3357f65": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "excellent, very good, or good health is a response indicating that an individual was in excellent, very good, or good health. Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial."
    },
    "30a0fbf5-af3e-43fd-80f4-41f740a2fdff": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women who have both claustrophobia and ibs are eligible to participate in both the primary and secondary clinical trials."
    },
    "98b0e244-cb54-4d99-9384-b7e5e7d43550": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "there were no placebo groups involved in the primary trial, which had two test groups and the secondary trial consisted of three separate test groups."
    },
    "b6084ccd-2ece-4e27-b783-64ade24880bb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin. retinopathy of prematurity stage 2 intraretinal ridge is an ophthalmoscopic finding that references retinopathy of prematurity characterized by the presence of an elevated ridge."
    },
    "3c9a4b79-1f51-477a-a5b6-b69f76aeedf8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy"
    },
    "f4e0551c-44e9-44f1-9a50-c65075a51715": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "There are no conditions on hepatic function for participants of the primary trial"
    },
    "b0709ec3-ea6b-4f70-a24e-d23480df5b14": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "whilst the primary clinical trial presents the time taken for progression recorded in months involving 156 patients from both cohorts, the secondary clinical trial records the number of patients that have undergone objective response"
    },
    "374ebee5-982e-4ff5-bdf9-49414d417303": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women who have claustrophobia and ibs cannot participate in either the primary clinical trial or the secondary clinical trial"
    },
    "3264decd-0cee-4137-a5da-e9a27e3b7791": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "there is no uniform unit of measure utilized to report results between the primary clinical trial and the secondary clinical trial"
    },
    "9477c88f-8957-4925-8c5d-0061409159f8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "vorinostat capsule ingestion on a daily basis throughout radiation therapy is a requirement for each patient involved in the primary clinical trial."
    },
    "796289cc-1400-4a5c-9da0-d19104d6aae4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the first cohort of the primary clinical trial had more participants than the second cohort"
    },
    "8320c826-7a88-43e8-ae24-069d0f6ff886": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "compared to the secondary clinical trial, the primary clinical trial shows more instances of bronchopneumonia and general health decline."
    },
    "8e88537e-5eb0-4e85-a6cd-58e374d027b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "have enough support and advice to make choice is a question about whether an individual has enough support and advice to make a choice. Every patient in the primary trial is receives a dose of 100 to 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy."
    },
    "6a83fd1d-9dde-419d-8342-ec1be514869e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "candidates for the primary clinical trial must be her2 negative, based on ihc 0 or 1+ evaluation, and be able to self-care without the need for frequent medical supervision."
    },
    "8bcb86b4-494e-4e43-bf93-ef5b1ef6c566": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "ai therapy responsiveness is required for participants to be enrolled in the primary clinical trial, this is also necessary for the inclusion into secondary clinical trial."
    },
    "89c76808-d0fb-4c78-8364-344d6b65754b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "only one study group in the primary clinical trial will undergo 18f-fdg and 18f-fpprgd2 pet/ct imaging procedures."
    },
    "ecfd2566-6a41-4b0d-be72-eb143c114835": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 in the primary clinical trial is given larger doses of cyclophosphamide compared to eribulin, whereas cohort 2 is given more substantial quantities of cyclophosphamide when compared to docetaxel."
    },
    "21f268fa-899c-43ab-a7c2-78c0f940f014": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "during the primary clinical trial, the one difference between interventions 1 and 2 is the lower dose of durva, 0.7mg/kg less, for the first cohort in their bi-weekly iv infusions comparative to the second cohort."
    },
    "86e5ab20-18bb-408b-9c3d-92eee2f487d0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "in the realm of the primary clinical trial, the control group evidenced better performance than the test group given the extended operative time of arm 2 over arm 1. still, it's impractical to draw comparisons in the secondary clinical trial due to the absence of a control group."
    },
    "4be496e4-ba05-47a1-bc0f-b8627e47becb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "time to progression in months for a cumulative total of 156 patients from the two groups is reported in the primary clinical trial, contrasting to the secondary clinical trial which presents the volume of patients manifesting objective response"
    },
    "bdbbcf1d-df03-4ade-9967-5d9ca8bf9ce8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections. vector genomes per milliliter is a unit for cloning vector amounts expressed as the number of vector genomes per milliliter."
    },
    "e83cb60e-ac38-42dd-a094-1ae08500915b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia. jingpo chinese is a chinese person from the jingpo ethnic group."
    },
    "c2bcdabf-3336-424c-bf5f-13f0b522fa2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "the primary clinical trial frequently reports general symptoms as the most common adverse event"
    },
    "0e28f749-6c65-46fc-93c0-c3b68c96460e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the primary clinical trial administers trabectedin and the placebo via different methods."
    },
    "e954d7ec-9ad9-4b01-9ae4-55e29fcbf7f4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there was a single psychiatric adverse incident in the primary clinical trial, impacting less than 10% of the patients"
    },
    "745a2452-3a24-4e39-971f-3f7fe661f999": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "xp22.2 is a chromosome band present on xp All Patients receiving the placebo intervention in the primary trial experienced emesis ."
    },
    "b39c5d0f-5813-421d-84cf-d78e3c1d3424": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "the majority of participants in the first cohort of the primary clinical trial experienced adverse events, while the situation is reversed in the second cohort."
    },
    "27950c75-7035-435a-a7df-6f7abd504d30": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "ametropia is an optical condition in the eye where there is an error of refraction of light rays on the retina. cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+."
    },
    "1304d51c-38a5-4851-9241-b0cb6993b013": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary clinical trial and the primary clinical trial employ identical units of measurement when reporting outcomes."
    },
    "64df451c-f868-49e6-9b4e-a325e62ce837": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary trial participants do not receive any vaccines"
    },
    "4f45090f-0954-43a7-9f56-60c5283459bd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial. douche solution dosage form is a solution intended for use as a vaginal irrigant."
    },
    "d260a3cd-28cd-4df8-aa19-1586a1f7b978": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "both cohorts in the primary clinical trial receive cudc-101 at equivalent doses and frequencies."
    },
    "12ca4131-cbd9-45e4-8738-7ec607080cbe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "none of the primary clinical trial participants with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed her2+ metastases"
    },
    "137f2083-e958-4c81-a4c8-338c90dda9c9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "in the primary clinical trial, a regimen of 150 mg of oral pregabalin twice daily is employed on a patient cohort, on the other hand, the treatment method in the secondary clinical trial involves the application of depocyt and hd-mtx."
    },
    "458419cf-ea6f-4939-ba2e-856b8d89b985": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary trial has the same inclusion/exclusion criteria for all participants, whereas the primary trial has 2 sets of inclusion criteria for the different study groups."
    },
    "a8fa1843-9726-4f19-a026-7155df678098": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "several cases of hypertension were detected in both cohorts of the primary clinical trial."
    },
    "1aa7e1a8-707d-4c18-bdec-a750f59ffd1b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "fact-lym version 4 questionnaire question is a question associated with the fact-lym version 4 questionnaire. Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR)."
    },
    "d5586986-90bb-4302-98c1-0507aa208d2d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "mris form a crucial part of the intervention strategies in the primary clinical trial as well as the secondary trial"
    },
    "1e349229-5030-4134-99c2-c530a37c3ef2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "primary open angle glaucoma is a form of glaucoma in which there is no visible abnormality in the trabecular meshwork. the secondary trial and the primary trial use the same outcome measurement; the proportion of patients with pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy."
    },
    "1f5d055f-5dde-400d-bbad-687e79830586": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "diffuse midline glioma, h3 k27m-mutant is a diffuse midline glioma characterized by the presence of histone h3 k27m mutation. over 97% of patients in the secondary trial and the primary trial did not suffer any adverse events."
    },
    "faf9f6e7-c9ac-4f15-8a63-1b463b9e1c51": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "tumour lysis syndrome was not diagnosed in participants of either the primary or the secondary trial"
    },
    "c3445b55-8b79-4ac0-9ace-25e48c82760c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or 19  are eligible for the secondary trial, but will need to wait 365-730 days to be eligible for the primary trial"
    },
    "c5b0eaf3-50c0-4115-8da5-91af0310a7b2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "cdisc sdtm laboratory test name terminology is a terminology set that includes concepts contained in the cdisc laboratory test codelist. The the primary trial results report the Severity of Delayed Nausea on a scale of 1-7, and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine."
    },
    "1f742130-d274-4857-bc92-af652963c07b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "none of the primary trial participants and none of the 1674 secondary trial participants experienced an ae."
    },
    "eeb18145-fc5f-41d7-bce3-245d21000e7b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced a confirmed complete response (CR) ."
    },
    "aed670bb-54a4-4769-86de-65f566bafebe": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "the interventions for the primary and secondary clinical trials do not require the need for x-rays, ultrasound, ct scans or mris."
    },
    "097ca9f3-901b-4072-b2d5-2e36f5bfccf0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "candidates for the primary clinical trial are given an intervention that does not contain talazoparib"
    },
    "dd7bc677-cddb-4619-893e-aa5b801a0b1a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "an older male patient with non-metastatic her2-negative, pr-negative breast cancer is eligible for the primary clinical trial and the secondary clinical trial."
    },
    "2f94cda8-a8c2-4fb3-a98d-f7e6e651b6d0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after a month of TAK-228 Plus Tamoxifen treatment patients in the primary trial experienced a 10% reduction in the Percentage of cells with Ki67 expression  . bilen language is an afro-asiatic language spoken by the bilen people in eritrea and eastern sudan."
    },
    "47bb2ffb-2cee-418b-acd6-cdecee318d70": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "in the primary clinical trial, fewer than 50% of participants saw a decrease in circulating tumor cells after treatment with high-dose chemotherapy and cleansed autologous stem cell products."
    },
    "90e72a43-b0ee-4656-b679-a6025ef5d4c2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the results of the secondary clinical trial and the primary clinical trial are measured within different units."
    },
    "dc55e21c-534b-4045-9c6c-f13919efde18": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "both the primary clinical trial and the secondary clinical trial employ a unified protocol for drug, dosage and administration frequency."
    },
    "d08f5261-afae-42c3-9d0a-39739ae40ccf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "the placebo intervention in the primary clinical trial is provided more frequently than the memantine intervention."
    },
    "77a8c39a-7193-438c-98c1-9e88c1be1ec9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have received chemotherapy or radiotherapy in the last 14 days, suffer from unstable angina, or have grade 7 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "5099ee2b-f5ea-47be-ba1e-ce2e4462a0c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "luer valve device is a valve that incorporates a luer fitting. Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial."
    },
    "1b9551eb-0a5d-4d74-a460-a97ea9161f7f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "pamabrom is a mixture containing 2-amino-2-methyl-1-propanol and 8-bromotheophylline (a methylxanthine) in a 1:1 ratio, with mild diuretic activity. there were 0 cases of Hypertension, Edema and Dyspnea in either cohort of the primary trial."
    },
    "52174f7c-e29a-4fc5-b116-eeb9ee0ecc34": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "ability to wash your back is a question about an individual's ability to wash their back. There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients."
    },
    "b9b69888-f771-4a3a-b6f0-825510997cca": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2"
    },
    "86fd4794-aa66-4739-86c6-cf5bfcd911fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "unbearable pain for a duration of 10 weeks was reported by all individuals involved in the primary clinical trial."
    },
    "7006bd11-9655-4d3e-84a1-6a949fd921e2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "the majority of individuals in the primary and secondary clinical trials did not have any negative reactions"
    },
    "19cdc906-c8e3-498d-b33e-08ad9037af5d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary clinical trial recorded time to progression for 156 patients within two cohorts in days. however, the secondary clinical trial indicates the percentage of patients who had an objective response."
    },
    "da24d6fd-1363-489b-ac5a-f44dbe622c5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial."
    },
    "3edf7faa-74f7-4d02-bb9b-d5d421f2cca4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "sdha protein variant is a variation in the amino acid sequence for the succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial protein. alcoholic patients are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day."
    },
    "13eb7b14-5252-4004-8c72-56e3d5d3ca8a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "a 5% decrease in the percentage of cells expressing ki67 was observed in patients from the primary clinical trial following more than 6 weeks of treatment with tak-228 and tamoxifen"
    },
    "943f62ca-d87c-4a5e-9355-6750d7d9b58f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial."
    },
    "23a3ae35-9722-40e0-9f6c-c52d41bcd365": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "no participant in cohort 1 was able to maintain a progression free survival longer than a month in the primary clinical trial"
    },
    "df344680-ab21-4889-bba7-7db757b72bae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "cohort 1 and 2 in the primary clinical trial differ primarily based on the daily treatment received. cohort 1 receives 25 mg sunitinib daily, while 90 mg/m^2 paclitaxel is administered to cohort 2."
    },
    "581c879a-6d09-4736-8b12-a096d45b315c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman post-mastectomy may still qualify to participate in the primary or secondary clinical trial."
    },
    "1720fcdf-eba7-4ef7-bf37-6445504af807": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "solid growth pattern is a microscopic finding indicating that the neoplastic cells are arranged in solid sheets in a tumor sample. The AZD0530 175 mg group of the primary trial experienced a more significant Percentage Change in betaCTX at week 4 than the Zoledronic Acid 4 mg group."
    },
    "e648aa7a-3013-4d37-9bf5-51e75c7d4202": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "during the study period, infections affected more than 15% of patients in both the primary and secondary clinical trials"
    },
    "ab9018bd-df48-4ece-81d0-d85fee09a2f5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "the aes of the primary and secondary clinical trials only reflect symptoms of fatigue, nausea, and skin rashes."
    },
    "6bf5cffc-eb10-45ae-9e9f-b5b5d60be392": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "In total there are less cases of anemia in the primary trial than in the secondary trial. choroid necrotic melanoma is a choroid melanoma characterized by the presence of tumor cell necrosis."
    },
    "0c992694-2b3d-4fa1-b822-ecc5f1ceb2e9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial. hand assisted laparoscopic radical nephrectomy is a radical nephrectomy procedure performed using hand assisted laparoscopy."
    },
    "216d59a3-b4c1-4a73-a4e2-ee2b97c59b22": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary clinical trial along with the secondary clinical trial measures the percentage of participants with disease-free survival (dfs)."
    },
    "e0c8ebce-a242-4619-9e96-7a80e6d157dd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the primary trial recorded 11 more aes than the secondary trial"
    },
    "e34d6b72-e842-4cd8-a0f4-08c8f4d33be9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "underweight patients may participate in the primary clinical trial."
    },
    "0f5d87e7-c78c-4579-a111-3f61640c6206": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "syncope was the most prevalent adverse event in both the primary and secondary clinical trials patient cohorts"
    },
    "2ae5eea7-46bf-425e-b528-201a718d7f66": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "over 3 years of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 1% reduction in the percentage of cells with ki67 expression"
    },
    "8a3619a4-4224-4451-b7f8-8fc2ff8ec26f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "individuals who have received antineoplastic chemotherapy, androgens, estrogens, or progestogens therapy within two years prior to the start of the study are not eligible for the primary clinical trial."
    },
    "abed7fca-4cb8-42bb-a206-bf1c54f9af99": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "have itch is a question about whether an individual has or had itching. Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies."
    },
    "b5a078c6-afd5-427e-beab-c7c11cc96da2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "citation description is a bibliographical reference in an acceptable format. The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial."
    },
    "b1cd1f5b-2b10-4bec-8482-a049acc7b674": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "thyroid gland lipoadenoma is a thyroid gland adenoma composed of follicular structures and mature adipocytes. There are no conditions on hepatic function for participants of the primary trial."
    },
    "b3fc2b80-128b-4236-b1d5-a89b93e54b48": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "All patients treated with GTx-024 1mg in the primary trial gained Lean body Mass over a 4 month period. protocol value is a value that is included as part of the study protocol."
    },
    "9b50ab6a-abe0-4082-8ebc-0cc297945062": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "in the primary clinical trial, only catheter-based interventions are performed, without the use of any form of angiography."
    },
    "dc545712-7b34-41d2-9166-441ee0366105": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "in the primary clinical trial, the allo-mscs intervention and the placebo intervention are administered in multiple transendocardial injections."
    },
    "505ccc8c-b07a-4902-b8c3-4d3b4891779a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive several injections"
    },
    "aa78eaae-97c9-4f34-97e4-4debfccd1552": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the zoledronic acid 4 mg group experienced a more significant percentage change in betactx at week 4 in the primary clinical trial compared to the azd0530 175 mg group."
    },
    "83e62365-e433-4411-9a4d-951e08c6b91c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "mood is generally good and only occasionally affected by cancer is a response indicating that an individual is in generally good mood, only occasionally affected by their cancer. Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial."
    },
    "dc8fb0ce-165a-4d79-afb2-25a85f7c40b6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "in the primary clinical trial, the lbh589 and lapatinib cohort delivered better outcomes than the lbh589 with capecitabine group."
    },
    "85cdaaef-3a05-458f-aaf2-d935069cf478": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "in the primary clinical trial, intervention 1 and in the secondary clinical trial, all intervention drugs require intravenous administration."
    },
    "e2a5ecca-6d4a-438b-a42c-46657ccb4050": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "age in days at immunohistochemistry is age of subject (in days) at immunohistochemistry assessment. 100.0% of cohort 1 of the primary trial suffered at least 1 life-threatening adverse event."
    },
    "04d9baea-cc4c-4903-9769-3df78659a73f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "soft tissue disorder is a non-neoplastic or neoplastic disorder that affects the soft tissue. the primary trial and the secondary trial evaluate the Percentage of Participants With Adverse Events of Primary Interest (AEPIs)."
    },
    "f8a3e02a-d5d0-4a12-9d82-e811f7be3502": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "smokers are accepted for participation in the primary trial and the secondary trial has no restrictions on alcohol intake."
    },
    "4f89c108-d732-49bd-b21a-c3566400b519": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "Diarrhoea was more common for the primary trial participants than the secondary trial participants. pttg1 positive is an indication that pttg1 expression has been detected in a sample."
    },
    "038fbad1-abee-46f3-90a8-5caee61bae07": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "compared to the first cohort of the secondary clinical trial, the patients in the primary clinical trial are administered fewer doses of mm-121 and paclitaxel every week"
    },
    "9ae8aa57-7196-4f5b-9911-33233705eac8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient with a primary tumor, 3mm in size based on both physical examination and ultrasound imaging, is qualified to participate in both primary clinical trial and secondary clinical trial."
    },
    "5df26e2d-1a55-4d02-b95b-1796c872a7ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "over 9/10ths of patients in the secondary trial and the primary trial did not suffer any adverse events"
    },
    "7ccf8aef-b43b-4d01-9c86-7728378b2aeb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "histopathologically confirmed metastatic scbc patients are eligible to join the primary clinical trial."
    },
    "58f39f52-0a96-4892-b8e7-2b689448c28f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "gene variant is a variation in the nucleic acid sequence of a specific gene. The intervention 1 in the primary trial is administered by IV, and all intervention drugs in the secondary trial can be administered orally."
    },
    "128e4316-cd80-4dff-9d54-3030e9921c77": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "cases of mucositis oral, thromboembolic events, and bladder infection were more prevalent in the primary trial than in the secondary trial"
    },
    "b447258d-c4d1-4f98-8cc0-9868cd316a3c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "patients in the primary trial reported conditions of anemia, pneumonia, and stupor more frequently than those in the secondary trial."
    },
    "ef734fea-a713-4fb3-b6e9-0be2dc2b055a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement. diffusion weighted imaging is a diffusion mri technique in which diffusion-sensitizing gradients are applied to the imaging sequence."
    },
    "665afeee-f623-4c57-8550-a5dbe71430cb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "individuals partaking in the secondary clinical trial are administered weekly subcutaneous injections, unlike the participants in the primary clinical trial who refrain from any injections."
    },
    "cb9a1bc3-cc8d-4d0d-a335-eb5c5071289f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than 0.10 of the primary trial participants had a reduction in circulating tumor cells following months of high-dose chemotherapy with purged autologous stem cell products"
    },
    "3f4231c5-0eae-43eb-b0df-b270cea08476": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "all patients in cohort 1 of the primary clinical trial were behind schedule for their cervical cancer screenings before the intervention."
    },
    "2a4b11b1-b14f-4fd8-a810-b6ad2f60e9fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "no patient treated with gtx-024 1mg in the primary clinical trial experienced any gain in lean body mass."
    },
    "0ef8fead-d77e-4aa4-8e40-ca20ac2ea325": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but 8mg/kg MM-121 less than cohort 2. have felt unusually tired during the day is a question about whether an individual has been feeling unusually tired during the day, on the average."
    },
    "1616266d-e1bf-4327-9523-f584f713b265": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "a reduction of 10% in the percentage of cells with ki67 expression was noted in the patients of the primary trial following a month treatment with tak-228 plus tamoxifen"
    },
    "5718421a-fc98-4df0-a866-21d4718ebf78": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "the administration of trastuzumab in the primary clinical trial does not align with the dosage provided to patients in the cohort 2 of the secondary clinical trial"
    },
    "901dac1a-6a67-4883-a883-06c5a91f85c1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial and the secondary trial recorded over 100 total adverse events in their cohorts. cane or crutch needed most of time is a response indicating that a person requires use of one cane or crutch most of the time."
    },
    "e299d6fb-d590-417b-a9d3-88ee887d9c00": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "several psychiatric issues, including an eating disorder and schizophrenia, were reported as adverse events in the primary clinical trial"
    },
    "e8edca4b-3a7c-43b6-aed4-8651d1dee36f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "infections occurred in over 15% of patients involved in both the primary and secondary clinical trials during the study period"
    },
    "e10d648e-a24d-4358-b81f-77b68fce3dc8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "quantitative chemistry is a subdiscipline of chemistry concerned with the study of reaction rates and equilibrium states of chemical reaction There are more cases of Biliary colic and Diarrhoea in the secondary trial than in the primary trial."
    },
    "95a5ceca-3b9c-4760-98be-98c78559a161": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "all inclusion and exclusion criteria are the same for both the primary and the secondary trial."
    },
    "45d94eb6-d3a6-47ae-8c80-75fb02520ef2": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "100% of the participants in group 1 of the primary trial were found to have lesions, and only 5% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "2f30372d-c143-495d-96d9-ad238ff94baf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "neither cohort 1 nor cohort 2 in the primary clinical trial receive dexamethasone; it is an exclusionary criterion."
    },
    "e8247d17-f420-4a08-9a2c-c2d8f1524d93": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients with stage 3 hepatocellular carcinoma that is estrogen and progesterone receptor negative and on chemotherapy, are eligible for the primary clinical trial."
    },
    "9f97138b-399f-42bf-9afe-e7195db4e5b4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates capable of only limited selfcare; confined to bed or chair about 10% of waking hours are eligible for both the primary trial and the secondary trial"
    },
    "a02a955a-9890-4347-8a6b-1377008f581b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients suffering from hypokalemia are ineligible for the primary clinical trial. however, those with hyperkalemia can consider participating in both the primary and secondary clinical trial."
    },
    "9484e4d1-8130-4d52-b362-faa1990946e9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "calla positive lymphoblastic leukemia is acute lymphoblastic leukemia which is positive for the common acute lymphoblastic leukemia antigen. cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel."
    },
    "f1c2db2e-dc72-4a69-a3b6-a8d846a6f7ee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "patients with a vitamin d deficiency are eligible for the primary trial, but may not qualify for the secondary trial."
    },
    "5ed2b8ad-5b6d-4397-80c5-48d08c8f51ed": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "primary amenorrhea is abnormally late or absent menarche in a female with normal secondary sexual characteristics. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often."
    },
    "f9442384-0c19-4ffe-8906-c461b6dda9f7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial. aggravated neurofibromatosis is a condition causing exacerbation of the clinical features of neurofibromatosis."
    },
    "1d828a72-b303-4395-bab6-31865552caff": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "adult mixed glioma is a mixed glioma that occurs during adulthood. the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial."
    },
    "344ac04d-cddb-4ef8-8a15-54e26ff58a86": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "the primary clinical trial recorded adverse events all of which affected not more than one patient individually"
    },
    "bcbde299-e3e8-40e6-8cea-d843a44e68d6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the intervention mode of the primary clinical trial provides an explicit arrangement of treatment cycles including dosage and delivery of radiation therapy."
    },
    "811978a1-2715-4174-84af-07a0ca3686e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "There are 0 shared inclusion/exclusion criteria between the secondary trial and the primary trial. how much did pain interfere with enjoyment of life is a question about how much a person's pain interferes or interfered with their enjoyment of life."
    },
    "a6f49268-2b84-49ff-a89a-86cb3d16cd07": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "in the primary clinical trial's initial cohort, over half of the participants faced acute vomiting as a side effect of being treated with aprepitant, dexamethasone, cytoxan, and kytril"
    },
    "c91a6c5a-27f1-4e7b-8f91-34e3d2236e8b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months"
    },
    "413156ec-dbfb-4c78-9518-cbde7d4765da": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "objective cognitive function scores, which are evaluated using cogstate, are used as units of measure in both the secondary clinical trial and the primary clinical trial."
    },
    "3ad9820f-4ef2-4624-b08a-b910adf25836": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial."
    },
    "dad36f27-f531-458c-a36f-c22182af3771": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "people with chronic lymphocytic leukemia or choriocarcinoma, established through cytogenetics, or infiltrating ductal carcinoma are prohibited from participating in the primary and the secondary trial."
    },
    "c79f4ed7-5e39-48ad-bc32-fef9ace77a76": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial cohort is given enteric-coated tablets"
    },
    "2a9e682e-382c-4361-a76f-f4cf5c39819d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+. substudy details is a textual description of the substudy."
    },
    "8df26566-8724-4ca3-b6be-f43b9b188724": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "eligible subjects for the primary clinical trial should have prostate cancer and need treatment through surgery."
    },
    "e9a96af7-c9f7-49cd-a291-2c0abb94719c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "following high-dose chemotherapy with purged autologous stem cell products, less than half of the individuals involved in the primary clinical trial experienced a reduction in circulating tumor cells."
    },
    "dce7c1b2-0e43-4c7b-8cc8-6a443fee7135": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "result classification is a category describing the result as distinguished by anatomical or physiological system, etiology, or purpose. cohort 1 of the primary trial is administered 0.035 mg of ALT-801 less than cohort 2."
    },
    "d5fe5d1e-b4c8-46d1-879f-06f14157c3ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "hormone therapy-requiring breast cancer patients are eligible for the primary clinical trial."
    },
    "1c72bbf7-1c5b-4326-a9d1-9dc7677aeefd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": " Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. cancer treatment trial is a clinical study designed to evaluate biomedical or behavioral cancer interventions, generating safety data and efficacy information."
    },
    "0fb60a4c-16d6-4517-a201-e16f78fd6dae": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "the diagnosis of either fibromyalgia, thalasemic syndromes or anemia does not obstruct the eligibility of cancer patients for the primary clinical trial and the secondary clinical trial."
    },
    "92935ccc-f20d-4e27-9a5f-cb8d47162de6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial."
    },
    "c31609ed-47a9-4a4a-94f1-92757a79033c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "in the primary clinical trial, pneumococcus vaccine is administered to the participants of the first cohort, while the influenza vaccine is given to the second cohort."
    },
    "3570b51a-d280-41b5-9c59-849436db5934": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "patients who have a histological documentation of metastatic scbc are not eligible for the primary clinical trial."
    },
    "23505a58-2e6a-4220-9148-f3b3102d2a91": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention. thoracic procedure postoperative complication is any disorder occurring postoperatively as a consequence of a thoracic procedure."
    },
    "1f23b5f1-2b28-4204-9e44-60f8ddc86963": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "adverse events were not reported in cohort 1 but were reported in cohort 2 in the primary clinical trial."
    },
    "66bf512a-c3fd-46a8-8a0b-4d64fde85082": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "unmutated immunoglobulin heavy chain variable region gene is a molecular finding indicating that the immunoglobulin heavy chain variable region has an unmutated germline configuration. Patients with NUT midline carcinoma or Castrate-resistant prostate cancer, determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial."
    },
    "baea8626-3768-47aa-a4ba-e792164302fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time. c3d format is a public domain, binary file format that is used to record synchronized 3d and analog motion capture data."
    },
    "87a7f86a-e915-4ea9-a2ba-c8e4d37dfa15": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "working at a desk or table is a question about an individual's ability to work at a desk or table. Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial."
    },
    "2d241b66-d0a0-4012-9d5b-1ef1a74bcd79": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the duration of intervention in the primary clinical trial extends 3 times longer than that of the secondary clinical trial."
    },
    "4a56cd2d-ce04-4515-a033-f140e44cf955": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "the first cohort of the primary clinical trial saw a single case of both anaemia and febrile neutropenia, however, there were no recorded instances of pancytopenia."
    },
    "698a471b-ead0-445f-93bb-4badc6382968": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "peritoneal and retroperitoneal disorder is a non-neoplastic or neoplastic disorder that affects the peritoneum and/or retroperitoneum. the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort."
    },
    "c7e1e07a-e363-47f7-9ec3-21fbd1da79b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria. breast feels heavy is a question about whether an individual feels their breast is or was heavy."
    },
    "16710aab-1003-447f-bf01-7275e653d263": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a radius of 0.003m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "98923c9c-1126-436a-9263-a9deca239ba6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "attachment is a file or document affixed to another file or document. the primary trial and the secondary trial do not test the same drugs."
    },
    "b443ed89-9fcb-451a-b0f5-3f23183fbeb0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "lung large cell carcinoma is an undifferentiated non-small cell lung carcinoma composed of large polygonal cells without evidence of glandular, squamous, or neuroendocrine differentiation. Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril."
    },
    "3977a1e3-3371-4577-9dc1-eea3a725469c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "the secondary clinical trial administers higher doses of necitumumab during the duration of the cohort 1 study, while the primary clinical trial provides a fixed dosage of alpha lipoic acid."
    },
    "6adaaefe-d699-4bce-87dc-8233140a14fa": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "the secondary trial uses muscle gains as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine. ovarian sex cord-stromal tumor associated with peutz-jeghers syndrome is a sex cord-stromal tumor that arises from the ovary in a patient diagnosed with peutz-jeghers syndrome."
    },
    "65cfa1ae-05d3-4a90-ad5a-852f3cfdf3fc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "primary anatomic site code is a coded value specifying the anatomic site of the entity. Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure."
    },
    "6a489a42-add9-40b7-ba9d-5d46da07b890": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "centimeter of water per milliliter is a unit of measure for pressure change that is expressed in cmh2o per milliliter. the primary trial had one test group and one placebo group, the secondary trial had 2 test groups."
    },
    "0feb3694-da20-4a30-b85d-e9dc4cdb55c3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the primary and the secondary trial reported an equal number of intestinal perforation cases"
    },
    "45daf2f3-8299-46f8-9016-edf2ce4a044a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01138046",
        "Secondary_id": "NCT00709761",
        "Statement": "the primary clinical trial and the secondary clinical trial are open to any person who is a national of japan."
    },
    "ff38ad83-d613-4797-a2a7-3b2e5e1a318d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "both the primary clinical trial and the secondary clinical trial accept patients with fluorescence in situ hybridization-identified nut midline carcinoma or inflammatory breast cancer."
    },
    "ecb7babe-941e-41bf-89a3-0b8387fdd239": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "dna adduct is a structure formed when a chemical is attached to dna by a covalent bond. The AZD0530 175 mg group of the primary trial experienced a greater reduction in primary tumour diameter than the Zoledronic Acid 4 mg group."
    },
    "947b0d76-6214-46c7-ac3c-f5794e0cfcb3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "although the primary clinical trial discloses the overall count of participants included in the study, it does not state the number of participants within each cohort."
    },
    "f37f99e0-a9eb-450f-850e-7bd96547bab1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "intellectual well-being is a question regarding the status of one's mental capacity and ability to think clearly, concentrate, and remember things. The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2."
    },
    "8c507ad1-b534-4d16-9a1b-5c92a432eb9d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial evaluates three types of drug-based treatments, whereas the secondary trial does not test any medication."
    },
    "ad4f2e14-4f6a-473d-bc6a-225e2f34159b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2. proton is a fundamental particle with a positive charge."
    },
    "c616276b-e187-44ee-a2fb-93704f1a64cc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "all patients in the primary clinical trial reported experiencing at least one adverse event, while those in the secondary clinical trial completed it without any adverse events."
    },
    "55eb3029-c826-4cae-a130-7cc8fbc80121": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "venezuela, bolivarian republic of is a country in northern south america, bordering the caribbean sea and the north atlantic ocean, between colombia and guyana. Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer."
    },
    "dd153492-5c53-4b8e-b860-71aaba62fa14": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "the primary clinical trial's intervention section solely demands pharmacological approaches."
    },
    "a8f421ec-e3c7-43b4-96da-b6bca22d68ed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "0% patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 4 weeks of the study"
    },
    "38acc5fa-c86b-4734-bdb6-7acbcd3c37c4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "in the primary trial, a patient cohort is treated with 150 mg of pregabalin injected intravenously every fortnight for over 6 weeks, in contrast, the secondary trial provides its patient cohort with a treatment of marqibo and ifosfamide."
    },
    "c3503b5e-ef92-4e90-bc0f-5ef7690a5908": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "there are no reported cases of asthenia or pyrexia in the patients of the primary clinical trial and the secondary clinical trial"
    },
    "fe5179d1-0090-4c87-9287-9bb26139acd0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "about as socially active as before is a response indicating that an individual has been about as socially active as before. Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial."
    },
    "ef79f4a4-d4ec-4a2a-a2a6-41ad41235927": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "every patient in the primary trial is receives a dose of 100 to 1600 microgram fentanyl sublingual spray during radiation therapy"
    },
    "401f0d8c-4f4e-4693-8baa-3ae8664480d3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial"
    },
    "7aef8aaf-9fc3-49b2-95e7-ed9b227cdd27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "neisseria gonorrhoeae, penicillinase negative is any bacterial species identified as neisseria gonorrhoeae that does not produce the enzyme penicillinase. the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib."
    },
    "62ecbc1b-eb8f-43ad-b997-a11c8d36b379": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "none of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "d7750102-df82-4668-8c6d-60e73b3241b5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 1 month cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. benign pericardial neoplasm is a non-metastasizing neoplasm that arises from the pericardium."
    },
    "7ade4e76-2f1d-452d-b9e4-499e0aabbe0c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "a number of instances of swelling, hypothermia, and confusion have been documented in the adverse events of both the primary clinical trial and the secondary clinical trial."
    },
    "927d72b0-1f55-4803-9a86-40838c08f923": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial also requires injection, adminstering 0.4 to 1.0 mCi of radioactive Tc99M sulfur colloid."
    },
    "88951a9e-179e-4284-9f98-141eb3d76369": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes were not recorded for the primary trial or the secondary trial."
    },
    "804742bb-2d69-45a8-a7a9-b6a269bf8d58": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "a specific level of hepatic enzyme in the blood is required to participate in the primary clinical trial."
    },
    "eab0f794-5caa-49fc-b951-7db4b7169a46": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "a history of conditions such as abdominal fistula, gastrointestinal perforation, postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess, or serious psychiatric illnesses within the preceding six months disqualifies patients from participation in the primary clinical trial"
    },
    "8c07a493-66a5-4728-ae22-d6c45b2215a8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab"
    },
    "73ac48a2-08b0-4ee5-8651-f65c88c08101": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "involvement in the primary clinical trial calls for participants to be unresponsive to ai therapy and mirtazapine, but this is not a criterion for the secondary clinical trial."
    },
    "7ea3fe58-fb27-48f8-9e3a-61af8847d23e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary clinical trial maintains identical inclusion and exclusion criteria for all its subjects, as opposed to the primary clinical trial, which establishes two distinct sets of eligibility conditions for its diverse study groups."
    },
    "1d121088-e2ff-4927-a989-d7b5de578714": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report the severity of delayed nausea on a scale of 1-10, and the secondary trial measures the change from baseline to 18 months in bone mineral density (bmd) of the lumbar spine"
    },
    "3ac1baef-7e74-405c-ae5a-897ac2b2fd5f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "all 100% of patients in the primary trial suffered aes"
    },
    "840c7b65-e801-4dec-b9dd-b97680e5e3ba": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial is applying immuno-oncology techniques, and the secondary clinical trial is using chemotherapy."
    },
    "a3e78ee7-57e9-47e4-a85f-e61451207043": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "gain of chromosome 17q is a cytogenetic abnormality that refers to the duplication of all or part of the long arm of chromosome 17. cohort 1 of the primary trial is administered less than half the dose of ALT-801 as cohort 2."
    },
    "98e89253-c343-4f1f-b2a0-0e09e5cba8ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "the participants of cohort 1 of the primary clinical trial did not report adverse events"
    },
    "823088ba-be25-4691-aa10-9e86b80fbf8c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "patients in the secondary clinical trial experienced anemia, pneumonia and stupor more frequently than those in the primary clinical trial."
    },
    "bf1cfc9e-1932-4b3f-b935-c71fb36e6716": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "in the primary clinical trial, multiple instances of anaemia and febrile neutropenia were registered in cohort 1, along with numerous cases of pancytopenia."
    },
    "e4221b6d-f3d7-4299-bcba-19c02be74cdd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic. non-continuous spinal cord parenchymal is a description that locations of interest are non-continuous and within the spinal parenchyma."
    },
    "87273b6d-f10d-4638-ab87-bceade2d6510": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients with a diagnosis of severe insomnia are not eligible for either the primary or secondary clinical trial"
    },
    "abc13f3b-54fa-4a1c-a063-5f1f00e2ae9a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 43 hours if they want to participate in the primary trial"
    },
    "607586af-260d-46ef-88ce-b8672e4aaa25": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "japanese is a person having origins in any of the original peoples of japan.. Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial."
    },
    "e0983a0e-1008-4845-bc61-082077d3d3d3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 100 mg po daily for 50 days prior to surgery and for 60 days after breast cancer surgery reduces the diameter of tumors by 70% on average."
    },
    "711fdd40-52ec-401c-90fc-5a11de547ab6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders were not common for the primary trial candidates"
    },
    "de2a7e0a-2046-4502-a23e-38d0753b43ec": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks. other investigational agent is an investigational agent that is not the lead agent being investigated in a clinical trial."
    },
    "32c2dfce-b209-49f3-9f03-5e39b97b18c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients diagnosed with ductal carcinoma in situ and contemplating ai therapy are suitable for the primary clinical trial."
    },
    "19275bdd-9964-4f3b-b2d5-b984203774d5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "both the primary clinical trial and the secondary clinical trial reported a minimum of one infection case"
    },
    "2d7737fc-95e6-4392-8a2e-d896e65ba3e6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the primary trial observes less adverse events in total than the secondary trial, yet higher counts of cardiac-ischemia/infarction are reported in the primary trial."
    },
    "ef73b41f-a188-41e1-af84-8ba9ee13d6c6": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "not a single life-threatening adverse event was registered among cohort 1 participants in the primary clinical trial."
    },
    "8a532b5a-1468-4de5-83ac-50179edb2ac8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "none of the patients in the primary clinical trial experienced any adverse events."
    },
    "1645d8e9-78e0-42e0-b46e-945c3c8e7d89": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "in the first cohort of the primary clinical trial, there were no instances of adverse events, whereas almost every individual in the second cohort encountered at least one"
    },
    "f9a8b80a-3191-4f53-865b-1ab2154174ad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "in the primary clinical trial, under a tenth of the participants experienced a decline in circulating tumor cells after months of high-dose chemotherapy accompanied by purged autologous stem cell products."
    },
    "a491bf7b-7327-48cd-ac0f-708a50c385b7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "primary clinical trial enrollment is open to individuals with her2 negative tumors according to ihc 1+ scores and those who have minimal need for medical care or assistance."
    },
    "fbde81ad-0d06-4d2a-8baa-eb5eace1b3ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the primary trial and the secondary trial do not have any recorded adverse events for their participants."
    },
    "2bf60bd1-4d11-4a7d-9d69-7f13e93df39c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "in the primary clinical trial, changes in lymphedema were notably better in acupuncture patients compared to those treated with testosterone cream."
    },
    "d5c262d5-584c-4417-a768-9374cd6c8bc2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "vomiting was the most prevalent adverse event recorded in the primary clinical trial, with an incidence rate above 10%, whereas the secondary clinical trial did not register any adverse events."
    },
    "9b120158-866e-4a68-ab9a-4d6241ead464": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the secondary trial and the primary trial report results using the same Unit of Measure. spinal leptomeningeal distant disease type is an indication the distant disease type is spinal/leptomeningeal."
    },
    "e2061005-22e7-4de3-90c2-e4ebfe055b0d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the evidence from the primary clinical trial indicates that the overall response rate was higher in the placebo arm than in arm a intervention. on the other hand, the zoledronic acid group in the secondary clinical trial displayed a superior time to first on-study sre as against the denosumab group."
    },
    "e7572377-d468-4b13-815a-f43887747c18": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "there are patients in the primary clinical trial who do not receive mcs110 at all."
    },
    "da24c082-7e08-4ed0-b72c-ee85098d7b3a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "in the primary clinical trial, the nacl 0.9% 3ml group showed a higher recurrence-free survival rate than the ketorolac 30 mg group"
    },
    "d8d046cc-99cc-4a31-94de-6dd290f504e7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "every patient in the primary clinical trial experienced at least five distinct adverse events."
    },
    "136ce42e-bf56-41ff-aed9-fe886636bc1c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "legacy project is an indication that project information or documentation has been deprecated. Patients in the primary trial that didn\u201a\u00c4\u00f6\u221a\u00d1\u221a\u00a5t receive paclitaxel infusions had worse symptoms than patients that did receive paclitaxel infusions."
    },
    "52f7d88d-78f0-4e5a-8fb9-e423679f2c61": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "while secondary trial participants are required to take oral medication, those enrolled in the primary clinical trial receive daily sc injections."
    },
    "b71a1480-2037-4a01-8a4f-95a34aa172c2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "the primary trial documented more instances of mucositis oral, thromboembolic events and bladder infection than the secondary trial"
    },
    "843b1c8e-8d10-4f20-8514-4ba986071878": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "infigratinib regimen is a regimen consisting of infigratinib that can be used for the treatment of hepatobiliary cancers. Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study."
    },
    "11714886-d3a2-496b-a883-6cd394478b03": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "human papillomavirus-negative squamous cell carcinoma is a squamous cell carcinoma not associated with human papilloma virus infection. the primary trial does not test any drug based treatments, whereas the secondary trial tests two different drugs."
    },
    "4a21310d-d0b8-44c7-ac08-ca9164bdc49f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "in the primary clinical trial, theraspheres are used in radioembolization as the chosen intervention, as opposed to the secondary clinical trial that uses ibrutinib and medi4736 for its intervention."
    },
    "f77c9775-9421-4d65-8860-c78a684fd886": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial, unless they have non-healing surgical wounds. diagnosis pathologically confirmed indicator is an indication whether the subject's diagnosis has been confirmed using histopathology."
    },
    "4cfe211a-a80a-48ee-993a-2b7c8a91b57c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary clinical trial and the secondary clinical trial are investigating the same pharmaceutical agent'"
    },
    "f3345897-b99a-4ff2-8bcd-5d1aeb3b698d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "infant acute undifferentiated leukemia is an acute undifferentiated leukemia that occurs in infancy. The the primary trial intervention section requires surgical and imaging procedures."
    },
    "82d23e4a-cdf8-4ab4-b2fa-7ea99d98d5a4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "feeding ability is a question about an individual's ability to self feed. Patients who have received chemotherapy or radiotherapy in the last 2 weeks, suffer from unstable angina, or have Grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "31b3aa86-f32c-4a10-ae36-6429b25995dc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "patients dealing with anorexia are suitable for the primary clinical trial"
    },
    "ffa6aa2b-661d-4e25-a893-6e03dea7e39e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "Neither the secondary trial or the primary trial measure the percentage of participants in their studies that experience Clinical Benefit (using (RECIST) criteria). off study reason code is a coded value specifying why the subject is removed from a study."
    },
    "77f1bdb0-c7eb-41ba-b05e-e8914b68370a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "validation batch is a batch intended for use in verification and demonstration of suitability of the designed process. Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "97322f7f-a311-4718-8a0c-5e4ecdd33f7f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "both the primary and secondary clinical trials comprise methods to examine the transformation in  ki67 expression in tumors."
    },
    "b994a073-e1a5-424a-9cdf-f0d9ad0c0766": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "the primary clinical trial is open to patients of all genders, provided they demonstrate evidence of er negative breast cancer, for each of its phases."
    },
    "045ad9d7-6830-4a3d-bba5-4e90ee838977": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, however the intervention for cohort one carries on for two weeks longer. leptospiraceae is a taxonomic family of mostile bacterium in the phylum spirochaetes that includes the genera leptospira and turneriella, among others."
    },
    "eca37c79-e36b-446d-bd9a-4cf546fc9ab7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "edema was a common adverse event in the primary trial"
    },
    "d9a63f26-68c3-431f-851f-131f7a547902": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "all the adverse events reported in the first cohort of the primary clinical trial are associated with psychological health issues."
    },
    "e7ca1067-1d50-4cb2-affc-2d859f9c20cf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "only patients with healthy eating habits and nutrition are eligible for the primary clinical trial."
    },
    "9a337e6e-70b7-420d-9679-cc0baf5a5ba8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "a number of patients involved in both the primary clinical trial and the secondary clinical trial were afflicted with tumour lysis syndrome."
    },
    "da4bfd68-6510-4a0d-aa9e-b925d2cef24a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "os is the determinant of outcome measurement in both the primary and secondary trials. the primary trial cohorts show marked difference in their results. in the secondary trial, arm 1 manifests better outcomes than arm 2, as fewer arm 1 patients experienced os."
    },
    "610662cd-053e-4396-a6d6-8aaac67a7440": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the primary clinical trial involves the use of a single medication, zd1839, in contrast, the secondary clinical trial necessitates the use of a minimum of three distinct medications, to include zoledronic acid, samarium-153 and pegfilgrastim."
    },
    "24e7fb4c-e279-4b61-8c7f-6dc6a09e8d55": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "Patients with malignant ductal carcinoma in situ and uncontrolled hypertension are eligible for the secondary trial but excluded from the primary trial."
    },
    "48b31ad3-f5d6-4250-9e84-e407d26f6bed": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "Patients participating in the primary trial receive oral medication twice a day for a full month. f-actin is a fibrillar actin polymer."
    },
    "61a1a0e2-bd62-43de-b3c9-1c2143417c5a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary trial requires candidates to have a fully functional mobility to participate, with this prime requirement also present in the primary clinical trial"
    },
    "0cecf602-ca3a-4fc4-a52a-135425f42911": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "in the primary clinical trial, at least one patient experienced multiple adverse incidents."
    },
    "4d33c738-d007-4e43-8d51-6c98c40631df": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "the variance in the primary clinical trial's interventions is in the dosage of tc99m sulfur colloid, with intervention 1 utilizing a significantly higher amount than intervention 2."
    },
    "f0d4e862-c9a1-48f4-9e4f-ddc67b35bbe0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the secondary trial and the primary trial use different outcome measurements and units of measure. concomitant medication start relative to reference timepoint is an indication or description of the start of concomitant medication usage in relation to a specific point in time."
    },
    "accef831-f126-4f90-bc47-182fd9699098": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has undergone a kidney transplant in the past week is eligible for the primary clinical trial but will not qualify for the secondary clinical trial"
    },
    "efbc4408-7a74-4857-8265-d1bf4eab4080": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "after 720 hours of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 1/10 reduction in the proportion of cells with ki67 expression"
    },
    "0d4acb50-cf28-4eb1-bd3f-1511d068e3a1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "a greater proportion of participants in the triple negative group of the primary clinical trial demonstrated a decrease in the growth factor signature than in the er-positive luminal b group"
    },
    "7ae48994-9b72-4bc5-aab2-adcc9f0e1735": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "complaint is a symptom or problem for which a patient seeks medical attention. Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "f2d85883-6334-4948-901e-22cc11da66ac": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "females with evidence of er positive, her2 negative breast cancer are eligible for the primary trial."
    },
    "599e8d04-e80f-4f54-9486-bcf5a39a1d37": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 1000 mg of fulvestrant in a tablet form to be taken bid."
    },
    "7452ab11-09d4-48bc-b275-4681acae5769": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "in the primary clinical trial, the group using paclitaxel plus bevacizumab recorded a higher orr than the group using paclitaxel plus bevacizumab plus gemcitabine."
    },
    "d5f5e4f5-9a58-485a-8646-649ce93e37c7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the participants of the primary clinical trial receive high-intensity focused ultrasound therapy, while the two cohorts in the secondary clinical trial receive a daily intravenous injection of 500 mg fulvestrant."
    },
    "fae99e77-42d1-4003-bb7a-3b98b88f7c27": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "adverse events were documented in both cohorts participating in the primary clinical trial"
    },
    "9fcf0873-73d2-48e3-87ac-ee5df19f7810": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "in the primary clinical trial, the patient who survived the longest, 3.5 months, without disease progression or death was from cohort 1"
    },
    "f5c83e99-e58f-4e5a-9fde-836480522184": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "squamous differentiation is a microscopic finding indicating the presence of cells with squamous differentiation in a tumor sample. 0/7 the primary trial participants, and 0/1674 the secondary trial participants suffered an AE."
    },
    "ed3e6033-e499-4743-9aca-a275a80a1e4e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes. human papillomavirus-related mucosal head and neck squamous cell carcinoma is a squamous cell carcinoma associated with human papilloma virus, arising from the mucosal sites of head and neck."
    },
    "8983bf9f-d977-4238-91df-2435d2eb4a38": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "20/73 the primary trial participants, and 23/10 the secondary trial participants suffered an acute myocardial infarction"
    },
    "429f2754-6edc-4969-99f3-7507b76e443a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "in the primary clinical trial, all group outcomes showed no considerable variations, but the reflexology group and control group displayed some significant differences in the secondary clinical trial."
    },
    "0dd1c6d6-5a35-452e-b058-ea0da7bd9f3a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "patients diagnosed with breast cancer may not be eligible for any study groups in the primary trial and the secondary trial."
    },
    "9c10ceed-9cc6-473d-87c0-fa0b51353222": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "for its treatment, the primary clinical trial does not conform to a specific cycle arrangement, but rather stands on a comprehensive, ongoing regimen. the secondary clinical trial, in contrast, implements an intensive, monthly cycle intervention."
    },
    "4afbbadf-10c0-4e7e-87d3-2516aeafbe73": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "study procedure deviation is an indication that a protocol deviation involved the trial processes or procedures defined in the study protocol. at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass."
    },
    "bb281225-8211-47ed-8789-a42a389fa379": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "chryseobacterium is a genus of aerobic, gram negative, rod shaped bacterium in the phylum bacteroidetes and the family flavobacteriaceae. Patients diagnosed stage 4 invasive carcinoma of the breast that is estrogen and/or progesterone receptor positive, and are considering AI therapy are eligible for the primary trial."
    },
    "40a16e0a-a4d4-49d0-8423-aa5b43688171": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "there were 150 cases of hypertension, dehydration and dyspnea in either cohort of the primary trial"
    },
    "36debc88-2f09-4ae8-9a37-5bee270f5f8c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the intervention segment of the primary clinical trial lacks definition or explanation of a treatment cycle."
    },
    "b60cdaf1-5a83-4738-b15d-d857c6d0924a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736. half pint is a non-si unit of volume equal to 8 fluid ounces or 0.2365 liter."
    },
    "d1424cd8-4dab-40a8-91b1-3ae5d1f57d56": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "several mortalities and admissions to the hospital occurred in the second cohort of the primary clinical trial, and atrial fibrillation was also frequently detected."
    },
    "36cbd8dd-9c77-496c-ab43-af1942c86339": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin"
    },
    "3df0eb9e-b9d9-4f8b-af9a-2d6259e1ed9c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography along with lateral radial incisions are employed for both interventions in the primary clinical trial."
    },
    "3d100b36-5765-4953-b072-b06f38b6958c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group"
    },
    "3693ad36-964f-4377-93a3-6137083b22dd": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 30000 mcg group of the primary trial had a -6.4% recurrence-free survival compared to the nacl 0.9% 3ml group"
    },
    "1cc9db7e-8214-46cd-bbe3-7ff873be5589": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "The difference between intervention one and two of the primary trial is that intervnetion 1 uses higher doses of radioactive Tc99M sulfur colloid  than intervention 2. sgk1 gene mutation is a change in the nucleotide sequence of the sgk1 gene."
    },
    "5dea6bbb-13c3-470c-98a6-3879f17de8c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort."
    },
    "57265519-b5e0-41f9-90b3-8a09e57bc282": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial focuses on chemotherapeutic interventions, and the secondary clinical trial centers on radiation therapy."
    },
    "f53c5344-36d7-459f-9f84-300e19decced": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "All Patients receiving the placebo intervention in the primary trial experienced emesis "
    },
    "f8f21f2b-9c9c-4f37-8c0d-b48061a14c9d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV. volume alarm device is a device designed to signal that a gas volume level is outside of an established range."
    },
    "d9e7c0cc-0850-4a8e-b389-092dfdc623fc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "Patients with histologically documented metastatic SCBC are excluded from the primary trial."
    },
    "f96fa263-12b2-475c-926d-57b8588e85ef": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "the primary clinical trial welcomes patients diagnosed with tx nx mx, t0 nx m0, or t1 n1 m1 tumors"
    },
    "9474451f-d601-4dcc-8304-50bc4d3ebf52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "previous use of gabapentin or pregabalin will disqualify a patient from participation in the secondary clinical trial, but not in the primary clinical trial."
    },
    "f0ca21dc-bf98-4c8b-b08e-d0821905846a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list."
    },
    "228308ea-2483-4311-a975-ca974ff797c6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "Nobody taking part in the primary trial suffered a UTI"
    },
    "53416cd6-ac0b-43c1-824f-719d43ad5af4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "various participants of group 1 in the primary clinical trial had clear evidence of skin lesions; under 10% of participants in group 1 of the secondary clinical trial showed symptoms of radiation dermatitis and hyperpigmentation."
    },
    "e9b973a3-aabd-484d-8c7c-0bd2296bf0c5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "mouth partial response gvhd is an nih modified oral mucosa rating scale (omrs) score that has decreased by 2 or more points. There are 3 total cases of Asthenia and 5 total cases of Pyrexia recorded in the patient cohorts of the primary trial and the secondary trial."
    },
    "cc6d64c8-a841-4a6b-bf57-df451ad47edb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "there were severe adverse events (aes) reported in cohort 1 of the primary clinical trial"
    },
    "d16039bf-c0d3-488f-8890-cb5b5d909ab8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "only one cohort in the primary trial is given daily armodafinil p.o., while all patients in the secondary trial are administered the same dosage of pdr001, though the quantity of mcs110 varies."
    },
    "586425fa-eb66-46c1-8792-f7a35c1a5ca5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "hypertension was reported in both cohorts of the primary clinical trial"
    },
    "2dac87e4-2a34-42e1-8aec-d2a23d61269a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "femtogram per milliliter per microgram is a unit of concentration equal to femtogram per milliliter, divided by micrograms. Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial."
    },
    "17413685-69fd-453f-af49-29982a6c95b6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "Participants in cohort 1 of the primary trial are administered with Pneumococcus vaccine and those in cohort 2 are administered an Influenza vaccine."
    },
    "d8079e7e-45eb-4387-a0e3-eb0777802644": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "age-days is age of subject in days. the secondary trial and the primary trial have completely unrelated outcome measurements."
    },
    "04178e95-d808-4a96-ab85-61eb52c17720": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "a total of 35 patients treated with Sunitinib + Docetaxel + Trastuzumab in the primary trial suffered a Treatment-Emergent adverse event."
    },
    "f32516f0-768d-48db-a449-74ac774abbe0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "patients receiving the placebo intervention in the primary clinical trial had the same likelihood of experiencing emesis as patients receiving aprepitant."
    },
    "071c3399-1525-4965-8a3e-b3dfac561b6b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "pre-operative dexamethasone is only given to one of the cohorts in the primary clinical trial."
    },
    "36426525-f3e0-426e-aae4-2fc677756ca9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients, apart from Skin infections. subject status test code is a character or string that represents the short code name of the subject status assessment."
    },
    "b3dd4df2-abff-4e7f-89ce-57b109d25bf2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 0.15 g of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "a8268e5e-d758-4dcf-8dd9-78c2016bc7f6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "Both the primary trial cohorts receive pre-operative Dexamethasone"
    },
    "d8d5125b-399a-4b78-b033-9603bfe8011e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary clinical trial has different inclusion and exclusion rules in its two phases, while the secondary clinical trial divides its criteria based on whether patients are healthy or diagnosed with cancer."
    },
    "5e3d1ff7-52f0-4ac5-a9e0-63536903cf84": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "caucasian patients residing in new york are eligible to participate in the primary clinical trial."
    },
    "a85102e4-fe19-4b6e-8dd5-4cb9ffd64176": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial, all cohorts are treated equally and are given the same dosage of simvastatin daily. in the secondary trial, different treatments are prescribed for different patients without a specific dose of pdr001 or mcs110."
    },
    "6b6150e0-6484-499a-83ae-a9fc6a7d167c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "adult acute megakaryoblastic leukemia is an acute megakaryoblastic leukemia occurring in adults. the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts."
    },
    "98300332-951a-4da5-bdd9-42b17fd489b0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "3.3% more participants in the dalotuzumab 20 mg/kg group of the primary trial demonstrated a decrease in the growth factor signature than in the triple negative group"
    },
    "e50a24aa-fbee-4cf7-b91b-661c5173c787": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "Any patients that is currently a smoker cannot participate in either the primary trial or the secondary trial. tsukamurellaceae is a taxonomic family of bacterium in the phylum actinobacteria that includes the genus tsukamurella."
    },
    "024c2c6d-e462-439c-baa2-a8639cd68d30": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event. source-date is a property representing the date each go annotation was added to a concept."
    },
    "0c105984-77ed-42cc-9d9f-aec464e02d12": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "Candidates for the primary trial and the secondary trial have to meet a baseline performance status, for the primary trial the baseline is a Karnofsky score >70, and for the secondary trial the baseline is a Karnofsky score >55. escape from interlabial space or lateral juncture; no extension is a finding of escape from interlabial space or lateral juncture during swallowing, but no extension."
    },
    "0c9bef83-0974-4de4-aaa9-2f109fe16d0d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "patients in the primary clinical trial reported no observed change in the percentage of cells with ki67 expression following the application of tak-228 plus tamoxifen treatment."
    },
    "4ae87355-7844-42a5-ad5b-a00c8103d102": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "there is a limited patient capacity in the primary clinical trial for those who have been diagnosed with metastatic colorectal cancer having the kras or braf mutation."
    },
    "a88d7c64-ec6f-4fb7-a84d-1047b68bda4f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "in the secondary clinical trial, only eyelid oedema and chest pain were the adverse events observed in patients, unlike the primary trial which did not record any."
    },
    "ebdac536-2654-45d4-896f-98875186b971": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day. liver angiosarcoma is a malignant vascular neoplasm arising from the liver."
    },
    "306374f7-40f9-45d5-a7cf-6cece3889a04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 2 patients in the primary clinical trial receive higher doses of docetaxel than cohort 1 patients receive of eribulin."
    },
    "3d2d011f-aff9-45c6-87e9-359b6d265c98": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have received chemotherapy or radiotherapy in the last 336 hours, suffer from unstable angina, or have grade 2 or above neuropathy cannot take part in the secondary trial, but can still take part in the primary trial if they satisfy all of the relevant inclusion criteria."
    },
    "9a6bed06-19da-4284-b5fd-e68ddad563c3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the primary clinical trial does not provide interventions through various methods, it relies on a single method of administration."
    },
    "8d685159-80a2-4b2c-8ca3-066d03e1cf66": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial"
    },
    "b7b355cd-5386-4b3c-bc5d-a9a05e7a83b5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "different units of measure are utilized in the results of the secondary clinical trial and the primary clinical trial."
    },
    "640ffbc4-cf15-4ab2-bf90-620e815f2694": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "from every cohort in the primary clinical trial, more than 50 individuals lived for more than two years, the average lifespan witnessed in the study participants."
    },
    "9006f1c5-2818-4edf-85e4-77d532b10820": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "while the primary clinical trial and the secondary clinical trial both utilize intravenous injections, they do not involve the same drugs, dosages or administer at the same rate."
    },
    "b8c9f988-e270-467e-b7a8-b71b1ae302ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "individuals with cdk4/6 mutation can participate in the primary clinical trial."
    },
    "dfde5d87-d03d-42a9-aa4c-f4e946a75102": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "in comparison, the secondary trial holds fewer anemia cases than the primary trial."
    },
    "47db0ed8-8607-4442-827c-20eb9e8db776": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "patients with benign brain tumor are eligible for the primary clinical trial"
    },
    "3f777627-6d5d-43c9-8686-677498316865": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "50% of the primary trial patients suffered an increase in blood bilirubin."
    },
    "85a50c0e-0dcf-4bd9-ac4e-179bc6f99067": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "in the primary clinical trial, ascites was noted more frequently, while pneumocystis jirovecii pneumonia was observed more often in the secondary clinical trial."
    },
    "966efbd3-dce6-400c-b5bc-87ca468c7225": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 150 mg group of the primary trial experienced a lesser reduction in primary tumour diameter than the zoledronic acid 1 mg group."
    },
    "829b14c1-9883-4dc4-93f9-40eadb9f9511": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "whole breast radiation therapy is administered to the participants of the primary clinical trial, whereas both cohorts in the secondary clinical trial receive intramuscular injections and medication that is consumed orally."
    },
    "63aa9e40-98df-4f09-a508-d0b03b9f93f1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 0.050 of patients in the primary trial suffered aes"
    },
    "f0d10d18-11a3-4fae-9a4d-f2277f6e5b43": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "there was an equal distribution of adverse events recorded in both the primary and secondary trials."
    },
    "587de897-adb2-4752-bd48-c9240b9bd956": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "the growth factor signature increased in more participants from the dalotuzumab 20 mg/kg group of the primary clinical trial than in those from the triple negative group."
    },
    "b971e3aa-d16a-4cca-8a69-c3e9793ada80": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients with t2 n2 m2 tumors meet the requirements for participation in the primary clinical trial"
    },
    "fc38a4bc-7c69-4ae2-9dad-f089f15e4d5e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "in the context of the primary clinical trial, 0.035 mg less of the drug alt-801 is administered to the first cohort compared to the second cohort"
    },
    "f05705d7-3be3-4d1d-9dca-c59c130446a1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": " Women with Newly diagnosed stage IV breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. rat insulinoma is an insulin-producing neuroendocrine tumor arising from beta cells of the rat pancreas."
    },
    "dc3aaeaa-d573-410b-a1f2-a55af755fc83": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary clinical trial are administered only one type of drug all throughout the study duration, with no prescribed dosage."
    },
    "41617f3f-76b1-41ca-b7c7-f902f84cd816": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. contact dermatitis is an inflammatory skin condition caused by direct contact between the skin and either an irritating substance or an allergen."
    },
    "83b92dd1-c68e-443b-b864-3ea87b3b557e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "my disease is out of control is a question about how strongly an individual agrees that they would think that their disease is out of control. The all recorded Aes in the primary trial occurred to cohort 1 patients."
    },
    "baf9254a-880a-4df9-b2fc-c118b6b273f8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial. this doctor understands what is important to me regarding my health is a question about whether an individual's doctor understands what is important to the individual regarding their health."
    },
    "5de4ae02-a1df-430d-a793-803bfefb7b0e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the primary clinical trial and the secondary clinical trial both focus on the same outcome measurements."
    },
    "84a23fa9-2758-4ea6-9eca-ca89b580378a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is given an injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine. fluorescence in situ hybridization was performed is an indication that fluorescence in situ hybridization was performed during the study."
    },
    "282a33db-aed6-4daa-bea6-299f424914bb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period"
    },
    "b9d16baf-ec50-40da-b2a4-68aa7abf1541": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "multiple deaths and hospitalizations were reported in cohort 2 of the primary clinical trial, along with various cases of atrial fibrillation."
    },
    "8b14dd2f-b02e-41be-a2bc-7dcc378ab426": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. apoptosis and single cell necrosis is a finding that generally has features of apoptosis and single cell necrosis."
    },
    "254e8b1c-de9f-467b-b32a-a41ee97421b9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": " patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (mi), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 2 decades if they want to participate in the primary trial"
    },
    "437d5311-f0fd-4d61-82a2-5db0d07415f6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary trial intervention is given orally, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein"
    },
    "caab457d-0650-4010-9d8e-4c8e474070ff": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "tachypnea is abnormal increase of rate of breathing. several cases of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but 0 cases of Pancytopenia."
    },
    "fd76b8a6-5305-4221-b48b-3a37d551c82a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "the primary clinical trial mandates regular physical activities as a part of the intervention for all participants."
    },
    "a83e8ca3-620b-47ab-a47b-3fc1fc4038c2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "All of the adverse events recorded in the primary trial were related to the musculoskeletal system this is not the case for the secondary trial. childhood bladder carcinoma is a rare carcinoma of the bladder that occurs during childhood."
    },
    "aad4638b-6c8d-4f55-bf3f-5a3e9d74ef50": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "individuals with quantifiable tumor growth in both breasts can participate in the primary clinical trial"
    },
    "d91d9ce6-365c-4b56-9eef-20922491f504": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "cohort 1 of the primary clinical trial is given 90 mg/m^2 paclitaxel daily while cohort 2 receives 25 mg of sunitinib"
    },
    "129d4bb1-11bc-4aa4-b75a-fa8d0832e2ff": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "in the primary clinical trial, the group taking azd0530 175 mg experienced a greater percentage change in betactx at the fourth week than the group on zoledronic acid 4 mg."
    },
    "08049ea6-03f6-457a-b74e-0012e02dc768": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "time to progression in days is reported for a pool of 156 patients in the two cohorts for the primary clinical trial, compared to the secondary clinical trial, which conveys the percentage of patients who underwent an objective response."
    },
    "215bc845-3485-423b-9c4c-1091cfb1a5cc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "Over 1/2 patients in the primary trial treated with Lapatinib 1000 mg + Nab-Paclitaxel experienced either a confirmed complete response (CR) or a confirmed partial response (PR). external iliac artery branch is any artery arising from the external iliac artery."
    },
    "20e22430-cc26-4cc4-b644-30dea07896e7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "the primary clinical trial administrates her2+ treatment for both cohort 1 and cohort 2."
    },
    "d58edc4e-2e7f-4c35-b24c-cd1239175b1a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "the primary participants reported no adverse events, specifically no occurrences of maculo-papular rash."
    },
    "23727e9e-6589-475f-9c29-0a7880f6d8af": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "all individuals in the primary clinical trial experienced a decline in cognitive performance, notably those in the ovarian function suppression group"
    },
    "494a4094-5a05-4c7d-b7a7-60baeb210e5a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial"
    },
    "74c47731-5e97-400b-bf85-52ae0b8b5e09": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 20000\u00b5g of mcs110 every 21 days, and over 130000\u00b5g of pdr001 every 14 days."
    },
    "e35505c9-4340-4f19-8756-925d96d65b44": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients who have undergone chemotherapy or radiotherapy in the recent fortnight, have stable angina, or exhibit grade 1 neuropathy are invited to participate in the secondary trial, but are excluded from the primary trial due to non-healing surgical wounds."
    },
    "059a48d5-3bf5-40ac-b06c-3107c0ea7cb9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "in the primary clinical trial, a patient group is treated with 150 mg of oral pregabalin, received bi-weekly over a six week period, in contrast to the secondary clinical trial, where treatments involve administration of depocyt and hd-mtx."
    },
    "0a3eabb5-68f0-4534-834a-d3e75dbb733e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg/kg less of Durva in their bi-weekly IV infusions compared to cohort 2. seventeen is a natural number greater than 16 and less than 18 and the quantity that it denotes."
    },
    "0483c5df-77db-4c42-897e-aca21b207503": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "numerous instances of pancytopenia were noted in cohort 1 of the primary clinical trial, but there were no records of anaemia and febrile neutropenia."
    },
    "a146a89a-9519-4515-b36a-b5f365481341": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "the primary clinical trial registered no instances of anaemia and febrile neutropenia in cohort 1, but there were several cases of pancytopenia."
    },
    "7de10e39-c06c-4941-ade6-3e60b864029c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial does not provide a time to progression report and instead focuses on the patient's subjective experience, whereas the secondary trial records the total duration of patient participation across both cohorts."
    },
    "9bea0473-ca9d-4a63-befe-db1825744484": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "there was no significant difference in the results produced by cohort 2 of the primary and secondary clinical trials."
    },
    "d43e7757-45d0-4f65-9735-6ba05f13337d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "candidates for the primary clinical trial are not permitted to undergo cbt-based treatments, but they may qualify for the secondary clinical trial."
    },
    "bc686408-6e00-414a-b5a4-2bae034aca57": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult who was diagnosed with diffuse parenchymal lung disease within the last three years would not be considered for the primary clinical trial"
    },
    "63bd708a-66ae-41fc-872d-277417bc2576": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial prescribes a regimen of oral multivitamins for its patients, and the secondary trial manages its patients with depomedroxyprogesterone acetate injection"
    },
    "2c95f252-a861-4569-a0b9-c214289da160": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary clinical trial and the secondary clinical trial documented over 100 adverse events within their study groups."
    },
    "07dab01c-f419-4079-bd0d-491740c5ec95": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "several patients in the primary clinical trial experienced identical adverse events."
    },
    "40123001-b9eb-4d75-aa74-83865de37e70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial. tricuspid valve regurgitant volume is a quantitative measurement of the amount of retrograde blood flow across the orifice of the tricuspid valve."
    },
    "81651022-ae46-4e69-aa0b-1e1d576845ce": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "erbb2 nm 004448.2:c.2324 2325ins12 is an insertion of 12 nucleotides, atacgtgatggc, between position 2324 and 2325 of the coding sequence of the erbb2 gene. There are no conditions on Life expectancy, pregnancy or age for participants of the primary trial."
    },
    "13765ddf-3be9-411a-ae7a-24a0bdffe2d8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "both the primary clinical trial and the secondary clinical trial necessitate that patients partake in a weekly regimen of 4-demethyl-4-cholestryloxycarbonylpenclomedine."
    },
    "c68e5909-668a-4b35-bf32-815624bf44da": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "in the primary clinical trial, 150 mg/m2 of lapatinib is administered orally once daily for two weeks to the patients."
    },
    "b681145e-4fd6-42ae-8250-b6d915e7a0cf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "the secondary trial and the primary trial follow identical sets of criteria for participant eligibility."
    },
    "5ce6e37b-2c84-44e1-8c5e-e441cec64872": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention. discharge indicator is an indication as to whether there is the presence of discharge."
    },
    "277c0ee2-5d34-4c87-80eb-6f5b630109ec": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "medulloblastoma, not otherwise specified is a medulloblastoma which has not been further characterized. Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial."
    },
    "1b5d6416-bf6d-4d0b-8b9b-b982d1bbd8a8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have Her2/neu+ breast cancer. abnormal vital capacity is a pulmonary function test result indicating an abnormal vital capacity as compared to the predicted value."
    },
    "ac762601-55f3-434a-bf5a-690ed8a3f735": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "within the primary clinical trial, a quarter of cohort 2 patients experience an increased occurrence of pleural effusion."
    },
    "b5b61f90-60b8-404f-872e-a58c84dbf43a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "no aes were registered in either the primary clinical trial or the secondary clinical trial."
    },
    "85645da7-cf87-4b4d-a5eb-cab03a857cc4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "hyoepiglottic ligament is a short elastic band that unites the epiglottis to the upper border of the hyoid bone. the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions."
    },
    "0d633cc2-339a-4caf-b252-ce50b826e3e3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "an instance of infection was reported in each of the primary and secondary clinical trial"
    },
    "f1315324-edf3-4d7c-a999-c3a668e67930": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "several of the primary trial candidates are administered 1000 mcg of talazoparib daily, as part of the intervention. marine-based natural product is any substance or product derived from any organism that lives in bodies of fresh or salt water."
    },
    "92fe4c4d-da02-4327-a2a1-86e731ba4fd9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "both cohorts participating in the primary clinical trial are administered identical dosages of abraxane and carboplatin"
    },
    "55c1905d-0e17-41b6-89ba-c29df13d2e30": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "each patient in cohort 1 of the primary clinical trial that experienced infections and fever were the only ones."
    },
    "951e007d-202c-4cd4-8db0-0218a7c9f851": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "the primary clinical trial employs unique treatment dosage and frequency for each cohort, excluding any usage of docetaxel, doxorubicin and cyclophosphamide."
    },
    "87c5a93d-fcef-46ca-8267-3d928c13c6f7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00656305",
        "Statement": "cohort 2 of the primary clinical trial reported no deaths or hospitalizations, except for a solitary case of atrial fibrillation."
    },
    "425f9738-1b09-446e-8c8c-5004ed91351d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "all the instances of infections and infestations in the primary clinical trial pertained to patients in cohort 1."
    },
    "076f0bbd-6b10-44e1-a7c6-9853d9457509": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "specify another form of birth control that was used is a directive to specify another form of birth control that was used. Sunitinib was administered orally every day, to every patient in the primary trial for the entire duration of the study."
    },
    "81d8da2f-add7-4c32-bc69-8eb22266f71e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "the first cohort of the primary clinical trial didn't document any adverse events"
    },
    "0a9675e4-c6cf-44a9-98ed-e50aadfe064a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "in the secondary clinical trial, the efficacy of physical therapy is gauged by measuring pain, unlike the primary clinical trial wherein the effectiveness of sulforaphane supplements is studied based on their impact on isothiocyanate concentration in urine."
    },
    "61b2e007-6e98-4923-8c07-d22ab6b62870": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "there were no adverse events reported by participants in either the primary or secondary clinical trials."
    },
    "08a467b9-3bf6-486f-9975-4e2b67a5b690": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "patients with a confirmed mutation in any of the following genes; pten, braf, kras, nras, pi3kca, erbb1, erbb2, met, ret, c-kit, gnaq or gna11 are required for participation in the secondary clinical trial, not the primary clinical trial"
    },
    "9e31c420-01cc-4232-9793-a3a4b7201fa6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "liter per meter squared is a unit of concentration equal to liter per meter squared. candidates must undergo a Mammography before being able to participate in the primary trial, this is not required for the secondary trial."
    },
    "202f56bf-1317-4abc-803d-5ec37cd27624": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "both the primary clinical trial and the secondary clinical trial present findings from a single patient cohort."
    },
    "62384871-8eb2-414b-8cc9-e756a188e19e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the MTD of different interventions, with the MTD of MM-111 for patients in the secondary trial being 15 mg per day"
    },
    "00ac087f-fc20-4ff1-be51-f32fa22f4e4e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "participants in the primary trial receive epacadostat with the same frequency as sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants receive sunitinib in the secondary trial."
    },
    "aa861098-a5f8-473e-be7d-eba94ccb4ab1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ild/dpld within the last 156 weeks, with a life expectancy of 0.5 years would be eligible for the primary trial"
    },
    "3ff601a7-b05a-4cc4-94e3-bbea555889cb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is not used in either of the primary trial interventions. posterior tongue neoplasm is a benign or malignant neoplasm that affects the base of the tongue."
    },
    "51a15c75-5a89-48c3-a93d-4f464e915ba2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients. coordinating committee is a committee that a sponsor may organize to coordinate the conduct of a multicenter trial. (ich)"
    },
    "e21904b2-3e78-4f20-80e3-562a82fc9cfe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "children are not eligible for the primary trial however they are not explicitly excluded from the secondary trial. coliform bacteria, lactose fermenting is any rod-shaped, gram-negative, non-spore forming bacteria that is capable of fermenting lactose to produce acid and gas."
    },
    "884486ed-0e11-41be-9792-d2765bd977a2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "every individual in the first cohort of the primary clinical trial experienced some form of adverse event."
    },
    "f48699d6-6352-4c94-9ef3-fe5060d07aeb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "There were more adverse events observed in the secondary trial than in the primary trial. physical activity lifestyle is a description of the subject's lifestyle with respect to physical activity."
    },
    "784e6940-fead-497a-8d68-2869d17385ea": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "esophageal hemangioma is a capillary or cavernous hemangioma that arises from the esophagus.  the majority of cases are polypoid intraluminal lesions. The placebo intervention and the Allo-MSCs intervention of the primary trial are administered in the same dose by transendocardial injection."
    },
    "286e098d-ca31-41ce-b8a9-f8bcf99447f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "anemia is more prevalent in the primary trial when opposed to the secondary trial."
    },
    "29ebe44e-58cf-4141-afaa-9518629c3868": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism within the last 156 weeks are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "782c9a26-ba09-4eef-8076-bd8831c9f986": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "patients with a confirmed diagnosis of leptomeningeal carcinoma can participate in the primary clinical trial"
    },
    "b27a5fe7-77f8-4d11-9e05-0609faf8b985": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "fertile men and women capable of becoming pregnant are fit to partake in the primary clinical trial, under the condition of committing to abstain for the length of the study"
    },
    "36a5e0dd-7e3a-4362-9726-0836f7a4c64e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "several patients with Normal Vitamin D Levels in the primary trial showed discernible pattern for expression of the set of 40 evaluated genes. 11q22-q23 is a chromosome band present on 11q"
    },
    "15f4f1d2-c4db-403e-83ed-85e6958ee7ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the number of adverse events in the secondary clinical trial was greater compared to those in the primary clinical trial."
    },
    "6b901ca0-1ec8-4d36-b43d-dcc6bf63b70f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "hexadecadienoic acid is a polyunsaturated long-chain fatty acid with a 16-carbon backbone and exactly two double bonds. More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2."
    },
    "cc369e33-07e2-441d-b4fd-8233478ba98a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "patients suffering from severe malnutrition are ineligible for the primary clinical trial."
    },
    "37df336b-2fc4-4986-957b-5f62219c5bd4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "all participants in the primary clinical trial are administered a cocktail of drugs as part of the intervention."
    },
    "3c2994b1-74be-4fe4-9262-00a5a8e42caa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the shortest pfs in the primary clinical trial came from cohort 1, and experienced disease progression within a week"
    },
    "62441471-f329-4540-9d4e-dc34c4d08d59": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial"
    },
    "1aedac43-a4c7-4c14-b217-8d76e853c76f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "every patient in the primary trial is receives a dose of 2000 to 5000 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy,  ,  "
    },
    "84f10108-19b7-499f-9144-b3e6c0b253d5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary trial and the secondary trial evaluate different patient characteristics in their results. appendiceal carcinoma pn0 tnm finding v7 is appendiceal carcinoma without regional lymph node metastasis.  (from ajcc 7th ed.)"
    },
    "451c8e9e-03c1-4b7a-9b84-5129c5623f1b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have breast cancer and require hormonal treatment."
    },
    "87f86955-0e57-459a-84aa-4a5feba745af": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "patients who have estrogen negative, progesterone negative and her2- breast cancer, can join the primary clinical trial"
    },
    "2ce21ccd-8f05-4618-8597-b1ad8be31f59": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography is used for both interventions in the primary trial. cisplatin/doxorubicin/paclitaxel regimen is a regimen consisting of cisplatin, doxorubicin and paclitaxel used for the treatment of advanced stage or recurrent endometrial cancer."
    },
    "94857a77-b822-4cb8-989b-b6efb0a105e0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "both trials saw a considerable number of adverse events throughout their duration"
    },
    "979f5a49-0af6-4ea3-a410-d79cf3540d01": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats part of its patient groups with iv infusions of amitriptyline biweekly for a period of 6 weeks, while the secondary trial utilizes carmustine and cyclophosphamide for its administration."
    },
    "efe92dca-7dd8-44da-b436-15a3c9f9f729": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "nasal cream dosage form is a cream intended for administration to the mucosa of the nose. There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial."
    },
    "63da892b-0385-43c5-8ed3-3ce7514ebb55": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "the adverse events reported for cohort 1 of the primary clinical trial pertain to cardiovascular complications"
    },
    "eaa447d4-2621-47ca-b543-5d1d956fec02": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients with severe insomnia and schizophrenia are eligible for the primary clinical trial, but not the secondary clinical trial"
    },
    "61a20e23-7b57-4acc-b594-273f4536941c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "there is no age restriction for candidates in the secondary clinical trial, but to be eligible for the primary clinical trial, patients need to be less than 30 years old."
    },
    "5e74a97b-ae6e-478b-bcf1-f681159ea1f7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 0.5 patients in the primary trial treated with lapatinib 1000 milligrams + nab-paclitaxel experienced a confirmed complete response (cr) ."
    },
    "a93f06ed-84a0-487e-bf93-f74cc7cb34ba": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "no adverse events have been reported for participants in both the primary and secondary clinical trial."
    },
    "a0e45f2f-6f88-496e-9b14-2fe595be1286": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "in the primary clinical trial, less than 10% of patients experienced one psychiatric adverse event"
    },
    "bb01dea7-5b49-41b7-997b-70cc1e980226": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "atypical carcinoid tumor is a carcinoid tumor characterized by a high mitotic rate, often associated with the presence of necrosis and nuclear pleomorphism. On average both cohorts of the primary trial suffered a deterioration in cognitive function, however this was not the case for all patients."
    },
    "4a349ab7-7fd2-4979-bf94-4e563c26b7f9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients suffering from stage 4 invasive breast carcinoma, with positive estrogen/progesterone receptors and thinking about ai therapy could be potential candidates for the primary clinical trial."
    },
    "3131f532-99b5-433e-9375-8af120cd4c0f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "while the patients in the second group of the primary clinical trial are administered with 0.5ug/kg of myalgias (5ml), none of the patients in the cohorts of the secondary clinical trial receives any myalgias."
    },
    "9f81f8a6-84d2-40b3-b8c5-3616f2f638a8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, the placebo intervention is administered intravenously and the memantine intervention is administered orally, twice daily."
    },
    "a830799d-017f-4656-aed0-d428d5e0c73f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "every documented adverse event in the primary clinical trial took place among the cohort 1 patients"
    },
    "517f5131-6807-4537-ae4c-308be1f98d17": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "There were more adverse events observed in the secondary trial than in the primary trial. irrecist stable disease is a failure to meet criteria for ircr or irpr in the absence of irpd."
    },
    "5cc29d9f-f81c-41c0-8a55-a98264f040c7": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "metastatic neuroendocrine carcinoma is a neuroendocrine carcinoma that has metastasized from its original site of growth to another anatomic site. Patients with measurable bilateral breast cancer are eligible for the primary trial."
    },
    "e244fc3a-53b3-4158-99c5-a45afc726af6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial."
    },
    "55cc22eb-91ad-423f-8d3e-e4b5ef61ed7d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient who has a 33mm primary tumour, as verified by clinical scrutiny and echography, is eligible for the primary clinical trial as well as the secondary clinical trial."
    },
    "11fd1d6e-0641-4b3d-91ff-9f048584db7b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "the primary clinical trial is available to individuals with fronto-temporal or mixed dementia"
    },
    "9c272853-cec0-43f0-9897-4657c5fd0b78": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a radius of 3000\u00b5m measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "4c0fbabb-2d9e-4da7-8a17-07272c77ece8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "the adverse event records from the primary and secondary clinical trials show more than 10 deaths."
    },
    "16aacacc-1ab7-46d2-a59e-ca207cb0282d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "patients with parathyroid carcinoma evidenced by immunofluorescence microscopy or peripheral blood smear are ineligible for both the primary trial and the secondary trial."
    },
    "15a422cf-fc00-4451-bddc-af67f7437e83": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, however cohort 1 is administered CUDC-101 more often. don't know or not sure when smoked a cigarette is a response indicating that an individual doesn't know or is not sure whether they smoked a cigarette."
    },
    "fb41d62d-4f75-463d-b71a-0b31dd0ade96": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "the same amounts of abraxane are provided to both groups in the primary clinical trial"
    },
    "c566ae79-b43a-4e83-8336-da8613e19e7f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "those suffering from alzheimer's disease are not applicable for participation in the primary clinical trial"
    },
    "d10a9ae2-cb0c-49e8-924c-906e3f2eb5a5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "the primary clinical trial is solely open to participants who have been sterilized surgically or are not sexually active."
    },
    "32c13f2f-7902-444f-8f99-c3ea2ecac0d0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the primary clinical trial records more types of adverse events, yet the total number of adverse events reported is less than in the secondary clinical trial."
    },
    "cf45d975-0c29-4cf3-8f21-c245482a2b32": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the secondary trial and the primary trial have completely unrelated outcome measurements, but the same interventions"
    },
    "4fec37ef-6e27-4b07-a0ba-d35434fe2d36": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "having a history of pulmonary embolism in the recent 60 days does not disqualify a patient from the primary clinical trial but eliminates the possibility of enrollment in the secondary clinical trial regardless of the investigator's opinion"
    },
    "8127d46a-3a48-4173-8d00-75e949755a74": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "Prior treatment with gabapentin or herceptin within the last year, will result in exclusion from the secondary trial, but not from the primary trial."
    },
    "04067434-b300-40f1-9e6c-c986b4c602c5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae. hard palate squamous cell carcinoma is a squamous cell carcinoma that arises from the hard palate.  it usually presents as a papillary or exophytic mass."
    },
    "54f0a585-98f8-49c2-a6b3-2700b3fc19ff": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "intravenous injections and mris are used in both the primary clinical trial and the secondary clinical trial, though they differ in the drugs, dosages, and administration frequency applied in their interventions."
    },
    "a4e6bb5b-69f1-451b-b278-0ce9c3e43bdf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00372424",
        "Statement": "in the primary clinical trial, a total of 35 patients who were administered sunitinib, docetaxel, and trastuzumab suffered treatment-emergent adverse events."
    },
    "f87a205c-5de6-4cda-a798-85b7308e25c2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "missouri is a state in the central midwest united states. its capital is jefferson city. There was at least 1 recorded gastro-intestinal adverse event and 2 or more psychiatric events in the primary trial."
    },
    "e9c0f175-b715-4b33-86a2-aa21c2990164": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "patients in cohort 1 of the primary clinical trial receive different radiation therapy doses in comparison to those in cohort 2."
    },
    "ff3d1bb2-393e-4798-a128-090e7308f5b1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "ezh2 gene mutation negative is a genetic finding indicating that ezh2 gene mutations have not been detected in a sample. an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial."
    },
    "ae5d8804-eada-4f5c-8889-18a7cc90bb9b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "different units of measure are used in the outcomes of the primary clinical trial and the secondary clinical trial, despite being the same form of measurement."
    },
    "1a11d957-c721-4cee-b540-e3ab8eaad1d0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a patient with age equivalent to 11520 weeks with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1.807 x 10^9/l, platelet count of 79 x 10^3/\u00b5l, hemoglobin level of 90000 mg/l, and a life expectancy exceeding 32 weeks would be eligible for both the primary trial and the secondary trial."
    },
    "8b59c6dc-98ec-4f07-9274-ba4cc1ff8950": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "germinal center b-lymphocyte is a mature b-lymphocyte that is present in the geminal center of a lymphoid follicle. There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial."
    },
    "378c5fe6-13ce-488e-a8c0-ec76cf2fb191": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "patients receiving aprepitant in the primary clinical trial were twice as likely to experience emesis as patients receiving the placebo intervention."
    },
    "972a66e9-09cc-4091-8c60-fa8f458955aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "the first patient group in the primary clinical trial is administered with higher doses of cyclophosphamide than eribulin, and the second patient group gets greater doses of cyclophosphamide than docetaxel."
    },
    "837329c4-d046-4997-ad41-f230d3db7255": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "There were no cardiac or psychiatric Aes recorded during the primary trial and the secondary trial."
    },
    "c4a67b84-c8c7-4922-a5fb-5fb9a1a3160a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "grade 2 follicular lymphoma is a follicular lymphoma which contains 6-15 centroblasts per 40x high-power microscopic field. the primary trial and the secondary trial adminster their interventions orally."
    },
    "074f66e7-18df-4ee9-a33c-127062dcb51f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00588640",
        "Secondary_id": "NCT03125941",
        "Statement": "the primary trial uses separate inclusion and exclusion criteria for its 2 phases whereas the secondary trial uses the same criteria for all participants. ms is a courtesy title used before the name of a woman without making a distinction between married and unmarried status."
    },
    "1f4fe504-06a7-40e6-ad0e-76c903ea80a2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary clinical trial, the occurrences of hepatotoxicity were tenfold compared to the cases of hypertension and pancreatectomy"
    },
    "bbb61326-9879-44f0-af97-523e7dc2231a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "no differences in symptom severity were noted between patients in the primary clinical trial who received topical cryotherapy and those who did not.'"
    },
    "f9d5b863-f0cb-4777-81a7-358efd8010d6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation. splenic rupture is a traumatic break in the fibrous connective tissue capsule surrounding the spleen."
    },
    "9b9d2ca0-acea-42a6-bd46-78eb4540a107": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 13.00% of the primary trial patients"
    },
    "70539b18-50b0-43f7-b676-2143de2dc3e8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "the primary trial and the secondary trial both administer cyclophosphamide to their patient cohorts"
    },
    "2f11c1f5-4e9c-4848-8de1-9df7d4403848": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "patient cohorts in both the primary and secondary trials receive cyclophosphamide"
    },
    "a171374b-4c87-4b1a-94f9-8f0238cdce4f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "throughout the period of the primary clinical trial, the study participants are given four distinct drugs."
    },
    "dd3d2183-d062-41ed-af63-ae475f2246ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "In both the primary trial and the secondary trial there were several adverse events which occurred in more than 30% of participants."
    },
    "d303ce9d-a00a-4ee7-8147-0bac063ee210": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "one specific adverse event type impacted multiple participants in the primary clinical trial"
    },
    "1514ac93-96a8-4d16-a572-d2a829af84c4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 4 different drugs throughout the study duration, with a maximum dose of 100 mg/m^2. cisplatin/topotecan is a combination of agents containing cisplatin and topotecan."
    },
    "591794ae-5578-4bb4-a527-106947636ddb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary and secondary clinical trials, more than 30% of participants experienced several adverse events."
    },
    "d2139fd7-7b3e-405a-a806-ca76d237c11f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial. hearing problem causes frustration when talking with family is a question about whether an individual's hearing problem causes them frustration when talking with family members."
    },
    "4988cb16-7dbb-4847-84e0-4a7957b32c72": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial"
    },
    "eada8d1a-7396-44e7-8f30-03814c7479fb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "there were no lesions found on any of the group 1 participants in the primary clinical trial and an overwhelming 95% of group 1 participants in the secondary clinical trial showed signs of radiation dermatitis and hyperpigmentation."
    },
    "ed8ce995-6417-4392-8608-d20f0087c730": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event in the primary trial. pigmentary change in skin is abnormal skin pigmentation."
    },
    "6d446eda-4dec-469d-9313-37c70eef8e0a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 of the primary clinical trial and the secondary trial had an equal number of patients."
    },
    "19356a21-1163-41b2-8780-7e8e7c956454": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial and the secondary trial have 55 recorded adverse events."
    },
    "d2e30364-0f79-46c7-8faa-7d7f6751c662": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "the primary clinical trial accepts patients regardless of gender, whereas the secondary clinical trial only considers females for participation."
    },
    "c0b9a42b-2440-46b5-8fbc-978e2699c76e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "only those with a histologically/cytologically confirmed diagnosis of colorectal cancer can participate in the primary clinical trial"
    },
    "256c210a-d33f-4708-8d86-2cb636227c4d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "infection, asymmetry and nausea were observed more frequently in the primary clinical trial compared to the secondary clinical trial."
    },
    "1e32317b-5301-461d-bdd9-0acb2e076522": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "adverse events were carefully documented in both the primary clinical trial and the secondary clinical trial."
    },
    "bea08563-704d-4475-9dbd-d7617d1a6a63": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement. prostate lymphoma is a rare non-hodgkin or hodgkin lymphoma that arises from the prostate gland."
    },
    "c7037258-f24b-40dd-9ce8-5026b019bfbe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "neither intestinal obstructions nor pancytopenia has been observed within the patient cohorts of the primary and secondary clinical trials."
    },
    "e3e8c1c5-ae1f-4f90-8584-b24096bb580a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, age, Karnofsky/ECOG score or previous treatments that need to be met in order to be eligible for the primary trial . ipss-r risk category very high is a total ipss-r score of 6.5 or higher, indicating very high risk."
    },
    "d9682530-105c-4e04-a26b-5d5985aac260": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "stage 4 cancer patients are excluded from the secondary clinical trial, but may participate in the primary clinical trial."
    },
    "5e23cc12-12c7-42e9-ab55-595bb427adad": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial. grade 1 hypophysitis, ctcae is asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated"
    },
    "fe470456-ea60-433f-905c-21189377531a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "ophthalmic route of administration is administration of a drug to the external eye. Hypokalemic patients are excluded from the primary trial, but hyperkalemic patients may be eligible for the secondary trial and the primary trial."
    },
    "ec1b0aa0-0d0b-45b9-9ba5-ad8b941d8647": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 110,034/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. first course treatment completion measure of success of outcome not applicable is a response that the first course treatment completion measure of success of outcome is not applicable."
    },
    "d47eb708-7ca4-4894-bc28-e276e61c0333": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "the primary clinical trial does not involve administering any vaccines to the participants."
    },
    "65edf675-63e7-4b5f-b131-9e5cdf9eeec4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "The dosage of Denosumab in Intervention 1 of the primary trial is 12 times higher than the dosage of Tamoxifen in intervention 1 of the secondary trial. cytolytic process is any cell death process resulting from rupture of cell membranes and loss of cytoplasm."
    },
    "7c192c20-49e2-4b5c-b4ac-1131b7e9e4d0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "More Palpitations, Pericardial effusions and Abdominal pains were recorded in the primary trial than in the secondary trial. deleterious atm gene mutation is a change in the nucleotide sequence of the atm gene that is associated with increased risk of disease."
    },
    "342026c4-e3de-48c7-8688-e214f5ece431": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the intervention segment of the primary clinical trial fails to delineate either a treatment regimen or the specifics of radiation dosages."
    },
    "d5b131c2-0835-4f00-a0ba-2db26d1fe581": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "throughout the primary clinical trial, there were no reported cases of gastro-intestinal complications"
    },
    "2610ce20-2875-4677-a55b-fbd094ca3abb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "cohort 1 in the primary clinical trial does not receive pd-0332991 as part of their treatment regime."
    },
    "428340b6-e87b-4e03-920b-f2e3f62f05d6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "in the primary clinical trial, the intervention's educational dvd will be made available solely to the members of cohort 1"
    },
    "e517c026-4c5e-43ac-a734-1bcfd6d8edf1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes, however almost all of cohort 2 candidates suffered at least one ae. prefer not to answer is a response indicating that an individual prefers or preferred not to answer."
    },
    "a031053e-a514-4484-9624-bcddef1628d3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "counselling is a key component of the interventions in the primary clinical trial."
    },
    "c472d895-f7f4-474f-8664-b7af887b1339": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "cohort b reported significantly lower adverse events compared to cohort a in the primary clinical trial."
    },
    "1fec40c0-4c6f-4e9d-ae16-a962eb45b4dd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "apalutamide regimen is a chemotherapy regimen consisting of apalutamide that may be used in the treatment of prostate cancer. Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial."
    },
    "838e1a74-56e5-4dde-aeba-f26d2d3f8983": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 500mg in the primary trial gained lean body mass over a 1 month period"
    },
    "91db7925-da19-4373-bfba-78ee49b34f99": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 504 hour cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place."
    },
    "98e146d6-bc16-460b-92eb-826ddeb79a3d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months. cordonnier grade 3 viral complication, viral encephalitis is any viral encephalitis."
    },
    "6b48128c-3103-4266-bd7f-3f9d13dc5949": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "cohort 1 of the primary trial is administered a standard dose of warfarin and cohort 1 of the secondary trial is given an injection of fluvoxamine."
    },
    "d11e7175-a122-475f-862e-c5215d821f34": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "male patients under the age of 18 can participate in the primary trial, regardless of race or ethnic origin or cancer type, however for the secondary trial, they must have prostate cancer."
    },
    "d91ee458-d6de-4d45-8511-cabb52d2a64e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "the eligibility criteria for both the primary and secondary clinical trial does not depend on the gender of the participant"
    },
    "7b860f15-132f-423e-ac6d-1c73f7a2d0d5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial provides a patient population with 200 mg of oral cymbalta biweekly for a duration of 6 weeks, and depocyt together with hd-mtx are not used in the secondary trial's patient treatment."
    },
    "5a954b09-cbc7-47dd-891c-4c998eb72979": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "participants in cohort 1 of the primary clinical trial are not administered with pneumococcus vaccine."
    },
    "84942825-f636-4dcf-af2e-172012c0cc9d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Cyclophosphamide than Eribulin and cohort 2 patients receive higher doses of Cyclophosphamide than Docetaxel"
    },
    "ce40b0b9-d8d4-45f4-a2dc-4adb8e7103ac": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2."
    },
    "ed12f8ae-3bda-46b8-8bf1-5ad6d1527c57": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "received all the services needed is a response indicating that an individual feels or felt that they received all the services they needed.  Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial."
    },
    "172e14bc-4f23-4d47-9e94-1d65291ef090": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "there is no single common inclusion criteria between the secondary trial and the primary trial."
    },
    "1a76bce8-07e2-4b30-adc8-3c095f0d62b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial"
    },
    "8b54773e-b9b0-400f-af71-8fd2cbd16473": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "all the primary trial participants receive the same doses of alt-801 as the secondary trial participants"
    },
    "890c305f-bd6d-4db4-adf5-2aaf8e28d6c6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "The most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was Syncope, which occurred in 25.00% of the primary trial patients. severe problems performing usual activities is a response indicating that an individual has or had severe problems with performing their usual activities."
    },
    "f69e913e-7050-463f-aa18-ad022451d483": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "patients that have participated in antineoplastic chemotherapy, androgens, estrogens, or progestogens therapy in the two years preceding study initiation are barred from the primary clinical trial."
    },
    "e504c08b-c348-4307-9cfe-d20f7003ec15": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event. injection site reaction, ctcae is a disorder characterized by an intense adverse reaction (usually immunologic) developing at the site of an injection."
    },
    "a8bb394a-d996-4174-8800-a38db8905fce": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the secondary clinical trial concentrates its studies on time to progression for a total of 300 patients in three distinct cohorts, while the primary clinical trial measures the number of patients with successful treatment response."
    },
    "a855848e-4097-4755-90e0-e612f1bfc54c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. apache ii - arterial ph is acute physiology and chronic health evaluation ii (apache ii) arterial ph (preferred)."
    },
    "64f9b5b3-cd20-4b90-94b5-14e08a9999f0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "chest pain has been more frequently observed in patients participating in the secondary clinical trial than in those in the primary clinical trial."
    },
    "88574a43-d4c9-4db7-8f47-307722095b0d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "for the secondary trial, the impact of physical therapy on joint flexibility is quantified, whereas the primary trial examines how zinc supplements affect serum zinc level."
    },
    "aff21004-0238-46bb-b68b-99d1e3035947": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "both the primary clinical trial and secondary clinical trial may permit the involvement of morbidly obese patients."
    },
    "55af1301-2370-48bf-8dde-50c589448da1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "it was unusual for individuals with eating disorders to be candidates in the primary clinical trial"
    },
    "03c087ae-9ad2-4db3-a913-e6ba85dc15b0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates who are bedridden for less than 50% of their waking hours are eligible for both primary clinical trial and secondary clinical trial"
    },
    "95c7070d-76e7-4618-b95f-56b233dffb16": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates. terrified by thoughts of the future is a response indicating that an individual is or was terrified by thoughts of the future."
    },
    "e53fdbd4-4375-409d-ad00-322822909d5b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "participants in the secondary clinical trial are scheduled for three weekly sc injections, on the other hand, a single injection is given to primary clinical trial candidates at the inception of the study."
    },
    "6b531884-77d9-4cdc-bab7-324596ec998e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "primary trial's group 2 receive 1.5ug/kg dexmedetomidine and patients in grades 2 and 3 of the secondary trial also receive the same amount of dexmedetomidine."
    },
    "6e6cecbf-ea24-4cf8-83f5-5fd627941028": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "intervention 1 in the primary clinical trial, along with all intervention drugs in the secondary clinical trial, necessitate intravenous delivery."
    },
    "bbc8e272-7c58-4e53-a78b-4b634add9932": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary clinical trial employs a higher dosage of lenalidomide during the first intervention in comparison to the smaller dosage used for lapatinib in the secondary clinical trial, furthermore, the primary clinical trial's treatment period is extended."
    },
    "f1b7b902-d67b-489f-9c93-de59c708d2fa": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "adverse events connected to treatment in patients are being examined in the primary clinical trial, in contrast to the secondary clinical trial which determines the mean hours for which its patients sleep."
    },
    "7b76950c-8ac8-451f-93d4-bfac4ba36e49": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "in comparison to the first group that received enzalutamide intravenously in the primary clinical trial, the second group received it orally"
    },
    "46065ce7-6618-4f08-890c-6bd0f8fa4573": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "men with newly diagnosed stage ii prostate cancer not undergoing any surgery are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "eb7d6866-d56b-437c-a48c-78478afdfac8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary clinical trial noted fewer adverse events in its patient cohort compared to the primary clinical trial."
    },
    "9e960679-ac10-4893-a777-94baac5a89f3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "participants in cohort 2 of the primary clinical trial are not administered with an influenza vaccine."
    },
    "c114301e-f64f-468b-95f7-8debdc840a74": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "both cohort 1 and cohort 2 receive equal amounts of cudc-101 with identical frequency in the primary clinical trial. however, cohort 1 also obtains pd-0332991 every week."
    },
    "b70ec50e-cbcd-4edd-a730-267c5b0f3fec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": ",  the primary trial and the secondary trial have zero recorded adverse events."
    },
    "be268f6b-8123-4cd7-a495-c82453034b67": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients suffering from lobular carcinoma in situ and well-regulated high blood pressure are permitted in the primary clinical trial, but are barred from the secondary clinical trial."
    },
    "62581915-0fde-4cfb-8205-7c1b8c8bacbb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "higher doses of lenalidomide are utilized in the primary clinical trial compared to the doses of lapatinib used in the secondary clinical trial in the first intervention."
    },
    "81a3bd04-5dff-45a6-a4eb-7a41c59b0023": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial. lung carcinoma metastatic in the bone is a carcinoma that arises from the lung and has metastasized to the bone."
    },
    "0bfa5116-f8a5-4bba-b279-bc071c6ff725": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or older are eligible for the secondary trial and the primary trial. have poor or reduced appetite is a question about whether an individual's appetite is or was reduced from normal."
    },
    "1692f569-44d0-4b60-aabe-87dc3f7d3513": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "candidates in the primary trial get a higher weekly dose of mm-121 and paclitaxel than those in cohort 1 of the secondary trial, and also a lower weekly dose of herceptin and doxatel."
    },
    "9b2023d2-09bd-4362-ae66-afc69497e468": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial. nonpsychotic mental disorder following organic brain damage is any mental disorder that occurs secondary to organic brain damage, and that is not associated with psychosis."
    },
    "ee0e333a-4b42-4078-a126-d3a1101f7f4c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary trial provides a report on the severity of delayed nausea on a scale of 1-7, whilst the secondary trial measures the change in bone mineral density (bmd) at the lumbar spine from baseline to 9 months."
    },
    "e93765e3-d596-4009-8fc0-6d8433f19679": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 1mg in the primary clinical trial lost lean body mass over a 4 month period"
    },
    "57dae782-9901-446f-93d1-047097623f45": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "igf1r immunohistochemical expression is an immunohistochemical diagnostic test utilizing an antibody to detect igf1r in tissues. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic."
    },
    "3e0a4b38-bafb-4a0e-a1be-8506f23aa1f6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "compared to the secondary clinical trial, the primary trial shows a decreased percentage of patients reporting palpitations, pericardial effusions and abdominal pains."
    },
    "eea61494-780f-4a38-aa12-dd88ef3d520b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the study groups in the primary clinical trial are being tested with various types of gels, while the secondary clinical trial evaluates the effects of different doses of one particular treatment on its study group."
    },
    "a2cdb319-3410-467d-94f0-0908534ebf22": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time. found dead is an indication that a subject was found in a deceased state."
    },
    "2cde3c46-f21a-4177-afc8-94f851854b98": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "There was at least 1 recorded gastro-intestinal adverse event in the primary trial"
    },
    "8bdac388-c2bd-4634-9073-6862aaa7a5cf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "in the primary clinical trial, participants are given four separate drugs throughout the duration of the research, with the maximum dosage capped at 100 mg/m^2."
    },
    "ece744da-a8d6-401a-972c-3a9f5cd60b14": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "each individual adverse event in the primary clinical trial was reported in only one patient"
    },
    "176093eb-7c7f-4bca-80e2-566d4a135c47": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients. bergeyella is a genus of aerobic, gram-negative, rod shaped bacterium assigned to the phylum bacteroidetes and the family flavobacteriaceae."
    },
    "2792a2f8-898b-4aee-a617-df468f3a1eaf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary clinical trial are administered single medication for the entire study duration."
    },
    "56ab098d-56f4-401e-a173-a0c99cd8efd0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "both the primary clinical trial and the secondary clinical trial would accept a 32 year old patient diagnosed with stage iii breast cancer who exhibits an absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bl, a platelet count of 79000/\u2248\u00ed\u00ac\u222bl, a hemoglobin concentration of 90 g/l, and a life expectancy that surpasses 8 months."
    },
    "a86b695b-6bfb-4c1f-982c-2e10c1b392ae": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "one patient or more who were administered with gtx-024 1mg in the primary clinical trial saw an increase of more than 10 kilos in lean body mass."
    },
    "be30d480-b4d8-4768-8244-3a3d267418d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary clinical trial implements identical criteria for participant inclusion or exclusion, while the primary clinical trial delineates two separate inclusion standards for age groups 18-50 and 50+ respectively."
    },
    "55c933c1-1de0-4a15-9a17-e1216cb84b4b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "Candidates for the primary trial and the secondary trial have to meet a baseline performance status, each trial is using a different performance status scoring system. symptom interference with life score 10 is a subjective score of 10 on a scale that ranges from 0: did not interfere to 10: interfered completely."
    },
    "c2aea351-6ce5-4d26-9ba5-2632c6367b93": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "at least one patient in the primary trial suffered several different adverse events"
    },
    "8203056c-37a1-4fbf-a3cf-ddf28608d1ad": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial. lip infection, ctcae is a disorder characterized by an infectious process involving the lips."
    },
    "05f34052-08b6-4b98-91d3-326b4f77844c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "only topical treatments will be administered to the patients in the primary clinical trial."
    },
    "b586fc1f-656e-477b-89d5-84aa4cb55814": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "Aes were not recorded for the primary trial or the secondary trial. staff not available is a staff member is or was not available."
    },
    "dcad163d-b572-4dcc-a052-8bfb81f05ad5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "individuals part of the primary clinical trial receive a lower quantity of drug dosage compared to those participating in the secondary clinical trial."
    },
    "db52c7f4-cfb8-40d2-83f2-3514cb04794b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "cohort 1 patients in the primary clinical trial enjoyed a primarily favorable prognosis, reflecting the same trend in cohort 2."
    },
    "0f434232-d1a2-4d35-a49c-dd52c8353b9f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the majority of patients in the primary trial experienced complete response by month 24."
    },
    "0ab8abd1-3e9e-4c51-95c3-6a1114180100": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "seem to get full quickly is a question about whether an individual gets full quickly when they eat. Patients with a breast tumor 0.2-0.8 cm in diameter, with confirmed HR positive and her2 negative status are eligible for both the primary trial and the secondary trial."
    },
    "20a9c28d-88d5-4cd8-b346-19a1123ede25": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "all the patients in the primary clinical trial see no symptoms of increased pleural effusion or rapid disease progression"
    },
    "84166f85-0a62-47fd-8dfa-a01dd778c748": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00843167",
        "Secondary_id": "NCT02239601",
        "Statement": "malignant oropharyngeal neoplasm is a primary or metastatic malignant neoplasm that affects the oropharynx. the secondary trial uses pain as a measure of effectiveness for Physical Therapy, whereas the primary trial studies the effect of Sulforaphane Supplements on Isothiocyanate concentration in Urine."
    },
    "8a79949b-06e3-4943-a63d-248e1a432a7b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "unlimited enrolment is available for the primary clinical trial, targeting patients with early stage colorectal cancer without kras or braf mutations."
    },
    "07f85ee2-4e95-4648-a492-4011837ddc7f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the primary clinical trial has disclosed findings for the lbh589 and lapatinib group."
    },
    "a680a9d1-387f-48e3-8e30-01b306c0b964": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "Any patients with Documented allergy to cephalosporin or trimethoprim/sulfamethoxazole will not be eligible for the secondary trial and documented allergy to levofloxacin or celecoxib will also result in exclusion from the primary trial. non-neoplastic esophageal disorder is a non-neoplastic disorder that affects the esophagus. representative examples include infections, ulcers, and gastroesophageal reflux disease."
    },
    "44c3f65f-6b0d-401d-9aad-b323d7511b1c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Two IM injections of LD V935, at the same point in the cycle. 17q11.2 is a chromosome band present on 17q"
    },
    "edb8f244-cc5e-4cc5-b473-3b93f8640e65": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial consisted of numerous test groups with the absence of a placebo group, while two test groups were absent in the secondary trial which had two control groups."
    },
    "edd1533a-dc7c-441d-adcd-f8b020a4fdd3": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "all participants in the primary clinical trial, regardless of their cohort, are required to view the educational dvd as part of the intervention"
    },
    "f0278adc-ef45-43ab-b957-d26918e3a5e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "utilization of gabapentin or pregabalin in the past will dismiss the option of partaking in the secondary clinical trial, but the primary clinical trial will not impose this restriction."
    },
    "a108f3f0-f18c-4bb3-87f1-5a1eee525f71": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "adverse events, spanning a variety of types, were evenly distributed among patients across multiple cohorts in the primary clinical trial"
    },
    "7814620b-23de-463b-8fd1-efdf51ce26b3": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial"
    },
    "e1040054-0fe6-4c92-be82-f2b5b79282a5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered."
    },
    "4d18c0c9-1317-4c04-9b86-f6e7e8906f5e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "smoked cigarettes since last visit to this clinic is a question about whether an individual smoked cigarettes since their last visit to this clinic. the primary trial and the secondary trial report on the MTD of different interventions."
    },
    "0a44470c-bf27-4795-aa25-f30a58771625": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "nervous system part is any component of the entire nerve apparatus, including the brain, spinal cord, spinal nerves, autonomic ganglia, and plexuses. Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average."
    },
    "79385974-de52-4d05-b6b1-dc1086d484d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "We cannot compare the adverse events in the primary trial and the secondary trial, as they do not appear to have been recorded for the primary trial. hypothyroidism is abnormally low levels of thyroid hormone."
    },
    "1b4c8f0a-2d3e-40d3-b26a-426a4f32cb86": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "grade 1 uveitis, ctcae is anterior uveitis with trace cells Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period ."
    },
    "bfc4e387-9404-498e-903b-5ca9f88dcc3b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 20000 micrograms po daily for 7 days prior to surgery and for 14 days after breast cancer surgery reduces ki67 expression in tumors by 0.4 on average."
    },
    "59f54656-5444-4b6d-a011-2921eb624626": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "the primary clinical trial's intervention section does not provide a clear outline of the treatment cycle or radiation dose details."
    },
    "41219409-bd82-4df0-82aa-d72fc4aec1fd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. megacystis - megaureter is a condition characterized by a large capacity, thin-walled bladder and megaureter(s)."
    },
    "ae134e5a-97f7-4c42-9135-ea44d3d45939": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list. vestibulocochlear nerve disorder is a non-neoplastic or neoplastic disorder affecting the acoustic nerve."
    },
    "04d76027-45a0-46e3-9308-acc4f8c02a73": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial measures the stage of chronic kidney disease using glomerular filtration rate (gfr), on the other hand, the secondary trial marks improvement from baseline at 12 months using cardiopulmonary exercise testing (cpet)"
    },
    "0919109a-9ee1-4fa0-b612-a9902379e48d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the primary clinical trial saw the use of multiple drugs as interventions, however the route of administration remains the same."
    },
    "57bf60c1-b440-4fa1-854e-91d2947360e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 300% the number of hepatotoxicity cases as there were cases of hypertension and pancreatectomy"
    },
    "4db16d69-4db6-410a-a48a-215903320e43": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "medical device time-to-event dataset is a dataset containing data that is used for medical device time-to-event analyses. Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for the primary trial."
    },
    "a95eba72-3c28-4c9b-a79f-011f1578907c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "past treatment with gabapentin or herceptin within the last three months, is necessary for inclusion in the secondary trial, but will result in exclusion from the primary trial"
    },
    "9022a69a-98fa-45ab-8a03-3a6e81102d03": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "patients with tumors exhibiting ccnd1 amplification, cdk4/6 mutation, or ccnd2 amplification are not eligible for the primary clinical trial."
    },
    "18c281a1-43bd-47f5-9534-feddfcf0a282": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "Both cohorts of the primary trial receive the same dosage of Docetaxel, Doxorubicin and Cyclophosphamide throughout the trial at the same frequency, however cohort 2 includes three extra treatment cycles of these particular drugs"
    },
    "ce8a4f39-efff-4fd3-b850-4fc5c30270ef": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections."
    },
    "eca608f4-6f65-4fc9-96cb-d1bb45749048": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "several of the patients in the primary trial experienced the no pain whatsoever during the 1680 hours of the study."
    },
    "c69a6bb3-93f7-4597-9359-64fd2541b1aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the primary clinical trial records and reports the number of participants in each subdivision."
    },
    "62de4057-c709-4110-9986-642428c1d534": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "in the primary clinical trial, the placebo and trabectedin are delivered identically, but on separate days."
    },
    "5ee999ab-5129-4ea2-a988-b2a223d82acd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, the frequency and duration of administration are identical for both the placebo and the memantine interventions."
    },
    "0c72a56a-de46-498d-8706-04c1283bea04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "cohort a of the primary clinical trial is administered a single infusion of hd v934"
    },
    "eb853544-9c67-43a4-bbfa-c5e35dec2a33": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "atrial myxoma is a cardiac myxoma arising from the atrium. The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days."
    },
    "bd18948b-345b-48be-a1a0-45c4ee688747": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 500ng/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "04d8d180-a06f-4eef-9c67-b51babbd8f10": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "percentage food eaten score 30 is a subjective score of 30% on a scale that ranges from 0%: none to 100%: all of my food. The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial."
    },
    "3958b171-1f79-4dae-958a-be87bb3b44c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "participants in the primary clinical trial are required to take more than seven distinct drug types and undergo a surgical procedure, while those in the secondary clinical trial only need to take two different medications and are not required to have surgery"
    },
    "3fa1e0aa-7c62-4a1e-bd7d-452fa87a7baf": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "splitting pain is an intense sensation of discomfort or distress that feels like being cut apart. Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial."
    },
    "100aa305-3df6-42ff-b3ba-68bed68e39b0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the main focus of the primary trial is on the mean sleep duration of its patients, in contrast to the secondary trial that is investigating the number of participants who experience treatment-associated issues."
    },
    "4ecc7382-526a-4bf5-9c17-92dc78446ea0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "the primary clinical trial and the secondary clinical trial do not have any common inclusion or exclusion criteria."
    },
    "ac4e121f-e159-49e0-84cb-83218232ebbb": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "light cell is a cell located in the collecting tube of the nephron.. Patients can not have a history of abdominal fistula, gastrointestinal perforation,Postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial."
    },
    "98b0c6c3-73c0-40d9-95d7-48e5340aa2f8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial and secondary trial both uses the same dose of lenalidomide and lapatinib respectively in intervention 1, with equal periods for the intervention."
    },
    "452458d2-6372-4ac9-a7f9-0be77cc28eea": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "the primary clinical trial involved 13 participants who were administered the globo-h-gm2-lewis-y-muc1-32(aa)-stn(c)-tf(c)-tn(c)-klh conjugate vaccine"
    },
    "70c3a676-7000-465c-9d6d-3c53fbf185c0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention timeline in the secondary clinical trial is exactly identical as in the primary clinical trial."
    },
    "fe6abe4b-e77b-4ab7-a52c-3157a90f7a2d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or 19 are eligible for the secondary trial, but will need to wait 1-2 years to be eligible for the primary trial. infraorder is a taxonomic category of related organisms ranking below a suborder and above a family."
    },
    "b32a43a7-cac0-4434-bdb2-4c4d8b26d947": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "recovering alcoholics who currently abstain from drinking can participate in the primary clinical trial, but for the secondary clinical trial, regular drinking is a requirement."
    },
    "eb088d03-7fdc-48bd-9175-0e7a9cfc7b9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "100.0% of cohort 1 of the primary trial suffered some kind of adverse event"
    },
    "0a068f7d-0892-428d-889b-153d579cba78": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "patients with a diagnosis of breast cancer could be suitable for all study groups in both the primary clinical trial and the secondary clinical trial."
    },
    "12586895-bb1c-4772-ab01-94163d0393ab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "the most common adverse event in the secondary trial was anaemia, affecting more than 99.9% of patients, there were no recorded aes in the primary trial."
    },
    "cc321a3c-a09d-4354-8601-d665f428a831": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. cgi questionnaire question is a question associated with the cgi questionnaire."
    },
    "9289ca32-0fa0-44ae-8cc0-49510f2fed23": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00496860",
        "Statement": "in the primary clinical trial, cohort 1 receives less than half the dose of alt-801 that cohort 2 does"
    },
    "c0915bad-2882-4f25-a6d5-5f2b71bc8850": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "no restrictions are placed on the hepatic function of individuals participating in the primary clinical trial"
    },
    "396eb2aa-c85e-4477-bdf5-a0926499350a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient who underwent an organ transplant less than four weeks ago may participate in the primary clinical trial but is excluded from the secondary clinical trial"
    },
    "fbe81247-571c-43a1-a2eb-439e579cf229": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "laryngeal fistula, ctcae is a disorder characterized by an abnormal communication between the larynx and another organ or anatomic site. There are several cases of swelling, hypothermia and confusion recorded in the Aes of the primary trial and the secondary trial."
    },
    "80cb39bd-c370-4e7f-8f19-74725fed8805": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "the primary trial is found to have fewer total adverse events as compared to the secondary trial, while at the same time reporting lower instances of cardiac-ischemia/infarction than the secondary trial."
    },
    "4c7b87a1-ac43-4d8c-b6cf-2c95f3a3a074": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "intervention 2 of the primary clinical trial uses higher doses of radioactive tc99m sulfur colloid than intervention 1."
    },
    "d9444db3-e6d5-43d4-ba21-b934f8e0f77e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "microscopic findings group identifier is a character or string that represents a microscopic findings group. the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation."
    },
    "98c16e6f-17a1-436f-833f-4f69e14f52db": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "both acupuncture and testosterone cream showed similar effectiveness in treating lymphedema in the primary trial, with no apparent advantage of one over the other."
    },
    "b5976fd8-b3cf-4879-bead-2410a6e1f1f1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "43 participants from the ketorolac 30 mg group of the primary trial experienced recurrence-free survival compared to the 20 from the nacl 0.9% 3.86ml group"
    },
    "956a23c9-f76f-4492-9f00-acdbaf6ac083": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial."
    },
    "c20768c0-36c2-44ff-9d4f-36d34e02c1a2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "hepatitis b virus surface antigen negative is an indication that the hepatitis b virus surface protein antigen has not been detected in a sample.  intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously."
    },
    "86cc51ee-ff9e-4396-9c2a-85feaa52c215": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report the severity of delayed nausea on a scale of 1-20, and the secondary trial measures the change from baseline to 12 weeks in bone mineral density (bmd) of the lumbar spine"
    },
    "45e2f6cb-6ab2-424e-bd21-c2086ab6def3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the bevacizumab + capecitabine cohort in the primary clinical trial demonstrated a higher rate of disease progression or death than the bevacizumab only cohort."
    },
    "072b76ba-9fd5-4313-b484-c353f61ecca9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "representation in either the primary clinical trial or the secondary clinical trial is not open to cancer patients diagnosed with fibromyalgia, thalasemic syndromes, or anemia."
    },
    "455d059c-c3c4-4a09-be0d-a14b9568a0d2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "cohort 1 of the primary trial is administered PR negative, ER negative and HER- whereas cohort 2 recieves HER2+"
    },
    "02cf528a-17da-4ea6-a65e-7a9efe2cf3cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "both the primary and secondary trials used multiple test groups without any placebo group in either case."
    },
    "2aa37ee1-47f4-4ee2-a2d5-b11181a89e78": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "Cohort A and B of the primary trial are administered the same Three electroporation injections of LD V934. preterm birth complication is a complication related to a premature birth that occurs to a baby born prior to 37 weeks gestation."
    },
    "eb3891b2-5320-4b6e-9a9f-08c7aa8bdd29": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "a diagnosis indicating 2-3 cerebral metastases within the brainstem will cause the patient to be ineligible for the secondary clinical trial, yet this diagnosis may still qualify patients for the primary clinical trial."
    },
    "6a3053ef-4495-4c18-9da7-68cf5ed254e0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "Every patient in the primary trial is receives a dose of 100 to 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy"
    },
    "85b158a4-1754-47b2-91b4-5165c38d270c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the unit of measure reported in the primary clinical trial differs from that used in the secondary clinical trial."
    },
    "58acb205-1f9d-4dd2-9405-720b28f8581f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the patients in the primary clinical trial receive a greater dosage of radiation treatment than those involved in the secondary clinical trial"
    },
    "9b230310-d16f-47a4-bf3b-341d2de6f9c4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary clinical trial is focused on the use of external treatments, and the secondary trial is centered around the study of inhalable ones."
    },
    "7774f54f-4f08-4c6d-8fa4-af4979ba5bac": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 18cm in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "cbb4daf6-f35a-4832-b071-a17ffbe86e13": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "several adverse events occurred during the primary clinical trial and skin infections in the secondary clinical trial affected the majority of patients"
    },
    "d3302027-c157-4d58-8653-cf5053658fad": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "did you cough up blood is a question about whether an individual coughed up blood. Both the primary trial cohorts receive pre-operative Dexamethasone."
    },
    "32cd31d2-605b-4419-89a7-a6881bb792dd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation. alpha thalassemia is a genetic hematologic disorder characterized by partial or complete absence of the alpha globin chains of the heme molecule."
    },
    "a0294da5-368d-4341-9084-1d42b995be34": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "no adverse events were documented for cohort 1 patients in the primary clinical trial"
    },
    "3f0e9340-88df-433f-8bdb-e32523b86a86": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "a dosage of zoledronic acid 12 times greater than the dosage of denosumab is used in the first intervention of the primary clinical trial, as compared to the first intervention in the secondary clinical trial."
    },
    "7714e6f7-814a-4088-9116-60f5ceef4336": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient recuperating from an organ transplant within the last month and still being bedridden would be disqualified from the primary clinical trial but might qualify for the secondary clinical trial"
    },
    "af1a2e8d-2b8e-4690-b32c-9d044d9aa15f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "ie rhabdomyosarcoma regimen is a chemotherapy regimen consisting of etoposide and ifosfamide that may be used in the treatment of rhabdomyosarcoma. Both the primary trial study groups will undergo the same 18F-FDG and 18F-FPPRGD2 positron emission tomography / computed tomography (PET/CT) imaging procedures, with the exception that cohort 1 will receive a slightly higher dose of 18F-FPPRGD2."
    },
    "6cc1c5e4-b45a-486f-be8d-1c49abc327c9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "in the secondary clinical trial, participants are administered lower doses of drugs than the participants in the primary clinical trial"
    },
    "c39031be-e4dd-4943-a3fe-97164ac7a5e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "in the secondary clinical trial, the intervention involves proton-beam therapy combined with capecitabine."
    },
    "6d5ac8ed-53a0-4b48-a521-7a9b53e82017": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "although the interventions in the primary clinical trial and the secondary clinical trial both involve intravenous injections, there is a considerable distinction in the drugs, dosages, and frequency of administration used."
    },
    "292a2905-b407-4068-8c2e-e6d596e494ca": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "primary clinical trial does not allow candidates to engage in cbt-based treatments, while the secondary clinical trial might still consider them as potential candidates."
    },
    "ef0cf72d-6cc3-4589-8016-e96db1b9f33a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "not a single kind of adverse event registered in the primary clinical trial influenced more than a quarter of the patient group"
    },
    "13fb11f0-9307-4576-887c-75896dd7bfd1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "Nobody taking part in the primary trial suffered a UTI. mediastinal sarcoma is a rare sarcoma that arises from the mediastinum.  examples include liposarcoma, leiomyosarcoma, and angiosarcoma."
    },
    "97a8ede9-e46f-4b17-be7d-b05e9bd2f86e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01013740",
        "Secondary_id": "NCT00978250",
        "Statement": "patients enrolled in both the primary and secondary trial remained free from tumour lysis syndrome"
    },
    "50dae016-a6b4-4ee6-a66a-bf35587cd835": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "On average patients from the primary trial survive over 2 years, however at least one patient from both cohorts died in under 2 years."
    },
    "10acc981-00c5-4c74-b2ce-58bc69406955": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "the primary clinical trial has a multitude of adverse events recorded for its patient cohort."
    },
    "e2551c0f-9b6a-4d0c-9f11-b5e301d7ff3c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "in the primary clinical trial, numerous psychiatric side effects were observed, such as an eating disorder and schizophrenia"
    },
    "d9dff3a0-537b-4297-bc58-766d366ba5a0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "97% of patients in the primary trial did not experience any Adverse Events. bilateral malignant neoplasm is a malignant neoplasm that affects both sides of an organ in a simultaneous or non-simultaneous manner."
    },
    "25b01c06-612c-4cfb-b30b-50ebe4d98750": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare."
    },
    "bd7ca920-80f7-4bf8-a09c-3f619056e700": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "there were minimal adverse events observed in the secondary clinical trial as compared to the primary clinical trial.'"
    },
    "e547ee04-f454-4ec3-b2fb-9ea04c97bdab": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "numerous adverse events were noted in the primary clinical trial and over half of the patients in the secondary clinical trial were affected by skin infections"
    },
    "a55a8c7f-7e1a-4bd4-8f2b-9222002f5d27": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the drugs tested in the primary clinical trial and the secondary clinical trial are not the same"
    },
    "07687788-b44f-4f2a-9117-6b55cbdc3f7a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the interventions in both the primary trial and secondary trial leverage the same medication for treatment."
    },
    "bad8129b-64a4-4dfc-bb88-8bcea4fe2dc4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "cohort 2 of the primary clinical trial experienced significantly fewer incidents of neutropenia compared to cohort 1 of the secondary clinical trial, despite receiving larger doses of empegfilgrastim."
    },
    "ea1d804d-bac9-4ebd-a6bd-0705c988927f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or any description of the treatment"
    },
    "8b6e90d0-d3e2-41db-9d70-ce8b216f3795": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "the primary clinical trial is open to african-american participants, given that they are residing in texas throughout the study period."
    },
    "b4db304d-9445-44e0-9f0a-a4df38c1301b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group. covid-19-associated acute hemorrhagic necrotizing encephalitis is acute hemorrhagic necrotizing encephalitis caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2)."
    },
    "993a3b60-def6-421c-a8a5-964062336a2c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "clinical status ordinal scale is a scale designed to assess a patient's clinical status at enrollment, prior to any on-study therapy. Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average."
    },
    "7128da72-a0ed-48cb-b167-c2b6176faa71": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "patients in the primary clinical trial that received paclitaxel infusions experienced more severe symptoms than those who did not receive paclitaxel infusions."
    },
    "a7c5f410-1001-4c4c-884d-cdbb9e8d69e4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01252290",
        "Statement": "less than 0.05 of patients in the primary trial suffered aes"
    },
    "40d84c7b-e126-4d6f-9588-eb9c385ca716": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "Group 2 of the primary trial recieves 0.5ug/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "88a40578-17e1-499b-8b7b-10a85e2c3d88": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "vital signs sequence number is an identifier that describes the relative position of vital signs data within a series. Patients with a TNBC tumor of 100mm in diameter, are eligible for both the primary trial and the secondary trial."
    },
    "af1e26a0-09d7-408f-89ec-be5bf4bfc88c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "in the primary clinical trial, patients in the fast, shallow respiration group experienced fewer hot flashes per day on average than those in the paced respiration intervention group."
    },
    "7dbe6e8e-5971-41e2-bc70-46dc3cb3cd5c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there are 0.0 shared inclusion/exclusion criteria between the secondary trial and the primary trial."
    },
    "41756298-3326-499e-99f5-f34bcf718cbe": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "Any cancer patient diagnosed with either fibromyalgia, thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial. specify kit exons assessed is a request to enter the kit exons assessed for mutations in this section of the form."
    },
    "731e38ac-1da8-4b94-a501-606a49570767": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "cyp3a4 polymorphism positive is an indication that polymorphism of the cyp3a4 gene has been detected in a sample. African-american patients can participate in the primary trial, but they must reside in the state of texas for the duration of the study."
    },
    "9324259a-88b9-441b-a6ee-ec7f6f5914aa": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "colorectal adenoma with moderate dysplasia is an adenoma that arises from the colon or rectum.  it is characterized by the presence of moderate epithelial dysplasia. The patient with the longest PFS in the primary trial was in cohort 1, and he survived 3.5 months without disease progression or death ."
    },
    "66ff33e2-be79-4e47-a3f9-68a57f5f377b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "nickel is an element with atomic symbol ni, atomic number 28, and atomic weight 58.69. the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy."
    },
    "ffb8a143-9dd7-4e61-8967-b0744c2dfa49": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 18 months in bone mineral density (bmd) of the lumbar spine"
    },
    "02365d25-1a64-4415-aae7-c0254d234fa9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan. paraguay is a country in central south america, northeast of argentina."
    },
    "2c618027-fde9-4d2f-8552-bc071708d627": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "over 10 fatalities were documented as adverse events in both the primary clinical trial and the secondary clinical trial."
    },
    "70c0fbc1-8eb8-4634-a595-898784718d09": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the administration of zd1839 is the sole intervention for the primary clinical trial, whereas the secondary clinical trial commands a multi-drug therapy which includes zoledronic acid, samarium-153, and pegfilgrastim."
    },
    "1605cfcf-22e5-4a48-a89a-cd7b44e3109f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "deafness is an inherited or acquired condition characterized by the inability to hear in one or both ears. CBT based treatments are prohibited for the primary trial candidates, however they may still be eligible for the secondary trial."
    },
    "7d3e5dce-744f-4f7b-81f8-085c7ce2bee0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "all participants in the primary clinical trial showed a drop in cognitive abilities, especially those in the ovarian function suppression group"
    },
    "11d451c7-7354-44f6-95b4-2b794a72fdbb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention in the secondary trial last 300% longer than the intervention detailed in the primary trial."
    },
    "292a7346-b4f6-4fc1-92a7-80297532eeff": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "both cohorts 1 and 2 in the primary clinical trial adhere to the same instruction cd for paced breathing, however, the practice sessions are doubled for cohort 2."
    },
    "f8858128-03f8-4721-a0f5-5f3fce7ab1c4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "those having assessable bilateral breast cancer are qualified to join the primary clinical trial"
    },
    "2c4acb3d-7009-4a19-ac0e-703a96740738": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention"
    },
    "881871fa-1546-46da-acab-c8b67ef7e5c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients with a low potassium count are ineligible for the primary clinical trial, yet may qualify for the secondary clinical trial"
    },
    "f6dee97d-0025-4837-97a5-dc7748b859a0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "all the participants of cohort 1 and cohort 2 in the primary clinical trial are prescribed a uniform dosage of 5 mg/kg of bevacizumab"
    },
    "d2885dd5-eb3f-4dcd-9980-c02d3c1c6924": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "one shingles case was reported in the secondary clinical trial, specifically in group 2. however, both the primary clinical trial and group 1 of the secondary trial recorded no instances of shingles."
    },
    "d83f5fcf-2a52-4612-b548-060ece7749f9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "2p16.3 is a chromosome band present on 2p the primary trial and the secondary trial both administer cyclophosphamide, Paclitaxel and pegfilgrastim to their patient cohorts."
    },
    "e945ad07-11b2-48f7-8022-40f0af7883af": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "none of the participants, neither in the primary nor in the secondary trial, suffered an acute myocardial infarction."
    },
    "5e094086-297e-44c7-9119-aa451e326e8c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 18 or older are eligible for the secondary trial and the primary trial. high inspiratory pressure alarm device is a device designed to signal the occurrence of a high pressure event associated with a mechanical ventilation device."
    },
    "eba82ab1-0348-4090-81e6-fcb63ac45537": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 730 days, however at least one patient from both cohorts died in under 730 days."
    },
    "bb5873a3-4c28-49f6-9f70-f3f1d8ac7db2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 in the primary trial receive placebo, and patients in the secondary trial cohorts get 0.5ug/kg of myalgias(5ml)."
    },
    "e92e432c-9e5c-451c-9bb2-ff89a618126c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients with hyperkalemia, are disqualified from both the primary and the secondary clinical trials, while hypokalemic patients could participate in both trials."
    },
    "328417f9-8f45-4114-82d7-9396b6bc578e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive one single injection on day 8 of the study."
    },
    "9f978634-637c-472f-a588-6f4bb2fb121f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "Women suffering from both claustrophobia and IBS or not eligible for either the primary trial or the secondary trial."
    },
    "ee2fe2ab-dc6f-434e-b0dd-1deee5fb3d31": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "Participants must be resistant to AI therapy to participate in the primary trial, but this is not necessary to be included in the secondary trial"
    },
    "de3effdb-0854-48a8-b66c-b61378ec7a6f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "primary clinical trial patients are administered with larger amounts of radiation therapy compared to the participants of the secondary clinical trial"
    },
    "f7de4d97-31e4-48e0-ab1a-1e3d8a152e8b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "Most patients in the secondary trial and the primary trial did not suffer any adverse events"
    },
    "6247182c-7b14-46b7-9452-a4072ed79a7b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "dialpack dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a reusable circular compact package. There are no unexpected deaths or Hospitalizations that occurred in the primary trial or the secondary trial."
    },
    "c01204e3-a0fd-4153-a27d-d17c0bb4773b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "many patients in the first cohort of the primary clinical trial did not adhere to their screening schedules following the intervention, independent of their cancer type."
    },
    "0025afa1-ef06-42c9-9a6d-0f2aaf94c403": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "bone marrow collection is any process that harvests bone marrow for clinical or manufacturing purposes. the primary trial reports the total Number of Participants Analyzed in the study, but does not report the number of participants in each cohort."
    },
    "d3630897-ec5d-4c22-b2cd-5a8355dfdd88": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive, or HER2/neu negative are eligible for both the secondary trial and the primary trial. tdi clinical classification question is a question associated with the tdi questionnaire."
    },
    "66362fd1-8e4f-49ad-9098-a67f65cb91c2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "5% of the primary trial participants with her2- primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab developed imagable her2+ metastases"
    },
    "e65ecb06-ff14-432b-826f-9bd26c456215": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "cyclophosphamide, paclitaxel, and pegfilgrastim are not part of the treatment protocols in either the primary clinical trial or the secondary clinical trial"
    },
    "205a0d18-ba5e-4efd-b403-557bf188daa2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "under 50% of the primary clinical trial's participants experienced a decrease in circulating tumor cells after receiving high-dose chemotherapy along with purged autologous stem cell products."
    },
    "bee98681-7738-44a5-b437-0c172bdd3eeb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "oral administration of interventions is utilized by both the primary and the secondary clinical trials."
    },
    "0a0778f4-c085-45fe-a085-e079256d634b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary clinical trial recorded multiple adverse events."
    },
    "1e1830e7-f7bd-4bf4-99c4-c36f6da015e3": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "5 patients in the primary trial suffered 3 or more adverse events. intestinal route of administration is administration of a medicinal product to the intestine (duodenum, jejunum, ileum and colon) by means of an appropriate device."
    },
    "9a78f293-8ab9-4b2d-9224-3f4ae8fc45d5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "participants with quantifiable bilateral breast cancer are suitable for the primary clinical trial"
    },
    "cf33b6d5-f59c-4b24-be84-4aeba15f6c5e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "having the ability to offer written informed consent is the only mutual inclusion/exclusion condition in both the primary and secondary clinical trials."
    },
    "666ca16f-864e-48b1-9e5e-543759d50b4a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00146172",
        "Secondary_id": "NCT00262834",
        "Statement": "candidates who are completely independent and physically active, engaged in light work activities for long hours are eligible for both primary clinical trial and secondary clinical trial"
    },
    "282c18a2-64b1-47cf-8563-db8db40dadb6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "Patients in cohort 1 and 2 of the primary trial receive the same doses of radiation therapy, and all undergo a SPECT scan."
    },
    "60a1579f-8115-4fec-bdba-fd3031f64e19": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "unresectable gallbladder carcinoma is a carcinoma that arises from the gallbladder and it is not amenable to surgical resection. There are more cases of Biliary colic and Clostridium difficile colitis in the secondary trial than in the primary trial."
    },
    "3ad0bf0d-7929-4d29-9629-4fea3e6c8fc5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "vinblastine and doxorubicin are routinely used in the primary clinical trial and the agent for the secondary clinical trial remains undisclosed."
    },
    "55b2acbc-30a6-43ef-bca6-0e7a5b3f6a8f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "various techniques are used to administer the interventions in the primary clinical trial."
    },
    "8920d439-7233-461b-a343-3c264f0918de": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "Not a single one of the participants in group 1 of the primary trial were found to have lesions, and more than 95% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation. structured title data type is a data type comprised of structured text that comprises a title."
    },
    "54c9c0a9-c38d-46b1-a96b-1335daaaef85": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "the primary trial requires that intervention 1 be administered transdermally, and in the secondary trial, all intervention drugs are delivered intramuscularly."
    },
    "91e585c8-503f-4253-b749-80caa8ebc3e1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "type 2 renal papillary adenoma is a renal papillary adenoma which is characterized by eosinophilic cells. Ascites was more common for patients in the primary trial, and Pneumocystis jirovecii pneumonia was more common in the secondary trial."
    },
    "e6954b69-b723-4a51-8a5b-6e7461028b60": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "get ringing or buzzing in ears is a question about whether an individual gets or has gotten a ringing or buzzing in their ears. In the primary trial the placebo intervention and the Memantine intervention are administered at the same frequency for the same duration of time."
    },
    "ce29883b-654b-4124-ac60-40ff13cb9f3e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "any patients with a well-documented allergy to cefuroxime or nitrofurantoin can participate in both the primary and secondary trials."
    },
    "1e5ed892-07f9-409a-bc45-edd43978e9b1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention. have not received treatment is a response indicating that an individual has not been treated for cancer."
    },
    "82582964-823a-4765-b22c-201660fcca08": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 30 or 35 are eligible for the secondary trial, but will need to wait 5-6 years to be eligible for the primary trial"
    },
    "ba5d4784-f20f-4d77-b133-ab700624da3e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the primary trial presented fewer cases of intestinal perforation than the secondary trial"
    },
    "bfb34bfd-74f8-4f11-b28b-643fe6e79d10": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the primary and secondary trials share matching outcome measures in their results"
    },
    "d9a5cbf6-51ae-4c80-a222-534e7507c7f8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary clinical trial, the number of cases of hepatotoxicity was less than the cases of hypertension and pancreatectomy"
    },
    "38c5a69a-ad2f-4f2c-b234-74c93e8f6c72": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "only the first cohort participating in the primary clinical trial will be exposed to the educational dvd as part of the intervention"
    },
    "d478ad25-2445-48f1-9308-2d6025dfead2": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "acquired cytomegaloviral infection is an infection with the cytomegalovirus that is not present from birth. at least one patient treated with GTx-024 1mg in the primary trial gained over 10 kilos of Lean body Mass."
    },
    "18c8db1c-2d31-481b-923d-0415861bd6d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "the primary clinical trial and the secondary clinical trial are open to patients with a lung tumor that is 0.9-3.2 cm in diameter, and have a confirmed kras mutation"
    },
    "f6bfaa2d-0171-4bbe-a65c-0e3b217ac61f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736. spinal chordoma is a chordoma that arises from the spine."
    },
    "e6577f53-5752-4fd5-bcfb-2d4f03b2ce60": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "no patients treated with gtx-024 1mg in the primary clinical trial gained lean body mass over a 4 month period"
    },
    "be07b8e7-1858-4182-b37f-56681f56c273": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00319748",
        "Secondary_id": "NCT01194440",
        "Statement": "the ki67 expression in tumors is not assessed in either the primary or secondary clinical trial."
    },
    "b995d047-8aaf-48fd-9fd7-ebed843b0877": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "in both the primary clinical trial and the secondary clinical trial, a single death was noted in the adverse events."
    },
    "616edea0-8cb7-44c3-a866-af72680d31d3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "the secondary clinical trial requires that patients take a daily dosage of florbetaben (18f), the primary clinical trial, however, demands no medication intake"
    },
    "06c2d2d2-93dc-44dd-a729-a11a4397db44": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "between interventions 1 and 2 in the primary clinical trial, the only variances exist in the durva dosage; as cohort 1 receives 0.7mg less in their monthly injections than cohort 2."
    },
    "e7f5c09e-9d3d-4081-a926-9f89647a0e3b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "patients, regardless of their gender, having a solid tumor that is either locally advanced or metastatic may participate in both phases of the primary clinical trial."
    },
    "496667f2-e493-4b4e-a257-7b8de3833e8b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days."
    },
    "8084d30e-d99a-4b02-88e2-dd8194ef538f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "few participants in the primary and secondary clinical trials experienced adverse incidents."
    },
    "3ebd71b1-9b66-438a-9623-27aaf0725786": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "a patient's nationality, ethnicity, mental conditions, or gender are not factors considered when determining eligibility for the primary and secondary clinical trials"
    },
    "b95b7438-ec16-4d4d-826d-5891e7982b36": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial."
    },
    "62dbb697-f709-40c2-a4b9-8ed098473bde": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "male patients with neuroblastoma over the age of 60 can participate in the primary clinical trial, regardless of race or ethnic origin. however, for the secondary clinical trial, they must have brca1+ ovarian cancer."
    },
    "06ec7728-efe1-408c-afa8-a6b679a9cd57": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "details regarding the mode of administration, dosage, or cycle are absent in the intervention sector of the primary clinical trial."
    },
    "f9e4988c-a325-40bc-8220-e7d0c404fd37": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "None of the individual adverse event types recorded in the primary trial affected more than a quarter of the patient cohort"
    },
    "543c8639-a266-42af-9896-05a77d822c79": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "notable disparities were evident in the assessment of groups in the primary clinical trial, on the contrary, uniform results were recorded between the reflexology group and control group in the secondary clinical trial."
    },
    "1cebe988-ac21-4b72-a652-36778fb2cccf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "during the primary clinical trial, patients not receiving topical cryotherapy suffered worse symptoms than the group who underwent the procedure."
    },
    "67f1754a-420c-4605-a41d-784c4d1e77b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial."
    },
    "33668f2b-29b5-49e2-a0ee-4718913ea856": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "the primary clinical trial prescribes no medication for the duration of the study."
    },
    "0ebc75cd-f87b-46a6-aaa3-9b511cdb90ae": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "Patients with a histologically/cytologically confirmed diagnosis of a resectable Non-small cell lung breast cancer or Small cell lung cancer are eligible for the primary trial. specify tumor location is a request to specify the anatomic site of the tumor."
    },
    "40fc3a97-0a5d-4f19-ba94-7c4668d0538d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial"
    },
    "b0bedf1c-a1ed-4bf5-9ad1-ac22f0681d03": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00828516",
        "Secondary_id": "NCT00843167",
        "Statement": "is value for gdc property is an association that that connects a concept representing a gdc value to any associated gdc property concept(s). Neither the secondary trial or the primary trial use the Number of Participants With Treatment-emergent Aes as the outcome measurement for their studies."
    },
    "adbb33ae-2076-4850-bfd7-967119d8e169": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "neither centimeters, number of individuals, or time duration are used as units of measure in the primary or secondary clinical trial."
    },
    "ee84e692-4923-4cb8-acad-8f27f64f4b9e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "both the primary trial and the secondary clinical trial reported no adverse events in their cohorts."
    },
    "0d95a819-09cb-49a0-9ec0-76a64bc50732": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the intervention in the primary trial is given through a needle inserted into a vein, while the secondary trial involves a topical application"
    },
    "2cd6db4c-83e4-4ca5-8650-6638521a27a2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "the primary clinical trial involves patients receiving a number of injections"
    },
    "6c41e8b2-2878-44b1-bf2d-6158d8f20dda": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "telecommunication address type is a particular category of telecommunication address regarded as having particular characteristics, qualities, type of usage, and defined similarities. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly."
    },
    "0c5d58a3-a565-4b42-ae6f-24bd3be00b06": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients can not have a history of abdominal fistula, gastrointestinal perforation,postmenopausal adenocarcinoma, stroke, transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 60 years if they want to participate in the primary trial"
    },
    "1c31539a-7fd9-4e81-ae88-c0e05a34946a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer and Ovarian/ Peritoneal Cancer patients in the primary trial undergo the same intervention. adhesion g protein-coupled receptor e1 staining method is an immunohistochemical technique used to detect the presence of adhesion g protein-coupled receptor e1 in a tissue sample."
    },
    "8747d88a-efc9-42ae-ba7c-5e25c8693b34": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "pervasive pain was a common experience reported by patients throughout the full course of the primary clinical trial."
    },
    "b0a8feea-e233-4a75-992e-698a978045a5": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "substantial variations were seen in the results of the groups participating in the primary clinical trial, while a disparity was observed between the reflexology group and the control group in the secondary clinical trial."
    },
    "82d0df12-0e0b-4721-b54f-ecb6bccdc8c3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "eligibility for the primary clinical trial is determined by being a female cancer patient aged 18 or above, of any race or ethnicity and diagnosed with any type of cancer, while the secondary clinical trial specifically requires patients with brca+ breast cancer."
    },
    "81694850-fb70-4062-8dab-a52dd8083ebb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "four unique adverse events impacted patients in cohort 2 of the primary clinical trial."
    },
    "b56bc509-6ed3-4125-9587-407192b9b597": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "All Patients receiving the placebo intervention in the primary trial experienced emesis . dysuria, ctcae is a disorder characterized by painful urination."
    },
    "77b0fb73-3157-4ceb-a366-7ae4f143e2b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID. biospecimen condition is a characteristic that refers to the physical and organoleptic state of a biospecimen."
    },
    "58ce2166-b909-4442-9118-11b9163fa9b1": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 80 mg po daily for 21 days prior to surgery and for 10 days after breast cancer surgery reduces the diameter of tumors by 90% on average."
    },
    "46c9f061-408a-4845-b1ac-01b9c8eb5606": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "cohort 2 of the primary clinical trial reported more cases of palpitations, pericardial effusions, and abdominal pains than cohort 1 of the secondary clinical trial."
    },
    "7852457b-3915-431f-adbf-cdba2b736c46": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "lig4 gene mutation is a change in the nucleotide sequence of the lig4 gene. There were 0 adverse events in the primary trial and the secondary trial."
    },
    "8665ed72-5c94-4c4f-8dbc-a6950275ca98": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "those patients with a history of chemotherapy or radiotherapy within the preceding 2 weeks or those exhibiting signs of unstable angina or showing grade 2 or better neuropathy, are not eligible for the secondary clinical trial, but could remain eligible for the primary clinical trial if all applicable inclusion criteria are satisfied."
    },
    "448d6b4e-e05a-4971-9aea-cabeb8ce2c00": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "individuals suffering from bilateral non-cancerous breast lesions are eligible for the primary clinical trial."
    },
    "6add1cab-1458-4cca-a419-7bfc5acdc1cc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary clinical trial does not conduct any drug-related tests, in contrast, the secondary clinical trial carries out assessments of two varied medications."
    },
    "deff33e5-6172-4caa-940e-4ca7aaca8d80": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial recorded a greater number of adverse events in its cohort compared to the secondary trial."
    },
    "60f6302e-f888-4bc2-b689-f0620024f93e": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "in the primary clinical trial, cohort 1 experienced a higher incidence of adverse events as compared to those in cohort 2."
    },
    "56f41ab4-6a20-4593-af47-b5cab9dabdd2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "candidates for the secondary trial study group receive 6 daily subcutaneous (sc) injections, whereas the primary trial participants only receive 2 injections at the beginning of the study."
    },
    "e0b061e1-ee74-46e0-a223-de370cfffc8a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were several adverse events which occurred in more than 0.3 of participants."
    },
    "7506e58c-a44a-4410-a519-59a81686fe12": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "participants in the primary clinical trial must have responded positively to ai therapy and mirtazapine, and the same response to these treatments is required in the secondary clinical trial"
    },
    "043f8072-1e16-4e74-8ad4-50ff1786fb48": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "less than 3% of patients in the primary clinical trial and the secondary clinical trial documented adverse events"
    },
    "7ebbbace-7ced-4e16-bfa7-681b1c6f00f3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, all cohorts receive lisdexamfetamine orally, and in the secondary clinical trial, patients receive different doses of pdr001 but the same dose of mcs110."
    },
    "01593a0d-0547-4ed6-8ad6-6c5ecdbeb74a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "only one type of route is used for administering interventions in the primary clinical trial."
    },
    "22b44925-9577-462a-bf8b-cd3e5ba5ecb1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "all the participants of the primary clinical trial must have demonstrable hepatic disease."
    },
    "80b58d76-4a9b-461a-836a-bfb79e40b401": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "Both cohorts of the primary trial receive the same doses of Abraxane. viral laryngitis is acute inflammation of the larynx caused by viruses, including rhinovirus, influenza virus, parainfluenza virus, and adenovirus."
    },
    "4ec4fce7-e43e-46c8-ab5a-f5f04df1b940": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the primary clinical trial's results demonstrate a superior overall response rate for the arm a intervention compared to the placebo group. in addition, the secondary clinical trial indicates that the denosumab group had an improved time to first on-study sre compared to the zoledronic acid group."
    },
    "057e1439-4666-4373-a5b4-539c6cd24469": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "in the primary clinical trial, whole breast radiation therapy is given to participants, while in the secondary clinical trial, both cohorts receive intramuscular injections and also take prescribed medication orally."
    },
    "c574fb87-713c-43cd-a147-215f98ff6d35": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "breast cancer patients in the primary clinical trial undergo a different intervention compared to ovarian/ peritoneal cancer patients."
    },
    "a842c232-d17b-4257-84ff-02be26716c47": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "over 10 weeks of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 50% reduction in the percentage of cells with ki67 expression"
    },
    "c89d3665-091c-410b-83b1-0793a3b86d6a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, ZD1839, whereas in the secondary trial the intervention requires at least 3 different drugs, including Zoledronic acid, Samarium-153 and pegfilgrastim. haemophilus parahaemolyticus, penicillinase positive is any bacterial species identified as haemophilus parahaemolyticus that produces the enzyme penicillinase."
    },
    "6892893c-5c7b-492b-950f-e155bd928ebe": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "assamese language is an eastern indo-aryan language spoken mainly in the indian state of assam. the primary trial and the secondary trial do not have any recorded adverse events for their participants."
    },
    "974d4228-3dd6-42ab-b4e6-1b3f8e9ecdc5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "while both cohort 1 and cohort 2 of the primary clinical trial were given equal dosage of cetuximab, an additional collaborative care intervention was provided to cohort 1."
    },
    "c5a5aed2-c471-41a4-940c-9fa644e5a9fc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "perjeta is not used within any cohorts of the secondary trial, but is regularly administered during the primary trial."
    },
    "f896c335-0023-429c-b596-e7a30addbb2e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "There are more cases of Bronchopneumonia and General physical health deterioration in the primary trial than in the secondary trial. direct antiglobulin test is a measurement of the antibody or complement-coated erythrocytes in a blood specimen in vivo."
    },
    "7bbbfeb0-c4f2-4295-ae6c-3adbf6dc06ad": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "in the primary clinical trial, both cohorts observed more than a third of their patients achieving pathologic complete response in breast and axillary lymph nodes, approximately seven months into the investigation"
    },
    "f9d0c257-bd9a-484e-bae7-802c0246372c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the arm a intervention proved to be the most successful in terms of overall response rate in the primary trial. contrarily, in the secondary trial, the denosumab group showed a lesser performance in time to first on-study sre in comparison to the zoledronic acid group."
    },
    "7c7842f8-26c8-4b9f-8bb1-64f846e5e81e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "while the primary trial explores the impact of a single therapeutic agent, the secondary trial is dedicated to a completely different treatment modality, albeit at similar doses, and is based on similar outcome metrics."
    },
    "282cb769-7825-4b3e-b089-05a6103f60ff": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "A 20 year old female patient with a Newly diagnosed ER-positive, HER2-negative breast cancer, could be eligible for the secondary trial and the primary trial. how much bothered by discomfort or pain in affected underarm, arm, or hand is a question about how bothered an individual is by discomfort or pain in their affected underarm, arm, or hand."
    },
    "56d7443e-3522-40e2-bb3a-413fb5edea4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "although a patient meets all the criteria for the primary clinical trial, final entry is determined by the first of kin."
    },
    "141ee099-c8ae-4db1-9082-6fc138ad8093": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "the intervention schedule for both primary clinical trial and secondary clinical trial is of the same duration."
    },
    "d30d2472-9529-4206-8167-5bace92bb6d0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the primary trial uses a 3 week cycle for its intervention, the secondary trial, on the other hand does not have a cyclic treatment in place. spastic paraplegia 3a is an autosomal dominant subtype of hereditary spastic paraplegia caused by mutation(s) in the atl1 gene, encoding atlastin-1."
    },
    "aa2706a4-b145-400f-8e8c-23e70f006360": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "in the primary clinical trial, the participant count in cohort 2 is higher by 7 compared to cohort 1"
    },
    "57d8844c-d168-41c0-ad0c-6030e4c65905": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "over 42 days of tak-228 plus tamoxifen treatment patients in the primary trial experienced a 5% reduction in the percentage of cells with ki67 expression"
    },
    "1d1f2f55-c9b7-4a8b-bea7-b8ea291d96d5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial. application adapter is a software layer that converts data from an application into a form that will allow integration with other applications."
    },
    "6142265a-a110-42be-b03f-088d346e2389": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy. neonatal sinus tachycardia, ae is an adverse event in a newborn characterized by an abnormally high heart rate for age."
    },
    "cf19cee6-27d6-4d4b-ab20-52e35883d817": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 25 or 30 are eligible for the secondary trial, but will need to wait 3-4 years to be eligible for the primary trial"
    },
    "7f7c84c5-cc6b-4d4f-a47c-4d41454fd6d0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": "intravenous administration is mandatory for intervention 1 in the primary clinical trial, as well as all intervention drugs employed in the secondary clinical trial."
    },
    "aecffac5-b441-4cf6-b939-c7fb19ebac05": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "in the primary clinical trial, there was a minimum of 1 detected gastro-intestinal adverse event and more than one psychiatric event"
    },
    "a45aa828-dfd0-4b82-a1a1-7a8386520fe4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 12 weeks, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "8dc6e902-3dae-4bea-ba4b-605df19fabc1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "the intervention of the primary clinical trial involves the use of theraspheres for radioembolization, while the secondary clinical trial's intervention incorporates the use of ibrutinib and medi4736."
    },
    "bdfb5379-c659-4a09-b4f1-895468675f2e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "deriving is an explanation of the historical origins of a word, phrase, or object. Any patients with Documented allergy to cephalosporin, trimethoprim/sulfamethoxazole, levofloxacin or celecoxib will not be eligible for both the secondary trial and the primary trial."
    },
    "5f33e3b5-efa2-407c-9409-383024b8c652": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients who have been diagnosed with ductal carcinoma in situ and are considering getting ai therapy are eligible to participate in the primary clinical trial."
    },
    "91e178f6-c6ec-426d-8799-629c2f512038": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 30 mg group of the primary trial had a -0.4% recurrence-free survival compared to the nacl 0.9% 30ml group"
    },
    "0e7c3f86-cbc8-478d-b89c-1f75b53323fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the longest pfs in the primary trial survived 105 days without disease progression or death"
    },
    "85dcd465-ec0b-42ae-aec6-582831584bbf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "female cancer patients with brca- negative status can enroll in the primary clinical trial, with type, age, origin, or ethnicity not being discerning factors. nonetheless, the secondary clinical trial only considers patients with tnbc (triple negative breast cancer)."
    },
    "2e9d87da-10f2-4530-b200-87bb72cd9335": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "individuals suffering from malignant ductal carcinoma in situ and with uncontrolled hypertension are not permissible in the primary clinical trial, while the secondary clinical trial considers them eligible."
    },
    "56603bed-1e4b-41d2-919c-612ec6e9b4c4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 89/100 patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr)."
    },
    "fc839312-3b01-43e3-8cad-f1107759f462": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "gum dosage form category is a type of solid pharmaceutical dose form consisting of a basis composed of gum(s) or with a gum-like consistency. the primary trial requires patients to receive 120 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using Lymphoscintigraphy."
    },
    "d0fe5818-5954-41ea-9bcf-4ce7deba5ceb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "the secondary clinical trial will not accept any patients who have a known allergy to cephalosporin or trimethoprim/sulfamethoxazole, and those with an established allergy to levofloxacin or celecoxib are ineligible for the primary clinical trial."
    },
    "a62e526a-07c6-472a-acff-891375dd7fb0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "arm 2 in the primary trial exhibited an increased operative time relative to arm 1, thus marking the advanced effectiveness of intra-operative mammography over standard mammography. in the secondary trial, the lack of a control group makes it impossible to draw comparisons."
    },
    "e0265a05-590e-4f77-8e94-8bcdd1d9757e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "there were no recorded cases of palpitations, pericardial effusions and abdominal pains in the primary clinical trial, while multiple instances were noted in the secondary clinical trial."
    },
    "0a1cb41e-a5f8-42ca-bec7-f9bc1291037c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "The dosage of Zoledronic Acid  in Intervention 1 of the primary trial is 12 times higher than the dosage of Denosumab used in intervention 1 of the secondary trial."
    },
    "97acf304-2707-4a1b-81e7-339fde2ed0ee": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients with Fronto-temporal dementia or Mixed dementia are eligible for the primary trial"
    },
    "fdf14cde-dd7c-4b38-a127-5d857fb22bab": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "all patients treated with gtx-024 1000mcg in the primary trial gained lean body mass over a 120 day period"
    },
    "733d9f9f-9a01-4643-ab99-ac6086ad5cbc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "the duration of the memantine intervention in the primary clinical trial is shorter than the placebo intervention."
    },
    "44241e4d-31dc-487e-b42c-e8c47e3e82cf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "primary trial candidates receive weekly subcutaneous (sc) infusions, whereas secondary trial participants are not given any injections."
    },
    "36cb2716-6b66-49bd-bb22-7119bd022e28": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "while the primary clinical trial reveals the total number of participants examined in the study, it does not detail the number of participants belonging to each group."
    },
    "477389de-84aa-4438-87c9-3abccc80e1cb": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "attoliter is a unit of volume equal to one quintillionth of a liter (10e-18 liter) or one cubic micrometer. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial, but more cases of FEBRILE INFECTIONs were recorded in the primary trial."
    },
    "d82bb7da-6579-43be-969a-206d2235afd3": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "in the course of the study period, more than 15% of patients in the primary clinical trial and the secondary clinical trial experienced infections"
    },
    "e2fcdf94-c0b2-4d75-a40d-2c2ec8200208": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "uterus present is an indication that an individual's uterus is present. None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks."
    },
    "d504ff9e-bdcc-4609-9b57-b1cb4638bfdc": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "the participant count was the same for both cohorts in the primary clinical trial."
    },
    "edd794e6-12c6-4d30-80ac-009951273d44": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "women with recurrent stage i breast cancer, confirmed as er- considering lumpectomy are eligible for the primary clinical trial and the secondary clinical trial"
    },
    "a0428861-8e0f-42ca-889f-b2546ae3dbe6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "A woman who has had a mastectomy for stage IV BC could still be eligible for the secondary trial or the primary trial."
    },
    "a01bb73a-e620-4bb5-995b-9433d10090ab": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "drug-based treatments are not part of the examination process for the primary clinical trial, however, the secondary clinical trial tests two separate drugs."
    },
    "26731a57-6d43-4738-817a-74da5c372da2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "retroperitoneal undifferentiated pleomorphic sarcoma is a rare undifferentiated pleomorphic sarcoma that arises from the retroperitoneum. patients with Histologically or cytologically confirmed metastatic and/or advanced solid tumor in the breast are eligible for phase 1 of the primary trial and for all cohorts of the secondary trial."
    },
    "4b9aeee6-6ad8-477a-a09a-15fd52c8fec8": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00416715",
        "Secondary_id": "NCT02761642",
        "Statement": "Candidates for the secondary trial study group receive 3 weekly subcutaneous (SC) injections, whereas the primary trial participants only receive a single injection at the beginning of the study. sex genotype code is a coded value specifying the biological sex of the individual, based upon genetic analysis."
    },
    "6e02fc64-787b-47e7-a9d6-173b101baf71": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "the primary clinical trial would exclude a patient who has had an organ transplant in the past month and is currently bedridden, whereas the secondary clinical trial may admit such a patient"
    },
    "0f90b547-3d71-417f-ba02-deb31f70e5da": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "mandatory report is a report that is mandated by law and/or regulation. Both cohorts of the primary trial receive the same doses of Abraxane and Carboplatin."
    },
    "e1eb6c8e-61e1-474a-a01c-f7d18d2620e9": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "there were 4 more patients that suffered adverse events in cohort 1 of the primary trial than in cohort 2 of the primary trial . biologic entity administrative gender code is a coded value specifying the physical or societal properties by which male is distinguished from female."
    },
    "e29a77b0-a7de-44b8-8941-df0979682e4e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. have to leave in order to smoke is a question about whether an individual needs to leave the house to be able to smoke."
    },
    "e3a1c267-d715-40ef-b23a-9bfb6285bf6a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial involves drug-based treatment, in contrast, the secondary trial focuses on physiotherapy."
    },
    "c99a0652-8f34-49d1-b98b-182553c58dbc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "participants in the primary clinical trial maintain a consistent dosage of alpha lipoic acid throughout, never exceeding 50 mg twice daily, in contrast to the secondary clinical trial where cohort 1 patients receive a graduated increase of necitumumab up to a specific limit."
    },
    "542ebedc-ffda-406e-9ef5-d2f9edc30ac1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "study protocol version design configuration code is a coded value specifying a trial pattern developed to compare treatment groups in a clinical pre-clinical trial. CAPECITABINE was administered orally every day, to every patient in cohort 2 of the primary trial for the first 21-day cycle."
    },
    "75d3b7d9-3863-4b14-8007-8d8ade0440f1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "patients with a body mass index (bmi) of 20 and above are eligible for the primary clinical trial."
    },
    "a68e6309-12b7-445f-837b-ce8cef67a882": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "chest wall mass is an abnormal growth in the chest wall. eating disorders were not common for the primary trial candidates."
    },
    "af5daeb0-69f5-4d1c-93a5-7a76dfb4b5e7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "participants in cohort 2 of the primary clinical trial will also view the educational dvd instead of receiving a regular dosage of radiotherapy"
    },
    "174a00b4-2d77-4734-b02a-3603133fa8fe": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "in the primary clinical trial, the neratinib group demonstrated a lower incidence of idfs than the group given placebo"
    },
    "8db20184-7510-432f-aa95-c9f2c91326fd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the primary and secondary trials reported an equal number of infection, asymmetry and nausea cases."
    },
    "c78f1ce0-7597-415d-b5c3-203e696b48d5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the primary trial results there were fewer patients with stable disease in week 15 than week 30, but 8 patients with complete response in week 15 or 30'"
    },
    "c696105a-b6a3-4d13-9410-2b3f05346f96": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "the second cohort of the primary clinical trial has 7 participants more than the first cohort"
    },
    "e7505665-3677-4d18-87ec-8483dc002bd1": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg to 37.5 mg of sunitinib daily, whereas cohort 2 recieves 10 mg/kg of Bevacizumab. malignant pylorus neoplasm is a primary or metastatic malignant neoplasm that affects the pylorus."
    },
    "f12a3e2a-478e-4104-8f1a-c2d72efab4a3": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "Both cohorts of the primary trial contained the same number of participants. double is a twofold increase."
    },
    "44b41322-9fb1-4a02-b2c5-4faead5489aa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "Most patients in the secondary trial and the primary trial did not suffer any adverse events. sponsor protocol identifier is a unique code, which is assigned by the sponsor, that identifies a specific protocol."
    },
    "c0e3960b-923b-460f-a6e1-0b16f32af78f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "in the primary clinical trial, the number of adverse events was equal in both cohort 1 and cohort 2."
    },
    "4a06c463-8c8b-454e-9664-bac7871cbb95": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the outcome measures for the primary clinical trial and the secondary clinical trial are completely different."
    },
    "fc4ec229-5b69-409e-89c0-2b151f670382": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "patients are not mandated to meet any performance status conditions in either the primary or secondary trial"
    },
    "9625e56f-5de0-4cbd-8e30-a944bf6d6244": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "cohort 1 of the primary clinical trial is administered dexamethasone post-operatively, while cohort 2 receives the drug pre-operatively."
    },
    "3e7895ff-0e1a-40d9-830d-bab9c5b59706": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary clinical trial participants exclusively receive one type of oral medication and are not required to undergo surgery, while the secondary clinical trial participants are given an array of eight different drugs with a combination of surgical procedures'"
    },
    "9727b232-81fc-42cc-bd06-05cc81a7453b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "A Patient that has a primary tumour with a radius of 3mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "73981f59-887e-4778-a78a-0bf7b7a405b7": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the primary trial has 4 more adverse events recorded than the secondary trial"
    },
    "baea007a-c303-440b-a66c-0941729f416d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "was in situ hybridization performed is a question asking if in situ hybridization assays were performed during the study. In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants."
    },
    "e3b2d615-a7b7-475e-b757-a8de8cd2c6f7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "HER2 + Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial throughout the entire duration of the trial. new hampshire is a state in the northeastern united states. its capital is concord."
    },
    "cdd043e8-2430-409a-96b6-8e7b7a2d11f3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00749931",
        "Secondary_id": "NCT01310075",
        "Statement": "a patient may be able to participate in the secondary trial but be ineligible for the primary trial."
    },
    "2d007409-93ff-4753-a2e5-c5f94d4fe6dd": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response . dietary vegetables, red and orange measurement is a determination of the total red and orange vegetables in a nutritional product or meal, or a portion thereof."
    },
    "8719ae55-97f1-4d19-8e9c-85c086898291": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "in cohort 1 of the primary clinical trial, most participants fell behind in their screening schedules post-intervention, without being influenced by the type of their cancer."
    },
    "ce9ff719-a4b1-4506-91ef-eea478339ced": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "sunitinib was not administered to any patient during the primary clinical trial."
    },
    "3c558a0b-1e1a-4d42-af75-266ea0d93662": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "11% more Participants in the ER-positive Luminal B group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group. grade 1 brachial plexopathy, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated"
    },
    "99925da5-1a89-471d-b3d9-a3e083fc1bda": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "the number of aes was higher for one of the cohorts in the primary clinical trial"
    },
    "4229278c-db31-4842-8c04-1d5b30b39037": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "Breast Cancer patients in the primary trial are administered 1000 mcg/day of talazoparib whereas Ovarian/ Peritoneal Cancer patients in the primary trial receive only 25 mcg/day talazoparib instead. fact-bl questionnaire is a subscale complement to the fact-g developed specifically for evaluating the quality of life of patents with bladder cancer."
    },
    "825832eb-2b69-42a2-80b1-f210915da77c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "polycythemia (excluding polycythemia vera) is an increase in the concentration of red blood cells (hemoglobin) that is not caused by polycythemia vera. there were 0 cases of Hypertension, Dehydration and Dyspnea in either cohort of the primary trial."
    },
    "9bf4a35a-531f-4083-87ac-dec730cfea45": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the primary trial recorded 11 more instances of intestinal perforation than the secondary trial"
    },
    "c803b01e-6f64-4412-a3c2-6b1a70d5cf7e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "enrollment in the primary clinical trial requires a positive mental health assessment"
    },
    "d5e071e0-4705-474c-8820-9fbc7b377a8d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "only males belonging to a particular ethnic group are eligible to participate in the secondary clinical trial"
    },
    "51cd4ccd-2770-4189-ba70-f01147431843": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "multiple injections are essential for patients participating in the primary clinical trial"
    },
    "b25a8f34-96ce-4ea1-a140-bf5b0ffe7f52": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions."
    },
    "fe6baecc-71eb-4b15-ba15-66d57539c702": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same perecentage of patients suffered adverse events in both cohorts of the primary trial"
    },
    "df8f9622-e361-4283-bc4a-fef7eaa101b1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "corresponding author indicator is an indication that the specific author is considered the corresponding author. the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts."
    },
    "ef6ae88d-2d86-4786-8cec-5fad1c1671b8": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01106898",
        "Statement": "the primary clinical trial reported that 97% of its patients did not have any side effects."
    },
    "80b0b7be-91b4-40ba-a4db-d19f0b1865d7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "on average, cognitive function remained stable in one cohort, while it improved in the other cohort of the primary clinical trial."
    },
    "ad37e364-d3a8-4fcd-9033-90e7ec7d7fc7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "more than half of the patients in the first cohort of the primary clinical trial experienced severe nausea following treatment with aprepitant, dexamethasone, cytoxan, and kytril"
    },
    "e244bd1b-7ded-4cc5-a1f2-8afd358338b1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "More patients in cohort 1 of the primary trial suffered adverse events than in cohort 2. tuberculous bronchopneumonia is acute and progressive bronchopneumonia caused by mycobacterium tuberculosis bacteria.  it is characterized by widespread pulmonary patchy consolidations."
    },
    "d33d29d8-6d96-4f24-af22-2e86e73485d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01086605",
        "Statement": "dyspnea was observed in some participants of the primary clinical trial"
    },
    "232d082f-2684-445e-8ca6-9cf32c3d1b34": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "bronchial stricture, ctcae is a disorder characterized by a narrowing of the bronchial tube. the primary trial and the secondary trial do not test the same drugs."
    },
    "c4620792-b333-4232-ba8e-62595917256f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "arimidex is administered in both sections of the primary clinical trial, but it is absent from the secondary clinical trial's procedure."
    },
    "f866e011-f633-4481-9d58-fff6828d7f83": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "none of the patients in the primary clinical trial who were given lapatinib 1000 mg + nab-paclitaxel reached a confirmed complete response (cr)."
    },
    "e78237d7-bbb7-4586-9950-5eabb10254f9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "patients in the paced respiration intervention group for the primary clinical trial demonstrated fewer treatment emergent adverse events and serious treatment emergent adverse events on average than patients in the fast, shallow respiration group."
    },
    "fed83886-1413-49c9-91ab-3f1bea54db23": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00454532",
        "Secondary_id": "NCT01301729",
        "Statement": "the secondary clinical trial was unfortunately halted due to a number of significant adverse events encountered by most participants"
    },
    "84915e35-a8c9-4d26-ad09-4b1df48a6df8": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00956813",
        "Secondary_id": "NCT00320541",
        "Statement": "the secondary trial and the primary trial results contain completely different outcome measures "
    },
    "14045448-a003-4d3d-ace1-bcdf3a7479c2": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial recorded fewer adverse events than did the secondary trial within their cohorts."
    },
    "102bbdcd-14ea-4dd5-a0bb-4cea343bb6ed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "There were more cases of Mucositis Oral, Bladder Infection and Thromboembolic events recorded in the primary trial than in the secondary trial"
    },
    "fccade16-a6ed-4bc1-b767-d5d1ab20b780": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary trial evaluates the severity of delayed nausea on a numeric scale from 1 to 7. in contrast, the secondary trial focuses on the changes in bone mineral density (bmd) of the lumbar spine over a period of 9 months from the baseline."
    },
    "7a4a1281-d17b-4ad5-aa63-7329abdd0cdd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "there were fewer cases of infection, asymmetry and deflation in the primary trial compared to the secondary trial."
    },
    "4acf0568-59ce-4f6c-973b-9c603f65dac4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "patients in neither cohort of the primary clinical trial showed pathologic complete response in breast and axillary lymph nodes throughout the duration of the study"
    },
    "d42bd39b-e72e-418b-bd8a-6f1769fde12d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "to participate in the primary clinical trial, a candidate must have a minimum karnofsky score of 60"
    },
    "7e5ca0bb-bae1-493f-9a30-7f70d544fcf4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "those suffering from breast cancer and necessitating hormone treatment are potential participants in the primary clinical trial."
    },
    "5af90c4a-80c3-4f11-bbc0-7f84ad544186": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "patients diagnosed with estrogen-negative, progesterone-negative and her2- breast tumors may participate in the primary clinical trial"
    },
    "49f03133-66cf-4980-8e2b-d7fb001edefd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "the primary clinical trial does not involve the administration of talazoparib in its operation"
    },
    "7531054e-9cf3-43a1-bba4-19e90a2c5ef0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01631552",
        "Secondary_id": "NCT01286987",
        "Statement": "the outcome measures of the primary and secondary clinical trials are directly related, despite having different interventions"
    },
    "75753b6a-e963-4357-a225-102c1542f73d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "agreement likert scale is a 5-point likert scale for agreement that goes from 1: not at all to 5: very much. Several recorded Aes in the primary trial occurred to cohort 1 patients."
    },
    "f95613c7-63f9-4f97-adbd-176220391993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 220 milligrams of denosumab injected subcutaneously every week, the secondary trial also requires injection, adminstering 3.4 to 2.0 mci of radioactive tc99m sulfur colloid."
    },
    "5bdba14a-5c7f-4913-b543-9c791965c237": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with gtx-024 1mg in the primary trial gained over 10,000 grams of lean body mass."
    },
    "584c33f0-3bca-4276-a3f1-2c68e39898ac": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "in the secondary clinical trial, a single adverse event impacted more than 50% of the subjects involved"
    },
    "9bde44ff-5060-430d-9716-c34888483b9f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "distressed by awakening in the early morning is a question about whether an individual is or has been distressed because they are awakening in the early morning. There were 0 adverse events in the primary trial and the secondary trial."
    },
    "97e71457-8a63-4bf3-b1cf-b2743433e7f2": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "daxx gene mutation is a change in the nucleotide sequence of the daxx gene. Neither cohort of the primary trial recieves any drugs, radiotherapy or CBT in the interventions."
    },
    "09deff91-1b05-470a-aecd-60ce772b9a8e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. missing information is absence of information e.g. labeling, instruction for use."
    },
    "77aeeff2-38c4-41ce-8526-55ab056504f9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "neoadjuvant therapy clinical trial setting is a clinical trial or treatment setting in which the therapy of interest is considered neo-adjuvant. patients of any gender can be eligible for both phases of the primary trial if they have evidence of a solid tumor that is locally advanced and/or metastatic."
    },
    "0a279b67-be5a-4f7d-a21b-b178a556f8ae": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "8q21.13 is a chromosome band present on 8q the primary trial participants receive HER2/neu peptide vaccine admixed with sargramostim (GM-CSF) ID on days 1, 8, and 15."
    },
    "31332603-d84d-4806-b8bf-4cdc08514591": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "14.17% of the primary trial patients suffered an increase in blood bilirubin."
    },
    "4d501822-a118-4fe8-b92d-eb5085ab6dcc": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "all participants in the primary clinical trial are administered higher doses of medication than participants in the secondary clinical trial"
    },
    "95354d90-513a-4766-a860-307afa28fb7b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "anemia, pneumonia, and stupor were more frequent among patients in the secondary trial compared to the primary trial, although the primary trial recorded a greater number of febrile infections."
    },
    "5a286769-0146-41da-8daa-af8c7169023a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients with recent history (within the last three years) of pulmonary embolism will not be permitted to participate in the primary clinical trial, but might be considered for the secondary clinical trial upon review by the investigator."
    },
    "5e45f9e6-6a4f-4cf6-b24a-8755f700943f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "both the primary and secondary clinical trials administer their treatments orally."
    },
    "7432cb06-a4a3-4f9c-afc8-533e39b7337f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02002533",
        "Secondary_id": "NCT02734979",
        "Statement": "the number of adverse events recorded in the primary trial and the secondary trial is identical."
    },
    "d15bf489-0548-4cbc-b64c-2252a53b5f33": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "sellar germ cell tumor is a germ cell tumor that arises from or adjacent to the sellar region. The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent."
    },
    "080fe5be-37c4-4d7f-a985-58c520750620": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "the primary clinical trial has interventions where differing doses of paraplatin are administered"
    },
    "83c979cb-fb3a-4792-8a63-8f7e544bb8a8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial. gonadotroph cell is an endocrine cell of the adenohypophysis that affects certain cells of the ovary or testis."
    },
    "d6cde3f8-ef3c-4d8a-8afb-d3e9f8c5c1f8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "the primary clinical trial excludes patients with alzheimer's disease"
    },
    "2ea93619-d183-4989-b811-c4666059d456": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "at all times, the dosage of trastuzumab received by patients in the primary clinical trial differs from that administered to patients in cohort 2 of the secondary clinical trial"
    },
    "174215f6-99d9-482a-8aad-d477060cb062": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "There are no conditions on mental mental health, bodyweight, size of tumours, Karnofsky/ECOG score or Estimated life expectancy that need to be met in order to be eligible for the primary trial . hyperemia evaluation is an evaluation of hyperemia in a biological specimen or location."
    },
    "bad327e8-73f2-4903-a0bf-ed5d08c81f69": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the primary clinical trial and the secondary clinical trial assess patients' progress by the decrease in the size of the tumor following completion of chemotherapy"
    },
    "d8735c6c-1fc9-4fbc-93d2-651a5814d505": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "cardiovascular system findings derived flag is an indication or description that cardiovascular system data is a derived value. the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment."
    },
    "5da3a98b-ffa7-4c54-a340-37986d6dcc20": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "malignant sweat gland neoplasm is a malignant neoplasm that affects the sweat glands. in the primary trial there were 10 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy."
    },
    "bb3e3ca1-1b64-4ddc-9492-1fb11ec9356f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "both study groups in the primary clinical trial will undertake identical 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct) imaging procedures, but there will be a minor increase in the dosage of 18f-fpprgd2 administered to cohort 1."
    },
    "5c06c081-87ef-4e9a-ab22-c8c55253fc34": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "there were fewer instances of mucositis oral, bladder infection, and thromboembolic events noted in the primary clinical trial compared to the secondary clinical trial"
    },
    "05772f95-990c-40ee-b29c-b5b2591d0e56": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "A 32 year old patient with Histologically verified diagnosis of stage III breast cancer, Absolute neutrophil count of 1807/\u2248\u00ed\u00ac\u222bL, Platelet count of 110,034/\u2248\u00ed\u00ac\u222bL, Hemoglobin level of 90 g/l, and a Life expectancy exceeding 8 months would be eligible for both the primary trial and the secondary trial. fibroblastic neoplasm is a benign, intermediate, or malignant mesenchymal neoplasm characterized by the presence of neoplastic fibroblasts."
    },
    "8480a497-4ae7-4d4a-9b19-68667f70dc22": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "in the primary clinical trial, most of the reported adverse events were related to blood and bone marrow. this observation was not found in the secondary clinical trial."
    },
    "8bc0e440-faca-4386-8718-e306978edb67": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "minor salivary gland is a small salivary gland located within the aerodigestive tract. Patients with NUT midline carcinoma determined by fluorescence In situ hybridization, or inflammatory breast cancer are eligible for both the primary trial and the secondary trial."
    },
    "d6aab46f-9e05-43a5-9d57-ca7d34bed983": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "both the primary clinical trial and the secondary clinical trial administer drugs orally and rely on ultrasounds instead of mris."
    },
    "96e242e7-e1dc-4465-bb90-6f9ef0ab0f2a": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "none of the participants in the primary clinical trial are prescribed talazoparib on a daily basis"
    },
    "48b186f8-f41c-4582-8dbb-6918ce072ce8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00820872",
        "Secondary_id": "NCT00706030",
        "Statement": "muscle weakness upper limb, ctcae is a disorder characterized by a reduction in the strength of the upper limb muscles. Cholelithiasis was twice as common for the primary trial participants than the secondary trial participants."
    },
    "3c06901b-29be-43be-8da7-c23d80cc4d89": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "the occurrence of disease progression or death was more prevalent in the bevacizumab cohort in contrast to the bevacizumab + capecitabine cohort in the primary clinical trial."
    },
    "5b875c96-44e4-4123-921a-546382d4c806": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients participating in the primary trial receive 700 mg/week oral lapatinib twice a day for a full 4 weeks."
    },
    "710206ba-d90c-4341-a1ae-b937ffc50a2f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "In the primary trial results there were more patients with stable disease in week 12 than week 24, but 0 patients with complete response in week 12 or 24. feel angry is a question about whether an individual feels or felt angry."
    },
    "963bd695-f26a-4891-931e-9b417a7c81c0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the primary clinical trial reported a higher incidence of infection, asymmetry, and deflation compared to the secondary clinical trial."
    },
    "2bf9e0d9-1195-4c03-b2bc-d491ff1cd174": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "36.36% of the primary trial patients suffered an increase in Blood bilirubin."
    },
    "1ef3ec2f-1b26-4dbe-92ff-8c3dda42f071": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00404066",
        "Secondary_id": "NCT01111825",
        "Statement": "no adverse events were noted in the patients from the secondary clinical trial, however, in the primary clinical trial instances of dyspnoea, hyperkalaemia and renal failure were recorded"
    },
    "ceb3926f-4777-4cec-8582-7c109185e333": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 0.00027ug/kg of myalgias (0.005ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "2ea65099-018a-4230-87a1-e60303486743": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 65 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 5000/\u2248\u00ed\u00ac\u222bl, platelet count of 120000/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 200 g/l, and a life expectancy exceeding 20 months would be eligible for both the primary trial and the secondary trial."
    },
    "f5b27b4f-8fe1-4cc8-a4d6-aa1459797496": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs. egfr nm 005228.3:c.2315 2316insgacacaccc is an insertion of nine nucleotides, gacacaccc, between position 2315 and 2316 of the coding sequence of the egfr gene."
    },
    "2d36fa83-b68c-420e-873f-e69374d0741f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary trial uses higher doses of Lenalidomide than the secondary trial uses of Lapatinib in intervention 1, and the primary trial intervention lasts for a longer period of time."
    },
    "197c5300-0475-46e0-aa97-cfb145da896d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "every participant in group 1 of the primary trial were found to have lesions, and merely 1% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "e7e2f4af-f6c2-47cc-b03e-6e69210d14c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average patients from the primary trial survive over 4 years, however at least one patient from both cohorts died in under 3 days."
    },
    "cc2be8ad-6396-41da-a205-45d8bfca37f4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "male leukemia patients under the age of 18 can participate in the primary clinical trial, regardless of race or ethnic origin. for the secondary clinical trial, they must have her2/neu- lung cancer."
    },
    "f8f0d036-16aa-4a9f-816e-c52940709126": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "None of the primary trial patients in cohorts 1 or 2 showed discernible pattern for expression of the set of 40 evaluated genes. mouth sensitivity at its worst is a question about an individual's mouth sensitivity at its worst."
    },
    "ebe5f6c9-355c-4d69-8b0d-5ac8d5f861a1": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia. erbb2 mutation analysis is a procedure used to detect and identify mutations in the erbb2 gene."
    },
    "fc6ab4bb-43af-4008-a2dc-0e23dbf9abc0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a mastectomy may not disqualify a woman from being eligible for both the primary and secondary clinical trial."
    },
    "3c56fe49-cda1-4f0f-8597-63f1e8d6237c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "mechanical ventilation required is an indication that a patient required mechanical ventilation for respiratory support. the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel."
    },
    "0f0ccab9-517a-44e5-8dda-96d1cb9ead51": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "in the primary clinical trial, the placebo is administered orally, while trabectedin is injected directly into the bloodstream."
    },
    "a993a4e8-00bf-47c9-95d2-a63d4666658e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, the intervention is administered sublingually, while oral administration is used in the secondary clinical trial."
    },
    "4f5fb0bf-e5bf-47ad-876c-e9aea07feaee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01629615",
        "Statement": "eating disorders were frequently observed among the primary clinical trial candidates'"
    },
    "4f0e91c8-87f4-4af4-b47d-c5a8e459713d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "cohort 2 of the primary clinical trial will have access to the educational dvd as part of their intervention program."
    },
    "0cff9aa1-3486-4c0c-bda1-8850b3dc932e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "no instances of anorexia, hypothermia or hallucinations have been recorded in the adverse events (aes) of either the primary clinical trial or the secondary clinical trial."
    },
    "b819fe62-b8ce-4b35-bf5a-e2657f8d0efc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "only one arm of the primary clinical trial makes use of trastuzumab as part of its intervention"
    },
    "d73e5604-bcf0-465f-b147-7ed3cb036e4c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "rod device is any rod-shaped device. Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore Intra-operative Mammography performed better than the Standard Mammography in this regard. In the secondary trial there is no control group against which we can compare."
    },
    "b1695ed3-b79e-4e1a-8658-52f33b997fea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary clinical trial does not examine any pharmacological treatments, while the secondary clinical trial investigates varying dosages of a singular drug-based method."
    },
    "70b8c9a1-dcd5-459b-b138-d341132d2b5e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 32 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces the diameter of tumors by 40% on average. as bad as you can imagine is a response indicating a situation is as bad as can be imagined."
    },
    "e1cb3a7c-2881-41b9-8dc5-c6a1d311afc6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "compared to the primary clinical trial, the secondary clinical trial observed an increase of 11 adverse events"
    },
    "05fbffcf-c1a0-40f9-95dd-8e9010005773": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the secondary trial and the primary trial report results from one patient cohort."
    },
    "fe0da901-6c2a-4ae8-b35f-a3090f93f12d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01171924",
        "Statement": "rectal necrosis, ctcae is a disorder characterized by a necrotic process occurring in the rectal wall. cohort 1 and 2 of the primary trial receive the same dosage of CUDC-101, at the same frequency, with the only difference being that cohort 1 also recieves PD-0332991 once weekly."
    },
    "12ed5e10-5988-494c-8a88-6e4e30ddd355": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "patients in the paced respiration intervention group of the primary clinical trial endured more treatment emergent adverse events and serious treatment emergent adverse events on average than those in the fast, shallow respiration group."
    },
    "9b75138c-e074-43f0-866d-9a43ce7be217": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "patients involved in the primary clinical trial are administered oral drugs twice daily for an entire month."
    },
    "4318ce37-10b6-4318-868e-f533a1fd000e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "in the primary clinical trial, 13% of participants who had her2- primary breast cancer and received her2-targeted pet/ct. 89zr-trastuzumab treatment eventually developed imagable her2+ metastases."
    },
    "840d1cd7-85bd-4d25-a4db-0af6ff989e1d": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "during the primary clinical trial, there were no significant divergences noted in any group's results, but differences emerged between the reflexology group and the control group during the secondary clinical trial."
    },
    "70130418-63df-4ffb-9d78-7416daee50ba": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01390818",
        "Statement": "all adverse events recorded in the primary clinical trial were solely associated with members of cohort 2."
    },
    "f5a91b94-a81e-4c40-91df-b144e30df80b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "primary trial participants never receive epacadostat, while sunitinib-na\u201a\u00e0\u00f6\u221a\u00f2ve participants in the secondary trial always receive sunitinib."
    },
    "c9077c20-07f8-4137-b88a-9ef599052884": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "the primary clinical trial demonstrates that ki67 expression in tumors increases by 30% on average when tamoxifen 20 mg is administered orally each day for 7 days prior to surgery and 14 days post breast cancer surgery."
    },
    "dfdcc220-60e9-4ade-a21a-2dea12500959": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary clinical trial and the secondary clinical trial assess the participants' overall survival rates."
    },
    "3a4cc297-6f5a-489c-a841-95e2b3971167": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00313170",
        "Statement": "candidates for the primary trial must have colon cancer and be unresponsive to previous hormonal treatments. medulloblastoma, not otherwise specified is a medulloblastoma which has not been further characterized."
    },
    "92ea43b9-05d5-47a4-a78d-87bcb3326810": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "no primary trial participants experienced any form of rash."
    },
    "2db7c3cd-eb62-4ec4-8d89-effa9c9212e0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "both the primary and secondary clinical trials have recorded instances of anorexia, hypothermia and hallucinations in their aes."
    },
    "883cad2c-dee5-4530-bdde-5d616d4570ad": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients with severe insomnia and schizophrenia are not eligible for the primary clinical trial, but are eligible for the secondary clinical trial"
    },
    "96be8dc9-8873-475f-b91f-e92f3549861b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "the height criterion for the primary clinical trial disqualifies children and adolescents, but the secondary clinical trial does not expressly exclude them."
    },
    "670ba789-279e-420d-b45e-c63836169e9b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the primary trial results there were less patients with stable disease in week 20 than week 34, but 10 patients with complete response in week 20 or 34'"
    },
    "06695494-b56b-49da-9166-b0aae3f322f3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01376349",
        "Secondary_id": "NCT01048099",
        "Statement": "source type code is a coded value specifying the origination source of the entity. Neither the secondary trial or the primary trial use cm, Number of Participants or a unit of time as their units of measure."
    },
    "e44e25b6-1be6-4c35-a3c9-417c56052939": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "in the primary clinical trial, paclitaxel is incorporated into both therapeutic interventions"
    },
    "8563b314-6b0f-432c-9ffc-203c3dcb0a3f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive whole breast radiation therapy , and both cohorts of the secondary trial receive 500 mg of Fulvestrant in a tablet form to be taken BID. grade 1 anal mucositis, ctcae is asymptomatic or mild symptoms; intervention not indicated"
    },
    "20ee9640-9334-41a2-b8aa-62cc27aeab70": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "All the primary trial participants receive higher doses of ALT-801 than the secondary trial participants. anpep negative is an indication that anpep expression has not been detected in a sample."
    },
    "ad5ca7e8-3e5d-43b8-9618-99f56fc70290": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "There were no cardiac or phsyciatric Aes recorded during the primary trial and the secondary trial, however several other types of Aes were observed."
    },
    "0931fd2b-2ce8-4285-9c02-63318e60efc3": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report the severity of delayed nausea on a scale from 1 to 7, and the secondary trial measures the change from baseline to approximately 3 quarters of a year in bone mineral density (bmd) of the lumbar spine"
    },
    "a44a34b5-9f9e-4957-bb5e-5bb7bf834ecc": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "Patients can not have a history of abdominal fistula, gastrointestinal perforation,myocardial infarction (MI), stroke , transient ischemic attacks, intrabdominal abscess or significant psychiatric disorders within the last 6 months if they want to participate in the primary trial. grade 1 stomal ulcer, ctcae is asymptomatic; clinical or diagnostic observations only; intervention not indicated"
    },
    "25bc284b-0476-4950-96e5-3b08a2a1c33c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism within the last 13 months are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "6fce98e9-e48f-4b14-8a94-37c1ab124eed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial. past seven days unexpected decrease in sweating is a question about whether an individual had any unexpected decrease in sweating over the past seven days."
    },
    "d225c39d-4bd1-4129-a359-2909af912031": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the primary clinical trial results state that the most effective overall response rate was provided by the arm a intervention. in contrast, the secondary clinical trial found that the denosumab group had inferior time to first on-study sre compared to the zoledronic acid group."
    },
    "b3f59657-9278-41be-b740-433b0d38fdd5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "Patients with TX NX MX, T0 NX M0 or T1 N1 M1 tumors are eligible for the primary trial"
    },
    "25f963fe-42f5-4294-9489-17d8fd17b4f2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01205503",
        "Secondary_id": "NCT01286168",
        "Statement": "patients with a confirmed allergy to cephalosporin or trimethoprim/sulfamethoxazole cannot participate in the secondary clinical trial, and those with a documented allergy to levofloxacin or celecoxib will be excluded from the primary clinical trial."
    },
    "a06d2404-8265-4baf-907d-ddba1bb223d0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes. how long not feeling like eating lasted is a question about how long not feeling like eating lasted."
    },
    "2e054c61-23f1-46df-9c49-44e5f076163d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "Both interventions in the primary trial include trastuzumab. paranemin is a type iii intermediate filament protein found in striated muscle cells that provides cytoskeletal integrity and strength."
    },
    "bc318388-81b9-4bf5-94a7-db6443061abd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "interval point in time integer data type is a data type comprised of a set of consecutive values of an ordered point in time integer datatype. Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer."
    },
    "29eab9d1-1649-401a-8ff7-95fcd6a2c09a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 9ug/kg of dexmedetomidine (90ml), patients in the secondary trial cohorts do not receive any dexmedetomidine."
    },
    "7f2ecb22-ab29-4dfa-b9f6-b09cb7d4c56b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "neither the primary clinical trial, nor the secondary clinical trial have reported any episodes of anorexia, hypothermia, or hallucinations among the adverse events (aes)."
    },
    "892e63ba-619c-4458-8130-89bbac726edb": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "the majority of patients in the primary clinical trial experienced a certain type of adverse event."
    },
    "4e0fae11-64b8-403f-8001-45ef8078a145": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "syncope was the most frequently reported adverse event in both primary clinical trial and secondary clinical trial, affecting 25.00% of the patients in the primary trial."
    },
    "19a043cf-96b9-4285-9e9c-1405403bf608": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "individuals with histologically proven metastatic scbc are not permitted to participate in the primary clinical trial."
    },
    "7bbb79b9-9550-4a8b-a0a8-3af8ece50e04": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "rbm15 gene rearrangement is a molecular abnormality indicating rearrangement of the rbm15 gene. Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial."
    },
    "5bdc0c5e-236f-4dbf-92cd-8f582a16b2fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 0.5kg/ug of myalgias (5000ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "b032a728-a998-4b78-945a-048dbc5126f5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the zoledronic acid 4 mg group of the primary clinical trial experienced a greater reduction in primary tumour diameter than the azd0530 175 mg group."
    },
    "a3954ec9-3fdd-4183-844d-1a13f70350e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "in the primary clinical trial, there were no reported cases of adverse events amongst patients, while every patient had at least one recorded adverse event in the secondary clinical trial."
    },
    "34250dad-ad53-42bb-a8d3-80866141d548": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "worse than expected is a subjective response indicating something was worse than expected. the primary trial had one test group and one placebo group, the secondary trial had 1 test group and 1 control group."
    },
    "4b6aac05-1130-49c4-b5f6-9afe1227459c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "neither the primary clinical trial nor the secondary clinical trial consider gender as a criteria for eligibility"
    },
    "367bc142-7412-43c6-b946-6127aff25f9a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the primary tumor size reduction was more prominent in the primary clinical trial's azd0530 175 mg participants than those receiving 4mg zoledronic acid."
    },
    "6fa670ed-56af-4b06-b7f1-ab7429106d0d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00467844",
        "Statement": "at least one patient treated with gtx-024 1mg in the primary trial gained over 22 pounds of lean body mass."
    },
    "d5abbde0-b23c-4e60-91fc-cb6a7735b68f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "perfusion computed tomography target lesion is a target lesion that has been identified by computed tomography perfusion imaging. the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial."
    },
    "27d0d803-28d5-4b3d-a87e-8fbe577513a9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the administrated intervention for the primary clinical trial involves dermal patches, while the treatment for the secondary clinical trial necessitates oral administration"
    },
    "21afdaec-2db5-42b3-b201-b2dee4e23cb7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01770353",
        "Secondary_id": "NCT01138046",
        "Statement": "the primary trial and the secondary trial do not use the same drugs, dosages or frequency of administration in their interventions, however they do both use intravenous injections and MRIs."
    },
    "8af5402d-9065-412b-a7dc-053dfce01c63": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "the primary trial participants receive pembrolizumab twice as frequently as participants in the secondary trial receive sunitinib. connecticut is a state in the northeastern united states. its capital is hartford."
    },
    "f8a72a9e-357d-4786-8d5d-66ee4ce4d1b2": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery"
    },
    "1a4794c9-035c-4e78-b2e5-d8104428bdc0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "Diagnosis of 2-3 cerebral metastases will result in exclusion from the secondary trial, however patients with this diagnosis may still be eligilbe for the primary trial. have history of opportunistic or frequent infection is a question about whether an individual has a history of opportunistic or frequent infections."
    },
    "b3909182-2942-44c1-96e8-5650e48401df": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00088413",
        "Secondary_id": "NCT01989546",
        "Statement": "The majority of the adverse events recorded in the primary trial were blood and bone marrow related, this is not the case for the secondary trial. disseminated adenocarcinoma is adenocarcinoma that is spread throughout the body."
    },
    "849dbfea-186a-4983-b7a3-616679e3f2ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the the primary trial results report changes in pain intensity and the secondary trial measures the change from baseline to 36 weeks in bone mineral density (bmd) of the lumbar spine"
    },
    "cfce111d-8810-4915-98ee-1e280271de10": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "participants in the primary clinical trial are administered pembrolizumab with a frequency that is double of that given sunitinib in the secondary clinical trial."
    },
    "77fd9a89-4d9b-40ab-b4ad-fcf554ca68d2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "58f42b4f-c8f1-4471-a44b-35ac49604a3b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary clinical trial provides a duration in days until disease progression for 156 patients across both cohorts, whereas the secondary clinical trial shows the proportion of patients experiencing objective response."
    },
    "dbc4f576-220a-482d-a06c-2538c13fdb28": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 20 or 21 are immediately eligible for the primary clinical trial, but were eligible for the secondary trial 1-2 years prior"
    },
    "dd33f2de-6bfc-4a27-95da-630c9f0c0574": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "the patient's nationality, ethnicity, weight or gender do not have an impact on their eligibility to participate in either the primary or secondary clinical trial"
    },
    "b2caa135-c6ed-46b0-a1e3-6fd60ae12831": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "the differences between interventions 1 and 2 of the primary clinical trial do not involve the amount of durva administered monthly to each cohort."
    },
    "35fb0b2d-39d8-43f9-9e47-aceee416803b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "less than 50% of patients in cohort 1 of the primary clinical trial experienced acute vomiting post-treatment with aprepitant, dexamethasone, cytoxan, and kytril"
    },
    "0433b29d-6509-420d-ba83-4ddcf8907e2b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02336737",
        "Statement": "Cohort 1 of the primary trial did not report any Aes. sixteen is a natural number greater than 15 and less than 17 and the quantity that it denotes."
    },
    "c12d4dba-17b9-45d6-9a3f-75be190b7795": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "the primary trial and the secondary trial recorded the same number of adverse events in their cohorts."
    },
    "060b08af-40f5-4d26-8299-6f3d02c8fda7": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00021255",
        "Statement": "the primary clinical trial ensures a uniform dose of docetaxel, doxorubicin, and cyclophosphamide across both cohorts, and maintains a constant frequency of administration."
    },
    "7138e72c-d5e7-4c18-ba8c-b71be945ac2d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "participants in the primary clinical trial receive tailored interventions based on their cancer diagnosis"
    },
    "7c1aaf25-a7c2-410d-bc13-fe6192698184": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "cohort 2 of the primary clinical trial had a higher number of patients suffering adverse events compared to cohort 1"
    },
    "bfe7b8a8-8d7d-404c-b369-9bf059ae079c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "cancer patients suffering from either epilepsy, thalasemic syndromes or anemia are disqualified from the primary and secondary clinical trials."
    },
    "a06e0782-9249-48ae-a2a3-70dffa452aab": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "there are no set limitations concerning life expectancy, pregnancy, or age for individuals participating in the primary clinical trial"
    },
    "1ddf526c-beb2-43e1-846e-a133e321a66a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00076024",
        "Statement": "participants of the primary clinical trial must have a life expectancy of more than 6 months"
    },
    "0bca53f6-c609-4c49-a684-a2d71cff7086": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01535040",
        "Statement": "in the primary clinical trial, the placebo intervention is delivered via intramuscular injection, once weekly and the memantine is administered topically, twice weekly."
    },
    "03a7663e-0937-437a-b095-642e363a6703": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00792077",
        "Secondary_id": "NCT00553358",
        "Statement": "the primary clinical trial abstains from using lenalidomide, whereas the secondary clinical trial uses high doses of lapatinib in intervention 1."
    },
    "9d447ab6-f75c-40b6-88ca-db2e904ef02d": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "the eligibility for the primary clinical trial imposes no restrictions on mental health, bodyweight, age, karnofsky/ecog score or prior treatments."
    },
    "9bd55a1f-e5dc-4620-ba52-73b4bf792459": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "individuals with a history of pulmonary embolisms and current breast implants are allowed to participate in the primary clinical trial."
    },
    "dcea72d4-afb6-4565-8d92-fd259ed8ee15": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "patients actively recovering from recent organ transplantation can be enrolled in the primary clinical trial but not in the secondary clinical trial"
    },
    "f8e8c733-3fc0-4699-814f-b5d505c71435": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel"
    },
    "f9ac9b4b-4033-416b-b66c-0ecf23a9a06c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "the primary clinical trial has observed more instances of mucositis oral, epileptic seizures, and thromboembolic events compared to the secondary clinical trial"
    },
    "47dbd397-7aa3-4c9b-9241-d148a255902a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "0% of the participants in group 1 of the primary trial were found to have lesions, and over 0.95 of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "3793f6d8-1a56-48aa-b3d3-1216f7bf5d29": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "maculo-papular Rash was a common adverse event for the primary trial participants. eosinophilic infiltrate is an inflammatory infiltrate composed exclusively or predominantly of eosinophils."
    },
    "65f9af41-9bb8-438a-b967-94acfd0e08a9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the primary clinical trial has not documented any outcomes for the lbh589 and lapatinib cohort"
    },
    "e68875c8-9905-4821-ac2a-8fe4576a2071": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "the primary trial had one test group and one placebo group, the secondary trial had 2 test groups. nucleolar granular material is a collection of preribosomes in the nucleolus."
    },
    "fd4c7d94-8d93-46b1-b467-3f169c6af30e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "patients confirmed to have metastatic or unresectable scbc based on histology are not allowed into the primary clinical trial unless they test positive for either er or pr or both."
    },
    "50252016-e56e-4dc0-99d0-589c3dfe05e8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00687102",
        "Secondary_id": "NCT00819182",
        "Statement": "both the primary and secondary clinical trials reported increased occurrences of intestinal obstructions and case of pancytopenia among the test subjects."
    },
    "9d94e597-591d-409e-a8e2-b205a83533a5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01498458",
        "Statement": "in the primary trial there were 3 times the number of Hepatotoxicity cases as there were cases of hypertension and Pancreatectomy"
    },
    "3d52b3c6-d110-4442-8a2f-1cf87b1092c5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "anal cancer pmx tnm finding v6 is anal cancer in which distant metastasis cannot be assessed. (from ajcc 6th ed.) A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "8d94a62d-400f-4d9d-92aa-d39dd1f37823": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "cohort 1 was the group where all the cases of infections and infestations were recorded in the primary clinical trial."
    },
    "8fcaece4-a0c7-44bf-82b0-50e494825b81": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 52% patients in the primary trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) .,  .,  "
    },
    "b5c0af13-187b-4f3f-8e46-c06d2df27d1c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "cancer patients diagnosed with conditions such as fibromyalgia, thalasemic syndromes or anemia cannot participate in either the primary clinical trial or the secondary clinical trial."
    },
    "5da1c2df-9374-4de9-b43a-c19a03d5652c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "patients with a negative diagnosis for any type of solid tumor are able to participate in phase 1 of the primary clinical trial and for all stages of the secondary clinical trial"
    },
    "66d9fdb8-ea66-43e2-b497-340bc7832155": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "among the primary trial participants, 13% with her2- primary breast cancer who underwent her2-targeted pet/ct. 89zr-trastuzumab treatment developed imagable her2+ metastases"
    },
    "f008bad4-fa46-4187-b784-434238a5992b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "higher doses of alt-801 are given to participants in the primary clinical trial than to those in the secondary clinical trial"
    },
    "151ebcdf-fc4e-443e-8c2d-5189b65cee5b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "the secondary trial  candidates must meet some Performance Status condition to participate, whereas this is not required to be accepted into the primary trial. eurotium is a genus of filamentous fungi in the phylum ascomycota that are the sexual states of aspergillus species."
    },
    "d4b299e3-f371-4311-9ea6-b3301632d7df": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02504424",
        "Statement": "go ontology object is an object providing entry to a gene object's position in the gene ontology consortium's controlled vocabularies. one patient in the primary trial had an incident where a surgical incision reopened after the surgery."
    },
    "b0c426df-6a70-4d19-a120-e3bc56c49918": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "healthy individuals, not diagnosed with any form of cancer, may be eligible for all study groups in the primary trial and the secondary trial."
    },
    "9f08a841-c0c4-42e4-984f-0700bb46f18f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "all patients in the primary trial receive at least 20000mcg of mcs110 every 21 days."
    },
    "ab0a9eb7-2f28-425a-aa06-2389f0c1e9f7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the primary clinical trial does not involve any unit of measurement, while the secondary clinical trial does.'"
    },
    "117067e9-9bde-4d49-a4d2-51e9ac9886f6": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 8 weeks over 6 weeks, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "9c7521a7-87fc-4dc0-8c1e-5720836763e2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "Participants must be resistant to AI therapy and mirtazapine to participate in the primary trial, but this is not necessary to be included in the secondary trial"
    },
    "6c5d5b1a-e7e0-427f-b21b-a9fbc5e2b69e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "indwelling urinary catheter is a hollow tube that is inserted and left in the bladder to promote the drainage of urine. the primary trial intervention is given topically, whereas the secondary trial intervention is exclusively administered through a needle or tube inserted into a vein."
    },
    "bca4c94d-4a49-4e05-82ed-0d5c9707685b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "The intervention in the primary trial consists of a single drug, whereas in the secondary trial the intervention requires at least 3 different drugs."
    },
    "f5b7285d-3b0a-496a-84c8-012c4873a7be": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "secondary clinical trial stipulates that patients who have been subjected to chemotherapy or radiotherapy within a fortnight, those suffering from unstable angina, or experiencing grade 2 or above neuropathy, are unable to participate. the primary clinical trial, however, remains open to such patients unless they possess non-healing surgical wounds."
    },
    "a012091a-9e07-4878-81bf-fee2e3282cbd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "Patients with histologically documented metastatic SCBC are excluded from the primary trial. how big a problem is bleeding with urination is a question about an individual's assessment of how big a problem bleeding with urination has been."
    },
    "5976b8b7-0f88-4e52-8ad7-39609dabbf8e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00254592",
        "Secondary_id": "NCT00404066",
        "Statement": "patient cohorts in both the primary and secondary clinical trials receive cyclophosphamide, paclitaxel and pegfilgrastim."
    },
    "37b9368c-1aae-4acd-ad7a-ffe4422c9e5d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "brucella is a genus of aerobic, gram-negative, coccobacilli shaped bacteria assigned to the phylum proteobacteria and the family brucellaceae. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin twice daily, and the secondary trial administers its patients with Depocyt and HD-MTX."
    },
    "e78805f7-1b81-4cd9-a3c7-591886fd5d70": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "Paclitaxel is only used in the cohort 1 intervention of the primary trial, whereas cohort 2 is administered fulvestrant instead"
    },
    "71c0cfa6-88a6-4efa-8204-7252f6e6ef57": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "psa level less than four is a blood concentration of prostate specific antigen less than 4 ng/ml. The Interventions in the primary trial are administered through different routes."
    },
    "cafb9767-9320-40fc-a862-53530450f96f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine. high calcium level is a higher than average level of calcium in a sample."
    },
    "ba8e855f-8cff-474d-a2dd-d5061a039b47": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "1 case of Anaemia and Febrile neutropenia were recorded in cohort 1 of the primary trial, but no cases of Pancytopenia. clinical trial subject questionnaire is a document intended to capture specific subject-related information through a series of questions."
    },
    "51220352-fff0-4e70-b36d-7f9e87498a58": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00030823",
        "Statement": "13 participants in the primary clinical trial received the fix-dm1 therapeutic agent as a treatment"
    },
    "475fbb72-9858-40cf-b7f0-50236d032582": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "the secondary clinical trial allows participation of patients irrespective of their age, while the primary clinical trial accepts only those between the ages of 18 to 45."
    },
    "42f1e6c1-7775-4513-b810-a5559fcf60be": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ILD/DPLD within the last 3 years, with a life expectancy of 6 months would be eligible for the primary trial. lead site v10 is a unipolar chest lead at which the electrode is placed over the dorsal spinous process of 7th thoracic vertebra."
    },
    "3ca94519-994e-4921-95ef-fdd1daf0932c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01310075",
        "Secondary_id": "NCT02796755",
        "Statement": "a woman who has undergone breast conservation therapy would be excluded from the secondary trial and the primary trial."
    },
    "066d1275-7efd-47d6-aba2-96bc464cbe2f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "the occurrence of emesis was non-existent among patients who received the placebo intervention in the primary clinical trial"
    },
    "72921dd1-88c7-4aff-a98e-8af859e4f04f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "global partial response gvhd is a clinician overall severity score that has decreased by 2 or more points on a 0-10 scale. Both the primary trial cohorts receive pre-operative Dexamethasone."
    },
    "19ec40c8-5482-490f-9418-5667705632df": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the primary trial and the secondary trial recorded the same total number of adverse events in their patient cohorts. drug used since last visit is an indication that a specified drug was used during the time since the last visit."
    },
    "66816aea-0de7-486c-b9d4-4ca6d9f09d52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02404441",
        "Secondary_id": "NCT01008904",
        "Statement": "the secondary clinical trial uses just one set of criteria for all study participants, whereas the primary clinical trial categorizes participants into different groups, each with their unique inclusion/exclusion criteria."
    },
    "40034c62-a8d9-424f-ac22-2d5fcab4dfc0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "while the educational dvd will be an intervention element for the initial cohort in the primary clinical trial, the succeeding cohort will instead undergo standard radiotherapy treatment"
    },
    "effcbfa0-9271-4463-9e48-5523d5cedeb6": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "despite satisfying all eligibility conditions for the primary clinical trial, the final call for participation will be taken by the patient's closest family member."
    },
    "5f36a4ca-cd2f-4c38-8040-9b36da0ebbe4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "only american patients who fall into a specific weight range are eligible for the primary clinical trial"
    },
    "6432c266-a7b8-4cda-b5b8-7fd13cb023fb": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "the groups in the primary clinical trial differed significantly in their results, and the reflexology group and control group in the secondary clinical trial generated divergent results."
    },
    "5261c924-d9ef-43ed-8f2a-6c5b1552cc62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will have to meet some additional requirements."
    },
    "6aa80695-37e9-4a46-aa19-2fd1f75d8f11": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 150,000 mcg of oral pregabalin every fortnight over 1.5 months, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "12c5e376-9a01-4581-9d78-db71f92ef23d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "The placebo and Trabectedin intervention in the primary trial are administered in the same manner, but on different days. double is a 64-bit floating point primitive. when wrapped in an immutable object, it is called a double."
    },
    "e42e5fc5-cdf8-40c3-9cf7-44ff5bdff413": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "neither the primary nor the secondary trial imposes restrictions based on age, but patients must be between 25-55 years old for the primary clinical trial."
    },
    "aecd2958-c3b4-4d87-82f1-07add215b1e8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "cohort 1 of the primary trial receive pre-operative Dexamethasone, whereas cohort 2 recieves Dexamethasone 2 hours after the operation."
    },
    "e255fdb7-4e8b-4e62-bbb8-875687948bed": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "all the participants of the primary clinical trial subjected to the placebo intervention experienced incidences of vomit"
    },
    "55e1354d-d4b5-4bd0-92e7-9c461f2e2808": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "candidates for the primary clinical trial must have a confirmed her2 positive tumor, as ascertained by ihc 3+, and need significant assistance along with regular medical attention"
    },
    "6e125367-3fa8-46b3-a58d-b3baa894bc70": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "women aged 60 or 70 are eligible for the secondary trial, but will need to wait 10-20 years to be eligible for the primary trial"
    },
    "1b56f68b-a4b1-433c-a634-73ff99fce7aa": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "box dosing unit is a dosing unit equal to the amount of active ingredient(s) contained in a box. There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial."
    },
    "1dcd53cf-49bf-4a4e-857d-008139ceb6a9": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "participation in the primary clinical trial is contingent upon a mammography, whereas the secondary clinical trial does not impose such requirement."
    },
    "263e2baf-2196-42fb-8d68-e6dea7cad9b5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "there was no increase in blood bilirubin levels in any of the patients in the primary clinical trial."
    },
    "a411d500-0770-42d9-8621-ca6b4b63553e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "the growth factor signature decreased by 49.2% more in the dalotuzumab 20 mg/kg group than in the triple negative group in the primary clinical trial."
    },
    "90432ec4-8df5-408b-8998-39f2a698314d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "patients who have been bedridden following a recent heart transplant are accepted into the primary clinical trial but are disqualified from the secondary clinical trial"
    },
    "1c594930-3c65-42d3-86ed-a0a8f46d369c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial. thymic adenocarcinoma, not otherwise specified is a primary thymic adenocarcinoma that does not conform to either low-grade papillary adenocarcinoma or enteric-type adenocarcinoma."
    },
    "4c9638ac-5716-4657-9279-f756aea52867": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "seven different drugs are administered to participants of the primary clinical trial, who also have to undergo a surgical operation. in comparison, participants in the secondary clinical trial only receive a pair of drugs and do not need surgery"
    },
    "29c084b6-6c7c-4f6b-abcc-6740b951f139": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "in cohort 2, the primary clinical trial had a significantly higher patient enrollment compared to the secondary clinical trial."
    },
    "5553674a-4eab-4515-be9e-147eef2f0d09": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00819182",
        "Statement": "protective face mask is a barrier device that covers the nose and mouth, used in infection control. the primary trial patients in The paced respiration intervention group suffered more Treatment Emergent Adverse Events and Serious Treatment Emergent Adverse Events on average than patients in the The fast, shallow respiration group."
    },
    "6088eecc-56f9-475b-a27a-a23bc646028b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "all participants in the primary clinical trial experienced less than 3 adverse events."
    },
    "8d60b35c-e6df-4e22-a92e-b9c782b9ed1b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "There are less total adverse events and less types of adverse events recorded in the primary trial than in the secondary trial. status code is a coded value specifying the state of the entity or event."
    },
    "f3598d65-2288-40bd-abe1-45eaa69ee03e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "the placebo and trabectedin intervention in the primary trial are both administered on the same day."
    },
    "e8351b8b-d707-4766-b875-777557f0653f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "Pericardial effusions were more common for patients in the primary trial, and Corneal deposits were more common in the secondary trial."
    },
    "c2634312-bbf3-4b44-8cdc-23922a16b9fd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the number of infection, asymmetry, and deflation cases were found to be greater in the primary trial than those detected in the secondary trial."
    },
    "57a1a667-ac8e-49d3-95f5-26aca0d8bfa6": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00373256",
        "Statement": "radiation anemia is anemia arising due to radiation therapy. The difference between cohort 1 and 2 of the primary trial is that cohort 1 is administered 25 mg of sunitinib daily, whereas cohort 2 recieves 90 mg/m^2 paclitaxel."
    },
    "626fbbe0-8d56-40bf-8809-0e5d1d587a4d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00583700",
        "Secondary_id": "NCT02431676",
        "Statement": "only men aged 60 and above can participate in the secondary trial and the primary trial"
    },
    "84781347-ce91-4e60-ba5f-f1bd795d898b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "participants of the primary clinical trial are not administered any vaccines."
    },
    "b9a1b80e-4c45-4a78-962b-13dfe98ab56c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "while 2 in 73 participants of the primary clinical trial had an acute myocardial infarction, none out of the 1674 participants in the secondary clinical trial experienced this."
    },
    "47b36e1f-90d5-4a42-b359-95783c7ae965": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "the primary trial patients receive higher doses of radiation therapy than the secondary trial participants. oropharyngeal polyp is a benign exophytic growth that arises from the oropharynx."
    },
    "c291c60f-fb5e-4c0d-83dc-a8fe9eee445c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "behavioral rating scale is a range of values designed to quantify the qualitative responses of an individual to a set of challenges. All the primary trial candidates must have a HER2 positive tumor confirmed by either positive FISH or IHC 3+."
    },
    "8c1414dd-20b2-415e-8d0e-1f9b8e7951d1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "enteric-coated tablets are not received by any of the participants in either the primary or secondary clinical trial"
    },
    "de8bb37e-838b-4ac0-bd2b-b866feadac64": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "have difficulty getting up from chairs is a question about whether an individual has or had difficulty getting up from chairs. In both the primary trial and the secondary trial there were 0 adverse events which occurred in more than 1% of participants."
    },
    "f8457301-53ba-4316-a6a5-36462bf8167c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients with a body mass index (bmi) in the overweight category can be eligible for the primary clinical trial and the secondary clinical trial."
    },
    "7b1befbe-fec3-4554-89f7-323acfc66d62": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average. tibia is a bone located between the femur and the tarsus, being part of the lower leg."
    },
    "df3a590c-02f9-4dc2-84da-da4d5534c542": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "Neiter of the primary trial cohorts receive any invasive surgery or Neratinib . icd-10 procedure coding system is an international system of medical classification used for procedural coding."
    },
    "a698cb41-106c-4d9c-b4e9-1381f9329079": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00786838",
        "Statement": "both the placebo and trabectedin used in the primary clinical trial are given as three-hour intravenous infusions biweekly."
    },
    "e6ba45db-66f8-4f45-a45a-9217e65c7bbd": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "enrollment in the primary clinical trial is not possible for patients who are at present involved in the secondary clinical trial."
    },
    "93c0565f-98d6-4f6b-92a6-8464567027c7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary clinical trial does not reveal data about the time to progression among patients, while the secondary clinical trial does not keep track of patients experiencing objective response."
    },
    "b6d2381f-f049-4747-ae82-5a9a321ec001": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "only patients with a body mass index within a normal range may enroll in the primary clinical trial."
    },
    "c3f4b547-8d11-42ba-800c-7ccbe1283741": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01421472",
        "Statement": "Breast cancer patients with estrogen negative, progesterone negative and HER2- tumors are eligible for all cohorts of the primary trial"
    },
    "f9dfbdb7-3248-450e-a7d4-782f2e68e057": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "intravascular ultrasound and transverse radial incisions form the backbone of the surgical procedures in the primary clinical trial."
    },
    "f994d3fb-5191-4800-beb7-02fdd6887e3e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "it was reported that the secondary clinical trial had multiple adverse effects affecting over 90% of the enrolled patients"
    },
    "7af8a41a-c4b2-402e-bf50-a14aa2758926": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "hour times milligram per milliliter per milligram per kilogram per day is a dose calculation unit expressed in hours times milligrams per milliliter, divided by milligram per kilogram per day. Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial."
    },
    "b87ab44e-6cbe-4567-98ff-bd820aa7edeb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with HER2- Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed Imagable HER2+ Metastases"
    },
    "df0874d1-340f-4e10-b7eb-275770f79f6f": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "women of child-bearing potential and sexually active men are excluded from the primary clinical trial."
    },
    "ed6a6f04-0b3d-4dc7-96fd-2f0547d6fe17": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "a diagnosis of a single cerebral metastasis will lead to an automatic exclusion from the primary trial yet it allows eligibility for the secondary trial."
    },
    "c8b6ed79-b613-4ed4-b2ad-2e2ca4f5dcd4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "no adverse events have been recorded for the patient cohort of the primary clinical trial."
    },
    "56daf92a-2c6e-4b2d-b532-3035e757e98c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the most commonly occuring adverse event across the patient cohorts of the primary trial and the secondary trial was syncope, which occurred in 5.00% of the primary trial patients"
    },
    "687b9bc0-7328-4ecc-9bae-6b63f2df3cdb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00305695",
        "Secondary_id": "NCT00475085",
        "Statement": " intervention 1 in the primary trial, and all intervention drugs in the secondary trial must be administered intravenously. residual cancer burden is an indication of the amount of invasive cancer in breast or lymph node tissue after completion of neoadjuvant chemotherapy."
    },
    "038bc748-0ea5-4d83-b799-b986177f9dbf": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial only three cohorts recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 800 mg dose of pdr001, and 10 mg/kg dose of mcs110."
    },
    "726add6d-9f17-4e3e-a43e-8b391fbb953b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "Patients in the primary trial will receive higher doses of Alpha Lipoic Acid throughout the study duration, whereas, patients in cohort 1 of the secondary trial receive the same dose of Necitumumab for the entire duration of the trial."
    },
    "89f8f42e-0ac7-4fc4-bbd3-d58ffb933005": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "benign oral cavity soft tissue neoplasm is a non-metastasizing soft tissue neoplasm that arises from the oral cavity. the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel."
    },
    "ba5f6986-4060-4bcb-92ab-6423657d51ba": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the main procedure for participants in the primary trial involves insulin injections, and both groups of the secondary trial are offered tryptophan supplements as well as deep sleep therapy."
    },
    "594bf055-6c27-4319-b7b6-11ef47fab70c": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "in the initial cohort of the primary clinical trial, one instance each of anaemia and febrile neutropenia was documented, while pancytopenia was not observed."
    },
    "ed50607e-8c46-4565-9192-4d5c4ca5fea5": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 2 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril. aortic valve regurgitant volume is a quantitative measurement of the amount of retrograde blood flow across the orifice of the aortic valve."
    },
    "ce26a25e-c6ff-4bba-bd54-b0e069440746": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "not a single instance of a maculo-papular rash was reported in the primary clinical trial."
    },
    "128fd57d-cc06-40a3-8eb5-570441a19652": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "the interventions implemented in the primary clinical trial skip the use of laser-assisted fluorescence angiography and adopt different techniques."
    },
    "b54f065f-7b3e-42b0-8dc6-61dc466f7f59": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00791037",
        "Secondary_id": "NCT01702571",
        "Statement": "the primary clinical trial and the secondary clinical trial assess various patient traits in their outcomes."
    },
    "64e0d68e-9fdb-4625-b179-316cf3772ee9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "the primary clinical trial implements its interventions via multiple routes."
    },
    "d9f28f1f-3a09-4ef9-a80a-9caa02f9069b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent. glandular odontogenic cyst is a developmental odontogenic cyst with epithelial features that simulate salivary gland or glandular differentiation. (who 2017)"
    },
    "1046f15f-8bef-4d73-99a1-34ab32da6ea6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "there was a total of 3 cases of shingles across both the patient cohorts of the primary trial and the secondary trial. vasectomy reversal procedure is a surgical procedure to reattach a previously cut vas deferens."
    },
    "4e9ce538-8418-4432-b3e7-8f3ecfefee6d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "The the primary trial Paclitaxel Plus Bevacizumab Plus Gemcitabine group had a better ORR than the Paclitaxel Plus Bevacizumab group and had more participants in it. internal auditory canal meningioma is a meningioma that affects the internal auditory canal."
    },
    "262e8bd4-da64-4158-b23d-b875050e66af": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00148668",
        "Statement": "in the primary clinical trial, both treatments involve the use of an identical paraplatin dose"
    },
    "2529171f-85e8-4d19-8023-dc1a28416fa1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there are 5 shared inclusion/exclusion criteria between the secondary trial and the primary trial"
    },
    "f8accdcd-5a92-4fff-9e6b-6a2d141b5ee4": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "Patients with a history of severe anaphylactic reactions to trastuzumab cannot take part in the primary trial. maid regimen is a regimen consisting of doxorubicin, ifosfamide, dacarbazine and mesna used to treat unresectable soft tissue sarcoma."
    },
    "700f4bd9-6d39-4d3a-a425-bcb34d6712b6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "Women suffering from both claustrophobia and osteoporosis or not eligible for either the primary trial or the secondary trial. usual severity difficulty sleeping is a question about the usual severity of an individual's difficulty sleeping."
    },
    "2aa1c4f5-a46c-4004-9a8a-52e2ac476181": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00706030",
        "Statement": "Only 4 different types of adverse events affected patients in the primary trial, all of which were in cohort 2. lordosis is abnormally increased curvature of the lumbar portion of the spinal column."
    },
    "693c9e39-1648-4f3a-8a23-d642d7355b98": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "squamous papillomatosis is a benign squamous neoplasm characterized by a papillary growth pattern, diffusely involving a specific anatomic site. the Ketorolac 30 mg group of the primary trial had a -6.4% Recurrence-free Survival compared to the NaCl 0.9% 3mL group."
    },
    "d85fd7f3-2765-407e-a8a3-49c19d9a4311": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00867217",
        "Secondary_id": "NCT00800436",
        "Statement": "Patients diagnosed with breact cancer may be eligible for all study groups in the primary trial and the secondary trial."
    },
    "1b82cbd2-8f68-4c23-974c-b9ebc4fe52aa": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "four different medications are administered to the participants during the primary clinical trial."
    },
    "ee8170da-a81f-42bf-b286-cbb8824040cf": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has received an organ transplant within the last month, would be excluded from the primary trial but may be eligible for the secondary trial. debug is act to locate and correct errors in a computer program code."
    },
    "f13b3dd4-fe4a-4189-b51b-cf72af22deab": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01256567",
        "Secondary_id": "NCT00429182",
        "Statement": "a patient that has received an organ transplant within the last month, and is still bedridden would be excluded from the primary trial but may be eligible for the secondary trial. congo is a country in western africa, bordering the south atlantic ocean, between gabon and the democratic republic of the congo."
    },
    "b83fe708-6ce5-4b18-9d6a-51741249c7df": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "patients who consume alcohol are ineligible for the primary clinical trial, yet those who limit their intake to less than five drinks per day may qualify for the secondary clinical trial."
    },
    "980fb8cd-9ba0-4bac-a2ae-0aea58c2f837": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01383174",
        "Secondary_id": "NCT00749931",
        "Statement": "cohort 2 of the primary clinical trial had a smaller patient count compared to cohort 2 of the secondary trial."
    },
    "8f8be6b6-df75-4757-bc64-b2fbc8849f70": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "There was one case of shingles recorded in group 2 of the secondary trial, but no cases in group 1 of the secondary trial and the primary trial."
    },
    "47485ca0-43cb-4525-9417-a8222961e1cd": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "complete absences of swelling, hypothermia, and confusion were observed in the aes reports from both the primary and secondary clinical trials."
    },
    "37b1b3cc-069a-4597-9375-4e856eeb6f9d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "in the secondary trial, it is acceptable for patients to have undergone cancer treatments such as chemotherapy and radiotherapy within the last 14 days, have unstable angina, or grade 2 or above neuropathy. however, these conditions disqualify them from participation in the primary trial if they have non-healing surgical wounds."
    },
    "481d1201-72b1-41b4-82cc-78b79ea8938a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "In the primary trial only one cohort recieves Armodafinil P.O. daily, and in the secondary trial all patients receive the same dose of PDR001, but different doses of MCS110. sinonasal lymphoma is a lymphoma that arises from the sinonasal tract."
    },
    "8ca66388-46d0-4a5f-9be8-84d35961c823": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "13% of the primary trial participants with PR+ Primary Breast Cancer treated with HER2-targeted PET/CT. 89Zr-trastuzumab developed HER2+ Metastases. male non-neoplastic reproductive system disorder is a non-neoplastic disorder that affects the male reproductive system. representative examples include prostatitis, balanitis, and phimosis."
    },
    "b00e48fb-d5db-46f8-8f16-6f538d178b26": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "a high frequency of cardiac and psychiatric aes were found in the primary clinical trial and secondary clinical trial, while the record showed a low frequency of other aes."
    },
    "5484288d-bc10-458f-a516-d0019792d765": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "candidates for the primary clinical trial are acceptable with any performance status, while those for the secondary clinical trial must have a karnofsky score less than 50."
    },
    "ba873942-b869-4596-bbd6-30d54c94e31b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01314963",
        "Statement": "intervention 1 of the primary clinical trial uses lower doses of radioactive tc99m sulfur colloid than intervention 2."
    },
    "055374e1-939d-4366-835a-edf8e587f45c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "any patients that have undergone antineoplastic chemotherapy, androgens, estrogens or progestogens therapy in the last 730 days before study entry are excluded from the primary trial."
    },
    "0935ad04-3112-4443-8f3a-6b3a07ac9d33": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a radius of 0.3cm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "f2fea6be-a072-4a75-8092-09acdd07d135": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "in the primary clinical trial, both cohorts receive equal doses of cyclophosphamide, eribulin, and docetaxel."
    },
    "de99de33-5cd3-4f28-8859-9297a230ab94": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "during radiation therapy, all patients participating in the primary clinical trial are given a dosage of fentanyl sublingual spray, ranging from 100 to 1600 \u00ac\u00a8\u00ac\u00b5g"
    },
    "5e3fa8fd-a886-411d-8de0-fcbf6ef953fb": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "colon non-hodgkin lymphoma is an extranodal non-hodgkin lymphoma that arises from the colon.  the majority are b-cell non-hodgkin lymphomas. the secondary trial  candidates must be Completely disabled to participate, whereas this is not required to be accepted into the primary trial."
    },
    "073d8ed7-d1ff-4fb7-bc5f-b33397ad6b6c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00896454",
        "Secondary_id": "NCT00588640",
        "Statement": "the primary and secondary clinical trial both use the same unit of measure for reporting their results."
    },
    "f442b08f-4429-412f-99d2-24625bf8bdcd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00104650",
        "Statement": "feel worn out is a question about whether an individual feels or felt worn out. The Interventions in the primary trial included different medications but are administered through the same routes."
    },
    "a77a5845-0747-4291-b6de-4903e453ae6a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "a greater number of patients in the secondary clinical trial were documented as having experienced aes compared to patients in the primary clinical trial."
    },
    "354a388c-18b1-476a-b372-3ac4be472cbc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "the severity of adverse reactions were somewhat higher in the primary clinical trial as compared to the secondary clinical trial proportion wise."
    },
    "4927c9bb-aa2b-4c3c-999b-068e1dca959a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary trial participants receive intra-venous chemotherapy, and all cohorts of the secondary trial are put through a radiotherapy regimen only."
    },
    "e5e13d2e-11bd-4f7c-867d-ab3d0e26666b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 1 drug throughout the study duration, with a maximum dose of 1000 kg/m^2"
    },
    "4ce3082f-28f9-4e23-8808-dde496f77535": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "adverse events observed during the secondary clinical trial exceeded those in the primary clinical trial."
    },
    "4c4e621c-abe5-4a19-b517-31778992b424": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "no patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "d4b54b4a-d675-4d59-b489-2c1a025b2b4e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "patients with a clinically speculated diagnosis of an inoperable non-small cell lung cancer or small cell lung cancer are eligible for the primary clinical trial"
    },
    "a8d30960-8533-42a5-949d-3fe706508806": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT03125941",
        "Statement": "the administration of dexamethasone in the primary clinical trial is pre-operative for the first cohort, while post-operative (specifically two hours later) for the second cohort."
    },
    "46ac728d-deb3-4559-bc71-1729c70c26e7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "the primary clinical trial's cohorts do not receive alisertib; however, each cohort in the secondary clinical trial is given distinctive dosages."
    },
    "45f78c14-258f-4db0-a0f4-10a46761ae2f": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "inclusion/exclusion criteria not met supplemental qualifiers dataset is a dataset containing supplemental information, specifically non-standard variables, to parent records in the inclusion/exclusion criteria not met domain. The the primary trial results report changes in Pain intensity and the secondary trial measures the change from baseline to 9 months in bone mineral density (BMD) of the lumbar spine."
    },
    "cc807530-f293-4c99-921b-f6e303d2b825": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00999921",
        "Secondary_id": "NCT00569166",
        "Statement": "patients who are healthy and not diagnosed with any form of cancer, are permitted to join the primary clinical trial but are excluded from the secondary clinical trial."
    },
    "1907f058-1b77-441e-8824-9cf6be7f1243": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00686127",
        "Secondary_id": "NCT00075764",
        "Statement": "in comparison to the secondary trial, the primary trial has fewer adverse events overall but a higher occurrence of cardiac-ischemia/infarction."
    },
    "1d75f8ad-2c35-4481-b6f7-58db73eeea7b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00911898",
        "Statement": "cbfa2t3 gene rearrangement is a molecular abnormality indicating rearrangement of the cbfa2t3 gene. The the primary trial intervention section requires surgical and imaging procedures."
    },
    "d035a6bb-0d8f-4a6b-b725-f8b2535883eb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "the primary clinical trial consists of one cohort that utilize the focused breathing instructional audio guide thrice daily and do not undergo regular chemotherapy sessions."
    },
    "44b1585a-3a5f-4ff7-a523-04923546b2c0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "some patients participating in the primary clinical trial receive mcs110 more frequently than every 3 weeks."
    },
    "bcbe90f9-602b-45bc-aa97-28e50238e2fb": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "relational and item-specific encoding task is a clinical test designed to assess episodic memory encoding and retrieval processes in individuals with cognitive impairment. Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial."
    },
    "4417c4c8-522f-4e46-8b8d-310995182d70": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00475085",
        "Statement": "cohort 2 of the primary clinical trial has 10 participants fewer than cohort 1"
    },
    "256cd40a-7afc-401d-9d02-c013ee3ee68d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00963911",
        "Statement": "in the primary clinical trial, the intervention includes obligatory fitness routines for all the participants."
    },
    "2a2a6190-619e-478b-a97d-5a253a8f916c": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00405938",
        "Statement": "patients with a recent history of abdominal fistula or gastrointestinal perforation can participate in the primary clinical trial"
    },
    "2d61f68b-3907-4337-bc4c-20f219a1c678": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "in the primary clinical trial, all patients with pr+ primary breast cancer treated with her2-targeted pet/ct. 89zr-trastuzumab remained metastases-free"
    },
    "84859b73-1029-4815-a059-79c20cc06f91": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "no psychiatric disorders like eating disorder or schizophrenia emerged as a consequence of the primary clinical trial."
    },
    "8c002058-a160-4eab-bb58-5874ac1a86d4": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00587964",
        "Statement": "specific symptoms are predominantly reported as adverse events in the primary clinical trial"
    },
    "bd6fc6e9-c2ad-4803-b9ef-5a92d10e4155": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 36 year old patient with clinically confirmed diagnosis of stage ii lung cancer, absolute neutrophil count of 1200/\u03bcl, platelet count of 80,034/\u03bcl, hemoglobin level of 70 g/l, and a life expectancy not surpassing 4 months would not meet the criteria for the primary clinical trial and the secondary clinical trial."
    },
    "ceb02a85-73a3-4c00-823e-fb88bc91d239": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day."
    },
    "3d85fd79-27cc-4e06-b4e0-88348ab9ac0a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "there is no overlap in the inclusion and exclusion criteria for the primary and secondary clinical trials."
    },
    "2669332d-8907-4f82-afbf-e7be6b3c81b3": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "not all patients participating in the secondary clinical trial meet the requirements for inclusion in the primary clinical trial due to differing standards"
    },
    "4dc8e4d2-0265-4de1-98df-bcfb33c044e3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "suramin and paclitaxel are given to every participant in the primary clinical trial, unlike the secondary clinical trial which doesn't disclose the drugs to be used in its intervention section."
    },
    "5e38b301-c67d-47dc-8117-ad86b9eeb524": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "participants in the primary trial are treated with only 1 drug and no surgery is involved, whereas the participants of the secondary trial are treated with a combination of 5 drugs and surgical intervention is required"
    },
    "42dca69f-0e7b-4945-9123-90e576db8c25": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial does not require injections, instead compels patients to adhere to a protocol of guaiacum based treatments; the secondary trial on the other hand requires patients to submit to the administration of a 200 milligrams of selumetinib intravenously every fortnight."
    },
    "7e4c273a-fc2f-4589-beb8-4e90f3198962": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02234479",
        "Secondary_id": "NCT01920061",
        "Statement": "the primary trial is testing the effects of different gels on its study groups, whereas the secondary trial is testing different doses of the same treatment on its study group. oral cavity lipoma is a benign adipose tissue neoplasm of the oral cavity. it usually occurs within the lingual and buccal mucosa."
    },
    "00831e0c-eaad-4fe9-a791-f105815fa215": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Patients suffering from severe insomnia are excluded from both the primary trial and the secondary trial"
    },
    "94604a45-9867-4ccd-b38b-de2a3368130e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "no notable variances were present in the outcomes of the primary clinical trial groups, and both the reflexology group and control group in the secondary clinical trial garnered matching results."
    },
    "a127c618-ace8-46cf-9b52-7655f2ccee9c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01743560",
        "Secondary_id": "NCT01730729",
        "Statement": "for the primary clinical trial, children and adolescents are not accepted due to not meeting the height requirement. however, the secondary clinical trial does not overtly rule them out."
    },
    "dfc09a24-8631-4fa3-893e-4d10a9bac4b8": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01286987",
        "Statement": "breast cancer patients in the primary trial are administered 50 mcg/day of talazoparib whereas ovarian/ peritoneal cancer patients in the primary trial receive only 100 mcg/day talazoparib instead."
    },
    "d81e386d-9799-44bc-b006-8fdd7c14103c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "the primary trial treats one of its patient cohorts with 1000 mg of oral pregabalin twice daily, and the secondary trial administers its patients with depocyt and hd-mtx."
    },
    "e5f60086-55a3-4432-9e9d-74690054db5d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "A Patient that has a primary tumour with a diameter of 33mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial. carotid artery disorder is a non-neoplastic or neoplastic disorder affecting the carotid artery."
    },
    "52b055fd-9e0d-41ad-9eb7-1a724cbc0112": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "There were no significant differences in the results from the groups in the primary trial, however some differences where found between the Reflexology Group and control group results in the secondary trial."
    },
    "62d189a0-04ee-44d7-962e-35629b28736c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism in the last 1440 hours are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "d99663b8-44bb-4480-9171-e10fc1ef25b1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00245050",
        "Secondary_id": "NCT02961790",
        "Statement": "one test group and one placebo group constituted the primary clinical trial, in contrast, the secondary clinical trial was composed of two test groups."
    },
    "2ceabe21-98c6-44e3-9cb2-03d3e73124a7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "if a person smokes, they won't be permitted in the primary clinical trial, however, they may qualify for the secondary clinical trial if their daily alcohol consumption is under 5 drinks."
    },
    "45741764-5967-4905-83dc-06481353f56b": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "robotic-assisted imaging is an imaging technique that uses a specially designed robotic system to aid with the imaging of the desired object. the primary trial and the secondary trial report on the MTD of different interventions."
    },
    "5461003b-2108-4302-96ad-d843b5b9e938": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03346161",
        "Statement": "zero adverse events were documented in both cohorts of the primary clinical trial"
    },
    "3cc54fbb-86c4-44f1-b623-0a613adbc7e8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00377156",
        "Secondary_id": "NCT00741039",
        "Statement": "having multiple cerebral metastases is necessary for admission to the secondary trial, however, for the primary trial, a diagnosis of multiple brain metastases will lead to exclusion."
    },
    "67b2e192-d596-4951-b6d0-75f957072bdb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "every patient in the primary trial is receives a dose of 500 to 10000 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy"
    },
    "aba3d5b6-63f0-4eaa-a345-2e9624932e9b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "patients with quantifiable metastasis or with cancer that has spread to other parts of body are eligible for the primary clinical trial."
    },
    "d88235dd-c37b-4971-9c1f-42b282ff41c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent."
    },
    "afdafe17-63a8-4fca-b923-a2bb964493d1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 3 years would be excluded from the primary trial"
    },
    "79f436e1-8238-4d99-824f-6b19bfbd4ec4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00001832",
        "Secondary_id": "NCT02038218",
        "Statement": "drug-based cures in the primary and the secondary trial are utterly diverse in nature."
    },
    "28d5dbe8-5006-4735-8274-fc37e55dbbbd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01920061",
        "Statement": "The same perecentage of patients suffered adverse events in both cohorts of the primary trial. skin condition bleeds is a response indicating that an individual's skin condition bleeds."
    },
    "6acfb64a-4e08-4cdb-b52d-f0a5c466de4d": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "The LBH589 With Capecitabine cohort of the primary trial produced worse results than the LBH589 and Lapatinib cohort. bio event is an abstract class to capture the concept of an event (either in the laboratory or a computational analysis). (camage)"
    },
    "094e7aec-88db-4ad0-b995-ece8587fd48b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01222390",
        "Secondary_id": "NCT02509156",
        "Statement": "There are no X-rays, transendocardial injections,  CT scans or MRIs included the interventions of the primary trial and the secondary trial"
    },
    "475a8280-5855-4c8c-a9ca-7720f9a9be7f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02165839",
        "Secondary_id": "NCT01205503",
        "Statement": "for admission into both the primary and secondary clinical trials, it is necessary for applicants to achieve a baseline performance score. this is demarcated by a karnofsky score of more than 70 in the primary trial, and for the secondary clinical trial, a karnofsky score above 55 is necessary."
    },
    "c660c228-b490-4779-9ead-ad8b2be40520": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "jug dosing unit is a dosing unit equal to the amount of active ingredient(s) in a jug. 36.36% of the primary trial patients suffered an increase in Blood bilirubin."
    },
    "57c87de4-06c1-4d6f-9ed8-ed09e82cd3c7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00756496",
        "Secondary_id": "NCT00825682",
        "Statement": "significant differences were observed among the groups participating in the primary clinical trial, while all groups including the reflexology group showed similar results in the secondary clinical trial."
    },
    "943db9fb-b25b-4e58-bf2f-af46b1d9df54": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "hospital admissions were reported during the primary clinical trial"
    },
    "ead18343-9437-4aa4-9bbc-2e20f7c28025": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial reports the overall survival in months for all 300 patients included in the study, while the secondary trial reports the percentage of non-responding patients"
    },
    "775258b4-fe6f-4487-a162-ce25e5a665c0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01823991",
        "Statement": "patients diagnosed with alzheimer's disease are eligible for the primary clinical trial"
    },
    "1d8450d1-ac32-4f98-ac75-1d6e212b0879": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial. met gene mutation negative is a genetic finding indicating that met gene mutations have not been detected in a sample."
    },
    "922b377f-efa2-4bee-9689-f019c011057e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00569166",
        "Statement": "btc gene product is a protein encoded by the btc gene. Cohorts 1 and 2 of the primary trial follow the same paced breathing instructional CD, however cohort 2 practices twice a day."
    },
    "8bc20833-6293-47e3-aafe-c7a0ca3be9a6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism in the last 20 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "6690be43-edee-4061-a850-47540cc49bee": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01466972",
        "Statement": "No two patients in the primary trial suffered the same type of adverse event. juvenile idiopathic arthritis is a group of chronic, inflammatory childhood disorders of unknown etiology that primarily involve joints."
    },
    "0aab1829-69a6-4db5-ae99-78b1f9c9cbc0": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography and Lateral radial incisions are used for both interventions in the primary trial. t-cell non-hodgkin lymphoma by ann arbor stage is an anatomic stage for t-cell non-hodgkin lymphoma based on the ann arbor classification criteria."
    },
    "b4fca47f-894d-47b9-a6a2-38867864c1bc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a radius of 0.3cm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "01d0c4bf-e697-4565-906b-edd21fd2227f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients with severe cases of schizophrenia and insomnia are unable to partake in the primary and secondary clinical trials"
    },
    "c640af56-cef3-432a-87f2-b2b446b7ab96": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial receives 0.5mcg/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any dexmedetomidine."
    },
    "d8af88b9-e015-4eec-b49f-6b2398e38a5d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "synchronous nodules without dominant lesion(s) is a finding of multiple pulmonary nodules in which radiologic imaging shows no evidence of a dominant lesion. Across both the primary trial and the secondary trial over 10 deaths were recorded in the adverse events."
    },
    "e6bbed17-0fdf-4008-b56e-4d901490ce1a": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00513292",
        "Secondary_id": "NCT00148668",
        "Statement": "the primary trial and the secondary trial both use pCR as their outcome measurement, there is a small difference in results between the two cohorts of the primary trial, whereas in the secondary trial, Arm 2 had much better results than arm 1."
    },
    "25efd6b7-dd3c-472e-babe-6d5397241653": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "individuals who are significantly overweight are fit for the primary clinical trial"
    },
    "a08b1e1e-385a-40e6-990d-05b9aebc7335": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary trial requires patients to receive 240 milligrams of denosumab injected subcutaneously every month, the secondary trial does not require injection, instead using lymphoscintigraphy."
    },
    "201c2df5-585d-4d20-a19b-c2b12db5dc5f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "Smokers are excluded from the primary trial but may be eligible for the secondary trial if they drink less than 5 alcoholic drinks a day. megakaryopoiesis is a hematopoietic process that refers to the production of megakaryocytes in the bone marrow."
    },
    "2853d135-6a33-4c1f-bf2c-251ef936c5dd": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "0.25 of patients in the primary trial suffer increased pleural effusion and rapid disease progression"
    },
    "28061f9c-36e0-4f1f-9f51-1c01efd608a1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01178411",
        "Secondary_id": "NCT01772004",
        "Statement": "history of medication is a history of the medication that the patient has taken. the nationality, ethnicity, weight or gender of a patient will not affect their eligibility for the primary trial or the secondary trial."
    },
    "a003e152-72e6-4c28-9f7d-1d2086174992": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "under half of the patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel experienced a confirmed complete response (cr) or a confirmed partial response (pr)."
    },
    "3ce10e1a-24fe-4575-8f08-583c93fd5274": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02259114",
        "Secondary_id": "NCT01246973",
        "Statement": "primary clinical trial and secondary clinical trial host patients diagnosed with nut midline carcinoma via fluorescence in situ hybridization and those with inflammatory breast cancer."
    },
    "3f532833-d78c-41a1-b364-81228e03027e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial receives 500ng/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any dexmedetomidine."
    },
    "0a1f17fb-d58d-46e3-a726-bf7ef647e88e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00429299",
        "Statement": "positive fish or ihc 3+ results confirming a diagnosis of a her2 positive tumor is essential for all primary clinical trial candidates."
    },
    "0c902de2-30b5-4ab8-9739-70be987d043a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00623831",
        "Statement": "25% of cohort 2 patients in the primary trial suffer Increased pleural effusion"
    },
    "4960cf63-01e8-4fc5-b6ea-fe10063c6e6c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01591746",
        "Secondary_id": "NCT01045421",
        "Statement": "in the primary clinical trial, alisertib isn't included in the treatment of both cohorts, yet the secondary clinical trial uses varying doses for its two cohorts."
    },
    "b7b61d5d-629d-43a4-8d75-5897864b6443": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "over 1/2 patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel had progression of disease."
    },
    "9dd03978-dc7f-4c73-a199-92f7247dbf29": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "There were more cases of Mucositis Oral, epileptic seizures and Thromboembolic events recorded in the primary trial than in the secondary trial. acquired factor x deficiency is an acquired coagulation disorder characterized by the partial or complete absence of factor x activity in the blood."
    },
    "c6c56d8f-1e0a-4dad-9993-e47e34c146e7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01419717",
        "Secondary_id": "NCT01314963",
        "Statement": "the primary clinical trial necessitates a monthly subcutaneous administration of 120 milligrams of denosumab to patients, while the secondary clinical trial involves the injection of 0.4 to 1.0 mci of radioactive tc99m sulfur colloid."
    },
    "c389c3cc-2e76-4219-996d-3aa5a925fec7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02038218",
        "Secondary_id": "NCT02187783",
        "Statement": "the secondary trial and the primary trial use different units of measure in their results, for the same outcome measurement."
    },
    "47ff584c-f344-45ab-afec-1c1561453a36": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01606748",
        "Statement": "the primary clinical trial found no traces of anaemia, febrile neutropenia, or pancytopenia in cohort 1."
    },
    "75961bc5-20b9-4161-83e0-a59429ce18e9": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "Over 50% of patients in cohort 1 of the primary trial suffered Acute Vomiting after treatment with Aprepitant, Dexamethasone, Cytoxan and Kytril"
    },
    "5a96ef9e-57ed-4f5a-95b3-db64e3268993": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "group 2 of the primary trial recieves 0.0000005g/kg of myalgias (5ml), patients in the secondary trial cohorts do not receive any myalgias."
    },
    "388cc99c-4cb3-4ff9-9496-07f4a6bf6ac7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream."
    },
    "dece1720-0c33-4000-b6e1-879b75541c33": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00256698",
        "Secondary_id": "NCT02286843",
        "Statement": "Arimidex is used in both cohorts of the primary trial but not applied at all in the secondary trial. nova scotia is a canadian province located on canada's southeastern coast. its capital is halifax."
    },
    "d07ab8cf-9e2e-4ac2-b8e0-20d9fa9bf16a": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "those who have received estrogens or progestogens within the month preceding the clinical study can be included in the primary clinical trial."
    },
    "524f9dd3-ec1a-44fa-b440-59eaa49fe204": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "refractory acute myelomonocytic leukemia is acute myelomonocytic leukemia that does not respond to treatment. All AE types in the primary trial affected less than 10% of patients."
    },
    "a764d548-7ef1-4ec1-bfaf-958536b7342c": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00698035",
        "Secondary_id": "NCT01706081",
        "Statement": "the primary trial is using hormonal interventions, and the secondary trial is testing an acupuncture intervention. wwtr1 gene rearrangement is a molecular abnormality indicating rearrangement of the wwtr1 gene."
    },
    "039b25b3-517a-4663-9b95-94c941ffa30f": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "in the primary clinical trial, both cohorts 1 and 2 were administered identical doses of cetuximab, however, cohort 1 received a supplementary collaborative care intervention."
    },
    "d9c0a0a4-0bdf-4b77-b442-78d609b06854": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "both cohorts a and b in the primary clinical trial are given identical two im injections of ld v935 at similar stages of the cycle."
    },
    "438a978d-ac7e-4260-bb24-d2129cb3dfc6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial"
    },
    "382c5afb-42ce-4711-90c2-c72f34f03729": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00317603",
        "Secondary_id": "NCT00293540",
        "Statement": "the least frequently reported adverse event across the patient cohorts of the primary trial and the secondary trial was syncope"
    },
    "c3c644d4-1964-454a-af82-4e82c2567f6e": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01806675",
        "Statement": "all groups in the primary trial study are subjected to the same imaging processes, including 18f-fdg and 18f-fpprgd2 positron emission tomography / computed tomography (pet/ct)."
    },
    "6815208b-ad2d-4564-b723-2d8e44af78b0": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "active smokers are barred from participating in both the primary clinical trial and the secondary clinical trial."
    },
    "5ecfe0a7-2d7c-4207-b62e-0b28b699951d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00950911",
        "Secondary_id": "NCT00999921",
        "Statement": "the primary clinical trial's intervention 1 includes a 12-fold higher dosage of zoledronic acid compared to the dosage of denosumab used in the secondary clinical trial's first intervention."
    },
    "e4b57c09-4069-463e-9db3-70860f520524": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary trial participants are administered over 7 different types of drugs and have to undergo surgery, whereas the secondary trial participants only receive two different drugs and do not have to undergo any surgery. ambamustine is a tripeptidic nitrogen mustard compound and bifunctional alkylating agent with antineoplastic activity."
    },
    "437fedde-1e69-4514-ac5f-d8d532497280": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01008904",
        "Statement": "The only AE recorded in the primary trial was Stomatitis. drug accountability assessment test code is a character or string that represents the short code name of the drug accountability assessment."
    },
    "6bbcd12e-4105-478b-a402-1374ce8a01df": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00370552",
        "Statement": "Women of child-bearing potential and Sexually active fertile men are eligible for the primary trial, but they will need to commit to abstinence for the entire study period . skin signet ring cell basal cell carcinoma is a rare type of basal cell carcinoma. it is characterized by the presence of mucin containing signet ring cells."
    },
    "a36a79c9-39aa-493e-a7f9-18771e4a50cf": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "no notable occurrence of pathologic complete response was observed in breast and axillary lymph nodes among trial participants in either cohort of the primary clinical trial after around 7 months post-surgery"
    },
    "91aed56a-2b8e-4f23-9885-4f05e6115537": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "acupuncture patients in the primary clinical trial did not see any significant improvements in their lymphedema as compared to those on the waiting list."
    },
    "38ca4d41-1f13-4735-983d-9ac5b1b816f0": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "in the context of the primary and secondary clinical trials, the maximum tolerated dose of mm-111, for patients involved in the secondary clinical trial, is reallocated at 15 mg on a daily basis"
    },
    "bf00cf4b-27eb-4c1a-88e2-f86df10f2727": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "more than 10 patients in both cohorts of the primary trial experienced pathologic complete response in breast and axillary lymph nodes after approximately 24 weeks after the surgery"
    },
    "4c926c31-8786-47b0-a032-1d59f759bca5": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "the primary trial and the secondary trial adminster their interventions orally."
    },
    "c8a83ca7-bc34-4afe-9323-7439ed841bca": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01008150",
        "Statement": "almost 7 months following the surgical process, more than 42 patients across both batches of the primary clinical trial demonstrated a pathologic complete response in breast and axillary lymph nodes"
    },
    "c21d4d07-87ea-46ba-b930-9fd3fb0797a5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "patients who are currently engaged in smoking are ineligible for both the primary clinical trial and the secondary clinical trial."
    },
    "b464cd26-7734-455c-85c1-04a4ec324c55": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the month before study entry are excluded from the primary trial. supermarket is a large self-serving retail or wholesale market that sells food and household goods. (webs84)"
    },
    "ca7e6cda-c7dc-4cc7-82d5-732998d7993e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01129622",
        "Secondary_id": "NCT01156987",
        "Statement": "women without any health conditions are not eligible for either the primary clinical trial or the secondary clinical trial."
    },
    "99eb2e5a-77d2-4ab1-a25b-b6d8a8bcf412": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00209092",
        "Statement": "despite fulfilling all the exclusion and inclusion requirements for the primary clinical trial, the ultimate choice of participation is at the discretion of a court appointed guardian or representative."
    },
    "6151cf03-78f0-4404-87bc-beacea52cd95": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "patients who have had instances of pulmonary embolisms are ruled out from the secondary clinical trial, likewise, patients with breast implants at the moment are also barred from the primary clinical trial."
    },
    "85d61aaf-5255-4203-9ccf-f9c3da7a352e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00075764",
        "Statement": "Patients who's Metastasis cannot be measured, or who's Cancer has not spread to other parts of the body are not eligible for the primary trial"
    },
    "cfa6601b-af52-4eee-883c-89d42b73e02b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03557801",
        "Secondary_id": "NCT00432562",
        "Statement": "the secondary trial patients suffered from anemia, pneumonia and stupor more often than patients in the primary trial."
    },
    "ee42e602-9409-49fa-a454-7a2637ed9d7a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00656019",
        "Statement": "in the primary clinical trial, numerous patients with regular vitamin d levels exhibited noticeable trends in the expression of 40 studied genes."
    },
    "27180597-864a-4375-97c8-e9e41fd297dc": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01250379",
        "Secondary_id": "NCT02988986",
        "Statement": "the primary clinical trial and the secondary clinical trial may be suitable for a 20 year old female recently diagnosed with er-positive, her2-negative breast cancer"
    },
    "70eac1ab-54b0-460d-abda-86f0c5d04483": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03202472",
        "Secondary_id": "NCT01554371",
        "Statement": "patients experiencing unstable angina, or who have undergone chemotherapy or radiotherapy within the last 2 weeks, or are suffering from grade 2 or higher neuropathy, are ruled out from the secondary clinical trial, although may still be considered for the primary clinical trial if they fulfil the necessary inclusion requirements."
    },
    "37e14df5-fd3b-4c30-bda4-6527febc5e2b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01831089",
        "Statement": "those with a confirmed cytological or histological diagnosis of non-small cell lung cancer or small cell lung cancer are suitable for the primary clinical trial"
    },
    "596e650e-f860-4055-b3a6-35fcd9fd33b0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02239601",
        "Secondary_id": "NCT01537029",
        "Statement": "level is a position on a scale measuring intensity, quality, or amount. the secondary trial recorded slightly more total adverse events in its patient cohorts than the primary trial."
    },
    "0997d5fe-8df2-4b29-983a-3d3d2921e320": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01156987",
        "Secondary_id": "NCT02234479",
        "Statement": "all of the participants in group 1 of the primary trial were found to have lesions, and less than 5% of particpants in group 1 of the secondary trial had radiation dermatitis and hyperpigmentation."
    },
    "b0308df2-5725-4b3a-9c80-0d5390bf3149": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "bone marrow transplant recipient is an individual receiving a bone marrow transplant. On average patients from the primary trial survive over 2 years, over 50 patients from each cohort survived more than 24 months."
    },
    "6c31de8a-736c-4741-99d3-fcd0c921e83f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00428220",
        "Secondary_id": "NCT03092934",
        "Statement": "compared to the secondary clinical trial, the frequency of pericardial effusions was higher in the primary clinical trial, whereas corneal deposits were more often noted in the latter."
    },
    "0a7569de-fb79-41f8-acc6-fd155a26e3c8": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "Patients that have a history of pulmonary embolisms cannot take part in the secondary trial, and those who currently have breast implants cannot participate in the primary trial. ulnar length is a measurement of the length of the ulna."
    },
    "87e90ba6-44b6-4dc9-9bac-9ceb0c8cf6f6": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00538850",
        "Secondary_id": "NCT00305695",
        "Statement": "the primary clinical trial results do not concern changes in pain intensity and the secondary trial does not measure the change from baseline to 9 months in bone mineral density (bmd) of the lumbar spine."
    },
    "315f4573-d5b1-4cbc-9efb-74c27a98dc6d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "Patients with histologically confirmed stage 4 breast adenocarcinoma that is either ER positive, PR positive or HER2/neu negative are eligible for both the secondary trial and the primary trial."
    },
    "ef3e540e-b8dc-4fd5-9eaa-f32a657a57c6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00971945",
        "Secondary_id": "NCT00418028",
        "Statement": "both primary and secondary trials demand fulfillment of some performance status conditions for patient participation"
    },
    "18395ec3-337c-4e51-aef9-5b91423999ed": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "The results from the primary trial indicate that the Arm A intervention better overall response rate than the placebo arm, additionally, in the secondary trial the Denosumab cohort had a better Time to First On-Study SRE than the Zoledronic Acid cohort. independent to propel wheelchair is a response indicating that an individual is able to propel their wheelchair independent of help from others."
    },
    "e9e1b48b-55a2-479b-93cd-33db74d3053c": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01969448",
        "Statement": "laser-assisted fluorescence angiography is used for both interventions in the primary trial. gross income is a person's total income before taxes, exclusions, and deductions."
    },
    "ad3c8700-e49c-404e-af40-e9329033f2a7": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "blood bilirubin levels remained unchanged in all the patients in the primary clinical trial."
    },
    "2c29a565-bdcd-464c-85a4-361ab767c0d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "the adverse events of the primary and secondary trials each resulted in multiple deaths."
    },
    "8ddc286d-ac51-4c92-a163-2d9a65b52ae7": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02761642",
        "Secondary_id": "NCT02640053",
        "Statement": "minor help to transfer is a response indicating that an individual needs minor verbal or physical help to transfer. Any cancer patient diagnosed with either Epilepsy , thalasemic syndromes or anemia cannot be eligible for both the primary trial and the secondary trial."
    },
    "19e0531d-7907-46b0-ab0c-e616746498e9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "Group 2 of the primary trial recieves 0.5ug/kg of dexmedetomidine (5ml), patients in the secondary trial cohorts do not receive any Dexmedetomidine."
    },
    "bf103149-cfe0-453f-9b83-d06c0a8958a0": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01037790",
        "Statement": "map2k2 gene amplification is a molecular genetic abnormality indicating the presence of multiple copies of the map2k2 gene. There are a limited number of available places in the primary trial for patients diagnosed with Metastatic colorectal cancer that harbors the Kras or BRAF mutation ."
    },
    "466321f2-f997-47c7-a166-faeffe581547": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT03069313",
        "Secondary_id": "NCT01535040",
        "Statement": "response table is a table of data specifically regarding response. the primary trial adminsters its intervention sublingually, and the secondary trial adminsters it orally."
    },
    "47f5a5c6-964c-40f8-b7b0-2278333f8fe9": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00978250",
        "Statement": "patients diagnosed with metastatic scbc are allowed to participate in the primary clinical trial."
    },
    "365dc837-fcfb-49f6-8dc3-bb74a0f60507": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary clinical trial involves prescribing seven different medications through subcutaneous injection and performing surgical procedures on its participants, on the other hand, the secondary clinical trial restricts its medical intervention to two different drugs and a series of imaging scans"
    },
    "82c8c33d-a45b-4897-8ac5-407ec39564fd": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "one of the patient groups in the primary clinical trial is treated with 150 mg of oral pregabalin twice a day, contrastingly, the secondary clinical trial applies depocyt and hd-mtx for its patients."
    },
    "4e3b9642-3f02-4f4b-bfee-f2e3b1673186": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01313117",
        "Secondary_id": "NCT01606748",
        "Statement": "during the primary clinical trial, patients are administered elevated doses of alpha lipoic acid of up to 100 mg three times daily, in contrast to patients in cohort 1 of the secondary clinical trial who consistently receive the same dosage of necitumumab."
    },
    "a83ed07f-5ce3-44db-83d4-1629e6838c4a": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "for the primary clinical trial, prospective candidates are required to have a mammography, but this is not a pre-requisite for the secondary clinical trial."
    },
    "5f45e043-f49d-42cd-941d-baa17257d46c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "96 participants from the Ketorolac 30 mg group of the primary trial experienced Recurrence-free Survival compared to the 67 from the NaCl 0.9% 3mL group. mold mix antigen igg antibody measurement is a measurement of the mold mix antigen igg antibody in a biological specimen."
    },
    "4fb8207e-292f-4f97-9587-bf028abd57be": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "inactive comment is additional description why an entity is no longer active. All Infections and Infestations cases in the primary trial were for patients in cohort 1."
    },
    "31ec9b33-fa24-4cd9-9341-c54adaa250cd": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with diffuse parenchymal lung disease within the last 36 months would be excluded from the primary trial"
    },
    "0d7d2408-c51f-4b3a-a47f-6f0ee8dedacc": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT00418028",
        "Secondary_id": "NCT00662025",
        "Statement": "the primary trial reports the Time to Progression in months for a total of 156 patients across the two cohorts, on the other hand, the secondary trial reports the number of patients that experience Objective Response "
    },
    "2cc2ce51-0ac2-4e55-baf0-d26f88105aa0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": ",  0.0274 of the primary trial participants, and 0/1674 the secondary trial participants suffered an acute myocardial infarction"
    },
    "340721ab-42f9-4ac3-8608-58007d89b87b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01702571",
        "Statement": "the documented adverse events for cohort 1 of the primary clinical trial are connected to respiratory issues"
    },
    "3cbea791-dc12-4c0e-b672-031b43c49bf2": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "Most patients in cohort 1 of the primary trial suffered adverse events, the inverse is true in cohort 2. ring chromosome 12 is an aberration of chromosome 12 where the arms have fused to form a ring."
    },
    "1f63524b-443d-4382-9df4-ea83eda85940": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "normal weighted, non-pregnant individuals can participate in the primary clinical trial and the secondary clinical trial."
    },
    "487046b0-2368-40da-9cba-407f65177f0b": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "more than 75% of the patients in the primary clinical trial suffered a specific adverse event type."
    },
    "eaf2bb85-799b-47e9-af79-4fc7a54f0fcd": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01597193",
        "Statement": "the primary clinical trial administers a dosage of enzalutamide to cohort 2 that is double the corresponding dosage for cohort 1"
    },
    "fceee201-8b1b-4cd0-ab16-75fed1f2530f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "there was one psychiatric adverse event in the primary trial, which affected less than 0.1 of patients"
    },
    "5accf90d-2307-441f-ae8d-d055d9564a26": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT04080297",
        "Secondary_id": "NCT00929240",
        "Statement": "both the primary clinical trial and secondary clinical trial have distinct criteria for participation, preventing overlap of participants between the two studies."
    },
    "38e0b539-6f73-4e11-bb55-0b021f66ee84": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "in the primary clinical trial, patients in both cohort 1 and 2 are subjected to the same radiation therapy doses, but the procedure for cohort one extends for an extra two weeks."
    },
    "c4e419c4-f227-4c0c-b8b5-c8e0f62585a7": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "the results from the primary clinical trial suggest that the arm b intervention yielded the most promising overall response rate. moreover, in the secondary clinical trial, the denosumab cohort demonstrated a better time to first on-study sre than the zoledronic acid cohort."
    },
    "b34700cb-eba7-431e-9508-75e49298d003": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "in the primary clinical trial, 50% of participants experienced adverse events (aes) of various types"
    },
    "de91b720-a7f8-4c27-8182-f642de29ddee": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01989546",
        "Secondary_id": "NCT01171924",
        "Statement": "candidates undergoing treatments based on warfarin are not permitted for the primary clinical trial, but their participation in the secondary clinical trial might still be possible."
    },
    "e12e5ed1-9a64-4183-9b9d-419e6679ab3d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "Any patients with Significant or uncontrolled cardiovascular impairment cannot participate in either the primary trial or the secondary trial."
    },
    "95cb9c0a-0725-4108-aebb-f114f77b577c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products"
    },
    "7e193fec-c5ef-4c86-8f5c-c7f6dffe11ec": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "pharmacodynamics assay development laboratory is a laboratory that specializes in developing biomarkers for use during drug development. More Palpitations, Pericardial effusions and Abdominal pains were recorded in cohort 2 of the primary trial than in cohort 1 of the secondary trial."
    },
    "efa3cd46-9230-4078-b024-6de0386bfe80": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01306032",
        "Secondary_id": "NCT01614210",
        "Statement": "none of the adverse events seen in secondary clinical trial are faced by patients in the primary clinical trial."
    },
    "dc41de0b-7f1d-4294-8f3c-c0ba6d2fb4d9": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. pseudomonas oryzihabitans is a species of gram-negative, rod-shaped, motile bacterium in the phylum proteobacteria."
    },
    "338fc59d-601e-42b6-8718-858ffe20928d": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01975831",
        "Statement": "The only difference between interventions 1 and 2 of the primary trial is that cohort 1 recieves 0.7mg less of Durva in their monthly injections compared to cohort 2. loss of chromosome 5 is a cytogenic abnormality that refers to loss of all or part of chromosome 5."
    },
    "213bae99-da68-4307-a7c9-71343afbcd39": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01920061",
        "Secondary_id": "NCT01766102",
        "Statement": "the treatment intervention in the primary clinical trial adheres to a three-week cycle whereas the secondary clinical trial does not implement cyclic treatment."
    },
    "c6788d02-11df-4099-a395-c1e3dbc17f35": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01286168",
        "Secondary_id": "NCT01419717",
        "Statement": "The most common adverse event in the secondary trial was Anaemia, affecting more than 5% of patients, there were no recorded AEs in the primary trial. somewhat difficult is a subjective response indicating that an individual finds something to be somewhat difficult."
    },
    "eaad4acd-8fc1-41c6-92aa-1a4488ffdfed": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "cdisc adas-cog - delayed word recall: word 8 is alzheimer's disease assessment scale-cognitive cdisc version (adas-cog cdisc version) delayed word recall task for word 8. There was at least 1 case of infection in both the primary trial and the secondary trial."
    },
    "232cfca0-08b4-45e3-ac2a-01ce31ecb857": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02320123",
        "Statement": "gray commissure is a small area of gray matter surrounding the central canal in the spinal cord. Only cohort 1 of the primary trial will view the Educational DVD as part of the intervention, Cohort 2 will instead receive a regular dosage of radiotherapy."
    },
    "b98c3e78-273c-46dd-ad36-db7aabf5f3a9": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "the operative time was notably longer in arm 2 than in arm 1 during the primary clinical trial, an indication that the control group outperformed the test group. the secondary clinical trial, on the other hand, lacks a control group for suitable comparisons."
    },
    "f2d20a53-59b4-42bf-8d21-1ead0e113107": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "patients who are diagnosed with severe schizophrenia and chronic insomnia are not allowed to participate in both the primary clinical trial and the secondary clinical trial"
    },
    "9a814107-778f-43ba-bd59-383ae14594ed": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": " Women with Newly diagnosed locally advanced breast cancer, confirmed as ER+  Considering a mastectomy are eligible for the primary trial and the secondary trial. bartholin gland adenocarcinoma is an adenocarcinoma that arises from the bartholin gland. subtypes include papillary and mucinous adenocarcinoma."
    },
    "103134aa-c3f2-4ebb-8919-72bdb5611b07": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "no adverse events were reported in both the primary clinical trial and the secondary clinical trial"
    },
    "551bc048-5bac-47a0-a2bf-17844970c8dc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00266110",
        "Statement": "Patients in the primary trial will need to receive several injections. gas cylinder is a container designed specifically to hold gases."
    },
    "5b100056-e657-4b2a-9ecf-8b949233ab50": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00143390",
        "Statement": "the primary clinical trial reported at least one gastro-intestinal side effect and two psychiatric events"
    },
    "ffbff911-ea0e-4f8b-97fd-a54b8f88007a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02122796",
        "Secondary_id": "NCT01421472",
        "Statement": "periodontitis is an acute or chronic inflammatory process that affects the tissues that surround and support the teeth. the primary trial candidates receive less weekly MM-121 and Paclitaxel than cohort 1 the secondary trial candidates, but higher doses of herceptin and doxatel."
    },
    "f82d082e-896d-4d9e-ad92-d64b655dafb8": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "an adult patient diagnosed with ild/dpld within the last 9 months, with a life expectancy of 16 days would be eligible for the primary trial"
    },
    "1641b323-b136-4104-81e5-744ceac933de": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "all ae types witnessed in the primary clinical trial affected less than a tenth of the patients"
    },
    "c67afffa-bf41-4562-bf5e-1ba035fe653c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02403271",
        "Secondary_id": "NCT01649271",
        "Statement": "biliary colic and clostridium difficile colitis are less prevalent in the secondary trial compared to the primary trial"
    },
    "fc7722bc-9fed-46cf-881d-265c3f3762b4": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01803282",
        "Secondary_id": "NCT00963911",
        "Statement": "ikzf1 gene rearrangement is a molecular abnormality indicating rearrangement of the ikzf1 gene. 2/73 the primary trial participants, and 0/1674 the secondary trial participants suffered an Acute myocardial infarction ."
    },
    "4094d002-a140-4eea-aa50-5005989e2057": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02273206",
        "Statement": "in the primary clinical trial's first cohort, most patients had undergone their screenings post-intervention, no matter the type of cancer they had"
    },
    "5119953d-f226-4e3d-96c9-a05862188b6d": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "neither the primary nor the secondary trial reported any cases of infection, asymmetry or nausea."
    },
    "41cc607f-05e2-4377-bca4-328906e47116": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03015649",
        "Secondary_id": "NCT00583700",
        "Statement": "in the primary and secondary clinical trials, the number of adverse events reported by participating cohorts exceeded 100."
    },
    "dffbf597-b236-4aa5-bd94-b471c9e593ea": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00836186",
        "Secondary_id": "NCT00451555",
        "Statement": "the primary clinical trial involves radioembolization treatment for patients and the detainees from all cohorts of the secondary clinical trial are prescribed 500mg of fulvestrant via intramuscular injection twice a day."
    },
    "e0a61eb2-f5c0-4885-94f5-4048944acd1c": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01766102",
        "Secondary_id": "NCT01664091",
        "Statement": "to some extent is an indication that something has been accomplished to some degree or has resulted in some amount of satisfaction. Arm 2 of the primary trial had higher Operative Time than Arm 1, therefore the control group performed better than the test group in this regard. In the secondary trial there is no control group against which we can compare."
    },
    "cd2874dc-b435-4319-8ae9-d413b3f43499": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00871858",
        "Statement": "fulvestrant is only used in the cohort 1 intervention of the primary clinical trial, whereas cohort 2 is administered paclitaxel instead"
    },
    "7d818afc-93da-4098-a0f0-558bc0095687": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer."
    },
    "9ebcda5d-0914-4015-b5d3-9446f9582d01": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "multiple shingles cases were observed in both groups of the secondary trial, but none in the primary trial."
    },
    "957f4300-757b-40ee-926c-3c7deae05ade": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "individuals who have a severe anaphylactic history to trastuzumab are excluded from the primary clinical trial."
    },
    "f0eaf3f3-5c84-4cd8-8a13-ef1af710cf9e": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "adcs-adl severe dementia questionnaire question is a question associated with the adcs-adl severe dementia questionnaire.  Suspected Serious Adverse reactions were more common in the adverse events section of the primary trial than in the secondary trial."
    },
    "a6718ad8-0ba6-4513-aae0-92610b1421e6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00992602",
        "Secondary_id": "NCT00357734",
        "Statement": "there are no cases of bronchopneumonia and general physical health deterioration reported in either the primary or secondary clinical trials."
    },
    "ac3dfb95-6558-4815-b5ed-4887505dedf8": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01434342",
        "Secondary_id": "NCT02599194",
        "Statement": "the secondary clinical trial noted a higher prevalence of mucositis oral, bladder infection, and thromboembolic incidents than what the primary clinical trial recorded"
    },
    "1022a719-eef0-4fbe-ac15-b0398adbf45b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00766532",
        "Secondary_id": "NCT01468675",
        "Statement": "There are no cases of anorexia, hypothermia or hallucinations recorded in the Aes of the primary trial or the secondary trial. kit protein variant is a variation in the amino acid sequence for the mast/stem cell growth factor receptor kit protein."
    },
    "d921df56-8a29-45a9-bb0b-66ba14dbc193": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02961790",
        "Statement": "Any patients that have undergone Antineoplastic chemotherapy, Androgens, Estrogens or Progestogens therapy in the last 2 years before study entry are excluded from the primary trial."
    },
    "2c4fbaa0-f62c-4a7b-9d9d-7b61a8383ec4": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00878709",
        "Statement": "granuloma assessment is an evaluation of the presence or degree of granuloma in a sample. The Neratinib group of the primary trial had a lower rate of iDFS than the placebo group."
    },
    "c7fd3efb-5319-40f3-aba0-a54c76a50768": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "in the primary clinical trial, there were less patients with stable disease in week 12 compared to week 24, and there were reports of complete response in both weeks"
    },
    "f3f438bb-2af4-44b9-9bf7-28dc232feacb": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00662025",
        "Statement": "carboplatin, not capecitabine, was administered orally twice a week, to all participants in the second cohort of the primary clinical trial over a 21-day cycle"
    },
    "14be6911-9b8c-4eb2-bcb9-bb5e892a57d1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00253708",
        "Secondary_id": "NCT02222922",
        "Statement": "the primary trial does not test any drug based treatments, whereas the secondary trial tests different doses of one drug based-treatment. 12q11-q13 is a chromosome band present on 12q"
    },
    "8d1ad83d-8298-46fe-971d-3fadc862bd5e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the paclitaxel plus bevacizumab group had a higher orr compared to the paclitaxel plus bevacizumab plus gemcitabine group during the primary clinical trial"
    },
    "8b9a4f04-25f6-45d2-a4fe-52e5bd3d22de": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02807844",
        "Statement": "All patients in the primary trial receive at least 20mg of MCS110 every 3 weeks, and over 130 mg of PDR001 every other week."
    },
    "8f74daa8-19d7-4b51-9296-9b61e885690c": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02312934",
        "Secondary_id": "NCT00293384",
        "Statement": "the primary clinical trial does not accept patients who regularly consume alcohol, yet those who typically have fewer than five drinks daily could be acceptable for the secondary clinical trial."
    },
    "bcdef75a-f013-4d65-84e1-6004a054d574": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "a patient with a diagnosis of neoplastic meningitis might qualify for the primary clinical trial"
    },
    "2fcef697-683a-4b99-9da3-5527e80c9e5b": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial. pdgfrb protein variant is a variation in the amino acid sequence of the platelet-derived growth factor receptor beta protein."
    },
    "2909913c-9739-497b-8bbb-481d3b5c4832": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00544167",
        "Secondary_id": "NCT01597193",
        "Statement": "patients that have suffered a pulmonary embolism in the last 6 years are excluded from the primary trial, but may be eligible for the secondary trial depending on the investigators decision"
    },
    "2df3c784-8e32-4d92-9770-63087b7c7f62": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "ability to get up from kneeling is a question about an individual's ability to get up from kneeling. Both cohorts of the primary trial receive the same doses of Abraxane."
    },
    "bca56f4d-9c3c-4615-8b56-3f6ca86d047b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT02509156",
        "Statement": "the identical dose of allo-mscs and placebo interventions are delivered in the primary clinical trial, using a single transendocardial injection."
    },
    "a7e702b9-3e27-47ed-bf09-3ce3c3f22b6e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "compared to the group that received nacl 0.9% 3ml in the primary clinical trial, the group that was administered ketorolac 30 mg had a -6.4% lower recurrence-free survival rate"
    },
    "bea94e26-3706-492c-af45-d35ef7e43ff1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02796755",
        "Secondary_id": "NCT00756496",
        "Statement": "the primary trial and the secondary trial do not have any recorded adverse events for their participants. clavicle fracture is a traumatic or pathologic injury to the clavicle in which the continuity of the clavicle is broken."
    },
    "df26264a-98ef-47f9-9493-e2398529e39f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "Far more patients in the secondary trial were recorded to have experienced Aes, than patients in the primary trial. megacolon is an abnormal dilation of the colon not due to obstruction."
    },
    "fc35b082-3d3c-4ccc-971b-1f008c224a28": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00270894",
        "Statement": "participants in the primary trial receive 14 different drugs throughout the study duration, with a maximum dose of 200 mg/m^2"
    },
    "570eadad-adf1-4e5a-bae7-8455d2a07f0e": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02104830",
        "Secondary_id": "NCT01569087",
        "Statement": "hemolytic uremic syndrome, ctcae is a disorder characterized by a form of thrombotic microangiopathy with renal failure, hemolytic anemia, and severe thrombocytopenia. the primary trial and the secondary trial are studying the same drug, in different doses and with a different outcome measurement."
    },
    "586b08dc-8323-46ff-873f-5d262f7eae35": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "10 adverse events were observed in the primary trial, and 90% of the adverse events in the secondary trial affected more than 95% of patients."
    },
    "2312576f-7c8d-4fcd-80e8-42cf3d81dd04": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01527487",
        "Statement": "cohort 1 of the primary trial recieves higher doses of Eribulin than cohort 2 patients receive of Docetaxel"
    },
    "d6cd0501-9b29-41f5-ba8a-6209c8cfad84": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial only two cohorts recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 200 mg dose of pdr001, and 4 mg/kg dose of mcs110."
    },
    "0f36a35d-d86b-41d0-9878-df4ef7ad0e9f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "the infection, asymmetry and deflation cases were less prevalent in the primary trial than in the secondary trial."
    },
    "62af11ae-461f-4e31-b104-3467b2210208": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "the outcomes of both the primary and secondary clinical trials were not marred by any instances of infection"
    },
    "21b261e7-4b78-4c70-ba0c-b98c5c082bee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 0.175 g group of the primary trial experienced a more significant percentage change in betactx at week 28 days than the zoledronic acid 4 mg group."
    },
    "ab3fc92f-0d8a-472f-b652-e10bcd03ff19": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "None of the individual adverse event types recorded in the primary trial affected more than one patient. reconstructive plastic surgery is a surgical procedure to reconstruct a damaged or deformed part of the body to improve function or aesthetics."
    },
    "dfd33619-98ec-43e0-83c4-a22bae9f1b52": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02306265",
        "Secondary_id": "NCT03202472",
        "Statement": "millimole per liter per microgram per kilogram per day is a unit of concentration equal to millimoles per liter, divided by micrograms per kilogram per day. candidates must undergo a Mammography before being able to participate in the primary trial, whereas for the secondary trial patients must first have a CT scan and blood tests."
    },
    "973b8d05-863f-4978-a197-bd08355b7834": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01908101",
        "Secondary_id": "NCT00076024",
        "Statement": "higher doses of radiation therapy are given to the patients of the primary clinical trial as compared to the secondary clinical trial participants"
    },
    "fc37e929-f3f3-43fb-b0c4-86521a18592f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "100.0% of cohort 1 of the primary trial suffered some kind of adverse event. self-evident change is an information error that can be quickly and accurately fixed based on existing data on the form."
    },
    "8d27bb53-e66e-4eab-bea4-0597fd5760b5": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02734979",
        "Secondary_id": "NCT02306265",
        "Statement": "Patients that have a history of pulmonary embolisms and currently have breast implants cannot participate in the secondary trial or the primary trial."
    },
    "3eecf12f-23fb-45ab-bf91-cc84c01a1b6a": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02550795",
        "Secondary_id": "NCT00416715",
        "Statement": "in the primary clinical trial, group 2 patients receive a dosage of 0.5ug/kg of dexmedetomidine (5ml), whereas the secondary clinical trial does not administer dexmedetomidine to its cohorts."
    },
    "a02a0c3b-3c6c-45ce-a382-636abd7e1bef": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT01869192",
        "Secondary_id": "NCT00321464",
        "Statement": "in the primary clinical trial, the outcomes from the placebo arm suggest superior overall response rate than the arm a intervention. however, in the secondary clinical trial, the zoledronic acid cohort recorded a shorter time to first on-study sre compared to the denosumab cohort."
    },
    "cfcfc39b-c969-474d-b85c-090dda68b1f1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "the primary clinical trial and secondary clinical trial saw no instances of cardiac or psychiatric adverse events."
    },
    "22031bc7-9954-4b2b-b905-a5d34e0eea98": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02286843",
        "Statement": "her2+ metastases developed in 13% of the participants with pr+ primary breast cancer treated using her2-targeted pet/ct. 89zr-trastuzumab in the primary clinical trial"
    },
    "70310501-6b9e-4283-9981-5f709b9517b6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 0.15 of patients in the primary trial and the secondary trial suffered from infections during the study period"
    },
    "f4e91f1d-d645-4759-904d-12e509336562": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02640053",
        "Statement": "the symptoms experienced by patients who didn't receive topical cryotherapy in the primary clinical trial were more intense than those who did receive the treatment."
    },
    "32e81a4f-0434-46d3-8da4-04037c77a56b": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "helcococcus is a genus of gram positive, cocci shaped bacterium assigned to the phylum firmicutes and the family clostridiales xi. cohort 1 of the primary trial is given an intraosseous injection of Fluciclatide and cohort 1 of the secondary trial is administered a standard dose of Chloroquine by IV."
    },
    "1ec46b05-25a0-45c2-a6aa-31f5a2209ac5": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "global complete response in blood is a score of b0 by repeat bone marrow biopsy with no residual disease. 5 patients in the primary trial suffered 3 or more adverse events."
    },
    "fe6418cd-e255-4f27-bb63-63b4f37a0f56": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00262834",
        "Secondary_id": "NCT00820872",
        "Statement": "deleterious fancd2 gene mutation is a change in the nucleotide sequence of the fancd2 gene that is associated with increased risk of disease. 0 adverse events were observed in the primary trial, and none of the adverse events in the secondary trial affected more than 30% of patients."
    },
    "ee93ea09-f0a8-42ab-880d-8284fe0d716e": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "in the primary clinical trial, there was an 11% higher rate of participants showing a reduction in the growth factor signature in the er-positive luminal b group as compared to the triple negative group."
    },
    "786542cd-3793-47a4-b954-9b6c5aa2e652": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00753415",
        "Statement": "the same three electroporation injections of ld v934 are given to cohort a and b in the primary clinical trial"
    },
    "ccce8199-a89f-40b4-9c27-755f2d99c98d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "in the primary clinical trial, a single type of adverse event was noticed in more than one patient"
    },
    "f66e21d9-801f-4613-99da-c033734189e4": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "in both the primary and secondary clinical trials, eligibility is not determined by the gender of the individual"
    },
    "80e6c613-24ab-4d10-bed6-49388de175d4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00825682",
        "Secondary_id": "NCT00867217",
        "Statement": "The intervention in the secondary trial last 15 more weeks than the intervention detailed in the primary trial. arterial access site is anatomical location where an artery was accessed for a diagnostic or therapeutic procedure."
    },
    "a8353a78-23fe-4aba-aaef-06d3fb8dd41a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "the patient with the longest pfs in the primary trial survived 14 days without disease progression or death"
    },
    "47e524f0-a370-4845-848a-89fb6b743c96": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02187783",
        "Secondary_id": "NCT01222390",
        "Statement": "the secondary clinical trial showed a higher incidence rate of palpitations, pericardial effusions and abdominal pains than the primary clinical trial."
    },
    "0de24040-4a99-4f16-8bba-6f2e78018aad": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary clinical trial, armodafinil p.o. is delivered daily to a specific cohort, while in the secondary clinical trial, all participants receive a uniform dose of 100 mg pdr001 and 1mg/kg of mcs110."
    },
    "31bb177c-1a8b-4699-a7f2-4c442801770f": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01617668",
        "Statement": "the frequency of adverse events was higher in the first cohort of the primary clinical trial than in the second cohort."
    },
    "7552c836-8753-455e-923f-8364d6c63b03": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01111825",
        "Statement": "in the primary clinical trial, cohort 1 is given pr negative, er negative, and her-, while cohort 2 is administered her2+"
    },
    "7a831a11-8edd-42ef-81e7-fd8bca5ca0cc": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00321048",
        "Statement": "equal amounts of radiation therapy are provided to patients of cohort 1 and 2 in the primary clinical trial, and a spect scan is performed on each of them."
    },
    "e21cdb34-eb9d-4439-81ff-6dae554954c6": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "there were 11 additional instances of intestinal perforation reported in the secondary clinical trial compared to the primary clinical trial"
    },
    "31837502-2949-4dc4-bfbe-fc54ca5ccb01": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00122369",
        "Secondary_id": "NCT03069313",
        "Statement": "abnormal involuntary movement scale aims0108 through aims0109 original result - moderate is abnormal involuntary movement scale aims0108 through aims0109 original result - moderate. the secondary trial requires patients to be over a certain age, but the primary trial does not specify an age range for participation."
    },
    "10a9dcfe-bbdd-44b2-9bc7-f406a2ff835a": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00659373",
        "Statement": "on average, there was no change in cognitive function for patients in either cohort of the primary clinical trial."
    },
    "046763cb-f08d-4032-8b54-03bc14cb9d69": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "the primary clinical trial is open to patients suffering from anorexia."
    },
    "8078bf53-15fe-414d-837f-abe03ab9e56d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02891681",
        "Secondary_id": "NCT00321048",
        "Statement": "patients with healthy weight according to body mass index (bmi) standards can be eligible for the primary clinical trial and the secondary clinical trial."
    },
    "1cdbbd44-21df-4279-9e3c-ff501f1361ec": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the MTD of different interventions"
    },
    "e57df144-6c3e-4855-a2d3-fcbec0396750": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "There was at least 1 case of infection in both the primary trial and the secondary trial. malignant bronchial neoplasm is a malignant neoplasm that affects the bronchial tree."
    },
    "e0d92d90-958e-435b-bb1b-7135ed0b2fac": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01128543",
        "Statement": "the majority of patients in the primary trial experienced complete response by the 24th week."
    },
    "90783994-6867-4dfe-bbd0-71c4004d9a20": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00586326",
        "Statement": "The the primary trial intervention section does not outline a treatment cycle or any description of the treatment. senior is a suffix used to distinguish a father from his son when they have the same given name."
    },
    "dd909039-da2a-4c24-9b6f-1776bc51e3a2": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00432562",
        "Secondary_id": "NCT00122369",
        "Statement": "The only shared inclusion/exclusion criteria between the secondary trial and the primary trial is the ability to provide written informed consent. malignant cervical soft tissue neoplasm is a rare malignant mesenchymal neoplasm that arises from the cervix."
    },
    "13d5fd15-4fe1-4152-8987-050cfb32c8fb": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01806259",
        "Statement": "the ketorolac 30 milligram group of the primary trial had a -0.064 recurrence-free survival compared to the nacl 0.9% 3mL group"
    },
    "97d1e0d2-2f6f-45f1-8e85-33c92d71f0bf": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "every single patient in the primary clinical trial experienced a decrease in blood bilirubin levels."
    },
    "2a5561f9-399d-4651-9a54-1a15f251c070": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02178722",
        "Secondary_id": "NCT00428220",
        "Statement": "participants in the primary trial receive sunitinib twice as frequently as participants in the secondary trial receive pembrolizumab."
    },
    "a9faa655-1f16-41b0-911e-0a560a1c1dc0": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00775645",
        "Secondary_id": "NCT02002533",
        "Statement": "in both the primary trial and the secondary trial there were 0 adverse events which occurred in less than 2% of participants."
    },
    "4dc9c970-22dc-4117-8169-255a0b3f80d8": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia. food consumption is a measurement of a subject's nutritional intake."
    },
    "a9e14c3b-bf03-4ca1-b9d9-4693b231902c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients on the waiting list. 6p21.33 is a chromosome band present on 6p"
    },
    "f2640a7c-0890-40e2-a2dc-1dcdeefcd3bf": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00118157",
        "Statement": "recipients in the primary clinical trial receive injectable medication thrice per day for two weeks."
    },
    "a89e4c9e-86e0-4d21-b805-2a593ed71a7c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00756717",
        "Secondary_id": "NCT01252290",
        "Statement": "There were 0 cases of Febrile neutropenia or Cholelithiasis in the primary trial and the secondary trial. monoclonal antibody b1 is a monoclonal antibody that targets cd20, a b-cell-specific cell surface protein expressed on mature b lymphocytes. (nci)"
    },
    "8623aaca-7fb2-44d5-b968-a064007b7112": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01194440",
        "Statement": "patients with a diagnosis of stage 4 invasive breast carcinoma, positive for estrogen and/or progesterone receptors, and weighing the option of ai therapy, are suitable for the primary clinical trial."
    },
    "ac0de5f6-14ed-44a1-9112-bce1b197553b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "trichomonas infection is an infection that is caused by trichomonas. There were no patients with recorded Aes in the primary trial, whereas every patient in the secondary trial suffered at least one adverse event."
    },
    "003a36ac-4091-4ca9-96f3-1108302eb9e1": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01301729",
        "Secondary_id": "NCT00021255",
        "Statement": "At several points during the trials Patients in the primary trial receive the same dosage of Trastuzumab as patients in cohort 2 of the secondary trial. negative biospecimen is a grouping category for samples that tested negative."
    },
    "63acd7b4-dc08-415b-af25-c09e1db4e913": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "the primary clinical trial uses a topical administration of it's intervention, contrasting the secondary clinical trial\u2019s exclusive use of an intravenous route"
    },
    "7c28d575-cd75-418e-83bb-fae7457d9428": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01706081",
        "Statement": "satisfaction with overall sexual life is a question about how satisfied an individual is or has been with their overall sexual life. Acupuncture Patients in the primary trial saw better changes in their Lymphedema than patients administered with testosterone Cream."
    },
    "bac5180a-b51f-4a2d-a1d2-eaead122d693": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00709761",
        "Statement": "the majority of patients in the primary clinical trial treated with lapatinib 1000 mg + nab-paclitaxel did not achieve a confirmed complete response (cr)."
    },
    "fdc7efac-ca90-4897-9660-a42dbba2bd84": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "during the fourth week of the primary clinical trial, a more significant percentage change in betactx was observed in the azd0530 175 mg group than in those taking zoledronic acid 4 mg."
    },
    "a0e47b7d-7f2d-43ba-8f93-dc5f9dcd648b": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "over 15% of patients in the primary trial and the secondary trial suffered from infections during the study period. cell surface receptor is a receptor protein that is localized to the plasma membrane and may have exposure to the extracellular milieu."
    },
    "a7e93d6e-e8d0-4b87-b2a1-be2b821e5a94": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00320541",
        "Statement": "the paclitaxel plus bevacizumab plus gemcitabine group had a worse orr than the paclitaxel plus bevacizumab group in the primary clinical trial"
    },
    "8d16932d-a485-4c58-828e-70f805bd82ef": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01554371",
        "Secondary_id": "NCT02550795",
        "Statement": "both the primary clinical trial and the secondary clinical trial do not entertain the participation of patients who are currently smoking."
    },
    "fc16338c-2505-48c4-ab18-e7de394cab62": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01772004",
        "Statement": "African-american patients can participate in the primary trial. borderline resectable mass is a tumor mass finding that refers to a continuum between resectable and locally advanced unresectable disease."
    },
    "575eb6a5-bbeb-46a4-af85-87303a9fc321": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00182793",
        "Secondary_id": "NCT00632489",
        "Statement": "there were no recorded incidents of infections among patients in both the primary clinical trial and the secondary clinical trial during the study period"
    },
    "a62aed40-ac98-4cdc-a7b2-4b1c57e6010b": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01881230",
        "Statement": "abraxane and carboplatin dosages differentiate between the cohorts of the primary clinical trial"
    },
    "6a119107-7a0d-421f-bfea-3671d97ed082": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00929240",
        "Statement": "3q21-q24 is a chromosome band present on 3q the Bevacizumab cohort of the primary trial had a higher incidence of Disease Progression or Death than the Bevacizumab + Capecitabine cohort."
    },
    "022c87c6-e5c0-4401-92f7-2570af8f8ac1": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02041429",
        "Secondary_id": "NCT00911898",
        "Statement": "the primary trial and the secondary trial report on the MTD of different interventions. smoked cigarettes after diagnosis and before treatment start is a question about whether an individual smoked cigarettes after diagnosis and before treatment started."
    },
    "294df8e3-8ba1-41e7-acdc-6448bfab99f1": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00256217",
        "Secondary_id": "NCT00182767",
        "Statement": "every patient in the primary clinical trial experienced multiple adverse events, while patients in the secondary clinical trial were unscathed by any."
    },
    "f52235c3-a9c6-4eb2-a9c6-929afe1bf49a": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT03384316",
        "Statement": "all infections and infestations cases in the primary clinical trial were evenly distributed among all cohorts."
    },
    "ca8c2bae-ba14-4791-b995-e1555696d182": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00800436",
        "Secondary_id": "NCT00702949",
        "Statement": "exposure to gabapentin or herceptin within the last 12 months disqualifies patients from the secondary clinical trial, yet it won't prevent them from being part of the primary clinical trial"
    },
    "af9cfc7a-95f4-494a-b68f-128961cf1a5b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "a patient diagnosed with a non-neoplastic disorder is eligible for the primary clinical trial"
    },
    "207602e0-9ba8-437e-a8c2-deb34b3eaef9": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00194779",
        "Secondary_id": "NCT01743560",
        "Statement": "the primary clinical trial entails a medical plan where participants are given multiple drug types via subcutaneous injection and surgery. however, the secondary clinical trial approach involves only two basic drugs and employs several imaging scans for follow-ups"
    },
    "17adb81b-92e7-4ed5-b443-287a5df2fb37": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00365365",
        "Statement": "in the primary clinical trial, participants are provided her2/neu peptide vaccine in combination with sargramostim (gm-csf) id on days 1, 8, and 15."
    },
    "9b1d58dd-30d8-4df2-856e-4cae783cbd6e": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00357734",
        "Secondary_id": "NCT00365105",
        "Statement": "the intervention in the primary trial involves a drug cocktail, including paclitaxel, bevacizumab, and gemcitabine. the secondary trial includes only doxorubicin as its intervention."
    },
    "d8da21ea-52ef-4b97-8344-6214bd3565b3": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00918281",
        "Secondary_id": "NCT01023477",
        "Statement": "in the primary clinical trial, cohort 1 is given a subcutaneous injection of docetaxel and in the secondary clinical trial, cohort 1 receives a high dose of methotrexate orally."
    },
    "a60a8f30-02a6-46a4-bb00-bea702d5103d": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02441946",
        "Secondary_id": "NCT00693719",
        "Statement": "patients with a tnbc tumor of 50cm in diameter, are eligible for both the primary trial and the secondary trial"
    },
    "4dcbfb0d-cb67-4d74-a21a-0920159dfafc": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02599194",
        "Secondary_id": "NCT02312934",
        "Statement": "both the primary clinical trial and the secondary clinical trial did not make a record of any adverse events."
    },
    "f49abd8e-7440-40ec-a512-c2420c9a207b": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01351376",
        "Statement": "Patients with measurable tumors in both breasts are excluded from the primary trial. mixed endometrial stromal and smooth muscle neoplasm is a rare primary neoplasm of the uterine corpus characterized by the presence of endometrial stromal and smooth muscle components."
    },
    "f1494243-0e25-48d1-b7d8-e92ffed41e1d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "activity tracking is a method to track an individual's physical activity using an activity monitor or other tracking device. There were severalpsychiatric adverse event in the primary trial, including an eating disorder and Schizophrenia."
    },
    "7cd38d1e-009b-40f6-a8f8-1352ae821aa4": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT03403712",
        "Secondary_id": "NCT00792077",
        "Statement": "the primary trial is assessing the length of patients' slumber while the secondary trial is evaluating the frequency of the patients' post treatment complications."
    },
    "e4eba352-415f-44bd-8fe0-244240a80513": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293384",
        "Statement": "less than half of the patients in cohort 2 of the primary clinical trial experienced acute vomiting following treatment with aprepitant, dexamethasone, cytoxan and kytril"
    },
    "41b6a327-e552-4e26-971f-25096f53e72d": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01967823",
        "Statement": "4.9% of the primary trial patients suffered an increase in blood bilirubin."
    },
    "18d3b58f-42ca-4178-adb6-4a5f0c9fafde": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00708019",
        "Statement": "None of the patients in the primary trial experienced the worst pain imaginable for 10 weeks."
    },
    "cbbd5644-6e63-4f6d-b948-fe52b5df89c7": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01997333",
        "Statement": "in the primary clinical trial, the individual with maximum pfs managed to live 3.5 months without disease advancement or death."
    },
    "920f9642-c8b0-4b1d-9b2a-c12c4801b714": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01023477",
        "Secondary_id": "NCT00687102",
        "Statement": "patients with normal potassium levels are disqualified from the primary clinical trial while they have potential eligibility for the secondary clinical trial"
    },
    "61fbddc4-94cb-4105-8090-03dd97a3bc53": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01439282",
        "Secondary_id": "NCT01783444",
        "Statement": "Gender is not a determining factor for eligibility in the primary trial, but only female patients are eligible for the secondary trial. keyword code is a coded value specifying the words or phrases that best describe an entity and/or its context and content."
    },
    "34b09027-2195-448e-ab3d-fb9d5a91301a": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01649271",
        "Secondary_id": "NCT02165839",
        "Statement": "in the patient groups of the primary and secondary clinical trials, a total of three shingles cases were identified."
    },
    "2945688b-8ee8-43ce-8ed3-30c0a4fdf489": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01730729",
        "Secondary_id": "NCT01086605",
        "Statement": "unlike the secondary clinical trial that specifically administers treatment intravenously, the intervention in the primary clinical trial is given topically"
    },
    "38ea3ca5-d5b1-4432-b6f6-52e8ca0d3e41": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "in the primary clinical trial, there was a 49.2% higher reduction in the growth factor signature in the dalotuzumab 20 mg/kg group than in the triple negative group."
    },
    "9a111f3a-a29a-42fa-bf73-9f178286198c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "defined notification delivery mechanism code is a coded value specifying how the notification message is to be delivered. Results from the primary trial show that tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after Breast cancer surgery reduces Ki67 Expression in Tumors by 40% on average."
    },
    "8839dd14-8457-44c0-88a1-8bb0764e326c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT00795769",
        "Secondary_id": "NCT00408681",
        "Statement": "a larger percentage of participants in the primary trial were reported to have experienced chest pain than in the secondary trial."
    },
    "8150f869-b9e6-422b-a13a-1bdccee14f19": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00838929",
        "Statement": "aids-related non-hodgkin lymphoma is a non-hodgkin lymphoma that develops in a patient with aids. Every patient in the primary trial is receives a dose of 100 to 1600 \u00ac\u00a8\u00ac\u00b5g fentanyl sublingual spray during radiation therapy."
    },
    "3a85c9cb-b4e8-46cb-84c5-e618f0307b26": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00632489",
        "Statement": "the lbh589 with capecitabine cohort of the primary clinical trial outperformed the lbh589 and lapatinib cohort."
    },
    "871e4e1f-9d73-46d0-9eda-04099b38ea4b": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00558272",
        "Statement": "the azd0530 175,000 microgram group of the primary trial experienced a more significant percentage change in betactx at week 4 than the zoledronic acid 0.004 g group."
    },
    "43b9c2c8-0785-4885-901b-91a1f893858f": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01290536",
        "Secondary_id": "NCT02403271",
        "Statement": "The the primary trial intervention consists of Radioembolization using TheraSpheres, on the other hand the secondary trial intervention is based on ibrutinib and MEDI4736."
    },
    "66030da0-0335-44c8-97dd-a620f3d9961f": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "insomnia patients irrespective of the severity of their condition are invited to take part in both the primary clinical trial and the secondary clinical trial"
    },
    "7a4c195c-e5a6-49b5-b8de-842704bfe7f4": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01468675",
        "Statement": "in the primary clinical trial, interventions do not include any drug usage, radiotherapy or cognitive behavioral therapy (cbt) for either cohort."
    },
    "d6c5a9e6-8db3-44f7-b865-4250c057f194": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00321464",
        "Secondary_id": "NCT01963481",
        "Statement": "patients with clinically diagnosed stage 4 lung adenocarcinoma that is either egfr positive, alk positive or ros1 negative are signed up for both the secondary trial and the primary trial."
    },
    "82bcea65-bca6-46f5-9e3b-32098e20c46f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "gain of chromosome 2p is a cytogenetic abnormality that refers to the duplication of all or part of the short arm of chromosome 2. the secondary trial recorded 11 more Aes than the primary trial."
    },
    "1cb125fb-0be1-49c6-b68b-64b525278c9c": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "Across both the primary trial and the secondary trial only one death was recorded in the adverse events."
    },
    "da4a10c9-b04c-4439-84f5-918325786672": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "individuals who have had severe anaphylactic responses to herceptin or have shown no response to herceptin treatment are suitable candidates for the primary clinical trial."
    },
    "1100945c-51b9-4687-b518-d9b426239583": {
        "Type": "Comparison",
        "Section_id": "Results",
        "Primary_id": "NCT02413008",
        "Secondary_id": "NCT02041429",
        "Statement": "the identical outcome measure for the secondary and primary clinical trials is the proportion of patients with pcr within the breast; in other words, no evidence of invasive tumor remaining in the breast after the completion of chemotherapy and surgery."
    },
    "c648cc67-b490-4cfe-be5e-4706b94ac0df": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01781299",
        "Secondary_id": "NCT02413008",
        "Statement": "in the primary clinical trial as well as secondary clinical trial, there were neither unexpected deaths nor hospital stays, just three known cases of lymphoma."
    },
    "56c00437-a067-4734-9b55-f1041c10190e": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00284180",
        "Statement": "patients who have previously experienced serious anaphylactic reactions to herceptin, or those who experienced no improvement with herceptin treatment may participate in the primary clinical trial."
    },
    "32cc173a-b271-47c9-997d-df17ce1c7494": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01048099",
        "Statement": "None of the individual adverse event types recorded in the primary trial affected more than one patient"
    },
    "2dfe7dda-41ae-48bc-aac5-1309cb87e4c1": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "Patients with stage 4 cancer are eligible for the secondary trial and the primary trial, if they provide informed consent. surface immunoglobulin-positive cells present is a microscopic finding indicating that immunoglobulins are bound to or expressed on the surface of cells in a sample."
    },
    "a263d5ff-4c27-4881-9209-87b1c1d69f94": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00451555",
        "Secondary_id": "NCT01781299",
        "Statement": "the primary clinical trial necessitates participants to display resistance towards ai therapy and mirtazapine, a condition not enforced in the secondary clinical trial."
    },
    "57526ef1-a6b9-419e-86c9-0a2d6db7ad23": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT02431676",
        "Statement": "anorexic patients can be considered for the primary clinical trial"
    },
    "b9b32a2d-94f0-413e-95f3-08177622a743": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00693719",
        "Statement": "A patient diagnosed with a neoplastic meningitis could be eligible for the primary trial. patent delivery system vial is a vial that has a patented delivery system."
    },
    "36969517-2743-4fc8-970a-0846cebda02f": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00429182",
        "Statement": "feelings about ability to deal with treatment and recovery is a question about an individual's feelings regarding their ability to deal with treatment and recovery. less than half of the primary trial participants had a Reduction in circulating tumor cells Following High-dose Chemotherapy With Purged Autologous Stem Cell Products."
    },
    "96aaaf64-1a1e-4a5b-a2db-f99e2c199bec": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00365105",
        "Secondary_id": "NCT02104830",
        "Statement": "a 42 year old patient with histologically verified diagnosis of stage iii breast cancer, absolute neutrophil count of 1600/\u2248\u00ed\u00ac\u222bl, platelet count of 132,040/\u2248\u00ed\u00ac\u222bl, hemoglobin level of 110 g/l, and a life expectancy exceeding 16 months would be eligible for both the primary trial and the secondary trial."
    },
    "1ad82f60-7f4e-4e29-967f-c83e64180807": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT01614210",
        "Statement": "results from the primary trial show that tamoxifen 45 mg po daily for 15 days prior to surgery and for 30 days after breast cancer surgery reduces the diameter of tumors by 20% on average."
    },
    "04b2b1f2-5d87-4b89-8fcd-c1c988bd22de": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01011218",
        "Secondary_id": "NCT00775645",
        "Statement": "across the primary clinical trial and the secondary clinical trial, it was recorded that there were no deaths in the adverse events."
    },
    "5a54ce72-5d02-48fb-9cc0-2a31123f3583": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02179515",
        "Statement": "none of the participants of cohort 1 of the primary clinical trial experienced any adverse events"
    },
    "f119d419-b22b-4b4d-84ea-f7ab7dba7522": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "food preparation and serving, related occupations is a class of professional or vocational positions of employment that involve food preparation or serving. All the primary trial participants receive lower doses of drugs than the secondary trial participants."
    },
    "fa5e894c-13be-4786-ac47-16d31de8a7ce": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01963481",
        "Secondary_id": "NCT01011218",
        "Statement": "distress over family problem with family health issues is a question about an individual's distress related to their family problems dealing with family health issues. Patients suffering from severe insomnia and schizophrenia are excluded from both the primary trial and the secondary trial."
    },
    "a220e90b-6fd7-449f-878a-f870cd360de6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00553358",
        "Secondary_id": "NCT01770353",
        "Statement": "a patient that has a primary tumour with a diameter of 100mm measured by clinical examination and echography, would be eligible for both the primary trial and the secondary trial."
    },
    "f0cbb267-5a5b-412e-a474-2ad091a031d7": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "in the primary trial only 1 group recieves armodafinil p.o. daily, and in the secondary trial all patients receive the same 100,000 \u03bcg dose of pdr001, and 1 mg/kg dose of mcs110."
    },
    "50e4558f-a9a2-425b-911f-5bea986e90b4": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00702949",
        "Secondary_id": "NCT00992602",
        "Statement": "diffuse midline glioma, egfr-mutant is a diffuse midline glioma, h3 k27-altered, characterized by the presence of egfr gene mutation. the primary trial treats one of its patient cohorts with 150 mg of oral pregabalin every 2 weeks over 6 weeks, and the secondary trial administers its patients with Depocyt and HD-MTX."
    },
    "e8f582a2-31f8-4b30-a2bb-1d236706333d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT01091974",
        "Secondary_id": "NCT02807844",
        "Statement": "everyone in the primary clinical trial gets the same dosage of armodafinil orally daily, and in the secondary clinical trial, all participants get varied dosages of chs828 and mvc110."
    },
    "2dce1806-9ce1-4448-9888-052def540a43": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "a single psychiatric adverse event was reported in the primary clinical trial, affecting fewer than 10% of the patients"
    },
    "24493091-48f3-4e50-ae2c-5d23fb12c376": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01537029",
        "Secondary_id": "NCT01306032",
        "Statement": "Female cancer patients over the age of 18 can participate in the primary trial, regardless of race, ethnic origin or cancer type, however for the secondary trial, they must have BRCA+ breast cancer. human fetal tissue is any tissue from a human fetus."
    },
    "9068887d-3b93-4345-9b59-01ceb05725b1": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01964924",
        "Statement": "for the primary clinical trial, adults who have been diagnosed with ild/dpld within the previous 3 years and have a projected life span of 6 months are considered eligible"
    },
    "9d742d77-5754-4e6f-a913-90dc71c6b6f5": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT00741039",
        "Statement": "all participants of the primary clinical trial undergo the same treatment, irrespective of their cancer status."
    },
    "a44d4aaf-a761-46a1-a803-63d6ede293a5": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT02115607",
        "Secondary_id": "NCT00372424",
        "Statement": "the secondary trial recorded 11 more cases of Intestinal perforation than the primary trial. percentage relief from pain treatment or medication score answer is an answer for a percentage relief from pain treatment or medication score query."
    },
    "f2b4adf3-ccbc-4bea-94a6-50887d7aeea0": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00293540",
        "Statement": "on average, patients from the primary clinical trial do not survive beyond 2 years and there were no cases where any patient from either cohort died in under 2 years."
    },
    "f05dd895-7d03-45d2-ab9c-69db39c386e5": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT00322374",
        "Statement": "inclusion in the primary clinical trial is restricted to those who have not received chemotherapy or radiotherapy in the past 6 months and have a proven clean mental health record."
    },
    "ae6b9c00-10a6-437a-a83b-b46fce724269": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00248547",
        "Statement": "emesis was not a reported symptom for patients receiving the placebo intervention in the primary clinical trial"
    },
    "ff07ae9a-9106-443b-b584-a7522ec3f71d": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT00054028",
        "Secondary_id": "NCT02122796",
        "Statement": "Suramin and Paclitaxel are administered to all patients in the primary trial, and the secondary trial intervention section does not describe what drugs are to be administered. kbtbd4 gene mutation is a change in the nucleotide sequence of the kbtbd4 gene."
    },
    "3b8d5e1e-4c1e-4e6e-9890-8851c275cc0f": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01246973",
        "Secondary_id": "NCT01091974",
        "Statement": "a number of psychiatric aes were noted in the secondary clinical trial."
    },
    "7e288efd-8755-4393-b372-effd1c3feb91": {
        "Type": "Comparison",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01664091",
        "Secondary_id": "NCT01383174",
        "Statement": "tpm3 gene product is a protein encoded by the tpm3 gene. There were more cases of Infection, Asymmetry and Deflation in the primary trial than in the secondary trial."
    },
    "726f25cd-4611-43a5-b7c6-15f7393b67ee": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT00759785",
        "Statement": "monophasic synovial sarcoma is a synovial sarcoma characterized by the presence of an epithelial or a spindle cell component only. 49.2% more Participants in the dalotuzumab 20 mg/kg group of the primary trial Demonstrated a Decrease in the Growth Factor Signature than in the Triple Negative group."
    },
    "f50bcaa7-7424-4977-ac06-f47e545e2e00": {
        "Type": "Single",
        "Section_id": "Eligibility",
        "Primary_id": "NCT03092934",
        "Statement": "individuals with er negative prostate cancer are eligible for the primary clinical trial."
    },
    "a9cbf72a-fd01-403d-8afa-d9d6a69622a0": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01127763",
        "Statement": "treadmill is a piece of exercise equipment used to walk or run on, for the purposes of cardiovascular training or testing. 5 patients in the primary trial suffered 3 or more adverse events."
    },
    "959883cf-50ff-42e8-8da9-9ad0be3e18b6": {
        "Type": "Single",
        "Section_id": "Adverse Events",
        "Primary_id": "NCT01855828",
        "Statement": "locally advanced breast carcinoma is a breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes. There was one psychiatric adverse event in the primary trial, which affected less than 10% of patients."
    },
    "b06e2353-00ae-4f10-b072-a4ae5f608d3e": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01569087",
        "Secondary_id": "NCT01869192",
        "Statement": "patients who have completed their treatment and are now cancer-free, can participate in the primary clinical trial and the secondary clinical trial, regardless of their consent status."
    },
    "a7ff54ef-32cc-4cda-b4a2-39d5f6e1559c": {
        "Type": "Single",
        "Section_id": "Results",
        "Primary_id": "NCT02988986",
        "Statement": "patients in the primary trial noted a 10% decrease in the percentage of cells with ki67 expression after a month of undergoing tak-228 plus tamoxifen treatment"
    },
    "5e14d0f3-e63e-40e8-93cc-a07c90c226d6": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01045421",
        "Secondary_id": "NCT01390818",
        "Statement": "diffuse laminar endocervical hyperplasia is a benign band-like proliferation of tightly-packed, small to medium sized endocervical glands below the surface of the endocervical canal. Unlike the primary trial, patients must be diagnosed with a mutation in the one of the following genes; PTEN, BRAF, KRAS, NRAS, PI3KCA, ErbB1, ErbB2, MET, RET, c-KIT, GNAQ or GNA11 to be included in the secondary trial."
    },
    "037ef54b-03fa-49f8-ae4b-ea645d268ea9": {
        "Type": "Single",
        "Section_id": "Intervention",
        "Primary_id": "NCT01451632",
        "Statement": "Cohort 1 of the primary trial received the same dose of Cetuximab as cohort 2, but had an additional Collaborative Care Intervention. folliculitis, ctcae is a disorder characterized by inflammation or infection of the hair follicles."
    },
    "c831a231-8b84-41ca-a825-d11060c44d64": {
        "Type": "Comparison",
        "Section_id": "Eligibility",
        "Primary_id": "NCT01783444",
        "Secondary_id": "NCT03346161",
        "Statement": "women recently identified with locally advanced er-positive breast cancer who are contemplating mastectomy, qualify for both the primary clinical trial and the secondary clinical trial"
    },
    "bfeb1617-a5a5-40f7-8f09-f20c40a4cee0": {
        "Type": "Comparison",
        "Section_id": "Intervention",
        "Primary_id": "NCT02222922",
        "Secondary_id": "NCT00496860",
        "Statement": "paternal half sibling is a relative with whom you share a biological father but you have different mothers. All the primary trial participants receive lower doses of drugs than the secondary trial participants."
    }
}